data_2kcy_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kcy _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.0 m . . . . . 0 CA--C 1.54 0.572 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -106.95 144.97 32.81 Favored 'General case' 0 C--O 1.243 0.752 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -177.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.9 tt -146.17 139.36 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.772 0 C-N-CA 123.589 0.756 . . . . 0.0 110.061 -178.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 -89.39 101.58 14.26 Favored 'General case' 0 C--O 1.239 0.543 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 175.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.2 t -87.29 110.17 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.8 t -98.22 100.24 10.2 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -61.2 112.29 5.61 Favored Pre-proline 0 CA--C 1.549 0.929 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 175.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -77.18 -17.78 14.77 Favored 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 122.268 1.979 . . . . 0.0 113.209 -168.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -96.87 -48.89 5.27 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 122.714 0.406 . . . . 0.0 110.996 178.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.508 HG21 ' HE3' ' A' ' 34' ' ' LYS . 2.8 m -90.93 -31.26 16.45 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.215 0.606 . . . . 0.0 111.581 -172.498 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 95.14 6.27 60.26 Favored Glycine 0 N--CA 1.476 1.316 0 CA-C-O 119.479 -0.623 . . . . 0.0 114.003 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.508 ' HE3' HG21 ' A' ' 32' ' ' THR . 92.1 mttt -63.78 106.72 1.04 Allowed 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 123.089 0.556 . . . . 0.0 110.839 177.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.6 t -103.93 106.86 21.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 175.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.495 ' HB3' HD13 ' A' ' 68' ' ' LEU . 10.3 tp10 -138.43 139.44 38.88 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 123.763 0.825 . . . . 0.0 109.812 -173.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 50.0 mt -83.15 100.85 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 176.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.8 173.24 7.41 Favored 'General case' 0 C--O 1.239 0.509 0 C-N-CA 123.962 0.905 . . . . 0.0 110.079 176.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -107.56 134.59 50.35 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 175.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 59.3 mt -75.57 110.26 10.23 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 173.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -82.01 -48.07 11.87 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.645 1.178 . . . . 0.0 110.236 -173.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -135.97 153.82 51.28 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 175.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.496 HG13 HG11 ' A' ' 64' ' ' VAL . 16.8 t . . . . . 0 N--CA 1.479 1.023 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 173.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 67.9 mt . . . . . 0 CA--C 1.542 0.658 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.4 mt -102.98 116.0 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 114.041 -1.436 . . . . 0.0 108.944 -174.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 39.4 p -117.54 162.89 17.26 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.631 0.772 . . . . 0.0 110.765 -176.358 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -67.02 135.66 54.07 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 123.006 0.522 . . . . 0.0 110.127 176.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.07 -2.94 85.77 Favored Glycine 0 C--N 1.344 0.991 0 O-C-N 123.595 0.56 . . . . 0.0 113.571 -175.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.02 145.79 30.04 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 117.283 0.541 . . . . 0.0 110.749 179.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.423 HG13 HD11 ' A' ' 88' ' ' ILE . 50.8 t -90.1 112.17 24.33 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 172.067 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.496 HG11 HG13 ' A' ' 43' ' ' VAL . 26.5 m -107.42 159.6 6.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 174.277 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -102.6 137.46 40.8 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 172.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 30.6 p -133.46 -175.46 3.82 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.418 0.687 . . . . 0.0 109.797 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -60.59 -27.0 67.38 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 123.692 0.797 . . . . 0.0 111.889 175.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.495 HD13 ' HB3' ' A' ' 36' ' ' GLU . 74.1 mt -100.24 -0.67 38.15 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.269 0.628 . . . . 0.0 111.167 -175.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 112.06 -161.66 12.67 Favored Glycine 0 C--N 1.351 1.415 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.432 ' HA ' ' O ' ' A' ' 64' ' ' VAL . 17.5 m120 -73.69 138.14 44.52 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-N 117.16 0.48 . . . . 0.0 111.568 -178.212 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 92.8 t -130.45 146.62 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 124.748 1.219 . . . . 0.0 110.126 -176.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.565 ' HG2' HD12 ' A' ' 88' ' ' ILE . 34.6 mmt180 -85.23 126.68 33.87 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 167.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 43.0 t -73.54 111.7 8.89 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 172.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 77.6 p -95.36 -21.92 18.07 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-O 120.981 0.42 . . . . 0.0 109.907 -175.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 23.3 t -107.23 -171.29 1.85 Allowed 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.453 1.101 . . . . 0.0 110.578 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.28 136.68 20.91 Favored Pre-proline 0 CA--C 1.547 0.851 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 169.237 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -59.75 103.83 0.21 Allowed 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.502 2.135 . . . . 0.0 111.314 173.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 130.2 -6.08 6.01 Favored Glycine 0 C--N 1.342 0.904 0 CA-C-O 119.1 -0.833 . . . . 0.0 113.46 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 16.9 mm100 -67.31 -71.8 0.19 Allowed 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 117.876 0.838 . . . . 0.0 110.502 177.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -89.27 30.84 0.94 Allowed 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 172.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 64.63 -74.66 0.07 OUTLIER Glycine 0 C--N 1.355 1.618 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 -160.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.9 p -57.87 156.17 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.255 0 C-N-CA 125.387 1.475 . . . . 0.0 112.095 174.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 39.3 mt -84.04 151.51 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.526 1.13 . . . . 0.0 108.232 175.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -138.0 158.03 45.15 Favored 'General case' 0 N--CA 1.482 1.155 0 CA-C-N 118.298 0.499 . . . . 0.0 110.211 167.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.68 -171.71 34.77 Favored Glycine 0 C--N 1.344 0.994 0 CA-C-N 115.427 -0.806 . . . . 0.0 113.124 -174.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.2 m -122.91 135.23 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 123.441 0.696 . . . . 0.0 110.256 178.076 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 30.8 tp -68.37 134.12 49.76 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 122.969 0.508 . . . . 0.0 110.176 -177.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.565 HD12 ' HG2' ' A' ' 72' ' ' ARG . 16.7 pt -132.02 167.21 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 123.81 0.844 . . . . 0.0 111.062 -175.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 62.5 mtt-85 -117.66 49.42 1.23 Allowed 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 123.71 0.804 . . . . 0.0 110.166 -175.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -68.2 -58.74 3.96 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.072 0.463 . . . . 0.0 110.515 177.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 95.5 mt . . . . . 0 C--O 1.241 0.639 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.112 179.523 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.499 HG22 HD11 ' A' ' 40' ' ' ILE . 29.9 m . . . . . 0 C--O 1.239 0.526 0 CA-C-O 121.416 0.627 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.595 ' HD3' ' HG2' ' A' ' 39' ' ' GLU . 39.4 ttp180 -123.47 163.33 21.1 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 124.377 1.071 . . . . 0.0 108.265 177.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.1 tt -135.77 142.85 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.201 0.601 . . . . 0.0 110.183 -171.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.0 m-80 -84.98 102.5 13.23 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.6 t -95.2 107.93 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -172.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 42.1 t -93.58 103.09 14.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -64.24 116.68 29.85 Favored Pre-proline 0 CA--C 1.546 0.797 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 174.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.5 ' HG2' ' HG3' ' A' ' 31' ' ' GLU . 82.3 Cg_endo -73.33 -18.08 23.55 Favored 'Trans proline' 0 C--N 1.365 1.426 0 C-N-CA 122.361 2.04 . . . . 0.0 113.455 -173.513 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.5 ' HG3' ' HG2' ' A' ' 30' ' ' PRO . 20.8 mt-10 -95.86 -51.78 4.34 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.937 0.895 . . . . 0.0 110.757 -169.556 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 61.1 p -96.02 -7.26 36.79 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 123.56 0.744 . . . . 0.0 111.648 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.48 -0.65 80.19 Favored Glycine 0 C--N 1.355 1.595 0 CA-C-O 119.556 -0.58 . . . . 0.0 114.208 173.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.491 ' HB2' ' HZ3' ' A' ' 34' ' ' LYS . 9.3 mtmp? -67.17 106.89 2.14 Favored 'General case' 0 C--N 1.353 0.758 0 C-N-CA 123.267 0.627 . . . . 0.0 111.572 -174.461 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.4 t -82.71 99.78 5.86 Favored 'Isoleucine or valine' 0 C--N 1.346 0.446 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 169.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -130.02 114.28 15.6 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 -167.056 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.466 HG22 ' HG2' ' A' ' 24' ' ' ARG . 26.7 mt -79.04 100.01 3.55 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -171.371 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.415 ' O ' ' HG3' ' A' ' 24' ' ' ARG . . . -104.61 163.3 12.58 Favored 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 123.523 0.729 . . . . 0.0 110.755 -175.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.595 ' HG2' ' HD3' ' A' ' 24' ' ' ARG . 17.8 mt-10 -105.92 136.11 46.16 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 123.242 0.617 . . . . 0.0 109.932 -167.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.499 HD11 HG22 ' A' ' 23' ' ' THR . 68.1 mt -77.41 112.4 15.31 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.972 0 CA-C-O 121.417 0.627 . . . . 0.0 110.668 -174.391 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 9.2 mtp180 -74.93 -55.04 6.18 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 124.308 1.043 . . . . 0.0 110.152 174.352 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -140.51 168.46 19.75 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 124.249 1.02 . . . . 0.0 108.81 -176.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.1 t . . . . . 0 N--CA 1.478 0.93 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 167.757 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 40.5 mm . . . . . 0 C--O 1.244 0.773 0 CA-C-O 121.658 0.742 . . . . 0.0 109.749 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 37.8 mt -81.5 105.62 11.61 Favored 'Isoleucine or valine' 0 C--N 1.344 0.331 0 N-CA-C 107.699 -1.222 . . . . 0.0 107.699 174.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 5.7 p -139.62 168.24 20.27 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.414 1.086 . . . . 0.0 108.509 -177.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 52.5 mtm180 -61.03 125.24 23.01 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 122.754 0.422 . . . . 0.0 111.105 -178.424 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.82 -10.24 68.38 Favored Glycine 0 C--N 1.34 0.783 0 CA-C-N 115.196 -0.911 . . . . 0.0 114.154 -176.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.62 156.83 36.33 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-N 117.482 0.641 . . . . 0.0 110.847 177.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.443 HG22 ' HG3' ' A' ' 90' ' ' GLU . 99.2 t -109.08 124.39 65.71 Favored 'Isoleucine or valine' 0 C--O 1.242 0.699 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 175.042 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.1 m -105.58 146.19 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 172.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -94.73 139.24 31.52 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 124.206 1.003 . . . . 0.0 109.011 176.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 76.7 p -138.09 177.38 7.92 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 124.799 1.24 . . . . 0.0 107.816 177.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.7 m-80 -84.04 8.93 13.77 Favored 'General case' 0 N--CA 1.481 1.092 0 O-C-N 122.339 -0.226 . . . . 0.0 111.419 175.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 62.8 mt -104.8 -14.22 15.6 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 123.386 0.674 . . . . 0.0 110.498 171.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 134.7 -148.49 19.54 Favored Glycine 0 C--N 1.343 0.942 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 -176.023 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -101.9 145.9 28.58 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 176.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.1 t -129.82 141.28 46.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 C-N-CA 123.62 0.768 . . . . 0.0 109.706 -176.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.571 ' HG2' HD11 ' A' ' 88' ' ' ILE . 26.8 mmt180 -81.14 139.17 35.76 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 170.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 67.3 t -84.62 103.74 12.12 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.747 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 169.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 72.1 p -100.06 -17.29 17.55 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.176 0.59 . . . . 0.0 110.854 -171.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 60.2 p -118.67 179.63 4.08 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.966 0.906 . . . . 0.0 109.963 176.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 14.4 ptp180 -78.75 151.85 77.13 Favored Pre-proline 0 CA--C 1.552 1.032 0 C-N-CA 123.082 0.553 . . . . 0.0 110.645 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.652 ' HA ' HG13 ' A' ' 83' ' ' ILE . 85.1 Cg_endo -76.41 16.07 0.93 Allowed 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 122.879 2.386 . . . . 0.0 114.58 -178.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.81 58.88 0.42 Allowed Glycine 0 C--N 1.346 1.093 0 N-CA-C 112.216 -0.354 . . . . 0.0 112.216 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 -118.83 110.26 17.0 Favored 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 171.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.3 t70 67.62 -1.37 1.64 Allowed 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 124.433 1.093 . . . . 0.0 111.217 -169.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.47 5.83 60.1 Favored Glycine 0 C--N 1.349 1.3 0 CA-C-O 119.479 -0.623 . . . . 0.0 112.677 -174.355 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 11.4 p -126.26 164.29 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 123.435 0.694 . . . . 0.0 111.07 -175.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.652 HG13 ' HA ' ' A' ' 77' ' ' PRO . 3.4 mp -109.61 147.02 14.32 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 124.473 1.109 . . . . 0.0 108.664 178.263 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -119.69 155.82 31.68 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 123.596 0.759 . . . . 0.0 109.345 169.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.63 -175.12 36.57 Favored Glycine 0 C--N 1.345 1.065 0 N-CA-C 114.017 0.367 . . . . 0.0 114.017 -176.286 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.6 m -130.71 140.37 48.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 C-N-CA 123.469 0.707 . . . . 0.0 110.419 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 33.6 tp -75.47 112.85 12.22 Favored 'General case' 0 CA--C 1.549 0.937 0 CA-C-O 121.303 0.573 . . . . 0.0 111.624 -172.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.571 HD11 ' HG2' ' A' ' 72' ' ' ARG . 9.3 pt -110.02 179.01 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.19 0 C-N-CA 125.059 1.344 . . . . 0.0 110.488 178.062 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 47.5 mmt-85 -132.03 62.48 1.64 Allowed 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 123.438 0.695 . . . . 0.0 109.412 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.443 ' HG3' HG22 ' A' ' 63' ' ' VAL . 37.6 mm-40 -68.77 -63.06 1.13 Allowed 'General case' 0 N--CA 1.491 1.605 0 CA-C-O 121.464 0.65 . . . . 0.0 110.09 177.736 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 70.6 mt . . . . . 0 C--O 1.242 0.66 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 172.029 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.5 ' HB ' ' HB ' ' A' ' 40' ' ' ILE . 6.4 m . . . . . 0 CA--C 1.547 0.843 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 22.9 mmt85 -104.95 134.31 48.28 Favored 'General case' 0 C--O 1.244 0.768 0 C-N-CA 124.275 1.03 . . . . 0.0 109.45 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.4 tt -140.29 135.91 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 123.995 0.918 . . . . 0.0 109.394 -178.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 20.7 m-80 -87.14 103.36 15.33 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.5 t -98.42 110.11 25.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 C-N-CA 123.884 0.874 . . . . 0.0 109.196 -172.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.457 HG22 HG22 ' A' ' 35' ' ' VAL . 38.2 t -92.66 103.54 14.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -60.51 116.82 19.72 Favored Pre-proline 0 CA--C 1.549 0.918 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -76.75 -11.17 18.43 Favored 'Trans proline' 0 C--N 1.363 1.326 0 C-N-CA 122.958 2.439 . . . . 0.0 113.379 -174.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -81.89 -52.47 7.06 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 123.087 0.555 . . . . 0.0 109.583 -176.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 65.4 p -96.37 -31.85 12.66 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 114.774 -1.103 . . . . 0.0 112.026 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 94.03 8.61 60.21 Favored Glycine 0 N--CA 1.475 1.247 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.494 -173.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.7 mmtp -72.66 108.92 5.93 Favored 'General case' 0 C--N 1.359 0.982 0 C-N-CA 123.18 0.592 . . . . 0.0 111.678 -177.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.457 HG22 HG22 ' A' ' 28' ' ' VAL . 24.8 t -82.91 120.17 33.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 172.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 13.1 tp10 -140.29 130.33 24.83 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.463 0.705 . . . . 0.0 109.479 -177.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 46.0 mt -78.0 103.79 5.37 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -179.025 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.419 ' HB2' ' HB ' ' A' ' 66' ' ' THR . . . -89.83 166.12 13.72 Favored 'General case' 0 C--O 1.24 0.558 0 C-N-CA 123.694 0.798 . . . . 0.0 111.037 177.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 -114.39 124.94 53.2 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 115.314 -0.857 . . . . 0.0 108.925 176.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.5 ' HB ' ' HB ' ' A' ' 23' ' ' THR . 67.8 mt -79.79 111.37 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 C-N-CA 122.958 0.503 . . . . 0.0 109.775 -173.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 71.9 mtt180 -64.86 -46.83 80.19 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 123.798 0.839 . . . . 0.0 110.376 176.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 62.5 t30 -164.5 172.51 13.21 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.932 -170.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 25.2 m . . . . . 0 CA--C 1.549 0.929 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 170.644 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 50.1 mt . . . . . 0 C--O 1.241 0.635 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 71.3 mt -61.98 116.93 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 114.372 -1.285 . . . . 0.0 109.952 -178.174 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' THR . . . . . 0.429 ' HA ' ' HG2' ' A' ' 77' ' ' PRO . 40.6 p -126.8 167.2 16.11 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 124.073 0.949 . . . . 0.0 110.017 -177.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 32.5 ttp180 -64.03 138.5 58.49 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 123.127 0.571 . . . . 0.0 110.269 177.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.32 -39.17 3.04 Favored Glycine 0 C--N 1.335 0.521 0 CA-C-O 119.926 -0.374 . . . . 0.0 112.778 -176.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -61.63 135.87 57.79 Favored 'General case' 0 C--N 1.356 0.859 0 C-N-CA 123.665 0.786 . . . . 0.0 110.821 179.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 42.2 t -87.51 133.15 31.01 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 176.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 18.4 m -113.52 150.5 15.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 C-N-CA 124.171 0.989 . . . . 0.0 109.024 177.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -95.65 125.44 40.24 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 106.098 -1.815 . . . . 0.0 106.098 174.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.419 ' HB ' ' HB2' ' A' ' 38' ' ' ALA . 61.3 p -122.05 177.71 5.21 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 26.7 p-10 -69.54 -18.26 63.65 Favored 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.063 175.08 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.6 mt -85.12 -43.7 13.63 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 122.965 0.506 . . . . 0.0 110.582 174.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 155.93 -150.8 22.26 Favored Glycine 0 C--N 1.344 0.984 0 N-CA-C 111.925 -0.47 . . . . 0.0 111.925 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -79.94 126.02 30.48 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-N 117.488 0.644 . . . . 0.0 109.335 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 57.7 t -125.07 138.2 55.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 123.741 0.817 . . . . 0.0 110.638 -178.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.585 ' HG2' HD11 ' A' ' 88' ' ' ILE . 17.8 mmt180 -83.65 131.46 34.95 Favored 'General case' 0 N--CA 1.483 1.188 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 168.368 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.508 HG11 ' HG3' ' A' ' 77' ' ' PRO . 66.3 t -79.02 105.86 9.04 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 169.251 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 41.6 p -93.8 -30.94 14.58 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 123.392 0.677 . . . . 0.0 110.727 -171.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 49.0 m -96.88 178.05 5.42 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.248 177.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.764 ' HB2' ' HB2' ' A' ' 79' ' ' GLN . 80.2 mtp180 -74.36 124.52 89.94 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.109 170.288 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.508 ' HG3' HG11 ' A' ' 73' ' ' VAL . 32.0 Cg_exo -62.12 104.01 0.32 Allowed 'Trans proline' 0 C--N 1.373 1.841 0 C-N-CA 122.481 2.12 . . . . 0.0 111.293 173.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.34 24.82 17.86 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-N 116.06 -0.518 . . . . 0.0 113.347 -178.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . 0.764 ' HB2' ' HB2' ' A' ' 76' ' ' ARG . 24.7 tm0? -65.9 -58.65 5.09 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 176.329 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -84.12 -9.3 58.69 Favored 'General case' 0 N--CA 1.487 1.377 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.763 173.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 117.33 -53.14 0.65 Allowed Glycine 0 C--N 1.336 0.559 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -163.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 10.1 p -87.03 165.7 2.09 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.131 0 C-N-CA 123.886 0.874 . . . . 0.0 110.703 177.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 18.5 mt -96.38 148.49 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.888 0 C-N-CA 124.039 0.936 . . . . 0.0 108.605 173.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 17.4 m-80 -131.75 149.01 52.61 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 123.252 0.621 . . . . 0.0 109.699 177.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.45 -173.27 32.92 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 115.735 -0.666 . . . . 0.0 114.092 -174.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.6 m -129.79 141.72 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 C-N-CA 123.551 0.74 . . . . 0.0 110.107 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 20.1 tp -75.88 105.31 6.85 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 121.022 0.439 . . . . 0.0 109.924 -178.003 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.585 HD11 ' HG2' ' A' ' 72' ' ' ARG . 11.0 pt -107.21 -173.46 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 123.432 0.693 . . . . 0.0 110.222 -179.413 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 60.7 mtt85 -139.95 77.47 1.61 Allowed 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 123.146 0.578 . . . . 0.0 109.734 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.576 ' HG2' HD12 ' A' ' 88' ' ' ILE . 56.5 mm-40 -68.58 -65.51 0.69 Allowed 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 167.023 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 60.7 mt . . . . . 0 CA--C 1.549 0.927 0 CA-C-N 114.429 -1.26 . . . . 0.0 108.934 170.881 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.451 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 6.9 m . . . . . 0 N--CA 1.471 0.61 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 38.6 mmt180 -107.12 145.13 32.85 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.731 0.812 . . . . 0.0 110.362 -177.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.9 tt -147.41 144.34 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 C-N-CA 124.167 0.987 . . . . 0.0 109.441 175.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -91.59 100.85 13.52 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 173.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 62.0 t -89.56 111.03 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 123.808 0.843 . . . . 0.0 109.247 -175.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.507 HG22 HG23 ' A' ' 35' ' ' VAL . 41.4 t -101.45 108.72 24.12 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 C-N-CA 123.666 0.786 . . . . 0.0 109.333 -176.303 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -58.74 114.82 9.79 Favored Pre-proline 0 N--CA 1.473 0.715 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 171.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -78.1 -5.89 15.42 Favored 'Trans proline' 0 C--N 1.363 1.334 0 C-N-CA 122.374 2.049 . . . . 0.0 112.911 -175.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -95.86 -53.31 3.73 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 123.827 0.851 . . . . 0.0 111.203 -178.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 59.3 p -90.67 -30.85 16.88 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.485 0.714 . . . . 0.0 111.44 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.9 -11.54 57.52 Favored Glycine 0 C--N 1.343 0.952 0 CA-C-N 116.139 -0.482 . . . . 0.0 113.158 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -68.53 124.73 24.38 Favored 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 123.482 0.713 . . . . 0.0 111.426 -170.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.507 HG23 HG22 ' A' ' 28' ' ' VAL . 22.2 t -95.95 133.99 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 175.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -140.99 137.19 32.84 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 171.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 39.7 mt -79.82 129.5 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 178.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.29 167.71 18.05 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 123.88 0.872 . . . . 0.0 111.289 -171.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 23' ' ' THR . 56.0 mm-40 -104.32 118.77 37.43 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 124.441 1.096 . . . . 0.0 110.98 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.463 HG21 ' HB ' ' A' ' 64' ' ' VAL . 68.1 mt -78.85 111.4 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 122.704 0.402 . . . . 0.0 110.544 -175.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -82.81 -56.48 3.8 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.358 1.063 . . . . 0.0 111.623 178.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.565 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 33.9 t30 -106.25 133.95 50.15 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 175.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.42 ' HA ' HG13 ' A' ' 64' ' ' VAL . 33.6 m . . . . . 0 N--CA 1.477 0.922 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -175.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 64.4 mt . . . . . 0 C--O 1.242 0.696 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 57.7 mt -65.83 119.85 11.59 Favored 'Isoleucine or valine' 0 C--N 1.348 0.515 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 173.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 26.7 m -118.1 147.97 42.76 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -178.139 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 31.6 ttt-85 -60.69 134.09 56.74 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 172.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.57 -41.71 2.74 Favored Glycine 0 C--N 1.346 1.112 0 CA-C-O 119.892 -0.393 . . . . 0.0 112.43 -175.152 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -60.56 134.89 57.52 Favored 'General case' 0 C--N 1.357 0.896 0 C-N-CA 123.53 0.732 . . . . 0.0 110.708 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 98.2 t -73.55 120.48 22.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 O-C-N 123.722 0.639 . . . . 0.0 110.634 -178.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.463 ' HB ' HG21 ' A' ' 40' ' ' ILE . 26.3 m -105.41 126.89 60.54 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.294 171.167 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.565 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 33.8 tt0 -92.68 134.82 34.65 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 106.087 -1.82 . . . . 0.0 106.087 177.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 71.3 p -117.22 -178.59 3.48 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 -177.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -59.44 -23.15 62.44 Favored 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 123.057 0.543 . . . . 0.0 110.896 171.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 89.0 mt -88.79 -51.76 5.48 Favored 'General case' 0 C--N 1.353 0.733 0 C-N-CA 124.267 1.027 . . . . 0.0 110.018 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 164.53 -170.36 39.65 Favored Glycine 0 C--N 1.337 0.608 0 CA-C-N 115.549 -0.751 . . . . 0.0 112.155 -177.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.467 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 14.0 m120 -75.73 143.49 42.02 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.393 0.677 . . . . 0.0 110.772 -174.116 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.2 t -137.04 147.48 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 123.857 0.863 . . . . 0.0 110.079 -174.049 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.636 ' HG2' HD12 ' A' ' 88' ' ' ILE . 36.4 mmt180 -93.01 120.75 33.64 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 168.454 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 43.9 t -75.82 98.65 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 71.1 p -74.36 -34.52 63.4 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.715 0.806 . . . . 0.0 111.417 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' SER . . . . . 0.522 ' HB2' ' HB2' ' A' ' 84' ' ' ASN . 39.2 t -79.8 170.08 17.01 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.778 0.831 . . . . 0.0 111.581 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -82.73 106.43 6.82 Favored Pre-proline 0 CA--C 1.546 0.816 0 N-CA-C 107.246 -1.391 . . . . 0.0 107.246 166.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -82.16 69.62 7.41 Favored 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 123.443 2.762 . . . . 0.0 112.44 -172.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.09 -32.15 0.1 Allowed Glycine 0 C--N 1.333 0.37 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.817 -178.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -64.58 111.37 2.68 Favored 'General case' 0 C--N 1.359 0.981 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 174.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.4 t70 76.71 -22.95 0.26 Allowed 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 125.338 1.455 . . . . 0.0 112.384 -177.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 102.55 -8.58 54.97 Favored Glycine 0 C--N 1.345 1.078 0 CA-C-O 119.932 -0.371 . . . . 0.0 112.487 -175.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -86.57 116.95 30.1 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 CA-C-O 121.641 0.734 . . . . 0.0 109.94 -179.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.6 mt -98.54 132.75 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 175.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.522 ' HB2' ' HB2' ' A' ' 75' ' ' SER . 66.3 m-20 -136.07 154.52 51.0 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 123.725 0.81 . . . . 0.0 109.03 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.93 -173.98 37.12 Favored Glycine 0 C--N 1.34 0.754 0 O-C-N 123.385 0.428 . . . . 0.0 113.992 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.7 m -123.47 134.24 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.075 0 C-N-CA 124.028 0.931 . . . . 0.0 110.364 177.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 46.7 tp -66.21 127.55 32.62 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 123.182 0.593 . . . . 0.0 111.447 -176.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.636 HD12 ' HG2' ' A' ' 72' ' ' ARG . 33.2 pt -126.21 -176.67 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 C-N-CA 125.189 1.396 . . . . 0.0 109.378 173.25 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 82.0 mtt85 -137.83 88.29 2.32 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 123.321 0.649 . . . . 0.0 109.923 -177.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -100.85 -48.22 4.54 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 123.4 0.68 . . . . 0.0 109.44 178.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 88.8 mt . . . . . 0 N--CA 1.476 0.855 0 C-N-CA 124.911 1.284 . . . . 0.0 109.793 -178.043 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.513 HG23 HD13 ' A' ' 40' ' ' ILE . 33.0 m . . . . . 0 N--CA 1.473 0.715 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.529 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 17.0 mtm180 -130.81 166.0 21.77 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.918 0.887 . . . . 0.0 111.497 -173.019 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 14.0 tt -150.88 150.28 13.54 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.447 -170.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.8 m-80 -94.08 100.39 12.51 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 175.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.7 t -88.7 112.39 23.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.022 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.41 HG11 HG22 ' A' ' 35' ' ' VAL . 17.3 t -101.41 100.6 10.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.437 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -178.206 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -58.38 120.39 43.93 Favored Pre-proline 0 CA--C 1.552 1.021 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 177.311 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -71.78 -15.75 29.88 Favored 'Trans proline' 0 C--N 1.366 1.469 0 C-N-CA 122.845 2.364 . . . . 0.0 113.555 -172.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -91.75 -52.12 4.9 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.919 0.487 . . . . 0.0 110.325 -175.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.3 p -88.66 -32.85 17.81 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.637 0.775 . . . . 0.0 112.375 -177.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.64 3.9 68.29 Favored Glycine 0 N--CA 1.479 1.559 0 CA-C-O 120.097 -0.28 . . . . 0.0 113.14 -174.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.0 mmtm -63.05 109.24 1.42 Allowed 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.753 0.821 . . . . 0.0 111.692 179.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.41 HG22 HG11 ' A' ' 28' ' ' VAL . 41.1 t -90.45 111.82 23.99 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 172.161 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -129.62 131.42 46.46 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.608 0.763 . . . . 0.0 110.233 -174.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 53.4 mt -76.26 115.23 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.75 153.81 40.38 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.946 0.898 . . . . 0.0 109.977 -174.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.529 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 2.7 mp0 -93.58 124.09 37.34 Favored 'General case' 0 C--O 1.244 0.79 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 -176.065 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.513 HD13 HG23 ' A' ' 23' ' ' THR . 56.0 mt -75.04 109.46 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -178.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 67.8 mtp180 -71.72 -42.62 67.12 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 124.59 1.156 . . . . 0.0 110.349 -178.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -159.64 170.13 22.25 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-N 114.822 -1.081 . . . . 0.0 108.646 -176.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.649 HG13 HG12 ' A' ' 64' ' ' VAL . 3.5 m . . . . . 0 CA--C 1.545 0.77 0 C-N-CA 124.712 1.205 . . . . 0.0 107.964 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.3 mt . . . . . 0 CA--C 1.553 1.09 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.9 mt -82.68 151.92 4.04 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.701 -179.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 75.8 p -128.69 170.53 13.17 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.852 0.861 . . . . 0.0 109.615 174.183 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.3 ttm180 -71.9 138.14 47.94 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 171.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.77 -14.62 51.43 Favored Glycine 0 C--N 1.343 0.97 0 C-N-CA 123.249 0.452 . . . . 0.0 113.028 -177.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -70.85 141.36 51.27 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 123.334 0.653 . . . . 0.0 109.486 177.194 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 77.1 t -91.16 118.42 36.39 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.81 -179.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.649 HG12 HG13 ' A' ' 43' ' ' VAL . 34.1 m -103.31 135.85 38.88 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.422 174.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -86.27 127.01 34.71 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 174.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 32.6 p -128.6 174.32 9.5 Favored 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.501 ' ND2' ' HB2' ' A' ' 39' ' ' GLU . 94.2 m-20 -65.03 -12.64 52.77 Favored 'General case' 0 N--CA 1.482 1.128 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 178.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.1 mt -95.6 -47.89 6.04 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 176.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 167.57 -161.96 35.76 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.828 178.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -75.12 142.69 43.58 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.189 0.596 . . . . 0.0 110.015 175.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.0 t -135.88 146.45 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.268 0 C-N-CA 123.155 0.582 . . . . 0.0 110.111 -174.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.625 ' HG2' HD12 ' A' ' 88' ' ' ILE . 33.7 mmt180 -91.65 119.7 31.77 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 171.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.2 t -73.36 122.62 26.64 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.2 p -108.56 -32.67 7.29 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.536 0.735 . . . . 0.0 110.26 -172.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.6 t -97.73 -178.77 4.22 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.62 0.768 . . . . 0.0 110.147 178.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.44 128.92 73.65 Favored Pre-proline 0 CA--C 1.552 1.033 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 174.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -68.66 103.66 1.02 Allowed 'Trans proline' 0 C--N 1.373 1.843 0 C-N-CA 123.024 2.483 . . . . 0.0 113.837 -173.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 73.37 -0.78 46.57 Favored Glycine 0 C--N 1.344 1.004 0 CA-C-N 115.217 -0.901 . . . . 0.0 114.961 171.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 31.8 mm-40 -67.81 -43.51 79.49 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 123.28 0.632 . . . . 0.0 111.689 -172.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.524 ' HB3' HG12 ' A' ' 82' ' ' VAL . 24.6 t70 -89.06 3.68 50.9 Favored 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 123.618 0.767 . . . . 0.0 110.75 175.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 81.42 37.16 18.37 Favored Glycine 0 C--N 1.343 0.933 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -171.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.524 HG12 ' HB3' ' A' ' 80' ' ' ASP . 13.3 p -162.28 140.54 2.26 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 CA-C-N 114.541 -0.83 . . . . 0.0 109.809 -174.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.4 mt -121.61 128.8 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 N-CA-C 104.904 -2.258 . . . . 0.0 104.904 165.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -120.81 153.35 37.21 Favored 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -172.7 179.66 44.06 Favored Glycine 0 N--CA 1.446 -0.643 0 O-C-N 123.99 0.806 . . . . 0.0 113.588 175.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.1 m -123.36 136.16 60.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 124.05 0.94 . . . . 0.0 110.007 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 27.0 tp -66.56 134.16 51.81 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 123.011 0.524 . . . . 0.0 111.133 -174.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.625 HD12 ' HG2' ' A' ' 72' ' ' ARG . 34.1 pt -135.06 175.1 11.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.785 1.234 . . . . 0.0 109.59 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 39.1 mtt180 -130.88 84.15 2.17 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.451 0.7 . . . . 0.0 109.284 -176.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.8 mm-40 -95.8 -77.05 0.48 Allowed 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 77.4 mt . . . . . 0 C--O 1.238 0.486 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 169.096 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 26.3 m . . . . . 0 CA--C 1.543 0.706 0 CA-C-O 120.807 0.337 . . . . 0.0 110.35 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 17.3 tpp85 -110.22 141.48 43.1 Favored 'General case' 0 C--O 1.241 0.637 0 C-N-CA 123.561 0.745 . . . . 0.0 110.446 -171.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 16.2 tt -139.94 147.41 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.953 0.901 . . . . 0.0 109.506 178.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -97.59 102.38 14.13 Favored 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 170.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.536 HG21 HG22 ' A' ' 71' ' ' VAL . 96.5 t -82.91 106.14 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 C-N-CA 123.957 0.903 . . . . 0.0 109.698 -177.287 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 86' ' ' VAL . 40.0 t -97.21 102.86 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -56.1 116.59 12.86 Favored Pre-proline 0 CA--C 1.549 0.923 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 173.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -72.91 -19.48 23.39 Favored 'Trans proline' 0 C--N 1.368 1.556 0 C-N-CA 122.332 2.022 . . . . 0.0 113.378 -172.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -81.88 -51.21 8.32 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 123.264 0.626 . . . . 0.0 110.465 -175.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.7 p -92.31 -25.78 18.42 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.876 0.87 . . . . 0.0 111.446 -177.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.2 4.65 71.18 Favored Glycine 0 N--CA 1.473 1.113 0 CA-C-O 119.597 -0.557 . . . . 0.0 113.119 -178.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -72.08 112.68 8.37 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.157 0.583 . . . . 0.0 111.811 -173.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.447 HG23 HG21 ' A' ' 28' ' ' VAL . 39.1 t -82.6 115.18 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 171.503 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -130.79 130.0 43.13 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.96 0.904 . . . . 0.0 109.123 -179.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 59.4 mt -78.93 125.61 38.42 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 C-N-CA 122.91 0.484 . . . . 0.0 110.139 -177.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -134.17 170.99 14.86 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 124.575 1.15 . . . . 0.0 110.02 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -117.79 135.73 53.87 Favored 'General case' 0 C--O 1.243 0.748 0 C-N-CA 123.329 0.652 . . . . 0.0 109.547 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.1 mt -78.51 112.35 16.43 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.726 0 O-C-N 123.893 0.746 . . . . 0.0 110.311 -175.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 72.6 mtp180 -64.69 -53.93 39.6 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.842 1.257 . . . . 0.0 110.365 175.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 55.5 t30 -143.75 157.65 44.24 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.522 0.729 . . . . 0.0 109.535 -176.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 55.3 t . . . . . 0 N--CA 1.485 1.311 0 C-N-CA 122.925 0.49 . . . . 0.0 110.374 179.134 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 41.1 mm . . . . . 0 C--O 1.241 0.63 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.4 mt -72.71 118.26 17.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 CA-C-N 114.726 -1.125 . . . . 0.0 108.222 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 7.5 p -131.61 170.46 14.73 Favored 'General case' 0 C--O 1.243 0.726 0 C-N-CA 124.872 1.269 . . . . 0.0 108.952 -175.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -69.52 130.79 43.43 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 177.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.95 -15.34 63.62 Favored Glycine 0 C--N 1.345 1.029 0 CA-C-O 119.48 -0.622 . . . . 0.0 113.531 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.62 134.3 49.74 Favored 'General case' 0 C--O 1.246 0.878 0 C-N-CA 122.957 0.503 . . . . 0.0 110.342 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 67.1 t -88.55 112.88 24.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 176.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.3 m -102.94 138.56 26.73 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -88.11 126.45 35.12 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 61.3 p -134.0 172.49 12.75 Favored 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 124.097 0.959 . . . . 0.0 109.091 -175.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -71.88 -13.12 61.57 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 112.331 0.493 . . . . 0.0 112.331 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 88.5 mt -97.12 -15.34 21.0 Favored 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 123.3 0.64 . . . . 0.0 111.336 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.09 -147.88 19.52 Favored Glycine 0 C--N 1.341 0.848 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 -173.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -109.75 143.0 40.17 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 117.486 0.643 . . . . 0.0 109.404 177.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.536 HG22 HG21 ' A' ' 27' ' ' VAL . 22.0 t -128.73 144.96 36.42 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 123.425 0.69 . . . . 0.0 109.862 -174.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.607 ' HG2' HD13 ' A' ' 88' ' ' ILE . 10.5 mmt180 -94.94 123.71 38.56 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 168.295 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 56.9 t -76.22 94.92 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.4 p -85.15 -39.84 17.42 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.307 0.643 . . . . 0.0 111.109 -178.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.4 m -77.65 164.55 25.22 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.911 173.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 24.3 mmt180 -65.88 130.23 94.41 Favored Pre-proline 0 CA--C 1.548 0.87 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 172.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -77.62 43.16 1.29 Allowed 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 123.502 2.801 . . . . 0.0 112.387 175.586 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -170.95 -137.3 2.27 Favored Glycine 0 C--N 1.334 0.461 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -172.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 21.2 tm0? 67.88 -72.33 0.1 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 124.608 1.163 . . . . 0.0 110.136 -177.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.407 ' HB3' HG11 ' A' ' 82' ' ' VAL . 33.3 t70 -91.45 -12.93 33.25 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 124.211 1.004 . . . . 0.0 110.31 171.106 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 94.56 -6.49 70.9 Favored Glycine 0 C--N 1.343 0.968 0 C-N-CA 123.386 0.517 . . . . 0.0 112.981 -174.06 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.407 HG11 ' HB3' ' A' ' 80' ' ' ASP . 14.5 p -92.83 141.42 14.68 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.512 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 31.5 mt -96.09 146.87 6.58 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -152.66 152.07 31.33 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -169.0 -167.34 29.48 Favored Glycine 0 C--N 1.343 0.972 0 CA-C-O 120.015 -0.325 . . . . 0.0 113.028 -178.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.509 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 35.9 m -116.46 132.68 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 123.776 0.83 . . . . 0.0 110.925 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 38.8 tp -71.63 106.07 3.91 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.463 0.705 . . . . 0.0 111.13 -176.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.607 HD13 ' HG2' ' A' ' 72' ' ' ARG . 41.4 pt -97.34 171.65 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.524 0.73 . . . . 0.0 110.262 175.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 16.7 mmt180 -115.22 21.15 14.4 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.671 0.788 . . . . 0.0 110.235 -173.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.43 ' HB2' HD11 ' A' ' 88' ' ' ILE . 33.9 tt0 -64.8 -75.9 0.08 Allowed 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.433 0.693 . . . . 0.0 112.657 -164.343 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 58.3 mt . . . . . 0 N--CA 1.482 1.16 0 CA-C-O 121.834 0.826 . . . . 0.0 110.316 -173.446 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 26.2 m . . . . . 0 CA--C 1.537 0.455 0 CA-C-O 120.547 0.213 . . . . 0.0 110.694 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.406 ' HD2' HG21 ' A' ' 37' ' ' ILE . 77.3 mmt-85 -102.21 134.8 44.89 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.418 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 14.2 tt -140.18 136.11 37.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 123.85 0.86 . . . . 0.0 109.745 -175.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.2 m-80 -85.55 100.59 12.02 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 177.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.2 t -87.4 108.23 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -176.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 40.9 t -95.54 101.67 12.7 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -63.83 116.43 26.69 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 175.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -71.47 -19.76 28.17 Favored 'Trans proline' 0 C--N 1.368 1.559 0 C-N-CA 123.232 2.621 . . . . 0.0 113.194 -171.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -92.67 -52.94 4.39 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 123.499 0.72 . . . . 0.0 110.822 -171.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 62.8 p -90.9 -27.83 18.5 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 123.424 0.69 . . . . 0.0 111.476 -177.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.62 4.73 69.87 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-N 116.416 -0.356 . . . . 0.0 113.369 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -71.45 118.74 14.65 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 123.293 0.637 . . . . 0.0 110.818 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.4 t -108.33 134.84 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 123.679 0.792 . . . . 0.0 108.908 177.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -152.22 148.81 28.02 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 122.87 0.468 . . . . 0.0 110.357 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.406 HG21 ' HD2' ' A' ' 24' ' ' ARG . 51.6 mt -87.12 98.31 7.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.89 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.21 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -95.87 172.21 8.16 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 124.282 1.033 . . . . 0.0 110.646 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -108.26 131.99 54.13 Favored 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 176.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.47 HG12 HG22 ' A' ' 66' ' ' THR . 57.1 mt -75.27 112.66 13.1 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 177.697 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 40.4 mtt-85 -73.11 -52.9 12.52 Favored 'General case' 0 N--CA 1.475 0.825 0 CA-C-O 122.253 1.025 . . . . 0.0 109.418 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.599 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 29.8 t30 -126.04 112.3 15.71 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 113.365 -1.743 . . . . 0.0 108.73 -169.663 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.8 m . . . . . 0 N--CA 1.478 0.933 0 C-N-CA 123.175 0.59 . . . . 0.0 111.282 -179.013 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.1 mt . . . . . 0 CA--C 1.535 0.366 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 82.9 mt -93.75 128.68 44.97 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.379 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 38.1 p -126.3 164.29 21.37 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.569 0.748 . . . . 0.0 109.657 -177.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 45.2 ttp180 -73.47 141.41 46.83 Favored 'General case' 0 N--CA 1.482 1.138 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 176.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.88 2.57 90.33 Favored Glycine 0 C--N 1.345 1.06 0 O-C-N 123.198 0.311 . . . . 0.0 112.971 -176.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.0 163.12 16.46 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 123.525 0.73 . . . . 0.0 110.774 179.285 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 38.8 t -110.01 124.85 67.09 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 173.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 20.9 m -112.88 168.45 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 168.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.599 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 28.0 tt0 -115.19 134.33 55.24 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 170.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.47 HG22 HG12 ' A' ' 40' ' ' ILE . 43.8 p -123.87 -177.77 3.85 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.843 0.857 . . . . 0.0 109.551 -173.611 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.8 m-20 -58.38 -28.72 65.42 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 122.933 0.493 . . . . 0.0 111.318 175.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 77.8 mt -90.07 -45.71 8.97 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.258 0.623 . . . . 0.0 110.748 -178.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 165.66 -166.04 38.29 Favored Glycine 0 N--CA 1.477 1.416 0 CA-C-O 119.715 -0.492 . . . . 0.0 112.093 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -73.26 132.98 43.78 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 117.653 0.727 . . . . 0.0 109.843 176.609 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 65.2 t -128.74 144.89 36.67 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.905 0 C-N-CA 124.402 1.081 . . . . 0.0 110.29 -174.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.517 ' HG2' HD11 ' A' ' 88' ' ' ILE . 33.2 mmt180 -84.98 121.25 27.51 Favored 'General case' 0 N--CA 1.479 1.017 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 168.309 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.5 t -73.21 122.88 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 70.9 p -107.72 -23.9 11.92 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 123.179 0.592 . . . . 0.0 110.999 -176.129 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 45.7 m -93.05 176.92 6.23 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-O 121.309 0.576 . . . . 0.0 111.751 176.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 30.8 mmt180 -106.65 127.09 28.8 Favored Pre-proline 0 C--O 1.241 0.635 0 CA-C-N 114.839 -1.073 . . . . 0.0 108.404 171.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -60.24 120.24 7.89 Favored 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 123.228 2.619 . . . . 0.0 112.474 -176.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 91.38 -36.68 3.56 Favored Glycine 0 C--N 1.341 0.824 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.994 176.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 14.3 mm100 -64.24 -31.81 73.15 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.691 0.796 . . . . 0.0 111.836 -174.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -106.24 6.23 30.55 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.718 0.807 . . . . 0.0 111.566 178.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 85.57 -61.32 4.59 Favored Glycine 0 C--N 1.349 1.276 0 C-N-CA 123.086 0.374 . . . . 0.0 112.273 -175.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -113.26 159.52 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 124.467 1.107 . . . . 0.0 108.793 175.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.418 ' O ' ' HA ' ' A' ' 25' ' ' ILE . 41.1 mt -92.52 147.68 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 174.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -125.37 162.98 23.58 Favored 'General case' 0 C--O 1.246 0.888 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 171.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.28 179.38 41.41 Favored Glycine 0 C--N 1.335 0.519 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.952 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.2 m -121.42 131.0 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 C-N-CA 123.433 0.693 . . . . 0.0 109.437 175.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 21.4 tp -67.26 131.27 45.42 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.132 0.573 . . . . 0.0 110.006 -177.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.517 HD11 ' HG2' ' A' ' 72' ' ' ARG . 33.4 pt -123.15 161.12 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 121.665 0.745 . . . . 0.0 111.276 -176.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 26.5 mmt180 -115.94 8.29 14.63 Favored 'General case' 0 CA--C 1.548 0.884 0 CA-C-N 114.195 -1.366 . . . . 0.0 109.636 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -60.28 -62.14 2.09 Favored 'General case' 0 C--N 1.358 0.951 0 C-N-CA 123.959 0.904 . . . . 0.0 112.237 -172.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 22.4 mt . . . . . 0 N--CA 1.473 0.721 0 O-C-N 123.364 0.415 . . . . 0.0 111.035 -179.031 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.432 HG23 HD12 ' A' ' 40' ' ' ILE . 91.4 m . . . . . 0 CA--C 1.548 0.868 0 CA-C-O 121.624 0.726 . . . . 0.0 111.177 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.511 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 36.8 mtm180 -127.23 170.1 12.79 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.835 1.254 . . . . 0.0 110.81 177.276 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.1 tt -135.7 136.21 50.51 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-N 114.566 -1.197 . . . . 0.0 108.95 -179.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 -89.78 102.1 14.8 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.421 HG22 HG13 ' A' ' 71' ' ' VAL . 58.5 t -98.78 136.38 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 123.873 0.869 . . . . 0.0 110.563 -170.006 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.578 HG23 HG23 ' A' ' 35' ' ' VAL . 30.1 t -122.0 122.29 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -63.98 124.43 85.15 Favored Pre-proline 0 N--CA 1.48 1.027 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 171.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -68.79 -20.0 40.31 Favored 'Trans proline' 0 CA--C 1.554 1.488 0 C-N-CA 122.145 1.897 . . . . 0.0 112.476 178.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.453 ' HG3' HG23 ' A' ' 32' ' ' THR . 12.8 pt-20 -88.2 -51.35 5.82 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.02 0.928 . . . . 0.0 112.115 -176.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.453 HG23 ' HG3' ' A' ' 31' ' ' GLU . 70.4 p -97.87 -21.49 16.87 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.125 0.57 . . . . 0.0 111.792 -173.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.8 5.28 89.54 Favored Glycine 0 C--N 1.349 1.269 0 CA-C-O 119.682 -0.51 . . . . 0.0 113.524 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -73.68 123.89 24.94 Favored 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 123.27 0.628 . . . . 0.0 111.352 -174.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.578 HG23 HG23 ' A' ' 28' ' ' VAL . 24.8 t -95.73 128.86 46.55 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.712 0 C-N-CA 123.872 0.869 . . . . 0.0 109.422 176.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -141.42 133.8 28.18 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 124.483 1.113 . . . . 0.0 108.574 175.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 46.6 mt -79.32 98.92 3.14 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.449 ' HB2' ' HB ' ' A' ' 66' ' ' THR . . . -86.02 158.93 19.73 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.703 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.511 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 38.9 mt-10 -101.82 124.95 48.31 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.48 0.712 . . . . 0.0 109.433 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.432 HD12 HG23 ' A' ' 23' ' ' THR . 61.7 mt -76.44 108.69 9.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 47.8 mtt180 -82.87 -53.26 6.0 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.261 1.024 . . . . 0.0 110.672 -179.389 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -146.04 160.07 42.39 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -176.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.9 m . . . . . 0 C--O 1.246 0.877 0 C-N-CA 123.523 0.729 . . . . 0.0 112.03 -174.313 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 72.9 mt . . . . . 0 N--CA 1.472 0.646 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.2 mt -115.29 140.45 36.64 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.558 0 C-N-CA 124.488 1.115 . . . . 0.0 108.434 179.6 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 33.9 p -126.15 174.4 8.52 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 124.134 0.974 . . . . 0.0 109.149 178.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 52.7 ttp180 -71.25 139.92 50.21 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 122.716 0.406 . . . . 0.0 110.154 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.76 -8.48 70.94 Favored Glycine 0 C--N 1.337 0.595 0 C-N-CA 123.644 0.64 . . . . 0.0 112.83 -177.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.94 134.54 52.21 Favored 'General case' 0 C--N 1.351 0.669 0 C-N-CA 123.611 0.765 . . . . 0.0 111.89 -177.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 44.1 t -90.76 112.87 25.69 Favored 'Isoleucine or valine' 0 C--N 1.344 0.341 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 169.624 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.6 m -106.26 147.13 12.07 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 123.482 0.713 . . . . 0.0 109.271 177.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -90.73 126.44 36.0 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 175.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.449 ' HB ' ' HB2' ' A' ' 38' ' ' ALA . 67.2 p -130.85 179.79 5.77 Favored 'General case' 0 C--O 1.239 0.552 0 C-N-CA 123.259 0.623 . . . . 0.0 109.774 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 19.2 p-10 -73.59 -14.69 61.23 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 123.341 0.656 . . . . 0.0 111.192 175.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.1 mt -91.16 -41.09 11.21 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 123.249 0.62 . . . . 0.0 110.325 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 155.79 -149.97 21.2 Favored Glycine 0 C--N 1.345 1.074 0 CA-C-N 116.239 -0.437 . . . . 0.0 112.056 175.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -78.91 128.49 33.38 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 173.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.421 HG13 HG22 ' A' ' 27' ' ' VAL . 48.7 t -126.85 140.33 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 122.792 0.437 . . . . 0.0 110.4 -178.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.627 ' HG2' HD12 ' A' ' 88' ' ' ILE . 29.2 mmt180 -88.89 131.5 35.09 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 169.461 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 82.2 t -76.87 106.72 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 171.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 40.5 p -96.38 -19.92 18.85 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.044 0.538 . . . . 0.0 110.92 -172.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' SER . . . . . 0.482 ' HB2' ' HB2' ' A' ' 84' ' ' ASN . 32.4 t -87.49 171.08 10.79 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.378 0.671 . . . . 0.0 110.391 175.32 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 -93.48 92.84 0.72 Allowed Pre-proline 0 CA--C 1.559 1.315 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 173.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -62.73 -46.36 11.41 Favored 'Trans proline' 0 C--N 1.384 2.422 0 C-N-CA 123.431 2.754 . . . . 0.0 113.958 -163.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -81.19 -13.5 80.71 Favored Glycine 0 C--N 1.345 1.039 0 CA-C-O 119.959 -0.356 . . . . 0.0 113.54 -177.201 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 18.5 mm-40 -90.14 -48.39 7.21 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 122.981 0.513 . . . . 0.0 111.352 -178.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -80.67 -14.05 58.48 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 122.82 0.448 . . . . 0.0 111.294 174.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 68.36 18.53 71.6 Favored Glycine 0 C--N 1.349 1.254 0 O-C-N 123.205 0.316 . . . . 0.0 112.785 -175.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 11.6 p -143.25 143.87 24.3 Favored 'Isoleucine or valine' 0 C--O 1.24 0.555 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 178.211 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 29.0 mt -106.37 117.63 52.5 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -176.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.482 ' HB2' ' HB2' ' A' ' 75' ' ' SER . 9.4 m120 -124.7 151.4 45.04 Favored 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.585 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.9 -178.26 34.72 Favored Glycine 0 C--N 1.339 0.733 0 N-CA-C 115.141 0.816 . . . . 0.0 115.141 -174.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.416 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 30.0 m -121.51 139.5 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.637 0.775 . . . . 0.0 110.147 175.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.3 tp -74.03 122.23 22.32 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.093 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.627 HD12 ' HG2' ' A' ' 72' ' ' ARG . 46.8 pt -124.06 -177.89 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 124.615 1.166 . . . . 0.0 109.198 175.208 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 29.5 mmm180 -139.45 90.67 2.43 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -176.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -88.95 -50.07 6.4 Favored 'General case' 0 N--CA 1.484 1.229 0 CA-C-O 121.496 0.665 . . . . 0.0 109.629 178.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 69.1 mt . . . . . 0 C--O 1.245 0.843 0 CA-C-N 114.508 -1.224 . . . . 0.0 109.735 176.402 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 52.8 m . . . . . 0 N--CA 1.47 0.557 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.1 mmt180 -117.74 152.81 34.52 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-O 121.469 0.652 . . . . 0.0 111.599 -173.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.515 ' HB ' HD12 ' A' ' 40' ' ' ILE . 15.8 tt -141.96 142.18 28.3 Favored 'Isoleucine or valine' 0 C--O 1.241 0.643 0 CA-C-N 114.139 -1.391 . . . . 0.0 109.054 176.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -90.82 100.82 13.61 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 173.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.6 t -86.17 112.85 23.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.538 0 C-N-CA 124.623 1.169 . . . . 0.0 109.205 -175.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.421 HG21 HG21 ' A' ' 35' ' ' VAL . 41.5 t -94.81 100.33 10.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.549 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 176.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -64.16 113.65 11.07 Favored Pre-proline 0 CA--C 1.546 0.821 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 172.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.52 -1.18 11.38 Favored 'Trans proline' 0 C--N 1.364 1.378 0 C-N-CA 122.518 2.146 . . . . 0.0 113.591 -172.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -91.97 -52.68 4.6 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.337 0.655 . . . . 0.0 109.325 -177.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 66.7 p -93.29 -32.58 14.26 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 124.468 1.107 . . . . 0.0 111.909 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 93.51 6.98 62.17 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.986 -173.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -69.89 107.77 3.7 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 123.08 0.552 . . . . 0.0 110.994 -178.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.421 HG21 HG21 ' A' ' 28' ' ' VAL . 23.6 t -90.9 119.92 38.91 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 172.597 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -142.52 143.48 32.54 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 122.993 0.517 . . . . 0.0 110.466 -174.302 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 62.1 mt -77.45 123.85 34.82 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.86 0 C-N-CA 123.555 0.742 . . . . 0.0 109.661 179.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.41 158.12 36.8 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 123.89 0.876 . . . . 0.0 110.149 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -97.74 121.05 39.19 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.515 HD12 ' HB ' ' A' ' 25' ' ' ILE . 54.7 mt -77.74 112.55 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 72.3 mtm180 -80.71 -38.21 29.24 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 124.512 1.125 . . . . 0.0 111.113 -178.098 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 47.4 t-20 -140.76 138.95 34.51 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.7 m . . . . . 0 N--CA 1.478 0.969 0 C-N-CA 123.324 0.65 . . . . 0.0 112.425 -176.584 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 15.8 tt . . . . . 0 N--CA 1.476 0.864 0 CA-C-O 121.268 0.556 . . . . 0.0 109.703 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 76.3 mt -91.58 143.56 11.02 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.698 0 C-N-CA 124.426 1.09 . . . . 0.0 109.723 175.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' THR . . . . . 0.431 HG21 ' HB2' ' A' ' 62' ' ' ALA . 3.3 t -131.32 172.16 12.49 Favored 'General case' 0 C--O 1.244 0.766 0 C-N-CA 123.915 0.886 . . . . 0.0 109.261 177.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 25.3 ttm180 -74.03 133.79 42.97 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -178.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.88 -2.83 82.36 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.956 -0.358 . . . . 0.0 112.924 -176.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.431 ' HB2' HG21 ' A' ' 59' ' ' THR . . . -77.6 132.06 38.1 Favored 'General case' 0 C--O 1.244 0.796 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 176.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.577 HG21 ' HG3' ' A' ' 90' ' ' GLU . 21.9 t -83.18 114.08 23.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 177.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 33.4 m -101.57 146.45 9.85 Favored 'Isoleucine or valine' 0 C--O 1.244 0.793 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 177.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.8 tp10 -95.83 128.24 42.54 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 63.2 p -124.86 177.86 5.8 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 24.0 p-10 -72.42 -12.26 61.03 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 122.794 0.438 . . . . 0.0 110.743 175.372 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.3 mt -93.41 -49.77 5.77 Favored 'General case' 0 C--N 1.357 0.918 0 C-N-CA 123.079 0.551 . . . . 0.0 110.425 175.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 168.73 -150.66 16.33 Favored Glycine 0 C--N 1.348 1.21 0 O-C-N 123.177 0.298 . . . . 0.0 113.253 178.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -88.23 118.09 27.59 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 123.836 0.854 . . . . 0.0 109.122 -178.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.2 t -121.27 144.86 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 C-N-CA 123.467 0.707 . . . . 0.0 109.4 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.49 ' HG3' HD13 ' A' ' 88' ' ' ILE . 24.4 mtt180 -109.66 131.91 54.63 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 171.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.1 t -80.36 98.99 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 O-C-N 124.172 0.92 . . . . 0.0 109.243 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 35.5 p -74.48 -28.59 61.08 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.792 0.837 . . . . 0.0 111.781 177.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.1 m -90.58 -170.78 2.83 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.921 177.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.408 ' HD2' ' N ' ' A' ' 76' ' ' ARG . 8.4 mpt_? -96.54 112.15 59.23 Favored Pre-proline 0 CA--C 1.545 0.784 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.301 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -62.37 96.02 0.15 Allowed 'Trans proline' 0 C--N 1.377 2.03 0 C-N-CA 123.148 2.565 . . . . 0.0 112.837 -172.11 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.77 -23.45 32.5 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.69 -0.686 . . . . 0.0 113.999 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -72.97 -30.43 63.83 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-N 117.956 0.878 . . . . 0.0 110.491 175.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -77.04 4.33 10.37 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 123.569 0.748 . . . . 0.0 111.287 171.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 90.62 -33.95 4.39 Favored Glycine 0 C--N 1.356 1.682 0 N-CA-C 111.596 -0.602 . . . . 0.0 111.596 -172.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.0 p -140.2 164.27 22.75 Favored 'Isoleucine or valine' 0 C--O 1.243 0.751 0 C-N-CA 124.729 1.212 . . . . 0.0 108.395 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 45.2 mt -84.5 132.88 30.53 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 173.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -133.66 144.66 49.34 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 -177.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -171.73 -172.74 38.02 Favored Glycine 0 C--N 1.342 0.901 0 N-CA-C 114.825 0.69 . . . . 0.0 114.825 -177.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 16.5 m -119.28 137.38 53.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 C-N-CA 123.943 0.897 . . . . 0.0 110.357 -176.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 41.8 tp -74.08 109.35 7.51 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 122.632 0.373 . . . . 0.0 110.438 -179.118 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.49 HD13 ' HG3' ' A' ' 72' ' ' ARG . 31.6 pt -102.52 179.6 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.83 0 C-N-CA 123.802 0.841 . . . . 0.0 109.865 174.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 5.0 mpt_? -125.76 55.96 1.42 Allowed 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.577 ' HG3' HG21 ' A' ' 63' ' ' VAL . 0.8 OUTLIER -60.47 -57.84 11.02 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 -179.967 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 74.9 mt . . . . . 0 CA--C 1.545 0.77 0 CA-C-N 114.7 -1.136 . . . . 0.0 107.946 169.974 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.515 HG23 HD11 ' A' ' 40' ' ' ILE . 52.4 m . . . . . 0 CA--C 1.537 0.448 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -127.18 158.82 36.08 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.543 0.737 . . . . 0.0 111.516 -175.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.479 ' HB ' HD12 ' A' ' 40' ' ' ILE . 16.1 tt -145.6 148.75 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.731 0.813 . . . . 0.0 110.395 -171.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 37.7 m-80 -89.32 103.6 16.22 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 172.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 75.8 t -89.39 109.82 20.84 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 C-N-CA 123.932 0.893 . . . . 0.0 109.053 -176.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 37.0 t -100.01 110.05 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 123.199 0.6 . . . . 0.0 109.654 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -59.2 112.68 5.48 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 170.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.2 -16.97 19.48 Favored 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 121.926 1.751 . . . . 0.0 111.747 179.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -94.37 -45.18 7.57 Favored 'General case' 0 CA--C 1.552 1.032 0 C-N-CA 124.344 1.058 . . . . 0.0 111.184 178.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.6 m -90.2 -20.01 23.54 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 123.362 0.665 . . . . 0.0 112.02 -175.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.17 -11.52 57.54 Favored Glycine 0 C--N 1.35 1.317 0 C-N-CA 123.422 0.534 . . . . 0.0 114.223 178.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -75.39 150.59 38.32 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.814 0.846 . . . . 0.0 112.132 -173.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 21.1 t -126.12 133.83 67.94 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.797 0.839 . . . . 0.0 108.774 174.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -147.61 141.3 25.61 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.611 0.764 . . . . 0.0 109.537 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 47.5 mt -81.92 122.87 37.43 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.8 0 N-CA-C 108.264 -1.014 . . . . 0.0 108.264 178.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.35 161.41 27.88 Favored 'General case' 0 C--O 1.236 0.382 0 C-N-CA 124.796 1.238 . . . . 0.0 109.517 -174.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -106.43 123.7 48.47 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -175.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.515 HD11 HG23 ' A' ' 23' ' ' THR . 59.5 mt -76.41 113.29 15.23 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 123.388 0.675 . . . . 0.0 109.955 -176.259 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -77.4 -53.29 7.83 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.634 1.174 . . . . 0.0 110.264 -178.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -140.23 166.61 24.22 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 124.158 0.983 . . . . 0.0 108.704 178.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 43.9 t . . . . . 0 N--CA 1.475 0.787 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 167.997 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 49.4 mm . . . . . 0 N--CA 1.484 1.255 0 CA-C-O 122.566 1.174 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 37.1 mt -83.23 144.4 10.14 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 113.962 -1.472 . . . . 0.0 109.595 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 17.5 p -122.82 167.94 12.89 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.051 0.941 . . . . 0.0 109.052 173.05 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 35.7 ttt180 -74.16 131.38 41.22 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 175.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.94 9.4 77.52 Favored Glycine 0 N--CA 1.465 0.613 0 O-C-N 124.076 0.86 . . . . 0.0 112.843 -175.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -83.16 160.95 21.73 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.145 0.578 . . . . 0.0 109.603 176.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.7 t -105.99 120.9 57.67 Favored 'Isoleucine or valine' 0 C--O 1.243 0.748 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 172.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.4 m -106.5 159.55 6.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.228 175.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -106.85 130.08 54.59 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 173.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 34.0 p -129.61 -175.18 3.51 Favored 'General case' 0 C--O 1.24 0.556 0 C-N-CA 123.241 0.616 . . . . 0.0 109.813 -176.06 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 73.3 m-20 -70.28 -19.26 63.11 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 123.134 0.574 . . . . 0.0 111.024 175.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 93.8 mt -99.45 -13.73 19.41 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.907 0.883 . . . . 0.0 111.755 -178.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.45 -164.16 22.42 Favored Glycine 0 C--N 1.35 1.32 0 O-C-N 123.349 0.406 . . . . 0.0 112.528 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -80.09 130.45 35.26 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.142 0.577 . . . . 0.0 110.394 177.76 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.6 t -125.5 138.9 52.93 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 C-N-CA 124.468 1.107 . . . . 0.0 110.663 -173.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.679 ' HG2' HD13 ' A' ' 88' ' ' ILE . 9.5 mmt180 -86.4 121.03 28.38 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 169.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 48.9 t -72.98 116.75 15.6 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.768 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 43.8 p -96.97 -24.58 15.75 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.456 0.702 . . . . 0.0 111.238 -172.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 23.3 t -108.55 178.5 4.47 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.533 0.733 . . . . 0.0 109.84 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 85.8 mtm180 -90.62 106.69 16.18 Favored Pre-proline 0 CA--C 1.552 1.049 0 C-N-CA 123.383 0.673 . . . . 0.0 109.976 -177.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -66.22 114.44 3.03 Favored 'Trans proline' 0 C--N 1.373 1.835 0 C-N-CA 123.101 2.534 . . . . 0.0 112.357 -175.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 141.94 -29.88 2.18 Favored Glycine 0 C--N 1.344 0.981 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.339 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -60.84 110.73 1.4 Allowed 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.342 0.657 . . . . 0.0 110.49 178.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.488 ' HB2' HG12 ' A' ' 82' ' ' VAL . 26.8 m-20 70.26 -15.79 0.33 Allowed 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 125.66 1.584 . . . . 0.0 114.04 178.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 98.05 12.52 45.84 Favored Glycine 0 C--N 1.342 0.907 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -169.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.488 HG12 ' HB2' ' A' ' 80' ' ' ASP . 3.7 p -111.32 118.59 57.81 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 C-N-CA 123.603 0.761 . . . . 0.0 109.573 175.085 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.2 mt -98.24 148.03 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 170.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -135.16 149.14 49.91 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 122.937 0.495 . . . . 0.0 109.819 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.25 -175.54 37.97 Favored Glycine 0 C--N 1.346 1.102 0 O-C-N 123.648 0.592 . . . . 0.0 113.482 -176.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.2 m -129.1 138.7 53.8 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 C-N-CA 124.248 1.019 . . . . 0.0 110.42 178.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.6 tp -73.86 122.73 22.96 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 121.094 0.473 . . . . 0.0 111.271 -175.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.679 HD13 ' HG2' ' A' ' 72' ' ' ARG . 40.1 pt -119.17 -179.65 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 123.884 0.874 . . . . 0.0 109.623 175.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 57.4 mtt180 -122.79 83.29 2.1 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 -176.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 36.2 mm-40 -93.2 -80.91 0.37 Allowed 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 175.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 50.8 mt . . . . . 0 C--N 1.344 0.327 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -175.435 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.482 HG23 HD13 ' A' ' 40' ' ' ILE . 62.9 m . . . . . 0 N--CA 1.473 0.723 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 41.8 mtt180 -115.01 163.6 15.36 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.732 0.813 . . . . 0.0 110.519 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.494 ' HB ' HD11 ' A' ' 40' ' ' ILE . 16.6 tt -141.75 135.49 30.03 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 124.025 0.93 . . . . 0.0 108.802 175.666 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -85.67 103.27 14.33 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 177.154 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -92.08 133.27 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 123.802 0.841 . . . . 0.0 109.886 -171.495 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 46.7 t -109.8 109.81 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 178.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -66.61 119.07 60.24 Favored Pre-proline 0 CA--C 1.545 0.78 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 176.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -66.11 -33.84 39.3 Favored 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 123.003 2.468 . . . . 0.0 113.667 -166.003 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -95.36 -40.4 9.54 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 112.85 0.685 . . . . 0.0 112.85 -171.61 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 71.3 p -89.51 -21.24 23.03 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 122.464 0.306 . . . . 0.0 111.533 179.673 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.49 2.76 90.63 Favored Glycine 0 C--N 1.347 1.192 0 CA-C-O 119.882 -0.399 . . . . 0.0 113.572 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.6 mmtp -68.25 107.26 2.73 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.504 0.722 . . . . 0.0 110.971 -177.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.2 t -92.59 126.11 45.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 174.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -154.21 146.79 24.12 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 123.831 0.853 . . . . 0.0 108.813 -176.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 45.2 mt -80.87 137.41 21.41 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -177.523 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.98 159.49 32.52 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.672 0.789 . . . . 0.0 109.713 -179.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 17.1 mm-40 -103.17 122.57 44.98 Favored 'General case' 0 C--O 1.241 0.651 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.494 HD11 ' HB ' ' A' ' 25' ' ' ILE . 44.5 mt -76.95 110.11 12.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -176.612 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 62.3 mtt180 -73.85 -52.3 13.45 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.149 0.979 . . . . 0.0 110.91 178.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -140.75 164.11 31.09 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.817 0.847 . . . . 0.0 110.14 -176.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 70.8 t . . . . . 0 N--CA 1.482 1.168 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 176.691 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.8 mm . . . . . 0 CA--C 1.538 0.513 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.1 mt -80.37 127.43 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 123.424 0.69 . . . . 0.0 109.764 -176.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 74.0 p -124.74 160.6 28.26 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 123.79 0.836 . . . . 0.0 109.427 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -75.68 128.23 34.77 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 122.964 0.506 . . . . 0.0 110.261 179.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.31 -1.24 58.82 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.441 -176.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.1 148.12 22.49 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.642 0.777 . . . . 0.0 111.479 -176.767 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 94.6 t -83.49 118.94 31.89 Favored 'Isoleucine or valine' 0 C--O 1.24 0.592 0 C-N-CA 123.406 0.682 . . . . 0.0 109.604 171.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.0 m -102.77 143.32 15.29 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 165.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -94.18 123.68 37.72 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 66.2 p -123.19 -173.08 2.64 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.141 0.577 . . . . 0.0 110.047 -175.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 58.2 m-20 -73.38 -26.99 61.23 Favored 'General case' 0 N--CA 1.478 0.932 0 CA-C-O 119.851 -0.118 . . . . 0.0 110.902 170.131 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.1 mt -84.13 -28.25 27.6 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 122.916 0.486 . . . . 0.0 111.843 -176.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 146.96 -149.55 21.71 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 178.579 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -85.55 128.11 34.65 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 175.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.7 t -121.72 128.6 75.78 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.526 0 C-N-CA 122.656 0.383 . . . . 0.0 110.862 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.518 ' HG2' HD12 ' A' ' 88' ' ' ILE . 22.6 mmt85 -85.58 123.29 30.83 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 171.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.6 t -72.32 100.13 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.415 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 47.5 p -95.4 -22.55 17.65 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 123.253 0.621 . . . . 0.0 110.803 -169.372 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 21.6 t -98.32 -177.81 3.83 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 169.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.618 ' HE ' ' HB3' ' A' ' 79' ' ' GLN . 39.6 ptt180 -75.26 144.0 77.71 Favored Pre-proline 0 CA--C 1.551 1.014 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 173.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.441 ' HA ' HG23 ' A' ' 83' ' ' ILE . 87.3 Cg_endo -76.71 50.63 3.08 Favored 'Trans proline' 0 CA--C 1.559 1.762 0 C-N-CA 123.091 2.527 . . . . 0.0 113.273 174.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 172.8 67.08 0.05 OUTLIER Glycine 0 C--N 1.346 1.126 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.977 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . 0.618 ' HB3' ' HE ' ' A' ' 76' ' ' ARG . 1.7 pt20 -123.41 115.33 21.43 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.999 0.92 . . . . 0.0 108.604 172.562 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 62.39 19.3 11.01 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 124.339 1.055 . . . . 0.0 111.335 -176.013 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 92.86 -6.25 76.68 Favored Glycine 0 C--N 1.353 1.474 0 CA-C-N 116.033 -0.53 . . . . 0.0 112.496 178.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.8 p -120.3 163.71 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 123.004 0.522 . . . . 0.0 111.008 -175.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.441 HG23 ' HA ' ' A' ' 77' ' ' PRO . 42.3 mt -109.31 147.54 13.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 C-N-CA 124.696 1.198 . . . . 0.0 109.169 -178.753 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -130.03 155.5 46.03 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 118.414 0.552 . . . . 0.0 110.774 174.449 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.415 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -166.84 -169.38 30.37 Favored Glycine 0 C--N 1.348 1.199 0 CA-C-N 115.367 -0.833 . . . . 0.0 113.652 -177.611 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.1 m -125.61 146.8 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 CA-C-N 117.789 0.795 . . . . 0.0 111.045 178.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 17.5 tp -84.6 104.61 14.74 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 122.607 0.363 . . . . 0.0 111.224 -176.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.518 HD12 ' HG2' ' A' ' 72' ' ' ARG . 50.0 pt -93.71 174.95 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 123.08 0.552 . . . . 0.0 110.765 178.077 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -119.57 27.39 8.78 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 124.022 0.929 . . . . 0.0 110.298 -170.206 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.95 -61.41 2.4 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 124.378 1.071 . . . . 0.0 110.792 -170.361 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.541 0.606 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 165.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 63.7 m . . . . . 0 C--O 1.242 0.672 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 13.4 mmt85 -97.56 165.08 12.15 Favored 'General case' 0 C--O 1.244 0.771 0 CA-C-O 121.713 0.768 . . . . 0.0 110.441 -178.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.0 tt -136.54 134.18 49.2 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 CA-C-N 114.09 -1.413 . . . . 0.0 107.893 174.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 -88.68 100.53 13.19 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 179.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 91.7 t -87.32 116.04 28.96 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.169 -173.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.403 HG21 HG23 ' A' ' 35' ' ' VAL . 58.2 t -95.17 99.65 9.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -178.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -59.88 110.98 3.24 Favored Pre-proline 0 CA--C 1.545 0.774 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 170.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -82.73 -4.63 11.47 Favored 'Trans proline' 0 CA--C 1.547 1.131 0 C-N-CA 122.535 2.157 . . . . 0.0 113.043 -174.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -76.23 -58.58 3.2 Favored 'General case' 0 C--N 1.353 0.759 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -177.079 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.9 p -95.76 -32.73 12.58 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 114.578 -1.192 . . . . 0.0 112.127 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.01 14.39 19.05 Favored Glycine 0 N--CA 1.477 1.427 0 CA-C-O 119.793 -0.448 . . . . 0.0 113.224 -178.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -63.15 148.44 48.0 Favored 'General case' 0 N--CA 1.486 1.369 0 C-N-CA 122.757 0.423 . . . . 0.0 111.589 175.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.403 HG23 HG21 ' A' ' 28' ' ' VAL . 44.1 t -127.04 120.29 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 167.528 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -130.77 139.93 50.26 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.74 0.816 . . . . 0.0 110.062 -176.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 53.5 mt -79.15 120.46 30.39 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 177.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.24 155.5 33.08 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.964 0.905 . . . . 0.0 111.175 -173.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -99.19 127.32 45.15 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 174.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 61.6 mt -77.58 111.28 14.21 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 123.035 0.534 . . . . 0.0 110.612 -175.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 15.6 mmm180 -66.77 -44.34 81.63 Favored 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 123.718 0.807 . . . . 0.0 110.77 174.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.551 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 37.4 t30 -140.32 125.65 18.83 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.68 -169.583 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.415 HG12 HD11 ' A' ' 58' ' ' ILE . 17.9 m . . . . . 0 N--CA 1.478 0.932 0 O-C-N 124.031 0.832 . . . . 0.0 111.686 -178.063 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 49.9 mm . . . . . 0 C--O 1.24 0.561 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.415 HD11 HG12 ' A' ' 43' ' ' VAL . 67.9 mt -101.67 144.23 13.45 Favored 'Isoleucine or valine' 0 C--O 1.24 0.58 0 CA-C-N 114.48 -1.236 . . . . 0.0 109.065 -176.302 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 11.2 p -136.08 165.3 26.03 Favored 'General case' 0 C--O 1.242 0.675 0 C-N-CA 123.934 0.893 . . . . 0.0 109.702 -178.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -63.77 140.82 58.91 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 123.934 0.893 . . . . 0.0 111.118 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.01 -25.34 25.86 Favored Glycine 0 C--N 1.341 0.845 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.938 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.87 139.51 56.51 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.314 0.646 . . . . 0.0 110.987 -178.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.2 t -93.57 110.56 23.52 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 172.378 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.3 m -100.64 141.79 16.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 177.185 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.551 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 40.7 tt0 -94.01 136.99 33.72 Favored 'General case' 0 C--O 1.234 0.243 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 81.5 p -130.03 176.52 8.0 Favored 'General case' 0 C--O 1.246 0.875 0 C-N-CA 123.972 0.909 . . . . 0.0 109.144 -179.184 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 18.6 p-10 -63.45 -24.44 67.83 Favored 'General case' 0 CA--C 1.542 0.661 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.986 173.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 86.5 mt -88.66 -34.01 17.39 Favored 'General case' 0 C--N 1.354 0.782 0 C-N-CA 123.143 0.577 . . . . 0.0 110.555 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 150.37 -150.09 22.06 Favored Glycine 0 C--N 1.343 0.923 0 CA-C-N 116.593 -0.276 . . . . 0.0 112.423 173.332 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -78.9 129.73 34.85 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.582 0.753 . . . . 0.0 109.038 -179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.8 t -127.85 137.5 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 123.063 0.545 . . . . 0.0 110.635 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.669 ' HG2' HD11 ' A' ' 88' ' ' ILE . 13.4 mmt180 -90.77 118.26 30.05 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 169.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.1 t -72.04 109.1 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 178.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.3 p -98.54 -50.97 4.09 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 -171.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' SER . . . . . 0.503 ' HB3' ' HB3' ' A' ' 84' ' ' ASN . 31.1 t -82.71 150.91 26.45 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.113 176.671 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.45 ' HD2' ' HD2' ' A' ' 77' ' ' PRO . 23.8 tpt180 -72.83 125.5 91.12 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 123.482 0.713 . . . . 0.0 109.611 175.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.45 ' HD2' ' HD2' ' A' ' 76' ' ' ARG . 85.2 Cg_exo -51.72 101.61 0.05 OUTLIER 'Trans proline' 0 C--N 1.378 2.084 0 C-N-CA 123.269 2.646 . . . . 0.0 111.509 163.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 140.4 -32.63 2.14 Favored Glycine 0 C--N 1.339 0.747 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 -176.009 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -65.94 113.34 4.34 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 171.343 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 30.5 t70 76.89 -19.12 0.44 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 125.523 1.529 . . . . 0.0 111.686 -170.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 109.4 -47.57 1.03 Allowed Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -171.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.3 p -75.11 165.77 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 C-N-CA 123.756 0.822 . . . . 0.0 111.074 178.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 30.2 mt -93.8 148.15 5.05 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 169.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.503 ' HB3' ' HB3' ' A' ' 75' ' ' SER . 25.6 t-20 -136.56 147.35 46.97 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 174.603 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.53 -175.8 26.1 Favored Glycine 0 C--N 1.336 0.574 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.257 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.5 m -121.3 138.1 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 123.223 0.609 . . . . 0.0 109.9 174.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 41.9 tp -67.78 128.93 38.31 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 123.543 0.737 . . . . 0.0 110.128 178.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.669 HD11 ' HG2' ' A' ' 72' ' ' ARG . 44.5 pt -129.94 179.74 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 123.658 0.783 . . . . 0.0 110.702 -177.19 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 10.7 mmm180 -123.45 119.78 31.01 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 125.276 1.431 . . . . 0.0 107.247 171.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -149.83 -68.51 0.2 Allowed 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -177.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 2.0 pt? . . . . . 0 N--CA 1.477 0.893 0 CA-C-O 122.318 1.056 . . . . 0.0 110.917 -177.008 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 m . . . . . 0 N--CA 1.471 0.594 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.414 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 57.4 mtm180 -123.34 161.15 25.25 Favored 'General case' 0 C--O 1.244 0.8 0 C-N-CA 123.296 0.638 . . . . 0.0 110.807 178.106 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.9 tt -145.65 141.24 22.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.745 -170.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -84.07 102.57 12.62 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 175.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.7 t -93.9 115.26 32.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 C-N-CA 124.18 0.992 . . . . 0.0 109.085 -171.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.5 t -104.65 106.97 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 124.327 1.051 . . . . 0.0 109.011 -177.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -69.16 111.48 8.69 Favored Pre-proline 0 CA--C 1.544 0.725 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 175.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -74.1 -7.43 19.84 Favored 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.712 2.274 . . . . 0.0 113.506 -170.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -96.02 -52.75 3.91 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 122.685 0.394 . . . . 0.0 111.221 -177.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 77.1 p -102.14 -29.86 11.48 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 123.367 0.667 . . . . 0.0 112.548 -175.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.39 20.91 14.0 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-O 119.734 -0.481 . . . . 0.0 113.766 177.583 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 60.8 mttp -67.43 105.66 1.87 Allowed 'General case' 0 N--CA 1.484 1.25 0 CA-C-N 117.308 0.554 . . . . 0.0 110.665 175.04 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 44.5 t -108.85 115.65 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.7 tp10 -153.72 147.55 25.38 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.111 0.564 . . . . 0.0 109.66 -174.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 44.7 mt -83.77 100.07 6.9 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -177.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -90.82 160.09 15.94 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.975 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.453 ' HB2' ' ND2' ' A' ' 67' ' ' ASN . 37.5 mt-10 -105.61 122.24 45.62 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -177.17 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.438 HG12 HG21 ' A' ' 66' ' ' THR . 50.9 mt -75.76 111.81 12.64 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -172.751 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -73.77 -40.16 63.67 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 123.807 0.843 . . . . 0.0 110.335 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -143.89 130.68 20.3 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.864 -173.231 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.4 m . . . . . 0 N--CA 1.483 1.184 0 C-N-CA 122.99 0.516 . . . . 0.0 111.754 -175.298 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.7 tp . . . . . 0 C--O 1.24 0.587 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.498 HD11 HG11 ' A' ' 64' ' ' VAL . 61.6 mt -114.42 144.37 22.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 124.171 0.988 . . . . 0.0 108.493 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 31.2 p -121.9 167.98 12.42 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.265 0.626 . . . . 0.0 110.55 179.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 39.5 ttp180 -71.72 131.09 42.64 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.005 178.108 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.2 -2.3 83.45 Favored Glycine 0 C--N 1.342 0.914 0 C-N-CA 123.607 0.622 . . . . 0.0 113.005 -177.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -85.18 132.55 34.27 Favored 'General case' 0 C--O 1.246 0.881 0 C-N-CA 123.408 0.683 . . . . 0.0 110.137 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 41.4 t -82.73 113.61 22.24 Favored 'Isoleucine or valine' 0 C--N 1.352 0.69 0 CA-C-O 121.01 0.433 . . . . 0.0 110.029 178.537 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.498 HG11 HD11 ' A' ' 58' ' ' ILE . 34.1 m -102.28 166.94 2.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 169.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -120.98 134.89 55.31 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 175.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.438 HG21 HG12 ' A' ' 40' ' ' ILE . 43.6 p -130.68 -176.23 3.91 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 124.263 1.025 . . . . 0.0 110.099 -171.347 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.453 ' ND2' ' HB2' ' A' ' 39' ' ' GLU . 97.3 m-20 -68.96 -23.59 64.15 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.06 175.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 73.8 mt -86.22 -41.34 14.72 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 123.183 0.302 . . . . 0.0 110.464 175.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 159.08 -159.29 30.25 Favored Glycine 0 C--N 1.345 1.045 0 O-C-N 123.443 0.464 . . . . 0.0 112.976 178.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 21.5 m120 -77.43 124.45 27.9 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 177.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 46.1 t -123.58 145.21 30.94 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.733 0 C-N-CA 124.438 1.095 . . . . 0.0 109.562 -175.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.446 ' HG3' HD12 ' A' ' 88' ' ' ILE . 30.1 mtt85 -107.7 137.04 46.44 Favored 'General case' 0 N--CA 1.483 1.18 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 168.337 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.474 HG13 ' HD3' ' A' ' 77' ' ' PRO . 58.1 t -75.09 120.26 24.32 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 O-C-N 124.273 0.983 . . . . 0.0 109.594 179.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.402 HG22 HG12 ' A' ' 86' ' ' VAL . 40.2 p -98.38 -20.95 16.86 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 123.447 0.699 . . . . 0.0 110.429 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' SER . . . . . 0.421 ' HB3' ' HB2' ' A' ' 84' ' ' ASN . 95.0 p -91.9 -173.16 3.41 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.379 0.672 . . . . 0.0 109.713 174.807 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 74.8 mtt180 -116.23 103.4 53.12 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 172.32 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.474 ' HD3' HG13 ' A' ' 73' ' ' VAL . 21.1 Cg_endo -57.71 151.54 54.86 Favored 'Trans proline' 0 C--N 1.382 2.297 0 C-N-CA 123.659 2.906 . . . . 0.0 113.632 -168.082 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.52 -35.01 4.2 Favored Glycine 0 C--N 1.349 1.292 0 CA-C-O 119.7 -0.5 . . . . 0.0 113.553 176.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 89.8 mt-30 -61.59 -57.77 10.75 Favored 'General case' 0 C--N 1.359 1.015 0 CA-C-O 121.351 0.596 . . . . 0.0 109.921 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -91.73 32.87 1.06 Allowed 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.376 177.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 65.07 -78.04 0.07 OUTLIER Glycine 0 C--N 1.361 1.949 0 C-N-CA 123.643 0.64 . . . . 0.0 112.831 -176.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.1 p -73.72 164.6 3.48 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.523 1.129 . . . . 0.0 110.441 178.476 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.436 HG12 ' HB3' ' A' ' 77' ' ' PRO . 15.9 mt -93.82 147.82 5.28 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 175.171 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.421 ' HB2' ' HB3' ' A' ' 75' ' ' SER . 1.0 OUTLIER -123.79 147.73 47.3 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 171.11 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.3 -176.49 36.92 Favored Glycine 0 CA--C 1.526 0.755 0 O-C-N 123.383 0.427 . . . . 0.0 113.177 -177.172 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.402 HG12 HG22 ' A' ' 74' ' ' THR . 16.0 m -122.62 139.11 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 C-N-CA 123.826 0.85 . . . . 0.0 110.871 178.576 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 19.4 tp -74.82 113.47 12.14 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 123.522 0.514 . . . . 0.0 109.968 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.446 HD12 ' HG3' ' A' ' 72' ' ' ARG . 34.5 pt -112.71 -177.17 0.82 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.733 0 C-N-CA 123.776 0.831 . . . . 0.0 109.883 178.019 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -133.04 100.77 4.98 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -178.377 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 70.2 mm-40 -119.26 -64.57 1.26 Allowed 'General case' 0 N--CA 1.477 0.897 0 CA-C-O 121.362 0.601 . . . . 0.0 109.491 177.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 70.8 mt . . . . . 0 N--CA 1.479 0.999 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.966 -173.853 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 29.8 m . . . . . 0 CA--C 1.54 0.579 0 CA-C-O 120.933 0.397 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 71.8 mtm180 -112.96 170.64 8.05 Favored 'General case' 0 C--O 1.243 0.727 0 C-N-CA 123.618 0.767 . . . . 0.0 110.119 177.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.9 tt -143.57 139.54 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.313 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 22.7 m-80 -88.2 100.16 12.76 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -84.0 109.89 17.99 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 C-N-CA 124.098 0.959 . . . . 0.0 109.187 -175.067 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.41 HG22 HG21 ' A' ' 35' ' ' VAL . 48.8 t -101.34 113.61 38.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.568 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -62.52 121.04 64.75 Favored Pre-proline 0 CA--C 1.547 0.835 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 177.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -71.91 -18.42 27.98 Favored 'Trans proline' 0 C--N 1.363 1.317 0 C-N-CA 122.344 2.029 . . . . 0.0 113.326 -172.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -92.94 -52.02 4.79 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.592 0.757 . . . . 0.0 110.881 -174.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 47.2 p -96.97 -29.08 13.88 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.638 0.775 . . . . 0.0 111.992 -176.175 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.34 4.41 55.07 Favored Glycine 0 N--CA 1.481 1.665 0 CA-C-O 119.272 -0.738 . . . . 0.0 114.388 176.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.622 ' HZ1' ' HB2' ' A' ' 34' ' ' LYS . 9.9 mtmp? -63.19 108.0 1.17 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.528 0.731 . . . . 0.0 112.335 -173.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.41 HG21 HG22 ' A' ' 28' ' ' VAL . 26.2 t -90.62 116.47 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 C-N-CA 123.39 0.676 . . . . 0.0 109.378 176.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -144.59 139.4 28.09 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.329 0.652 . . . . 0.0 110.092 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 36.1 mt -79.76 133.84 28.87 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.885 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 -179.452 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.69 158.3 37.97 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 123.555 0.742 . . . . 0.0 111.441 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 32.6 mm-40 -92.15 121.43 33.69 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 177.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.0 mt -77.21 112.28 14.95 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 178.52 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -76.2 -51.98 11.01 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.086 0.954 . . . . 0.0 110.225 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -151.48 174.1 13.79 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 CA--C 1.543 0.698 0 C-N-CA 123.208 0.603 . . . . 0.0 110.727 177.072 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 43.0 pt . . . . . 0 N--CA 1.475 0.81 0 CA-C-O 122.083 0.944 . . . . 0.0 111.143 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.426 ' O ' ' HG3' ' A' ' 77' ' ' PRO . 57.5 mt -102.47 108.72 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 107.721 -1.215 . . . . 0.0 107.721 173.036 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.9 p -99.53 151.93 20.59 Favored 'General case' 0 C--O 1.241 0.614 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 174.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 73.0 ttt180 -67.2 128.27 35.77 Favored 'General case' 0 CA--C 1.546 0.793 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 176.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.81 11.46 70.6 Favored Glycine 0 C--N 1.338 0.691 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.827 -176.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.94 148.21 23.92 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-N 117.353 0.577 . . . . 0.0 110.112 176.405 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.6 t -84.11 114.63 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 171.406 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 28.8 m -104.46 144.73 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 C-N-CA 123.025 0.53 . . . . 0.0 109.686 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -91.68 127.85 37.29 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 175.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 49.5 p -128.8 -179.97 5.38 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -68.29 -19.17 64.68 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 122.854 0.461 . . . . 0.0 111.585 176.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 96.4 mt -90.35 -46.72 8.2 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.242 0.617 . . . . 0.0 109.804 178.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 162.99 -153.46 24.02 Favored Glycine 0 C--N 1.339 0.74 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.749 177.078 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -76.78 137.36 39.22 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 122.864 0.465 . . . . 0.0 110.284 176.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.4 t -132.03 142.65 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 122.957 0.503 . . . . 0.0 109.861 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.53 ' HG2' HD11 ' A' ' 88' ' ' ILE . 33.4 mmt180 -89.75 123.02 33.38 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 170.311 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 66.2 t -75.78 95.79 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 -179.404 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 60.8 p -78.84 -41.72 29.37 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 122.925 0.49 . . . . 0.0 111.179 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' SER . . . . . 0.48 ' HB2' ' H ' ' A' ' 84' ' ' ASN . 50.3 m -91.42 115.1 27.76 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.0 176.254 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 7.3 tmm_? -55.75 135.22 72.2 Favored Pre-proline 0 CA--C 1.563 1.453 0 C-N-CA 125.099 1.359 . . . . 0.0 110.188 177.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.426 ' HG3' ' O ' ' A' ' 58' ' ' ILE . 36.9 Cg_endo -60.85 129.69 30.01 Favored 'Trans proline' 0 C--N 1.377 2.068 0 C-N-CA 123.026 2.484 . . . . 0.0 112.398 -177.343 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 115.23 -18.55 15.81 Favored Glycine 0 C--N 1.34 0.791 0 CA-C-O 119.678 -0.512 . . . . 0.0 112.688 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -67.74 98.3 0.7 Allowed 'General case' 0 C--N 1.355 0.842 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 177.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 74.33 -2.47 2.8 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 125.754 1.621 . . . . 0.0 112.083 -174.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.93 -0.42 82.19 Favored Glycine 0 C--N 1.348 1.233 0 C-N-CA 123.082 0.372 . . . . 0.0 112.469 -178.04 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -115.37 148.59 17.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 124.464 1.106 . . . . 0.0 109.671 175.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 35.6 mt -104.44 145.36 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 C-N-CA 123.081 0.553 . . . . 0.0 109.601 173.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.48 ' H ' ' HB2' ' A' ' 75' ' ' SER . 42.9 m-20 -130.19 154.86 47.11 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 174.345 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.87 -178.06 37.16 Favored Glycine 0 C--N 1.336 0.579 0 CA-C-O 119.825 -0.43 . . . . 0.0 112.837 -177.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.18 136.93 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 123.306 0.642 . . . . 0.0 110.739 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 45.7 tp -66.13 124.68 23.27 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 122.862 0.465 . . . . 0.0 111.753 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.53 HD11 ' HG2' ' A' ' 72' ' ' ARG . 45.4 pt -119.59 164.99 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 CA-C-O 121.586 0.708 . . . . 0.0 109.788 168.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.92 88.27 2.59 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -175.106 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -101.24 -64.63 1.03 Allowed 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 63.3 mt . . . . . 0 CA--C 1.54 0.581 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.371 174.68 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 28.0 m . . . . . 0 CA--C 1.541 0.607 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 24.6 mmt85 -116.72 147.78 41.69 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 123.994 0.917 . . . . 0.0 111.409 -170.093 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.6 tt -148.63 142.2 18.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-N 114.185 -1.37 . . . . 0.0 108.527 -178.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . 0.557 ' ND2' HG22 ' A' ' 82' ' ' VAL . 29.4 m-80 -93.89 100.65 12.78 Favored 'General case' 0 C--O 1.241 0.644 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 175.532 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 87.5 t -91.71 116.57 33.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.439 0 CA-C-N 114.353 -1.294 . . . . 0.0 108.461 -176.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.447 HG21 HG22 ' A' ' 35' ' ' VAL . 35.0 t -98.51 109.88 24.84 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.366 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -62.86 117.69 34.83 Favored Pre-proline 0 CA--C 1.548 0.891 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 172.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -66.1 -31.94 44.52 Favored 'Trans proline' 0 C--N 1.366 1.475 0 C-N-CA 122.698 2.265 . . . . 0.0 113.269 -170.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -94.33 -46.15 7.17 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 123.179 0.592 . . . . 0.0 110.857 -175.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.6 m -84.87 -29.34 25.34 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.125 0.57 . . . . 0.0 111.006 -173.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.66 5.96 73.86 Favored Glycine 0 C--N 1.345 1.038 0 CA-C-O 119.567 -0.574 . . . . 0.0 113.976 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 95.6 mttt -60.12 106.08 0.47 Allowed 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.052 0.541 . . . . 0.0 111.228 178.042 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.447 HG22 HG21 ' A' ' 28' ' ' VAL . 61.6 t -94.47 107.84 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 168.535 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -137.0 137.67 39.68 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 122.799 0.439 . . . . 0.0 109.944 -171.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 37.9 mt -75.74 99.14 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 177.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.442 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -89.45 157.4 18.14 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 123.737 0.815 . . . . 0.0 111.503 175.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -107.33 122.41 46.51 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.804 0.842 . . . . 0.0 109.179 178.466 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 64.7 mt -78.0 115.44 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 123.363 0.665 . . . . 0.0 110.845 -171.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 35.1 mmt180 -78.15 -53.78 6.98 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.417 1.087 . . . . 0.0 110.42 178.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -131.54 153.88 49.39 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 123.666 0.786 . . . . 0.0 110.043 -175.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.449 ' HA ' HG13 ' A' ' 64' ' ' VAL . 33.7 m . . . . . 0 N--CA 1.475 0.808 0 C-N-CA 124.117 0.967 . . . . 0.0 110.97 177.621 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 2.0 pp . . . . . 0 CA--C 1.54 0.589 0 CA-C-O 120.943 0.402 . . . . 0.0 110.116 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.7 mt -102.34 130.68 51.84 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 C-N-CA 124.495 1.118 . . . . 0.0 109.162 -179.308 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 35.2 p -123.73 156.1 36.63 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.499 0.719 . . . . 0.0 109.737 177.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 60.5 ttt180 -74.71 123.51 25.04 Favored 'General case' 0 CA--C 1.544 0.715 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -178.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.99 4.19 67.27 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.086 -173.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.62 158.69 22.93 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.146 0.473 . . . . 0.0 110.737 175.837 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 68.8 t -97.26 111.24 26.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 171.752 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.449 HG13 ' HA ' ' A' ' 43' ' ' VAL . 29.6 m -108.38 137.97 37.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 173.726 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -91.16 142.32 27.87 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.109 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.442 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 61.7 p -128.07 178.76 5.99 Favored 'General case' 0 C--O 1.246 0.898 0 C-N-CA 124.146 0.979 . . . . 0.0 109.144 179.481 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -57.92 -25.72 61.26 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 123.584 0.754 . . . . 0.0 111.571 173.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 75.0 mt -83.52 -49.48 9.21 Favored 'General case' 0 C--N 1.351 0.632 0 C-N-CA 123.526 0.73 . . . . 0.0 109.244 178.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 161.01 -163.89 34.51 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-N 115.27 -0.877 . . . . 0.0 111.394 -177.065 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 -75.46 139.08 42.04 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-O 121.084 0.469 . . . . 0.0 110.148 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 83.9 t -133.72 144.59 35.37 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 C-N-CA 125.096 1.358 . . . . 0.0 109.272 -171.18 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.707 ' HG2' HD12 ' A' ' 88' ' ' ILE . 7.0 mmt85 -96.33 122.43 39.21 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 171.603 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 47.2 t -70.57 109.09 2.76 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.437 HG22 HG13 ' A' ' 86' ' ' VAL . 44.6 p -90.48 -30.45 17.3 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.13 0.572 . . . . 0.0 110.986 -171.078 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 25.9 t -113.71 -169.9 1.6 Allowed 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.871 0.868 . . . . 0.0 109.416 -178.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 18.4 mtp180 -70.11 144.57 92.81 Favored Pre-proline 0 CA--C 1.554 1.104 0 C-N-CA 123.432 0.693 . . . . 0.0 110.711 174.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -78.8 162.02 27.05 Favored 'Trans proline' 0 C--N 1.366 1.486 0 C-N-CA 122.307 2.004 . . . . 0.0 112.29 173.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.431 ' H ' HG12 ' A' ' 83' ' ' ILE . . . 57.4 -89.18 0.02 OUTLIER Glycine 0 C--N 1.346 1.089 0 CA-C-N 115.635 -0.712 . . . . 0.0 113.283 -175.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . 0.257 12.3 pt20 53.23 -66.41 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 C-N-CA 127.74 2.416 . . . . 0.0 114.328 -178.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -146.38 41.75 1.16 Allowed 'General case' 0 N--CA 1.476 0.854 0 CA-C-O 122.255 1.026 . . . . 0.0 108.518 178.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 64.47 16.99 61.51 Favored Glycine 0 C--N 1.351 1.377 0 CA-C-N 115.026 -0.988 . . . . 0.0 113.061 -173.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.557 HG22 ' ND2' ' A' ' 26' ' ' ASN . 3.8 p -132.69 88.92 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 CA-C-O 122.595 1.188 . . . . 0.0 110.074 -174.031 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.431 HG12 ' H ' ' A' ' 78' ' ' GLY . 34.2 mt -83.31 149.06 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 171.273 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -118.04 143.67 46.23 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 172.156 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.7 179.49 30.75 Favored Glycine 0 C--N 1.336 0.539 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.829 178.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.437 HG13 HG22 ' A' ' 74' ' ' THR . 15.7 m -129.36 137.34 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 C-N-CA 123.784 0.834 . . . . 0.0 110.235 174.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.16 105.71 3.5 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 122.655 0.382 . . . . 0.0 110.082 -178.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.707 HD12 ' HG2' ' A' ' 72' ' ' ARG . 39.1 pt -96.83 168.07 1.63 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.588 0 CA-C-O 121.583 0.706 . . . . 0.0 110.477 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 84.3 mtt180 -127.96 26.91 5.77 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.936 177.683 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -58.12 -62.91 1.48 Allowed 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 172.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.0 mt . . . . . 0 C--N 1.333 -0.129 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 158.031 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.435 HG22 HD13 ' A' ' 40' ' ' ILE . 34.1 m . . . . . 0 C--O 1.243 0.723 0 CA-C-O 121.474 0.654 . . . . 0.0 110.903 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.441 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 99.0 mtt180 -128.9 175.36 8.71 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-N 114.867 -1.06 . . . . 0.0 111.148 -176.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 14.3 tt -144.97 148.16 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.932 0.893 . . . . 0.0 109.347 -173.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -90.61 102.95 15.69 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 174.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 97.2 t -87.87 113.3 24.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 124.1 0.96 . . . . 0.0 108.904 -178.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.454 HG23 HG21 ' A' ' 35' ' ' VAL . 26.3 t -98.83 103.88 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.722 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -53.85 107.93 0.99 Allowed Pre-proline 0 CA--C 1.544 0.713 0 C-N-CA 123.677 0.791 . . . . 0.0 108.981 167.442 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -69.09 -24.21 33.0 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.273 1.982 . . . . 0.0 113.022 -174.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -80.41 -50.4 10.16 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 123.213 0.605 . . . . 0.0 111.13 -177.014 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 40.9 p -94.21 -9.69 35.42 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -178.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.03 -3.18 66.29 Favored Glycine 0 N--CA 1.478 1.476 0 N-CA-C 114.166 0.426 . . . . 0.0 114.166 178.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -75.1 125.34 28.73 Favored 'General case' 0 N--CA 1.479 1.013 0 C-N-CA 123.774 0.83 . . . . 0.0 112.932 -170.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.454 HG21 HG23 ' A' ' 28' ' ' VAL . 17.1 t -104.03 135.4 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 123.535 0.734 . . . . 0.0 109.549 177.685 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -146.77 146.53 30.31 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.503 0.721 . . . . 0.0 109.41 174.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 49.2 mt -78.15 100.71 3.39 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 174.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -92.72 153.82 18.69 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.294 0.638 . . . . 0.0 111.331 176.029 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.441 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 36.8 mt-10 -93.34 123.17 36.45 Favored 'General case' 0 C--O 1.244 0.804 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -178.29 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.435 HD13 HG22 ' A' ' 23' ' ' THR . 53.4 mt -74.93 112.26 12.13 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.85 0 O-C-N 123.43 0.456 . . . . 0.0 109.974 -175.602 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.6 mtp180 -77.24 -53.86 7.2 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 124.188 0.995 . . . . 0.0 111.036 178.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.516 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 53.8 t30 -134.81 146.58 49.44 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.032 -172.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.4 m . . . . . 0 N--CA 1.481 1.096 0 C-N-CA 123.625 0.77 . . . . 0.0 111.638 178.551 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 10.7 tp . . . . . 0 C--O 1.243 0.749 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 55.5 mt -93.83 130.06 43.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 173.225 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 76.2 p -117.15 159.26 22.89 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.222 0.609 . . . . 0.0 110.005 -176.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 77.7 ttt180 -74.4 115.43 13.91 Favored 'General case' 0 CA--C 1.546 0.813 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.047 -177.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.84 6.12 49.81 Favored Glycine 0 N--CA 1.47 0.959 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.78 -177.284 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.25 162.24 25.81 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.118 0.567 . . . . 0.0 111.014 -178.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.0 t -103.3 110.61 30.31 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 174.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.6 m -105.82 142.52 18.67 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 176.049 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.516 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 34.8 tt0 -92.24 134.84 34.51 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 176.522 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 51.4 p -129.99 179.99 5.55 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 123.926 0.89 . . . . 0.0 108.87 178.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -76.1 -1.47 26.19 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 122.52 0.328 . . . . 0.0 111.336 175.066 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 82.8 mt -106.36 -9.07 16.91 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.704 0.802 . . . . 0.0 111.065 171.542 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 120.62 -166.04 13.85 Favored Glycine 0 C--N 1.351 1.393 0 C-N-CA 122.826 0.251 . . . . 0.0 113.018 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 20.2 m120 -77.64 137.87 38.78 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 123.01 0.524 . . . . 0.0 110.745 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.1 t -133.85 142.24 41.88 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.001 0 C-N-CA 124.727 1.211 . . . . 0.0 110.546 -171.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.612 ' HG2' HG22 ' A' ' 88' ' ' ILE . 30.0 mmt180 -85.15 132.34 34.31 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 170.646 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 45.6 t -76.94 106.52 6.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 172.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.461 HG23 HG12 ' A' ' 86' ' ' VAL . 74.1 p -95.93 -32.55 12.56 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 121.562 0.696 . . . . 0.0 110.629 -170.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.1 t -92.38 174.41 7.31 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.925 175.175 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 85.0 mtp180 -75.73 114.89 40.97 Favored Pre-proline 0 CA--C 1.546 0.802 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 171.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -62.46 112.93 1.73 Allowed 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 123.415 2.743 . . . . 0.0 113.084 -171.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.96 36.99 26.77 Favored Glycine 0 C--N 1.348 1.196 0 CA-C-N 115.388 -0.824 . . . . 0.0 112.245 -178.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 57.4 tp60 -70.7 -49.89 42.29 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.283 0.633 . . . . 0.0 109.946 179.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -121.39 56.15 1.05 Allowed 'General case' 0 N--CA 1.482 1.146 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 175.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 67.12 -16.98 0.3 Allowed Glycine 0 CA--C 1.538 1.52 0 N-CA-C 115.412 0.925 . . . . 0.0 115.412 -173.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 13.7 p -119.93 151.75 22.57 Favored 'Isoleucine or valine' 0 C--O 1.243 0.711 0 C-N-CA 124.229 1.012 . . . . 0.0 110.756 -171.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 28.3 mt -109.25 143.34 19.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 114.935 -1.03 . . . . 0.0 108.61 174.077 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -124.21 152.63 42.69 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 122.967 0.507 . . . . 0.0 109.647 172.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.5 -176.7 35.73 Favored Glycine 0 C--N 1.344 1.011 0 CA-C-N 115.323 -0.853 . . . . 0.0 112.956 -175.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.461 HG12 HG23 ' A' ' 74' ' ' THR . 27.7 m -130.33 144.24 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 123.317 0.647 . . . . 0.0 110.242 178.039 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.9 tp -72.14 126.86 30.84 Favored 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.585 -178.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.612 HG22 ' HG2' ' A' ' 72' ' ' ARG . 12.7 pt -125.21 171.31 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.189 0 C-N-CA 123.919 0.887 . . . . 0.0 110.319 -178.246 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 93.0 mtt180 -120.94 71.24 0.93 Allowed 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.424 0.69 . . . . 0.0 109.257 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 21.4 mm-40 -93.47 -78.74 0.42 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 122.86 0.464 . . . . 0.0 110.244 179.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 35.5 mt . . . . . 0 N--CA 1.468 0.429 0 C-N-CA 123.868 0.867 . . . . 0.0 109.057 -170.261 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.463 HG22 HD11 ' A' ' 40' ' ' ILE . 14.1 m . . . . . 0 CA--C 1.555 1.143 0 CA-C-O 120.509 0.195 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 14.3 mmt180 -113.34 145.54 40.92 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.997 0.919 . . . . 0.0 110.929 -177.577 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 17.5 tt -140.26 145.73 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 123.48 0.712 . . . . 0.0 110.674 -177.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -93.08 102.86 15.19 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 171.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.6 t -88.79 106.95 17.27 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 C-N-CA 123.972 0.909 . . . . 0.0 109.185 -176.505 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 61.8 t -95.85 100.53 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -62.47 111.78 5.32 Favored Pre-proline 0 CA--C 1.547 0.834 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 172.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -71.84 -22.83 23.02 Favored 'Trans proline' 0 C--N 1.365 1.401 0 C-N-CA 122.295 1.997 . . . . 0.0 113.648 -165.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -95.66 -44.16 7.59 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 122.802 0.441 . . . . 0.0 112.166 -176.058 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 44.4 p -87.17 -25.34 24.11 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 122.465 0.306 . . . . 0.0 111.376 -178.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.12 6.57 74.91 Favored Glycine 0 C--N 1.348 1.213 0 CA-C-O 119.35 -0.694 . . . . 0.0 114.04 179.028 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -71.87 107.15 4.5 Favored 'General case' 0 CA--C 1.544 0.714 0 CA-C-N 117.406 0.603 . . . . 0.0 111.016 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.7 t -97.19 109.61 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 174.275 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -136.02 137.59 41.34 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.336 0.654 . . . . 0.0 109.723 -171.652 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 62.1 mt -77.14 131.46 34.74 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.568 0 C-N-CA 123.547 0.739 . . . . 0.0 109.113 179.204 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.449 ' HB3' ' HB ' ' A' ' 66' ' ' THR . . . -131.04 165.02 24.13 Favored 'General case' 0 C--O 1.241 0.612 0 C-N-CA 123.544 0.738 . . . . 0.0 111.061 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -103.79 116.85 33.06 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 114.633 -1.167 . . . . 0.0 108.682 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.463 HD11 HG22 ' A' ' 23' ' ' THR . 62.9 mt -76.88 110.05 12.03 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.4 mtm180 -82.26 -39.58 22.81 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.822 178.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.488 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 93.7 m-20 -128.26 129.53 46.53 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.445 0.698 . . . . 0.0 109.949 -178.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.479 1.006 0 C-N-CA 123.92 0.888 . . . . 0.0 109.809 173.618 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.6 mt . . . . . 0 CA--C 1.546 0.805 0 CA-C-O 121.306 0.574 . . . . 0.0 109.517 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 79.9 mt -83.17 134.1 27.65 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.484 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 177.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 59.2 p -117.5 166.24 12.59 Favored 'General case' 0 C--O 1.242 0.679 0 C-N-CA 122.949 0.5 . . . . 0.0 110.873 -176.47 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.404 ' HA ' ' O ' ' A' ' 73' ' ' VAL . 57.3 mtt180 -70.89 127.13 31.56 Favored 'General case' 0 C--N 1.349 0.55 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 175.342 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.47 -6.13 77.69 Favored Glycine 0 C--N 1.341 0.812 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.823 -175.752 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.76 139.54 38.41 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 117.28 0.54 . . . . 0.0 110.519 177.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.51 HG13 HD11 ' A' ' 88' ' ' ILE . 48.6 t -89.63 118.54 35.11 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 C-N-CA 123.43 0.692 . . . . 0.0 110.122 178.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.4 m -104.15 151.46 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 O-C-N 121.603 -0.685 . . . . 0.0 109.331 171.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.488 ' HB3' ' HB2' ' A' ' 42' ' ' ASN . 34.2 tt0 -102.84 134.09 46.83 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 176.834 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.449 ' HB ' ' HB3' ' A' ' 38' ' ' ALA . 60.0 p -132.28 -176.74 4.18 Favored 'General case' 0 C--O 1.243 0.762 0 C-N-CA 123.665 0.786 . . . . 0.0 109.379 -179.739 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -76.69 -8.26 56.92 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.846 175.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 58.4 mt -97.02 -14.96 21.29 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 123.58 0.752 . . . . 0.0 110.653 174.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 120.94 -156.97 16.04 Favored Glycine 0 C--N 1.347 1.141 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.742 -176.193 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -80.4 138.87 36.7 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 122.993 0.517 . . . . 0.0 111.48 179.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.9 t -125.87 135.17 64.72 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 C-N-CA 123.83 0.852 . . . . 0.0 109.82 178.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.521 ' HG2' HD12 ' A' ' 88' ' ' ILE . 10.9 mmt-85 -83.19 114.77 21.58 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 167.629 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 60' ' ' ARG . 45.3 t -80.03 96.45 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.9 p -78.67 -22.1 47.28 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 123.951 0.9 . . . . 0.0 110.897 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 49.3 m -95.92 -169.08 1.87 Allowed 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.926 0.89 . . . . 0.0 110.886 176.289 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -108.05 156.43 38.31 Favored Pre-proline 0 CA--C 1.547 0.848 0 C-N-CA 123.288 0.635 . . . . 0.0 109.652 173.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.409 ' HA ' HG12 ' A' ' 83' ' ' ILE . 68.5 Cg_endo -71.41 132.02 19.98 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.085 1.857 . . . . 0.0 111.946 178.488 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.408 ' H ' HG12 ' A' ' 83' ' ' ILE . . . 72.84 12.52 78.64 Favored Glycine 0 C--N 1.35 1.315 0 CA-C-O 119.571 -0.572 . . . . 0.0 114.331 174.737 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -74.28 134.1 42.62 Favored 'General case' 0 C--N 1.351 0.666 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.2 t70 68.08 -3.65 1.2 Allowed 'General case' 0 CA--C 1.565 1.537 0 C-N-CA 123.642 0.777 . . . . 0.0 111.579 -179.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 122.18 -13.93 8.95 Favored Glycine 0 C--N 1.355 1.623 0 CA-C-O 119.23 -0.761 . . . . 0.0 113.735 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.4 p -148.77 163.91 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 CA-C-N 118.469 1.134 . . . . 0.0 111.377 -179.006 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.409 HG12 ' HA ' ' A' ' 77' ' ' PRO . 10.0 mt -83.8 149.37 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 175.281 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 27.5 m-80 -140.17 152.96 46.45 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 122.775 0.43 . . . . 0.0 110.173 -178.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -170.8 -170.33 34.89 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-O 119.98 -0.345 . . . . 0.0 113.061 179.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.7 m -126.07 136.81 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 124.096 0.958 . . . . 0.0 110.943 179.098 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 18.9 tp -72.26 127.02 31.26 Favored 'General case' 0 N--CA 1.483 1.221 0 CA-C-O 120.852 0.358 . . . . 0.0 111.602 -174.327 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.521 HD12 ' HG2' ' A' ' 72' ' ' ARG . 7.8 pt -118.67 170.32 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 C-N-CA 124.79 1.236 . . . . 0.0 109.488 177.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 12.8 mmt180 -118.56 19.88 13.15 Favored 'General case' 0 N--CA 1.486 1.371 0 C-N-CA 122.738 0.415 . . . . 0.0 110.535 -169.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -50.43 -75.84 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.876 0 C-N-CA 124.422 1.089 . . . . 0.0 113.85 -164.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.6 mt . . . . . 0 C--O 1.24 0.576 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -178.915 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.1 m . . . . . 0 C--O 1.243 0.737 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 12.9 tpp85 -113.28 136.16 53.05 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 123.477 0.711 . . . . 0.0 110.64 -175.113 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.8 tt -133.89 144.11 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 123.398 0.679 . . . . 0.0 110.451 177.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -93.98 107.85 19.72 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 171.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 86.6 t -91.63 108.37 19.91 Favored 'Isoleucine or valine' 0 C--O 1.241 0.654 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 -177.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.506 HG11 HG22 ' A' ' 35' ' ' VAL . 51.6 t -107.32 99.27 8.24 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.128 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -59.02 116.55 16.14 Favored Pre-proline 0 CA--C 1.55 0.964 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 174.134 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_endo -73.79 -23.62 16.41 Favored 'Trans proline' 0 C--N 1.366 1.495 0 C-N-CA 122.279 1.986 . . . . 0.0 114.007 -171.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.461 ' HG3' HG23 ' A' ' 32' ' ' THR . 12.9 pt-20 -91.57 -50.33 5.83 Favored 'General case' 0 N--CA 1.479 0.975 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -176.059 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.461 HG23 ' HG3' ' A' ' 31' ' ' GLU . 75.3 p -91.38 -33.02 15.44 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 122.7 0.4 . . . . 0.0 111.452 -176.616 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.11 21.35 23.14 Favored Glycine 0 C--N 1.344 1.017 0 CA-C-O 119.292 -0.727 . . . . 0.0 114.106 177.23 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.0 mttp -56.92 106.48 0.31 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 117.364 0.582 . . . . 0.0 109.711 168.374 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.506 HG22 HG11 ' A' ' 28' ' ' VAL . 54.9 t -108.46 97.71 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 172.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -143.51 144.6 32.04 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 123.558 0.743 . . . . 0.0 109.295 -176.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 23.0 mt -85.43 133.21 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.43 173.43 10.85 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.283 1.433 . . . . 0.0 109.61 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -122.84 141.19 52.13 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 174.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 75.7 mt -83.03 114.16 23.4 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 C-N-CA 123.02 0.528 . . . . 0.0 110.041 -176.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 47.1 mtp180 -76.62 -49.6 15.85 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.13 0.972 . . . . 0.0 110.114 179.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -143.65 166.9 23.55 Favored 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.802 0.841 . . . . 0.0 108.951 -179.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.9 p . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 170.325 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.1 mm . . . . . 0 N--CA 1.474 0.734 0 CA-C-O 121.679 0.752 . . . . 0.0 109.193 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 75.6 mt -100.11 122.8 52.44 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 114.359 -1.291 . . . . 0.0 109.276 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 41.5 p -121.52 168.19 12.0 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 124.366 1.066 . . . . 0.0 109.284 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 59.0 ttp180 -74.59 130.26 39.24 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 176.137 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.36 -0.16 68.14 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 115.752 -0.658 . . . . 0.0 113.251 -172.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.3 149.94 35.29 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 122.812 0.445 . . . . 0.0 110.964 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.0 t -99.41 110.4 26.55 Favored 'Isoleucine or valine' 0 C--O 1.244 0.765 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 173.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.1 m -104.83 142.25 18.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.228 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -101.79 120.32 40.18 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -178.411 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 38.5 p -125.14 179.13 5.19 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.313 0.645 . . . . 0.0 109.466 -173.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 23.2 p-10 -68.79 -14.92 63.33 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 123.008 0.523 . . . . 0.0 111.038 178.151 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.9 mt -93.51 -46.76 7.16 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.309 0.644 . . . . 0.0 109.501 175.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 159.18 -154.95 26.03 Favored Glycine 0 C--N 1.344 0.977 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.891 175.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -77.04 130.17 37.06 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.902 0.481 . . . . 0.0 110.615 178.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 36.9 t -128.18 140.47 49.1 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.871 0 C-N-CA 124.463 1.105 . . . . 0.0 109.355 -178.321 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.542 HH11 HD13 ' A' ' 88' ' ' ILE . 7.3 mmt-85 -85.57 131.59 34.33 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 170.076 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 59.0 t -76.16 110.13 10.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 173.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 68.9 p -101.54 -42.75 6.12 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 121.207 0.527 . . . . 0.0 109.737 -173.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 20.3 m -94.33 136.97 34.03 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.622 172.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 17.4 mtp180 -60.25 132.39 90.28 Favored Pre-proline 0 CA--C 1.553 1.067 0 O-C-N 124.047 0.842 . . . . 0.0 110.743 -178.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.454 ' HA ' HG12 ' A' ' 83' ' ' ILE . 76.2 Cg_exo -52.73 116.9 3.19 Favored 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 123.807 3.005 . . . . 0.0 114.847 -176.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.46 20.59 71.49 Favored Glycine 0 C--N 1.348 1.206 0 N-CA-C 115.491 0.956 . . . . 0.0 115.491 166.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -73.44 -48.16 35.87 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-N 118.111 0.955 . . . . 0.0 110.521 177.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -85.87 -3.44 58.92 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 123.401 0.68 . . . . 0.0 110.888 170.708 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 111.85 -9.12 27.65 Favored Glycine 0 C--O 1.219 -0.782 0 N-CA-C 111.97 -0.452 . . . . 0.0 111.97 -178.594 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.6 p -140.63 163.81 22.19 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.895 0 C-N-CA 123.34 0.656 . . . . 0.0 109.931 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.454 HG12 ' HA ' ' A' ' 77' ' ' PRO . 23.3 mt -91.99 147.39 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 172.273 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -130.92 156.69 44.64 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 171.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -169.74 -172.86 36.73 Favored Glycine 0 C--N 1.344 1.027 0 N-CA-C 114.172 0.429 . . . . 0.0 114.172 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 31.2 m -123.92 135.95 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 C-N-CA 123.694 0.798 . . . . 0.0 111.119 -179.472 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.0 tp -74.04 117.17 15.52 Favored 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.459 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.542 HD13 HH11 ' A' ' 72' ' ' ARG . 12.4 pt -116.22 168.75 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 124.191 0.997 . . . . 0.0 111.394 -169.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 17.1 mmt180 -112.55 92.09 3.89 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -121.42 -75.62 0.59 Allowed 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 123.278 0.631 . . . . 0.0 111.417 -173.492 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 39.5 mt . . . . . 0 N--CA 1.473 0.676 0 C-N-CA 123.331 0.652 . . . . 0.0 110.261 -168.767 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.8 m . . . . . 0 N--CA 1.477 0.909 0 CA-C-O 121.227 0.536 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.571 HH11 ' HG3' ' A' ' 24' ' ' ARG . 4.1 ttm-85 -119.65 170.17 9.43 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.049 -178.163 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.3 tt -136.69 140.68 42.7 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 CA-C-O 121.251 0.548 . . . . 0.0 111.194 -175.134 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.5 m-80 -92.05 100.71 13.3 Favored 'General case' 0 C--O 1.242 0.664 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 175.332 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 99.5 t -92.78 114.27 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 C-N-CA 123.734 0.813 . . . . 0.0 109.91 -173.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.448 HG23 HG21 ' A' ' 35' ' ' VAL . 38.8 t -103.89 120.74 54.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 123.627 0.771 . . . . 0.0 109.103 -178.188 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -58.68 117.25 19.31 Favored Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 167.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.8 -17.66 28.98 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 121.867 1.711 . . . . 0.0 111.348 170.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -78.5 -53.96 6.66 Favored 'General case' 0 CA--C 1.555 1.137 0 C-N-CA 123.489 0.715 . . . . 0.0 112.107 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 47.0 p -100.9 -26.66 13.67 Favored 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -176.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.37 7.23 65.5 Favored Glycine 0 N--CA 1.476 1.348 0 CA-C-O 119.964 -0.353 . . . . 0.0 112.927 -178.032 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.2 mmtt -73.57 142.68 46.62 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 123.39 0.676 . . . . 0.0 110.846 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.448 HG21 HG23 ' A' ' 28' ' ' VAL . 25.1 t -118.55 122.12 68.72 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 123.417 0.687 . . . . 0.0 109.463 179.122 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -135.37 136.46 41.49 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 123.738 0.815 . . . . 0.0 109.015 178.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 56.8 mt -79.19 100.19 3.75 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.092 0 C-N-CA 123.258 0.623 . . . . 0.0 109.383 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -95.67 163.23 13.28 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 172.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.447 ' HA ' ' HG3' ' A' ' 24' ' ' ARG . 34.0 mt-10 -102.65 137.13 41.27 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -175.672 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 57.5 mt -80.36 110.29 15.76 Favored 'Isoleucine or valine' 0 C--N 1.355 0.806 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 177.323 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 14.1 mtp180 -79.15 -53.82 6.61 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 124.58 1.152 . . . . 0.0 109.535 179.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -148.84 165.75 30.57 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.911 -175.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 N--CA 1.48 1.068 0 C-N-CA 123.593 0.757 . . . . 0.0 111.694 -179.39 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 69.6 mt . . . . . 0 C--O 1.24 0.56 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.3 mt -82.13 142.68 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 171.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 67.5 p -119.19 166.48 12.91 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 123.536 0.734 . . . . 0.0 110.19 177.095 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 36.4 ttm105 -71.74 115.55 11.07 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 171.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.97 2.41 55.0 Favored Glycine 0 C--N 1.341 0.841 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.599 -174.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.81 132.71 34.38 Favored 'General case' 0 C--O 1.244 0.795 0 C-N-CA 122.875 0.47 . . . . 0.0 110.107 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.4 HG22 ' HG3' ' A' ' 90' ' ' GLU . 54.1 t -79.59 125.58 38.77 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.726 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 174.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 19.6 m -116.14 147.89 19.23 Favored 'Isoleucine or valine' 0 C--O 1.245 0.853 0 C-N-CA 123.885 0.874 . . . . 0.0 109.052 176.286 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -84.69 122.78 29.57 Favored 'General case' 0 N--CA 1.462 0.147 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -179.516 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 47.4 p -129.03 176.99 7.45 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -178.107 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 -65.82 -23.24 66.65 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 123.86 0.864 . . . . 0.0 111.362 177.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 85.1 mt -93.62 -38.61 11.26 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.122 0.569 . . . . 0.0 110.849 -179.148 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 152.22 -146.97 16.16 Favored Glycine 0 C--N 1.347 1.148 0 C-N-CA 121.573 -0.346 . . . . 0.0 113.175 174.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -68.38 109.18 3.53 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.008 0.923 . . . . 0.0 109.453 176.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 85.6 t -120.03 137.68 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 O-C-N 121.886 -0.509 . . . . 0.0 110.379 -179.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.449 ' HG3' HD12 ' A' ' 88' ' ' ILE . 31.1 mtt85 -105.08 129.77 53.43 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.669 0.387 . . . . 0.0 110.335 174.601 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.478 HG11 ' HG3' ' A' ' 77' ' ' PRO . 85.1 t -71.68 123.18 25.47 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 O-C-N 124.455 1.097 . . . . 0.0 110.259 -178.603 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.416 HG22 HG13 ' A' ' 86' ' ' VAL . 45.7 p -101.04 -22.28 14.78 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.971 0.908 . . . . 0.0 111.06 -174.89 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 20.7 t -105.11 -173.65 2.35 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 123.738 0.815 . . . . 0.0 110.268 -178.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 86.7 mtt180 -74.36 120.88 83.61 Favored Pre-proline 0 CA--C 1.544 0.717 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 168.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . 0.478 ' HG3' HG11 ' A' ' 73' ' ' VAL . 73.0 Cg_exo -54.32 102.17 0.08 OUTLIER 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 123.252 2.635 . . . . 0.0 112.98 178.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.488 ' N ' HG12 ' A' ' 83' ' ' ILE . . . 82.91 47.81 5.71 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.336 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 54.7 tp60 -64.93 -58.11 7.01 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 123.463 0.705 . . . . 0.0 110.405 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -98.31 16.49 21.35 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 123.616 0.766 . . . . 0.0 110.015 175.16 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 100.08 -20.99 46.62 Favored Glycine 0 C--N 1.35 1.31 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -173.08 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 14.1 p -110.92 158.31 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.542 1.137 . . . . 0.0 108.57 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.488 HG12 ' N ' ' A' ' 78' ' ' GLY . 8.7 mt -110.78 151.3 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 123.624 0.769 . . . . 0.0 109.828 -177.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 79.9 m-20 -118.31 148.13 42.77 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 172.172 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.7 -179.97 36.71 Favored Glycine 0 C--N 1.348 1.207 0 O-C-N 123.452 0.47 . . . . 0.0 113.136 -179.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 11.9 m -124.48 136.81 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 123.642 0.777 . . . . 0.0 111.423 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 50.8 tp -78.82 105.96 10.5 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.403 0.681 . . . . 0.0 110.982 -177.446 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.449 HD12 ' HG3' ' A' ' 72' ' ' ARG . 30.4 pt -123.41 -172.92 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 123.889 0.875 . . . . 0.0 109.507 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -132.68 110.91 10.74 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.159 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.4 ' HG3' HG22 ' A' ' 63' ' ' VAL . 41.3 mm-40 -115.94 -60.8 1.82 Allowed 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.027 0.531 . . . . 0.0 110.135 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.2 mt . . . . . 0 N--CA 1.474 0.744 0 C-N-CA 122.888 0.475 . . . . 0.0 110.256 179.008 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.5 m . . . . . 0 CA--C 1.535 0.376 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -101.14 147.81 25.81 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.445 0.698 . . . . 0.0 109.392 -177.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.441 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 17.4 tt -146.61 151.17 14.38 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 122.972 0.509 . . . . 0.0 110.324 177.683 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -100.03 102.45 13.81 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 168.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.419 HG22 HG21 ' A' ' 71' ' ' VAL . 61.6 t -87.33 110.9 21.12 Favored 'Isoleucine or valine' 0 C--O 1.243 0.724 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 178.449 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 53.5 t -100.51 99.51 8.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -60.14 114.09 9.01 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 172.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -76.25 -8.21 18.48 Favored 'Trans proline' 0 C--N 1.369 1.647 0 C-N-CA 122.795 2.33 . . . . 0.0 113.136 -173.317 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -84.17 -53.97 5.14 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.251 0.621 . . . . 0.0 109.867 -172.175 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 58.6 p -99.57 -33.21 10.73 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 124.032 0.933 . . . . 0.0 111.449 177.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.4 10.33 36.32 Favored Glycine 0 N--CA 1.476 1.359 0 CA-C-O 119.828 -0.429 . . . . 0.0 113.272 -176.374 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.2 mmmt -66.12 113.67 4.68 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.654 0.782 . . . . 0.0 111.484 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 38.1 t -104.26 125.44 59.04 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 C-N-CA 123.731 0.813 . . . . 0.0 109.268 176.278 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.425 ' HB3' HD12 ' A' ' 68' ' ' LEU . 8.9 tp10 -135.26 140.33 45.12 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.605 0.762 . . . . 0.0 109.612 178.191 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 65.5 mt -79.78 118.37 27.21 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 169.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.07 169.59 11.04 Favored 'General case' 0 C--O 1.242 0.706 0 C-N-CA 124.129 0.972 . . . . 0.0 109.083 -175.049 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -102.89 128.88 49.49 Favored 'General case' 0 C--O 1.244 0.771 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.5 mt -74.39 110.37 8.51 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 175.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 42.8 ttt180 -72.43 -37.74 68.52 Favored 'General case' 0 C--O 1.237 0.425 0 C-N-CA 124.28 1.032 . . . . 0.0 110.492 -175.037 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -160.67 148.8 16.21 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.036 -0.984 . . . . 0.0 108.624 -173.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.543 HG12 HG12 ' A' ' 64' ' ' VAL . 40.5 t . . . . . 0 C--O 1.243 0.753 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 178.635 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 50.8 mm . . . . . 0 C--O 1.243 0.74 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 57.5 mt -66.93 123.37 19.84 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.257 -0.883 . . . . 0.0 108.791 177.255 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 28.5 p -125.21 161.07 27.69 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 124.374 1.07 . . . . 0.0 109.648 -176.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 58.1 ttp180 -69.71 127.2 32.11 Favored 'General case' 0 CA--C 1.547 0.864 0 C-N-CA 123.26 0.624 . . . . 0.0 109.451 175.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.98 -16.33 58.49 Favored Glycine 0 C--N 1.346 1.113 0 CA-C-O 119.739 -0.478 . . . . 0.0 112.994 -173.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.36 153.05 30.06 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 122.732 0.413 . . . . 0.0 110.742 179.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.427 HG12 ' HG3' ' A' ' 90' ' ' GLU . 78.0 t -98.19 124.26 51.16 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 CA-C-N 115.888 -0.597 . . . . 0.0 109.762 175.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.543 HG12 HG12 ' A' ' 43' ' ' VAL . 21.8 m -118.97 138.46 49.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 123.853 0.861 . . . . 0.0 109.068 174.548 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -101.07 137.43 39.44 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' THR . . . . . 0.418 HG23 HG21 ' A' ' 25' ' ' ILE . 71.2 p -129.17 -173.09 2.89 Favored 'General case' 0 C--O 1.242 0.681 0 C-N-CA 123.671 0.788 . . . . 0.0 110.113 -169.592 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -68.36 -9.98 51.83 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 123.381 0.673 . . . . 0.0 111.768 173.281 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.425 HD12 ' HB3' ' A' ' 36' ' ' GLU . 85.1 mt -106.65 -46.24 4.03 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.775 0.83 . . . . 0.0 110.459 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 167.37 -164.51 37.96 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 116.546 -0.297 . . . . 0.0 112.359 175.171 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -73.1 139.46 46.48 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.178 0.591 . . . . 0.0 109.507 175.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.419 HG21 HG22 ' A' ' 27' ' ' VAL . 61.5 t -134.81 142.14 41.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.754 0.822 . . . . 0.0 110.331 -170.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.501 ' HG2' HD12 ' A' ' 88' ' ' ILE . 8.3 mmt-85 -93.38 124.9 37.69 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 171.032 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 51.7 t -76.35 97.49 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.213 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 p -79.7 -38.62 33.09 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.659 0.784 . . . . 0.0 112.121 -177.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' SER . . . . . 0.469 ' HB3' ' HB2' ' A' ' 84' ' ' ASN . 23.2 t -90.55 -176.46 4.76 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.436 0.694 . . . . 0.0 110.457 179.804 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 59.6 mtt180 -83.59 113.6 48.08 Favored Pre-proline 0 CA--C 1.549 0.922 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.24 141.25 51.4 Favored 'Trans proline' 0 C--N 1.376 1.98 0 C-N-CA 123.254 2.636 . . . . 0.0 113.236 -171.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 83.13 18.91 63.81 Favored Glycine 0 C--N 1.347 1.142 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.112 177.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -70.68 103.21 2.48 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 63.53 41.49 7.32 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 124.168 0.987 . . . . 0.0 110.905 -174.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 61.05 33.61 84.73 Favored Glycine 0 C--N 1.339 0.737 0 CA-C-N 114.864 -1.062 . . . . 0.0 115.293 -175.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -143.31 141.47 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.591 0.71 . . . . 0.0 110.922 168.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 25' ' ' ILE . 2.0 mp -93.7 146.98 5.86 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 174.259 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.469 ' HB2' ' HB3' ' A' ' 75' ' ' SER . 2.6 m-20 -126.31 137.99 53.54 Favored 'General case' 0 N--CA 1.484 1.225 0 CA-C-N 118.971 0.805 . . . . 0.0 109.508 174.026 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.44 -175.06 34.03 Favored Glycine 0 C--N 1.345 1.073 0 CA-C-N 115.994 -0.548 . . . . 0.0 113.075 -175.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 34.5 m -127.47 142.89 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 C-N-CA 123.441 0.696 . . . . 0.0 110.78 -177.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.3 tp -68.28 130.99 44.54 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 123.159 0.583 . . . . 0.0 110.673 -178.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . 0.501 HD12 ' HG2' ' A' ' 72' ' ' ARG . 19.5 pt -133.42 170.21 20.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 124.157 0.983 . . . . 0.0 110.04 -175.417 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 13.2 mmt-85 -111.4 95.09 5.31 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 176.267 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' GLU . . . . . 0.427 ' HG3' HG12 ' A' ' 63' ' ' VAL . 47.7 mm-40 -105.93 -62.1 1.42 Allowed 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 171.338 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 74.6 mt . . . . . 0 C--O 1.239 0.532 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.155 174.731 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.575 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -67.62 116.82 8.77 Favored 'General case' 0 C--O 1.243 0.76 0 C-N-CA 123.503 0.721 . . . . 0.0 109.867 177.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 30.2 mmm180 -85.58 75.81 10.09 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.83 0.824 . . . . 0.0 109.668 -179.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.6 ptp180 -75.88 102.06 5.39 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 114.405 -1.27 . . . . 0.0 110.657 -176.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 58.9 t -87.75 118.63 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 CA-C-N 115.657 -0.702 . . . . 0.0 109.67 178.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 53.3 ttp180 -116.3 77.83 1.14 Allowed 'General case' 0 C--O 1.24 0.59 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 173.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 58.1 tp -76.56 97.43 4.37 Favored 'General case' 0 CA--C 1.541 0.626 0 CA-C-N 116.253 -0.43 . . . . 0.0 109.914 -177.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 37.0 mt -98.95 87.59 1.51 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.698 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 173.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 71.8 ttt180 -61.53 130.09 44.29 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.71 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 10.1 m -77.43 77.11 3.96 Favored 'General case' 0 CA--C 1.545 0.758 0 CA-C-O 121.744 0.783 . . . . 0.0 109.591 -177.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -87.47 112.28 22.03 Favored 'General case' 0 CA--C 1.544 0.747 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 -179.233 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.71 92.97 0.09 OUTLIER Glycine 0 C--N 1.345 1.076 0 O-C-N 123.619 0.574 . . . . 0.0 112.497 -177.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -112.93 -138.62 7.22 Favored Glycine 0 C--N 1.341 0.86 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 173.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.5 m120 -121.39 28.15 7.92 Favored 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 124.049 0.94 . . . . 0.0 109.763 177.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.1 p -65.36 108.53 1.98 Allowed 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 123.915 0.886 . . . . 0.0 111.27 -178.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 55.1 tttp -82.18 118.28 22.96 Favored 'General case' 0 C--O 1.238 0.487 0 C-N-CA 123.828 0.851 . . . . 0.0 109.644 177.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.6 p -166.4 155.13 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.908 0 C-N-CA 124.077 0.951 . . . . 0.0 109.203 -177.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 58.3 mtt180 -74.23 149.01 41.03 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 173.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.406 ' HA ' ' O ' ' A' ' 22' ' ' ASP . 1.8 pt? -48.43 100.09 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.135 0 C-N-CA 124.655 1.182 . . . . 0.0 113.404 -175.297 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -164.82 -55.97 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 124.86 1.264 . . . . 0.0 108.103 177.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 11.5 p -97.05 -10.85 25.3 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.723 0.809 . . . . 0.0 110.995 173.006 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . 0.406 ' O ' ' HA ' ' A' ' 19' ' ' LEU . 3.8 m-20 -148.27 94.44 2.31 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 124.643 1.177 . . . . 0.0 107.919 176.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.0 m -67.72 114.1 6.05 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 123.06 0.544 . . . . 0.0 109.709 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -106.95 144.97 32.81 Favored 'General case' 0 C--O 1.243 0.752 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -177.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.9 tt -146.17 139.36 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.772 0 C-N-CA 123.589 0.756 . . . . 0.0 110.061 -178.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 -89.39 101.58 14.26 Favored 'General case' 0 C--O 1.239 0.543 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 175.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.2 t -87.29 110.17 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.8 t -98.22 100.24 10.2 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -61.2 112.29 5.61 Favored Pre-proline 0 CA--C 1.549 0.929 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 175.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -77.18 -17.78 14.77 Favored 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 122.268 1.979 . . . . 0.0 113.209 -168.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -96.87 -48.89 5.27 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 122.714 0.406 . . . . 0.0 110.996 178.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.508 HG21 ' HE3' ' A' ' 34' ' ' LYS . 2.8 m -90.93 -31.26 16.45 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.215 0.606 . . . . 0.0 111.581 -172.498 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 95.14 6.27 60.26 Favored Glycine 0 N--CA 1.476 1.316 0 CA-C-O 119.479 -0.623 . . . . 0.0 114.003 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.508 ' HE3' HG21 ' A' ' 32' ' ' THR . 92.1 mttt -63.78 106.72 1.04 Allowed 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 123.089 0.556 . . . . 0.0 110.839 177.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.6 t -103.93 106.86 21.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 175.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.495 ' HB3' HD13 ' A' ' 68' ' ' LEU . 10.3 tp10 -138.43 139.44 38.88 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 123.763 0.825 . . . . 0.0 109.812 -173.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 50.0 mt -83.15 100.85 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 176.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.8 173.24 7.41 Favored 'General case' 0 C--O 1.239 0.509 0 C-N-CA 123.962 0.905 . . . . 0.0 110.079 176.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -107.56 134.59 50.35 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 175.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 59.3 mt -75.57 110.26 10.23 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 173.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -82.01 -48.07 11.87 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.645 1.178 . . . . 0.0 110.236 -173.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -135.97 153.82 51.28 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 175.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.496 HG13 HG11 ' A' ' 64' ' ' VAL . 16.8 t -110.16 42.31 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.023 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 173.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.2 p -70.8 87.68 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.942 0 CA-C-N 114.129 -1.396 . . . . 0.0 110.02 177.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -106.39 -50.35 3.16 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 171.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -129.21 -30.02 2.21 Favored 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.323 179.015 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.4 t -75.31 80.7 2.4 Favored 'General case' 0 CA--C 1.554 1.125 0 CA-C-O 122.386 1.089 . . . . 0.0 110.717 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.01 137.78 32.46 Favored 'General case' 0 C--O 1.24 0.557 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.589 -178.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 44.4 m-80 66.48 119.83 0.02 OUTLIER Pre-proline 0 N--CA 1.481 1.107 0 C-N-CA 125.507 1.523 . . . . 0.0 111.249 -176.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_exo -50.34 99.98 0.04 OUTLIER 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 123.34 2.694 . . . . 0.0 113.641 172.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 30.2 p-80 -121.05 73.12 1.01 Allowed 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 123.434 0.693 . . . . 0.0 109.692 175.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 61.6 t80 61.46 23.87 14.07 Favored 'General case' 0 N--CA 1.492 1.666 0 C-N-CA 124.3 1.04 . . . . 0.0 110.341 -178.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 16.3 m -100.12 137.14 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 O-C-N 121.333 -0.854 . . . . 0.0 111.418 -176.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 13.5 ptm180 -143.2 28.27 1.53 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 124.746 1.218 . . . . 0.0 108.44 174.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 26.3 ttm180 -59.06 112.02 1.53 Allowed 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.353 1.061 . . . . 0.0 111.696 -174.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -107.51 31.27 5.55 Favored 'General case' 0 CA--C 1.556 1.182 0 CA-C-O 122.057 0.932 . . . . 0.0 109.157 175.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 67.9 mt -81.96 84.79 1.64 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 169.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.4 mt -102.98 116.0 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 114.041 -1.436 . . . . 0.0 108.944 -174.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 39.4 p -117.54 162.89 17.26 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.631 0.772 . . . . 0.0 110.765 -176.358 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -67.02 135.66 54.07 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 123.006 0.522 . . . . 0.0 110.127 176.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.07 -2.94 85.77 Favored Glycine 0 C--N 1.344 0.991 0 O-C-N 123.595 0.56 . . . . 0.0 113.571 -175.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.02 145.79 30.04 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 117.283 0.541 . . . . 0.0 110.749 179.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.423 HG13 HD11 ' A' ' 88' ' ' ILE . 50.8 t -90.1 112.17 24.33 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 172.067 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.496 HG11 HG13 ' A' ' 43' ' ' VAL . 26.5 m -107.42 159.6 6.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 174.277 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -102.6 137.46 40.8 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 172.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 30.6 p -133.46 -175.46 3.82 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.418 0.687 . . . . 0.0 109.797 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -60.59 -27.0 67.38 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 123.692 0.797 . . . . 0.0 111.889 175.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.495 HD13 ' HB3' ' A' ' 36' ' ' GLU . 74.1 mt -100.24 -0.67 38.15 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.269 0.628 . . . . 0.0 111.167 -175.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 112.06 -161.66 12.67 Favored Glycine 0 C--N 1.351 1.415 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.432 ' HA ' ' O ' ' A' ' 64' ' ' VAL . 17.5 m120 -73.69 138.14 44.52 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-N 117.16 0.48 . . . . 0.0 111.568 -178.212 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 92.8 t -130.45 146.62 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 124.748 1.219 . . . . 0.0 110.126 -176.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.565 ' HG2' HD12 ' A' ' 88' ' ' ILE . 34.6 mmt180 -85.23 126.68 33.87 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 167.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 43.0 t -73.54 111.7 8.89 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 172.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 77.6 p -95.36 -21.92 18.07 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-O 120.981 0.42 . . . . 0.0 109.907 -175.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 23.3 t -107.23 -171.29 1.85 Allowed 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.453 1.101 . . . . 0.0 110.578 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.28 136.68 20.91 Favored Pre-proline 0 CA--C 1.547 0.851 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 169.237 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -59.75 103.83 0.21 Allowed 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.502 2.135 . . . . 0.0 111.314 173.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 130.2 -6.08 6.01 Favored Glycine 0 C--N 1.342 0.904 0 CA-C-O 119.1 -0.833 . . . . 0.0 113.46 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 16.9 mm100 -67.31 -71.8 0.19 Allowed 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 117.876 0.838 . . . . 0.0 110.502 177.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -89.27 30.84 0.94 Allowed 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 172.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 64.63 -74.66 0.07 OUTLIER Glycine 0 C--N 1.355 1.618 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 -160.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.9 p -57.87 156.17 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.255 0 C-N-CA 125.387 1.475 . . . . 0.0 112.095 174.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 39.3 mt -84.04 151.51 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.526 1.13 . . . . 0.0 108.232 175.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -138.0 158.03 45.15 Favored 'General case' 0 N--CA 1.482 1.155 0 CA-C-N 118.298 0.499 . . . . 0.0 110.211 167.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.68 -171.71 34.77 Favored Glycine 0 C--N 1.344 0.994 0 CA-C-N 115.427 -0.806 . . . . 0.0 113.124 -174.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.2 m -122.91 135.23 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 123.441 0.696 . . . . 0.0 110.256 178.076 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 30.8 tp -68.37 134.12 49.76 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 122.969 0.508 . . . . 0.0 110.176 -177.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.565 HD12 ' HG2' ' A' ' 72' ' ' ARG . 16.7 pt -132.02 167.21 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 123.81 0.844 . . . . 0.0 111.062 -175.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 62.5 mtt-85 -117.66 49.42 1.23 Allowed 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 123.71 0.804 . . . . 0.0 110.166 -175.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -68.2 -58.74 3.96 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.072 0.463 . . . . 0.0 110.515 177.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.78 166.8 11.47 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.112 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 56.94 73.0 0.47 Allowed 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 125.723 1.609 . . . . 0.0 113.057 174.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 22.7 m-70 -97.04 -69.97 0.74 Allowed 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 123.916 0.886 . . . . 0.0 109.249 174.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 9.3 t-80 -81.5 -64.17 1.24 Allowed 'General case' 0 C--N 1.351 0.666 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 178.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 33.6 p80 -79.36 140.06 37.59 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 172.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 80.6 m-70 -119.45 35.32 4.88 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 174.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 40.4 t60 -139.14 140.28 37.86 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.525 1.13 . . . . 0.0 108.686 178.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 50.8 p-80 . . . . . 0 CA--C 1.551 1.014 0 C-N-CA 124.382 1.073 . . . . 0.0 109.376 178.433 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.296 0 CA-C-O 119.693 -0.504 . . . . 0.0 112.226 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -158.67 153.11 24.25 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 123.178 0.591 . . . . 0.0 109.938 -176.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.16 84.5 4.38 Favored 'General case' 0 C--O 1.239 0.535 0 C-N-CA 123.513 0.725 . . . . 0.0 109.835 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 34.2 ttp180 -85.57 122.01 29.08 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.4 m -75.48 136.14 25.61 Favored 'Isoleucine or valine' 0 C--O 1.246 0.912 0 C-N-CA 123.144 0.578 . . . . 0.0 110.856 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -81.4 84.06 6.77 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 174.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . 0.401 HD12 ' HB2' ' A' ' 9' ' ' ARG . 0.3 OUTLIER -91.48 96.18 10.36 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 179.082 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 33.1 mm -74.17 80.86 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 175.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.401 ' HB2' HD12 ' A' ' 7' ' ' LEU . 20.0 tpt180 -88.69 97.2 10.99 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.32 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 58.8 p -86.08 107.26 17.74 Favored 'General case' 0 CA--C 1.539 0.549 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 175.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.524 ' HB2' ' HB3' ' A' ' 14' ' ' ASN . 1.9 ppt_? -68.78 -17.78 64.09 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -171.494 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.26 -128.08 45.11 Favored Glycine 0 C--N 1.346 1.094 0 O-C-N 123.456 0.472 . . . . 0.0 112.896 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -84.62 73.75 2.6 Favored Glycine 0 C--N 1.343 0.948 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 173.319 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . 0.524 ' HB3' ' HB2' ' A' ' 11' ' ' ARG . 18.5 p-10 -70.31 89.13 0.66 Allowed 'General case' 0 CA--C 1.548 0.894 0 CA-C-O 121.841 0.829 . . . . 0.0 111.299 -176.165 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 31.5 m -73.09 93.62 1.82 Allowed 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.378 177.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.503 ' HD2' HD13 ' A' ' 37' ' ' ILE . 24.5 ttmm -155.84 137.26 14.01 Favored 'General case' 0 C--O 1.241 0.647 0 C-N-CA 123.991 0.916 . . . . 0.0 109.383 -175.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 10.4 p -69.29 129.86 33.92 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.892 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 170.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.702 ' HB3' HG23 ' A' ' 82' ' ' VAL . 0.2 OUTLIER -71.72 -25.31 62.01 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 123.155 0.582 . . . . 0.0 111.294 -170.445 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.617 ' HB3' ' HB3' ' A' ' 24' ' ' ARG . 2.6 pp -155.42 137.77 14.88 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 123.252 0.621 . . . . 0.0 111.328 164.197 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -123.28 -45.1 2.11 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 172.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 38.2 t -72.2 139.32 48.13 Favored 'General case' 0 C--N 1.35 0.613 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 163.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -15.51 -63.35 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.019 0 C-N-CA 127.412 2.285 . . . . 0.0 116.224 -170.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.499 HG22 HD11 ' A' ' 40' ' ' ILE . 29.9 m -143.73 113.83 7.31 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 121.416 0.627 . . . . 0.0 109.906 -176.065 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.617 ' HB3' ' HB3' ' A' ' 19' ' ' LEU . 39.4 ttp180 -123.47 163.33 21.1 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 124.377 1.071 . . . . 0.0 108.265 177.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.1 tt -135.77 142.85 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.201 0.601 . . . . 0.0 110.183 -171.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.0 m-80 -84.98 102.5 13.23 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.6 t -95.2 107.93 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -172.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 42.1 t -93.58 103.09 14.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -64.24 116.68 29.85 Favored Pre-proline 0 CA--C 1.546 0.797 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 174.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.5 ' HG2' ' HG3' ' A' ' 31' ' ' GLU . 82.3 Cg_endo -73.33 -18.08 23.55 Favored 'Trans proline' 0 C--N 1.365 1.426 0 C-N-CA 122.361 2.04 . . . . 0.0 113.455 -173.513 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.5 ' HG3' ' HG2' ' A' ' 30' ' ' PRO . 20.8 mt-10 -95.86 -51.78 4.34 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.937 0.895 . . . . 0.0 110.757 -169.556 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 61.1 p -96.02 -7.26 36.79 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 123.56 0.744 . . . . 0.0 111.648 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.48 -0.65 80.19 Favored Glycine 0 C--N 1.355 1.595 0 CA-C-O 119.556 -0.58 . . . . 0.0 114.208 173.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.491 ' HB2' ' HZ3' ' A' ' 34' ' ' LYS . 9.3 mtmp? -67.17 106.89 2.14 Favored 'General case' 0 C--N 1.353 0.758 0 C-N-CA 123.267 0.627 . . . . 0.0 111.572 -174.461 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.4 t -82.71 99.78 5.86 Favored 'Isoleucine or valine' 0 C--N 1.346 0.446 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 169.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -130.02 114.28 15.6 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 -167.056 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.503 HD13 ' HD2' ' A' ' 16' ' ' LYS . 26.7 mt -79.04 100.01 3.55 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -171.371 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.415 ' O ' ' HG3' ' A' ' 24' ' ' ARG . . . -104.61 163.3 12.58 Favored 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 123.523 0.729 . . . . 0.0 110.755 -175.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.595 ' HG2' ' HD3' ' A' ' 24' ' ' ARG . 17.8 mt-10 -105.92 136.11 46.16 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 123.242 0.617 . . . . 0.0 109.932 -167.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.499 HD11 HG22 ' A' ' 23' ' ' THR . 68.1 mt -77.41 112.4 15.31 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.972 0 CA-C-O 121.417 0.627 . . . . 0.0 110.668 -174.391 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 9.2 mtp180 -74.93 -55.04 6.18 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 124.308 1.043 . . . . 0.0 110.152 174.352 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -140.51 168.46 19.75 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 124.249 1.02 . . . . 0.0 108.81 -176.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.1 t -120.07 97.5 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 167.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.1 p -140.62 129.44 25.38 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 CA-C-N 115.408 -0.815 . . . . 0.0 110.411 -166.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -132.82 -63.21 0.79 Allowed 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.925 0.89 . . . . 0.0 109.351 177.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 21.3 p-10 -121.66 88.54 2.95 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 121.927 0.87 . . . . 0.0 110.166 -178.046 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.5 p -128.68 107.07 9.38 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.733 0.813 . . . . 0.0 109.076 174.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -66.38 -60.77 2.45 Favored 'General case' 0 C--N 1.347 0.487 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 173.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -116.84 114.72 39.34 Favored Pre-proline 0 CA--C 1.544 0.717 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 175.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_exo -66.45 -6.84 16.04 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 123.363 2.709 . . . . 0.0 114.216 -177.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 79.4 t60 -56.93 119.3 6.02 Favored 'General case' 0 C--N 1.358 0.938 0 C-N-CA 123.414 0.685 . . . . 0.0 109.875 172.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 76.8 t80 59.51 87.44 0.08 Allowed 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.946 1.298 . . . . 0.0 110.546 -175.267 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.3 m -81.54 178.51 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.283 174.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -94.12 -175.2 3.61 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.296 0.638 . . . . 0.0 109.788 172.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 74.0 ttt180 -69.03 156.1 39.21 Favored 'General case' 0 CA--C 1.549 0.927 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 172.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -75.84 66.25 2.07 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 123.315 0.646 . . . . 0.0 110.597 178.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 40.5 mm -72.58 83.87 0.39 Allowed 'Isoleucine or valine' 0 C--O 1.244 0.773 0 C-N-CA 124.139 0.976 . . . . 0.0 109.749 176.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 37.8 mt -81.5 105.62 11.61 Favored 'Isoleucine or valine' 0 C--N 1.344 0.331 0 N-CA-C 107.699 -1.222 . . . . 0.0 107.699 174.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 5.7 p -139.62 168.24 20.27 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.414 1.086 . . . . 0.0 108.509 -177.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 52.5 mtm180 -61.03 125.24 23.01 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 122.754 0.422 . . . . 0.0 111.105 -178.424 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.82 -10.24 68.38 Favored Glycine 0 C--N 1.34 0.783 0 CA-C-N 115.196 -0.911 . . . . 0.0 114.154 -176.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.62 156.83 36.33 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-N 117.482 0.641 . . . . 0.0 110.847 177.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.443 HG22 ' HG3' ' A' ' 90' ' ' GLU . 99.2 t -109.08 124.39 65.71 Favored 'Isoleucine or valine' 0 C--O 1.242 0.699 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 175.042 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.1 m -105.58 146.19 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 172.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -94.73 139.24 31.52 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 124.206 1.003 . . . . 0.0 109.011 176.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 76.7 p -138.09 177.38 7.92 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 124.799 1.24 . . . . 0.0 107.816 177.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.7 m-80 -84.04 8.93 13.77 Favored 'General case' 0 N--CA 1.481 1.092 0 O-C-N 122.339 -0.226 . . . . 0.0 111.419 175.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 62.8 mt -104.8 -14.22 15.6 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 123.386 0.674 . . . . 0.0 110.498 171.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 134.7 -148.49 19.54 Favored Glycine 0 C--N 1.343 0.942 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 -176.023 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -101.9 145.9 28.58 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 176.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.1 t -129.82 141.28 46.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 C-N-CA 123.62 0.768 . . . . 0.0 109.706 -176.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.571 ' HG2' HD11 ' A' ' 88' ' ' ILE . 26.8 mmt180 -81.14 139.17 35.76 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 170.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 67.3 t -84.62 103.74 12.12 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.747 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 169.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 72.1 p -100.06 -17.29 17.55 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.176 0.59 . . . . 0.0 110.854 -171.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 60.2 p -118.67 179.63 4.08 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.966 0.906 . . . . 0.0 109.963 176.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 14.4 ptp180 -78.75 151.85 77.13 Favored Pre-proline 0 CA--C 1.552 1.032 0 C-N-CA 123.082 0.553 . . . . 0.0 110.645 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.652 ' HA ' HG13 ' A' ' 83' ' ' ILE . 85.1 Cg_endo -76.41 16.07 0.93 Allowed 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 122.879 2.386 . . . . 0.0 114.58 -178.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.81 58.88 0.42 Allowed Glycine 0 C--N 1.346 1.093 0 N-CA-C 112.216 -0.354 . . . . 0.0 112.216 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 -118.83 110.26 17.0 Favored 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 171.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.3 t70 67.62 -1.37 1.64 Allowed 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 124.433 1.093 . . . . 0.0 111.217 -169.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . 0.446 ' O ' HD22 ' A' ' 19' ' ' LEU . . . 95.47 5.83 60.1 Favored Glycine 0 C--N 1.349 1.3 0 CA-C-O 119.479 -0.623 . . . . 0.0 112.677 -174.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.702 HG23 ' HB3' ' A' ' 18' ' ' ARG . 11.4 p -126.26 164.29 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 123.435 0.694 . . . . 0.0 111.07 -175.444 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.652 HG13 ' HA ' ' A' ' 77' ' ' PRO . 3.4 mp -109.61 147.02 14.32 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 124.473 1.109 . . . . 0.0 108.664 178.263 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -119.69 155.82 31.68 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 123.596 0.759 . . . . 0.0 109.345 169.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.63 -175.12 36.57 Favored Glycine 0 C--N 1.345 1.065 0 N-CA-C 114.017 0.367 . . . . 0.0 114.017 -176.286 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.6 m -130.71 140.37 48.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 C-N-CA 123.469 0.707 . . . . 0.0 110.419 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 33.6 tp -75.47 112.85 12.22 Favored 'General case' 0 CA--C 1.549 0.937 0 CA-C-O 121.303 0.573 . . . . 0.0 111.624 -172.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.571 HD11 ' HG2' ' A' ' 72' ' ' ARG . 9.3 pt -110.02 179.01 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.19 0 C-N-CA 125.059 1.344 . . . . 0.0 110.488 178.062 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 47.5 mmt-85 -132.03 62.48 1.64 Allowed 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 123.438 0.695 . . . . 0.0 109.412 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.443 ' HG3' HG22 ' A' ' 63' ' ' VAL . 37.6 mm-40 -68.77 -63.06 1.13 Allowed 'General case' 0 N--CA 1.491 1.605 0 CA-C-O 121.464 0.65 . . . . 0.0 110.09 177.736 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 70.6 mt -105.57 127.77 53.22 Favored 'General case' 0 C--O 1.242 0.66 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 172.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -65.58 93.28 0.16 Allowed 'General case' 0 CA--C 1.548 0.88 0 O-C-N 123.78 0.675 . . . . 0.0 110.372 -178.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 37.5 m-70 -120.28 86.57 2.59 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 124.061 0.944 . . . . 0.0 109.051 177.03 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -159.56 164.05 34.6 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-N 115.306 -0.861 . . . . 0.0 108.783 173.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -110.72 168.67 9.29 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 122.817 0.447 . . . . 0.0 110.086 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 55.8 m80 -72.51 143.26 48.42 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 171.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 8.7 p80 -69.69 155.56 40.33 Favored 'General case' 0 CA--C 1.551 0.988 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 . . . . . 0 C--O 1.247 0.948 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 172.422 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.912 0 N-CA-C 112.005 -0.438 . . . . 0.0 112.005 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.433 ' HA ' HH11 ' A' ' 3' ' ' ARG . 2.9 p30 -140.63 173.92 11.02 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 124.019 0.928 . . . . 0.0 110.637 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.433 HH11 ' HA ' ' A' ' 2' ' ' ASP . 1.8 mpt_? -116.66 91.69 3.66 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.234 0.614 . . . . 0.0 109.697 -175.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 50.8 mtm180 -98.8 99.12 10.17 Favored 'General case' 0 C--O 1.242 0.685 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 174.22 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.3 p -119.25 109.62 27.12 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 168.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.6 tpt180 -91.05 95.84 10.31 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 123.227 0.611 . . . . 0.0 109.702 -172.281 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -88.25 89.73 8.11 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-O 121.263 0.554 . . . . 0.0 109.989 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 69.2 mt -92.42 130.18 41.92 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 175.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 6.0 ppt_? -147.79 155.18 41.4 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 123.568 0.747 . . . . 0.0 111.368 -177.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 29.0 p -127.99 106.15 8.89 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 124.023 0.929 . . . . 0.0 108.984 174.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 4.0 mmp_? -106.9 150.73 26.11 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 123.737 0.815 . . . . 0.0 110.665 -177.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -134.14 63.82 0.61 Allowed Glycine 0 C--N 1.338 0.639 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.19 87.89 0.12 Allowed Glycine 0 CA--C 1.53 0.995 0 O-C-N 123.974 0.455 . . . . 0.0 112.912 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 27.0 t-20 -73.07 116.89 14.14 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.658 0.783 . . . . 0.0 109.554 176.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 37.2 p -72.19 89.36 1.17 Allowed 'General case' 0 CA--C 1.549 0.915 0 CA-C-O 121.514 0.673 . . . . 0.0 110.092 178.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.73 152.97 19.2 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.271 -0.877 . . . . 0.0 112.009 -173.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.2 t -84.34 131.97 32.69 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 123.499 0.719 . . . . 0.0 109.741 -178.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 3.8 mpt_? -73.35 -35.08 65.93 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 124.058 0.943 . . . . 0.0 111.39 -170.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -151.2 152.32 33.12 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.297 0.639 . . . . 0.0 110.278 -176.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.94 -36.84 0.2 Allowed 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 123.43 0.692 . . . . 0.0 109.797 178.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 44.2 m -87.24 -158.28 0.43 Allowed 'General case' 0 CA--C 1.555 1.17 0 C-N-CA 124.104 0.962 . . . . 0.0 110.237 173.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -28.67 128.78 0.08 Allowed 'General case' 0 N--CA 1.501 2.123 0 C-N-CA 125.117 1.367 . . . . 0.0 112.931 169.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.5 ' HB ' ' HB ' ' A' ' 40' ' ' ILE . 6.4 m -64.49 131.52 47.33 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.772 0.829 . . . . 0.0 112.894 -164.363 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 22.9 mmt85 -104.95 134.31 48.28 Favored 'General case' 0 C--O 1.244 0.768 0 C-N-CA 124.275 1.03 . . . . 0.0 109.45 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.4 tt -140.29 135.91 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 123.995 0.918 . . . . 0.0 109.394 -178.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 20.7 m-80 -87.14 103.36 15.33 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.5 t -98.42 110.11 25.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 C-N-CA 123.884 0.874 . . . . 0.0 109.196 -172.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.457 HG22 HG22 ' A' ' 35' ' ' VAL . 38.2 t -92.66 103.54 14.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -60.51 116.82 19.72 Favored Pre-proline 0 CA--C 1.549 0.918 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -76.75 -11.17 18.43 Favored 'Trans proline' 0 C--N 1.363 1.326 0 C-N-CA 122.958 2.439 . . . . 0.0 113.379 -174.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -81.89 -52.47 7.06 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 123.087 0.555 . . . . 0.0 109.583 -176.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 65.4 p -96.37 -31.85 12.66 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 114.774 -1.103 . . . . 0.0 112.026 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 94.03 8.61 60.21 Favored Glycine 0 N--CA 1.475 1.247 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.494 -173.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.7 mmtp -72.66 108.92 5.93 Favored 'General case' 0 C--N 1.359 0.982 0 C-N-CA 123.18 0.592 . . . . 0.0 111.678 -177.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.457 HG22 HG22 ' A' ' 28' ' ' VAL . 24.8 t -82.91 120.17 33.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 172.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 13.1 tp10 -140.29 130.33 24.83 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.463 0.705 . . . . 0.0 109.479 -177.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 46.0 mt -78.0 103.79 5.37 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -179.025 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.419 ' HB2' ' HB ' ' A' ' 66' ' ' THR . . . -89.83 166.12 13.72 Favored 'General case' 0 C--O 1.24 0.558 0 C-N-CA 123.694 0.798 . . . . 0.0 111.037 177.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 -114.39 124.94 53.2 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 115.314 -0.857 . . . . 0.0 108.925 176.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.5 ' HB ' ' HB ' ' A' ' 23' ' ' THR . 67.8 mt -79.79 111.37 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 C-N-CA 122.958 0.503 . . . . 0.0 109.775 -173.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 71.9 mtt180 -64.86 -46.83 80.19 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 123.798 0.839 . . . . 0.0 110.376 176.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 62.5 t30 -164.5 172.51 13.21 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.932 -170.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 25.2 m -98.33 133.26 41.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.929 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 170.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.7 p -163.0 94.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-O 122.355 1.074 . . . . 0.0 109.563 176.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.676 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -94.45 -32.75 13.39 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.069 179.51 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -167.03 -17.48 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.814 0.846 . . . . 0.0 110.296 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.5 t -57.95 111.69 1.25 Allowed 'General case' 0 CA--C 1.557 1.243 0 CA-C-O 121.921 0.867 . . . . 0.0 111.41 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.08 164.08 22.7 Favored 'General case' 0 C--O 1.243 0.719 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.409 -178.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.3 m120 56.31 68.35 2.3 Favored Pre-proline 0 CA--C 1.553 1.071 0 C-N-CA 124.062 0.945 . . . . 0.0 109.356 -172.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo -77.54 11.81 2.06 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 123.006 2.47 . . . . 0.0 114.28 -170.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 33.5 m80 -74.26 -47.41 35.22 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 123.169 0.588 . . . . 0.0 110.85 -177.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 85.5 t80 -76.22 -29.62 57.64 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.222 175.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 85.6 t -58.21 105.0 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-O 121.531 0.682 . . . . 0.0 110.093 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 47.3 ttt180 -83.31 153.96 24.36 Favored 'General case' 0 C--O 1.242 0.668 0 C-N-CA 125.14 1.376 . . . . 0.0 108.932 177.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 37.6 ttm180 -59.23 94.21 0.02 OUTLIER 'General case' 0 C--N 1.355 0.846 0 CA-C-O 121.187 0.518 . . . . 0.0 109.627 176.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -80.17 -159.38 0.22 Allowed 'General case' 0 CA--C 1.552 1.047 0 C-N-CA 124.164 0.985 . . . . 0.0 109.035 178.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 50.1 mt -90.38 100.37 10.94 Favored 'Isoleucine or valine' 0 C--O 1.241 0.635 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -167.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 71.3 mt -61.98 116.93 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 114.372 -1.285 . . . . 0.0 109.952 -178.174 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' THR . . . . . 0.429 ' HA ' ' HG2' ' A' ' 77' ' ' PRO . 40.6 p -126.8 167.2 16.11 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 124.073 0.949 . . . . 0.0 110.017 -177.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 32.5 ttp180 -64.03 138.5 58.49 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 123.127 0.571 . . . . 0.0 110.269 177.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.32 -39.17 3.04 Favored Glycine 0 C--N 1.335 0.521 0 CA-C-O 119.926 -0.374 . . . . 0.0 112.778 -176.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -61.63 135.87 57.79 Favored 'General case' 0 C--N 1.356 0.859 0 C-N-CA 123.665 0.786 . . . . 0.0 110.821 179.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.676 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 42.2 t -87.51 133.15 31.01 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 176.472 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 18.4 m -113.52 150.5 15.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 C-N-CA 124.171 0.989 . . . . 0.0 109.024 177.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -95.65 125.44 40.24 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 106.098 -1.815 . . . . 0.0 106.098 174.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.419 ' HB ' ' HB2' ' A' ' 38' ' ' ALA . 61.3 p -122.05 177.71 5.21 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 26.7 p-10 -69.54 -18.26 63.65 Favored 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.063 175.08 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.6 mt -85.12 -43.7 13.63 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 122.965 0.506 . . . . 0.0 110.582 174.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 155.93 -150.8 22.26 Favored Glycine 0 C--N 1.344 0.984 0 N-CA-C 111.925 -0.47 . . . . 0.0 111.925 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -79.94 126.02 30.48 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-N 117.488 0.644 . . . . 0.0 109.335 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 57.7 t -125.07 138.2 55.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 123.741 0.817 . . . . 0.0 110.638 -178.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.585 ' HG2' HD11 ' A' ' 88' ' ' ILE . 17.8 mmt180 -83.65 131.46 34.95 Favored 'General case' 0 N--CA 1.483 1.188 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 168.368 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.508 HG11 ' HG3' ' A' ' 77' ' ' PRO . 66.3 t -79.02 105.86 9.04 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 169.251 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 41.6 p -93.8 -30.94 14.58 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 123.392 0.677 . . . . 0.0 110.727 -171.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 49.0 m -96.88 178.05 5.42 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.248 177.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.764 ' HB2' ' HB2' ' A' ' 79' ' ' GLN . 80.2 mtp180 -74.36 124.52 89.94 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.109 170.288 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.508 ' HG3' HG11 ' A' ' 73' ' ' VAL . 32.0 Cg_exo -62.12 104.01 0.32 Allowed 'Trans proline' 0 C--N 1.373 1.841 0 C-N-CA 122.481 2.12 . . . . 0.0 111.293 173.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.34 24.82 17.86 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-N 116.06 -0.518 . . . . 0.0 113.347 -178.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . 0.764 ' HB2' ' HB2' ' A' ' 76' ' ' ARG . 24.7 tm0? -65.9 -58.65 5.09 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 176.329 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -84.12 -9.3 58.69 Favored 'General case' 0 N--CA 1.487 1.377 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.763 173.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 117.33 -53.14 0.65 Allowed Glycine 0 C--N 1.336 0.559 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -163.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 10.1 p -87.03 165.7 2.09 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.131 0 C-N-CA 123.886 0.874 . . . . 0.0 110.703 177.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 18.5 mt -96.38 148.49 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.888 0 C-N-CA 124.039 0.936 . . . . 0.0 108.605 173.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 17.4 m-80 -131.75 149.01 52.61 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 123.252 0.621 . . . . 0.0 109.699 177.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.45 -173.27 32.92 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 115.735 -0.666 . . . . 0.0 114.092 -174.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.6 m -129.79 141.72 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 C-N-CA 123.551 0.74 . . . . 0.0 110.107 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 20.1 tp -75.88 105.31 6.85 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 121.022 0.439 . . . . 0.0 109.924 -178.003 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.585 HD11 ' HG2' ' A' ' 72' ' ' ARG . 11.0 pt -107.21 -173.46 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 123.432 0.693 . . . . 0.0 110.222 -179.413 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 60.7 mtt85 -139.95 77.47 1.61 Allowed 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 123.146 0.578 . . . . 0.0 109.734 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.576 ' HG2' HD12 ' A' ' 88' ' ' ILE . 56.5 mm-40 -68.58 -65.51 0.69 Allowed 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 167.023 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 60.7 mt -80.82 -164.51 0.74 Allowed 'General case' 0 CA--C 1.549 0.927 0 CA-C-N 114.429 -1.26 . . . . 0.0 108.934 170.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 62.42 21.18 12.41 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 123.226 0.61 . . . . 0.0 111.513 172.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 6.3 p80 -117.14 170.83 8.36 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.67 0.788 . . . . 0.0 110.807 -171.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -136.57 -59.44 0.72 Allowed 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.127 0.971 . . . . 0.0 108.463 172.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -94.16 -53.16 4.07 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.023 -177.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 60.6 t-80 -108.49 117.11 33.31 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 122.982 0.513 . . . . 0.0 111.63 -173.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 42.4 t60 -95.73 148.26 22.75 Favored 'General case' 0 N--CA 1.483 1.209 0 C-N-CA 124.96 1.304 . . . . 0.0 108.665 169.586 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 81.1 t60 . . . . . 0 N--CA 1.487 1.386 0 C-N-CA 123.241 0.616 . . . . 0.0 110.67 178.667 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.376 0 N-CA-C 111.591 -0.604 . . . . 0.0 111.591 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 36.6 m-20 -70.25 105.17 2.87 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.761 0.824 . . . . 0.0 110.224 -179.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -72.31 92.88 1.44 Allowed 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 177.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 -56.66 112.64 1.35 Allowed 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 123.775 0.83 . . . . 0.0 111.026 -173.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 61.7 t -77.72 104.77 5.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 36.7 ptt180 -60.97 123.49 17.75 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 123.693 0.797 . . . . 0.0 111.645 -176.093 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . 0.407 HD11 HH21 ' A' ' 9' ' ' ARG . 55.3 mt -81.55 83.22 7.07 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.545 0.738 . . . . 0.0 109.874 -177.147 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 41.4 mm -89.27 73.84 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 CA-C-O 121.703 0.763 . . . . 0.0 109.056 -175.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.417 ' HD3' HG21 ' A' ' 10' ' ' THR . 5.6 ppt_? -157.74 -176.34 5.88 Favored 'General case' 0 CA--C 1.538 0.494 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.735 -174.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.417 HG21 ' HD3' ' A' ' 9' ' ' ARG . 40.2 p 50.76 76.65 0.15 Allowed 'General case' 0 N--CA 1.482 1.151 0 C-N-CA 125.37 1.468 . . . . 0.0 112.37 178.062 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 2.4 ppt_? -153.92 170.4 21.13 Favored 'General case' 0 C--O 1.243 0.762 0 CA-C-N 114.876 -1.057 . . . . 0.0 109.657 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 118.22 -168.03 13.05 Favored Glycine 0 C--N 1.343 0.938 0 CA-C-N 116.717 -0.219 . . . . 0.0 112.734 176.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -85.65 61.95 4.49 Favored Glycine 0 C--N 1.341 0.841 0 N-CA-C 112.295 -0.322 . . . . 0.0 112.295 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -74.48 172.7 11.5 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.971 0.909 . . . . 0.0 111.385 176.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 40.3 p -68.37 81.46 0.25 Allowed 'General case' 0 CA--C 1.546 0.826 0 CA-C-O 121.767 0.794 . . . . 0.0 110.338 174.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -95.36 154.99 16.92 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.924 -179.041 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 16.4 m -124.2 -149.15 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.813 0 C-N-CA 124.119 0.967 . . . . 0.0 108.897 -176.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.6 mmm-85 -75.12 -156.74 0.06 Allowed 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 123.314 0.645 . . . . 0.0 110.713 174.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.401 ' HB3' ' HB2' ' A' ' 24' ' ' ARG . 2.9 pp -77.06 40.36 0.26 Allowed 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -178.071 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -62.53 -24.2 67.38 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.969 0.908 . . . . 0.0 111.655 174.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 16.7 p -53.12 -58.03 8.41 Favored 'General case' 0 CA--C 1.549 0.942 0 O-C-N 124.245 0.966 . . . . 0.0 110.15 172.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . 0.443 ' HB3' ' OE1' ' A' ' 39' ' ' GLU . 22.0 t70 -170.91 -76.06 0.02 OUTLIER 'General case' 0 N--CA 1.479 0.986 0 O-C-N 124.234 0.959 . . . . 0.0 108.513 167.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.451 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 6.9 m -145.4 116.02 7.67 Favored 'General case' 0 C--N 1.351 0.64 0 C-N-CA 123.185 0.594 . . . . 0.0 109.745 176.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.401 ' HB2' ' HB3' ' A' ' 19' ' ' LEU . 38.6 mmt180 -107.12 145.13 32.85 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.731 0.812 . . . . 0.0 110.362 -177.512 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.9 tt -147.41 144.34 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 C-N-CA 124.167 0.987 . . . . 0.0 109.441 175.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -91.59 100.85 13.52 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 173.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 62.0 t -89.56 111.03 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 123.808 0.843 . . . . 0.0 109.247 -175.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.507 HG22 HG23 ' A' ' 35' ' ' VAL . 41.4 t -101.45 108.72 24.12 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 C-N-CA 123.666 0.786 . . . . 0.0 109.333 -176.303 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -58.74 114.82 9.79 Favored Pre-proline 0 N--CA 1.473 0.715 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 171.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -78.1 -5.89 15.42 Favored 'Trans proline' 0 C--N 1.363 1.334 0 C-N-CA 122.374 2.049 . . . . 0.0 112.911 -175.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -95.86 -53.31 3.73 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 123.827 0.851 . . . . 0.0 111.203 -178.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 59.3 p -90.67 -30.85 16.88 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.485 0.714 . . . . 0.0 111.44 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.9 -11.54 57.52 Favored Glycine 0 C--N 1.343 0.952 0 CA-C-N 116.139 -0.482 . . . . 0.0 113.158 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -68.53 124.73 24.38 Favored 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 123.482 0.713 . . . . 0.0 111.426 -170.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.507 HG23 HG22 ' A' ' 28' ' ' VAL . 22.2 t -95.95 133.99 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 175.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -140.99 137.19 32.84 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 171.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 39.7 mt -79.82 129.5 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 178.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.29 167.71 18.05 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 123.88 0.872 . . . . 0.0 111.289 -171.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 23' ' ' THR . 56.0 mm-40 -104.32 118.77 37.43 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 124.441 1.096 . . . . 0.0 110.98 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.463 HG21 ' HB ' ' A' ' 64' ' ' VAL . 68.1 mt -78.85 111.4 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 122.704 0.402 . . . . 0.0 110.544 -175.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -82.81 -56.48 3.8 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.358 1.063 . . . . 0.0 111.623 178.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.565 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 33.9 t30 -106.25 133.95 50.15 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 175.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.42 ' HA ' HG13 ' A' ' 64' ' ' VAL . 33.6 m -102.99 -5.07 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -175.544 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.676 HG21 HG21 ' A' ' 53' ' ' VAL . 3.7 p -137.37 104.0 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 CA-C-O 121.297 0.57 . . . . 0.0 111.794 -170.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.553 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 33.5 mm-40 55.33 -164.36 0.13 Allowed 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 166.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 8.1 p30 -80.79 -3.98 52.96 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.1 0.96 . . . . 0.0 110.949 171.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 8.8 t -79.01 140.06 38.05 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-O 121.609 0.719 . . . . 0.0 110.951 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -130.16 27.16 5.13 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 114.378 -1.283 . . . . 0.0 108.705 172.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 48.0 t-20 -105.68 93.19 6.95 Favored Pre-proline 0 N--CA 1.474 0.775 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 176.041 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -82.37 13.07 2.65 Favored 'Trans proline' 0 C--N 1.372 1.775 0 C-N-CA 122.422 2.081 . . . . 0.0 113.628 -175.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 55.2 t-80 -69.71 -48.61 58.95 Favored 'General case' 0 C--N 1.351 0.67 0 C-N-CA 122.445 0.298 . . . . 0.0 110.498 176.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -88.37 -28.01 21.25 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 123.397 0.435 . . . . 0.0 111.144 -178.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.676 HG21 HG21 ' A' ' 44' ' ' VAL . 5.7 p -116.59 104.78 17.14 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 CA-C-O 122.204 1.002 . . . . 0.0 111.387 -179.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 34.0 mmt180 -114.33 -0.73 13.75 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 124.163 0.985 . . . . 0.0 110.366 167.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 16.2 mtm180 -78.83 79.82 5.21 Favored 'General case' 0 C--O 1.244 0.793 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 170.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -86.06 65.21 8.99 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 121.944 0.878 . . . . 0.0 110.052 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 64.4 mt -108.83 119.56 58.62 Favored 'Isoleucine or valine' 0 C--O 1.242 0.696 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 176.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 57.7 mt -65.83 119.85 11.59 Favored 'Isoleucine or valine' 0 C--N 1.348 0.515 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 173.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 26.7 m -118.1 147.97 42.76 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -178.139 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 31.6 ttt-85 -60.69 134.09 56.74 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 172.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.57 -41.71 2.74 Favored Glycine 0 C--N 1.346 1.112 0 CA-C-O 119.892 -0.393 . . . . 0.0 112.43 -175.152 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -60.56 134.89 57.52 Favored 'General case' 0 C--N 1.357 0.896 0 C-N-CA 123.53 0.732 . . . . 0.0 110.708 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.553 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 98.2 t -73.55 120.48 22.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 O-C-N 123.722 0.639 . . . . 0.0 110.634 -178.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.463 ' HB ' HG21 ' A' ' 40' ' ' ILE . 26.3 m -105.41 126.89 60.54 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.294 171.167 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.565 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 33.8 tt0 -92.68 134.82 34.65 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 106.087 -1.82 . . . . 0.0 106.087 177.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 71.3 p -117.22 -178.59 3.48 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 -177.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -59.44 -23.15 62.44 Favored 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 123.057 0.543 . . . . 0.0 110.896 171.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 89.0 mt -88.79 -51.76 5.48 Favored 'General case' 0 C--N 1.353 0.733 0 C-N-CA 124.267 1.027 . . . . 0.0 110.018 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 164.53 -170.36 39.65 Favored Glycine 0 C--N 1.337 0.608 0 CA-C-N 115.549 -0.751 . . . . 0.0 112.155 -177.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.467 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 14.0 m120 -75.73 143.49 42.02 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.393 0.677 . . . . 0.0 110.772 -174.116 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.2 t -137.04 147.48 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 123.857 0.863 . . . . 0.0 110.079 -174.049 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.636 ' HG2' HD12 ' A' ' 88' ' ' ILE . 36.4 mmt180 -93.01 120.75 33.64 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 168.454 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 43.9 t -75.82 98.65 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 71.1 p -74.36 -34.52 63.4 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.715 0.806 . . . . 0.0 111.417 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' SER . . . . . 0.522 ' HB2' ' HB2' ' A' ' 84' ' ' ASN . 39.2 t -79.8 170.08 17.01 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.778 0.831 . . . . 0.0 111.581 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -82.73 106.43 6.82 Favored Pre-proline 0 CA--C 1.546 0.816 0 N-CA-C 107.246 -1.391 . . . . 0.0 107.246 166.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -82.16 69.62 7.41 Favored 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 123.443 2.762 . . . . 0.0 112.44 -172.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.09 -32.15 0.1 Allowed Glycine 0 C--N 1.333 0.37 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.817 -178.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -64.58 111.37 2.68 Favored 'General case' 0 C--N 1.359 0.981 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 174.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.4 t70 76.71 -22.95 0.26 Allowed 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 125.338 1.455 . . . . 0.0 112.384 -177.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 102.55 -8.58 54.97 Favored Glycine 0 C--N 1.345 1.078 0 CA-C-O 119.932 -0.371 . . . . 0.0 112.487 -175.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -86.57 116.95 30.1 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 CA-C-O 121.641 0.734 . . . . 0.0 109.94 -179.186 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.6 mt -98.54 132.75 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 175.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.522 ' HB2' ' HB2' ' A' ' 75' ' ' SER . 66.3 m-20 -136.07 154.52 51.0 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 123.725 0.81 . . . . 0.0 109.03 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.93 -173.98 37.12 Favored Glycine 0 C--N 1.34 0.754 0 O-C-N 123.385 0.428 . . . . 0.0 113.992 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.7 m -123.47 134.24 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.075 0 C-N-CA 124.028 0.931 . . . . 0.0 110.364 177.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 46.7 tp -66.21 127.55 32.62 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 123.182 0.593 . . . . 0.0 111.447 -176.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.636 HD12 ' HG2' ' A' ' 72' ' ' ARG . 33.2 pt -126.21 -176.67 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 C-N-CA 125.189 1.396 . . . . 0.0 109.378 173.25 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 82.0 mtt85 -137.83 88.29 2.32 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 123.321 0.649 . . . . 0.0 109.923 -177.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -100.85 -48.22 4.54 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 123.4 0.68 . . . . 0.0 109.44 178.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 88.8 mt -119.37 -175.1 2.87 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 124.911 1.284 . . . . 0.0 109.793 -178.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -122.15 106.66 11.35 Favored 'General case' 0 C--O 1.239 0.515 0 C-N-CA 123.496 0.718 . . . . 0.0 109.675 177.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 20.2 t60 -115.16 -50.92 2.73 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 171.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 44.0 t-80 -144.15 60.57 1.36 Allowed 'General case' 0 C--O 1.241 0.615 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 167.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -74.3 148.24 41.58 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 114.11 -1.405 . . . . 0.0 108.523 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 47.7 t60 66.35 81.41 0.2 Allowed 'General case' 0 N--CA 1.48 1.05 0 O-C-N 124.112 0.883 . . . . 0.0 108.997 -171.077 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 10.6 t-160 -80.86 -25.75 37.43 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 123.133 0.573 . . . . 0.0 110.559 -176.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 47.2 t-80 . . . . . 0 C--O 1.252 1.2 0 CA-C-O 118.532 -0.747 . . . . 0.0 109.118 178.448 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.628 0 N-CA-C 112.29 -0.324 . . . . 0.0 112.29 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -85.84 143.14 28.43 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.672 0.789 . . . . 0.0 109.985 -179.125 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 74.3 mmt-85 -86.81 68.99 10.27 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 174.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.9 115.41 7.4 Favored 'General case' 0 CA--C 1.544 0.725 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.964 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 7.1 p -83.58 132.2 32.01 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 C-N-CA 123.123 0.569 . . . . 0.0 110.13 -178.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 28.0 ttm-85 -92.97 92.43 7.85 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 174.205 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 97.5 mt -73.65 96.18 2.44 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.716 0.806 . . . . 0.0 110.231 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 58.7 mt -104.72 109.43 27.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 174.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -77.98 177.13 8.51 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.539 1.136 . . . . 0.0 110.551 173.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.5 p -69.33 -74.78 0.12 Allowed 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 123.074 0.55 . . . . 0.0 110.141 176.046 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -174.46 -65.32 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.976 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 176.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -179.5 155.36 15.58 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.431 -178.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.54 85.39 0.35 Allowed Glycine 0 CA--C 1.533 1.212 0 CA-C-N 117.027 0.414 . . . . 0.0 113.732 -174.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -100.9 170.98 7.94 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 123.856 0.862 . . . . 0.0 110.17 175.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 49.0 m -85.15 114.55 22.36 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 123.241 0.616 . . . . 0.0 110.336 178.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -90.44 165.86 13.58 Favored 'General case' 0 C--O 1.243 0.739 0 C-N-CA 124.109 0.964 . . . . 0.0 108.65 172.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.6 p -80.51 158.87 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.815 175.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 32.8 ptt180 -63.76 -170.03 0.03 OUTLIER 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 124.623 1.169 . . . . 0.0 111.822 174.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.437 ' HB3' ' H ' ' A' ' 24' ' ' ARG . 1.9 pt? -57.1 90.61 0.01 OUTLIER 'General case' 0 CA--C 1.555 1.17 0 CA-C-O 122.215 1.007 . . . . 0.0 110.738 172.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -142.26 8.9 1.84 Allowed 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 124.651 1.18 . . . . 0.0 110.284 -177.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 25.5 m -157.26 -42.21 0.07 Allowed 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.64 1.176 . . . . 0.0 108.798 -171.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -145.14 150.79 37.39 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-N 114.232 -1.349 . . . . 0.0 108.526 178.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.513 HG23 HD13 ' A' ' 40' ' ' ILE . 33.0 m -63.35 113.51 3.27 Favored 'General case' 0 C--N 1.353 0.754 0 C-N-CA 123.272 0.629 . . . . 0.0 109.876 -179.556 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.529 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 17.0 mtm180 -130.81 166.0 21.77 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.918 0.887 . . . . 0.0 111.497 -173.019 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 14.0 tt -150.88 150.28 13.54 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.447 -170.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.8 m-80 -94.08 100.39 12.51 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 175.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.7 t -88.7 112.39 23.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.022 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.41 HG11 HG22 ' A' ' 35' ' ' VAL . 17.3 t -101.41 100.6 10.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.437 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -178.206 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -58.38 120.39 43.93 Favored Pre-proline 0 CA--C 1.552 1.021 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 177.311 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -71.78 -15.75 29.88 Favored 'Trans proline' 0 C--N 1.366 1.469 0 C-N-CA 122.845 2.364 . . . . 0.0 113.555 -172.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -91.75 -52.12 4.9 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.919 0.487 . . . . 0.0 110.325 -175.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.3 p -88.66 -32.85 17.81 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.637 0.775 . . . . 0.0 112.375 -177.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.64 3.9 68.29 Favored Glycine 0 N--CA 1.479 1.559 0 CA-C-O 120.097 -0.28 . . . . 0.0 113.14 -174.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.0 mmtm -63.05 109.24 1.42 Allowed 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.753 0.821 . . . . 0.0 111.692 179.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.41 HG22 HG11 ' A' ' 28' ' ' VAL . 41.1 t -90.45 111.82 23.99 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 172.161 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -129.62 131.42 46.46 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.608 0.763 . . . . 0.0 110.233 -174.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 53.4 mt -76.26 115.23 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.75 153.81 40.38 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.946 0.898 . . . . 0.0 109.977 -174.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.529 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 2.7 mp0 -93.58 124.09 37.34 Favored 'General case' 0 C--O 1.244 0.79 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 -176.065 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.513 HD13 HG23 ' A' ' 23' ' ' THR . 56.0 mt -75.04 109.46 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -178.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 67.8 mtp180 -71.72 -42.62 67.12 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 124.59 1.156 . . . . 0.0 110.349 -178.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -159.64 170.13 22.25 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-N 114.822 -1.081 . . . . 0.0 108.646 -176.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.649 HG13 HG12 ' A' ' 64' ' ' VAL . 3.5 m -119.58 90.68 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 C-N-CA 124.712 1.205 . . . . 0.0 107.964 176.328 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.7 p -147.37 141.53 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 CA-C-O 121.256 0.55 . . . . 0.0 111.442 -166.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.462 ' HB3' ' HB ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -142.42 -83.46 0.18 Allowed 'General case' 0 CA--C 1.549 0.933 0 C-N-CA 125.405 1.482 . . . . 0.0 108.526 178.823 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -114.37 15.1 18.03 Favored 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 124.927 1.291 . . . . 0.0 109.409 171.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 64.8 p 55.6 78.85 0.18 Allowed 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 125.744 1.618 . . . . 0.0 111.709 -177.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -71.66 -37.41 70.8 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.309 179.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 15.5 m120 -114.95 91.92 28.53 Favored Pre-proline 0 N--CA 1.484 1.227 0 C-N-CA 123.872 0.869 . . . . 0.0 108.719 174.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -62.24 110.94 1.13 Allowed 'Trans proline' 0 C--N 1.38 2.203 0 C-N-CA 123.573 2.848 . . . . 0.0 113.017 -176.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.0 t60 77.52 -7.26 1.86 Allowed 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 125.55 1.54 . . . . 0.0 112.88 172.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -68.16 117.07 9.5 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 122.881 0.472 . . . . 0.0 110.893 -177.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 18.5 t -71.04 -20.54 21.72 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.146 0 C-N-CA 123.525 0.73 . . . . 0.0 109.888 177.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 59.5 mtp85 -73.11 6.49 2.7 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 123.888 0.875 . . . . 0.0 112.504 173.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.73 -9.29 58.51 Favored 'General case' 0 CA--C 1.558 1.286 0 C-N-CA 123.248 0.619 . . . . 0.0 110.306 169.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 31.2 p-10 -56.96 -20.15 22.12 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 123.797 0.839 . . . . 0.0 111.388 172.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.3 mt -67.31 90.97 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.09 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 166.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.9 mt -82.68 151.92 4.04 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.701 -179.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 75.8 p -128.69 170.53 13.17 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.852 0.861 . . . . 0.0 109.615 174.183 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.3 ttm180 -71.9 138.14 47.94 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 171.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.77 -14.62 51.43 Favored Glycine 0 C--N 1.343 0.97 0 C-N-CA 123.249 0.452 . . . . 0.0 113.028 -177.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -70.85 141.36 51.27 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 123.334 0.653 . . . . 0.0 109.486 177.194 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.462 ' HB ' ' HB3' ' A' ' 45' ' ' GLU . 77.1 t -91.16 118.42 36.39 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.81 -179.695 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.649 HG12 HG13 ' A' ' 43' ' ' VAL . 34.1 m -103.31 135.85 38.88 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.422 174.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -86.27 127.01 34.71 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 174.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 32.6 p -128.6 174.32 9.5 Favored 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.501 ' ND2' ' HB2' ' A' ' 39' ' ' GLU . 94.2 m-20 -65.03 -12.64 52.77 Favored 'General case' 0 N--CA 1.482 1.128 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 178.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.1 mt -95.6 -47.89 6.04 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 176.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 167.57 -161.96 35.76 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.828 178.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -75.12 142.69 43.58 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.189 0.596 . . . . 0.0 110.015 175.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.0 t -135.88 146.45 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.268 0 C-N-CA 123.155 0.582 . . . . 0.0 110.111 -174.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.625 ' HG2' HD12 ' A' ' 88' ' ' ILE . 33.7 mmt180 -91.65 119.7 31.77 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 171.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.2 t -73.36 122.62 26.64 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.2 p -108.56 -32.67 7.29 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.536 0.735 . . . . 0.0 110.26 -172.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.6 t -97.73 -178.77 4.22 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.62 0.768 . . . . 0.0 110.147 178.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.44 128.92 73.65 Favored Pre-proline 0 CA--C 1.552 1.033 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 174.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -68.66 103.66 1.02 Allowed 'Trans proline' 0 C--N 1.373 1.843 0 C-N-CA 123.024 2.483 . . . . 0.0 113.837 -173.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 73.37 -0.78 46.57 Favored Glycine 0 C--N 1.344 1.004 0 CA-C-N 115.217 -0.901 . . . . 0.0 114.961 171.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 31.8 mm-40 -67.81 -43.51 79.49 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 123.28 0.632 . . . . 0.0 111.689 -172.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.524 ' HB3' HG12 ' A' ' 82' ' ' VAL . 24.6 t70 -89.06 3.68 50.9 Favored 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 123.618 0.767 . . . . 0.0 110.75 175.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 81.42 37.16 18.37 Favored Glycine 0 C--N 1.343 0.933 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -171.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.524 HG12 ' HB3' ' A' ' 80' ' ' ASP . 13.3 p -162.28 140.54 2.26 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 CA-C-N 114.541 -0.83 . . . . 0.0 109.809 -174.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.4 mt -121.61 128.8 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 N-CA-C 104.904 -2.258 . . . . 0.0 104.904 165.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -120.81 153.35 37.21 Favored 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -172.7 179.66 44.06 Favored Glycine 0 N--CA 1.446 -0.643 0 O-C-N 123.99 0.806 . . . . 0.0 113.588 175.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.1 m -123.36 136.16 60.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 124.05 0.94 . . . . 0.0 110.007 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 27.0 tp -66.56 134.16 51.81 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 123.011 0.524 . . . . 0.0 111.133 -174.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.625 HD12 ' HG2' ' A' ' 72' ' ' ARG . 34.1 pt -135.06 175.1 11.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.785 1.234 . . . . 0.0 109.59 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 39.1 mtt180 -130.88 84.15 2.17 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.451 0.7 . . . . 0.0 109.284 -176.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.8 mm-40 -95.8 -77.05 0.48 Allowed 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 77.4 mt -85.04 94.62 8.87 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 169.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -60.72 128.63 37.49 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 123.083 0.553 . . . . 0.0 111.725 -176.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.1 t60 -77.09 -29.8 55.12 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 169.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -167.81 133.03 1.89 Allowed 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 125.051 1.34 . . . . 0.0 107.692 170.361 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 54.2 t-80 -170.8 -33.83 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 123.412 0.685 . . . . 0.0 109.777 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -71.04 88.91 0.79 Allowed 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 123.913 0.885 . . . . 0.0 109.06 175.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 22.1 p80 -74.32 -35.81 63.67 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.549 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 48.3 t60 . . . . . 0 C--O 1.243 0.737 0 C-N-CA 124.219 1.007 . . . . 0.0 108.342 177.113 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.731 0 N-CA-C 112.494 -0.242 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -75.04 104.06 5.47 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 123.717 0.807 . . . . 0.0 110.41 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 56.4 mtm180 -79.94 73.19 6.73 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.636 0.774 . . . . 0.0 110.192 175.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 60.7 ttt180 -78.9 83.81 4.99 Favored 'General case' 0 CA--C 1.539 0.521 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 174.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.6 t -87.23 93.5 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 115.424 -0.807 . . . . 0.0 108.889 -178.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? -73.24 92.61 1.78 Allowed 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 93.8 mt -75.53 103.46 5.66 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.504 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.0 tt -74.05 130.72 35.78 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 124.026 0.93 . . . . 0.0 110.937 -178.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 53.7 ttp180 -142.62 156.25 45.05 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.773 0.829 . . . . 0.0 109.344 175.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 88.4 m 66.16 101.49 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 125.212 1.405 . . . . 0.0 110.25 -171.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 31.3 mmt180 -77.42 -38.76 49.02 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.497 174.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.55 158.55 25.81 Favored Glycine 0 C--N 1.339 0.7 0 CA-C-N 114.814 -1.084 . . . . 0.0 111.1 -174.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 173.99 109.9 0.24 Allowed Glycine 0 C--N 1.333 0.416 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -178.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 41.3 t-20 -142.29 93.58 2.55 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 -177.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 64.8 p -98.69 112.29 24.4 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 124.021 0.928 . . . . 0.0 109.582 177.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.9 mmtp -120.11 -80.22 0.62 Allowed 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 123.253 0.621 . . . . 0.0 110.643 -178.401 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 13.4 p -153.17 146.63 14.67 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 C-N-CA 123.59 0.756 . . . . 0.0 109.32 -175.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 18.3 mmm180 -82.35 -156.19 0.16 Allowed 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 123.647 0.779 . . . . 0.0 109.842 176.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -79.9 42.57 0.55 Allowed 'General case' 0 CA--C 1.56 1.335 0 CA-C-O 121.94 0.876 . . . . 0.0 110.736 171.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -87.33 48.96 1.72 Allowed 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 124.88 1.272 . . . . 0.0 110.135 -174.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.9 m -151.3 -57.35 0.16 Allowed 'General case' 0 C--O 1.24 0.564 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -162.33 172.63 15.34 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 125.153 1.381 . . . . 0.0 107.819 176.004 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 26.3 m -62.87 116.38 5.21 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.311 0.644 . . . . 0.0 110.35 -176.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 17.3 tpp85 -110.22 141.48 43.1 Favored 'General case' 0 C--O 1.241 0.637 0 C-N-CA 123.561 0.745 . . . . 0.0 110.446 -171.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 16.2 tt -139.94 147.41 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.953 0.901 . . . . 0.0 109.506 178.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -97.59 102.38 14.13 Favored 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 170.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.536 HG21 HG22 ' A' ' 71' ' ' VAL . 96.5 t -82.91 106.14 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 C-N-CA 123.957 0.903 . . . . 0.0 109.698 -177.287 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 86' ' ' VAL . 40.0 t -97.21 102.86 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -56.1 116.59 12.86 Favored Pre-proline 0 CA--C 1.549 0.923 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 173.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -72.91 -19.48 23.39 Favored 'Trans proline' 0 C--N 1.368 1.556 0 C-N-CA 122.332 2.022 . . . . 0.0 113.378 -172.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -81.88 -51.21 8.32 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 123.264 0.626 . . . . 0.0 110.465 -175.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.7 p -92.31 -25.78 18.42 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.876 0.87 . . . . 0.0 111.446 -177.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.2 4.65 71.18 Favored Glycine 0 N--CA 1.473 1.113 0 CA-C-O 119.597 -0.557 . . . . 0.0 113.119 -178.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -72.08 112.68 8.37 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.157 0.583 . . . . 0.0 111.811 -173.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.447 HG23 HG21 ' A' ' 28' ' ' VAL . 39.1 t -82.6 115.18 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 171.503 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -130.79 130.0 43.13 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.96 0.904 . . . . 0.0 109.123 -179.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 59.4 mt -78.93 125.61 38.42 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 C-N-CA 122.91 0.484 . . . . 0.0 110.139 -177.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -134.17 170.99 14.86 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 124.575 1.15 . . . . 0.0 110.02 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -117.79 135.73 53.87 Favored 'General case' 0 C--O 1.243 0.748 0 C-N-CA 123.329 0.652 . . . . 0.0 109.547 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.1 mt -78.51 112.35 16.43 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.726 0 O-C-N 123.893 0.746 . . . . 0.0 110.311 -175.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 72.6 mtp180 -64.69 -53.93 39.6 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.842 1.257 . . . . 0.0 110.365 175.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 55.5 t30 -143.75 157.65 44.24 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.522 0.729 . . . . 0.0 109.535 -176.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 55.3 t -121.33 -39.09 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 122.925 0.49 . . . . 0.0 110.374 179.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.3 p -64.18 122.0 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-O 121.179 0.514 . . . . 0.0 110.37 -179.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -86.54 13.65 8.12 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 123.901 0.881 . . . . 0.0 113.175 -168.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -70.44 -29.51 66.11 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 123.224 0.609 . . . . 0.0 112.092 -176.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 32.6 p 52.79 28.91 6.87 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 125.464 1.505 . . . . 0.0 111.447 -171.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -115.51 35.96 4.17 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 124.1 0.96 . . . . 0.0 110.864 -170.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 36.8 t30 67.53 94.88 0.05 OUTLIER Pre-proline 0 N--CA 1.484 1.23 0 C-N-CA 124.782 1.233 . . . . 0.0 110.916 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -71.52 78.42 1.63 Allowed 'Trans proline' 0 C--N 1.375 1.935 0 C-N-CA 122.899 2.399 . . . . 0.0 111.818 175.487 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.4 t-80 -65.61 105.81 1.31 Allowed 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 123.388 0.675 . . . . 0.0 109.497 179.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 60.83 74.15 0.46 Allowed 'General case' 0 C--O 1.239 0.524 0 O-C-N 124.757 1.286 . . . . 0.0 109.332 -169.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.9 p -57.81 104.6 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 CA-C-N 114.889 -1.051 . . . . 0.0 110.976 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 32.4 ptt180 -144.7 176.88 9.1 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.323 -173.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 11.4 mmt180 58.61 30.83 20.39 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 124.191 0.996 . . . . 0.0 110.706 178.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -70.76 79.17 0.61 Allowed 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.246 1.018 . . . . 0.0 110.859 -174.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 41.1 mm -79.32 83.77 1.13 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.63 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 178.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.4 mt -72.71 118.26 17.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 CA-C-N 114.726 -1.125 . . . . 0.0 108.222 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 7.5 p -131.61 170.46 14.73 Favored 'General case' 0 C--O 1.243 0.726 0 C-N-CA 124.872 1.269 . . . . 0.0 108.952 -175.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -69.52 130.79 43.43 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 177.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.95 -15.34 63.62 Favored Glycine 0 C--N 1.345 1.029 0 CA-C-O 119.48 -0.622 . . . . 0.0 113.531 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.62 134.3 49.74 Favored 'General case' 0 C--O 1.246 0.878 0 C-N-CA 122.957 0.503 . . . . 0.0 110.342 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 67.1 t -88.55 112.88 24.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 176.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.3 m -102.94 138.56 26.73 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -88.11 126.45 35.12 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 61.3 p -134.0 172.49 12.75 Favored 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 124.097 0.959 . . . . 0.0 109.091 -175.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -71.88 -13.12 61.57 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 112.331 0.493 . . . . 0.0 112.331 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 88.5 mt -97.12 -15.34 21.0 Favored 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 123.3 0.64 . . . . 0.0 111.336 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.09 -147.88 19.52 Favored Glycine 0 C--N 1.341 0.848 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 -173.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -109.75 143.0 40.17 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 117.486 0.643 . . . . 0.0 109.404 177.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.536 HG22 HG21 ' A' ' 27' ' ' VAL . 22.0 t -128.73 144.96 36.42 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 123.425 0.69 . . . . 0.0 109.862 -174.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.607 ' HG2' HD13 ' A' ' 88' ' ' ILE . 10.5 mmt180 -94.94 123.71 38.56 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 168.295 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 56.9 t -76.22 94.92 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.4 p -85.15 -39.84 17.42 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.307 0.643 . . . . 0.0 111.109 -178.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.4 m -77.65 164.55 25.22 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.911 173.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 24.3 mmt180 -65.88 130.23 94.41 Favored Pre-proline 0 CA--C 1.548 0.87 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 172.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -77.62 43.16 1.29 Allowed 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 123.502 2.801 . . . . 0.0 112.387 175.586 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -170.95 -137.3 2.27 Favored Glycine 0 C--N 1.334 0.461 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -172.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 21.2 tm0? 67.88 -72.33 0.1 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 124.608 1.163 . . . . 0.0 110.136 -177.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.407 ' HB3' HG11 ' A' ' 82' ' ' VAL . 33.3 t70 -91.45 -12.93 33.25 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 124.211 1.004 . . . . 0.0 110.31 171.106 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 94.56 -6.49 70.9 Favored Glycine 0 C--N 1.343 0.968 0 C-N-CA 123.386 0.517 . . . . 0.0 112.981 -174.06 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.407 HG11 ' HB3' ' A' ' 80' ' ' ASP . 14.5 p -92.83 141.42 14.68 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.512 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 31.5 mt -96.09 146.87 6.58 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -152.66 152.07 31.33 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -169.0 -167.34 29.48 Favored Glycine 0 C--N 1.343 0.972 0 CA-C-O 120.015 -0.325 . . . . 0.0 113.028 -178.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.509 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 35.9 m -116.46 132.68 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 123.776 0.83 . . . . 0.0 110.925 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 38.8 tp -71.63 106.07 3.91 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.463 0.705 . . . . 0.0 111.13 -176.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.607 HD13 ' HG2' ' A' ' 72' ' ' ARG . 41.4 pt -97.34 171.65 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.524 0.73 . . . . 0.0 110.262 175.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 16.7 mmt180 -115.22 21.15 14.4 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.671 0.788 . . . . 0.0 110.235 -173.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.43 ' HB2' HD11 ' A' ' 88' ' ' ILE . 33.9 tt0 -64.8 -75.9 0.08 Allowed 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.433 0.693 . . . . 0.0 112.657 -164.343 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 58.3 mt -81.33 69.08 7.88 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-O 121.834 0.826 . . . . 0.0 110.316 -173.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -77.77 121.27 23.83 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -62.52 -28.4 69.82 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 122.288 0.235 . . . . 0.0 111.497 -174.76 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 35.4 t60 -74.27 -36.59 63.82 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 122.966 0.506 . . . . 0.0 110.638 177.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -58.85 128.99 40.0 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 123.607 0.763 . . . . 0.0 109.949 -179.25 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 69.6 t60 -60.74 111.67 1.72 Allowed 'General case' 0 CA--C 1.544 0.741 0 O-C-N 124.26 0.975 . . . . 0.0 111.047 -175.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 74.5 t60 -63.88 137.15 57.9 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 115.256 -0.884 . . . . 0.0 109.217 172.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 38.9 p-80 . . . . . 0 C--O 1.25 1.124 0 C-N-CA 124.109 0.964 . . . . 0.0 109.312 -178.254 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.785 0 N-CA-C 112.651 -0.18 . . . . 0.0 112.651 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -84.01 117.02 23.13 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 123.537 0.735 . . . . 0.0 109.71 -179.28 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 22.6 mmm180 -110.3 123.84 50.56 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 123.049 0.54 . . . . 0.0 110.043 -179.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 15.7 ptt180 -145.16 97.41 3.0 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 124.23 1.012 . . . . 0.0 109.292 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 38.3 t -92.22 103.55 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 123.191 0.596 . . . . 0.0 109.515 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 55.3 ttt180 -110.03 138.74 45.98 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.598 0.759 . . . . 0.0 109.636 178.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -157.06 101.47 1.93 Allowed 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 177.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.2 tt -114.55 135.1 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 124.243 1.017 . . . . 0.0 109.244 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -125.64 117.68 24.03 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.704 0.802 . . . . 0.0 109.302 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 35.9 p -72.04 89.16 1.11 Allowed 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 123.79 0.836 . . . . 0.0 110.44 -178.381 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 25.1 mmt180 -105.42 117.24 33.5 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.011 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 177.7 50.99 0.07 OUTLIER Glycine 0 C--N 1.34 0.776 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 178.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.31 111.99 4.37 Favored Glycine 0 C--N 1.354 1.574 0 N-CA-C 112.259 -0.336 . . . . 0.0 112.259 -176.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 39.6 m-80 -76.19 107.43 8.42 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.108 0.563 . . . . 0.0 110.254 -178.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 15.4 p -72.46 96.93 1.99 Allowed 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.215 0.606 . . . . 0.0 110.076 174.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 13.2 ptmm? -76.45 99.22 4.82 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.107 173.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.9 p -163.53 162.34 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 123.74 0.816 . . . . 0.0 109.702 -169.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.1 mpt_? -74.05 171.4 13.58 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 123.975 0.91 . . . . 0.0 110.502 177.261 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.441 ' HB3' ' HB2' ' A' ' 24' ' ' ARG . 2.0 pp -62.04 143.08 57.09 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.078 0.551 . . . . 0.0 112.45 -178.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -159.7 116.02 2.52 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.798 0.839 . . . . 0.0 108.86 -179.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 45.4 m 68.55 -70.33 0.13 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 125.138 1.375 . . . . 0.0 111.174 -175.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . 0.522 ' HB2' HH12 ' A' ' 24' ' ' ARG . 3.7 m-20 -77.24 109.68 11.32 Favored 'General case' 0 C--O 1.247 0.945 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 175.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 26.2 m -65.24 132.59 49.49 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 122.984 0.514 . . . . 0.0 110.694 -177.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.522 HH12 ' HB2' ' A' ' 22' ' ' ASP . 77.3 mmt-85 -102.21 134.8 44.89 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.418 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 14.2 tt -140.18 136.11 37.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 123.85 0.86 . . . . 0.0 109.745 -175.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.2 m-80 -85.55 100.59 12.02 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 177.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.2 t -87.4 108.23 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -176.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 40.9 t -95.54 101.67 12.7 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -63.83 116.43 26.69 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 175.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -71.47 -19.76 28.17 Favored 'Trans proline' 0 C--N 1.368 1.559 0 C-N-CA 123.232 2.621 . . . . 0.0 113.194 -171.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -92.67 -52.94 4.39 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 123.499 0.72 . . . . 0.0 110.822 -171.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 62.8 p -90.9 -27.83 18.5 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 123.424 0.69 . . . . 0.0 111.476 -177.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.62 4.73 69.87 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-N 116.416 -0.356 . . . . 0.0 113.369 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -71.45 118.74 14.65 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 123.293 0.637 . . . . 0.0 110.818 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.4 t -108.33 134.84 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 123.679 0.792 . . . . 0.0 108.908 177.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -152.22 148.81 28.02 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 122.87 0.468 . . . . 0.0 110.357 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.406 HG21 ' HD2' ' A' ' 24' ' ' ARG . 51.6 mt -87.12 98.31 7.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.89 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.21 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -95.87 172.21 8.16 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 124.282 1.033 . . . . 0.0 110.646 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -108.26 131.99 54.13 Favored 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 176.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.47 HG12 HG22 ' A' ' 66' ' ' THR . 57.1 mt -75.27 112.66 13.1 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 177.697 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 40.4 mtt-85 -73.11 -52.9 12.52 Favored 'General case' 0 N--CA 1.475 0.825 0 CA-C-O 122.253 1.025 . . . . 0.0 109.418 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.599 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 29.8 t30 -126.04 112.3 15.71 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 113.365 -1.743 . . . . 0.0 108.73 -169.663 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.8 m -81.08 -15.8 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 123.175 0.59 . . . . 0.0 111.282 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -78.8 143.9 11.92 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.917 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 174.76 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.38 -57.85 3.56 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 175.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 7.2 p30 171.98 123.33 0.02 OUTLIER 'General case' 0 C--O 1.245 0.819 0 C-N-CA 125.994 1.717 . . . . 0.0 107.376 -176.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 20.2 p -143.91 -74.18 0.26 Allowed 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -175.12 115.3 0.15 Allowed 'General case' 0 C--O 1.239 0.514 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -177.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 72.2 m-20 62.78 88.73 0.12 Allowed Pre-proline 0 CA--C 1.551 0.993 0 C-N-CA 123.968 0.907 . . . . 0.0 109.913 -173.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -76.03 17.47 0.72 Allowed 'Trans proline' 0 C--N 1.375 1.945 0 C-N-CA 122.944 2.429 . . . . 0.0 114.219 -174.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.6 t60 -83.4 62.23 6.63 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 123.637 0.775 . . . . 0.0 110.005 178.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 48.6 t80 53.03 67.03 1.06 Allowed 'General case' 0 CA--C 1.556 1.19 0 C-N-CA 125.364 1.466 . . . . 0.0 112.128 179.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.432 HG23 ' HG2' ' A' ' 54' ' ' ARG . 12.2 m -94.15 -21.41 5.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.671 171.319 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.432 ' HG2' HG23 ' A' ' 53' ' ' VAL . 9.3 mmm180 -108.38 158.89 17.1 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 124.058 0.943 . . . . 0.0 108.754 177.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 31.2 mmm180 -82.29 171.07 14.65 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.447 0.699 . . . . 0.0 111.494 -176.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -78.5 21.05 0.39 Allowed 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.808 0.843 . . . . 0.0 111.83 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.1 mt -72.98 93.68 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 174.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 82.9 mt -93.75 128.68 44.97 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.379 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 38.1 p -126.3 164.29 21.37 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.569 0.748 . . . . 0.0 109.657 -177.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 45.2 ttp180 -73.47 141.41 46.83 Favored 'General case' 0 N--CA 1.482 1.138 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 176.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.88 2.57 90.33 Favored Glycine 0 C--N 1.345 1.06 0 O-C-N 123.198 0.311 . . . . 0.0 112.971 -176.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.0 163.12 16.46 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 123.525 0.73 . . . . 0.0 110.774 179.285 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 38.8 t -110.01 124.85 67.09 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 173.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 20.9 m -112.88 168.45 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 168.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.599 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 28.0 tt0 -115.19 134.33 55.24 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 170.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.47 HG22 HG12 ' A' ' 40' ' ' ILE . 43.8 p -123.87 -177.77 3.85 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.843 0.857 . . . . 0.0 109.551 -173.611 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.8 m-20 -58.38 -28.72 65.42 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 122.933 0.493 . . . . 0.0 111.318 175.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 77.8 mt -90.07 -45.71 8.97 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.258 0.623 . . . . 0.0 110.748 -178.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 165.66 -166.04 38.29 Favored Glycine 0 N--CA 1.477 1.416 0 CA-C-O 119.715 -0.492 . . . . 0.0 112.093 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -73.26 132.98 43.78 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 117.653 0.727 . . . . 0.0 109.843 176.609 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 65.2 t -128.74 144.89 36.67 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.905 0 C-N-CA 124.402 1.081 . . . . 0.0 110.29 -174.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.517 ' HG2' HD11 ' A' ' 88' ' ' ILE . 33.2 mmt180 -84.98 121.25 27.51 Favored 'General case' 0 N--CA 1.479 1.017 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 168.309 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.5 t -73.21 122.88 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 70.9 p -107.72 -23.9 11.92 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 123.179 0.592 . . . . 0.0 110.999 -176.129 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 45.7 m -93.05 176.92 6.23 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-O 121.309 0.576 . . . . 0.0 111.751 176.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 30.8 mmt180 -106.65 127.09 28.8 Favored Pre-proline 0 C--O 1.241 0.635 0 CA-C-N 114.839 -1.073 . . . . 0.0 108.404 171.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -60.24 120.24 7.89 Favored 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 123.228 2.619 . . . . 0.0 112.474 -176.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 91.38 -36.68 3.56 Favored Glycine 0 C--N 1.341 0.824 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.994 176.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 14.3 mm100 -64.24 -31.81 73.15 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.691 0.796 . . . . 0.0 111.836 -174.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -106.24 6.23 30.55 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.718 0.807 . . . . 0.0 111.566 178.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 85.57 -61.32 4.59 Favored Glycine 0 C--N 1.349 1.276 0 C-N-CA 123.086 0.374 . . . . 0.0 112.273 -175.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -113.26 159.52 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 124.467 1.107 . . . . 0.0 108.793 175.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.418 ' O ' ' HA ' ' A' ' 25' ' ' ILE . 41.1 mt -92.52 147.68 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 174.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -125.37 162.98 23.58 Favored 'General case' 0 C--O 1.246 0.888 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 171.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.28 179.38 41.41 Favored Glycine 0 C--N 1.335 0.519 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.952 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.2 m -121.42 131.0 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 C-N-CA 123.433 0.693 . . . . 0.0 109.437 175.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 21.4 tp -67.26 131.27 45.42 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.132 0.573 . . . . 0.0 110.006 -177.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.517 HD11 ' HG2' ' A' ' 72' ' ' ARG . 33.4 pt -123.15 161.12 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 121.665 0.745 . . . . 0.0 111.276 -176.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 26.5 mmt180 -115.94 8.29 14.63 Favored 'General case' 0 CA--C 1.548 0.884 0 CA-C-N 114.195 -1.366 . . . . 0.0 109.636 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -60.28 -62.14 2.09 Favored 'General case' 0 C--N 1.358 0.951 0 C-N-CA 123.959 0.904 . . . . 0.0 112.237 -172.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 22.4 mt -66.64 152.73 44.79 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 123.364 0.415 . . . . 0.0 111.035 -179.031 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 15.1 tp10 -58.93 -43.4 91.14 Favored 'General case' 0 N--CA 1.472 0.673 0 O-C-N 124.352 1.032 . . . . 0.0 110.039 -176.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 9.2 t-80 58.22 31.84 21.29 Favored 'General case' 0 CA--C 1.552 1.048 0 C-N-CA 124.646 1.178 . . . . 0.0 111.664 172.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 16.3 m170 -80.33 71.22 7.11 Favored 'General case' 0 N--CA 1.478 0.939 0 CA-C-O 122.188 0.994 . . . . 0.0 109.39 174.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -121.17 9.53 10.49 Favored 'General case' 0 CA--C 1.555 1.138 0 CA-C-N 113.86 -1.518 . . . . 0.0 108.542 178.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 40.5 t60 -150.69 145.37 25.77 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 126.175 1.79 . . . . 0.0 107.563 -177.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -69.71 119.96 14.74 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 123.411 0.684 . . . . 0.0 110.909 -177.024 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 4.2 t60 . . . . . 0 CA--C 1.551 0.985 0 C-N-CA 123.601 0.76 . . . . 0.0 109.133 178.938 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.325 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -167.89 172.25 9.17 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.037 0.935 . . . . 0.0 109.009 -177.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -68.02 144.64 55.04 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 122.762 0.425 . . . . 0.0 111.253 177.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 5.5 mmp_? -79.35 169.95 17.33 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-N 115.395 -0.821 . . . . 0.0 109.699 175.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.7 t -60.42 93.15 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 C-N-CA 123.402 0.681 . . . . 0.0 109.257 179.177 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.7 ptt180 -80.53 154.19 27.66 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.293 -171.211 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -81.27 -6.75 59.22 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.997 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 60.4 mt -70.83 97.16 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.76 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 169.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 3.2 ppt_? -107.02 -6.25 17.59 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.127 0.971 . . . . 0.0 111.198 -177.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 25.5 m -66.64 89.75 0.16 Allowed 'General case' 0 CA--C 1.552 1.033 0 C-N-CA 123.69 0.796 . . . . 0.0 111.146 -174.154 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 25.6 tpt180 -170.42 105.13 0.28 Allowed 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.261 1.424 . . . . 0.0 107.449 179.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 127.87 179.89 16.11 Favored Glycine 0 N--CA 1.466 0.699 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -175.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 162.33 -133.09 2.99 Favored Glycine 0 C--N 1.339 0.733 0 N-CA-C 111.532 -0.627 . . . . 0.0 111.532 -179.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -83.54 73.76 10.18 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 176.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 86.8 m -137.19 111.0 8.15 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.16 -0.927 . . . . 0.0 108.781 177.002 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.552 ' HE3' HD11 ' A' ' 37' ' ' ILE . 0.0 OUTLIER -165.11 158.57 16.82 Favored 'General case' 0 C--O 1.24 0.585 0 C-N-CA 123.374 0.67 . . . . 0.0 109.669 177.799 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 7.9 p -70.7 146.07 12.3 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 165.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.72 175.75 2.81 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 122.65 0.38 . . . . 0.0 110.76 174.283 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.438 HD22 ' HA ' ' A' ' 82' ' ' VAL . 2.2 pt? -52.41 102.72 0.05 Allowed 'General case' 0 CA--C 1.559 1.323 0 CA-C-O 121.94 0.876 . . . . 0.0 110.939 174.614 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -135.32 -54.3 0.79 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.079 -175.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 38.0 p -63.04 -40.09 96.67 Favored 'General case' 0 CA--C 1.546 0.816 0 CA-C-N 114.706 -1.133 . . . . 0.0 110.724 175.043 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -158.96 153.44 24.22 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 124.205 1.002 . . . . 0.0 109.158 178.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.432 HG23 HD12 ' A' ' 40' ' ' ILE . 91.4 m -76.21 110.39 10.67 Favored 'General case' 0 CA--C 1.548 0.868 0 CA-C-O 121.624 0.726 . . . . 0.0 111.177 -176.284 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.511 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 36.8 mtm180 -127.23 170.1 12.79 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.835 1.254 . . . . 0.0 110.81 177.276 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.1 tt -135.7 136.21 50.51 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-N 114.566 -1.197 . . . . 0.0 108.95 -179.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 -89.78 102.1 14.8 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.421 HG22 HG13 ' A' ' 71' ' ' VAL . 58.5 t -98.78 136.38 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 123.873 0.869 . . . . 0.0 110.563 -170.006 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.578 HG23 HG23 ' A' ' 35' ' ' VAL . 30.1 t -122.0 122.29 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -63.98 124.43 85.15 Favored Pre-proline 0 N--CA 1.48 1.027 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 171.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -68.79 -20.0 40.31 Favored 'Trans proline' 0 CA--C 1.554 1.488 0 C-N-CA 122.145 1.897 . . . . 0.0 112.476 178.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.453 ' HG3' HG23 ' A' ' 32' ' ' THR . 12.8 pt-20 -88.2 -51.35 5.82 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.02 0.928 . . . . 0.0 112.115 -176.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.453 HG23 ' HG3' ' A' ' 31' ' ' GLU . 70.4 p -97.87 -21.49 16.87 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.125 0.57 . . . . 0.0 111.792 -173.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.8 5.28 89.54 Favored Glycine 0 C--N 1.349 1.269 0 CA-C-O 119.682 -0.51 . . . . 0.0 113.524 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -73.68 123.89 24.94 Favored 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 123.27 0.628 . . . . 0.0 111.352 -174.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.578 HG23 HG23 ' A' ' 28' ' ' VAL . 24.8 t -95.73 128.86 46.55 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.712 0 C-N-CA 123.872 0.869 . . . . 0.0 109.422 176.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -141.42 133.8 28.18 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 124.483 1.113 . . . . 0.0 108.574 175.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.552 HD11 ' HE3' ' A' ' 16' ' ' LYS . 46.6 mt -79.32 98.92 3.14 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.449 ' HB2' ' HB ' ' A' ' 66' ' ' THR . . . -86.02 158.93 19.73 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.703 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.511 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 38.9 mt-10 -101.82 124.95 48.31 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.48 0.712 . . . . 0.0 109.433 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.432 HD12 HG23 ' A' ' 23' ' ' THR . 61.7 mt -76.44 108.69 9.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 47.8 mtt180 -82.87 -53.26 6.0 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.261 1.024 . . . . 0.0 110.672 -179.389 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -146.04 160.07 42.39 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -176.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.589 ' HB ' HH22 ' A' ' 54' ' ' ARG . 30.9 m -116.95 29.7 2.48 Favored 'Isoleucine or valine' 0 C--O 1.246 0.877 0 C-N-CA 123.523 0.729 . . . . 0.0 112.03 -174.313 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 m -68.05 90.67 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 CA-C-O 122.086 0.946 . . . . 0.0 110.59 173.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.51 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 37.9 mt-10 -67.47 -36.17 80.62 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 114.483 -1.235 . . . . 0.0 110.635 178.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -133.72 118.42 18.08 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-N 114.541 -1.209 . . . . 0.0 108.11 179.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.427 HG23 HD12 ' A' ' 91' ' ' LEU . 55.3 p -82.07 -15.96 51.7 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 122.516 0.327 . . . . 0.0 111.472 178.128 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -68.53 -43.35 76.91 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 123.462 0.705 . . . . 0.0 110.437 175.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -162.83 90.42 1.27 Allowed Pre-proline 0 CA--C 1.55 0.95 0 C-N-CA 123.882 0.873 . . . . 0.0 109.278 175.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.87 116.7 4.75 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.412 2.075 . . . . 0.0 110.823 174.114 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 46.8 m80 -73.44 92.91 1.91 Allowed 'General case' 0 C--O 1.243 0.711 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -80.36 74.86 7.2 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-O 121.86 0.838 . . . . 0.0 109.896 -176.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 11.5 t -111.59 -9.68 11.88 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.944 0 CA-C-N 114.576 -1.193 . . . . 0.0 108.075 169.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.589 HH22 ' HB ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -150.95 163.34 38.94 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.296 1.438 . . . . 0.0 109.554 -173.973 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 14.9 ptm180 -150.72 -49.24 0.12 Allowed 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 123.405 0.682 . . . . 0.0 110.594 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -96.19 -7.72 35.0 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 122.837 0.455 . . . . 0.0 110.291 177.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 72.9 mt -89.43 111.28 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 174.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.2 mt -115.29 140.45 36.64 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.558 0 C-N-CA 124.488 1.115 . . . . 0.0 108.434 179.6 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 33.9 p -126.15 174.4 8.52 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 124.134 0.974 . . . . 0.0 109.149 178.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 52.7 ttp180 -71.25 139.92 50.21 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 122.716 0.406 . . . . 0.0 110.154 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.76 -8.48 70.94 Favored Glycine 0 C--N 1.337 0.595 0 C-N-CA 123.644 0.64 . . . . 0.0 112.83 -177.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.94 134.54 52.21 Favored 'General case' 0 C--N 1.351 0.669 0 C-N-CA 123.611 0.765 . . . . 0.0 111.89 -177.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.51 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 44.1 t -90.76 112.87 25.69 Favored 'Isoleucine or valine' 0 C--N 1.344 0.341 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 169.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.6 m -106.26 147.13 12.07 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 123.482 0.713 . . . . 0.0 109.271 177.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -90.73 126.44 36.0 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 175.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.449 ' HB ' ' HB2' ' A' ' 38' ' ' ALA . 67.2 p -130.85 179.79 5.77 Favored 'General case' 0 C--O 1.239 0.552 0 C-N-CA 123.259 0.623 . . . . 0.0 109.774 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 19.2 p-10 -73.59 -14.69 61.23 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 123.341 0.656 . . . . 0.0 111.192 175.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.1 mt -91.16 -41.09 11.21 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 123.249 0.62 . . . . 0.0 110.325 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 155.79 -149.97 21.2 Favored Glycine 0 C--N 1.345 1.074 0 CA-C-N 116.239 -0.437 . . . . 0.0 112.056 175.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -78.91 128.49 33.38 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 173.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.421 HG13 HG22 ' A' ' 27' ' ' VAL . 48.7 t -126.85 140.33 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 122.792 0.437 . . . . 0.0 110.4 -178.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.627 ' HG2' HD12 ' A' ' 88' ' ' ILE . 29.2 mmt180 -88.89 131.5 35.09 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 169.461 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 82.2 t -76.87 106.72 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 171.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 40.5 p -96.38 -19.92 18.85 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.044 0.538 . . . . 0.0 110.92 -172.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' SER . . . . . 0.482 ' HB2' ' HB2' ' A' ' 84' ' ' ASN . 32.4 t -87.49 171.08 10.79 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.378 0.671 . . . . 0.0 110.391 175.32 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 -93.48 92.84 0.72 Allowed Pre-proline 0 CA--C 1.559 1.315 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 173.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -62.73 -46.36 11.41 Favored 'Trans proline' 0 C--N 1.384 2.422 0 C-N-CA 123.431 2.754 . . . . 0.0 113.958 -163.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -81.19 -13.5 80.71 Favored Glycine 0 C--N 1.345 1.039 0 CA-C-O 119.959 -0.356 . . . . 0.0 113.54 -177.201 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 18.5 mm-40 -90.14 -48.39 7.21 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 122.981 0.513 . . . . 0.0 111.352 -178.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -80.67 -14.05 58.48 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 122.82 0.448 . . . . 0.0 111.294 174.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 68.36 18.53 71.6 Favored Glycine 0 C--N 1.349 1.254 0 O-C-N 123.205 0.316 . . . . 0.0 112.785 -175.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.438 ' HA ' HD22 ' A' ' 19' ' ' LEU . 11.6 p -143.25 143.87 24.3 Favored 'Isoleucine or valine' 0 C--O 1.24 0.555 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 178.211 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 29.0 mt -106.37 117.63 52.5 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -176.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.482 ' HB2' ' HB2' ' A' ' 75' ' ' SER . 9.4 m120 -124.7 151.4 45.04 Favored 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.585 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.9 -178.26 34.72 Favored Glycine 0 C--N 1.339 0.733 0 N-CA-C 115.141 0.816 . . . . 0.0 115.141 -174.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.416 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 30.0 m -121.51 139.5 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.637 0.775 . . . . 0.0 110.147 175.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.3 tp -74.03 122.23 22.32 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.093 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.627 HD12 ' HG2' ' A' ' 72' ' ' ARG . 46.8 pt -124.06 -177.89 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 124.615 1.166 . . . . 0.0 109.198 175.208 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 29.5 mmm180 -139.45 90.67 2.43 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -176.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -88.95 -50.07 6.4 Favored 'General case' 0 N--CA 1.484 1.229 0 CA-C-O 121.496 0.665 . . . . 0.0 109.629 178.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.427 HD12 HG23 ' A' ' 47' ' ' THR . 69.1 mt -95.45 -179.2 4.68 Favored 'General case' 0 C--O 1.245 0.843 0 CA-C-N 114.508 -1.224 . . . . 0.0 109.735 176.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 64.91 70.9 0.47 Allowed 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.167 0.987 . . . . 0.0 111.457 175.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 8.5 p80 -161.19 161.53 30.96 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 115.036 -0.984 . . . . 0.0 110.025 -178.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 75.1 m-70 -70.84 102.74 2.43 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 175.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 -71.74 91.95 1.16 Allowed 'General case' 0 CA--C 1.554 1.101 0 C-N-CA 123.388 0.675 . . . . 0.0 111.974 -175.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 53.7 t-80 -76.1 -30.45 58.27 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.508 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -104.25 144.27 31.83 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 123.363 0.665 . . . . 0.0 109.537 176.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 49.8 t60 . . . . . 0 CA--C 1.548 0.904 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 176.347 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.965 0 CA-C-O 120.082 -0.288 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -70.48 98.78 1.5 Allowed 'General case' 0 C--N 1.354 0.763 0 C-N-CA 123.617 0.767 . . . . 0.0 109.178 175.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -89.13 120.56 30.63 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 122.888 0.475 . . . . 0.0 111.065 -176.424 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 24.1 ptt180 -157.14 141.09 16.15 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 123.723 0.809 . . . . 0.0 109.186 173.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 48.8 t -99.66 127.65 52.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 176.633 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 18.1 ttm180 -152.15 90.17 1.5 Allowed 'General case' 0 C--O 1.24 0.59 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 79.2 mt -81.75 91.32 6.45 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.551 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.6 tp -68.66 133.94 31.0 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.166 0 C-N-CA 123.387 0.675 . . . . 0.0 110.252 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -148.03 85.4 1.54 Allowed 'General case' 0 C--O 1.238 0.452 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 -176.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.1 m -95.77 90.28 5.6 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.486 -178.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -73.56 132.15 42.51 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 123.456 0.703 . . . . 0.0 110.394 176.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.2 64.27 0.07 OUTLIER Glycine 0 C--O 1.242 0.613 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.988 -175.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.39 75.65 0.66 Allowed Glycine 0 C--N 1.35 1.361 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 174.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -70.95 135.93 48.2 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 124.071 0.949 . . . . 0.0 110.878 -169.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 43.8 p -68.37 110.04 3.93 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 123.499 0.719 . . . . 0.0 109.597 176.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.68 -178.55 3.57 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 123.467 0.707 . . . . 0.0 111.514 -174.136 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.4 p -72.27 151.16 8.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.944 0 C-N-CA 124.396 1.078 . . . . 0.0 109.739 174.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 35.7 mmt180 -62.87 -68.69 0.32 Allowed 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -169.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.412 ' HA ' ' O ' ' A' ' 22' ' ' ASP . 2.6 pt? -140.52 26.13 2.16 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 -171.704 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.7 -21.69 59.25 Favored 'General case' 0 N--CA 1.484 1.227 0 N-CA-C 112.305 0.484 . . . . 0.0 112.305 178.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 70.7 m -132.81 -66.14 0.68 Allowed 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.69 0.796 . . . . 0.0 109.284 177.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . 0.412 ' O ' ' HA ' ' A' ' 19' ' ' LEU . 1.7 m-20 -84.96 111.74 19.96 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.912 0.885 . . . . 0.0 108.662 174.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 52.8 m -65.43 111.36 3.04 Favored 'General case' 0 C--N 1.351 0.635 0 CA-C-N 118.28 0.491 . . . . 0.0 109.693 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.1 mmt180 -117.74 152.81 34.52 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-O 121.469 0.652 . . . . 0.0 111.599 -173.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.515 ' HB ' HD12 ' A' ' 40' ' ' ILE . 15.8 tt -141.96 142.18 28.3 Favored 'Isoleucine or valine' 0 C--O 1.241 0.643 0 CA-C-N 114.139 -1.391 . . . . 0.0 109.054 176.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -90.82 100.82 13.61 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 173.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.6 t -86.17 112.85 23.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.538 0 C-N-CA 124.623 1.169 . . . . 0.0 109.205 -175.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.421 HG21 HG21 ' A' ' 35' ' ' VAL . 41.5 t -94.81 100.33 10.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.549 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 176.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -64.16 113.65 11.07 Favored Pre-proline 0 CA--C 1.546 0.821 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 172.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.52 -1.18 11.38 Favored 'Trans proline' 0 C--N 1.364 1.378 0 C-N-CA 122.518 2.146 . . . . 0.0 113.591 -172.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -91.97 -52.68 4.6 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.337 0.655 . . . . 0.0 109.325 -177.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 66.7 p -93.29 -32.58 14.26 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 124.468 1.107 . . . . 0.0 111.909 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 93.51 6.98 62.17 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.986 -173.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -69.89 107.77 3.7 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 123.08 0.552 . . . . 0.0 110.994 -178.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.421 HG21 HG21 ' A' ' 28' ' ' VAL . 23.6 t -90.9 119.92 38.91 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 172.597 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -142.52 143.48 32.54 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 122.993 0.517 . . . . 0.0 110.466 -174.302 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 62.1 mt -77.45 123.85 34.82 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.86 0 C-N-CA 123.555 0.742 . . . . 0.0 109.661 179.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.41 158.12 36.8 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 123.89 0.876 . . . . 0.0 110.149 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -97.74 121.05 39.19 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.515 HD12 ' HB ' ' A' ' 25' ' ' ILE . 54.7 mt -77.74 112.55 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 72.3 mtm180 -80.71 -38.21 29.24 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 124.512 1.125 . . . . 0.0 111.113 -178.098 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 47.4 t-20 -140.76 138.95 34.51 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.7 m -93.96 -27.05 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 123.324 0.65 . . . . 0.0 112.425 -176.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.7 m -93.23 148.28 4.87 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-O 121.193 0.52 . . . . 0.0 110.711 179.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -94.35 93.19 7.56 Favored 'General case' 0 N--CA 1.479 0.975 0 C-N-CA 123.7 0.8 . . . . 0.0 111.517 -171.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 64.2 t30 71.77 -19.43 0.27 Allowed 'General case' 0 N--CA 1.502 2.142 0 C-N-CA 125.483 1.513 . . . . 0.0 113.224 173.09 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 37.8 p -67.16 98.07 0.57 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 124.356 1.063 . . . . 0.0 111.277 -169.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.21 -36.35 58.62 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 123.649 0.779 . . . . 0.0 110.96 -176.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -112.03 117.97 47.07 Favored Pre-proline 0 CA--C 1.554 1.13 0 C-N-CA 122.923 0.489 . . . . 0.0 110.001 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo -72.18 128.51 13.93 Favored 'Trans proline' 0 C--N 1.379 2.145 0 C-N-CA 123.09 2.526 . . . . 0.0 112.171 178.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 55.8 p-80 -161.27 -42.26 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 123.681 0.793 . . . . 0.0 110.219 175.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 20.7 m-85 -92.65 -47.93 6.85 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 169.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 16.7 m -92.85 163.93 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 168.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 2.4 tmm_? -171.24 -32.83 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -177.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 26.2 mtm180 -66.3 157.01 32.75 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 124.262 1.025 . . . . 0.0 111.643 -177.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -105.43 29.52 6.43 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.32 0.648 . . . . 0.0 109.86 178.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 15.8 tt -117.36 147.89 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 123.113 0.565 . . . . 0.0 109.703 -173.136 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 76.3 mt -91.58 143.56 11.02 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.698 0 C-N-CA 124.426 1.09 . . . . 0.0 109.723 175.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' THR . . . . . 0.431 HG21 ' HB2' ' A' ' 62' ' ' ALA . 3.3 t -131.32 172.16 12.49 Favored 'General case' 0 C--O 1.244 0.766 0 C-N-CA 123.915 0.886 . . . . 0.0 109.261 177.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 25.3 ttm180 -74.03 133.79 42.97 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -178.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.88 -2.83 82.36 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.956 -0.358 . . . . 0.0 112.924 -176.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.431 ' HB2' HG21 ' A' ' 59' ' ' THR . . . -77.6 132.06 38.1 Favored 'General case' 0 C--O 1.244 0.796 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 176.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.577 HG21 ' HG3' ' A' ' 90' ' ' GLU . 21.9 t -83.18 114.08 23.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 177.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 33.4 m -101.57 146.45 9.85 Favored 'Isoleucine or valine' 0 C--O 1.244 0.793 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 177.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.8 tp10 -95.83 128.24 42.54 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 63.2 p -124.86 177.86 5.8 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 24.0 p-10 -72.42 -12.26 61.03 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 122.794 0.438 . . . . 0.0 110.743 175.372 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.3 mt -93.41 -49.77 5.77 Favored 'General case' 0 C--N 1.357 0.918 0 C-N-CA 123.079 0.551 . . . . 0.0 110.425 175.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 168.73 -150.66 16.33 Favored Glycine 0 C--N 1.348 1.21 0 O-C-N 123.177 0.298 . . . . 0.0 113.253 178.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -88.23 118.09 27.59 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 123.836 0.854 . . . . 0.0 109.122 -178.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.2 t -121.27 144.86 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 C-N-CA 123.467 0.707 . . . . 0.0 109.4 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.49 ' HG3' HD13 ' A' ' 88' ' ' ILE . 24.4 mtt180 -109.66 131.91 54.63 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 171.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.1 t -80.36 98.99 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 O-C-N 124.172 0.92 . . . . 0.0 109.243 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 35.5 p -74.48 -28.59 61.08 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.792 0.837 . . . . 0.0 111.781 177.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.1 m -90.58 -170.78 2.83 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.921 177.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.408 ' HD2' ' N ' ' A' ' 76' ' ' ARG . 8.4 mpt_? -96.54 112.15 59.23 Favored Pre-proline 0 CA--C 1.545 0.784 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.301 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -62.37 96.02 0.15 Allowed 'Trans proline' 0 C--N 1.377 2.03 0 C-N-CA 123.148 2.565 . . . . 0.0 112.837 -172.11 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.77 -23.45 32.5 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.69 -0.686 . . . . 0.0 113.999 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -72.97 -30.43 63.83 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-N 117.956 0.878 . . . . 0.0 110.491 175.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -77.04 4.33 10.37 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 123.569 0.748 . . . . 0.0 111.287 171.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 90.62 -33.95 4.39 Favored Glycine 0 C--N 1.356 1.682 0 N-CA-C 111.596 -0.602 . . . . 0.0 111.596 -172.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.0 p -140.2 164.27 22.75 Favored 'Isoleucine or valine' 0 C--O 1.243 0.751 0 C-N-CA 124.729 1.212 . . . . 0.0 108.395 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 45.2 mt -84.5 132.88 30.53 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 173.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -133.66 144.66 49.34 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 -177.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -171.73 -172.74 38.02 Favored Glycine 0 C--N 1.342 0.901 0 N-CA-C 114.825 0.69 . . . . 0.0 114.825 -177.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 16.5 m -119.28 137.38 53.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 C-N-CA 123.943 0.897 . . . . 0.0 110.357 -176.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 41.8 tp -74.08 109.35 7.51 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 122.632 0.373 . . . . 0.0 110.438 -179.118 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.49 HD13 ' HG3' ' A' ' 72' ' ' ARG . 31.6 pt -102.52 179.6 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.83 0 C-N-CA 123.802 0.841 . . . . 0.0 109.865 174.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 5.0 mpt_? -125.76 55.96 1.42 Allowed 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.577 ' HG3' HG21 ' A' ' 63' ' ' VAL . 0.8 OUTLIER -60.47 -57.84 11.02 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 -179.967 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 74.9 mt -99.63 -151.86 0.4 Allowed 'General case' 0 CA--C 1.545 0.77 0 CA-C-N 114.7 -1.136 . . . . 0.0 107.946 169.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -122.02 148.83 44.33 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 165.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 51.4 t60 -92.53 30.68 1.47 Allowed 'General case' 0 CA--C 1.554 1.123 0 CA-C-O 122.284 1.04 . . . . 0.0 108.775 170.048 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -133.3 140.64 47.56 Favored 'General case' 0 C--O 1.24 0.596 0 C-N-CA 125.354 1.462 . . . . 0.0 107.446 -175.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 15.0 m-70 -60.53 132.0 52.5 Favored 'General case' 0 N--CA 1.476 0.859 0 O-C-N 123.931 0.769 . . . . 0.0 111.62 -177.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 11.5 m-70 -94.83 152.28 18.53 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.7 0.8 . . . . 0.0 109.47 170.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -74.73 94.91 2.78 Favored 'General case' 0 CA--C 1.54 0.56 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 174.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 10.4 m170 . . . . . 0 CA--C 1.548 0.871 0 C-N-CA 123.73 0.812 . . . . 0.0 109.959 177.134 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.706 0 N-CA-C 111.727 -0.549 . . . . 0.0 111.727 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -158.98 163.78 36.16 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.765 0.826 . . . . 0.0 110.255 -175.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 19.6 mmt180 -71.33 -2.55 16.71 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 123.762 0.825 . . . . 0.0 112.689 -177.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.8 ptm85 -59.93 131.37 50.65 Favored 'General case' 0 CA--C 1.552 1.052 0 C-N-CA 123.868 0.867 . . . . 0.0 110.986 176.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 85.9 t -111.63 99.45 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 174.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 11.4 ptm180 -83.77 86.73 7.1 Favored 'General case' 0 C--O 1.239 0.542 0 CA-C-O 122.005 0.907 . . . . 0.0 109.061 175.281 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 6.3 tt -65.87 128.11 34.71 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 114.365 -1.289 . . . . 0.0 109.839 -176.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -140.29 148.6 22.27 Favored 'Isoleucine or valine' 0 C--O 1.243 0.76 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -74.11 70.99 1.61 Allowed 'General case' 0 N--CA 1.485 1.318 0 CA-C-O 122.122 0.963 . . . . 0.0 110.313 174.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 10.2 t -77.2 137.87 39.11 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 114.808 -1.087 . . . . 0.0 110.087 -175.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -94.84 86.15 4.61 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.503 0.721 . . . . 0.0 110.291 -173.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -152.66 174.77 31.45 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 114.441 -1.254 . . . . 0.0 111.493 177.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.95 81.16 0.91 Allowed Glycine 0 C--N 1.342 0.901 0 C-N-CA 122.728 0.204 . . . . 0.0 112.935 -177.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 67.2 t30 -84.56 -14.45 48.84 Favored 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 123.505 0.722 . . . . 0.0 109.976 173.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.425 HG22 ' HD2' ' A' ' 16' ' ' LYS . 4.3 m -76.63 165.48 24.7 Favored 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 123.971 0.908 . . . . 0.0 110.178 177.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.425 ' HD2' HG22 ' A' ' 15' ' ' THR . 13.0 mptt 60.96 56.74 2.75 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 123.97 0.908 . . . . 0.0 109.729 -173.437 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.5 t -69.15 113.65 5.14 Favored 'Isoleucine or valine' 0 C--O 1.24 0.584 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.915 -178.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -63.33 -178.05 0.23 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 123.591 0.756 . . . . 0.0 110.769 171.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.459 HD22 ' HA ' ' A' ' 23' ' ' THR . 0.7 OUTLIER -54.81 -33.65 61.8 Favored 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -179.847 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.428 ' H ' HD11 ' A' ' 19' ' ' LEU . . . 52.41 74.91 0.25 Allowed 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 125.143 1.377 . . . . 0.0 112.615 171.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 12.9 t 74.52 -16.54 0.54 Allowed 'General case' 0 N--CA 1.496 1.837 0 C-N-CA 125.295 1.438 . . . . 0.0 112.855 -178.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -89.89 -176.19 4.85 Favored 'General case' 0 CA--C 1.548 0.878 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 173.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.515 HG23 HD11 ' A' ' 40' ' ' ILE . 52.4 m -141.32 115.21 9.14 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -177.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -127.18 158.82 36.08 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.543 0.737 . . . . 0.0 111.516 -175.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.479 ' HB ' HD12 ' A' ' 40' ' ' ILE . 16.1 tt -145.6 148.75 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.731 0.813 . . . . 0.0 110.395 -171.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 37.7 m-80 -89.32 103.6 16.22 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 172.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 75.8 t -89.39 109.82 20.84 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 C-N-CA 123.932 0.893 . . . . 0.0 109.053 -176.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 37.0 t -100.01 110.05 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 123.199 0.6 . . . . 0.0 109.654 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -59.2 112.68 5.48 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 170.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.2 -16.97 19.48 Favored 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 121.926 1.751 . . . . 0.0 111.747 179.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -94.37 -45.18 7.57 Favored 'General case' 0 CA--C 1.552 1.032 0 C-N-CA 124.344 1.058 . . . . 0.0 111.184 178.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.6 m -90.2 -20.01 23.54 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 123.362 0.665 . . . . 0.0 112.02 -175.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.17 -11.52 57.54 Favored Glycine 0 C--N 1.35 1.317 0 C-N-CA 123.422 0.534 . . . . 0.0 114.223 178.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -75.39 150.59 38.32 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.814 0.846 . . . . 0.0 112.132 -173.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 21.1 t -126.12 133.83 67.94 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.797 0.839 . . . . 0.0 108.774 174.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -147.61 141.3 25.61 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.611 0.764 . . . . 0.0 109.537 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 47.5 mt -81.92 122.87 37.43 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.8 0 N-CA-C 108.264 -1.014 . . . . 0.0 108.264 178.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.35 161.41 27.88 Favored 'General case' 0 C--O 1.236 0.382 0 C-N-CA 124.796 1.238 . . . . 0.0 109.517 -174.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -106.43 123.7 48.47 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -175.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.515 HD11 HG23 ' A' ' 23' ' ' THR . 59.5 mt -76.41 113.29 15.23 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 123.388 0.675 . . . . 0.0 109.955 -176.259 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -77.4 -53.29 7.83 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.634 1.174 . . . . 0.0 110.264 -178.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -140.23 166.61 24.22 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 124.158 0.983 . . . . 0.0 108.704 178.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 43.9 t -112.62 87.87 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 167.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.2 p -133.08 127.71 55.22 Favored 'Isoleucine or valine' 0 C--O 1.242 0.687 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.727 -177.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.588 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 13.6 pt-20 -88.72 -56.11 3.43 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.406 -175.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 9.6 m120 -148.12 159.34 44.03 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.422 1.089 . . . . 0.0 108.85 -176.238 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.442 HG21 HD23 ' A' ' 91' ' ' LEU . 59.7 p -78.88 -31.93 45.67 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 122.864 0.466 . . . . 0.0 110.778 176.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -71.45 84.2 0.82 Allowed 'General case' 0 CA--C 1.54 0.594 0 O-C-N 123.866 0.729 . . . . 0.0 109.605 178.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 59.36 84.09 0.2 Allowed Pre-proline 0 CA--C 1.548 0.887 0 C-N-CA 125.11 1.364 . . . . 0.0 111.406 -176.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -71.94 102.63 1.36 Allowed 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 122.174 1.916 . . . . 0.0 109.897 176.076 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 83.0 t60 -61.01 -26.85 67.89 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 122.636 0.374 . . . . 0.0 110.918 -177.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -73.45 87.65 1.58 Allowed 'General case' 0 CA--C 1.547 0.834 0 N-CA-C 108.126 -1.065 . . . . 0.0 108.126 164.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.7 t -64.8 -49.21 81.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 175.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 4.0 ppt_? -79.59 140.99 36.97 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-N 114.31 -1.314 . . . . 0.0 109.352 168.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 6.7 ppt_? -94.3 29.71 2.14 Favored 'General case' 0 N--CA 1.482 1.151 0 CA-C-O 121.229 0.538 . . . . 0.0 110.637 179.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 -131.11 -178.69 4.94 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 125.035 1.334 . . . . 0.0 109.536 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 49.4 mm 60.42 82.08 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.255 0 C-N-CA 125.05 1.34 . . . . 0.0 110.42 177.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 37.1 mt -83.23 144.4 10.14 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 113.962 -1.472 . . . . 0.0 109.595 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 17.5 p -122.82 167.94 12.89 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.051 0.941 . . . . 0.0 109.052 173.05 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 35.7 ttt180 -74.16 131.38 41.22 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 175.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.94 9.4 77.52 Favored Glycine 0 N--CA 1.465 0.613 0 O-C-N 124.076 0.86 . . . . 0.0 112.843 -175.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -83.16 160.95 21.73 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.145 0.578 . . . . 0.0 109.603 176.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.588 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 47.7 t -105.99 120.9 57.67 Favored 'Isoleucine or valine' 0 C--O 1.243 0.748 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 172.325 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.4 m -106.5 159.55 6.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.228 175.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -106.85 130.08 54.59 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 173.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 34.0 p -129.61 -175.18 3.51 Favored 'General case' 0 C--O 1.24 0.556 0 C-N-CA 123.241 0.616 . . . . 0.0 109.813 -176.06 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 73.3 m-20 -70.28 -19.26 63.11 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 123.134 0.574 . . . . 0.0 111.024 175.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 93.8 mt -99.45 -13.73 19.41 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.907 0.883 . . . . 0.0 111.755 -178.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.45 -164.16 22.42 Favored Glycine 0 C--N 1.35 1.32 0 O-C-N 123.349 0.406 . . . . 0.0 112.528 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -80.09 130.45 35.26 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.142 0.577 . . . . 0.0 110.394 177.76 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.6 t -125.5 138.9 52.93 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 C-N-CA 124.468 1.107 . . . . 0.0 110.663 -173.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.679 ' HG2' HD13 ' A' ' 88' ' ' ILE . 9.5 mmt180 -86.4 121.03 28.38 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 169.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 48.9 t -72.98 116.75 15.6 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.768 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 43.8 p -96.97 -24.58 15.75 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.456 0.702 . . . . 0.0 111.238 -172.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 23.3 t -108.55 178.5 4.47 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.533 0.733 . . . . 0.0 109.84 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 85.8 mtm180 -90.62 106.69 16.18 Favored Pre-proline 0 CA--C 1.552 1.049 0 C-N-CA 123.383 0.673 . . . . 0.0 109.976 -177.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -66.22 114.44 3.03 Favored 'Trans proline' 0 C--N 1.373 1.835 0 C-N-CA 123.101 2.534 . . . . 0.0 112.357 -175.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 141.94 -29.88 2.18 Favored Glycine 0 C--N 1.344 0.981 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.339 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -60.84 110.73 1.4 Allowed 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.342 0.657 . . . . 0.0 110.49 178.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.488 ' HB2' HG12 ' A' ' 82' ' ' VAL . 26.8 m-20 70.26 -15.79 0.33 Allowed 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 125.66 1.584 . . . . 0.0 114.04 178.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 98.05 12.52 45.84 Favored Glycine 0 C--N 1.342 0.907 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -169.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.488 HG12 ' HB2' ' A' ' 80' ' ' ASP . 3.7 p -111.32 118.59 57.81 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 C-N-CA 123.603 0.761 . . . . 0.0 109.573 175.085 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.2 mt -98.24 148.03 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 170.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -135.16 149.14 49.91 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 122.937 0.495 . . . . 0.0 109.819 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.25 -175.54 37.97 Favored Glycine 0 C--N 1.346 1.102 0 O-C-N 123.648 0.592 . . . . 0.0 113.482 -176.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.2 m -129.1 138.7 53.8 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 C-N-CA 124.248 1.019 . . . . 0.0 110.42 178.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.6 tp -73.86 122.73 22.96 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 121.094 0.473 . . . . 0.0 111.271 -175.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.679 HD13 ' HG2' ' A' ' 72' ' ' ARG . 40.1 pt -119.17 -179.65 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 123.884 0.874 . . . . 0.0 109.623 175.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 57.4 mtt180 -122.79 83.29 2.1 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 -176.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 36.2 mm-40 -93.2 -80.91 0.37 Allowed 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 175.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.442 HD23 HG21 ' A' ' 47' ' ' THR . 50.8 mt -83.12 96.88 8.53 Favored 'General case' 0 C--N 1.344 0.327 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -175.435 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -72.56 -9.44 58.58 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 123.304 0.642 . . . . 0.0 110.701 175.035 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 3.2 p80 -134.16 141.92 47.26 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.848 1.659 . . . . 0.0 107.964 173.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 6.0 t-160 -84.65 -46.21 11.73 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -177.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -89.91 123.65 34.03 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.279 0.632 . . . . 0.0 110.11 176.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 7.0 p80 -86.39 104.83 16.25 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 12.7 t60 -162.08 132.77 4.96 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 122.725 0.41 . . . . 0.0 110.39 -170.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 . . . . . 0 C--O 1.251 1.166 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 173.022 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.619 0 N-CA-C 111.667 -0.573 . . . . 0.0 111.667 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -73.08 96.13 2.14 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 122.917 0.487 . . . . 0.0 109.831 177.28 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 27.8 mmm180 -84.17 69.3 10.38 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.992 0.901 . . . . 0.0 109.828 -178.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 77.1 mtp180 -97.79 21.37 10.59 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.693 1.197 . . . . 0.0 110.923 -176.104 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 p -39.44 96.5 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.566 1.591 0 C-N-CA 125.552 1.541 . . . . 0.0 114.528 -170.168 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 45.81 66.31 0.96 Allowed 'General case' 0 C--N 1.358 0.973 0 C-N-CA 126.492 1.917 . . . . 0.0 112.038 176.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 51.6 tp -62.37 -38.33 89.13 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.646 -176.559 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 tt -61.6 148.7 9.49 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.486 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.103 178.56 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 24.6 tpt180 -55.1 -30.37 59.55 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 125.006 1.323 . . . . 0.0 112.66 -175.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 46.1 p -64.74 92.3 0.09 Allowed 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 123.443 0.697 . . . . 0.0 111.31 -178.024 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.9 mmt85 -108.0 143.74 36.28 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.385 1.074 . . . . 0.0 109.688 177.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -172.8 89.86 0.08 OUTLIER Glycine 0 C--N 1.338 0.639 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.844 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.5 20.19 8.38 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 111.546 -0.621 . . . . 0.0 111.546 170.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 17.5 m120 -133.07 88.34 2.49 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 123.974 0.91 . . . . 0.0 108.806 179.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 11.2 t -148.48 170.17 18.64 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.788 0.835 . . . . 0.0 109.446 178.452 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt 67.15 128.44 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.425 0 C-N-CA 125.05 1.34 . . . . 0.0 111.099 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 10.9 p -100.7 131.79 47.63 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 172.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.05 178.13 4.69 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 123.645 0.778 . . . . 0.0 109.944 176.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -55.26 122.32 10.83 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.4 0.68 . . . . 0.0 110.443 178.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -121.06 -85.54 0.66 Allowed 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -175.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 19.7 m -88.68 -26.75 21.67 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 172.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -80.77 162.13 24.22 Favored 'General case' 0 CA--C 1.548 0.866 0 CA-C-N 114.099 -1.41 . . . . 0.0 110.462 168.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.482 HG23 HD13 ' A' ' 40' ' ' ILE . 62.9 m -127.25 118.07 23.52 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.118 0.567 . . . . 0.0 109.973 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 41.8 mtt180 -115.01 163.6 15.36 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.732 0.813 . . . . 0.0 110.519 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.494 ' HB ' HD11 ' A' ' 40' ' ' ILE . 16.6 tt -141.75 135.49 30.03 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 124.025 0.93 . . . . 0.0 108.802 175.666 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -85.67 103.27 14.33 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 177.154 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -92.08 133.27 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 123.802 0.841 . . . . 0.0 109.886 -171.495 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 46.7 t -109.8 109.81 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 178.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -66.61 119.07 60.24 Favored Pre-proline 0 CA--C 1.545 0.78 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 176.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -66.11 -33.84 39.3 Favored 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 123.003 2.468 . . . . 0.0 113.667 -166.003 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -95.36 -40.4 9.54 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 112.85 0.685 . . . . 0.0 112.85 -171.61 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 71.3 p -89.51 -21.24 23.03 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 122.464 0.306 . . . . 0.0 111.533 179.673 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.49 2.76 90.63 Favored Glycine 0 C--N 1.347 1.192 0 CA-C-O 119.882 -0.399 . . . . 0.0 113.572 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.6 mmtp -68.25 107.26 2.73 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.504 0.722 . . . . 0.0 110.971 -177.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.2 t -92.59 126.11 45.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 174.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -154.21 146.79 24.12 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 123.831 0.853 . . . . 0.0 108.813 -176.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 45.2 mt -80.87 137.41 21.41 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -177.523 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.98 159.49 32.52 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.672 0.789 . . . . 0.0 109.713 -179.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 17.1 mm-40 -103.17 122.57 44.98 Favored 'General case' 0 C--O 1.241 0.651 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.494 HD11 ' HB ' ' A' ' 25' ' ' ILE . 44.5 mt -76.95 110.11 12.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -176.612 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 62.3 mtt180 -73.85 -52.3 13.45 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.149 0.979 . . . . 0.0 110.91 178.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -140.75 164.11 31.09 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.817 0.847 . . . . 0.0 110.14 -176.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 70.8 t -132.14 103.25 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.168 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 176.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.2 p -162.33 96.81 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.562 1.431 0 CA-C-O 121.822 0.82 . . . . 0.0 109.603 -175.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.539 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 0.7 OUTLIER -72.83 -40.57 65.66 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.339 0.656 . . . . 0.0 112.769 -172.015 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -78.02 -21.15 51.19 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 122.812 0.445 . . . . 0.0 110.747 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 44.2 p 65.52 -58.45 0.3 Allowed 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 126.829 2.052 . . . . 0.0 111.733 -171.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -72.37 73.95 1.0 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 123.417 0.687 . . . . 0.0 110.978 173.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 50.4 t-20 -173.1 74.98 0.41 Allowed Pre-proline 0 CA--C 1.552 1.022 0 C-N-CA 125.213 1.405 . . . . 0.0 107.603 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -88.62 59.84 2.67 Favored 'Trans proline' 0 C--N 1.373 1.83 0 C-N-CA 123.314 2.676 . . . . 0.0 111.792 -177.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 8.1 t-160 -65.94 120.38 12.99 Favored 'General case' 0 CA--C 1.546 0.797 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.859 -175.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -52.81 -39.35 62.34 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 124.14 0.976 . . . . 0.0 113.241 -171.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 10.4 p -74.27 110.61 8.65 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.127 0 CA-C-O 121.525 0.679 . . . . 0.0 109.252 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 76.2 mtp180 -72.04 94.36 1.49 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.54 -178.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 28.8 mmm180 -122.48 103.93 9.04 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 175.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 25.3 p-10 -86.04 55.67 3.63 Favored 'General case' 0 CA--C 1.547 0.84 0 CA-C-O 122.119 0.962 . . . . 0.0 110.727 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.8 mm -77.55 93.02 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.539 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.1 mt -80.37 127.43 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 123.424 0.69 . . . . 0.0 109.764 -176.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 74.0 p -124.74 160.6 28.26 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 123.79 0.836 . . . . 0.0 109.427 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -75.68 128.23 34.77 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 122.964 0.506 . . . . 0.0 110.261 179.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.31 -1.24 58.82 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.441 -176.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.1 148.12 22.49 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.642 0.777 . . . . 0.0 111.479 -176.767 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.539 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 94.6 t -83.49 118.94 31.89 Favored 'Isoleucine or valine' 0 C--O 1.24 0.592 0 C-N-CA 123.406 0.682 . . . . 0.0 109.604 171.812 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.0 m -102.77 143.32 15.29 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 165.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -94.18 123.68 37.72 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 66.2 p -123.19 -173.08 2.64 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.141 0.577 . . . . 0.0 110.047 -175.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 58.2 m-20 -73.38 -26.99 61.23 Favored 'General case' 0 N--CA 1.478 0.932 0 CA-C-O 119.851 -0.118 . . . . 0.0 110.902 170.131 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.1 mt -84.13 -28.25 27.6 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 122.916 0.486 . . . . 0.0 111.843 -176.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 146.96 -149.55 21.71 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 178.579 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -85.55 128.11 34.65 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 175.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.7 t -121.72 128.6 75.78 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.526 0 C-N-CA 122.656 0.383 . . . . 0.0 110.862 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.518 ' HG2' HD12 ' A' ' 88' ' ' ILE . 22.6 mmt85 -85.58 123.29 30.83 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 171.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.6 t -72.32 100.13 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.415 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 47.5 p -95.4 -22.55 17.65 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 123.253 0.621 . . . . 0.0 110.803 -169.372 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 21.6 t -98.32 -177.81 3.83 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 169.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.618 ' HE ' ' HB3' ' A' ' 79' ' ' GLN . 39.6 ptt180 -75.26 144.0 77.71 Favored Pre-proline 0 CA--C 1.551 1.014 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 173.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.441 ' HA ' HG23 ' A' ' 83' ' ' ILE . 87.3 Cg_endo -76.71 50.63 3.08 Favored 'Trans proline' 0 CA--C 1.559 1.762 0 C-N-CA 123.091 2.527 . . . . 0.0 113.273 174.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 172.8 67.08 0.05 OUTLIER Glycine 0 C--N 1.346 1.126 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.977 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . 0.618 ' HB3' ' HE ' ' A' ' 76' ' ' ARG . 1.7 pt20 -123.41 115.33 21.43 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.999 0.92 . . . . 0.0 108.604 172.562 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 62.39 19.3 11.01 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 124.339 1.055 . . . . 0.0 111.335 -176.013 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 92.86 -6.25 76.68 Favored Glycine 0 C--N 1.353 1.474 0 CA-C-N 116.033 -0.53 . . . . 0.0 112.496 178.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.8 p -120.3 163.71 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 123.004 0.522 . . . . 0.0 111.008 -175.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.441 HG23 ' HA ' ' A' ' 77' ' ' PRO . 42.3 mt -109.31 147.54 13.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 C-N-CA 124.696 1.198 . . . . 0.0 109.169 -178.753 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -130.03 155.5 46.03 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 118.414 0.552 . . . . 0.0 110.774 174.449 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.415 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -166.84 -169.38 30.37 Favored Glycine 0 C--N 1.348 1.199 0 CA-C-N 115.367 -0.833 . . . . 0.0 113.652 -177.611 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.1 m -125.61 146.8 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 CA-C-N 117.789 0.795 . . . . 0.0 111.045 178.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 17.5 tp -84.6 104.61 14.74 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 122.607 0.363 . . . . 0.0 111.224 -176.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.518 HD12 ' HG2' ' A' ' 72' ' ' ARG . 50.0 pt -93.71 174.95 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 123.08 0.552 . . . . 0.0 110.765 178.077 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -119.57 27.39 8.78 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 124.022 0.929 . . . . 0.0 110.298 -170.206 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.95 -61.41 2.4 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 124.378 1.071 . . . . 0.0 110.792 -170.361 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -127.26 109.46 11.84 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 165.732 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -63.05 132.29 51.46 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.233 0.613 . . . . 0.0 110.773 -179.135 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 26.5 p-80 -64.5 -31.23 72.35 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.898 0.479 . . . . 0.0 111.042 -177.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 32.1 t60 -80.21 79.48 6.77 Favored 'General case' 0 CA--C 1.541 0.63 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 170.039 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 53.3 t-80 -108.51 72.57 0.84 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 124.095 0.958 . . . . 0.0 109.742 -172.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 9.9 t60 -171.53 88.63 0.11 Allowed 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 175.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 10.3 t60 -76.2 93.36 3.36 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 176.544 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 14.7 p-80 . . . . . 0 CA--C 1.556 1.201 0 C-N-CA 122.891 0.476 . . . . 0.0 110.07 -179.671 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.366 0 N-CA-C 111.763 -0.535 . . . . 0.0 111.763 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -64.39 132.45 50.12 Favored 'General case' 0 C--N 1.352 0.7 0 C-N-CA 123.63 0.772 . . . . 0.0 110.081 177.231 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -131.2 147.04 52.55 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 174.409 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -72.64 80.68 1.1 Allowed 'General case' 0 CA--C 1.544 0.715 0 O-C-N 123.543 0.527 . . . . 0.0 109.819 177.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 61.0 t -72.71 120.06 20.62 Favored 'Isoleucine or valine' 0 C--N 1.345 0.387 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 174.426 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 15.4 tpp180 -59.15 116.79 4.09 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.966 0.906 . . . . 0.0 110.923 -169.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -74.53 81.44 1.97 Allowed 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 174.035 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 50.4 mt -79.42 78.84 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.462 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 176.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 35.6 ttm180 -73.3 115.15 12.31 Favored 'General case' 0 C--O 1.238 0.451 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.625 -178.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 32.1 p -83.36 62.91 6.99 Favored 'General case' 0 CA--C 1.547 0.831 0 CA-C-O 121.926 0.869 . . . . 0.0 110.945 -173.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 4.8 mmp_? -120.01 112.27 18.94 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.239 1.416 . . . . 0.0 107.888 175.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.77 77.37 1.9 Allowed Glycine 0 CA--C 1.529 0.944 0 O-C-N 123.773 0.671 . . . . 0.0 112.646 -175.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.69 19.43 4.47 Favored Glycine 0 N--CA 1.473 1.149 0 CA-C-O 119.941 -0.366 . . . . 0.0 113.101 -179.242 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . 0.451 HD21 HG23 ' A' ' 17' ' ' VAL . 9.4 t30 -164.44 96.64 0.77 Allowed 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.803 0.841 . . . . 0.0 108.889 179.569 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 58.4 m -75.61 -37.98 59.35 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 123.426 0.69 . . . . 0.0 110.786 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -75.61 85.47 2.66 Favored 'General case' 0 CA--C 1.542 0.671 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.12 -178.199 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.451 HG23 HD21 ' A' ' 14' ' ' ASN . 23.7 t -119.22 139.85 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 123.866 0.866 . . . . 0.0 108.857 -179.573 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -65.25 148.75 51.13 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 171.14 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.58 HD21 ' HB2' ' A' ' 24' ' ' ARG . 0.9 OUTLIER -51.95 91.81 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 124.71 1.204 . . . . 0.0 112.745 -176.041 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -110.16 -14.08 14.25 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 114.449 -1.25 . . . . 0.0 111.424 -177.009 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 36.6 t -58.09 -46.21 85.9 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.846 0.858 . . . . 0.0 109.774 173.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -150.69 147.73 27.71 Favored 'General case' 0 C--O 1.244 0.782 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 168.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 63.7 m -68.98 111.84 5.25 Favored 'General case' 0 C--N 1.354 0.79 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 173.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.58 ' HB2' HD21 ' A' ' 19' ' ' LEU . 13.4 mmt85 -97.56 165.08 12.15 Favored 'General case' 0 C--O 1.244 0.771 0 CA-C-O 121.713 0.768 . . . . 0.0 110.441 -178.446 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.0 tt -136.54 134.18 49.2 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 CA-C-N 114.09 -1.413 . . . . 0.0 107.893 174.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 -88.68 100.53 13.19 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 179.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 91.7 t -87.32 116.04 28.96 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.169 -173.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.403 HG21 HG23 ' A' ' 35' ' ' VAL . 58.2 t -95.17 99.65 9.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -178.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -59.88 110.98 3.24 Favored Pre-proline 0 CA--C 1.545 0.774 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 170.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -82.73 -4.63 11.47 Favored 'Trans proline' 0 CA--C 1.547 1.131 0 C-N-CA 122.535 2.157 . . . . 0.0 113.043 -174.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -76.23 -58.58 3.2 Favored 'General case' 0 C--N 1.353 0.759 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -177.079 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.9 p -95.76 -32.73 12.58 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 114.578 -1.192 . . . . 0.0 112.127 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.01 14.39 19.05 Favored Glycine 0 N--CA 1.477 1.427 0 CA-C-O 119.793 -0.448 . . . . 0.0 113.224 -178.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -63.15 148.44 48.0 Favored 'General case' 0 N--CA 1.486 1.369 0 C-N-CA 122.757 0.423 . . . . 0.0 111.589 175.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.403 HG23 HG21 ' A' ' 28' ' ' VAL . 44.1 t -127.04 120.29 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 167.528 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -130.77 139.93 50.26 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.74 0.816 . . . . 0.0 110.062 -176.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 53.5 mt -79.15 120.46 30.39 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 177.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.24 155.5 33.08 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.964 0.905 . . . . 0.0 111.175 -173.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -99.19 127.32 45.15 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 174.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 61.6 mt -77.58 111.28 14.21 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 123.035 0.534 . . . . 0.0 110.612 -175.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 15.6 mmm180 -66.77 -44.34 81.63 Favored 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 123.718 0.807 . . . . 0.0 110.77 174.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.551 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 37.4 t30 -140.32 125.65 18.83 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.68 -169.583 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.415 HG12 HD11 ' A' ' 58' ' ' ILE . 17.9 m -87.86 -34.53 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 O-C-N 124.031 0.832 . . . . 0.0 111.686 -178.063 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.9 p -78.19 134.61 27.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 C-N-CA 122.784 0.434 . . . . 0.0 110.212 -177.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.428 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 14.5 pt-20 -59.35 111.97 1.57 Allowed 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 123.41 0.684 . . . . 0.0 111.8 -172.65 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.451 HD21 HD23 ' A' ' 91' ' ' LEU . 14.7 m120 64.93 6.27 3.31 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 124.889 1.276 . . . . 0.0 113.358 172.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.438 HG22 ' ND2' ' A' ' 42' ' ' ASN . 44.2 p 52.29 28.39 5.64 Favored 'General case' 0 N--CA 1.5 2.038 0 C-N-CA 124.797 1.239 . . . . 0.0 111.431 -161.544 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.34 -47.77 39.73 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 124.244 1.018 . . . . 0.0 110.404 177.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 55.3 m-20 -75.95 114.77 40.33 Favored Pre-proline 0 CA--C 1.551 0.981 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -90.03 26.94 0.49 Allowed 'Trans proline' 0 C--N 1.372 1.79 0 C-N-CA 123.316 2.677 . . . . 0.0 113.168 -175.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 53.5 m-70 -86.42 146.08 26.58 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 123.274 0.63 . . . . 0.0 110.144 -179.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 26.4 p90 -80.48 -2.6 46.61 Favored 'General case' 0 N--CA 1.486 1.33 0 C-N-CA 123.549 0.74 . . . . 0.0 112.54 -176.037 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.9 m -79.37 49.49 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 C-N-CA 123.977 0.911 . . . . 0.0 111.788 179.053 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 45.9 mtt180 -91.76 51.28 1.82 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.992 0.917 . . . . 0.0 110.796 -174.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 6.2 mpt_? -78.1 178.4 7.58 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 168.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -82.03 58.31 3.88 Favored 'General case' 0 CA--C 1.556 1.183 0 CA-C-O 122.206 1.003 . . . . 0.0 109.207 175.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 49.9 mm -106.88 81.51 0.59 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.561 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 175.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.415 HD11 HG12 ' A' ' 43' ' ' VAL . 67.9 mt -101.67 144.23 13.45 Favored 'Isoleucine or valine' 0 C--O 1.24 0.58 0 CA-C-N 114.48 -1.236 . . . . 0.0 109.065 -176.302 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 11.2 p -136.08 165.3 26.03 Favored 'General case' 0 C--O 1.242 0.675 0 C-N-CA 123.934 0.893 . . . . 0.0 109.702 -178.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -63.77 140.82 58.91 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 123.934 0.893 . . . . 0.0 111.118 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.01 -25.34 25.86 Favored Glycine 0 C--N 1.341 0.845 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.938 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.87 139.51 56.51 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.314 0.646 . . . . 0.0 110.987 -178.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 45' ' ' GLU . 93.2 t -93.57 110.56 23.52 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 172.378 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.3 m -100.64 141.79 16.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 177.185 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.551 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 40.7 tt0 -94.01 136.99 33.72 Favored 'General case' 0 C--O 1.234 0.243 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 81.5 p -130.03 176.52 8.0 Favored 'General case' 0 C--O 1.246 0.875 0 C-N-CA 123.972 0.909 . . . . 0.0 109.144 -179.184 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 18.6 p-10 -63.45 -24.44 67.83 Favored 'General case' 0 CA--C 1.542 0.661 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.986 173.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 86.5 mt -88.66 -34.01 17.39 Favored 'General case' 0 C--N 1.354 0.782 0 C-N-CA 123.143 0.577 . . . . 0.0 110.555 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 150.37 -150.09 22.06 Favored Glycine 0 C--N 1.343 0.923 0 CA-C-N 116.593 -0.276 . . . . 0.0 112.423 173.332 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -78.9 129.73 34.85 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.582 0.753 . . . . 0.0 109.038 -179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.8 t -127.85 137.5 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 123.063 0.545 . . . . 0.0 110.635 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.669 ' HG2' HD11 ' A' ' 88' ' ' ILE . 13.4 mmt180 -90.77 118.26 30.05 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 169.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.1 t -72.04 109.1 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 178.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.3 p -98.54 -50.97 4.09 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 -171.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' SER . . . . . 0.503 ' HB3' ' HB3' ' A' ' 84' ' ' ASN . 31.1 t -82.71 150.91 26.45 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.113 176.671 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.45 ' HD2' ' HD2' ' A' ' 77' ' ' PRO . 23.8 tpt180 -72.83 125.5 91.12 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 123.482 0.713 . . . . 0.0 109.611 175.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.45 ' HD2' ' HD2' ' A' ' 76' ' ' ARG . 85.2 Cg_exo -51.72 101.61 0.05 OUTLIER 'Trans proline' 0 C--N 1.378 2.084 0 C-N-CA 123.269 2.646 . . . . 0.0 111.509 163.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 140.4 -32.63 2.14 Favored Glycine 0 C--N 1.339 0.747 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 -176.009 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -65.94 113.34 4.34 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 171.343 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 30.5 t70 76.89 -19.12 0.44 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 125.523 1.529 . . . . 0.0 111.686 -170.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 109.4 -47.57 1.03 Allowed Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -171.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.3 p -75.11 165.77 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 C-N-CA 123.756 0.822 . . . . 0.0 111.074 178.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 30.2 mt -93.8 148.15 5.05 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 169.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.503 ' HB3' ' HB3' ' A' ' 75' ' ' SER . 25.6 t-20 -136.56 147.35 46.97 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 174.603 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.53 -175.8 26.1 Favored Glycine 0 C--N 1.336 0.574 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.257 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.5 m -121.3 138.1 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 123.223 0.609 . . . . 0.0 109.9 174.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 41.9 tp -67.78 128.93 38.31 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 123.543 0.737 . . . . 0.0 110.128 178.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.669 HD11 ' HG2' ' A' ' 72' ' ' ARG . 44.5 pt -129.94 179.74 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 123.658 0.783 . . . . 0.0 110.702 -177.19 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 10.7 mmm180 -123.45 119.78 31.01 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 125.276 1.431 . . . . 0.0 107.247 171.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -149.83 -68.51 0.2 Allowed 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -177.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.451 HD23 HD21 ' A' ' 46' ' ' ASN . 2.0 pt? -127.0 78.62 1.82 Allowed 'General case' 0 N--CA 1.477 0.893 0 CA-C-O 122.318 1.056 . . . . 0.0 110.917 -177.008 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -73.36 -10.31 59.61 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.247 174.284 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -63.87 95.35 0.11 Allowed 'General case' 0 C--O 1.241 0.617 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 169.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 85.8 m-70 -61.34 137.92 58.24 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.333 -0.849 . . . . 0.0 109.943 -178.365 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 52.6 m80 -72.17 86.86 1.07 Allowed 'General case' 0 CA--C 1.546 0.819 0 O-C-N 123.726 0.641 . . . . 0.0 111.188 -175.235 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 23.8 p-80 -97.6 90.36 4.99 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 124.644 1.178 . . . . 0.0 108.858 173.068 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 35.7 t-80 -87.72 118.79 27.46 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.759 0.824 . . . . 0.0 110.222 -176.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 19.6 p-80 . . . . . 0 CA--C 1.555 1.17 0 O-C-N 123.436 0.46 . . . . 0.0 109.912 173.984 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.582 0 N-CA-C 112.584 -0.206 . . . . 0.0 112.584 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 53.5 m-20 -103.44 125.19 49.89 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.433 0.693 . . . . 0.0 109.849 178.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -95.71 113.4 25.04 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 174.307 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 74.9 ttt180 -77.84 85.17 4.12 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 122.672 0.389 . . . . 0.0 110.377 -177.468 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 48.2 t -74.47 -25.4 19.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.77 174.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.2 tpp180 -70.68 85.77 0.65 Allowed 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 124.386 1.075 . . . . 0.0 110.166 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 1.6 tm? -116.26 89.7 3.17 Favored 'General case' 0 C--N 1.346 0.43 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.276 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 68.4 mt -91.01 134.74 28.72 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.841 173.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.75 138.83 39.68 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 123.809 0.843 . . . . 0.0 109.128 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 33.4 p -66.19 113.03 4.24 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 123.301 0.64 . . . . 0.0 110.883 -177.049 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -74.57 99.0 3.5 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 178.638 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -85.88 -172.79 49.07 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 116.374 -0.375 . . . . 0.0 112.522 176.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -169.42 -156.73 11.05 Favored Glycine 0 C--N 1.338 0.653 0 C-N-CA 121.933 -0.175 . . . . 0.0 112.775 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -88.9 10.09 22.53 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.637 0.775 . . . . 0.0 111.458 178.236 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 13.4 p -73.35 -174.89 1.75 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 123.886 0.874 . . . . 0.0 111.479 171.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.484 ' HZ2' ' HB2' ' A' ' 16' ' ' LYS . 3.9 ttmp? 65.63 91.53 0.08 Allowed 'General case' 0 C--N 1.36 1.037 0 C-N-CA 124.696 1.199 . . . . 0.0 109.475 -175.376 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.4 p -64.95 162.14 2.57 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.165 0 C-N-CA 122.943 0.497 . . . . 0.0 110.663 -178.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.517 ' H ' ' HD2' ' A' ' 18' ' ' ARG . 0.2 OUTLIER -54.76 -46.38 74.34 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 124.941 1.296 . . . . 0.0 111.079 -175.652 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.534 ' HA ' HH21 ' A' ' 24' ' ' ARG . 2.0 pp -160.37 156.69 26.6 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 124.902 1.281 . . . . 0.0 109.417 172.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -142.01 -70.73 0.34 Allowed 'General case' 0 N--CA 1.483 1.214 0 CA-C-O 120.609 0.242 . . . . 0.0 111.113 -177.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 24.7 m -111.32 33.68 4.53 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -160.96 179.59 8.34 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 114.79 -1.095 . . . . 0.0 110.393 -168.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 m -127.49 114.58 17.65 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 176.352 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.534 HH21 ' HA ' ' A' ' 19' ' ' LEU . 57.4 mtm180 -123.34 161.15 25.25 Favored 'General case' 0 C--O 1.244 0.8 0 C-N-CA 123.296 0.638 . . . . 0.0 110.807 178.106 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.9 tt -145.65 141.24 22.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.745 -170.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -84.07 102.57 12.62 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 175.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.7 t -93.9 115.26 32.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 C-N-CA 124.18 0.992 . . . . 0.0 109.085 -171.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.5 t -104.65 106.97 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 124.327 1.051 . . . . 0.0 109.011 -177.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -69.16 111.48 8.69 Favored Pre-proline 0 CA--C 1.544 0.725 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 175.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -74.1 -7.43 19.84 Favored 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.712 2.274 . . . . 0.0 113.506 -170.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -96.02 -52.75 3.91 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 122.685 0.394 . . . . 0.0 111.221 -177.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 77.1 p -102.14 -29.86 11.48 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 123.367 0.667 . . . . 0.0 112.548 -175.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.39 20.91 14.0 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-O 119.734 -0.481 . . . . 0.0 113.766 177.583 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 60.8 mttp -67.43 105.66 1.87 Allowed 'General case' 0 N--CA 1.484 1.25 0 CA-C-N 117.308 0.554 . . . . 0.0 110.665 175.04 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 44.5 t -108.85 115.65 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.7 tp10 -153.72 147.55 25.38 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.111 0.564 . . . . 0.0 109.66 -174.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 44.7 mt -83.77 100.07 6.9 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -177.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -90.82 160.09 15.94 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.975 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.453 ' HB2' ' ND2' ' A' ' 67' ' ' ASN . 37.5 mt-10 -105.61 122.24 45.62 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -177.17 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.438 HG12 HG21 ' A' ' 66' ' ' THR . 50.9 mt -75.76 111.81 12.64 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -172.751 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -73.77 -40.16 63.67 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 123.807 0.843 . . . . 0.0 110.335 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -143.89 130.68 20.3 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.864 -173.231 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.4 m -83.25 -7.49 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 122.99 0.516 . . . . 0.0 111.754 -175.298 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 35.1 m -119.45 167.84 12.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 C-N-CA 123.492 0.717 . . . . 0.0 109.974 176.373 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.507 ' HB3' ' HB ' ' A' ' 63' ' ' VAL . 11.2 pt-20 -89.88 -39.24 13.17 Favored 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 170.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -151.06 145.7 25.68 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.913 0.885 . . . . 0.0 108.966 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.5 t -132.23 135.11 46.07 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.505 0.722 . . . . 0.0 109.066 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -107.3 -45.65 4.05 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 123.516 0.726 . . . . 0.0 111.169 -175.289 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -146.16 115.55 4.67 Favored Pre-proline 0 N--CA 1.478 0.949 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.09 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -79.04 27.52 0.52 Allowed 'Trans proline' 0 C--N 1.371 1.722 0 C-N-CA 123.116 2.544 . . . . 0.0 114.484 -171.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.2 p80 -71.4 -29.0 64.42 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 122.646 0.378 . . . . 0.0 110.839 175.143 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -102.41 177.86 4.75 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.471 0.709 . . . . 0.0 109.342 168.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.9 t 55.97 43.71 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 C-N-CA 124.964 1.305 . . . . 0.0 110.194 -176.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 30.7 mmm180 -72.07 -50.24 29.89 Favored 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 174.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -71.25 123.44 22.24 Favored 'General case' 0 C--O 1.244 0.801 0 CA-C-N 114.843 -1.071 . . . . 0.0 108.168 165.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 35.3 m-80 -73.69 80.65 1.54 Allowed 'General case' 0 CA--C 1.544 0.712 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 174.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.7 tp -110.51 132.17 59.61 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.498 HD11 HG11 ' A' ' 64' ' ' VAL . 61.6 mt -114.42 144.37 22.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 124.171 0.988 . . . . 0.0 108.493 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 31.2 p -121.9 167.98 12.42 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.265 0.626 . . . . 0.0 110.55 179.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 39.5 ttp180 -71.72 131.09 42.64 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.005 178.108 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.2 -2.3 83.45 Favored Glycine 0 C--N 1.342 0.914 0 C-N-CA 123.607 0.622 . . . . 0.0 113.005 -177.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -85.18 132.55 34.27 Favored 'General case' 0 C--O 1.246 0.881 0 C-N-CA 123.408 0.683 . . . . 0.0 110.137 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.507 ' HB ' ' HB3' ' A' ' 45' ' ' GLU . 41.4 t -82.73 113.61 22.24 Favored 'Isoleucine or valine' 0 C--N 1.352 0.69 0 CA-C-O 121.01 0.433 . . . . 0.0 110.029 178.537 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.498 HG11 HD11 ' A' ' 58' ' ' ILE . 34.1 m -102.28 166.94 2.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 169.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -120.98 134.89 55.31 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 175.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.438 HG21 HG12 ' A' ' 40' ' ' ILE . 43.6 p -130.68 -176.23 3.91 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 124.263 1.025 . . . . 0.0 110.099 -171.347 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.453 ' ND2' ' HB2' ' A' ' 39' ' ' GLU . 97.3 m-20 -68.96 -23.59 64.15 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.06 175.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 73.8 mt -86.22 -41.34 14.72 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 123.183 0.302 . . . . 0.0 110.464 175.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 159.08 -159.29 30.25 Favored Glycine 0 C--N 1.345 1.045 0 O-C-N 123.443 0.464 . . . . 0.0 112.976 178.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 21.5 m120 -77.43 124.45 27.9 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 177.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 46.1 t -123.58 145.21 30.94 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.733 0 C-N-CA 124.438 1.095 . . . . 0.0 109.562 -175.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.446 ' HG3' HD12 ' A' ' 88' ' ' ILE . 30.1 mtt85 -107.7 137.04 46.44 Favored 'General case' 0 N--CA 1.483 1.18 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 168.337 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.474 HG13 ' HD3' ' A' ' 77' ' ' PRO . 58.1 t -75.09 120.26 24.32 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 O-C-N 124.273 0.983 . . . . 0.0 109.594 179.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.402 HG22 HG12 ' A' ' 86' ' ' VAL . 40.2 p -98.38 -20.95 16.86 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 123.447 0.699 . . . . 0.0 110.429 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' SER . . . . . 0.421 ' HB3' ' HB2' ' A' ' 84' ' ' ASN . 95.0 p -91.9 -173.16 3.41 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.379 0.672 . . . . 0.0 109.713 174.807 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 74.8 mtt180 -116.23 103.4 53.12 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 172.32 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.474 ' HD3' HG13 ' A' ' 73' ' ' VAL . 21.1 Cg_endo -57.71 151.54 54.86 Favored 'Trans proline' 0 C--N 1.382 2.297 0 C-N-CA 123.659 2.906 . . . . 0.0 113.632 -168.082 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.52 -35.01 4.2 Favored Glycine 0 C--N 1.349 1.292 0 CA-C-O 119.7 -0.5 . . . . 0.0 113.553 176.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 89.8 mt-30 -61.59 -57.77 10.75 Favored 'General case' 0 C--N 1.359 1.015 0 CA-C-O 121.351 0.596 . . . . 0.0 109.921 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -91.73 32.87 1.06 Allowed 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.376 177.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 65.07 -78.04 0.07 OUTLIER Glycine 0 C--N 1.361 1.949 0 C-N-CA 123.643 0.64 . . . . 0.0 112.831 -176.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.1 p -73.72 164.6 3.48 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.523 1.129 . . . . 0.0 110.441 178.476 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.436 HG12 ' HB3' ' A' ' 77' ' ' PRO . 15.9 mt -93.82 147.82 5.28 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 175.171 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.421 ' HB2' ' HB3' ' A' ' 75' ' ' SER . 1.0 OUTLIER -123.79 147.73 47.3 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 171.11 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -165.3 -176.49 36.92 Favored Glycine 0 CA--C 1.526 0.755 0 O-C-N 123.383 0.427 . . . . 0.0 113.177 -177.172 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.402 HG12 HG22 ' A' ' 74' ' ' THR . 16.0 m -122.62 139.11 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 C-N-CA 123.826 0.85 . . . . 0.0 110.871 178.576 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 19.4 tp -74.82 113.47 12.14 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 123.522 0.514 . . . . 0.0 109.968 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.446 HD12 ' HG3' ' A' ' 72' ' ' ARG . 34.5 pt -112.71 -177.17 0.82 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.733 0 C-N-CA 123.776 0.831 . . . . 0.0 109.883 178.019 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -133.04 100.77 4.98 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -178.377 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 70.2 mm-40 -119.26 -64.57 1.26 Allowed 'General case' 0 N--CA 1.477 0.897 0 CA-C-O 121.362 0.601 . . . . 0.0 109.491 177.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 70.8 mt -121.82 26.15 8.82 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.966 -173.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.96 -175.83 1.55 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 124.951 1.3 . . . . 0.0 112.19 -172.673 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 43.1 p-80 -57.66 109.86 0.78 Allowed 'General case' 0 CA--C 1.562 1.425 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 169.171 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -76.38 130.55 38.22 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.316 0.647 . . . . 0.0 111.373 -167.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 47.7 t-80 -83.94 74.29 10.24 Favored 'General case' 0 CA--C 1.551 0.996 0 C-N-CA 124.082 0.953 . . . . 0.0 111.109 -174.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 8.0 p80 -174.09 147.05 1.22 Allowed 'General case' 0 N--CA 1.484 1.244 0 C-N-CA 124.63 1.172 . . . . 0.0 109.826 175.321 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 64.0 t60 -66.23 -59.06 4.1 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 123.732 0.813 . . . . 0.0 110.907 177.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 62.9 t-80 . . . . . 0 CA--C 1.55 0.955 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.955 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.841 0 N-CA-C 112.704 -0.158 . . . . 0.0 112.704 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -123.98 128.29 49.17 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 123.963 0.905 . . . . 0.0 109.38 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 5.7 mmp_? -94.99 64.32 2.79 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 166.005 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 52.3 ttm-85 -70.16 112.96 6.89 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 113.763 -1.562 . . . . 0.0 110.661 -173.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.9 t -110.98 90.13 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 123.897 0.879 . . . . 0.0 109.016 177.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 74.8 mtp180 -79.43 110.52 14.8 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 177.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 87.5 mt -80.0 86.12 5.52 Favored 'General case' 0 CA--C 1.541 0.613 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 176.274 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 50.7 mm -91.3 111.3 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 N-CA-C 108.436 -0.949 . . . . 0.0 108.436 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.07 168.91 10.47 Favored 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 122.995 0.518 . . . . 0.0 111.845 -175.282 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 80.9 m -95.24 117.32 30.06 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 124.694 1.198 . . . . 0.0 110.146 -177.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.16 -33.99 1.47 Allowed 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 123.763 0.825 . . . . 0.0 110.973 -178.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 151.16 101.49 0.22 Allowed Glycine 0 C--N 1.341 0.814 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 -173.478 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -153.45 165.58 31.45 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 122.95 0.309 . . . . 0.0 112.549 -173.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 5.1 t30 -142.79 92.73 2.43 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 123.321 0.648 . . . . 0.0 109.802 -174.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 19.2 p -117.51 88.67 2.96 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 123.932 0.893 . . . . 0.0 109.088 174.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -118.83 153.44 34.49 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.738 0.815 . . . . 0.0 110.024 177.445 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 10.0 p -84.44 146.33 6.88 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 167.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 -81.54 -169.39 2.29 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 123.612 0.765 . . . . 0.0 110.42 177.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.542 HD22 ' HB2' ' A' ' 24' ' ' ARG . 1.1 pp -71.4 75.04 0.75 Allowed 'General case' 0 CA--C 1.558 1.279 0 CA-C-O 122.267 1.032 . . . . 0.0 111.663 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -89.41 -30.16 18.55 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.021 0.928 . . . . 0.0 111.565 -176.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.3 m -76.35 -44.64 35.64 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.402 0.681 . . . . 0.0 110.602 -177.406 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -147.77 131.21 16.67 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.511 ' HA ' HD11 ' A' ' 19' ' ' LEU . 29.8 m -68.27 119.18 12.4 Favored 'General case' 0 CA--C 1.54 0.579 0 O-C-N 123.993 0.808 . . . . 0.0 111.045 178.612 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.542 ' HB2' HD22 ' A' ' 19' ' ' LEU . 71.8 mtm180 -112.96 170.64 8.05 Favored 'General case' 0 C--O 1.243 0.727 0 C-N-CA 123.618 0.767 . . . . 0.0 110.119 177.71 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.9 tt -143.57 139.54 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.313 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 22.7 m-80 -88.2 100.16 12.76 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -84.0 109.89 17.99 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 C-N-CA 124.098 0.959 . . . . 0.0 109.187 -175.067 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.41 HG22 HG21 ' A' ' 35' ' ' VAL . 48.8 t -101.34 113.61 38.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.568 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -62.52 121.04 64.75 Favored Pre-proline 0 CA--C 1.547 0.835 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 177.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -71.91 -18.42 27.98 Favored 'Trans proline' 0 C--N 1.363 1.317 0 C-N-CA 122.344 2.029 . . . . 0.0 113.326 -172.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -92.94 -52.02 4.79 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.592 0.757 . . . . 0.0 110.881 -174.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 47.2 p -96.97 -29.08 13.88 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.638 0.775 . . . . 0.0 111.992 -176.175 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.34 4.41 55.07 Favored Glycine 0 N--CA 1.481 1.665 0 CA-C-O 119.272 -0.738 . . . . 0.0 114.388 176.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.622 ' HZ1' ' HB2' ' A' ' 34' ' ' LYS . 9.9 mtmp? -63.19 108.0 1.17 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.528 0.731 . . . . 0.0 112.335 -173.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.41 HG21 HG22 ' A' ' 28' ' ' VAL . 26.2 t -90.62 116.47 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 C-N-CA 123.39 0.676 . . . . 0.0 109.378 176.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -144.59 139.4 28.09 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.329 0.652 . . . . 0.0 110.092 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 36.1 mt -79.76 133.84 28.87 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.885 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 -179.452 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.69 158.3 37.97 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 123.555 0.742 . . . . 0.0 111.441 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 32.6 mm-40 -92.15 121.43 33.69 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 177.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.0 mt -77.21 112.28 14.95 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 178.52 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -76.2 -51.98 11.01 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.086 0.954 . . . . 0.0 110.225 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -151.48 174.1 13.79 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.627 HG22 ' HE ' ' A' ' 54' ' ' ARG . 27.0 m -112.02 29.88 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.698 0 C-N-CA 123.208 0.603 . . . . 0.0 110.727 177.072 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.661 ' HA ' ' HG3' ' A' ' 54' ' ' ARG . 7.4 p -64.31 115.55 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 CA-C-O 121.781 0.8 . . . . 0.0 111.902 -176.237 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.726 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 36.1 tt0 -95.05 43.65 1.09 Allowed 'General case' 0 CA--C 1.552 1.026 0 C-N-CA 123.835 0.854 . . . . 0.0 110.169 -177.574 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 8.9 t30 55.24 83.9 0.08 Allowed 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 124.385 1.074 . . . . 0.0 110.745 -176.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 89.6 m -135.8 -72.18 0.46 Allowed 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.401 0.68 . . . . 0.0 109.504 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -175.81 -175.72 0.78 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 124.728 1.211 . . . . 0.0 108.811 -177.669 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 62.4 t30 -163.36 77.23 1.76 Allowed Pre-proline 0 CA--C 1.546 0.805 0 C-N-CA 123.615 0.766 . . . . 0.0 109.084 169.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.79 -45.41 0.24 Allowed 'Trans proline' 0 C--N 1.372 1.8 0 C-N-CA 122.64 2.227 . . . . 0.0 111.973 176.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.0 t-160 -164.92 -57.03 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -177.131 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -121.39 150.25 41.78 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 167.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 6.9 p -156.98 -40.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 123.106 0.562 . . . . 0.0 110.333 -178.111 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.661 ' HG3' ' HA ' ' A' ' 44' ' ' VAL . 22.6 mmm180 -134.26 153.31 51.94 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.524 0.73 . . . . 0.0 110.32 -174.235 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.632 ' HB2' HG12 ' A' ' 57' ' ' ILE . 29.1 mmt180 -96.54 -161.26 0.86 Allowed 'General case' 0 CA--C 1.55 0.942 0 C-N-CA 123.83 0.852 . . . . 0.0 109.791 177.296 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -88.34 -2.21 58.47 Favored 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.844 0.858 . . . . 0.0 110.046 170.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.632 HG12 ' HB2' ' A' ' 55' ' ' ARG . 43.0 pt -63.08 110.27 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.359 1.007 0 CA-C-O 122.083 0.944 . . . . 0.0 111.143 -177.445 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.426 ' O ' ' HG3' ' A' ' 77' ' ' PRO . 57.5 mt -102.47 108.72 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 107.721 -1.215 . . . . 0.0 107.721 173.036 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.9 p -99.53 151.93 20.59 Favored 'General case' 0 C--O 1.241 0.614 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 174.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 73.0 ttt180 -67.2 128.27 35.77 Favored 'General case' 0 CA--C 1.546 0.793 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 176.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.81 11.46 70.6 Favored Glycine 0 C--N 1.338 0.691 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.827 -176.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.94 148.21 23.92 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-N 117.353 0.577 . . . . 0.0 110.112 176.405 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.726 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 61.6 t -84.11 114.63 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 171.406 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 28.8 m -104.46 144.73 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 C-N-CA 123.025 0.53 . . . . 0.0 109.686 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -91.68 127.85 37.29 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 175.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 49.5 p -128.8 -179.97 5.38 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -68.29 -19.17 64.68 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 122.854 0.461 . . . . 0.0 111.585 176.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 96.4 mt -90.35 -46.72 8.2 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.242 0.617 . . . . 0.0 109.804 178.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 162.99 -153.46 24.02 Favored Glycine 0 C--N 1.339 0.74 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.749 177.078 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -76.78 137.36 39.22 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 122.864 0.465 . . . . 0.0 110.284 176.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.4 t -132.03 142.65 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 122.957 0.503 . . . . 0.0 109.861 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.53 ' HG2' HD11 ' A' ' 88' ' ' ILE . 33.4 mmt180 -89.75 123.02 33.38 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 170.311 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 66.2 t -75.78 95.79 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 -179.404 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 60.8 p -78.84 -41.72 29.37 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 122.925 0.49 . . . . 0.0 111.179 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' SER . . . . . 0.48 ' HB2' ' H ' ' A' ' 84' ' ' ASN . 50.3 m -91.42 115.1 27.76 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.0 176.254 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 7.3 tmm_? -55.75 135.22 72.2 Favored Pre-proline 0 CA--C 1.563 1.453 0 C-N-CA 125.099 1.359 . . . . 0.0 110.188 177.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.426 ' HG3' ' O ' ' A' ' 58' ' ' ILE . 36.9 Cg_endo -60.85 129.69 30.01 Favored 'Trans proline' 0 C--N 1.377 2.068 0 C-N-CA 123.026 2.484 . . . . 0.0 112.398 -177.343 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 115.23 -18.55 15.81 Favored Glycine 0 C--N 1.34 0.791 0 CA-C-O 119.678 -0.512 . . . . 0.0 112.688 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -67.74 98.3 0.7 Allowed 'General case' 0 C--N 1.355 0.842 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 177.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 74.33 -2.47 2.8 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 125.754 1.621 . . . . 0.0 112.083 -174.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.93 -0.42 82.19 Favored Glycine 0 C--N 1.348 1.233 0 C-N-CA 123.082 0.372 . . . . 0.0 112.469 -178.04 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.403 HG22 HD23 ' A' ' 19' ' ' LEU . 7.3 p -115.37 148.59 17.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 124.464 1.106 . . . . 0.0 109.671 175.903 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 35.6 mt -104.44 145.36 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 C-N-CA 123.081 0.553 . . . . 0.0 109.601 173.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.48 ' H ' ' HB2' ' A' ' 75' ' ' SER . 42.9 m-20 -130.19 154.86 47.11 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 174.345 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.87 -178.06 37.16 Favored Glycine 0 C--N 1.336 0.579 0 CA-C-O 119.825 -0.43 . . . . 0.0 112.837 -177.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.18 136.93 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 123.306 0.642 . . . . 0.0 110.739 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 45.7 tp -66.13 124.68 23.27 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 122.862 0.465 . . . . 0.0 111.753 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.53 HD11 ' HG2' ' A' ' 72' ' ' ARG . 45.4 pt -119.59 164.99 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 CA-C-O 121.586 0.708 . . . . 0.0 109.788 168.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.92 88.27 2.59 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -175.106 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -101.24 -64.63 1.03 Allowed 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 63.3 mt -70.9 142.87 51.12 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.371 174.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 71.93 -31.86 0.23 Allowed 'General case' 0 N--CA 1.496 1.853 0 C-N-CA 127.464 2.306 . . . . 0.0 113.479 -178.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 13.3 t60 -71.42 -55.56 7.69 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 171.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 49.1 t-80 -82.62 74.93 9.55 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 165.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 16.2 p80 -82.8 176.13 9.56 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 114.521 -1.218 . . . . 0.0 111.221 -176.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 30.6 m170 -65.0 96.15 0.18 Allowed 'General case' 0 N--CA 1.474 0.752 0 O-C-N 123.951 0.782 . . . . 0.0 110.623 -177.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -144.74 92.78 2.32 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 178.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 36.9 m80 . . . . . 0 N--CA 1.477 0.882 0 C-N-CA 124.178 0.991 . . . . 0.0 108.886 -179.529 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.642 0 N-CA-C 112.09 -0.404 . . . . 0.0 112.09 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -69.0 83.09 0.32 Allowed 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.997 0.919 . . . . 0.0 111.214 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 25.7 mmt180 -132.6 43.53 2.98 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.652 1.181 . . . . 0.0 108.326 176.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -70.9 90.26 0.8 Allowed 'General case' 0 CA--C 1.551 1.008 0 CA-C-N 114.869 -1.059 . . . . 0.0 110.558 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 41.1 t -68.83 118.59 13.25 Favored 'Isoleucine or valine' 0 C--O 1.242 0.665 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.15 179.179 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 42.8 ttm180 -68.83 -28.22 66.54 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.854 0.862 . . . . 0.0 111.38 -177.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.8 tt 64.22 57.3 1.24 Allowed 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 -171.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 9.1 tt -85.19 129.63 37.49 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.76 0 CA-C-N 114.43 -1.259 . . . . 0.0 109.283 179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 63.4 mtm180 -135.31 94.67 3.15 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 177.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 20.6 p -97.17 139.89 32.48 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 123.486 0.715 . . . . 0.0 110.118 -179.192 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -136.84 110.55 8.09 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -123.21 164.45 16.22 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -93.7 -155.58 31.93 Favored Glycine 0 C--N 1.34 0.763 0 O-C-N 123.627 0.251 . . . . 0.0 113.168 -178.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.8 t-20 -129.09 102.06 6.31 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.781 0.832 . . . . 0.0 109.299 -176.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 34.2 m -94.65 112.35 24.1 Favored 'General case' 0 CA--C 1.541 0.605 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 176.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -71.79 149.97 44.81 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 123.538 0.735 . . . . 0.0 111.431 -174.453 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.1 p -119.55 151.26 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 C-N-CA 123.741 0.816 . . . . 0.0 110.959 -176.439 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.652 ' HE ' ' HA ' ' A' ' 18' ' ' ARG . 0.2 OUTLIER -105.01 126.63 52.27 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.074 0.95 . . . . 0.0 109.478 176.542 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.478 HD21 ' H ' ' A' ' 24' ' ' ARG . 86.0 mt 77.04 -41.98 0.4 Allowed 'General case' 0 N--CA 1.489 1.523 0 C-N-CA 125.859 1.664 . . . . 0.0 112.368 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 73.39 -76.92 0.06 Allowed 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 125.66 1.584 . . . . 0.0 111.94 172.304 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.535 ' HB2' ' NH2' ' A' ' 24' ' ' ARG . 16.8 m -102.5 -43.75 5.55 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 122.967 0.507 . . . . 0.0 110.847 -177.317 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . 0.413 ' O ' ' HG2' ' A' ' 24' ' ' ARG . 21.4 t70 -153.2 177.01 11.3 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.098 0.559 . . . . 0.0 110.522 -172.612 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 28.0 m -67.19 120.94 14.6 Favored 'General case' 0 C--N 1.352 0.685 0 C-N-CA 123.491 0.716 . . . . 0.0 110.141 177.026 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.535 ' NH2' ' HB2' ' A' ' 21' ' ' SER . 24.6 mmt85 -116.72 147.78 41.69 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 123.994 0.917 . . . . 0.0 111.409 -170.093 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.6 tt -148.63 142.2 18.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-N 114.185 -1.37 . . . . 0.0 108.527 -178.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . 0.557 ' ND2' HG22 ' A' ' 82' ' ' VAL . 29.4 m-80 -93.89 100.65 12.78 Favored 'General case' 0 C--O 1.241 0.644 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 175.532 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 87.5 t -91.71 116.57 33.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.439 0 CA-C-N 114.353 -1.294 . . . . 0.0 108.461 -176.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.447 HG21 HG22 ' A' ' 35' ' ' VAL . 35.0 t -98.51 109.88 24.84 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.366 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -62.86 117.69 34.83 Favored Pre-proline 0 CA--C 1.548 0.891 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 172.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -66.1 -31.94 44.52 Favored 'Trans proline' 0 C--N 1.366 1.475 0 C-N-CA 122.698 2.265 . . . . 0.0 113.269 -170.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -94.33 -46.15 7.17 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 123.179 0.592 . . . . 0.0 110.857 -175.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.6 m -84.87 -29.34 25.34 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.125 0.57 . . . . 0.0 111.006 -173.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.66 5.96 73.86 Favored Glycine 0 C--N 1.345 1.038 0 CA-C-O 119.567 -0.574 . . . . 0.0 113.976 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 95.6 mttt -60.12 106.08 0.47 Allowed 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.052 0.541 . . . . 0.0 111.228 178.042 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.447 HG22 HG21 ' A' ' 28' ' ' VAL . 61.6 t -94.47 107.84 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 168.535 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -137.0 137.67 39.68 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 122.799 0.439 . . . . 0.0 109.944 -171.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 37.9 mt -75.74 99.14 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 177.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.442 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -89.45 157.4 18.14 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 123.737 0.815 . . . . 0.0 111.503 175.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -107.33 122.41 46.51 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.804 0.842 . . . . 0.0 109.179 178.466 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 64.7 mt -78.0 115.44 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 123.363 0.665 . . . . 0.0 110.845 -171.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 35.1 mmt180 -78.15 -53.78 6.98 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.417 1.087 . . . . 0.0 110.42 178.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.476 ' HB3' HG11 ' A' ' 44' ' ' VAL . 49.5 m-80 -131.54 153.88 49.39 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 123.666 0.786 . . . . 0.0 110.043 -175.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.449 ' HA ' HG13 ' A' ' 64' ' ' VAL . 33.7 m -118.42 6.76 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.117 0.967 . . . . 0.0 110.97 177.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.476 HG11 ' HB3' ' A' ' 42' ' ' ASN . 6.3 p -68.51 107.55 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.058 0 CA-C-O 121.614 0.721 . . . . 0.0 110.681 -177.302 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -59.38 143.12 50.55 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.247 174.042 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.454 HD22 HG13 ' A' ' 63' ' ' VAL . 39.6 m-20 -75.74 82.44 2.71 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 176.443 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.3 m -117.15 149.77 39.82 Favored 'General case' 0 C--O 1.241 0.653 0 C-N-CA 124.92 1.288 . . . . 0.0 108.817 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -66.61 90.07 0.16 Allowed 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 171.021 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 60.84 90.81 0.09 OUTLIER Pre-proline 0 CA--C 1.552 1.042 0 C-N-CA 124.518 1.127 . . . . 0.0 110.752 -172.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_exo -70.89 81.14 1.13 Allowed 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.523 2.149 . . . . 0.0 111.553 175.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 28.3 p80 -98.91 84.35 3.07 Favored 'General case' 0 N--CA 1.481 1.101 0 CA-C-O 121.559 0.695 . . . . 0.0 110.323 -176.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 55.66 23.83 6.55 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 124.334 1.054 . . . . 0.0 112.454 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 18.0 m -71.02 -32.04 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 175.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -141.28 158.62 43.64 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 125.668 1.587 . . . . 0.0 107.766 167.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 89.7 mtm180 -84.17 -172.05 3.95 Favored 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 172.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 60.2 m-80 -81.26 64.13 5.87 Favored 'General case' 0 N--CA 1.483 1.209 0 CA-C-O 121.929 0.871 . . . . 0.0 109.971 176.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 2.0 pp -132.89 170.38 20.14 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 125.051 1.34 . . . . 0.0 110.116 177.698 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.7 mt -102.34 130.68 51.84 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 C-N-CA 124.495 1.118 . . . . 0.0 109.162 -179.308 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 35.2 p -123.73 156.1 36.63 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.499 0.719 . . . . 0.0 109.737 177.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 60.5 ttt180 -74.71 123.51 25.04 Favored 'General case' 0 CA--C 1.544 0.715 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -178.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.99 4.19 67.27 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.086 -173.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.62 158.69 22.93 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.146 0.473 . . . . 0.0 110.737 175.837 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.454 HG13 HD22 ' A' ' 46' ' ' ASN . 68.8 t -97.26 111.24 26.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 171.752 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.449 HG13 ' HA ' ' A' ' 43' ' ' VAL . 29.6 m -108.38 137.97 37.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 173.726 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -91.16 142.32 27.87 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.109 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.442 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 61.7 p -128.07 178.76 5.99 Favored 'General case' 0 C--O 1.246 0.898 0 C-N-CA 124.146 0.979 . . . . 0.0 109.144 179.481 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -57.92 -25.72 61.26 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 123.584 0.754 . . . . 0.0 111.571 173.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 75.0 mt -83.52 -49.48 9.21 Favored 'General case' 0 C--N 1.351 0.632 0 C-N-CA 123.526 0.73 . . . . 0.0 109.244 178.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 161.01 -163.89 34.51 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-N 115.27 -0.877 . . . . 0.0 111.394 -177.065 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 -75.46 139.08 42.04 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-O 121.084 0.469 . . . . 0.0 110.148 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 83.9 t -133.72 144.59 35.37 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 C-N-CA 125.096 1.358 . . . . 0.0 109.272 -171.18 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.707 ' HG2' HD12 ' A' ' 88' ' ' ILE . 7.0 mmt85 -96.33 122.43 39.21 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 171.603 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 47.2 t -70.57 109.09 2.76 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.437 HG22 HG13 ' A' ' 86' ' ' VAL . 44.6 p -90.48 -30.45 17.3 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.13 0.572 . . . . 0.0 110.986 -171.078 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 25.9 t -113.71 -169.9 1.6 Allowed 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.871 0.868 . . . . 0.0 109.416 -178.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 18.4 mtp180 -70.11 144.57 92.81 Favored Pre-proline 0 CA--C 1.554 1.104 0 C-N-CA 123.432 0.693 . . . . 0.0 110.711 174.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -78.8 162.02 27.05 Favored 'Trans proline' 0 C--N 1.366 1.486 0 C-N-CA 122.307 2.004 . . . . 0.0 112.29 173.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.431 ' H ' HG12 ' A' ' 83' ' ' ILE . . . 57.4 -89.18 0.02 OUTLIER Glycine 0 C--N 1.346 1.089 0 CA-C-N 115.635 -0.712 . . . . 0.0 113.283 -175.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . 0.257 12.3 pt20 53.23 -66.41 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 C-N-CA 127.74 2.416 . . . . 0.0 114.328 -178.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -146.38 41.75 1.16 Allowed 'General case' 0 N--CA 1.476 0.854 0 CA-C-O 122.255 1.026 . . . . 0.0 108.518 178.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 64.47 16.99 61.51 Favored Glycine 0 C--N 1.351 1.377 0 CA-C-N 115.026 -0.988 . . . . 0.0 113.061 -173.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.557 HG22 ' ND2' ' A' ' 26' ' ' ASN . 3.8 p -132.69 88.92 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 CA-C-O 122.595 1.188 . . . . 0.0 110.074 -174.031 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.431 HG12 ' H ' ' A' ' 78' ' ' GLY . 34.2 mt -83.31 149.06 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 171.273 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -118.04 143.67 46.23 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 172.156 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.7 179.49 30.75 Favored Glycine 0 C--N 1.336 0.539 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.829 178.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.437 HG13 HG22 ' A' ' 74' ' ' THR . 15.7 m -129.36 137.34 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 C-N-CA 123.784 0.834 . . . . 0.0 110.235 174.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.16 105.71 3.5 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 122.655 0.382 . . . . 0.0 110.082 -178.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.707 HD12 ' HG2' ' A' ' 72' ' ' ARG . 39.1 pt -96.83 168.07 1.63 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.588 0 CA-C-O 121.583 0.706 . . . . 0.0 110.477 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 84.3 mtt180 -127.96 26.91 5.77 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.936 177.683 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -58.12 -62.91 1.48 Allowed 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 172.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.0 mt -104.04 116.16 31.74 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 158.031 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -74.67 150.55 39.51 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 171.148 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 40.5 t60 -63.52 94.5 0.09 Allowed 'General case' 0 N--CA 1.481 1.107 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -178.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -63.0 113.06 2.87 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 124.644 1.178 . . . . 0.0 112.807 -165.045 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -84.21 135.57 34.3 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 123.952 0.901 . . . . 0.0 109.577 179.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 57.55 55.2 5.81 Favored 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 123.57 0.748 . . . . 0.0 111.66 177.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 27.8 t-80 -156.34 122.54 5.01 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 123.914 0.885 . . . . 0.0 109.221 -178.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 54.6 t-80 . . . . . 0 CA--C 1.558 1.253 0 C-N-CA 124.494 1.118 . . . . 0.0 109.641 -176.166 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.594 0 N-CA-C 111.457 -0.657 . . . . 0.0 111.457 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -135.65 114.94 12.47 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.633 0.773 . . . . 0.0 109.324 -177.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 5.5 mpt_? -110.37 91.97 3.86 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 171.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -101.5 82.95 2.37 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.625 -174.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 95.8 t -128.07 138.14 55.53 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 123.797 0.839 . . . . 0.0 109.793 -176.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -103.73 131.91 50.47 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 123.958 0.903 . . . . 0.0 109.031 171.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 6.6 tt -75.17 107.73 7.45 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 -178.573 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 17.3 tt -104.16 119.04 52.34 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.806 0 CA-C-O 121.274 0.559 . . . . 0.0 109.615 179.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 3.4 tmt_? -72.96 133.11 44.19 Favored 'General case' 0 C--O 1.241 0.632 0 C-N-CA 123.565 0.746 . . . . 0.0 109.536 177.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 38.2 p -66.98 100.93 0.78 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 122.911 0.484 . . . . 0.0 110.621 179.081 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.0 mmm180 -68.79 91.25 0.44 Allowed 'General case' 0 C--N 1.347 0.497 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.883 176.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -153.8 148.84 20.0 Favored Glycine 0 C--O 1.239 0.468 0 CA-C-N 115.072 -0.967 . . . . 0.0 112.029 -176.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -135.83 -62.04 0.06 OUTLIER Glycine 0 C--N 1.339 0.734 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 176.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -80.43 89.75 5.61 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 175.522 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 74.4 p -115.06 101.87 9.41 Favored 'General case' 0 C--O 1.24 0.592 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 176.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp -72.2 82.86 1.01 Allowed 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 122.975 0.51 . . . . 0.0 110.525 -177.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 84.2 t -80.86 145.3 9.17 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 124.053 0.941 . . . . 0.0 108.793 174.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -64.86 -172.24 0.08 Allowed 'General case' 0 CA--C 1.556 1.21 0 C-N-CA 123.722 0.809 . . . . 0.0 111.696 177.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.657 HD22 ' HB2' ' A' ' 24' ' ' ARG . 1.8 pp -75.96 57.96 1.12 Allowed 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 122.281 1.038 . . . . 0.0 113.131 -174.298 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -96.65 -20.87 17.97 Favored 'General case' 0 N--CA 1.469 0.492 0 C-N-CA 124.554 1.142 . . . . 0.0 110.079 174.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.9 p -68.2 -34.73 76.8 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 124.003 0.921 . . . . 0.0 110.575 175.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -149.61 126.27 11.01 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 173.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.435 HG22 HD13 ' A' ' 40' ' ' ILE . 34.1 m -70.16 112.48 6.55 Favored 'General case' 0 C--O 1.243 0.723 0 CA-C-O 121.474 0.654 . . . . 0.0 110.903 -176.705 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.657 ' HB2' HD22 ' A' ' 19' ' ' LEU . 99.0 mtt180 -128.9 175.36 8.71 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-N 114.867 -1.06 . . . . 0.0 111.148 -176.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 14.3 tt -144.97 148.16 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.932 0.893 . . . . 0.0 109.347 -173.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -90.61 102.95 15.69 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 174.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 97.2 t -87.87 113.3 24.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 124.1 0.96 . . . . 0.0 108.904 -178.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.454 HG23 HG21 ' A' ' 35' ' ' VAL . 26.3 t -98.83 103.88 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.722 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -53.85 107.93 0.99 Allowed Pre-proline 0 CA--C 1.544 0.713 0 C-N-CA 123.677 0.791 . . . . 0.0 108.981 167.442 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -69.09 -24.21 33.0 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.273 1.982 . . . . 0.0 113.022 -174.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -80.41 -50.4 10.16 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 123.213 0.605 . . . . 0.0 111.13 -177.014 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 40.9 p -94.21 -9.69 35.42 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -178.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.03 -3.18 66.29 Favored Glycine 0 N--CA 1.478 1.476 0 N-CA-C 114.166 0.426 . . . . 0.0 114.166 178.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -75.1 125.34 28.73 Favored 'General case' 0 N--CA 1.479 1.013 0 C-N-CA 123.774 0.83 . . . . 0.0 112.932 -170.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.454 HG21 HG23 ' A' ' 28' ' ' VAL . 17.1 t -104.03 135.4 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 123.535 0.734 . . . . 0.0 109.549 177.685 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -146.77 146.53 30.31 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.503 0.721 . . . . 0.0 109.41 174.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 49.2 mt -78.15 100.71 3.39 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 174.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -92.72 153.82 18.69 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.294 0.638 . . . . 0.0 111.331 176.029 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.441 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 36.8 mt-10 -93.34 123.17 36.45 Favored 'General case' 0 C--O 1.244 0.804 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -178.29 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.435 HD13 HG22 ' A' ' 23' ' ' THR . 53.4 mt -74.93 112.26 12.13 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.85 0 O-C-N 123.43 0.456 . . . . 0.0 109.974 -175.602 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.6 mtp180 -77.24 -53.86 7.2 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 124.188 0.995 . . . . 0.0 111.036 178.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.516 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 53.8 t30 -134.81 146.58 49.44 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.032 -172.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.4 m -123.5 -21.52 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 123.625 0.77 . . . . 0.0 111.638 178.551 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.503 HG12 ' OD1' ' A' ' 42' ' ' ASN . 12.6 p -70.88 89.88 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.365 1.246 0 CA-C-O 122.998 1.38 . . . . 0.0 110.729 -172.504 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.476 ' HG3' ' H ' ' A' ' 63' ' ' VAL . 1.3 tm-20 -88.97 164.28 15.18 Favored 'General case' 0 C--O 1.242 0.71 0 CA-C-N 114.007 -1.452 . . . . 0.0 107.651 178.464 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 49.8 t-20 -69.26 85.59 0.39 Allowed 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 121.499 0.666 . . . . 0.0 109.322 175.148 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.3 t -120.8 114.07 21.08 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.298 1.039 . . . . 0.0 108.312 176.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . 60.82 21.11 11.25 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 124.509 1.124 . . . . 0.0 111.939 -174.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 20.3 m120 56.68 95.71 0.05 OUTLIER Pre-proline 0 CA--C 1.555 1.164 0 C-N-CA 124.784 1.234 . . . . 0.0 110.543 -170.085 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -59.4 119.92 7.45 Favored 'Trans proline' 0 C--N 1.374 1.883 0 C-N-CA 123.377 2.718 . . . . 0.0 112.848 -173.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 19.3 p80 -140.89 104.18 4.63 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.628 0.771 . . . . 0.0 109.675 -178.527 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 38.1 t80 56.69 30.17 17.06 Favored 'General case' 0 CA--C 1.559 1.317 0 C-N-CA 124.268 1.027 . . . . 0.0 110.628 -179.032 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 7.2 p -81.35 113.85 21.38 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.929 0 CA-C-O 121.37 0.605 . . . . 0.0 110.563 -175.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -102.53 84.72 2.48 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 173.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 29.9 tpt180 -164.03 99.26 0.86 Allowed 'General case' 0 C--O 1.241 0.615 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 -174.138 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -87.43 54.56 3.18 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 123.762 0.825 . . . . 0.0 108.884 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 10.7 tp -95.15 121.64 45.9 Favored 'Isoleucine or valine' 0 C--O 1.243 0.749 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 -179.446 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 55.5 mt -93.83 130.06 43.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 173.225 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 76.2 p -117.15 159.26 22.89 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.222 0.609 . . . . 0.0 110.005 -176.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 77.7 ttt180 -74.4 115.43 13.91 Favored 'General case' 0 CA--C 1.546 0.813 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.047 -177.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.84 6.12 49.81 Favored Glycine 0 N--CA 1.47 0.959 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.78 -177.284 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.25 162.24 25.81 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.118 0.567 . . . . 0.0 111.014 -178.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.476 ' H ' ' HG3' ' A' ' 45' ' ' GLU . 59.0 t -103.3 110.61 30.31 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 174.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.6 m -105.82 142.52 18.67 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 176.049 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.516 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 34.8 tt0 -92.24 134.84 34.51 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 176.522 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 51.4 p -129.99 179.99 5.55 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 123.926 0.89 . . . . 0.0 108.87 178.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -76.1 -1.47 26.19 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 122.52 0.328 . . . . 0.0 111.336 175.066 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 82.8 mt -106.36 -9.07 16.91 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.704 0.802 . . . . 0.0 111.065 171.542 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 120.62 -166.04 13.85 Favored Glycine 0 C--N 1.351 1.393 0 C-N-CA 122.826 0.251 . . . . 0.0 113.018 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 20.2 m120 -77.64 137.87 38.78 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 123.01 0.524 . . . . 0.0 110.745 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.1 t -133.85 142.24 41.88 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.001 0 C-N-CA 124.727 1.211 . . . . 0.0 110.546 -171.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.612 ' HG2' HG22 ' A' ' 88' ' ' ILE . 30.0 mmt180 -85.15 132.34 34.31 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 170.646 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 45.6 t -76.94 106.52 6.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 172.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.461 HG23 HG12 ' A' ' 86' ' ' VAL . 74.1 p -95.93 -32.55 12.56 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 121.562 0.696 . . . . 0.0 110.629 -170.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.1 t -92.38 174.41 7.31 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.925 175.175 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 85.0 mtp180 -75.73 114.89 40.97 Favored Pre-proline 0 CA--C 1.546 0.802 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 171.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -62.46 112.93 1.73 Allowed 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 123.415 2.743 . . . . 0.0 113.084 -171.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.96 36.99 26.77 Favored Glycine 0 C--N 1.348 1.196 0 CA-C-N 115.388 -0.824 . . . . 0.0 112.245 -178.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 57.4 tp60 -70.7 -49.89 42.29 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.283 0.633 . . . . 0.0 109.946 179.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -121.39 56.15 1.05 Allowed 'General case' 0 N--CA 1.482 1.146 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 175.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 67.12 -16.98 0.3 Allowed Glycine 0 CA--C 1.538 1.52 0 N-CA-C 115.412 0.925 . . . . 0.0 115.412 -173.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.568 HG21 HD23 ' A' ' 19' ' ' LEU . 13.7 p -119.93 151.75 22.57 Favored 'Isoleucine or valine' 0 C--O 1.243 0.711 0 C-N-CA 124.229 1.012 . . . . 0.0 110.756 -171.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 28.3 mt -109.25 143.34 19.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 114.935 -1.03 . . . . 0.0 108.61 174.077 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -124.21 152.63 42.69 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 122.967 0.507 . . . . 0.0 109.647 172.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.5 -176.7 35.73 Favored Glycine 0 C--N 1.344 1.011 0 CA-C-N 115.323 -0.853 . . . . 0.0 112.956 -175.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.461 HG12 HG23 ' A' ' 74' ' ' THR . 27.7 m -130.33 144.24 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 123.317 0.647 . . . . 0.0 110.242 178.039 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.9 tp -72.14 126.86 30.84 Favored 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.585 -178.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.612 HG22 ' HG2' ' A' ' 72' ' ' ARG . 12.7 pt -125.21 171.31 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.189 0 C-N-CA 123.919 0.887 . . . . 0.0 110.319 -178.246 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 93.0 mtt180 -120.94 71.24 0.93 Allowed 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.424 0.69 . . . . 0.0 109.257 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 21.4 mm-40 -93.47 -78.74 0.42 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 122.86 0.464 . . . . 0.0 110.244 179.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 35.5 mt -104.64 140.24 38.32 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 123.868 0.867 . . . . 0.0 109.057 -170.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -90.61 120.53 31.76 Favored 'General case' 0 C--O 1.242 0.709 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 173.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 56.8 t-80 -70.61 83.16 0.61 Allowed 'General case' 0 CA--C 1.547 0.863 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 171.083 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 56.3 t60 -116.16 136.15 53.28 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 114.27 -1.332 . . . . 0.0 110.319 -168.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 1.5 p80 -64.63 105.58 1.0 Allowed 'General case' 0 CA--C 1.547 0.835 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 171.269 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -65.3 -22.8 66.88 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 123.25 0.62 . . . . 0.0 111.521 -172.429 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 35.4 m-70 -104.45 167.01 10.02 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.548 0.739 . . . . 0.0 109.616 175.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 49.8 t-80 . . . . . 0 CA--C 1.553 1.075 0 CA-C-O 118.809 -0.615 . . . . 0.0 109.763 -176.82 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.582 0 N-CA-C 112.033 -0.427 . . . . 0.0 112.033 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -150.65 134.71 16.85 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 123.32 0.648 . . . . 0.0 110.131 -178.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -90.3 86.21 6.43 Favored 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.42 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 23.9 ptt180 -77.35 79.88 3.86 Favored 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.896 0.855 . . . . 0.0 110.57 178.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 p -142.33 100.21 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.959 0 C-N-CA 123.937 0.895 . . . . 0.0 109.611 -179.204 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 43.3 ttm105 -78.7 -23.33 45.63 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.393 177.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.1 tm? 63.06 78.08 0.31 Allowed 'General case' 0 C--N 1.358 0.962 0 C-N-CA 125.082 1.353 . . . . 0.0 109.294 178.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.1 tt -98.89 105.64 17.66 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.373 -173.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -109.26 174.48 5.85 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 124.01 0.924 . . . . 0.0 110.177 177.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 44.3 p -52.02 118.17 3.28 Favored 'General case' 0 CA--C 1.556 1.178 0 C-N-CA 124.522 1.129 . . . . 0.0 112.584 -175.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.3 tpp180 -69.97 108.23 3.94 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 123.64 0.776 . . . . 0.0 109.98 177.58 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 166.87 -170.45 41.32 Favored Glycine 0 C--N 1.341 0.832 0 O-C-N 123.101 0.251 . . . . 0.0 112.799 177.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -85.12 62.5 4.51 Favored Glycine 0 C--N 1.348 1.227 0 N-CA-C 112.021 -0.432 . . . . 0.0 112.021 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 27.6 m-80 -86.24 60.54 6.29 Favored 'General case' 0 C--O 1.245 0.835 0 C-N-CA 124.105 0.962 . . . . 0.0 109.436 -178.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 41.8 p -78.27 78.52 4.74 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 122.002 0.906 . . . . 0.0 110.514 -174.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -114.35 -44.8 3.08 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 114.484 -1.234 . . . . 0.0 107.897 178.482 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 12.7 p -84.15 137.17 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.746 0 CA-C-N 115.259 -0.882 . . . . 0.0 108.626 168.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 7.0 mpt_? -78.53 -74.28 0.28 Allowed 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -179.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 8.7 mp -102.67 124.36 48.06 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.211 1.004 . . . . 0.0 108.497 175.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -98.9 65.16 1.48 Allowed 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.6 m 64.23 14.41 8.64 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 124.851 1.26 . . . . 0.0 112.226 -176.379 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -141.54 149.69 41.16 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 123.983 0.913 . . . . 0.0 109.272 -177.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.463 HG22 HD11 ' A' ' 40' ' ' ILE . 14.1 m -72.19 113.15 8.91 Favored 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 123.256 0.622 . . . . 0.0 110.763 -171.281 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 14.3 mmt180 -113.34 145.54 40.92 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.997 0.919 . . . . 0.0 110.929 -177.577 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 17.5 tt -140.26 145.73 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 123.48 0.712 . . . . 0.0 110.674 -177.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -93.08 102.86 15.19 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 171.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.6 t -88.79 106.95 17.27 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 C-N-CA 123.972 0.909 . . . . 0.0 109.185 -176.505 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 61.8 t -95.85 100.53 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -62.47 111.78 5.32 Favored Pre-proline 0 CA--C 1.547 0.834 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 172.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -71.84 -22.83 23.02 Favored 'Trans proline' 0 C--N 1.365 1.401 0 C-N-CA 122.295 1.997 . . . . 0.0 113.648 -165.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -95.66 -44.16 7.59 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 122.802 0.441 . . . . 0.0 112.166 -176.058 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 44.4 p -87.17 -25.34 24.11 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 122.465 0.306 . . . . 0.0 111.376 -178.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.12 6.57 74.91 Favored Glycine 0 C--N 1.348 1.213 0 CA-C-O 119.35 -0.694 . . . . 0.0 114.04 179.028 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -71.87 107.15 4.5 Favored 'General case' 0 CA--C 1.544 0.714 0 CA-C-N 117.406 0.603 . . . . 0.0 111.016 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.7 t -97.19 109.61 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 174.275 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -136.02 137.59 41.34 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.336 0.654 . . . . 0.0 109.723 -171.652 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 62.1 mt -77.14 131.46 34.74 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.568 0 C-N-CA 123.547 0.739 . . . . 0.0 109.113 179.204 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.449 ' HB3' ' HB ' ' A' ' 66' ' ' THR . . . -131.04 165.02 24.13 Favored 'General case' 0 C--O 1.241 0.612 0 C-N-CA 123.544 0.738 . . . . 0.0 111.061 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -103.79 116.85 33.06 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 114.633 -1.167 . . . . 0.0 108.682 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.463 HD11 HG22 ' A' ' 23' ' ' THR . 62.9 mt -76.88 110.05 12.03 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.4 mtm180 -82.26 -39.58 22.81 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.822 178.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.488 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 93.7 m-20 -128.26 129.53 46.53 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.445 0.698 . . . . 0.0 109.949 -178.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.419 HG22 ' HA ' ' A' ' 56' ' ' ASN . 27.5 m -97.16 -11.82 8.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 123.92 0.888 . . . . 0.0 109.809 173.618 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.4 p -67.89 107.46 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.142 0 O-C-N 124.014 0.822 . . . . 0.0 110.078 175.014 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.523 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -67.58 -38.12 83.6 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.728 1.211 . . . . 0.0 111.792 -179.724 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -151.91 130.53 12.28 Favored 'General case' 0 C--O 1.241 0.64 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 45.6 p -64.97 92.34 0.1 Allowed 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 121.626 0.727 . . . . 0.0 110.39 -179.117 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -139.52 86.35 2.11 Favored 'General case' 0 C--O 1.241 0.652 0 C-N-CA 124.395 1.078 . . . . 0.0 109.425 -176.368 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 56.23 51.21 5.86 Favored Pre-proline 0 CA--C 1.568 1.64 0 C-N-CA 124.802 1.241 . . . . 0.0 111.013 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.8 -15.51 29.89 Favored 'Trans proline' 0 C--N 1.387 2.566 0 C-N-CA 123.041 2.494 . . . . 0.0 113.69 -166.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 25.8 t-80 -71.01 -45.56 63.76 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 122.578 0.351 . . . . 0.0 110.147 176.315 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 87.1 t80 -63.54 -37.27 86.67 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.317 175.529 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.503 HG13 ' H ' ' A' ' 55' ' ' ARG . 46.4 t -71.65 -80.49 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.204 178.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 71.2 ttt180 64.83 7.74 4.11 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 124.848 1.259 . . . . 0.0 111.868 178.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.503 ' H ' HG13 ' A' ' 53' ' ' VAL . 29.3 mmt85 -81.19 125.86 30.8 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 123.276 0.631 . . . . 0.0 111.342 -170.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.419 ' HA ' HG22 ' A' ' 43' ' ' VAL . 20.2 t-20 -81.19 4.2 21.04 Favored 'General case' 0 CA--C 1.557 1.232 0 C-N-CA 123.71 0.804 . . . . 0.0 109.129 169.713 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.6 mt -60.59 87.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.364 1.216 0 C-N-CA 124.394 1.078 . . . . 0.0 109.517 171.315 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 79.9 mt -83.17 134.1 27.65 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.484 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 177.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 59.2 p -117.5 166.24 12.59 Favored 'General case' 0 C--O 1.242 0.679 0 C-N-CA 122.949 0.5 . . . . 0.0 110.873 -176.47 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.404 ' HA ' ' O ' ' A' ' 73' ' ' VAL . 57.3 mtt180 -70.89 127.13 31.56 Favored 'General case' 0 C--N 1.349 0.55 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 175.342 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.47 -6.13 77.69 Favored Glycine 0 C--N 1.341 0.812 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.823 -175.752 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.76 139.54 38.41 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 117.28 0.54 . . . . 0.0 110.519 177.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 45' ' ' GLU . 48.6 t -89.63 118.54 35.11 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 C-N-CA 123.43 0.692 . . . . 0.0 110.122 178.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.4 m -104.15 151.46 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 O-C-N 121.603 -0.685 . . . . 0.0 109.331 171.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.488 ' HB3' ' HB2' ' A' ' 42' ' ' ASN . 34.2 tt0 -102.84 134.09 46.83 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 176.834 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.449 ' HB ' ' HB3' ' A' ' 38' ' ' ALA . 60.0 p -132.28 -176.74 4.18 Favored 'General case' 0 C--O 1.243 0.762 0 C-N-CA 123.665 0.786 . . . . 0.0 109.379 -179.739 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -76.69 -8.26 56.92 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.846 175.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 58.4 mt -97.02 -14.96 21.29 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 123.58 0.752 . . . . 0.0 110.653 174.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 120.94 -156.97 16.04 Favored Glycine 0 C--N 1.347 1.141 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.742 -176.193 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -80.4 138.87 36.7 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 122.993 0.517 . . . . 0.0 111.48 179.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.9 t -125.87 135.17 64.72 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 C-N-CA 123.83 0.852 . . . . 0.0 109.82 178.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.521 ' HG2' HD12 ' A' ' 88' ' ' ILE . 10.9 mmt-85 -83.19 114.77 21.58 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 167.629 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 60' ' ' ARG . 45.3 t -80.03 96.45 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.9 p -78.67 -22.1 47.28 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 123.951 0.9 . . . . 0.0 110.897 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 49.3 m -95.92 -169.08 1.87 Allowed 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.926 0.89 . . . . 0.0 110.886 176.289 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -108.05 156.43 38.31 Favored Pre-proline 0 CA--C 1.547 0.848 0 C-N-CA 123.288 0.635 . . . . 0.0 109.652 173.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.409 ' HA ' HG12 ' A' ' 83' ' ' ILE . 68.5 Cg_endo -71.41 132.02 19.98 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.085 1.857 . . . . 0.0 111.946 178.488 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.408 ' H ' HG12 ' A' ' 83' ' ' ILE . . . 72.84 12.52 78.64 Favored Glycine 0 C--N 1.35 1.315 0 CA-C-O 119.571 -0.572 . . . . 0.0 114.331 174.737 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -74.28 134.1 42.62 Favored 'General case' 0 C--N 1.351 0.666 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.2 t70 68.08 -3.65 1.2 Allowed 'General case' 0 CA--C 1.565 1.537 0 C-N-CA 123.642 0.777 . . . . 0.0 111.579 -179.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 122.18 -13.93 8.95 Favored Glycine 0 C--N 1.355 1.623 0 CA-C-O 119.23 -0.761 . . . . 0.0 113.735 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.4 p -148.77 163.91 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 CA-C-N 118.469 1.134 . . . . 0.0 111.377 -179.006 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.409 HG12 ' HA ' ' A' ' 77' ' ' PRO . 10.0 mt -83.8 149.37 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 175.281 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 27.5 m-80 -140.17 152.96 46.45 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 122.775 0.43 . . . . 0.0 110.173 -178.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -170.8 -170.33 34.89 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-O 119.98 -0.345 . . . . 0.0 113.061 179.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.7 m -126.07 136.81 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 124.096 0.958 . . . . 0.0 110.943 179.098 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 18.9 tp -72.26 127.02 31.26 Favored 'General case' 0 N--CA 1.483 1.221 0 CA-C-O 120.852 0.358 . . . . 0.0 111.602 -174.327 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.521 HD12 ' HG2' ' A' ' 72' ' ' ARG . 7.8 pt -118.67 170.32 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 C-N-CA 124.79 1.236 . . . . 0.0 109.488 177.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 12.8 mmt180 -118.56 19.88 13.15 Favored 'General case' 0 N--CA 1.486 1.371 0 C-N-CA 122.738 0.415 . . . . 0.0 110.535 -169.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -50.43 -75.84 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.876 0 C-N-CA 124.422 1.089 . . . . 0.0 113.85 -164.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.6 mt -77.94 94.54 4.61 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -178.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -61.38 99.12 0.1 Allowed 'General case' 0 C--O 1.241 0.648 0 O-C-N 123.971 0.794 . . . . 0.0 109.478 176.038 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -75.38 80.77 2.45 Favored 'General case' 0 C--N 1.347 0.462 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 -178.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -76.45 99.11 4.79 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.422 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 75.2 t60 -95.0 68.25 3.16 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -176.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 34.4 m170 58.16 77.59 0.28 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 124.961 1.304 . . . . 0.0 111.959 -178.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -137.84 166.48 23.92 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 124.457 1.103 . . . . 0.0 109.336 177.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 67.8 m-70 . . . . . 0 N--CA 1.489 1.486 0 C-N-CA 124.137 0.975 . . . . 0.0 111.3 178.476 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.69 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -72.35 97.09 1.97 Allowed 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 123.582 0.753 . . . . 0.0 110.861 -175.09 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -90.16 95.77 10.36 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 176.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 42.1 ttm180 -150.41 93.91 2.04 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 123.77 0.828 . . . . 0.0 109.296 -177.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.9 p -84.95 85.37 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 CA-C-O 122.297 1.046 . . . . 0.0 109.067 173.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 28.7 tpt180 -76.3 105.74 7.52 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.331 -175.161 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 97.7 mt -128.02 118.58 23.76 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 124.124 0.97 . . . . 0.0 109.274 -179.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.1 tt -76.72 94.0 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.138 0 CA-C-O 121.631 0.729 . . . . 0.0 109.136 175.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 26.2 mmm180 -74.57 76.61 1.98 Allowed 'General case' 0 N--CA 1.48 1.059 0 CA-C-O 121.702 0.763 . . . . 0.0 111.001 -175.231 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 17.6 p -114.76 151.72 33.29 Favored 'General case' 0 C--O 1.242 0.702 0 C-N-CA 124.343 1.057 . . . . 0.0 108.839 177.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 22.8 tpp180 -62.08 97.39 0.08 Allowed 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.868 0.867 . . . . 0.0 111.083 -174.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -135.42 29.3 2.92 Favored Glycine 0 N--CA 1.472 1.078 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.546 179.411 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -174.27 171.02 44.21 Favored Glycine 0 C--N 1.338 0.685 0 N-CA-C 111.403 -0.679 . . . . 0.0 111.403 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -94.56 134.74 36.79 Favored 'General case' 0 C--O 1.244 0.807 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 176.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.0 m -69.84 93.79 0.78 Allowed 'General case' 0 C--O 1.24 0.581 0 O-C-N 123.72 0.637 . . . . 0.0 109.91 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 22.6 pttm -81.34 71.38 8.33 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-O 122.877 1.323 . . . . 0.0 109.454 176.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.6 p -93.09 142.41 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 CA-C-N 114.077 -1.419 . . . . 0.0 109.952 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.512 ' HB2' ' O ' ' A' ' 81' ' ' GLY . 0.0 OUTLIER -93.28 -160.98 0.8 Allowed 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 123.354 0.662 . . . . 0.0 109.547 174.06 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.79 64.78 1.83 Allowed 'General case' 0 N--CA 1.49 1.548 0 CA-C-O 121.857 0.837 . . . . 0.0 112.145 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -82.09 -31.71 30.61 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.727 0.811 . . . . 0.0 111.27 -176.524 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 32.4 t -125.11 -21.89 4.54 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 123.88 0.872 . . . . 0.0 110.631 -179.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -109.15 172.83 6.62 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 123.643 0.777 . . . . 0.0 109.572 -177.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.1 m -115.24 108.71 16.95 Favored 'General case' 0 C--O 1.243 0.737 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 167.24 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 12.9 tpp85 -113.28 136.16 53.05 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 123.477 0.711 . . . . 0.0 110.64 -175.113 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.8 tt -133.89 144.11 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 123.398 0.679 . . . . 0.0 110.451 177.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -93.98 107.85 19.72 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 171.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 86.6 t -91.63 108.37 19.91 Favored 'Isoleucine or valine' 0 C--O 1.241 0.654 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 -177.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.506 HG11 HG22 ' A' ' 35' ' ' VAL . 51.6 t -107.32 99.27 8.24 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.128 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -59.02 116.55 16.14 Favored Pre-proline 0 CA--C 1.55 0.964 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 174.134 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_endo -73.79 -23.62 16.41 Favored 'Trans proline' 0 C--N 1.366 1.495 0 C-N-CA 122.279 1.986 . . . . 0.0 114.007 -171.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.461 ' HG3' HG23 ' A' ' 32' ' ' THR . 12.9 pt-20 -91.57 -50.33 5.83 Favored 'General case' 0 N--CA 1.479 0.975 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -176.059 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.461 HG23 ' HG3' ' A' ' 31' ' ' GLU . 75.3 p -91.38 -33.02 15.44 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 122.7 0.4 . . . . 0.0 111.452 -176.616 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.11 21.35 23.14 Favored Glycine 0 C--N 1.344 1.017 0 CA-C-O 119.292 -0.727 . . . . 0.0 114.106 177.23 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.0 mttp -56.92 106.48 0.31 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 117.364 0.582 . . . . 0.0 109.711 168.374 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.506 HG22 HG11 ' A' ' 28' ' ' VAL . 54.9 t -108.46 97.71 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 172.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -143.51 144.6 32.04 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 123.558 0.743 . . . . 0.0 109.295 -176.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 23.0 mt -85.43 133.21 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.43 173.43 10.85 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.283 1.433 . . . . 0.0 109.61 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -122.84 141.19 52.13 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 174.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 75.7 mt -83.03 114.16 23.4 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 C-N-CA 123.02 0.528 . . . . 0.0 110.041 -176.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 47.1 mtp180 -76.62 -49.6 15.85 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.13 0.972 . . . . 0.0 110.114 179.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -143.65 166.9 23.55 Favored 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.802 0.841 . . . . 0.0 108.951 -179.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.9 p -132.92 116.79 27.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.821 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 170.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -137.22 82.37 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 CA-C-O 122.222 1.011 . . . . 0.0 109.845 -177.036 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.682 ' HB3' ' H ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -105.69 -10.29 16.85 Favored 'General case' 0 N--CA 1.477 0.912 0 CA-C-N 114.186 -1.37 . . . . 0.0 110.306 171.886 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 67.4 m-20 63.52 61.16 1.04 Allowed 'General case' 0 C--O 1.243 0.73 0 C-N-CA 125.345 1.458 . . . . 0.0 112.171 173.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.4 t -69.77 -37.76 76.51 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 163.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -179.26 -177.1 0.44 Allowed 'General case' 0 C--O 1.241 0.609 0 C-N-CA 125.75 1.62 . . . . 0.0 108.64 -178.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 -63.77 114.66 14.21 Favored Pre-proline 0 N--CA 1.479 0.978 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 170.054 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -67.32 80.93 0.4 Allowed 'Trans proline' 0 C--N 1.382 2.316 0 C-N-CA 122.99 2.46 . . . . 0.0 113.065 -174.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 43.4 t-80 -94.22 80.52 4.01 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 175.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 43.6 m-85 -127.26 12.28 7.05 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.22 -177.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 47.5 t 59.98 67.61 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.91 0 C-N-CA 124.176 0.99 . . . . 0.0 109.4 -173.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 2.6 ptm180 56.31 9.19 0.49 Allowed 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 127.657 2.383 . . . . 0.0 114.673 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.3 mtm180 -86.9 141.82 28.47 Favored 'General case' 0 N--CA 1.48 1.064 0 CA-C-O 121.281 0.563 . . . . 0.0 111.114 -178.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.7 p-10 -95.53 94.04 7.53 Favored 'General case' 0 CA--C 1.547 0.83 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.045 179.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.1 mm -77.49 101.38 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.679 0.752 . . . . 0.0 109.193 175.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 75.6 mt -100.11 122.8 52.44 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 114.359 -1.291 . . . . 0.0 109.276 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 41.5 p -121.52 168.19 12.0 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 124.366 1.066 . . . . 0.0 109.284 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 59.0 ttp180 -74.59 130.26 39.24 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 176.137 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.36 -0.16 68.14 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 115.752 -0.658 . . . . 0.0 113.251 -172.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.3 149.94 35.29 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 122.812 0.445 . . . . 0.0 110.964 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.682 ' H ' ' HB3' ' A' ' 45' ' ' GLU . 50.0 t -99.41 110.4 26.55 Favored 'Isoleucine or valine' 0 C--O 1.244 0.765 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 173.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.1 m -104.83 142.25 18.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.228 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -101.79 120.32 40.18 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -178.411 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 38.5 p -125.14 179.13 5.19 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.313 0.645 . . . . 0.0 109.466 -173.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 23.2 p-10 -68.79 -14.92 63.33 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 123.008 0.523 . . . . 0.0 111.038 178.151 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.9 mt -93.51 -46.76 7.16 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.309 0.644 . . . . 0.0 109.501 175.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 159.18 -154.95 26.03 Favored Glycine 0 C--N 1.344 0.977 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.891 175.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -77.04 130.17 37.06 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.902 0.481 . . . . 0.0 110.615 178.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 36.9 t -128.18 140.47 49.1 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.871 0 C-N-CA 124.463 1.105 . . . . 0.0 109.355 -178.321 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.542 HH11 HD13 ' A' ' 88' ' ' ILE . 7.3 mmt-85 -85.57 131.59 34.33 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 170.076 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 59.0 t -76.16 110.13 10.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 173.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 68.9 p -101.54 -42.75 6.12 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 121.207 0.527 . . . . 0.0 109.737 -173.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 20.3 m -94.33 136.97 34.03 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.622 172.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 17.4 mtp180 -60.25 132.39 90.28 Favored Pre-proline 0 CA--C 1.553 1.067 0 O-C-N 124.047 0.842 . . . . 0.0 110.743 -178.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.454 ' HA ' HG12 ' A' ' 83' ' ' ILE . 76.2 Cg_exo -52.73 116.9 3.19 Favored 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 123.807 3.005 . . . . 0.0 114.847 -176.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.46 20.59 71.49 Favored Glycine 0 C--N 1.348 1.206 0 N-CA-C 115.491 0.956 . . . . 0.0 115.491 166.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -73.44 -48.16 35.87 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-N 118.111 0.955 . . . . 0.0 110.521 177.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -85.87 -3.44 58.92 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 123.401 0.68 . . . . 0.0 110.888 170.708 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . 0.512 ' O ' ' HB2' ' A' ' 18' ' ' ARG . . . 111.85 -9.12 27.65 Favored Glycine 0 C--O 1.219 -0.782 0 N-CA-C 111.97 -0.452 . . . . 0.0 111.97 -178.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.6 p -140.63 163.81 22.19 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.895 0 C-N-CA 123.34 0.656 . . . . 0.0 109.931 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.454 HG12 ' HA ' ' A' ' 77' ' ' PRO . 23.3 mt -91.99 147.39 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 172.273 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -130.92 156.69 44.64 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 171.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -169.74 -172.86 36.73 Favored Glycine 0 C--N 1.344 1.027 0 N-CA-C 114.172 0.429 . . . . 0.0 114.172 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 31.2 m -123.92 135.95 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 C-N-CA 123.694 0.798 . . . . 0.0 111.119 -179.472 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.0 tp -74.04 117.17 15.52 Favored 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.459 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.542 HD13 HH11 ' A' ' 72' ' ' ARG . 12.4 pt -116.22 168.75 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 124.191 0.997 . . . . 0.0 111.394 -169.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 17.1 mmt180 -112.55 92.09 3.89 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -121.42 -75.62 0.59 Allowed 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 123.278 0.631 . . . . 0.0 111.417 -173.492 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 39.5 mt -109.31 144.64 37.21 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.331 0.652 . . . . 0.0 110.261 -168.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -84.78 170.1 13.54 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 170.633 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 50.4 t-80 -63.03 96.48 0.09 Allowed 'General case' 0 C--O 1.246 0.909 0 CA-C-O 121.18 0.514 . . . . 0.0 110.078 174.785 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 51.8 m170 -78.12 151.49 33.31 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.806 -178.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 25.9 m170 -83.03 -29.22 29.05 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.246 0.618 . . . . 0.0 109.521 172.593 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 29.4 t-80 51.87 85.35 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 125.846 1.658 . . . . 0.0 112.855 172.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -129.4 60.06 1.58 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 176.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 27.3 p80 . . . . . 0 N--CA 1.497 1.883 0 C-N-CA 125.819 1.648 . . . . 0.0 113.161 -178.86 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.069 0 CA-C-O 120.243 -0.199 . . . . 0.0 113.495 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 35.7 m-20 -104.28 110.36 22.55 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 123.124 0.57 . . . . 0.0 109.672 177.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 83.4 mtt180 -80.23 91.59 5.61 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 173.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 24.1 mtp180 -65.04 91.86 0.1 Allowed 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.902 0.881 . . . . 0.0 109.744 -178.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.8 p -80.16 133.6 29.25 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 115.252 -0.885 . . . . 0.0 111.2 -175.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 9.9 ptp180 -110.19 90.96 3.47 Favored 'General case' 0 CA--C 1.546 0.815 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 169.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 36.2 tp -84.78 86.16 7.37 Favored 'General case' 0 C--O 1.243 0.756 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -178.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.0 tt -149.62 128.55 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.908 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 26.9 ttm180 -147.74 90.62 1.86 Allowed 'General case' 0 C--O 1.241 0.625 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 37.2 p -80.38 84.76 5.96 Favored 'General case' 0 CA--C 1.544 0.745 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.364 -178.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 3.4 tmt_? -82.97 -59.79 2.37 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 177.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 66.44 -111.81 4.43 Favored Glycine 0 C--N 1.351 1.362 0 CA-C-N 115.67 -0.695 . . . . 0.0 113.742 177.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 153.13 156.38 7.56 Favored Glycine 0 C--N 1.343 0.968 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -176.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.5 t30 -143.88 128.16 17.77 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.515 0.726 . . . . 0.0 109.814 -176.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.9 p -136.87 140.08 42.11 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.413 1.085 . . . . 0.0 109.633 178.084 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -97.38 -179.48 4.51 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 121.383 0.611 . . . . 0.0 110.714 174.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.5 p -148.42 156.21 8.76 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.82 0 CA-C-N 114.643 -1.162 . . . . 0.0 108.486 177.049 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.31 179.6 1.94 Allowed 'General case' 0 N--CA 1.487 1.4 0 C-N-CA 122.491 0.316 . . . . 0.0 110.974 177.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.737 HD23 ' HB ' ' A' ' 82' ' ' VAL . 1.5 pt? -58.53 133.37 55.77 Favored 'General case' 0 CA--C 1.554 1.119 0 C-N-CA 123.236 0.614 . . . . 0.0 111.581 -179.085 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.25 -8.57 12.92 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.699 0.8 . . . . 0.0 110.035 172.39 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.499 ' HB2' HH21 ' A' ' 24' ' ' ARG . 33.4 m -104.18 -137.92 0.35 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 124.574 1.15 . . . . 0.0 109.378 179.195 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -82.28 -179.26 7.35 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.877 0.871 . . . . 0.0 110.941 -177.538 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.8 m -64.1 114.4 4.15 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 123.43 0.692 . . . . 0.0 110.889 -176.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.571 HH11 ' HG3' ' A' ' 24' ' ' ARG . 4.1 ttm-85 -119.65 170.17 9.43 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.049 -178.163 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.3 tt -136.69 140.68 42.7 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 CA-C-O 121.251 0.548 . . . . 0.0 111.194 -175.134 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.5 m-80 -92.05 100.71 13.3 Favored 'General case' 0 C--O 1.242 0.664 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 175.332 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 99.5 t -92.78 114.27 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 C-N-CA 123.734 0.813 . . . . 0.0 109.91 -173.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.448 HG23 HG21 ' A' ' 35' ' ' VAL . 38.8 t -103.89 120.74 54.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 123.627 0.771 . . . . 0.0 109.103 -178.188 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -58.68 117.25 19.31 Favored Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 167.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.8 -17.66 28.98 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 121.867 1.711 . . . . 0.0 111.348 170.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -78.5 -53.96 6.66 Favored 'General case' 0 CA--C 1.555 1.137 0 C-N-CA 123.489 0.715 . . . . 0.0 112.107 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 47.0 p -100.9 -26.66 13.67 Favored 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -176.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.37 7.23 65.5 Favored Glycine 0 N--CA 1.476 1.348 0 CA-C-O 119.964 -0.353 . . . . 0.0 112.927 -178.032 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.2 mmtt -73.57 142.68 46.62 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 123.39 0.676 . . . . 0.0 110.846 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.448 HG21 HG23 ' A' ' 28' ' ' VAL . 25.1 t -118.55 122.12 68.72 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 123.417 0.687 . . . . 0.0 109.463 179.122 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -135.37 136.46 41.49 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 123.738 0.815 . . . . 0.0 109.015 178.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 56.8 mt -79.19 100.19 3.75 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.092 0 C-N-CA 123.258 0.623 . . . . 0.0 109.383 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -95.67 163.23 13.28 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 172.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.447 ' HA ' ' HG3' ' A' ' 24' ' ' ARG . 34.0 mt-10 -102.65 137.13 41.27 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -175.672 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 57.5 mt -80.36 110.29 15.76 Favored 'Isoleucine or valine' 0 C--N 1.355 0.806 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 177.323 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 14.1 mtp180 -79.15 -53.82 6.61 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 124.58 1.152 . . . . 0.0 109.535 179.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -148.84 165.75 30.57 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.911 -175.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.503 HG11 ' HB3' ' A' ' 56' ' ' ASN . 30.3 m -103.33 13.02 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 123.593 0.757 . . . . 0.0 111.694 -179.39 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 p -67.34 92.47 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.06 0 CA-C-O 122.615 1.198 . . . . 0.0 109.966 177.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -61.43 -43.26 99.17 Favored 'General case' 0 N--CA 1.476 0.851 0 CA-C-N 114.029 -1.441 . . . . 0.0 109.862 173.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -177.12 -160.91 0.06 Allowed 'General case' 0 C--O 1.244 0.792 0 C-N-CA 125.999 1.719 . . . . 0.0 107.161 -179.572 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 19.0 m -63.42 -17.33 62.55 Favored 'General case' 0 CA--C 1.56 1.341 0 C-N-CA 122.829 0.452 . . . . 0.0 112.055 178.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.5 -37.05 72.33 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 124.474 1.11 . . . . 0.0 112.747 178.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -135.54 92.81 16.87 Favored Pre-proline 0 N--CA 1.48 1.033 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 173.58 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -96.34 7.51 1.66 Allowed 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 123.189 2.593 . . . . 0.0 112.587 169.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 61.6 m170 -84.67 106.23 16.07 Favored 'General case' 0 C--N 1.353 0.731 0 C-N-CA 123.544 0.738 . . . . 0.0 111.057 -172.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -116.62 75.22 0.95 Allowed 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 172.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 9.2 p -160.19 19.58 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.194 0 CA-C-O 122.442 1.115 . . . . 0.0 108.413 177.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 13.2 ptm180 -132.09 177.36 7.62 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 124.79 1.236 . . . . 0.0 110.604 -168.387 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.3 tpt180 -65.93 111.75 3.46 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 165.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.503 ' HB3' HG11 ' A' ' 43' ' ' VAL . 51.1 m-80 -66.14 89.2 0.12 Allowed 'General case' 0 CA--C 1.546 0.792 0 O-C-N 123.691 0.619 . . . . 0.0 110.238 179.327 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 69.6 mt -91.96 96.2 6.08 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.3 mt -82.13 142.68 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 171.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 67.5 p -119.19 166.48 12.91 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 123.536 0.734 . . . . 0.0 110.19 177.095 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 36.4 ttm105 -71.74 115.55 11.07 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 171.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.97 2.41 55.0 Favored Glycine 0 C--N 1.341 0.841 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.599 -174.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.81 132.71 34.38 Favored 'General case' 0 C--O 1.244 0.795 0 C-N-CA 122.875 0.47 . . . . 0.0 110.107 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.4 HG22 ' HG3' ' A' ' 90' ' ' GLU . 54.1 t -79.59 125.58 38.77 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.726 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 174.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 19.6 m -116.14 147.89 19.23 Favored 'Isoleucine or valine' 0 C--O 1.245 0.853 0 C-N-CA 123.885 0.874 . . . . 0.0 109.052 176.286 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -84.69 122.78 29.57 Favored 'General case' 0 N--CA 1.462 0.147 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -179.516 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 47.4 p -129.03 176.99 7.45 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -178.107 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 -65.82 -23.24 66.65 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 123.86 0.864 . . . . 0.0 111.362 177.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 85.1 mt -93.62 -38.61 11.26 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.122 0.569 . . . . 0.0 110.849 -179.148 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 152.22 -146.97 16.16 Favored Glycine 0 C--N 1.347 1.148 0 C-N-CA 121.573 -0.346 . . . . 0.0 113.175 174.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -68.38 109.18 3.53 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.008 0.923 . . . . 0.0 109.453 176.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 85.6 t -120.03 137.68 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 O-C-N 121.886 -0.509 . . . . 0.0 110.379 -179.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.449 ' HG3' HD12 ' A' ' 88' ' ' ILE . 31.1 mtt85 -105.08 129.77 53.43 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.669 0.387 . . . . 0.0 110.335 174.601 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.478 HG11 ' HG3' ' A' ' 77' ' ' PRO . 85.1 t -71.68 123.18 25.47 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 O-C-N 124.455 1.097 . . . . 0.0 110.259 -178.603 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.416 HG22 HG13 ' A' ' 86' ' ' VAL . 45.7 p -101.04 -22.28 14.78 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.971 0.908 . . . . 0.0 111.06 -174.89 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 20.7 t -105.11 -173.65 2.35 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 123.738 0.815 . . . . 0.0 110.268 -178.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 86.7 mtt180 -74.36 120.88 83.61 Favored Pre-proline 0 CA--C 1.544 0.717 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 168.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . 0.478 ' HG3' HG11 ' A' ' 73' ' ' VAL . 73.0 Cg_exo -54.32 102.17 0.08 OUTLIER 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 123.252 2.635 . . . . 0.0 112.98 178.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.488 ' N ' HG12 ' A' ' 83' ' ' ILE . . . 82.91 47.81 5.71 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.336 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 54.7 tp60 -64.93 -58.11 7.01 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 123.463 0.705 . . . . 0.0 110.405 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -98.31 16.49 21.35 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 123.616 0.766 . . . . 0.0 110.015 175.16 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 100.08 -20.99 46.62 Favored Glycine 0 C--N 1.35 1.31 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -173.08 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.737 ' HB ' HD23 ' A' ' 19' ' ' LEU . 14.1 p -110.92 158.31 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.542 1.137 . . . . 0.0 108.57 -178.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.488 HG12 ' N ' ' A' ' 78' ' ' GLY . 8.7 mt -110.78 151.3 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 123.624 0.769 . . . . 0.0 109.828 -177.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 79.9 m-20 -118.31 148.13 42.77 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 172.172 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.7 -179.97 36.71 Favored Glycine 0 C--N 1.348 1.207 0 O-C-N 123.452 0.47 . . . . 0.0 113.136 -179.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 11.9 m -124.48 136.81 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 123.642 0.777 . . . . 0.0 111.423 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 50.8 tp -78.82 105.96 10.5 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.403 0.681 . . . . 0.0 110.982 -177.446 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.449 HD12 ' HG3' ' A' ' 72' ' ' ARG . 30.4 pt -123.41 -172.92 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 123.889 0.875 . . . . 0.0 109.507 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -132.68 110.91 10.74 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.159 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.4 ' HG3' HG22 ' A' ' 63' ' ' VAL . 41.3 mm-40 -115.94 -60.8 1.82 Allowed 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.027 0.531 . . . . 0.0 110.135 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.2 mt -72.51 -27.99 62.6 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 122.888 0.475 . . . . 0.0 110.256 179.008 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -118.17 44.47 2.21 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 124.151 0.98 . . . . 0.0 109.962 173.008 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -76.07 -17.22 59.73 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 124.254 1.022 . . . . 0.0 111.924 177.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 17.1 m170 73.59 127.96 0.04 OUTLIER 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 125.507 1.523 . . . . 0.0 108.782 -162.214 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -64.32 167.14 7.14 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.404 0.682 . . . . 0.0 111.301 -178.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 32.0 m170 -83.99 16.59 2.79 Favored 'General case' 0 N--CA 1.484 1.238 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -170.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 25.9 t-80 75.19 -52.48 0.66 Allowed 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 125.88 1.672 . . . . 0.0 110.591 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 72.4 m-70 . . . . . 0 C--O 1.248 0.992 0 C-N-CA 123.754 0.822 . . . . 0.0 108.803 166.735 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.611 0 N-CA-C 111.715 -0.554 . . . . 0.0 111.715 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -75.65 108.31 8.4 Favored 'General case' 0 C--N 1.352 0.704 0 C-N-CA 123.371 0.668 . . . . 0.0 110.593 179.403 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 4.8 ppt_? -137.29 141.65 41.93 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.509 0.723 . . . . 0.0 109.885 174.005 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 6.2 mpt_? -101.23 77.71 1.83 Allowed 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.013 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.7 p -73.12 -42.39 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.95 -177.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.5 ttt85 -98.43 147.2 24.96 Favored 'General case' 0 C--O 1.243 0.747 0 C-N-CA 124.069 0.947 . . . . 0.0 109.712 -178.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 6.4 tt -75.48 90.79 2.74 Favored 'General case' 0 CA--C 1.541 0.631 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 175.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 68.1 mt -100.1 122.83 52.47 Favored 'Isoleucine or valine' 0 C--O 1.241 0.614 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 166.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 47.0 mtm180 -59.09 149.94 26.44 Favored 'General case' 0 N--CA 1.483 1.199 0 O-C-N 123.377 0.423 . . . . 0.0 111.256 -173.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 32.3 p -50.56 92.72 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 125.025 1.33 . . . . 0.0 113.307 -168.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 31.7 tpt180 -144.03 146.18 32.69 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 124.403 1.081 . . . . 0.0 108.443 178.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.32 -7.54 78.17 Favored Glycine 0 C--N 1.344 1.023 0 CA-C-O 120.02 -0.322 . . . . 0.0 112.819 -175.326 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.69 85.14 1.18 Allowed Glycine 0 C--N 1.35 1.348 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 177.146 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -67.26 95.26 0.41 Allowed 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 177.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 34.6 p -86.37 174.28 9.13 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.906 0.882 . . . . 0.0 110.772 -179.26 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.86 40.43 1.99 Allowed 'General case' 0 N--CA 1.481 1.083 0 CA-C-O 121.976 0.893 . . . . 0.0 109.527 177.576 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.7 t -77.79 115.58 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.672 -179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.3 mpt_? -84.93 -70.37 0.59 Allowed 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 169.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.453 HD22 ' HA ' ' A' ' 23' ' ' THR . 97.6 mt -104.51 -81.13 0.53 Allowed 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.487 0.715 . . . . 0.0 110.402 178.689 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 47.36 78.05 0.08 Allowed 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 125.286 1.434 . . . . 0.0 111.558 -174.13 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 19.5 t 76.18 -52.75 0.61 Allowed 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 125.399 1.48 . . . . 0.0 111.482 -176.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -69.91 177.04 3.31 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 124.08 0.952 . . . . 0.0 111.722 176.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.453 ' HA ' HD22 ' A' ' 19' ' ' LEU . 7.5 m -144.02 119.2 10.12 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.206 -172.784 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -101.14 147.81 25.81 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.445 0.698 . . . . 0.0 109.392 -177.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.441 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 17.4 tt -146.61 151.17 14.38 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 122.972 0.509 . . . . 0.0 110.324 177.683 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -100.03 102.45 13.81 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 168.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.419 HG22 HG21 ' A' ' 71' ' ' VAL . 61.6 t -87.33 110.9 21.12 Favored 'Isoleucine or valine' 0 C--O 1.243 0.724 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 178.449 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 53.5 t -100.51 99.51 8.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -60.14 114.09 9.01 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 172.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -76.25 -8.21 18.48 Favored 'Trans proline' 0 C--N 1.369 1.647 0 C-N-CA 122.795 2.33 . . . . 0.0 113.136 -173.317 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -84.17 -53.97 5.14 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.251 0.621 . . . . 0.0 109.867 -172.175 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 58.6 p -99.57 -33.21 10.73 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 124.032 0.933 . . . . 0.0 111.449 177.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.4 10.33 36.32 Favored Glycine 0 N--CA 1.476 1.359 0 CA-C-O 119.828 -0.429 . . . . 0.0 113.272 -176.374 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.2 mmmt -66.12 113.67 4.68 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.654 0.782 . . . . 0.0 111.484 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 38.1 t -104.26 125.44 59.04 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 C-N-CA 123.731 0.813 . . . . 0.0 109.268 176.278 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.425 ' HB3' HD12 ' A' ' 68' ' ' LEU . 8.9 tp10 -135.26 140.33 45.12 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.605 0.762 . . . . 0.0 109.612 178.191 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 65.5 mt -79.78 118.37 27.21 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 169.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.07 169.59 11.04 Favored 'General case' 0 C--O 1.242 0.706 0 C-N-CA 124.129 0.972 . . . . 0.0 109.083 -175.049 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -102.89 128.88 49.49 Favored 'General case' 0 C--O 1.244 0.771 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.5 mt -74.39 110.37 8.51 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 175.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 42.8 ttt180 -72.43 -37.74 68.52 Favored 'General case' 0 C--O 1.237 0.425 0 C-N-CA 124.28 1.032 . . . . 0.0 110.492 -175.037 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -160.67 148.8 16.21 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.036 -0.984 . . . . 0.0 108.624 -173.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.543 HG12 HG12 ' A' ' 64' ' ' VAL . 40.5 t -109.98 88.24 1.09 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.753 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 178.635 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.9 p -140.51 135.96 35.7 Favored 'Isoleucine or valine' 0 C--O 1.244 0.79 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -178.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.728 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 36.4 mt-10 -99.08 -54.44 2.98 Favored 'General case' 0 C--O 1.241 0.61 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.534 -176.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.699 ' H ' ' HG3' ' A' ' 50' ' ' PRO . 90.5 m-20 59.0 32.06 21.93 Favored 'General case' 0 N--CA 1.479 0.984 0 O-C-N 125.156 1.535 . . . . 0.0 110.236 -171.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 43.4 p -92.19 -59.4 2.1 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.389 175.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -156.33 75.87 0.88 Allowed 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 123.496 0.719 . . . . 0.0 109.465 176.472 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 64.27 95.25 0.05 OUTLIER Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 124.767 1.227 . . . . 0.0 111.257 178.072 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.699 ' HG3' ' H ' ' A' ' 46' ' ' ASN . 5.5 Cg_exo -73.87 -25.59 14.18 Favored 'Trans proline' 0 C--N 1.376 2.013 0 C-N-CA 123.267 2.645 . . . . 0.0 112.893 -178.558 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 33.9 m-70 -93.15 81.88 4.53 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.454 0.702 . . . . 0.0 109.498 -175.359 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 37.1 p90 -115.56 5.06 14.31 Favored 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 124.111 0.964 . . . . 0.0 110.26 173.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 7.1 p -155.29 148.96 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.73 0 C-N-CA 124.506 1.122 . . . . 0.0 108.919 -178.128 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.0 ttt180 -63.21 -64.64 0.85 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.153 0.581 . . . . 0.0 110.752 178.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 45.7 ttt180 -82.41 129.77 34.96 Favored 'General case' 0 C--N 1.348 0.507 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 176.067 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.1 m120 -79.6 70.49 6.09 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.397 0.679 . . . . 0.0 110.626 -176.595 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 50.8 mm -55.09 106.92 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.74 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.047 170.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 57.5 mt -66.93 123.37 19.84 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.257 -0.883 . . . . 0.0 108.791 177.255 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 28.5 p -125.21 161.07 27.69 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 124.374 1.07 . . . . 0.0 109.648 -176.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 58.1 ttp180 -69.71 127.2 32.11 Favored 'General case' 0 CA--C 1.547 0.864 0 C-N-CA 123.26 0.624 . . . . 0.0 109.451 175.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.98 -16.33 58.49 Favored Glycine 0 C--N 1.346 1.113 0 CA-C-O 119.739 -0.478 . . . . 0.0 112.994 -173.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.36 153.05 30.06 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 122.732 0.413 . . . . 0.0 110.742 179.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.728 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 78.0 t -98.19 124.26 51.16 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 CA-C-N 115.888 -0.597 . . . . 0.0 109.762 175.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.543 HG12 HG12 ' A' ' 43' ' ' VAL . 21.8 m -118.97 138.46 49.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 123.853 0.861 . . . . 0.0 109.068 174.548 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -101.07 137.43 39.44 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' THR . . . . . 0.418 HG23 HG21 ' A' ' 25' ' ' ILE . 71.2 p -129.17 -173.09 2.89 Favored 'General case' 0 C--O 1.242 0.681 0 C-N-CA 123.671 0.788 . . . . 0.0 110.113 -169.592 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -68.36 -9.98 51.83 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 123.381 0.673 . . . . 0.0 111.768 173.281 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.425 HD12 ' HB3' ' A' ' 36' ' ' GLU . 85.1 mt -106.65 -46.24 4.03 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.775 0.83 . . . . 0.0 110.459 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 167.37 -164.51 37.96 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 116.546 -0.297 . . . . 0.0 112.359 175.171 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -73.1 139.46 46.48 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.178 0.591 . . . . 0.0 109.507 175.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.419 HG21 HG22 ' A' ' 27' ' ' VAL . 61.5 t -134.81 142.14 41.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.754 0.822 . . . . 0.0 110.331 -170.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.501 ' HG2' HD12 ' A' ' 88' ' ' ILE . 8.3 mmt-85 -93.38 124.9 37.69 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 171.032 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 51.7 t -76.35 97.49 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.213 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 p -79.7 -38.62 33.09 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.659 0.784 . . . . 0.0 112.121 -177.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' SER . . . . . 0.469 ' HB3' ' HB2' ' A' ' 84' ' ' ASN . 23.2 t -90.55 -176.46 4.76 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.436 0.694 . . . . 0.0 110.457 179.804 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 59.6 mtt180 -83.59 113.6 48.08 Favored Pre-proline 0 CA--C 1.549 0.922 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.24 141.25 51.4 Favored 'Trans proline' 0 C--N 1.376 1.98 0 C-N-CA 123.254 2.636 . . . . 0.0 113.236 -171.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 83.13 18.91 63.81 Favored Glycine 0 C--N 1.347 1.142 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.112 177.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -70.68 103.21 2.48 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 63.53 41.49 7.32 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 124.168 0.987 . . . . 0.0 110.905 -174.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 61.05 33.61 84.73 Favored Glycine 0 C--N 1.339 0.737 0 CA-C-N 114.864 -1.062 . . . . 0.0 115.293 -175.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -143.31 141.47 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.591 0.71 . . . . 0.0 110.922 168.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 25' ' ' ILE . 2.0 mp -93.7 146.98 5.86 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 174.259 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.469 ' HB2' ' HB3' ' A' ' 75' ' ' SER . 2.6 m-20 -126.31 137.99 53.54 Favored 'General case' 0 N--CA 1.484 1.225 0 CA-C-N 118.971 0.805 . . . . 0.0 109.508 174.026 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.44 -175.06 34.03 Favored Glycine 0 C--N 1.345 1.073 0 CA-C-N 115.994 -0.548 . . . . 0.0 113.075 -175.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 34.5 m -127.47 142.89 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 C-N-CA 123.441 0.696 . . . . 0.0 110.78 -177.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.3 tp -68.28 130.99 44.54 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 123.159 0.583 . . . . 0.0 110.673 -178.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . 0.501 HD12 ' HG2' ' A' ' 72' ' ' ARG . 19.5 pt -133.42 170.21 20.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 124.157 0.983 . . . . 0.0 110.04 -175.417 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 13.2 mmt-85 -111.4 95.09 5.31 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 176.267 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' GLU . . . . . 0.427 ' HG3' HG12 ' A' ' 63' ' ' VAL . 47.7 mm-40 -105.93 -62.1 1.42 Allowed 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 171.338 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.512 HD23 HD21 ' A' ' 46' ' ' ASN . 74.6 mt -99.65 126.54 45.67 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.155 174.731 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -74.02 101.06 3.75 Favored 'General case' 0 CA--C 1.545 0.771 0 CA-C-O 121.667 0.746 . . . . 0.0 109.592 176.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 14.8 m-70 -65.65 141.88 58.24 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.056 178.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -115.74 97.45 6.13 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 123.119 0.568 . . . . 0.0 110.429 -174.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 13.5 p80 -128.61 -7.94 5.12 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.347 0.659 . . . . 0.0 109.885 169.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.7 m170 -68.46 -26.07 65.31 Favored 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 123.24 0.616 . . . . 0.0 109.83 173.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 31.8 t60 -62.7 -47.22 84.57 Favored 'General case' 0 C--N 1.349 0.551 0 C-N-CA 124.889 1.275 . . . . 0.0 110.657 179.462 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 21.1 t-80 . . . . . 0 C--O 1.25 1.131 0 C-N-CA 123.497 0.719 . . . . 0.0 109.838 -177.128 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.0 m . . . . . 0 CA--C 1.54 0.572 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -106.95 144.97 32.81 Favored 'General case' 0 C--O 1.243 0.752 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -177.91 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.9 tt -146.17 139.36 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.772 0 C-N-CA 123.589 0.756 . . . . 0.0 110.061 -178.148 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 -89.39 101.58 14.26 Favored 'General case' 0 C--O 1.239 0.543 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 175.012 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.2 t -87.29 110.17 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.436 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.8 t -98.22 100.24 10.2 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -61.2 112.29 5.61 Favored Pre-proline 0 CA--C 1.549 0.929 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 175.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -77.18 -17.78 14.77 Favored 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 122.268 1.979 . . . . 0.0 113.209 -168.465 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -96.87 -48.89 5.27 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 122.714 0.406 . . . . 0.0 110.996 178.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.534 HG21 ' HE3' ' A' ' 34' ' ' LYS . 2.8 m -90.93 -31.26 16.45 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.215 0.606 . . . . 0.0 111.581 -172.498 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 95.14 6.27 60.26 Favored Glycine 0 N--CA 1.476 1.316 0 CA-C-O 119.479 -0.623 . . . . 0.0 114.003 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.534 ' HE3' HG21 ' A' ' 32' ' ' THR . 92.1 mttt -63.78 106.72 1.04 Allowed 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 123.089 0.556 . . . . 0.0 110.839 177.9 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.6 t -103.93 106.86 21.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 175.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.503 ' HB3' HD11 ' A' ' 68' ' ' LEU . 10.3 tp10 -138.43 139.44 38.88 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 123.763 0.825 . . . . 0.0 109.812 -173.712 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 50.0 mt -83.15 100.85 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 176.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.8 173.24 7.41 Favored 'General case' 0 C--O 1.239 0.509 0 C-N-CA 123.962 0.905 . . . . 0.0 110.079 176.416 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -107.56 134.59 50.35 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 175.511 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 59.3 mt -75.57 110.26 10.23 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 173.24 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -82.01 -48.07 11.87 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.645 1.178 . . . . 0.0 110.236 -173.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -135.97 153.82 51.28 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 175.456 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.508 HG13 HG12 ' A' ' 64' ' ' VAL . 16.8 t . . . . . 0 N--CA 1.479 1.023 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 173.704 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 67.9 mt . . . . . 0 CA--C 1.542 0.658 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.4 mt -102.98 116.0 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 114.041 -1.436 . . . . 0.0 108.944 -174.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 39.4 p -117.54 162.89 17.26 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.631 0.772 . . . . 0.0 110.765 -176.358 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -67.02 135.66 54.07 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 123.006 0.522 . . . . 0.0 110.127 176.593 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.07 -2.94 85.77 Favored Glycine 0 C--N 1.344 0.991 0 O-C-N 123.595 0.56 . . . . 0.0 113.571 -175.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.02 145.79 30.04 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 117.283 0.541 . . . . 0.0 110.749 179.214 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.8 t -90.1 112.17 24.33 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 172.067 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.508 HG12 HG13 ' A' ' 43' ' ' VAL . 26.5 m -107.42 159.6 6.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 174.277 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -102.6 137.46 40.8 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 172.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 30.6 p -133.46 -175.46 3.82 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.418 0.687 . . . . 0.0 109.797 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -60.59 -27.0 67.38 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 123.692 0.797 . . . . 0.0 111.889 175.464 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.503 HD11 ' HB3' ' A' ' 36' ' ' GLU . 74.1 mt -100.24 -0.67 38.15 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.269 0.628 . . . . 0.0 111.167 -175.894 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 112.06 -161.66 12.67 Favored Glycine 0 C--N 1.351 1.415 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.438 ' HA ' ' O ' ' A' ' 64' ' ' VAL . 17.5 m120 -73.69 138.14 44.52 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-N 117.16 0.48 . . . . 0.0 111.568 -178.212 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 92.8 t -130.45 146.62 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 124.748 1.219 . . . . 0.0 110.126 -176.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.686 ' HG2' HD13 ' A' ' 88' ' ' ILE . 34.6 mmt180 -85.23 126.68 33.87 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 167.497 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 43.0 t -73.54 111.7 8.89 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 172.784 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 77.6 p -95.36 -21.92 18.07 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-O 120.981 0.42 . . . . 0.0 109.907 -175.258 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 23.3 t -107.23 -171.29 1.85 Allowed 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.453 1.101 . . . . 0.0 110.578 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.28 136.68 20.91 Favored Pre-proline 0 CA--C 1.547 0.851 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 169.237 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -59.75 103.83 0.21 Allowed 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.502 2.135 . . . . 0.0 111.314 173.32 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 130.2 -6.08 6.01 Favored Glycine 0 C--N 1.342 0.904 0 CA-C-O 119.1 -0.833 . . . . 0.0 113.46 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 16.9 mm100 -67.31 -71.8 0.19 Allowed 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 117.876 0.838 . . . . 0.0 110.502 177.524 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -89.27 30.84 0.94 Allowed 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 172.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 64.63 -74.66 0.07 OUTLIER Glycine 0 C--N 1.355 1.618 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 -160.187 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.9 p -57.87 156.17 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.255 0 C-N-CA 125.387 1.475 . . . . 0.0 112.095 174.309 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 39.3 mt -84.04 151.51 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.526 1.13 . . . . 0.0 108.232 175.022 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -138.0 158.03 45.15 Favored 'General case' 0 N--CA 1.482 1.155 0 CA-C-N 118.298 0.499 . . . . 0.0 110.211 167.177 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.68 -171.71 34.77 Favored Glycine 0 C--N 1.344 0.994 0 CA-C-N 115.427 -0.806 . . . . 0.0 113.124 -174.586 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.2 m -122.91 135.23 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 123.441 0.696 . . . . 0.0 110.256 178.076 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 30.8 tp -68.37 134.12 49.76 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 122.969 0.508 . . . . 0.0 110.176 -177.677 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.686 HD13 ' HG2' ' A' ' 72' ' ' ARG . 16.7 pt -132.02 167.21 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 123.81 0.844 . . . . 0.0 111.062 -175.539 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 62.5 mtt-85 -117.66 49.42 1.23 Allowed 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 123.71 0.804 . . . . 0.0 110.166 -175.077 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -68.2 -58.74 3.96 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.072 0.463 . . . . 0.0 110.515 177.587 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 95.5 mt . . . . . 0 C--O 1.241 0.639 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.112 179.523 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.532 HG22 HD12 ' A' ' 40' ' ' ILE . 29.9 m . . . . . 0 C--O 1.239 0.526 0 CA-C-O 121.416 0.627 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.598 ' HD3' ' HG2' ' A' ' 39' ' ' GLU . 39.4 ttp180 -123.47 163.33 21.1 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 124.377 1.071 . . . . 0.0 108.265 177.114 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.1 tt -135.77 142.85 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.201 0.601 . . . . 0.0 110.183 -171.385 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.0 m-80 -84.98 102.5 13.23 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.6 t -95.2 107.93 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -172.161 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 42.1 t -93.58 103.09 14.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -64.24 116.68 29.85 Favored Pre-proline 0 CA--C 1.546 0.797 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 174.63 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.5 ' HG2' ' HG3' ' A' ' 31' ' ' GLU . 82.3 Cg_endo -73.33 -18.08 23.55 Favored 'Trans proline' 0 C--N 1.365 1.426 0 C-N-CA 122.361 2.04 . . . . 0.0 113.455 -173.513 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.5 ' HG3' ' HG2' ' A' ' 30' ' ' PRO . 20.8 mt-10 -95.86 -51.78 4.34 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.937 0.895 . . . . 0.0 110.757 -169.556 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 61.1 p -96.02 -7.26 36.79 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 123.56 0.744 . . . . 0.0 111.648 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.48 -0.65 80.19 Favored Glycine 0 C--N 1.355 1.595 0 CA-C-O 119.556 -0.58 . . . . 0.0 114.208 173.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.3 mtmp? -67.17 106.89 2.14 Favored 'General case' 0 C--N 1.353 0.758 0 C-N-CA 123.267 0.627 . . . . 0.0 111.572 -174.461 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.4 t -82.71 99.78 5.86 Favored 'Isoleucine or valine' 0 C--N 1.346 0.446 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 169.387 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -130.02 114.28 15.6 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 -167.056 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.48 HG22 ' HG2' ' A' ' 24' ' ' ARG . 26.7 mt -79.04 100.01 3.55 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -171.371 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.43 ' O ' ' HG3' ' A' ' 24' ' ' ARG . . . -104.61 163.3 12.58 Favored 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 123.523 0.729 . . . . 0.0 110.755 -175.619 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.598 ' HG2' ' HD3' ' A' ' 24' ' ' ARG . 17.8 mt-10 -105.92 136.11 46.16 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 123.242 0.617 . . . . 0.0 109.932 -167.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.532 HD12 HG22 ' A' ' 23' ' ' THR . 68.1 mt -77.41 112.4 15.31 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.972 0 CA-C-O 121.417 0.627 . . . . 0.0 110.668 -174.391 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 9.2 mtp180 -74.93 -55.04 6.18 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 124.308 1.043 . . . . 0.0 110.152 174.352 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -140.51 168.46 19.75 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 124.249 1.02 . . . . 0.0 108.81 -176.573 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.1 t . . . . . 0 N--CA 1.478 0.93 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 167.757 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 40.5 mm . . . . . 0 C--O 1.244 0.773 0 CA-C-O 121.658 0.742 . . . . 0.0 109.749 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 37.8 mt -81.5 105.62 11.61 Favored 'Isoleucine or valine' 0 C--N 1.344 0.331 0 N-CA-C 107.699 -1.222 . . . . 0.0 107.699 174.58 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 5.7 p -139.62 168.24 20.27 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.414 1.086 . . . . 0.0 108.509 -177.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 52.5 mtm180 -61.03 125.24 23.01 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 122.754 0.422 . . . . 0.0 111.105 -178.424 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.82 -10.24 68.38 Favored Glycine 0 C--N 1.34 0.783 0 CA-C-N 115.196 -0.911 . . . . 0.0 114.154 -176.557 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.62 156.83 36.33 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-N 117.482 0.641 . . . . 0.0 110.847 177.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.464 HG21 ' HG3' ' A' ' 90' ' ' GLU . 99.2 t -109.08 124.39 65.71 Favored 'Isoleucine or valine' 0 C--O 1.242 0.699 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 175.042 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.1 m -105.58 146.19 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 172.527 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -94.73 139.24 31.52 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 124.206 1.003 . . . . 0.0 109.011 176.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 76.7 p -138.09 177.38 7.92 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 124.799 1.24 . . . . 0.0 107.816 177.512 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.7 m-80 -84.04 8.93 13.77 Favored 'General case' 0 N--CA 1.481 1.092 0 O-C-N 122.339 -0.226 . . . . 0.0 111.419 175.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 62.8 mt -104.8 -14.22 15.6 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 123.386 0.674 . . . . 0.0 110.498 171.388 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 134.7 -148.49 19.54 Favored Glycine 0 C--N 1.343 0.942 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 -176.023 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -101.9 145.9 28.58 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 176.133 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.1 t -129.82 141.28 46.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 C-N-CA 123.62 0.768 . . . . 0.0 109.706 -176.377 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.702 ' HG2' HD13 ' A' ' 88' ' ' ILE . 26.8 mmt180 -81.14 139.17 35.76 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 170.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 67.3 t -84.62 103.74 12.12 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.747 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 169.756 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 72.1 p -100.06 -17.29 17.55 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.176 0.59 . . . . 0.0 110.854 -171.138 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 60.2 p -118.67 179.63 4.08 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.966 0.906 . . . . 0.0 109.963 176.46 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 14.4 ptp180 -78.75 151.85 77.13 Favored Pre-proline 0 CA--C 1.552 1.032 0 C-N-CA 123.082 0.553 . . . . 0.0 110.645 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.656 ' HA ' HG13 ' A' ' 83' ' ' ILE . 85.1 Cg_endo -76.41 16.07 0.93 Allowed 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 122.879 2.386 . . . . 0.0 114.58 -178.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.81 58.88 0.42 Allowed Glycine 0 C--N 1.346 1.093 0 N-CA-C 112.216 -0.354 . . . . 0.0 112.216 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 -118.83 110.26 17.0 Favored 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 171.236 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.3 t70 67.62 -1.37 1.64 Allowed 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 124.433 1.093 . . . . 0.0 111.217 -169.864 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.47 5.83 60.1 Favored Glycine 0 C--N 1.349 1.3 0 CA-C-O 119.479 -0.623 . . . . 0.0 112.677 -174.355 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 11.4 p -126.26 164.29 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 123.435 0.694 . . . . 0.0 111.07 -175.444 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.656 HG13 ' HA ' ' A' ' 77' ' ' PRO . 3.4 mp -109.61 147.02 14.32 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 124.473 1.109 . . . . 0.0 108.664 178.263 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -119.69 155.82 31.68 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 123.596 0.759 . . . . 0.0 109.345 169.596 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.63 -175.12 36.57 Favored Glycine 0 C--N 1.345 1.065 0 N-CA-C 114.017 0.367 . . . . 0.0 114.017 -176.286 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.6 m -130.71 140.37 48.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 C-N-CA 123.469 0.707 . . . . 0.0 110.419 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 33.6 tp -75.47 112.85 12.22 Favored 'General case' 0 CA--C 1.549 0.937 0 CA-C-O 121.303 0.573 . . . . 0.0 111.624 -172.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.702 HD13 ' HG2' ' A' ' 72' ' ' ARG . 9.3 pt -110.02 179.01 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.19 0 C-N-CA 125.059 1.344 . . . . 0.0 110.488 178.062 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 47.5 mmt-85 -132.03 62.48 1.64 Allowed 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 123.438 0.695 . . . . 0.0 109.412 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.464 ' HG3' HG21 ' A' ' 63' ' ' VAL . 37.6 mm-40 -68.77 -63.06 1.13 Allowed 'General case' 0 N--CA 1.491 1.605 0 CA-C-O 121.464 0.65 . . . . 0.0 110.09 177.736 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 70.6 mt . . . . . 0 C--O 1.242 0.66 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 172.029 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.498 ' HB ' ' HB ' ' A' ' 40' ' ' ILE . 6.4 m . . . . . 0 CA--C 1.547 0.843 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 22.9 mmt85 -104.95 134.31 48.28 Favored 'General case' 0 C--O 1.244 0.768 0 C-N-CA 124.275 1.03 . . . . 0.0 109.45 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.4 tt -140.29 135.91 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 123.995 0.918 . . . . 0.0 109.394 -178.734 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 20.7 m-80 -87.14 103.36 15.33 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.5 t -98.42 110.11 25.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 C-N-CA 123.884 0.874 . . . . 0.0 109.196 -172.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.456 HG22 HG22 ' A' ' 35' ' ' VAL . 38.2 t -92.66 103.54 14.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -60.51 116.82 19.72 Favored Pre-proline 0 CA--C 1.549 0.918 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -76.75 -11.17 18.43 Favored 'Trans proline' 0 C--N 1.363 1.326 0 C-N-CA 122.958 2.439 . . . . 0.0 113.379 -174.13 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -81.89 -52.47 7.06 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 123.087 0.555 . . . . 0.0 109.583 -176.38 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 65.4 p -96.37 -31.85 12.66 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 114.774 -1.103 . . . . 0.0 112.026 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 94.03 8.61 60.21 Favored Glycine 0 N--CA 1.475 1.247 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.494 -173.514 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.7 mmtp -72.66 108.92 5.93 Favored 'General case' 0 C--N 1.359 0.982 0 C-N-CA 123.18 0.592 . . . . 0.0 111.678 -177.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.456 HG22 HG22 ' A' ' 28' ' ' VAL . 24.8 t -82.91 120.17 33.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 172.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 13.1 tp10 -140.29 130.33 24.83 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.463 0.705 . . . . 0.0 109.479 -177.36 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 46.0 mt -78.0 103.79 5.37 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -179.025 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.439 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -89.83 166.12 13.72 Favored 'General case' 0 C--O 1.24 0.558 0 C-N-CA 123.694 0.798 . . . . 0.0 111.037 177.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 -114.39 124.94 53.2 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 115.314 -0.857 . . . . 0.0 108.925 176.577 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.498 ' HB ' ' HB ' ' A' ' 23' ' ' THR . 67.8 mt -79.79 111.37 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 C-N-CA 122.958 0.503 . . . . 0.0 109.775 -173.658 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 71.9 mtt180 -64.86 -46.83 80.19 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 123.798 0.839 . . . . 0.0 110.376 176.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 62.5 t30 -164.5 172.51 13.21 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.932 -170.134 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 25.2 m . . . . . 0 CA--C 1.549 0.929 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 170.644 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 50.1 mt . . . . . 0 C--O 1.241 0.635 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 71.3 mt -61.98 116.93 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 114.372 -1.285 . . . . 0.0 109.952 -178.174 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.438 ' HA ' ' HG2' ' A' ' 77' ' ' PRO . 40.6 p -126.8 167.2 16.11 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 124.073 0.949 . . . . 0.0 110.017 -177.854 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 32.5 ttp180 -64.03 138.5 58.49 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 123.127 0.571 . . . . 0.0 110.269 177.303 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.32 -39.17 3.04 Favored Glycine 0 C--N 1.335 0.521 0 CA-C-O 119.926 -0.374 . . . . 0.0 112.778 -176.364 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -61.63 135.87 57.79 Favored 'General case' 0 C--N 1.356 0.859 0 C-N-CA 123.665 0.786 . . . . 0.0 110.821 179.334 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 42.2 t -87.51 133.15 31.01 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 176.472 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 18.4 m -113.52 150.5 15.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 C-N-CA 124.171 0.989 . . . . 0.0 109.024 177.325 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -95.65 125.44 40.24 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 106.098 -1.815 . . . . 0.0 106.098 174.276 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.439 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 61.3 p -122.05 177.71 5.21 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 26.7 p-10 -69.54 -18.26 63.65 Favored 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.063 175.08 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.6 mt -85.12 -43.7 13.63 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 122.965 0.506 . . . . 0.0 110.582 174.596 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 155.93 -150.8 22.26 Favored Glycine 0 C--N 1.344 0.984 0 N-CA-C 111.925 -0.47 . . . . 0.0 111.925 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.408 ' N ' HD22 ' A' ' 70' ' ' ASN . 1.0 OUTLIER -79.94 126.02 30.48 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-N 117.488 0.644 . . . . 0.0 109.335 178.118 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 57.7 t -125.07 138.2 55.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 123.741 0.817 . . . . 0.0 110.638 -178.245 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.718 ' HG2' HD13 ' A' ' 88' ' ' ILE . 17.8 mmt180 -83.65 131.46 34.95 Favored 'General case' 0 N--CA 1.483 1.188 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 168.368 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.519 HG11 ' HG3' ' A' ' 77' ' ' PRO . 66.3 t -79.02 105.86 9.04 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 169.251 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 41.6 p -93.8 -30.94 14.58 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 123.392 0.677 . . . . 0.0 110.727 -171.38 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 49.0 m -96.88 178.05 5.42 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.248 177.877 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.774 ' HB2' ' HB2' ' A' ' 79' ' ' GLN . 80.2 mtp180 -74.36 124.52 89.94 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.109 170.288 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.519 ' HG3' HG11 ' A' ' 73' ' ' VAL . 32.0 Cg_exo -62.12 104.01 0.32 Allowed 'Trans proline' 0 C--N 1.373 1.841 0 C-N-CA 122.481 2.12 . . . . 0.0 111.293 173.562 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.34 24.82 17.86 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-N 116.06 -0.518 . . . . 0.0 113.347 -178.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLN . . . . . 0.774 ' HB2' ' HB2' ' A' ' 76' ' ' ARG . 24.7 tm0? -65.9 -58.65 5.09 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 176.329 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -84.12 -9.3 58.69 Favored 'General case' 0 N--CA 1.487 1.377 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.763 173.622 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 117.33 -53.14 0.65 Allowed Glycine 0 C--N 1.336 0.559 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -163.244 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 10.1 p -87.03 165.7 2.09 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.131 0 C-N-CA 123.886 0.874 . . . . 0.0 110.703 177.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 18.5 mt -96.38 148.49 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.888 0 C-N-CA 124.039 0.936 . . . . 0.0 108.605 173.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 17.4 m-80 -131.75 149.01 52.61 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 123.252 0.621 . . . . 0.0 109.699 177.356 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.45 -173.27 32.92 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 115.735 -0.666 . . . . 0.0 114.092 -174.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.6 m -129.79 141.72 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 C-N-CA 123.551 0.74 . . . . 0.0 110.107 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 20.1 tp -75.88 105.31 6.85 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 121.022 0.439 . . . . 0.0 109.924 -178.003 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.718 HD13 ' HG2' ' A' ' 72' ' ' ARG . 11.0 pt -107.21 -173.46 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 123.432 0.693 . . . . 0.0 110.222 -179.413 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 60.7 mtt85 -139.95 77.47 1.61 Allowed 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 123.146 0.578 . . . . 0.0 109.734 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.458 ' HG2' HD12 ' A' ' 88' ' ' ILE . 56.5 mm-40 -68.58 -65.51 0.69 Allowed 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 167.023 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 60.7 mt . . . . . 0 CA--C 1.549 0.927 0 CA-C-N 114.429 -1.26 . . . . 0.0 108.934 170.881 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.459 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 6.9 m . . . . . 0 N--CA 1.471 0.61 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 38.6 mmt180 -107.12 145.13 32.85 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.731 0.812 . . . . 0.0 110.362 -177.512 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.9 tt -147.41 144.34 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 C-N-CA 124.167 0.987 . . . . 0.0 109.441 175.513 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -91.59 100.85 13.52 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 173.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 62.0 t -89.56 111.03 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 123.808 0.843 . . . . 0.0 109.247 -175.923 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.502 HG22 HG22 ' A' ' 35' ' ' VAL . 41.4 t -101.45 108.72 24.12 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 C-N-CA 123.666 0.786 . . . . 0.0 109.333 -176.303 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -58.74 114.82 9.79 Favored Pre-proline 0 N--CA 1.473 0.715 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 171.67 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -78.1 -5.89 15.42 Favored 'Trans proline' 0 C--N 1.363 1.334 0 C-N-CA 122.374 2.049 . . . . 0.0 112.911 -175.571 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -95.86 -53.31 3.73 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 123.827 0.851 . . . . 0.0 111.203 -178.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 59.3 p -90.67 -30.85 16.88 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.485 0.714 . . . . 0.0 111.44 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.9 -11.54 57.52 Favored Glycine 0 C--N 1.343 0.952 0 CA-C-N 116.139 -0.482 . . . . 0.0 113.158 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -68.53 124.73 24.38 Favored 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 123.482 0.713 . . . . 0.0 111.426 -170.128 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.502 HG22 HG22 ' A' ' 28' ' ' VAL . 22.2 t -95.95 133.99 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 175.198 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -140.99 137.19 32.84 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 171.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 39.7 mt -79.82 129.5 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 178.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.29 167.71 18.05 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 123.88 0.872 . . . . 0.0 111.289 -171.678 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.459 ' HA ' ' O ' ' A' ' 23' ' ' THR . 56.0 mm-40 -104.32 118.77 37.43 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 124.441 1.096 . . . . 0.0 110.98 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.446 HG23 ' HB ' ' A' ' 64' ' ' VAL . 68.1 mt -78.85 111.4 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 122.704 0.402 . . . . 0.0 110.544 -175.764 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -82.81 -56.48 3.8 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.358 1.063 . . . . 0.0 111.623 178.558 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.587 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 33.9 t30 -106.25 133.95 50.15 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 175.709 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.432 ' HA ' HG12 ' A' ' 64' ' ' VAL . 33.6 m . . . . . 0 N--CA 1.477 0.922 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -175.544 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 64.4 mt . . . . . 0 C--O 1.242 0.696 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 57.7 mt -65.83 119.85 11.59 Favored 'Isoleucine or valine' 0 C--N 1.348 0.515 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 173.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 26.7 m -118.1 147.97 42.76 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -178.139 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 31.6 ttt-85 -60.69 134.09 56.74 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 172.599 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.57 -41.71 2.74 Favored Glycine 0 C--N 1.346 1.112 0 CA-C-O 119.892 -0.393 . . . . 0.0 112.43 -175.152 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -60.56 134.89 57.52 Favored 'General case' 0 C--N 1.357 0.896 0 C-N-CA 123.53 0.732 . . . . 0.0 110.708 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 98.2 t -73.55 120.48 22.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 O-C-N 123.722 0.639 . . . . 0.0 110.634 -178.592 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.446 ' HB ' HG23 ' A' ' 40' ' ' ILE . 26.3 m -105.41 126.89 60.54 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.294 171.167 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.587 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 33.8 tt0 -92.68 134.82 34.65 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 106.087 -1.82 . . . . 0.0 106.087 177.602 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 71.3 p -117.22 -178.59 3.48 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 -177.72 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -59.44 -23.15 62.44 Favored 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 123.057 0.543 . . . . 0.0 110.896 171.287 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 89.0 mt -88.79 -51.76 5.48 Favored 'General case' 0 C--N 1.353 0.733 0 C-N-CA 124.267 1.027 . . . . 0.0 110.018 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 164.53 -170.36 39.65 Favored Glycine 0 C--N 1.337 0.608 0 CA-C-N 115.549 -0.751 . . . . 0.0 112.155 -177.407 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.451 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 14.0 m120 -75.73 143.49 42.02 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.393 0.677 . . . . 0.0 110.772 -174.116 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.2 t -137.04 147.48 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 123.857 0.863 . . . . 0.0 110.079 -174.049 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.687 ' HG2' HD13 ' A' ' 88' ' ' ILE . 36.4 mmt180 -93.01 120.75 33.64 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 168.454 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 43.9 t -75.82 98.65 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.438 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 71.1 p -74.36 -34.52 63.4 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.715 0.806 . . . . 0.0 111.417 178.732 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' SER . . . . . 0.554 ' HB2' ' HB2' ' A' ' 84' ' ' ASN . 39.2 t -79.8 170.08 17.01 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.778 0.831 . . . . 0.0 111.581 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -82.73 106.43 6.82 Favored Pre-proline 0 CA--C 1.546 0.816 0 N-CA-C 107.246 -1.391 . . . . 0.0 107.246 166.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.404 ' HB3' HG23 ' A' ' 83' ' ' ILE . 65.9 Cg_endo -82.16 69.62 7.41 Favored 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 123.443 2.762 . . . . 0.0 112.44 -172.021 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.09 -32.15 0.1 Allowed Glycine 0 C--N 1.333 0.37 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.817 -178.129 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -64.58 111.37 2.68 Favored 'General case' 0 C--N 1.359 0.981 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 174.696 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.4 t70 76.71 -22.95 0.26 Allowed 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 125.338 1.455 . . . . 0.0 112.384 -177.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 102.55 -8.58 54.97 Favored Glycine 0 C--N 1.345 1.078 0 CA-C-O 119.932 -0.371 . . . . 0.0 112.487 -175.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -86.57 116.95 30.1 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 CA-C-O 121.641 0.734 . . . . 0.0 109.94 -179.186 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.404 HG23 ' HB3' ' A' ' 77' ' ' PRO . 38.6 mt -98.54 132.75 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 175.669 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.554 ' HB2' ' HB2' ' A' ' 75' ' ' SER . 66.3 m-20 -136.07 154.52 51.0 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 123.725 0.81 . . . . 0.0 109.03 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.438 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -168.93 -173.98 37.12 Favored Glycine 0 C--N 1.34 0.754 0 O-C-N 123.385 0.428 . . . . 0.0 113.992 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.7 m -123.47 134.24 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.075 0 C-N-CA 124.028 0.931 . . . . 0.0 110.364 177.536 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 46.7 tp -66.21 127.55 32.62 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 123.182 0.593 . . . . 0.0 111.447 -176.037 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.687 HD13 ' HG2' ' A' ' 72' ' ' ARG . 33.2 pt -126.21 -176.67 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 C-N-CA 125.189 1.396 . . . . 0.0 109.378 173.25 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 82.0 mtt85 -137.83 88.29 2.32 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 123.321 0.649 . . . . 0.0 109.923 -177.032 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -100.85 -48.22 4.54 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 123.4 0.68 . . . . 0.0 109.44 178.573 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 88.8 mt . . . . . 0 N--CA 1.476 0.855 0 C-N-CA 124.911 1.284 . . . . 0.0 109.793 -178.043 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.528 HG22 HD12 ' A' ' 40' ' ' ILE . 33.0 m . . . . . 0 N--CA 1.473 0.715 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.554 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 17.0 mtm180 -130.81 166.0 21.77 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.918 0.887 . . . . 0.0 111.497 -173.019 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 14.0 tt -150.88 150.28 13.54 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.447 -170.108 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.8 m-80 -94.08 100.39 12.51 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 175.008 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.7 t -88.7 112.39 23.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.022 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.434 HG13 HG22 ' A' ' 35' ' ' VAL . 17.3 t -101.41 100.6 10.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.437 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -178.206 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -58.38 120.39 43.93 Favored Pre-proline 0 CA--C 1.552 1.021 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 177.311 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -71.78 -15.75 29.88 Favored 'Trans proline' 0 C--N 1.366 1.469 0 C-N-CA 122.845 2.364 . . . . 0.0 113.555 -172.092 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -91.75 -52.12 4.9 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.919 0.487 . . . . 0.0 110.325 -175.735 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.3 p -88.66 -32.85 17.81 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.637 0.775 . . . . 0.0 112.375 -177.42 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.64 3.9 68.29 Favored Glycine 0 N--CA 1.479 1.559 0 CA-C-O 120.097 -0.28 . . . . 0.0 113.14 -174.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.0 mmtm -63.05 109.24 1.42 Allowed 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.753 0.821 . . . . 0.0 111.692 179.142 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.434 HG22 HG13 ' A' ' 28' ' ' VAL . 41.1 t -90.45 111.82 23.99 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 172.161 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -129.62 131.42 46.46 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.608 0.763 . . . . 0.0 110.233 -174.557 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 53.4 mt -76.26 115.23 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.426 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.75 153.81 40.38 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.946 0.898 . . . . 0.0 109.977 -174.492 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.554 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 2.7 mp0 -93.58 124.09 37.34 Favored 'General case' 0 C--O 1.244 0.79 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 -176.065 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.528 HD12 HG22 ' A' ' 23' ' ' THR . 56.0 mt -75.04 109.46 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -178.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 67.8 mtp180 -71.72 -42.62 67.12 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 124.59 1.156 . . . . 0.0 110.349 -178.173 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -159.64 170.13 22.25 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-N 114.822 -1.081 . . . . 0.0 108.646 -176.439 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.679 HG12 HG12 ' A' ' 64' ' ' VAL . 3.5 m . . . . . 0 CA--C 1.545 0.77 0 C-N-CA 124.712 1.205 . . . . 0.0 107.964 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.3 mt . . . . . 0 CA--C 1.553 1.09 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.9 mt -82.68 151.92 4.04 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.701 -179.579 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 75.8 p -128.69 170.53 13.17 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.852 0.861 . . . . 0.0 109.615 174.183 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.3 ttm180 -71.9 138.14 47.94 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 171.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.77 -14.62 51.43 Favored Glycine 0 C--N 1.343 0.97 0 C-N-CA 123.249 0.452 . . . . 0.0 113.028 -177.385 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -70.85 141.36 51.27 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 123.334 0.653 . . . . 0.0 109.486 177.194 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 77.1 t -91.16 118.42 36.39 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.81 -179.695 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.679 HG12 HG12 ' A' ' 43' ' ' VAL . 34.1 m -103.31 135.85 38.88 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.422 174.291 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -86.27 127.01 34.71 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 174.634 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 32.6 p -128.6 174.32 9.5 Favored 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.491 ' ND2' ' HB2' ' A' ' 39' ' ' GLU . 94.2 m-20 -65.03 -12.64 52.77 Favored 'General case' 0 N--CA 1.482 1.128 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 178.775 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.1 mt -95.6 -47.89 6.04 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 176.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 167.57 -161.96 35.76 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.828 178.833 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -75.12 142.69 43.58 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.189 0.596 . . . . 0.0 110.015 175.761 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.0 t -135.88 146.45 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.268 0 C-N-CA 123.155 0.582 . . . . 0.0 110.111 -174.801 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.65 ' HG2' HD13 ' A' ' 88' ' ' ILE . 33.7 mmt180 -91.65 119.7 31.77 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 171.446 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.2 t -73.36 122.62 26.64 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.2 p -108.56 -32.67 7.29 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.536 0.735 . . . . 0.0 110.26 -172.814 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.6 t -97.73 -178.77 4.22 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.62 0.768 . . . . 0.0 110.147 178.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.44 128.92 73.65 Favored Pre-proline 0 CA--C 1.552 1.033 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 174.462 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -68.66 103.66 1.02 Allowed 'Trans proline' 0 C--N 1.373 1.843 0 C-N-CA 123.024 2.483 . . . . 0.0 113.837 -173.092 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 73.37 -0.78 46.57 Favored Glycine 0 C--N 1.344 1.004 0 CA-C-N 115.217 -0.901 . . . . 0.0 114.961 171.128 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 31.8 mm-40 -67.81 -43.51 79.49 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 123.28 0.632 . . . . 0.0 111.689 -172.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.539 ' HB3' HG12 ' A' ' 82' ' ' VAL . 24.6 t70 -89.06 3.68 50.9 Favored 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 123.618 0.767 . . . . 0.0 110.75 175.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 81.42 37.16 18.37 Favored Glycine 0 C--N 1.343 0.933 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -171.375 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.539 HG12 ' HB3' ' A' ' 80' ' ' ASP . 13.3 p -162.28 140.54 2.26 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 CA-C-N 114.541 -0.83 . . . . 0.0 109.809 -174.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.4 mt -121.61 128.8 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 N-CA-C 104.904 -2.258 . . . . 0.0 104.904 165.568 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -120.81 153.35 37.21 Favored 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -172.7 179.66 44.06 Favored Glycine 0 N--CA 1.446 -0.643 0 O-C-N 123.99 0.806 . . . . 0.0 113.588 175.385 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.1 m -123.36 136.16 60.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 124.05 0.94 . . . . 0.0 110.007 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 27.0 tp -66.56 134.16 51.81 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 123.011 0.524 . . . . 0.0 111.133 -174.338 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.65 HD13 ' HG2' ' A' ' 72' ' ' ARG . 34.1 pt -135.06 175.1 11.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.785 1.234 . . . . 0.0 109.59 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 39.1 mtt180 -130.88 84.15 2.17 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.451 0.7 . . . . 0.0 109.284 -176.185 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.8 mm-40 -95.8 -77.05 0.48 Allowed 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.145 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 77.4 mt . . . . . 0 C--O 1.238 0.486 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 169.096 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 26.3 m . . . . . 0 CA--C 1.543 0.706 0 CA-C-O 120.807 0.337 . . . . 0.0 110.35 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 17.3 tpp85 -110.22 141.48 43.1 Favored 'General case' 0 C--O 1.241 0.637 0 C-N-CA 123.561 0.745 . . . . 0.0 110.446 -171.908 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 16.2 tt -139.94 147.41 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.953 0.901 . . . . 0.0 109.506 178.109 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -97.59 102.38 14.13 Favored 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 170.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.537 HG22 HG21 ' A' ' 71' ' ' VAL . 96.5 t -82.91 106.14 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 C-N-CA 123.957 0.903 . . . . 0.0 109.698 -177.287 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 86' ' ' VAL . 40.0 t -97.21 102.86 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.24 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -56.1 116.59 12.86 Favored Pre-proline 0 CA--C 1.549 0.923 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 173.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -72.91 -19.48 23.39 Favored 'Trans proline' 0 C--N 1.368 1.556 0 C-N-CA 122.332 2.022 . . . . 0.0 113.378 -172.686 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -81.88 -51.21 8.32 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 123.264 0.626 . . . . 0.0 110.465 -175.181 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.7 p -92.31 -25.78 18.42 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.876 0.87 . . . . 0.0 111.446 -177.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.2 4.65 71.18 Favored Glycine 0 N--CA 1.473 1.113 0 CA-C-O 119.597 -0.557 . . . . 0.0 113.119 -178.634 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -72.08 112.68 8.37 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.157 0.583 . . . . 0.0 111.811 -173.216 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.451 HG22 HG22 ' A' ' 28' ' ' VAL . 39.1 t -82.6 115.18 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 171.503 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -130.79 130.0 43.13 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.96 0.904 . . . . 0.0 109.123 -179.817 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 59.4 mt -78.93 125.61 38.42 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 C-N-CA 122.91 0.484 . . . . 0.0 110.139 -177.319 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -134.17 170.99 14.86 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 124.575 1.15 . . . . 0.0 110.02 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -117.79 135.73 53.87 Favored 'General case' 0 C--O 1.243 0.748 0 C-N-CA 123.329 0.652 . . . . 0.0 109.547 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.1 mt -78.51 112.35 16.43 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.726 0 O-C-N 123.893 0.746 . . . . 0.0 110.311 -175.817 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 72.6 mtp180 -64.69 -53.93 39.6 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.842 1.257 . . . . 0.0 110.365 175.417 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 55.5 t30 -143.75 157.65 44.24 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.522 0.729 . . . . 0.0 109.535 -176.209 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 55.3 t . . . . . 0 N--CA 1.485 1.311 0 C-N-CA 122.925 0.49 . . . . 0.0 110.374 179.134 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.4 HG22 HG23 ' A' ' 59' ' ' THR . 41.1 mm . . . . . 0 C--O 1.241 0.63 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.4 mt -72.71 118.26 17.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 CA-C-N 114.726 -1.125 . . . . 0.0 108.222 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.4 HG23 HG22 ' A' ' 57' ' ' ILE . 7.5 p -131.61 170.46 14.73 Favored 'General case' 0 C--O 1.243 0.726 0 C-N-CA 124.872 1.269 . . . . 0.0 108.952 -175.366 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -69.52 130.79 43.43 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 177.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.95 -15.34 63.62 Favored Glycine 0 C--N 1.345 1.029 0 CA-C-O 119.48 -0.622 . . . . 0.0 113.531 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.62 134.3 49.74 Favored 'General case' 0 C--O 1.246 0.878 0 C-N-CA 122.957 0.503 . . . . 0.0 110.342 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 67.1 t -88.55 112.88 24.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 176.291 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.3 m -102.94 138.56 26.73 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -88.11 126.45 35.12 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 61.3 p -134.0 172.49 12.75 Favored 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 124.097 0.959 . . . . 0.0 109.091 -175.725 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -71.88 -13.12 61.57 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 112.331 0.493 . . . . 0.0 112.331 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 88.5 mt -97.12 -15.34 21.0 Favored 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 123.3 0.64 . . . . 0.0 111.336 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.09 -147.88 19.52 Favored Glycine 0 C--N 1.341 0.848 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 -173.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -109.75 143.0 40.17 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 117.486 0.643 . . . . 0.0 109.404 177.823 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.537 HG21 HG22 ' A' ' 27' ' ' VAL . 22.0 t -128.73 144.96 36.42 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 123.425 0.69 . . . . 0.0 109.862 -174.345 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.632 ' HG2' HD13 ' A' ' 88' ' ' ILE . 10.5 mmt180 -94.94 123.71 38.56 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 168.295 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 56.9 t -76.22 94.92 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.4 p -85.15 -39.84 17.42 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.307 0.643 . . . . 0.0 111.109 -178.237 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.4 m -77.65 164.55 25.22 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.911 173.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 24.3 mmt180 -65.88 130.23 94.41 Favored Pre-proline 0 CA--C 1.548 0.87 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 172.339 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -77.62 43.16 1.29 Allowed 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 123.502 2.801 . . . . 0.0 112.387 175.586 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -170.95 -137.3 2.27 Favored Glycine 0 C--N 1.334 0.461 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -172.383 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 21.2 tm0? 67.88 -72.33 0.1 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 124.608 1.163 . . . . 0.0 110.136 -177.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.425 ' HB3' HG12 ' A' ' 82' ' ' VAL . 33.3 t70 -91.45 -12.93 33.25 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 124.211 1.004 . . . . 0.0 110.31 171.106 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 94.56 -6.49 70.9 Favored Glycine 0 C--N 1.343 0.968 0 C-N-CA 123.386 0.517 . . . . 0.0 112.981 -174.06 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.425 HG12 ' HB3' ' A' ' 80' ' ' ASP . 14.5 p -92.83 141.42 14.68 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.512 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 31.5 mt -96.09 146.87 6.58 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -152.66 152.07 31.33 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -169.0 -167.34 29.48 Favored Glycine 0 C--N 1.343 0.972 0 CA-C-O 120.015 -0.325 . . . . 0.0 113.028 -178.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.509 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 35.9 m -116.46 132.68 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 123.776 0.83 . . . . 0.0 110.925 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 38.8 tp -71.63 106.07 3.91 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.463 0.705 . . . . 0.0 111.13 -176.457 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.632 HD13 ' HG2' ' A' ' 72' ' ' ARG . 41.4 pt -97.34 171.65 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.524 0.73 . . . . 0.0 110.262 175.252 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 16.7 mmt180 -115.22 21.15 14.4 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.671 0.788 . . . . 0.0 110.235 -173.108 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.449 ' HB2' HD12 ' A' ' 88' ' ' ILE . 33.9 tt0 -64.8 -75.9 0.08 Allowed 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.433 0.693 . . . . 0.0 112.657 -164.343 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 58.3 mt . . . . . 0 N--CA 1.482 1.16 0 CA-C-O 121.834 0.826 . . . . 0.0 110.316 -173.446 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 26.2 m . . . . . 0 CA--C 1.537 0.455 0 CA-C-O 120.547 0.213 . . . . 0.0 110.694 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.429 ' HD2' HG22 ' A' ' 37' ' ' ILE . 77.3 mmt-85 -102.21 134.8 44.89 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.42 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 14.2 tt -140.18 136.11 37.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 123.85 0.86 . . . . 0.0 109.745 -175.771 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.2 m-80 -85.55 100.59 12.02 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 177.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.2 t -87.4 108.23 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -176.313 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 40.9 t -95.54 101.67 12.7 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -63.83 116.43 26.69 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 175.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -71.47 -19.76 28.17 Favored 'Trans proline' 0 C--N 1.368 1.559 0 C-N-CA 123.232 2.621 . . . . 0.0 113.194 -171.77 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -92.67 -52.94 4.39 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 123.499 0.72 . . . . 0.0 110.822 -171.423 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 62.8 p -90.9 -27.83 18.5 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 123.424 0.69 . . . . 0.0 111.476 -177.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.62 4.73 69.87 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-N 116.416 -0.356 . . . . 0.0 113.369 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -71.45 118.74 14.65 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 123.293 0.637 . . . . 0.0 110.818 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.4 t -108.33 134.84 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 123.679 0.792 . . . . 0.0 108.908 177.255 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -152.22 148.81 28.02 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 122.87 0.468 . . . . 0.0 110.357 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.429 HG22 ' HD2' ' A' ' 24' ' ' ARG . 51.6 mt -87.12 98.31 7.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.89 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.21 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -95.87 172.21 8.16 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 124.282 1.033 . . . . 0.0 110.646 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -108.26 131.99 54.13 Favored 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 176.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.495 HG12 HG22 ' A' ' 66' ' ' THR . 57.1 mt -75.27 112.66 13.1 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 177.697 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 40.4 mtt-85 -73.11 -52.9 12.52 Favored 'General case' 0 N--CA 1.475 0.825 0 CA-C-O 122.253 1.025 . . . . 0.0 109.418 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.613 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 29.8 t30 -126.04 112.3 15.71 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 113.365 -1.743 . . . . 0.0 108.73 -169.663 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.8 m . . . . . 0 N--CA 1.478 0.933 0 C-N-CA 123.175 0.59 . . . . 0.0 111.282 -179.013 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.1 mt . . . . . 0 CA--C 1.535 0.366 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.403 ' O ' ' HG3' ' A' ' 77' ' ' PRO . 82.9 mt -93.75 128.68 44.97 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.379 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 38.1 p -126.3 164.29 21.37 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.569 0.748 . . . . 0.0 109.657 -177.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 45.2 ttp180 -73.47 141.41 46.83 Favored 'General case' 0 N--CA 1.482 1.138 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 176.504 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.88 2.57 90.33 Favored Glycine 0 C--N 1.345 1.06 0 O-C-N 123.198 0.311 . . . . 0.0 112.971 -176.338 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.0 163.12 16.46 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 123.525 0.73 . . . . 0.0 110.774 179.285 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 38.8 t -110.01 124.85 67.09 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 173.319 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 20.9 m -112.88 168.45 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 168.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.613 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 28.0 tt0 -115.19 134.33 55.24 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 170.711 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.495 HG22 HG12 ' A' ' 40' ' ' ILE . 43.8 p -123.87 -177.77 3.85 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.843 0.857 . . . . 0.0 109.551 -173.611 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.8 m-20 -58.38 -28.72 65.42 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 122.933 0.493 . . . . 0.0 111.318 175.402 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 77.8 mt -90.07 -45.71 8.97 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.258 0.623 . . . . 0.0 110.748 -178.668 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 165.66 -166.04 38.29 Favored Glycine 0 N--CA 1.477 1.416 0 CA-C-O 119.715 -0.492 . . . . 0.0 112.093 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 65.6 m-80 -73.26 132.98 43.78 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 117.653 0.727 . . . . 0.0 109.843 176.609 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 65.2 t -128.74 144.89 36.67 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.905 0 C-N-CA 124.402 1.081 . . . . 0.0 110.29 -174.006 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.553 ' HG2' HG21 ' A' ' 88' ' ' ILE . 33.2 mmt180 -84.98 121.25 27.51 Favored 'General case' 0 N--CA 1.479 1.017 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 168.309 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.5 t -73.21 122.88 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.063 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 70.9 p -107.72 -23.9 11.92 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 123.179 0.592 . . . . 0.0 110.999 -176.129 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 45.7 m -93.05 176.92 6.23 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-O 121.309 0.576 . . . . 0.0 111.751 176.645 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 30.8 mmt180 -106.65 127.09 28.8 Favored Pre-proline 0 C--O 1.241 0.635 0 CA-C-N 114.839 -1.073 . . . . 0.0 108.404 171.159 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.403 ' HG3' ' O ' ' A' ' 58' ' ' ILE . 37.1 Cg_endo -60.24 120.24 7.89 Favored 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 123.228 2.619 . . . . 0.0 112.474 -176.54 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 91.38 -36.68 3.56 Favored Glycine 0 C--N 1.341 0.824 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.994 176.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 14.3 mm100 -64.24 -31.81 73.15 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.691 0.796 . . . . 0.0 111.836 -174.316 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -106.24 6.23 30.55 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.718 0.807 . . . . 0.0 111.566 178.639 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 85.57 -61.32 4.59 Favored Glycine 0 C--N 1.349 1.276 0 C-N-CA 123.086 0.374 . . . . 0.0 112.273 -175.467 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -113.26 159.52 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 124.467 1.107 . . . . 0.0 108.793 175.757 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 25' ' ' ILE . 41.1 mt -92.52 147.68 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 174.443 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -125.37 162.98 23.58 Favored 'General case' 0 C--O 1.246 0.888 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 171.577 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.28 179.38 41.41 Favored Glycine 0 C--N 1.335 0.519 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.952 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.2 m -121.42 131.0 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 C-N-CA 123.433 0.693 . . . . 0.0 109.437 175.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 21.4 tp -67.26 131.27 45.42 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.132 0.573 . . . . 0.0 110.006 -177.028 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.553 HG21 ' HG2' ' A' ' 72' ' ' ARG . 33.4 pt -123.15 161.12 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 121.665 0.745 . . . . 0.0 111.276 -176.647 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 26.5 mmt180 -115.94 8.29 14.63 Favored 'General case' 0 CA--C 1.548 0.884 0 CA-C-N 114.195 -1.366 . . . . 0.0 109.636 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -60.28 -62.14 2.09 Favored 'General case' 0 C--N 1.358 0.951 0 C-N-CA 123.959 0.904 . . . . 0.0 112.237 -172.445 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 22.4 mt . . . . . 0 N--CA 1.473 0.721 0 O-C-N 123.364 0.415 . . . . 0.0 111.035 -179.031 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.44 HG22 HD12 ' A' ' 40' ' ' ILE . 91.4 m . . . . . 0 CA--C 1.548 0.868 0 CA-C-O 121.624 0.726 . . . . 0.0 111.177 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.518 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 36.8 mtm180 -127.23 170.1 12.79 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.835 1.254 . . . . 0.0 110.81 177.276 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.1 tt -135.7 136.21 50.51 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-N 114.566 -1.197 . . . . 0.0 108.95 -179.226 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ASN . . . . . 0.437 ' HB2' HD22 ' A' ' 84' ' ' ASN . 71.1 m-20 -89.78 102.1 14.8 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 177.825 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.44 HG22 HG11 ' A' ' 71' ' ' VAL . 58.5 t -98.78 136.38 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 123.873 0.869 . . . . 0.0 110.563 -170.006 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.58 HG22 HG22 ' A' ' 35' ' ' VAL . 30.1 t -122.0 122.29 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -63.98 124.43 85.15 Favored Pre-proline 0 N--CA 1.48 1.027 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 171.098 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -68.79 -20.0 40.31 Favored 'Trans proline' 0 CA--C 1.554 1.488 0 C-N-CA 122.145 1.897 . . . . 0.0 112.476 178.67 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.465 ' HG3' HG23 ' A' ' 32' ' ' THR . 12.8 pt-20 -88.2 -51.35 5.82 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.02 0.928 . . . . 0.0 112.115 -176.794 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.465 HG23 ' HG3' ' A' ' 31' ' ' GLU . 70.4 p -97.87 -21.49 16.87 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.125 0.57 . . . . 0.0 111.792 -173.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.8 5.28 89.54 Favored Glycine 0 C--N 1.349 1.269 0 CA-C-O 119.682 -0.51 . . . . 0.0 113.524 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -73.68 123.89 24.94 Favored 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 123.27 0.628 . . . . 0.0 111.352 -174.364 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.58 HG22 HG22 ' A' ' 28' ' ' VAL . 24.8 t -95.73 128.86 46.55 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.712 0 C-N-CA 123.872 0.869 . . . . 0.0 109.422 176.126 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -141.42 133.8 28.18 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 124.483 1.113 . . . . 0.0 108.574 175.656 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 46.6 mt -79.32 98.92 3.14 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.46 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -86.02 158.93 19.73 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.703 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.518 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 38.9 mt-10 -101.82 124.95 48.31 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.48 0.712 . . . . 0.0 109.433 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.44 HD12 HG22 ' A' ' 23' ' ' THR . 61.7 mt -76.44 108.69 9.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 47.8 mtt180 -82.87 -53.26 6.0 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.261 1.024 . . . . 0.0 110.672 -179.389 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -146.04 160.07 42.39 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -176.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.9 m . . . . . 0 C--O 1.246 0.877 0 C-N-CA 123.523 0.729 . . . . 0.0 112.03 -174.313 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 72.9 mt . . . . . 0 N--CA 1.472 0.646 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.2 mt -115.29 140.45 36.64 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.558 0 C-N-CA 124.488 1.115 . . . . 0.0 108.434 179.6 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 33.9 p -126.15 174.4 8.52 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 124.134 0.974 . . . . 0.0 109.149 178.484 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 52.7 ttp180 -71.25 139.92 50.21 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 122.716 0.406 . . . . 0.0 110.154 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.76 -8.48 70.94 Favored Glycine 0 C--N 1.337 0.595 0 C-N-CA 123.644 0.64 . . . . 0.0 112.83 -177.16 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.94 134.54 52.21 Favored 'General case' 0 C--N 1.351 0.669 0 C-N-CA 123.611 0.765 . . . . 0.0 111.89 -177.008 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 44.1 t -90.76 112.87 25.69 Favored 'Isoleucine or valine' 0 C--N 1.344 0.341 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 169.624 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.6 m -106.26 147.13 12.07 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 123.482 0.713 . . . . 0.0 109.271 177.264 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -90.73 126.44 36.0 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 175.475 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.46 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 67.2 p -130.85 179.79 5.77 Favored 'General case' 0 C--O 1.239 0.552 0 C-N-CA 123.259 0.623 . . . . 0.0 109.774 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 19.2 p-10 -73.59 -14.69 61.23 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 123.341 0.656 . . . . 0.0 111.192 175.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.1 mt -91.16 -41.09 11.21 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 123.249 0.62 . . . . 0.0 110.325 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 155.79 -149.97 21.2 Favored Glycine 0 C--N 1.345 1.074 0 CA-C-N 116.239 -0.437 . . . . 0.0 112.056 175.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -78.91 128.49 33.38 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 173.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.44 HG11 HG22 ' A' ' 27' ' ' VAL . 48.7 t -126.85 140.33 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 122.792 0.437 . . . . 0.0 110.4 -178.42 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.743 ' HG2' HD13 ' A' ' 88' ' ' ILE . 29.2 mmt180 -88.89 131.5 35.09 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 169.461 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 82.2 t -76.87 106.72 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 171.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 40.5 p -96.38 -19.92 18.85 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.044 0.538 . . . . 0.0 110.92 -172.711 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' SER . . . . . 0.509 ' HB2' ' HB2' ' A' ' 84' ' ' ASN . 32.4 t -87.49 171.08 10.79 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.378 0.671 . . . . 0.0 110.391 175.32 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 -93.48 92.84 0.72 Allowed Pre-proline 0 CA--C 1.559 1.315 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 173.413 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -62.73 -46.36 11.41 Favored 'Trans proline' 0 C--N 1.384 2.422 0 C-N-CA 123.431 2.754 . . . . 0.0 113.958 -163.445 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -81.19 -13.5 80.71 Favored Glycine 0 C--N 1.345 1.039 0 CA-C-O 119.959 -0.356 . . . . 0.0 113.54 -177.201 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 18.5 mm-40 -90.14 -48.39 7.21 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 122.981 0.513 . . . . 0.0 111.352 -178.271 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -80.67 -14.05 58.48 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 122.82 0.448 . . . . 0.0 111.294 174.364 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 68.36 18.53 71.6 Favored Glycine 0 C--N 1.349 1.254 0 O-C-N 123.205 0.316 . . . . 0.0 112.785 -175.307 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 11.6 p -143.25 143.87 24.3 Favored 'Isoleucine or valine' 0 C--O 1.24 0.555 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 178.211 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 29.0 mt -106.37 117.63 52.5 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -176.745 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.509 ' HB2' ' HB2' ' A' ' 75' ' ' SER . 9.4 m120 -124.7 151.4 45.04 Favored 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.585 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.9 -178.26 34.72 Favored Glycine 0 C--N 1.339 0.733 0 N-CA-C 115.141 0.816 . . . . 0.0 115.141 -174.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.402 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 30.0 m -121.51 139.5 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.637 0.775 . . . . 0.0 110.147 175.699 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.3 tp -74.03 122.23 22.32 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.093 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.743 HD13 ' HG2' ' A' ' 72' ' ' ARG . 46.8 pt -124.06 -177.89 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 124.615 1.166 . . . . 0.0 109.198 175.208 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 29.5 mmm180 -139.45 90.67 2.43 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -176.623 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -88.95 -50.07 6.4 Favored 'General case' 0 N--CA 1.484 1.229 0 CA-C-O 121.496 0.665 . . . . 0.0 109.629 178.513 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 69.1 mt . . . . . 0 C--O 1.245 0.843 0 CA-C-N 114.508 -1.224 . . . . 0.0 109.735 176.402 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 52.8 m . . . . . 0 N--CA 1.47 0.557 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.1 mmt180 -117.74 152.81 34.52 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-O 121.469 0.652 . . . . 0.0 111.599 -173.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.511 ' HB ' HD11 ' A' ' 40' ' ' ILE . 15.8 tt -141.96 142.18 28.3 Favored 'Isoleucine or valine' 0 C--O 1.241 0.643 0 CA-C-N 114.139 -1.391 . . . . 0.0 109.054 176.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -90.82 100.82 13.61 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 173.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.6 t -86.17 112.85 23.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.538 0 C-N-CA 124.623 1.169 . . . . 0.0 109.205 -175.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.405 HG22 HG22 ' A' ' 35' ' ' VAL . 41.5 t -94.81 100.33 10.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.549 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 176.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -64.16 113.65 11.07 Favored Pre-proline 0 CA--C 1.546 0.821 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 172.272 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.52 -1.18 11.38 Favored 'Trans proline' 0 C--N 1.364 1.378 0 C-N-CA 122.518 2.146 . . . . 0.0 113.591 -172.343 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -91.97 -52.68 4.6 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.337 0.655 . . . . 0.0 109.325 -177.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 66.7 p -93.29 -32.58 14.26 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 124.468 1.107 . . . . 0.0 111.909 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 93.51 6.98 62.17 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.986 -173.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -69.89 107.77 3.7 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 123.08 0.552 . . . . 0.0 110.994 -178.022 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.405 HG22 HG22 ' A' ' 28' ' ' VAL . 23.6 t -90.9 119.92 38.91 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 172.597 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -142.52 143.48 32.54 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 122.993 0.517 . . . . 0.0 110.466 -174.302 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 62.1 mt -77.45 123.85 34.82 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.86 0 C-N-CA 123.555 0.742 . . . . 0.0 109.661 179.068 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.41 158.12 36.8 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 123.89 0.876 . . . . 0.0 110.149 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -97.74 121.05 39.19 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.511 HD11 ' HB ' ' A' ' 25' ' ' ILE . 54.7 mt -77.74 112.55 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 72.3 mtm180 -80.71 -38.21 29.24 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 124.512 1.125 . . . . 0.0 111.113 -178.098 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 47.4 t-20 -140.76 138.95 34.51 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.7 m . . . . . 0 N--CA 1.478 0.969 0 C-N-CA 123.324 0.65 . . . . 0.0 112.425 -176.584 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 15.8 tt . . . . . 0 N--CA 1.476 0.864 0 CA-C-O 121.268 0.556 . . . . 0.0 109.703 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 76.3 mt -91.58 143.56 11.02 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.698 0 C-N-CA 124.426 1.09 . . . . 0.0 109.723 175.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.46 HG23 ' HB2' ' A' ' 62' ' ' ALA . 3.3 t -131.32 172.16 12.49 Favored 'General case' 0 C--O 1.244 0.766 0 C-N-CA 123.915 0.886 . . . . 0.0 109.261 177.509 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 25.3 ttm180 -74.03 133.79 42.97 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -178.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.88 -2.83 82.36 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.956 -0.358 . . . . 0.0 112.924 -176.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.46 ' HB2' HG23 ' A' ' 59' ' ' THR . . . -77.6 132.06 38.1 Favored 'General case' 0 C--O 1.244 0.796 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 176.709 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.601 HG21 ' HG3' ' A' ' 90' ' ' GLU . 21.9 t -83.18 114.08 23.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 177.509 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 33.4 m -101.57 146.45 9.85 Favored 'Isoleucine or valine' 0 C--O 1.244 0.793 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 177.475 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.8 tp10 -95.83 128.24 42.54 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.354 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 63.2 p -124.86 177.86 5.8 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 24.0 p-10 -72.42 -12.26 61.03 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 122.794 0.438 . . . . 0.0 110.743 175.372 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.3 mt -93.41 -49.77 5.77 Favored 'General case' 0 C--N 1.357 0.918 0 C-N-CA 123.079 0.551 . . . . 0.0 110.425 175.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 168.73 -150.66 16.33 Favored Glycine 0 C--N 1.348 1.21 0 O-C-N 123.177 0.298 . . . . 0.0 113.253 178.585 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -88.23 118.09 27.59 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 123.836 0.854 . . . . 0.0 109.122 -178.688 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.2 t -121.27 144.86 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 C-N-CA 123.467 0.707 . . . . 0.0 109.4 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.497 ' HG3' HD13 ' A' ' 88' ' ' ILE . 24.4 mtt180 -109.66 131.91 54.63 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 171.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.1 t -80.36 98.99 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 O-C-N 124.172 0.92 . . . . 0.0 109.243 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 35.5 p -74.48 -28.59 61.08 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.792 0.837 . . . . 0.0 111.781 177.693 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.1 m -90.58 -170.78 2.83 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.921 177.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.412 ' HD2' ' N ' ' A' ' 76' ' ' ARG . 8.4 mpt_? -96.54 112.15 59.23 Favored Pre-proline 0 CA--C 1.545 0.784 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.301 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -62.37 96.02 0.15 Allowed 'Trans proline' 0 C--N 1.377 2.03 0 C-N-CA 123.148 2.565 . . . . 0.0 112.837 -172.11 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.77 -23.45 32.5 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.69 -0.686 . . . . 0.0 113.999 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -72.97 -30.43 63.83 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-N 117.956 0.878 . . . . 0.0 110.491 175.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -77.04 4.33 10.37 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 123.569 0.748 . . . . 0.0 111.287 171.038 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 90.62 -33.95 4.39 Favored Glycine 0 C--N 1.356 1.682 0 N-CA-C 111.596 -0.602 . . . . 0.0 111.596 -172.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.0 p -140.2 164.27 22.75 Favored 'Isoleucine or valine' 0 C--O 1.243 0.751 0 C-N-CA 124.729 1.212 . . . . 0.0 108.395 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 45.2 mt -84.5 132.88 30.53 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 173.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -133.66 144.66 49.34 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 -177.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -171.73 -172.74 38.02 Favored Glycine 0 C--N 1.342 0.901 0 N-CA-C 114.825 0.69 . . . . 0.0 114.825 -177.477 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 16.5 m -119.28 137.38 53.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 C-N-CA 123.943 0.897 . . . . 0.0 110.357 -176.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 41.8 tp -74.08 109.35 7.51 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 122.632 0.373 . . . . 0.0 110.438 -179.118 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.497 HD13 ' HG3' ' A' ' 72' ' ' ARG . 31.6 pt -102.52 179.6 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.83 0 C-N-CA 123.802 0.841 . . . . 0.0 109.865 174.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 5.0 mpt_? -125.76 55.96 1.42 Allowed 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.601 ' HG3' HG21 ' A' ' 63' ' ' VAL . 0.8 OUTLIER -60.47 -57.84 11.02 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 -179.967 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 74.9 mt . . . . . 0 CA--C 1.545 0.77 0 CA-C-N 114.7 -1.136 . . . . 0.0 107.946 169.974 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.539 HG22 HD12 ' A' ' 40' ' ' ILE . 52.4 m . . . . . 0 CA--C 1.537 0.448 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -127.18 158.82 36.08 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.543 0.737 . . . . 0.0 111.516 -175.465 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.479 ' HB ' HD11 ' A' ' 40' ' ' ILE . 16.1 tt -145.6 148.75 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.731 0.813 . . . . 0.0 110.395 -171.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 37.7 m-80 -89.32 103.6 16.22 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 172.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 75.8 t -89.39 109.82 20.84 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 C-N-CA 123.932 0.893 . . . . 0.0 109.053 -176.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 37.0 t -100.01 110.05 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 123.199 0.6 . . . . 0.0 109.654 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -59.2 112.68 5.48 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 170.338 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.2 -16.97 19.48 Favored 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 121.926 1.751 . . . . 0.0 111.747 179.104 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -94.37 -45.18 7.57 Favored 'General case' 0 CA--C 1.552 1.032 0 C-N-CA 124.344 1.058 . . . . 0.0 111.184 178.073 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.6 m -90.2 -20.01 23.54 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 123.362 0.665 . . . . 0.0 112.02 -175.14 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.17 -11.52 57.54 Favored Glycine 0 C--N 1.35 1.317 0 C-N-CA 123.422 0.534 . . . . 0.0 114.223 178.319 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -75.39 150.59 38.32 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.814 0.846 . . . . 0.0 112.132 -173.821 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 21.1 t -126.12 133.83 67.94 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.797 0.839 . . . . 0.0 108.774 174.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -147.61 141.3 25.61 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.611 0.764 . . . . 0.0 109.537 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 47.5 mt -81.92 122.87 37.43 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.8 0 N-CA-C 108.264 -1.014 . . . . 0.0 108.264 178.322 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.35 161.41 27.88 Favored 'General case' 0 C--O 1.236 0.382 0 C-N-CA 124.796 1.238 . . . . 0.0 109.517 -174.051 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -106.43 123.7 48.47 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -175.543 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.539 HD12 HG22 ' A' ' 23' ' ' THR . 59.5 mt -76.41 113.29 15.23 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 123.388 0.675 . . . . 0.0 109.955 -176.259 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -77.4 -53.29 7.83 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.634 1.174 . . . . 0.0 110.264 -178.183 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -140.23 166.61 24.22 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 124.158 0.983 . . . . 0.0 108.704 178.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 43.9 t . . . . . 0 N--CA 1.475 0.787 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 167.997 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 49.4 mm . . . . . 0 N--CA 1.484 1.255 0 CA-C-O 122.566 1.174 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 37.1 mt -83.23 144.4 10.14 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 113.962 -1.472 . . . . 0.0 109.595 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 17.5 p -122.82 167.94 12.89 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.051 0.941 . . . . 0.0 109.052 173.05 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 35.7 ttt180 -74.16 131.38 41.22 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 175.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.94 9.4 77.52 Favored Glycine 0 N--CA 1.465 0.613 0 O-C-N 124.076 0.86 . . . . 0.0 112.843 -175.386 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -83.16 160.95 21.73 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.145 0.578 . . . . 0.0 109.603 176.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.7 t -105.99 120.9 57.67 Favored 'Isoleucine or valine' 0 C--O 1.243 0.748 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 172.325 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.4 m -106.5 159.55 6.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.228 175.335 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -106.85 130.08 54.59 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 173.61 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.421 HG22 HG12 ' A' ' 40' ' ' ILE . 34.0 p -129.61 -175.18 3.51 Favored 'General case' 0 C--O 1.24 0.556 0 C-N-CA 123.241 0.616 . . . . 0.0 109.813 -176.06 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 73.3 m-20 -70.28 -19.26 63.11 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 123.134 0.574 . . . . 0.0 111.024 175.02 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 93.8 mt -99.45 -13.73 19.41 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.907 0.883 . . . . 0.0 111.755 -178.079 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.45 -164.16 22.42 Favored Glycine 0 C--N 1.35 1.32 0 O-C-N 123.349 0.406 . . . . 0.0 112.528 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -80.09 130.45 35.26 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.142 0.577 . . . . 0.0 110.394 177.76 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.6 t -125.5 138.9 52.93 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 C-N-CA 124.468 1.107 . . . . 0.0 110.663 -173.177 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.829 ' HG2' HD13 ' A' ' 88' ' ' ILE . 9.5 mmt180 -86.4 121.03 28.38 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 169.374 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 48.9 t -72.98 116.75 15.6 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.768 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.599 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 43.8 p -96.97 -24.58 15.75 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.456 0.702 . . . . 0.0 111.238 -172.757 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 23.3 t -108.55 178.5 4.47 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.533 0.733 . . . . 0.0 109.84 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 85.8 mtm180 -90.62 106.69 16.18 Favored Pre-proline 0 CA--C 1.552 1.049 0 C-N-CA 123.383 0.673 . . . . 0.0 109.976 -177.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -66.22 114.44 3.03 Favored 'Trans proline' 0 C--N 1.373 1.835 0 C-N-CA 123.101 2.534 . . . . 0.0 112.357 -175.356 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 141.94 -29.88 2.18 Favored Glycine 0 C--N 1.344 0.981 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.339 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -60.84 110.73 1.4 Allowed 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.342 0.657 . . . . 0.0 110.49 178.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.506 ' HB2' HG12 ' A' ' 82' ' ' VAL . 26.8 m-20 70.26 -15.79 0.33 Allowed 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 125.66 1.584 . . . . 0.0 114.04 178.565 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 98.05 12.52 45.84 Favored Glycine 0 C--N 1.342 0.907 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -169.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 80' ' ' ASP . 3.7 p -111.32 118.59 57.81 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 C-N-CA 123.603 0.761 . . . . 0.0 109.573 175.085 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.2 mt -98.24 148.03 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 170.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -135.16 149.14 49.91 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 122.937 0.495 . . . . 0.0 109.819 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.25 -175.54 37.97 Favored Glycine 0 C--N 1.346 1.102 0 O-C-N 123.648 0.592 . . . . 0.0 113.482 -176.597 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.2 m -129.1 138.7 53.8 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 C-N-CA 124.248 1.019 . . . . 0.0 110.42 178.493 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.6 tp -73.86 122.73 22.96 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 121.094 0.473 . . . . 0.0 111.271 -175.333 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.829 HD13 ' HG2' ' A' ' 72' ' ' ARG . 40.1 pt -119.17 -179.65 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 123.884 0.874 . . . . 0.0 109.623 175.738 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 57.4 mtt180 -122.79 83.29 2.1 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 -176.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 36.2 mm-40 -93.2 -80.91 0.37 Allowed 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 175.087 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 50.8 mt . . . . . 0 C--N 1.344 0.327 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -175.435 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.495 HG22 HD12 ' A' ' 40' ' ' ILE . 62.9 m . . . . . 0 N--CA 1.473 0.723 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 41.8 mtt180 -115.01 163.6 15.36 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.732 0.813 . . . . 0.0 110.519 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.493 ' HB ' HD11 ' A' ' 40' ' ' ILE . 16.6 tt -141.75 135.49 30.03 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 124.025 0.93 . . . . 0.0 108.802 175.666 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -85.67 103.27 14.33 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 177.154 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -92.08 133.27 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 123.802 0.841 . . . . 0.0 109.886 -171.495 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 46.7 t -109.8 109.81 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 178.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -66.61 119.07 60.24 Favored Pre-proline 0 CA--C 1.545 0.78 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 176.184 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -66.11 -33.84 39.3 Favored 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 123.003 2.468 . . . . 0.0 113.667 -166.003 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -95.36 -40.4 9.54 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 112.85 0.685 . . . . 0.0 112.85 -171.61 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 71.3 p -89.51 -21.24 23.03 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 122.464 0.306 . . . . 0.0 111.533 179.673 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.49 2.76 90.63 Favored Glycine 0 C--N 1.347 1.192 0 CA-C-O 119.882 -0.399 . . . . 0.0 113.572 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.6 mmtp -68.25 107.26 2.73 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.504 0.722 . . . . 0.0 110.971 -177.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.2 t -92.59 126.11 45.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 174.664 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -154.21 146.79 24.12 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 123.831 0.853 . . . . 0.0 108.813 -176.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 45.2 mt -80.87 137.41 21.41 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -177.523 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.98 159.49 32.52 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.672 0.789 . . . . 0.0 109.713 -179.396 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 17.1 mm-40 -103.17 122.57 44.98 Favored 'General case' 0 C--O 1.241 0.651 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.495 HD12 HG22 ' A' ' 23' ' ' THR . 44.5 mt -76.95 110.11 12.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -176.612 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 62.3 mtt180 -73.85 -52.3 13.45 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.149 0.979 . . . . 0.0 110.91 178.722 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -140.75 164.11 31.09 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.817 0.847 . . . . 0.0 110.14 -176.759 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 70.8 t . . . . . 0 N--CA 1.482 1.168 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 176.691 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.8 mm . . . . . 0 CA--C 1.538 0.513 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.1 mt -80.37 127.43 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 123.424 0.69 . . . . 0.0 109.764 -176.468 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 74.0 p -124.74 160.6 28.26 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 123.79 0.836 . . . . 0.0 109.427 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -75.68 128.23 34.77 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 122.964 0.506 . . . . 0.0 110.261 179.656 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.31 -1.24 58.82 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.441 -176.381 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.1 148.12 22.49 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.642 0.777 . . . . 0.0 111.479 -176.767 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 94.6 t -83.49 118.94 31.89 Favored 'Isoleucine or valine' 0 C--O 1.24 0.592 0 C-N-CA 123.406 0.682 . . . . 0.0 109.604 171.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.0 m -102.77 143.32 15.29 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 165.765 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -94.18 123.68 37.72 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.71 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 66.2 p -123.19 -173.08 2.64 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.141 0.577 . . . . 0.0 110.047 -175.05 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 58.2 m-20 -73.38 -26.99 61.23 Favored 'General case' 0 N--CA 1.478 0.932 0 CA-C-O 119.851 -0.118 . . . . 0.0 110.902 170.131 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.1 mt -84.13 -28.25 27.6 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 122.916 0.486 . . . . 0.0 111.843 -176.776 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 146.96 -149.55 21.71 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 178.579 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -85.55 128.11 34.65 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 175.522 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.7 t -121.72 128.6 75.78 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.526 0 C-N-CA 122.656 0.383 . . . . 0.0 110.862 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.546 ' HG2' HD13 ' A' ' 88' ' ' ILE . 22.6 mmt85 -85.58 123.29 30.83 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 171.845 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.6 t -72.32 100.13 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.555 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.515 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 47.5 p -95.4 -22.55 17.65 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 123.253 0.621 . . . . 0.0 110.803 -169.372 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 21.6 t -98.32 -177.81 3.83 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 169.498 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.663 ' HE ' ' HB3' ' A' ' 79' ' ' GLN . 39.6 ptt180 -75.26 144.0 77.71 Favored Pre-proline 0 CA--C 1.551 1.014 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 173.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -76.71 50.63 3.08 Favored 'Trans proline' 0 CA--C 1.559 1.762 0 C-N-CA 123.091 2.527 . . . . 0.0 113.273 174.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 172.8 67.08 0.05 OUTLIER Glycine 0 C--N 1.346 1.126 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.977 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLN . . . . . 0.663 ' HB3' ' HE ' ' A' ' 76' ' ' ARG . 1.7 pt20 -123.41 115.33 21.43 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.999 0.92 . . . . 0.0 108.604 172.562 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 62.39 19.3 11.01 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 124.339 1.055 . . . . 0.0 111.335 -176.013 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 92.86 -6.25 76.68 Favored Glycine 0 C--N 1.353 1.474 0 CA-C-N 116.033 -0.53 . . . . 0.0 112.496 178.547 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.8 p -120.3 163.71 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 123.004 0.522 . . . . 0.0 111.008 -175.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 42.3 mt -109.31 147.54 13.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 C-N-CA 124.696 1.198 . . . . 0.0 109.169 -178.753 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -130.03 155.5 46.03 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 118.414 0.552 . . . . 0.0 110.774 174.449 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.515 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -166.84 -169.38 30.37 Favored Glycine 0 C--N 1.348 1.199 0 CA-C-N 115.367 -0.833 . . . . 0.0 113.652 -177.611 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.1 m -125.61 146.8 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 CA-C-N 117.789 0.795 . . . . 0.0 111.045 178.144 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 17.5 tp -84.6 104.61 14.74 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 122.607 0.363 . . . . 0.0 111.224 -176.059 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.546 HD13 ' HG2' ' A' ' 72' ' ' ARG . 50.0 pt -93.71 174.95 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 123.08 0.552 . . . . 0.0 110.765 178.077 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -119.57 27.39 8.78 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 124.022 0.929 . . . . 0.0 110.298 -170.206 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.95 -61.41 2.4 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 124.378 1.071 . . . . 0.0 110.792 -170.361 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.541 0.606 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 165.732 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 63.7 m . . . . . 0 C--O 1.242 0.672 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 13.4 mmt85 -97.56 165.08 12.15 Favored 'General case' 0 C--O 1.244 0.771 0 CA-C-O 121.713 0.768 . . . . 0.0 110.441 -178.446 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.0 tt -136.54 134.18 49.2 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 CA-C-N 114.09 -1.413 . . . . 0.0 107.893 174.233 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 -88.68 100.53 13.19 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 179.177 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 91.7 t -87.32 116.04 28.96 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.169 -173.592 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.408 HG22 HG22 ' A' ' 35' ' ' VAL . 58.2 t -95.17 99.65 9.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -178.347 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.418 ' HB3' ' HB2' ' A' ' 34' ' ' LYS . 11.5 t70 -59.88 110.98 3.24 Favored Pre-proline 0 CA--C 1.545 0.774 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 170.277 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -82.73 -4.63 11.47 Favored 'Trans proline' 0 CA--C 1.547 1.131 0 C-N-CA 122.535 2.157 . . . . 0.0 113.043 -174.828 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -76.23 -58.58 3.2 Favored 'General case' 0 C--N 1.353 0.759 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -177.079 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.9 p -95.76 -32.73 12.58 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 114.578 -1.192 . . . . 0.0 112.127 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.01 14.39 19.05 Favored Glycine 0 N--CA 1.477 1.427 0 CA-C-O 119.793 -0.448 . . . . 0.0 113.224 -178.747 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.418 ' HB2' ' HB3' ' A' ' 29' ' ' ASP . 63.6 mttp -63.15 148.44 48.0 Favored 'General case' 0 N--CA 1.486 1.369 0 C-N-CA 122.757 0.423 . . . . 0.0 111.589 175.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.408 HG22 HG22 ' A' ' 28' ' ' VAL . 44.1 t -127.04 120.29 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 167.528 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -130.77 139.93 50.26 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.74 0.816 . . . . 0.0 110.062 -176.629 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 53.5 mt -79.15 120.46 30.39 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 177.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.24 155.5 33.08 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.964 0.905 . . . . 0.0 111.175 -173.367 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -99.19 127.32 45.15 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 174.638 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 61.6 mt -77.58 111.28 14.21 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 123.035 0.534 . . . . 0.0 110.612 -175.182 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.412 ' H ' ' HA ' ' A' ' 66' ' ' THR . 15.6 mmm180 -66.77 -44.34 81.63 Favored 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 123.718 0.807 . . . . 0.0 110.77 174.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.573 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 37.4 t30 -140.32 125.65 18.83 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.68 -169.583 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.436 HG12 HD11 ' A' ' 58' ' ' ILE . 17.9 m . . . . . 0 N--CA 1.478 0.932 0 O-C-N 124.031 0.832 . . . . 0.0 111.686 -178.063 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 49.9 mm . . . . . 0 C--O 1.24 0.561 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.436 HD11 HG12 ' A' ' 43' ' ' VAL . 67.9 mt -101.67 144.23 13.45 Favored 'Isoleucine or valine' 0 C--O 1.24 0.58 0 CA-C-N 114.48 -1.236 . . . . 0.0 109.065 -176.302 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 11.2 p -136.08 165.3 26.03 Favored 'General case' 0 C--O 1.242 0.675 0 C-N-CA 123.934 0.893 . . . . 0.0 109.702 -178.643 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -63.77 140.82 58.91 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 123.934 0.893 . . . . 0.0 111.118 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.01 -25.34 25.86 Favored Glycine 0 C--N 1.341 0.845 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.938 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.87 139.51 56.51 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.314 0.646 . . . . 0.0 110.987 -178.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.2 t -93.57 110.56 23.52 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 172.378 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.3 m -100.64 141.79 16.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 177.185 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.573 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 40.7 tt0 -94.01 136.99 33.72 Favored 'General case' 0 C--O 1.234 0.243 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.814 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.412 ' HA ' ' H ' ' A' ' 41' ' ' ARG . 81.5 p -130.03 176.52 8.0 Favored 'General case' 0 C--O 1.246 0.875 0 C-N-CA 123.972 0.909 . . . . 0.0 109.144 -179.184 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 18.6 p-10 -63.45 -24.44 67.83 Favored 'General case' 0 CA--C 1.542 0.661 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.986 173.812 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 86.5 mt -88.66 -34.01 17.39 Favored 'General case' 0 C--N 1.354 0.782 0 C-N-CA 123.143 0.577 . . . . 0.0 110.555 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 150.37 -150.09 22.06 Favored Glycine 0 C--N 1.343 0.923 0 CA-C-N 116.593 -0.276 . . . . 0.0 112.423 173.332 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -78.9 129.73 34.85 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.582 0.753 . . . . 0.0 109.038 -179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.8 t -127.85 137.5 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 123.063 0.545 . . . . 0.0 110.635 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.711 ' HG2' HD13 ' A' ' 88' ' ' ILE . 13.4 mmt180 -90.77 118.26 30.05 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 169.868 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.1 t -72.04 109.1 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 178.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.3 p -98.54 -50.97 4.09 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 -171.882 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' SER . . . . . 0.525 ' HB3' ' HB3' ' A' ' 84' ' ' ASN . 31.1 t -82.71 150.91 26.45 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.113 176.671 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.442 ' HD2' ' HD2' ' A' ' 77' ' ' PRO . 23.8 tpt180 -72.83 125.5 91.12 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 123.482 0.713 . . . . 0.0 109.611 175.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.442 ' HD2' ' HD2' ' A' ' 76' ' ' ARG . 85.2 Cg_exo -51.72 101.61 0.05 OUTLIER 'Trans proline' 0 C--N 1.378 2.084 0 C-N-CA 123.269 2.646 . . . . 0.0 111.509 163.713 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 140.4 -32.63 2.14 Favored Glycine 0 C--N 1.339 0.747 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 -176.009 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -65.94 113.34 4.34 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 171.343 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 30.5 t70 76.89 -19.12 0.44 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 125.523 1.529 . . . . 0.0 111.686 -170.667 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 109.4 -47.57 1.03 Allowed Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -171.556 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.3 p -75.11 165.77 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 C-N-CA 123.756 0.822 . . . . 0.0 111.074 178.754 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 30.2 mt -93.8 148.15 5.05 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 169.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.525 ' HB3' ' HB3' ' A' ' 75' ' ' SER . 3.4 t30 -136.56 147.35 46.97 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 174.603 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.53 -175.8 26.1 Favored Glycine 0 C--N 1.336 0.574 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.257 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.5 m -121.3 138.1 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 123.223 0.609 . . . . 0.0 109.9 174.776 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.4 ' HB3' ' HA ' ' A' ' 29' ' ' ASP . 41.9 tp -67.78 128.93 38.31 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 123.543 0.737 . . . . 0.0 110.128 178.32 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.711 HD13 ' HG2' ' A' ' 72' ' ' ARG . 44.5 pt -129.94 179.74 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 123.658 0.783 . . . . 0.0 110.702 -177.19 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 10.7 mmm180 -123.45 119.78 31.01 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 125.276 1.431 . . . . 0.0 107.247 171.59 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -149.83 -68.51 0.2 Allowed 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -177.913 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.408 ' H ' HD23 ' A' ' 91' ' ' LEU . 2.0 pt? . . . . . 0 N--CA 1.477 0.893 0 CA-C-O 122.318 1.056 . . . . 0.0 110.917 -177.008 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.418 HG22 HD12 ' A' ' 40' ' ' ILE . 5.2 m . . . . . 0 N--CA 1.471 0.594 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.429 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 57.4 mtm180 -123.34 161.15 25.25 Favored 'General case' 0 C--O 1.244 0.8 0 C-N-CA 123.296 0.638 . . . . 0.0 110.807 178.106 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.9 tt -145.65 141.24 22.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.745 -170.518 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -84.07 102.57 12.62 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 175.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.7 t -93.9 115.26 32.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 C-N-CA 124.18 0.992 . . . . 0.0 109.085 -171.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.5 t -104.65 106.97 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 124.327 1.051 . . . . 0.0 109.011 -177.543 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -69.16 111.48 8.69 Favored Pre-proline 0 CA--C 1.544 0.725 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 175.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -74.1 -7.43 19.84 Favored 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.712 2.274 . . . . 0.0 113.506 -170.101 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -96.02 -52.75 3.91 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 122.685 0.394 . . . . 0.0 111.221 -177.527 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 77.1 p -102.14 -29.86 11.48 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 123.367 0.667 . . . . 0.0 112.548 -175.82 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.39 20.91 14.0 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-O 119.734 -0.481 . . . . 0.0 113.766 177.583 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 60.8 mttp -67.43 105.66 1.87 Allowed 'General case' 0 N--CA 1.484 1.25 0 CA-C-N 117.308 0.554 . . . . 0.0 110.665 175.04 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 44.5 t -108.85 115.65 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.503 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.7 tp10 -153.72 147.55 25.38 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.111 0.564 . . . . 0.0 109.66 -174.741 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 44.7 mt -83.77 100.07 6.9 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -177.726 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -90.82 160.09 15.94 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.975 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.448 ' HB2' ' ND2' ' A' ' 67' ' ' ASN . 37.5 mt-10 -105.61 122.24 45.62 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -177.17 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.463 HG12 HG22 ' A' ' 66' ' ' THR . 50.9 mt -75.76 111.81 12.64 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -172.751 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -73.77 -40.16 63.67 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 123.807 0.843 . . . . 0.0 110.335 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -143.89 130.68 20.3 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.864 -173.231 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.405 HG12 HD11 ' A' ' 58' ' ' ILE . 29.4 m . . . . . 0 N--CA 1.483 1.184 0 C-N-CA 122.99 0.516 . . . . 0.0 111.754 -175.298 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.7 tp . . . . . 0 C--O 1.24 0.587 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.487 HD13 HG11 ' A' ' 64' ' ' VAL . 61.6 mt -114.42 144.37 22.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 124.171 0.988 . . . . 0.0 108.493 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 31.2 p -121.9 167.98 12.42 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.265 0.626 . . . . 0.0 110.55 179.416 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 39.5 ttp180 -71.72 131.09 42.64 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.005 178.108 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.2 -2.3 83.45 Favored Glycine 0 C--N 1.342 0.914 0 C-N-CA 123.607 0.622 . . . . 0.0 113.005 -177.698 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -85.18 132.55 34.27 Favored 'General case' 0 C--O 1.246 0.881 0 C-N-CA 123.408 0.683 . . . . 0.0 110.137 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 41.4 t -82.73 113.61 22.24 Favored 'Isoleucine or valine' 0 C--N 1.352 0.69 0 CA-C-O 121.01 0.433 . . . . 0.0 110.029 178.537 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.487 HG11 HD13 ' A' ' 58' ' ' ILE . 34.1 m -102.28 166.94 2.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 169.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -120.98 134.89 55.31 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 175.518 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.463 HG22 HG12 ' A' ' 40' ' ' ILE . 43.6 p -130.68 -176.23 3.91 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 124.263 1.025 . . . . 0.0 110.099 -171.347 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.448 ' ND2' ' HB2' ' A' ' 39' ' ' GLU . 97.3 m-20 -68.96 -23.59 64.15 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.06 175.772 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 73.8 mt -86.22 -41.34 14.72 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 123.183 0.302 . . . . 0.0 110.464 175.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 159.08 -159.29 30.25 Favored Glycine 0 C--N 1.345 1.045 0 O-C-N 123.443 0.464 . . . . 0.0 112.976 178.297 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 21.5 m120 -77.43 124.45 27.9 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 177.212 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 46.1 t -123.58 145.21 30.94 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.733 0 C-N-CA 124.438 1.095 . . . . 0.0 109.562 -175.704 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.443 ' HG3' HD13 ' A' ' 88' ' ' ILE . 30.1 mtt85 -107.7 137.04 46.44 Favored 'General case' 0 N--CA 1.483 1.18 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 168.337 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.476 HG11 ' HD3' ' A' ' 77' ' ' PRO . 58.1 t -75.09 120.26 24.32 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 O-C-N 124.273 0.983 . . . . 0.0 109.594 179.632 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.421 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 40.2 p -98.38 -20.95 16.86 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 123.447 0.699 . . . . 0.0 110.429 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' SER . . . . . 0.413 ' HB3' ' HB2' ' A' ' 84' ' ' ASN . 95.0 p -91.9 -173.16 3.41 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.379 0.672 . . . . 0.0 109.713 174.807 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 74.8 mtt180 -116.23 103.4 53.12 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 172.32 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.476 ' HD3' HG11 ' A' ' 73' ' ' VAL . 21.1 Cg_endo -57.71 151.54 54.86 Favored 'Trans proline' 0 C--N 1.382 2.297 0 C-N-CA 123.659 2.906 . . . . 0.0 113.632 -168.082 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.52 -35.01 4.2 Favored Glycine 0 C--N 1.349 1.292 0 CA-C-O 119.7 -0.5 . . . . 0.0 113.553 176.534 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 89.8 mt-30 -61.59 -57.77 10.75 Favored 'General case' 0 C--N 1.359 1.015 0 CA-C-O 121.351 0.596 . . . . 0.0 109.921 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -91.73 32.87 1.06 Allowed 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.376 177.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 65.07 -78.04 0.07 OUTLIER Glycine 0 C--N 1.361 1.949 0 C-N-CA 123.643 0.64 . . . . 0.0 112.831 -176.149 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.1 p -73.72 164.6 3.48 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.523 1.129 . . . . 0.0 110.441 178.476 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.448 HG12 ' HB3' ' A' ' 77' ' ' PRO . 15.9 mt -93.82 147.82 5.28 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 175.171 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.413 ' HB2' ' HB3' ' A' ' 75' ' ' SER . 3.0 m120 -123.79 147.73 47.3 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 171.11 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.421 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -165.3 -176.49 36.92 Favored Glycine 0 CA--C 1.526 0.755 0 O-C-N 123.383 0.427 . . . . 0.0 113.177 -177.172 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 16.0 m -122.62 139.11 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 C-N-CA 123.826 0.85 . . . . 0.0 110.871 178.576 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 19.4 tp -74.82 113.47 12.14 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 123.522 0.514 . . . . 0.0 109.968 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.443 HD13 ' HG3' ' A' ' 72' ' ' ARG . 34.5 pt -112.71 -177.17 0.82 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.733 0 C-N-CA 123.776 0.831 . . . . 0.0 109.883 178.019 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -133.04 100.77 4.98 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -178.377 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 70.2 mm-40 -119.26 -64.57 1.26 Allowed 'General case' 0 N--CA 1.477 0.897 0 CA-C-O 121.362 0.601 . . . . 0.0 109.491 177.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 70.8 mt . . . . . 0 N--CA 1.479 0.999 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.966 -173.853 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 29.8 m . . . . . 0 CA--C 1.54 0.579 0 CA-C-O 120.933 0.397 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 71.8 mtm180 -112.96 170.64 8.05 Favored 'General case' 0 C--O 1.243 0.727 0 C-N-CA 123.618 0.767 . . . . 0.0 110.119 177.71 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.9 tt -143.57 139.54 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.313 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 22.7 m-80 -88.2 100.16 12.76 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -84.0 109.89 17.99 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 C-N-CA 124.098 0.959 . . . . 0.0 109.187 -175.067 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 48.8 t -101.34 113.61 38.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.568 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -62.52 121.04 64.75 Favored Pre-proline 0 CA--C 1.547 0.835 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 177.87 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -71.91 -18.42 27.98 Favored 'Trans proline' 0 C--N 1.363 1.317 0 C-N-CA 122.344 2.029 . . . . 0.0 113.326 -172.474 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -92.94 -52.02 4.79 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.592 0.757 . . . . 0.0 110.881 -174.642 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 47.2 p -96.97 -29.08 13.88 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.638 0.775 . . . . 0.0 111.992 -176.175 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.34 4.41 55.07 Favored Glycine 0 N--CA 1.481 1.665 0 CA-C-O 119.272 -0.738 . . . . 0.0 114.388 176.743 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.9 mtmp? -63.19 108.0 1.17 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.528 0.731 . . . . 0.0 112.335 -173.669 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.2 t -90.62 116.47 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 C-N-CA 123.39 0.676 . . . . 0.0 109.378 176.742 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -144.59 139.4 28.09 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.329 0.652 . . . . 0.0 110.092 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 36.1 mt -79.76 133.84 28.87 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.885 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 -179.452 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.69 158.3 37.97 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 123.555 0.742 . . . . 0.0 111.441 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 32.6 mm-40 -92.15 121.43 33.69 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 177.664 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.0 mt -77.21 112.28 14.95 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 178.52 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -76.2 -51.98 11.01 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.086 0.954 . . . . 0.0 110.225 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -151.48 174.1 13.79 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 CA--C 1.543 0.698 0 C-N-CA 123.208 0.603 . . . . 0.0 110.727 177.072 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 43.0 pt . . . . . 0 N--CA 1.475 0.81 0 CA-C-O 122.083 0.944 . . . . 0.0 111.143 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.444 ' O ' ' HG3' ' A' ' 77' ' ' PRO . 57.5 mt -102.47 108.72 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 107.721 -1.215 . . . . 0.0 107.721 173.036 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.9 p -99.53 151.93 20.59 Favored 'General case' 0 C--O 1.241 0.614 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 174.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 73.0 ttt180 -67.2 128.27 35.77 Favored 'General case' 0 CA--C 1.546 0.793 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 176.108 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.81 11.46 70.6 Favored Glycine 0 C--N 1.338 0.691 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.827 -176.841 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.94 148.21 23.92 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-N 117.353 0.577 . . . . 0.0 110.112 176.405 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.6 t -84.11 114.63 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 171.406 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 28.8 m -104.46 144.73 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 C-N-CA 123.025 0.53 . . . . 0.0 109.686 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -91.68 127.85 37.29 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 175.708 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 49.5 p -128.8 -179.97 5.38 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -68.29 -19.17 64.68 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 122.854 0.461 . . . . 0.0 111.585 176.149 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 96.4 mt -90.35 -46.72 8.2 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.242 0.617 . . . . 0.0 109.804 178.599 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 162.99 -153.46 24.02 Favored Glycine 0 C--N 1.339 0.74 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.749 177.078 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -76.78 137.36 39.22 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 122.864 0.465 . . . . 0.0 110.284 176.099 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.4 t -132.03 142.65 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 122.957 0.503 . . . . 0.0 109.861 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.572 ' HG2' HD13 ' A' ' 88' ' ' ILE . 33.4 mmt180 -89.75 123.02 33.38 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 170.311 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 66.2 t -75.78 95.79 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 -179.404 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 60.8 p -78.84 -41.72 29.37 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 122.925 0.49 . . . . 0.0 111.179 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' SER . . . . . 0.552 ' HB2' ' H ' ' A' ' 84' ' ' ASN . 50.3 m -91.42 115.1 27.76 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.0 176.254 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 7.3 tmm_? -55.75 135.22 72.2 Favored Pre-proline 0 CA--C 1.563 1.453 0 C-N-CA 125.099 1.359 . . . . 0.0 110.188 177.812 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.444 ' HG3' ' O ' ' A' ' 58' ' ' ILE . 36.9 Cg_endo -60.85 129.69 30.01 Favored 'Trans proline' 0 C--N 1.377 2.068 0 C-N-CA 123.026 2.484 . . . . 0.0 112.398 -177.343 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 115.23 -18.55 15.81 Favored Glycine 0 C--N 1.34 0.791 0 CA-C-O 119.678 -0.512 . . . . 0.0 112.688 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -67.74 98.3 0.7 Allowed 'General case' 0 C--N 1.355 0.842 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 177.662 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 74.33 -2.47 2.8 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 125.754 1.621 . . . . 0.0 112.083 -174.589 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.93 -0.42 82.19 Favored Glycine 0 C--N 1.348 1.233 0 C-N-CA 123.082 0.372 . . . . 0.0 112.469 -178.04 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -115.37 148.59 17.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 124.464 1.106 . . . . 0.0 109.671 175.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 35.6 mt -104.44 145.36 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 C-N-CA 123.081 0.553 . . . . 0.0 109.601 173.457 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.552 ' H ' ' HB2' ' A' ' 75' ' ' SER . 42.9 m-20 -130.19 154.86 47.11 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 174.345 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.87 -178.06 37.16 Favored Glycine 0 C--N 1.336 0.579 0 CA-C-O 119.825 -0.43 . . . . 0.0 112.837 -177.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.18 136.93 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 123.306 0.642 . . . . 0.0 110.739 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 45.7 tp -66.13 124.68 23.27 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 122.862 0.465 . . . . 0.0 111.753 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.572 HD13 ' HG2' ' A' ' 72' ' ' ARG . 45.4 pt -119.59 164.99 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 CA-C-O 121.586 0.708 . . . . 0.0 109.788 168.787 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ARG . . . . . 0.421 ' N ' HH11 ' A' ' 89' ' ' ARG . 0.0 OUTLIER -130.92 88.27 2.59 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -175.106 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -101.24 -64.63 1.03 Allowed 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 63.3 mt . . . . . 0 CA--C 1.54 0.581 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.371 174.68 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 28.0 m . . . . . 0 CA--C 1.541 0.607 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 24.6 mmt85 -116.72 147.78 41.69 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 123.994 0.917 . . . . 0.0 111.409 -170.093 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.6 tt -148.63 142.2 18.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-N 114.185 -1.37 . . . . 0.0 108.527 -178.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ASN . . . . . 0.408 ' OD1' HG23 ' A' ' 82' ' ' VAL . 14.5 m120 -93.89 100.65 12.78 Favored 'General case' 0 C--O 1.241 0.644 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 175.532 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 87.5 t -91.71 116.57 33.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.439 0 CA-C-N 114.353 -1.294 . . . . 0.0 108.461 -176.287 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.447 HG22 HG22 ' A' ' 35' ' ' VAL . 35.0 t -98.51 109.88 24.84 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.366 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -62.86 117.69 34.83 Favored Pre-proline 0 CA--C 1.548 0.891 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 172.472 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -66.1 -31.94 44.52 Favored 'Trans proline' 0 C--N 1.366 1.475 0 C-N-CA 122.698 2.265 . . . . 0.0 113.269 -170.079 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -94.33 -46.15 7.17 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 123.179 0.592 . . . . 0.0 110.857 -175.556 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.6 m -84.87 -29.34 25.34 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.125 0.57 . . . . 0.0 111.006 -173.624 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.66 5.96 73.86 Favored Glycine 0 C--N 1.345 1.038 0 CA-C-O 119.567 -0.574 . . . . 0.0 113.976 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 95.6 mttt -60.12 106.08 0.47 Allowed 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.052 0.541 . . . . 0.0 111.228 178.042 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.447 HG22 HG22 ' A' ' 28' ' ' VAL . 61.6 t -94.47 107.84 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 168.535 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -137.0 137.67 39.68 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 122.799 0.439 . . . . 0.0 109.944 -171.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 37.9 mt -75.74 99.14 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 177.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.458 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -89.45 157.4 18.14 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 123.737 0.815 . . . . 0.0 111.503 175.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -107.33 122.41 46.51 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.804 0.842 . . . . 0.0 109.179 178.466 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 64.7 mt -78.0 115.44 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 123.363 0.665 . . . . 0.0 110.845 -171.284 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 35.1 mmt180 -78.15 -53.78 6.98 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.417 1.087 . . . . 0.0 110.42 178.535 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -131.54 153.88 49.39 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 123.666 0.786 . . . . 0.0 110.043 -175.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.459 ' HA ' HG12 ' A' ' 64' ' ' VAL . 33.7 m . . . . . 0 N--CA 1.475 0.808 0 C-N-CA 124.117 0.967 . . . . 0.0 110.97 177.621 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 2.0 pp . . . . . 0 CA--C 1.54 0.589 0 CA-C-O 120.943 0.402 . . . . 0.0 110.116 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.7 mt -102.34 130.68 51.84 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 C-N-CA 124.495 1.118 . . . . 0.0 109.162 -179.308 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 35.2 p -123.73 156.1 36.63 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.499 0.719 . . . . 0.0 109.737 177.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 60.5 ttt180 -74.71 123.51 25.04 Favored 'General case' 0 CA--C 1.544 0.715 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -178.864 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.99 4.19 67.27 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.086 -173.137 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.62 158.69 22.93 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.146 0.473 . . . . 0.0 110.737 175.837 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 68.8 t -97.26 111.24 26.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 171.752 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.459 HG12 ' HA ' ' A' ' 43' ' ' VAL . 29.6 m -108.38 137.97 37.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 173.726 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -91.16 142.32 27.87 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.109 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.458 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 61.7 p -128.07 178.76 5.99 Favored 'General case' 0 C--O 1.246 0.898 0 C-N-CA 124.146 0.979 . . . . 0.0 109.144 179.481 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -57.92 -25.72 61.26 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 123.584 0.754 . . . . 0.0 111.571 173.12 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 75.0 mt -83.52 -49.48 9.21 Favored 'General case' 0 C--N 1.351 0.632 0 C-N-CA 123.526 0.73 . . . . 0.0 109.244 178.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 161.01 -163.89 34.51 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-N 115.27 -0.877 . . . . 0.0 111.394 -177.065 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 -75.46 139.08 42.04 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-O 121.084 0.469 . . . . 0.0 110.148 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 83.9 t -133.72 144.59 35.37 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 C-N-CA 125.096 1.358 . . . . 0.0 109.272 -171.18 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.747 ' HG2' HD13 ' A' ' 88' ' ' ILE . 7.0 mmt85 -96.33 122.43 39.21 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 171.603 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 47.2 t -70.57 109.09 2.76 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.438 HG21 HG13 ' A' ' 86' ' ' VAL . 44.6 p -90.48 -30.45 17.3 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.13 0.572 . . . . 0.0 110.986 -171.078 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 25.9 t -113.71 -169.9 1.6 Allowed 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.871 0.868 . . . . 0.0 109.416 -178.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 18.4 mtp180 -70.11 144.57 92.81 Favored Pre-proline 0 CA--C 1.554 1.104 0 C-N-CA 123.432 0.693 . . . . 0.0 110.711 174.724 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.407 ' HA ' HG12 ' A' ' 83' ' ' ILE . 88.3 Cg_endo -78.8 162.02 27.05 Favored 'Trans proline' 0 C--N 1.366 1.486 0 C-N-CA 122.307 2.004 . . . . 0.0 112.29 173.879 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.437 ' H ' HG12 ' A' ' 83' ' ' ILE . . . 57.4 -89.18 0.02 OUTLIER Glycine 0 C--N 1.346 1.089 0 CA-C-N 115.635 -0.712 . . . . 0.0 113.283 -175.561 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . 0.257 12.3 pt20 53.23 -66.41 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 C-N-CA 127.74 2.416 . . . . 0.0 114.328 -178.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -146.38 41.75 1.16 Allowed 'General case' 0 N--CA 1.476 0.854 0 CA-C-O 122.255 1.026 . . . . 0.0 108.518 178.284 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 64.47 16.99 61.51 Favored Glycine 0 C--N 1.351 1.377 0 CA-C-N 115.026 -0.988 . . . . 0.0 113.061 -173.293 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.408 HG23 ' OD1' ' A' ' 26' ' ' ASN . 3.8 p -132.69 88.92 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 CA-C-O 122.595 1.188 . . . . 0.0 110.074 -174.031 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.437 HG12 ' H ' ' A' ' 78' ' ' GLY . 34.2 mt -83.31 149.06 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 171.273 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -118.04 143.67 46.23 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 172.156 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.7 179.49 30.75 Favored Glycine 0 C--N 1.336 0.539 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.829 178.741 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.438 HG13 HG21 ' A' ' 74' ' ' THR . 15.7 m -129.36 137.34 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 C-N-CA 123.784 0.834 . . . . 0.0 110.235 174.536 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.16 105.71 3.5 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 122.655 0.382 . . . . 0.0 110.082 -178.197 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.747 HD13 ' HG2' ' A' ' 72' ' ' ARG . 39.1 pt -96.83 168.07 1.63 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.588 0 CA-C-O 121.583 0.706 . . . . 0.0 110.477 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 84.3 mtt180 -127.96 26.91 5.77 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.936 177.683 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -58.12 -62.91 1.48 Allowed 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 172.546 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.0 mt . . . . . 0 C--N 1.333 -0.129 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 158.031 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.448 HG22 HD12 ' A' ' 40' ' ' ILE . 34.1 m . . . . . 0 C--O 1.243 0.723 0 CA-C-O 121.474 0.654 . . . . 0.0 110.903 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.453 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 99.0 mtt180 -128.9 175.36 8.71 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-N 114.867 -1.06 . . . . 0.0 111.148 -176.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 14.3 tt -144.97 148.16 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.932 0.893 . . . . 0.0 109.347 -173.08 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -90.61 102.95 15.69 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 174.833 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 97.2 t -87.87 113.3 24.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 124.1 0.96 . . . . 0.0 108.904 -178.675 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.464 HG22 HG22 ' A' ' 35' ' ' VAL . 26.3 t -98.83 103.88 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.722 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -53.85 107.93 0.99 Allowed Pre-proline 0 CA--C 1.544 0.713 0 C-N-CA 123.677 0.791 . . . . 0.0 108.981 167.442 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -69.09 -24.21 33.0 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.273 1.982 . . . . 0.0 113.022 -174.275 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -80.41 -50.4 10.16 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 123.213 0.605 . . . . 0.0 111.13 -177.014 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 40.9 p -94.21 -9.69 35.42 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -178.627 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.03 -3.18 66.29 Favored Glycine 0 N--CA 1.478 1.476 0 N-CA-C 114.166 0.426 . . . . 0.0 114.166 178.854 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -75.1 125.34 28.73 Favored 'General case' 0 N--CA 1.479 1.013 0 C-N-CA 123.774 0.83 . . . . 0.0 112.932 -170.209 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.464 HG22 HG22 ' A' ' 28' ' ' VAL . 17.1 t -104.03 135.4 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 123.535 0.734 . . . . 0.0 109.549 177.685 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -146.77 146.53 30.31 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.503 0.721 . . . . 0.0 109.41 174.122 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 49.2 mt -78.15 100.71 3.39 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 174.344 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -92.72 153.82 18.69 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.294 0.638 . . . . 0.0 111.331 176.029 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.453 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 36.8 mt-10 -93.34 123.17 36.45 Favored 'General case' 0 C--O 1.244 0.804 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -178.29 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.448 HD12 HG22 ' A' ' 23' ' ' THR . 53.4 mt -74.93 112.26 12.13 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.85 0 O-C-N 123.43 0.456 . . . . 0.0 109.974 -175.602 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.6 mtp180 -77.24 -53.86 7.2 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 124.188 0.995 . . . . 0.0 111.036 178.486 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.532 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 53.8 t30 -134.81 146.58 49.44 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.032 -172.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.4 m . . . . . 0 N--CA 1.481 1.096 0 C-N-CA 123.625 0.77 . . . . 0.0 111.638 178.551 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 10.7 tp . . . . . 0 C--O 1.243 0.749 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 55.5 mt -93.83 130.06 43.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 173.225 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 76.2 p -117.15 159.26 22.89 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.222 0.609 . . . . 0.0 110.005 -176.802 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 77.7 ttt180 -74.4 115.43 13.91 Favored 'General case' 0 CA--C 1.546 0.813 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.047 -177.335 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.84 6.12 49.81 Favored Glycine 0 N--CA 1.47 0.959 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.78 -177.284 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.25 162.24 25.81 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.118 0.567 . . . . 0.0 111.014 -178.853 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.0 t -103.3 110.61 30.31 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 174.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.6 m -105.82 142.52 18.67 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 176.049 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.532 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 34.8 tt0 -92.24 134.84 34.51 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 176.522 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 51.4 p -129.99 179.99 5.55 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 123.926 0.89 . . . . 0.0 108.87 178.216 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -76.1 -1.47 26.19 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 122.52 0.328 . . . . 0.0 111.336 175.066 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 82.8 mt -106.36 -9.07 16.91 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.704 0.802 . . . . 0.0 111.065 171.542 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 120.62 -166.04 13.85 Favored Glycine 0 C--N 1.351 1.393 0 C-N-CA 122.826 0.251 . . . . 0.0 113.018 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 20.2 m120 -77.64 137.87 38.78 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 123.01 0.524 . . . . 0.0 110.745 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.1 t -133.85 142.24 41.88 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.001 0 C-N-CA 124.727 1.211 . . . . 0.0 110.546 -171.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.669 ' HG2' HG21 ' A' ' 88' ' ' ILE . 30.0 mmt180 -85.15 132.34 34.31 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 170.646 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 45.6 t -76.94 106.52 6.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 172.891 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.463 HG21 HG13 ' A' ' 86' ' ' VAL . 74.1 p -95.93 -32.55 12.56 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 121.562 0.696 . . . . 0.0 110.629 -170.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.1 t -92.38 174.41 7.31 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.925 175.175 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 85.0 mtp180 -75.73 114.89 40.97 Favored Pre-proline 0 CA--C 1.546 0.802 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 171.185 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -62.46 112.93 1.73 Allowed 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 123.415 2.743 . . . . 0.0 113.084 -171.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.96 36.99 26.77 Favored Glycine 0 C--N 1.348 1.196 0 CA-C-N 115.388 -0.824 . . . . 0.0 112.245 -178.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 57.4 tp60 -70.7 -49.89 42.29 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.283 0.633 . . . . 0.0 109.946 179.259 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -121.39 56.15 1.05 Allowed 'General case' 0 N--CA 1.482 1.146 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 175.668 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 67.12 -16.98 0.3 Allowed Glycine 0 CA--C 1.538 1.52 0 N-CA-C 115.412 0.925 . . . . 0.0 115.412 -173.745 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 13.7 p -119.93 151.75 22.57 Favored 'Isoleucine or valine' 0 C--O 1.243 0.711 0 C-N-CA 124.229 1.012 . . . . 0.0 110.756 -171.829 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 28.3 mt -109.25 143.34 19.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 114.935 -1.03 . . . . 0.0 108.61 174.077 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -124.21 152.63 42.69 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 122.967 0.507 . . . . 0.0 109.647 172.662 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.5 -176.7 35.73 Favored Glycine 0 C--N 1.344 1.011 0 CA-C-N 115.323 -0.853 . . . . 0.0 112.956 -175.48 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.463 HG13 HG21 ' A' ' 74' ' ' THR . 27.7 m -130.33 144.24 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 123.317 0.647 . . . . 0.0 110.242 178.039 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.9 tp -72.14 126.86 30.84 Favored 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.585 -178.473 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.669 HG21 ' HG2' ' A' ' 72' ' ' ARG . 12.7 pt -125.21 171.31 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.189 0 C-N-CA 123.919 0.887 . . . . 0.0 110.319 -178.246 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 93.0 mtt180 -120.94 71.24 0.93 Allowed 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.424 0.69 . . . . 0.0 109.257 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 21.4 mm-40 -93.47 -78.74 0.42 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 122.86 0.464 . . . . 0.0 110.244 179.387 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 35.5 mt . . . . . 0 N--CA 1.468 0.429 0 C-N-CA 123.868 0.867 . . . . 0.0 109.057 -170.261 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.469 HG22 HD12 ' A' ' 40' ' ' ILE . 14.1 m . . . . . 0 CA--C 1.555 1.143 0 CA-C-O 120.509 0.195 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 14.3 mmt180 -113.34 145.54 40.92 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.997 0.919 . . . . 0.0 110.929 -177.577 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 17.5 tt -140.26 145.73 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 123.48 0.712 . . . . 0.0 110.674 -177.83 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -93.08 102.86 15.19 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 171.576 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.6 t -88.79 106.95 17.27 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 C-N-CA 123.972 0.909 . . . . 0.0 109.185 -176.505 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.402 HG13 HG22 ' A' ' 35' ' ' VAL . 61.8 t -95.85 100.53 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -62.47 111.78 5.32 Favored Pre-proline 0 CA--C 1.547 0.834 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 172.817 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -71.84 -22.83 23.02 Favored 'Trans proline' 0 C--N 1.365 1.401 0 C-N-CA 122.295 1.997 . . . . 0.0 113.648 -165.533 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -95.66 -44.16 7.59 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 122.802 0.441 . . . . 0.0 112.166 -176.058 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 44.4 p -87.17 -25.34 24.11 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 122.465 0.306 . . . . 0.0 111.376 -178.748 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.12 6.57 74.91 Favored Glycine 0 C--N 1.348 1.213 0 CA-C-O 119.35 -0.694 . . . . 0.0 114.04 179.028 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -71.87 107.15 4.5 Favored 'General case' 0 CA--C 1.544 0.714 0 CA-C-N 117.406 0.603 . . . . 0.0 111.016 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.402 HG22 HG13 ' A' ' 28' ' ' VAL . 40.7 t -97.19 109.61 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 174.275 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -136.02 137.59 41.34 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.336 0.654 . . . . 0.0 109.723 -171.652 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 62.1 mt -77.14 131.46 34.74 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.568 0 C-N-CA 123.547 0.739 . . . . 0.0 109.113 179.204 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.471 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -131.04 165.02 24.13 Favored 'General case' 0 C--O 1.241 0.612 0 C-N-CA 123.544 0.738 . . . . 0.0 111.061 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -103.79 116.85 33.06 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 114.633 -1.167 . . . . 0.0 108.682 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.469 HD12 HG22 ' A' ' 23' ' ' THR . 62.9 mt -76.88 110.05 12.03 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.4 mtm180 -82.26 -39.58 22.81 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.822 178.728 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.501 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 93.7 m-20 -128.26 129.53 46.53 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.445 0.698 . . . . 0.0 109.949 -178.876 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.479 1.006 0 C-N-CA 123.92 0.888 . . . . 0.0 109.809 173.618 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.6 mt . . . . . 0 CA--C 1.546 0.805 0 CA-C-O 121.306 0.574 . . . . 0.0 109.517 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 79.9 mt -83.17 134.1 27.65 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.484 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 177.622 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 59.2 p -117.5 166.24 12.59 Favored 'General case' 0 C--O 1.242 0.679 0 C-N-CA 122.949 0.5 . . . . 0.0 110.873 -176.47 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.405 ' HA ' ' O ' ' A' ' 73' ' ' VAL . 57.3 mtt180 -70.89 127.13 31.56 Favored 'General case' 0 C--N 1.349 0.55 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 175.342 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.47 -6.13 77.69 Favored Glycine 0 C--N 1.341 0.812 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.823 -175.752 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.76 139.54 38.41 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 117.28 0.54 . . . . 0.0 110.519 177.265 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.465 HG13 HD11 ' A' ' 88' ' ' ILE . 48.6 t -89.63 118.54 35.11 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 C-N-CA 123.43 0.692 . . . . 0.0 110.122 178.787 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.4 m -104.15 151.46 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 O-C-N 121.603 -0.685 . . . . 0.0 109.331 171.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.501 ' HB3' ' HB2' ' A' ' 42' ' ' ASN . 34.2 tt0 -102.84 134.09 46.83 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 176.834 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.471 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 60.0 p -132.28 -176.74 4.18 Favored 'General case' 0 C--O 1.243 0.762 0 C-N-CA 123.665 0.786 . . . . 0.0 109.379 -179.739 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -76.69 -8.26 56.92 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.846 175.078 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 58.4 mt -97.02 -14.96 21.29 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 123.58 0.752 . . . . 0.0 110.653 174.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 120.94 -156.97 16.04 Favored Glycine 0 C--N 1.347 1.141 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.742 -176.193 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.409 ' O ' HD12 ' A' ' 87' ' ' LEU . 18.9 m120 -80.4 138.87 36.7 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 122.993 0.517 . . . . 0.0 111.48 179.388 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.9 t -125.87 135.17 64.72 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 C-N-CA 123.83 0.852 . . . . 0.0 109.82 178.549 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.643 ' HG2' HD13 ' A' ' 88' ' ' ILE . 10.9 mmt-85 -83.19 114.77 21.58 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 167.629 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 60' ' ' ARG . 45.3 t -80.03 96.45 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.9 p -78.67 -22.1 47.28 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 123.951 0.9 . . . . 0.0 110.897 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 49.3 m -95.92 -169.08 1.87 Allowed 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.926 0.89 . . . . 0.0 110.886 176.289 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -108.05 156.43 38.31 Favored Pre-proline 0 CA--C 1.547 0.848 0 C-N-CA 123.288 0.635 . . . . 0.0 109.652 173.509 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.449 ' HA ' HG12 ' A' ' 83' ' ' ILE . 68.5 Cg_endo -71.41 132.02 19.98 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.085 1.857 . . . . 0.0 111.946 178.488 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.412 ' H ' HG12 ' A' ' 83' ' ' ILE . . . 72.84 12.52 78.64 Favored Glycine 0 C--N 1.35 1.315 0 CA-C-O 119.571 -0.572 . . . . 0.0 114.331 174.737 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -74.28 134.1 42.62 Favored 'General case' 0 C--N 1.351 0.666 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.2 t70 68.08 -3.65 1.2 Allowed 'General case' 0 CA--C 1.565 1.537 0 C-N-CA 123.642 0.777 . . . . 0.0 111.579 -179.157 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 122.18 -13.93 8.95 Favored Glycine 0 C--N 1.355 1.623 0 CA-C-O 119.23 -0.761 . . . . 0.0 113.735 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.4 p -148.77 163.91 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 CA-C-N 118.469 1.134 . . . . 0.0 111.377 -179.006 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.449 HG12 ' HA ' ' A' ' 77' ' ' PRO . 10.0 mt -83.8 149.37 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 175.281 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 27.5 m-80 -140.17 152.96 46.45 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 122.775 0.43 . . . . 0.0 110.173 -178.648 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -170.8 -170.33 34.89 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-O 119.98 -0.345 . . . . 0.0 113.061 179.483 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.7 m -126.07 136.81 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 124.096 0.958 . . . . 0.0 110.943 179.098 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.409 HD12 ' O ' ' A' ' 70' ' ' ASN . 18.9 tp -72.26 127.02 31.26 Favored 'General case' 0 N--CA 1.483 1.221 0 CA-C-O 120.852 0.358 . . . . 0.0 111.602 -174.327 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.643 HD13 ' HG2' ' A' ' 72' ' ' ARG . 7.8 pt -118.67 170.32 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 C-N-CA 124.79 1.236 . . . . 0.0 109.488 177.382 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 12.8 mmt180 -118.56 19.88 13.15 Favored 'General case' 0 N--CA 1.486 1.371 0 C-N-CA 122.738 0.415 . . . . 0.0 110.535 -169.723 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -50.43 -75.84 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.876 0 C-N-CA 124.422 1.089 . . . . 0.0 113.85 -164.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.6 mt . . . . . 0 C--O 1.24 0.576 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -178.915 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.1 m . . . . . 0 C--O 1.243 0.737 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 12.9 tpp85 -113.28 136.16 53.05 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 123.477 0.711 . . . . 0.0 110.64 -175.113 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.8 tt -133.89 144.11 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 123.398 0.679 . . . . 0.0 110.451 177.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -93.98 107.85 19.72 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 171.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.407 HG22 HG21 ' A' ' 71' ' ' VAL . 86.6 t -91.63 108.37 19.91 Favored 'Isoleucine or valine' 0 C--O 1.241 0.654 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 -177.9 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 35' ' ' VAL . 51.6 t -107.32 99.27 8.24 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.128 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -59.02 116.55 16.14 Favored Pre-proline 0 CA--C 1.55 0.964 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 174.134 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_endo -73.79 -23.62 16.41 Favored 'Trans proline' 0 C--N 1.366 1.495 0 C-N-CA 122.279 1.986 . . . . 0.0 114.007 -171.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.47 ' HG3' HG23 ' A' ' 32' ' ' THR . 12.9 pt-20 -91.57 -50.33 5.83 Favored 'General case' 0 N--CA 1.479 0.975 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -176.059 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.47 HG23 ' HG3' ' A' ' 31' ' ' GLU . 75.3 p -91.38 -33.02 15.44 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 122.7 0.4 . . . . 0.0 111.452 -176.616 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.11 21.35 23.14 Favored Glycine 0 C--N 1.344 1.017 0 CA-C-O 119.292 -0.727 . . . . 0.0 114.106 177.23 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.0 mttp -56.92 106.48 0.31 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 117.364 0.582 . . . . 0.0 109.711 168.374 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.515 HG22 HG13 ' A' ' 28' ' ' VAL . 54.9 t -108.46 97.71 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 172.797 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -143.51 144.6 32.04 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 123.558 0.743 . . . . 0.0 109.295 -176.95 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 23.0 mt -85.43 133.21 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.43 173.43 10.85 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.283 1.433 . . . . 0.0 109.61 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -122.84 141.19 52.13 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 174.667 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 75.7 mt -83.03 114.16 23.4 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 C-N-CA 123.02 0.528 . . . . 0.0 110.041 -176.652 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 47.1 mtp180 -76.62 -49.6 15.85 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.13 0.972 . . . . 0.0 110.114 179.536 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -143.65 166.9 23.55 Favored 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.802 0.841 . . . . 0.0 108.951 -179.476 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.9 p . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 170.325 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.1 mm . . . . . 0 N--CA 1.474 0.734 0 CA-C-O 121.679 0.752 . . . . 0.0 109.193 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 75.6 mt -100.11 122.8 52.44 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 114.359 -1.291 . . . . 0.0 109.276 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 41.5 p -121.52 168.19 12.0 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 124.366 1.066 . . . . 0.0 109.284 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 59.0 ttp180 -74.59 130.26 39.24 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 176.137 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.36 -0.16 68.14 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 115.752 -0.658 . . . . 0.0 113.251 -172.868 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.3 149.94 35.29 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 122.812 0.445 . . . . 0.0 110.964 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.0 t -99.41 110.4 26.55 Favored 'Isoleucine or valine' 0 C--O 1.244 0.765 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 173.89 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.1 m -104.83 142.25 18.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.228 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -101.79 120.32 40.18 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -178.411 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 38.5 p -125.14 179.13 5.19 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.313 0.645 . . . . 0.0 109.466 -173.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 23.2 p-10 -68.79 -14.92 63.33 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 123.008 0.523 . . . . 0.0 111.038 178.151 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.9 mt -93.51 -46.76 7.16 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.309 0.644 . . . . 0.0 109.501 175.546 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 159.18 -154.95 26.03 Favored Glycine 0 C--N 1.344 0.977 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.891 175.502 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -77.04 130.17 37.06 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.902 0.481 . . . . 0.0 110.615 178.488 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.407 HG21 HG22 ' A' ' 27' ' ' VAL . 36.9 t -128.18 140.47 49.1 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.871 0 C-N-CA 124.463 1.105 . . . . 0.0 109.355 -178.321 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.587 ' HG2' HD13 ' A' ' 88' ' ' ILE . 7.3 mmt-85 -85.57 131.59 34.33 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 170.076 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 59.0 t -76.16 110.13 10.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 173.239 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 68.9 p -101.54 -42.75 6.12 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 121.207 0.527 . . . . 0.0 109.737 -173.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 20.3 m -94.33 136.97 34.03 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.622 172.644 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 17.4 mtp180 -60.25 132.39 90.28 Favored Pre-proline 0 CA--C 1.553 1.067 0 O-C-N 124.047 0.842 . . . . 0.0 110.743 -178.626 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.411 ' HA ' HG12 ' A' ' 83' ' ' ILE . 76.2 Cg_exo -52.73 116.9 3.19 Favored 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 123.807 3.005 . . . . 0.0 114.847 -176.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.46 20.59 71.49 Favored Glycine 0 C--N 1.348 1.206 0 N-CA-C 115.491 0.956 . . . . 0.0 115.491 166.639 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -73.44 -48.16 35.87 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-N 118.111 0.955 . . . . 0.0 110.521 177.419 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -85.87 -3.44 58.92 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 123.401 0.68 . . . . 0.0 110.888 170.708 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 111.85 -9.12 27.65 Favored Glycine 0 C--O 1.219 -0.782 0 N-CA-C 111.97 -0.452 . . . . 0.0 111.97 -178.594 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.6 p -140.63 163.81 22.19 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.895 0 C-N-CA 123.34 0.656 . . . . 0.0 109.931 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.411 HG12 ' HA ' ' A' ' 77' ' ' PRO . 23.3 mt -91.99 147.39 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 172.273 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -130.92 156.69 44.64 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 171.763 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -169.74 -172.86 36.73 Favored Glycine 0 C--N 1.344 1.027 0 N-CA-C 114.172 0.429 . . . . 0.0 114.172 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 31.2 m -123.92 135.95 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 C-N-CA 123.694 0.798 . . . . 0.0 111.119 -179.472 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.0 tp -74.04 117.17 15.52 Favored 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.459 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.587 HD13 ' HG2' ' A' ' 72' ' ' ARG . 12.4 pt -116.22 168.75 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 124.191 0.997 . . . . 0.0 111.394 -169.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 17.1 mmt180 -112.55 92.09 3.89 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.418 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -121.42 -75.62 0.59 Allowed 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 123.278 0.631 . . . . 0.0 111.417 -173.492 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 39.5 mt . . . . . 0 N--CA 1.473 0.676 0 C-N-CA 123.331 0.652 . . . . 0.0 110.261 -168.767 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.8 m . . . . . 0 N--CA 1.477 0.909 0 CA-C-O 121.227 0.536 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.579 HH11 ' HG3' ' A' ' 24' ' ' ARG . 4.1 ttm-85 -119.65 170.17 9.43 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.049 -178.163 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.3 tt -136.69 140.68 42.7 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 CA-C-O 121.251 0.548 . . . . 0.0 111.194 -175.134 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.5 m-80 -92.05 100.71 13.3 Favored 'General case' 0 C--O 1.242 0.664 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 175.332 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 99.5 t -92.78 114.27 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 C-N-CA 123.734 0.813 . . . . 0.0 109.91 -173.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 35' ' ' VAL . 38.8 t -103.89 120.74 54.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 123.627 0.771 . . . . 0.0 109.103 -178.188 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -58.68 117.25 19.31 Favored Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 167.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.8 -17.66 28.98 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 121.867 1.711 . . . . 0.0 111.348 170.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -78.5 -53.96 6.66 Favored 'General case' 0 CA--C 1.555 1.137 0 C-N-CA 123.489 0.715 . . . . 0.0 112.107 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 47.0 p -100.9 -26.66 13.67 Favored 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -176.704 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.37 7.23 65.5 Favored Glycine 0 N--CA 1.476 1.348 0 CA-C-O 119.964 -0.353 . . . . 0.0 112.927 -178.032 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.2 mmtt -73.57 142.68 46.62 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 123.39 0.676 . . . . 0.0 110.846 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 28' ' ' VAL . 25.1 t -118.55 122.12 68.72 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 123.417 0.687 . . . . 0.0 109.463 179.122 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -135.37 136.46 41.49 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 123.738 0.815 . . . . 0.0 109.015 178.038 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 56.8 mt -79.19 100.19 3.75 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.092 0 C-N-CA 123.258 0.623 . . . . 0.0 109.383 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -95.67 163.23 13.28 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 172.57 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.457 ' HA ' ' HG3' ' A' ' 24' ' ' ARG . 34.0 mt-10 -102.65 137.13 41.27 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -175.672 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 57.5 mt -80.36 110.29 15.76 Favored 'Isoleucine or valine' 0 C--N 1.355 0.806 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 177.323 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 14.1 mtp180 -79.15 -53.82 6.61 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 124.58 1.152 . . . . 0.0 109.535 179.199 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -148.84 165.75 30.57 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.911 -175.711 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 N--CA 1.48 1.068 0 C-N-CA 123.593 0.757 . . . . 0.0 111.694 -179.39 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 69.6 mt . . . . . 0 C--O 1.24 0.56 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.3 mt -82.13 142.68 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 171.341 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 67.5 p -119.19 166.48 12.91 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 123.536 0.734 . . . . 0.0 110.19 177.095 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 36.4 ttm105 -71.74 115.55 11.07 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 171.655 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.97 2.41 55.0 Favored Glycine 0 C--N 1.341 0.841 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.599 -174.677 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.81 132.71 34.38 Favored 'General case' 0 C--O 1.244 0.795 0 C-N-CA 122.875 0.47 . . . . 0.0 110.107 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.455 HG21 ' HG3' ' A' ' 90' ' ' GLU . 54.1 t -79.59 125.58 38.77 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.726 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 174.855 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 19.6 m -116.14 147.89 19.23 Favored 'Isoleucine or valine' 0 C--O 1.245 0.853 0 C-N-CA 123.885 0.874 . . . . 0.0 109.052 176.286 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -84.69 122.78 29.57 Favored 'General case' 0 N--CA 1.462 0.147 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -179.516 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 47.4 p -129.03 176.99 7.45 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -178.107 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 -65.82 -23.24 66.65 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 123.86 0.864 . . . . 0.0 111.362 177.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 85.1 mt -93.62 -38.61 11.26 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.122 0.569 . . . . 0.0 110.849 -179.148 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 152.22 -146.97 16.16 Favored Glycine 0 C--N 1.347 1.148 0 C-N-CA 121.573 -0.346 . . . . 0.0 113.175 174.126 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -68.38 109.18 3.53 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.008 0.923 . . . . 0.0 109.453 176.727 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 85.6 t -120.03 137.68 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 O-C-N 121.886 -0.509 . . . . 0.0 110.379 -179.218 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.487 ' HG3' HD11 ' A' ' 88' ' ' ILE . 31.1 mtt85 -105.08 129.77 53.43 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.669 0.387 . . . . 0.0 110.335 174.601 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.478 HG11 ' HG3' ' A' ' 77' ' ' PRO . 85.1 t -71.68 123.18 25.47 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 O-C-N 124.455 1.097 . . . . 0.0 110.259 -178.603 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.418 HG21 HG13 ' A' ' 86' ' ' VAL . 45.7 p -101.04 -22.28 14.78 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.971 0.908 . . . . 0.0 111.06 -174.89 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 20.7 t -105.11 -173.65 2.35 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 123.738 0.815 . . . . 0.0 110.268 -178.84 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 86.7 mtt180 -74.36 120.88 83.61 Favored Pre-proline 0 CA--C 1.544 0.717 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 168.779 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' PRO . . . . . 0.478 ' HG3' HG11 ' A' ' 73' ' ' VAL . 73.0 Cg_exo -54.32 102.17 0.08 OUTLIER 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 123.252 2.635 . . . . 0.0 112.98 178.36 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.497 ' N ' HG12 ' A' ' 83' ' ' ILE . . . 82.91 47.81 5.71 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.336 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 54.7 tp60 -64.93 -58.11 7.01 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 123.463 0.705 . . . . 0.0 110.405 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -98.31 16.49 21.35 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 123.616 0.766 . . . . 0.0 110.015 175.16 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 100.08 -20.99 46.62 Favored Glycine 0 C--N 1.35 1.31 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -173.08 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 14.1 p -110.92 158.31 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.542 1.137 . . . . 0.0 108.57 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.497 HG12 ' N ' ' A' ' 78' ' ' GLY . 8.7 mt -110.78 151.3 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 123.624 0.769 . . . . 0.0 109.828 -177.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 79.9 m-20 -118.31 148.13 42.77 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 172.172 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.7 -179.97 36.71 Favored Glycine 0 C--N 1.348 1.207 0 O-C-N 123.452 0.47 . . . . 0.0 113.136 -179.348 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.418 HG13 HG21 ' A' ' 74' ' ' THR . 11.9 m -124.48 136.81 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 123.642 0.777 . . . . 0.0 111.423 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 50.8 tp -78.82 105.96 10.5 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.403 0.681 . . . . 0.0 110.982 -177.446 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.487 HD11 ' HG3' ' A' ' 72' ' ' ARG . 30.4 pt -123.41 -172.92 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 123.889 0.875 . . . . 0.0 109.507 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -132.68 110.91 10.74 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.159 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.455 ' HG3' HG21 ' A' ' 63' ' ' VAL . 41.3 mm-40 -115.94 -60.8 1.82 Allowed 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.027 0.531 . . . . 0.0 110.135 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.2 mt . . . . . 0 N--CA 1.474 0.744 0 C-N-CA 122.888 0.475 . . . . 0.0 110.256 179.008 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.5 m . . . . . 0 CA--C 1.535 0.376 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -101.14 147.81 25.81 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.445 0.698 . . . . 0.0 109.392 -177.751 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 17.4 tt -146.61 151.17 14.38 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 122.972 0.509 . . . . 0.0 110.324 177.683 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -100.03 102.45 13.81 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 168.755 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.33 110.9 21.12 Favored 'Isoleucine or valine' 0 C--O 1.243 0.724 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 178.449 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 53.5 t -100.51 99.51 8.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -60.14 114.09 9.01 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 172.855 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -76.25 -8.21 18.48 Favored 'Trans proline' 0 C--N 1.369 1.647 0 C-N-CA 122.795 2.33 . . . . 0.0 113.136 -173.317 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -84.17 -53.97 5.14 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.251 0.621 . . . . 0.0 109.867 -172.175 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 58.6 p -99.57 -33.21 10.73 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 124.032 0.933 . . . . 0.0 111.449 177.719 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.4 10.33 36.32 Favored Glycine 0 N--CA 1.476 1.359 0 CA-C-O 119.828 -0.429 . . . . 0.0 113.272 -176.374 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.2 mmmt -66.12 113.67 4.68 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.654 0.782 . . . . 0.0 111.484 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 38.1 t -104.26 125.44 59.04 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 C-N-CA 123.731 0.813 . . . . 0.0 109.268 176.278 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.433 ' HB3' HD11 ' A' ' 68' ' ' LEU . 8.9 tp10 -135.26 140.33 45.12 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.605 0.762 . . . . 0.0 109.612 178.191 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 65.5 mt -79.78 118.37 27.21 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 169.853 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.07 169.59 11.04 Favored 'General case' 0 C--O 1.242 0.706 0 C-N-CA 124.129 0.972 . . . . 0.0 109.083 -175.049 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -102.89 128.88 49.49 Favored 'General case' 0 C--O 1.244 0.771 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.5 mt -74.39 110.37 8.51 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 175.769 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 42.8 ttt180 -72.43 -37.74 68.52 Favored 'General case' 0 C--O 1.237 0.425 0 C-N-CA 124.28 1.032 . . . . 0.0 110.492 -175.037 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -160.67 148.8 16.21 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.036 -0.984 . . . . 0.0 108.624 -173.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 64' ' ' VAL . 40.5 t . . . . . 0 C--O 1.243 0.753 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 178.635 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 50.8 mm . . . . . 0 C--O 1.243 0.74 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 57.5 mt -66.93 123.37 19.84 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.257 -0.883 . . . . 0.0 108.791 177.255 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 28.5 p -125.21 161.07 27.69 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 124.374 1.07 . . . . 0.0 109.648 -176.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 58.1 ttp180 -69.71 127.2 32.11 Favored 'General case' 0 CA--C 1.547 0.864 0 C-N-CA 123.26 0.624 . . . . 0.0 109.451 175.51 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.98 -16.33 58.49 Favored Glycine 0 C--N 1.346 1.113 0 CA-C-O 119.739 -0.478 . . . . 0.0 112.994 -173.277 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.36 153.05 30.06 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 122.732 0.413 . . . . 0.0 110.742 179.289 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.453 HG11 ' HG3' ' A' ' 90' ' ' GLU . 78.0 t -98.19 124.26 51.16 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 CA-C-N 115.888 -0.597 . . . . 0.0 109.762 175.673 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.559 HG12 HG13 ' A' ' 43' ' ' VAL . 21.8 m -118.97 138.46 49.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 123.853 0.861 . . . . 0.0 109.068 174.548 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -101.07 137.43 39.44 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.436 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.437 HG21 HG21 ' A' ' 25' ' ' ILE . 71.2 p -129.17 -173.09 2.89 Favored 'General case' 0 C--O 1.242 0.681 0 C-N-CA 123.671 0.788 . . . . 0.0 110.113 -169.592 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -68.36 -9.98 51.83 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 123.381 0.673 . . . . 0.0 111.768 173.281 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.433 HD11 ' HB3' ' A' ' 36' ' ' GLU . 85.1 mt -106.65 -46.24 4.03 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.775 0.83 . . . . 0.0 110.459 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 167.37 -164.51 37.96 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 116.546 -0.297 . . . . 0.0 112.359 175.171 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -73.1 139.46 46.48 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.178 0.591 . . . . 0.0 109.507 175.236 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 61.5 t -134.81 142.14 41.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.754 0.822 . . . . 0.0 110.331 -170.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.599 ' HG2' HD13 ' A' ' 88' ' ' ILE . 8.3 mmt-85 -93.38 124.9 37.69 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 171.032 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 51.7 t -76.35 97.49 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.213 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 p -79.7 -38.62 33.09 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.659 0.784 . . . . 0.0 112.121 -177.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' SER . . . . . 0.487 ' HB3' ' HB2' ' A' ' 84' ' ' ASN . 23.2 t -90.55 -176.46 4.76 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.436 0.694 . . . . 0.0 110.457 179.804 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 59.6 mtt180 -83.59 113.6 48.08 Favored Pre-proline 0 CA--C 1.549 0.922 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.88 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.24 141.25 51.4 Favored 'Trans proline' 0 C--N 1.376 1.98 0 C-N-CA 123.254 2.636 . . . . 0.0 113.236 -171.062 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 83.13 18.91 63.81 Favored Glycine 0 C--N 1.347 1.142 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.112 177.801 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 12.8 pt20 -70.68 103.21 2.48 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.365 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 63.53 41.49 7.32 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 124.168 0.987 . . . . 0.0 110.905 -174.585 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 61.05 33.61 84.73 Favored Glycine 0 C--N 1.339 0.737 0 CA-C-N 114.864 -1.062 . . . . 0.0 115.293 -175.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -143.31 141.47 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.591 0.71 . . . . 0.0 110.922 168.676 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.444 ' O ' ' HA ' ' A' ' 25' ' ' ILE . 2.0 mp -93.7 146.98 5.86 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 174.259 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.487 ' HB2' ' HB3' ' A' ' 75' ' ' SER . 2.6 m-20 -126.31 137.99 53.54 Favored 'General case' 0 N--CA 1.484 1.225 0 CA-C-N 118.971 0.805 . . . . 0.0 109.508 174.026 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.44 -175.06 34.03 Favored Glycine 0 C--N 1.345 1.073 0 CA-C-N 115.994 -0.548 . . . . 0.0 113.075 -175.259 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 34.5 m -127.47 142.89 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 C-N-CA 123.441 0.696 . . . . 0.0 110.78 -177.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.3 tp -68.28 130.99 44.54 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 123.159 0.583 . . . . 0.0 110.673 -178.461 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.599 HD13 ' HG2' ' A' ' 72' ' ' ARG . 19.5 pt -133.42 170.21 20.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 124.157 0.983 . . . . 0.0 110.04 -175.417 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 13.2 mmt-85 -111.4 95.09 5.31 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 176.267 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' GLU . . . . . 0.453 ' HG3' HG11 ' A' ' 63' ' ' VAL . 47.7 mm-40 -105.93 -62.1 1.42 Allowed 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 171.338 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 74.6 mt . . . . . 0 C--O 1.239 0.532 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.155 174.731 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.575 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -67.62 116.82 8.77 Favored 'General case' 0 C--O 1.243 0.76 0 C-N-CA 123.503 0.721 . . . . 0.0 109.867 177.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 30.2 mmm180 -85.58 75.81 10.09 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.83 0.824 . . . . 0.0 109.668 -179.464 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.6 ptp180 -75.88 102.06 5.39 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 114.405 -1.27 . . . . 0.0 110.657 -176.445 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 58.9 t -87.75 118.63 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 CA-C-N 115.657 -0.702 . . . . 0.0 109.67 178.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 53.3 ttp180 -116.3 77.83 1.14 Allowed 'General case' 0 C--O 1.24 0.59 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 173.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 58.1 tp -76.56 97.43 4.37 Favored 'General case' 0 CA--C 1.541 0.626 0 CA-C-N 116.253 -0.43 . . . . 0.0 109.914 -177.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 37.0 mt -98.95 87.59 1.51 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.698 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 173.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 71.8 ttt180 -61.53 130.09 44.29 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.71 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 10.1 m -77.43 77.11 3.96 Favored 'General case' 0 CA--C 1.545 0.758 0 CA-C-O 121.744 0.783 . . . . 0.0 109.591 -177.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -87.47 112.28 22.03 Favored 'General case' 0 CA--C 1.544 0.747 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 -179.233 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.71 92.97 0.09 OUTLIER Glycine 0 C--N 1.345 1.076 0 O-C-N 123.619 0.574 . . . . 0.0 112.497 -177.175 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -112.93 -138.62 7.22 Favored Glycine 0 C--N 1.341 0.86 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 173.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.5 m120 -121.39 28.15 7.92 Favored 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 124.049 0.94 . . . . 0.0 109.763 177.332 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.1 p -65.36 108.53 1.98 Allowed 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 123.915 0.886 . . . . 0.0 111.27 -178.199 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 55.1 tttp -82.18 118.28 22.96 Favored 'General case' 0 C--O 1.238 0.487 0 C-N-CA 123.828 0.851 . . . . 0.0 109.644 177.023 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.6 p -166.4 155.13 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.908 0 C-N-CA 124.077 0.951 . . . . 0.0 109.203 -177.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 58.3 mtt180 -74.23 149.01 41.03 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 173.291 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.46 ' H ' HD23 ' A' ' 19' ' ' LEU . 1.8 pt? -48.43 100.09 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.135 0 C-N-CA 124.655 1.182 . . . . 0.0 113.404 -175.297 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -164.82 -55.97 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 124.86 1.264 . . . . 0.0 108.103 177.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 11.5 p -97.05 -10.85 25.3 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.723 0.809 . . . . 0.0 110.995 173.006 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ASP . . . . . 0.4 ' O ' ' HA ' ' A' ' 19' ' ' LEU . 3.8 m-20 -148.27 94.44 2.31 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 124.643 1.177 . . . . 0.0 107.919 176.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.0 m -67.72 114.1 6.05 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 123.06 0.544 . . . . 0.0 109.709 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -106.95 144.97 32.81 Favored 'General case' 0 C--O 1.243 0.752 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -177.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.9 tt -146.17 139.36 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.772 0 C-N-CA 123.589 0.756 . . . . 0.0 110.061 -178.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 -89.39 101.58 14.26 Favored 'General case' 0 C--O 1.239 0.543 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 175.012 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.2 t -87.29 110.17 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.436 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.8 t -98.22 100.24 10.2 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -61.2 112.29 5.61 Favored Pre-proline 0 CA--C 1.549 0.929 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 175.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -77.18 -17.78 14.77 Favored 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 122.268 1.979 . . . . 0.0 113.209 -168.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -96.87 -48.89 5.27 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 122.714 0.406 . . . . 0.0 110.996 178.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.534 HG21 ' HE3' ' A' ' 34' ' ' LYS . 2.8 m -90.93 -31.26 16.45 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.215 0.606 . . . . 0.0 111.581 -172.498 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 95.14 6.27 60.26 Favored Glycine 0 N--CA 1.476 1.316 0 CA-C-O 119.479 -0.623 . . . . 0.0 114.003 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.534 ' HE3' HG21 ' A' ' 32' ' ' THR . 92.1 mttt -63.78 106.72 1.04 Allowed 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 123.089 0.556 . . . . 0.0 110.839 177.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.6 t -103.93 106.86 21.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 175.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.503 ' HB3' HD11 ' A' ' 68' ' ' LEU . 10.3 tp10 -138.43 139.44 38.88 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 123.763 0.825 . . . . 0.0 109.812 -173.712 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 50.0 mt -83.15 100.85 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 176.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.8 173.24 7.41 Favored 'General case' 0 C--O 1.239 0.509 0 C-N-CA 123.962 0.905 . . . . 0.0 110.079 176.416 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -107.56 134.59 50.35 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 175.511 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 59.3 mt -75.57 110.26 10.23 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 173.24 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -82.01 -48.07 11.87 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.645 1.178 . . . . 0.0 110.236 -173.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -135.97 153.82 51.28 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 175.456 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.508 HG13 HG12 ' A' ' 64' ' ' VAL . 16.8 t -110.16 42.31 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.023 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 173.704 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.2 p -70.8 87.68 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.942 0 CA-C-N 114.129 -1.396 . . . . 0.0 110.02 177.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.401 ' HG2' ' H ' ' A' ' 63' ' ' VAL . 3.1 tm-20 -106.39 -50.35 3.16 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 171.791 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -129.21 -30.02 2.21 Favored 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.323 179.015 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.4 t -75.31 80.7 2.4 Favored 'General case' 0 CA--C 1.554 1.125 0 CA-C-O 122.386 1.089 . . . . 0.0 110.717 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.01 137.78 32.46 Favored 'General case' 0 C--O 1.24 0.557 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.589 -178.287 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 44.4 m-80 66.48 119.83 0.02 OUTLIER Pre-proline 0 N--CA 1.481 1.107 0 C-N-CA 125.507 1.523 . . . . 0.0 111.249 -176.45 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_exo -50.34 99.98 0.04 OUTLIER 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 123.34 2.694 . . . . 0.0 113.641 172.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 30.2 p-80 -121.05 73.12 1.01 Allowed 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 123.434 0.693 . . . . 0.0 109.692 175.495 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 61.6 t80 61.46 23.87 14.07 Favored 'General case' 0 N--CA 1.492 1.666 0 C-N-CA 124.3 1.04 . . . . 0.0 110.341 -178.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 16.3 m -100.12 137.14 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 O-C-N 121.333 -0.854 . . . . 0.0 111.418 -176.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 13.5 ptm180 -143.2 28.27 1.53 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 124.746 1.218 . . . . 0.0 108.44 174.47 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.409 ' HG2' ' H ' ' A' ' 57' ' ' ILE . 26.3 ttm180 -59.06 112.02 1.53 Allowed 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.353 1.061 . . . . 0.0 111.696 -174.44 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -107.51 31.27 5.55 Favored 'General case' 0 CA--C 1.556 1.182 0 CA-C-O 122.057 0.932 . . . . 0.0 109.157 175.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.409 ' H ' ' HG2' ' A' ' 55' ' ' ARG . 67.9 mt -81.96 84.79 1.64 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 169.333 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.4 mt -102.98 116.0 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 114.041 -1.436 . . . . 0.0 108.944 -174.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 39.4 p -117.54 162.89 17.26 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.631 0.772 . . . . 0.0 110.765 -176.358 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -67.02 135.66 54.07 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 123.006 0.522 . . . . 0.0 110.127 176.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.07 -2.94 85.77 Favored Glycine 0 C--N 1.344 0.991 0 O-C-N 123.595 0.56 . . . . 0.0 113.571 -175.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.02 145.79 30.04 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 117.283 0.541 . . . . 0.0 110.749 179.214 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.401 ' H ' ' HG2' ' A' ' 45' ' ' GLU . 50.8 t -90.1 112.17 24.33 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 172.067 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.508 HG12 HG13 ' A' ' 43' ' ' VAL . 26.5 m -107.42 159.6 6.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 174.277 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -102.6 137.46 40.8 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 172.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 30.6 p -133.46 -175.46 3.82 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.418 0.687 . . . . 0.0 109.797 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -60.59 -27.0 67.38 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 123.692 0.797 . . . . 0.0 111.889 175.464 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.503 HD11 ' HB3' ' A' ' 36' ' ' GLU . 74.1 mt -100.24 -0.67 38.15 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.269 0.628 . . . . 0.0 111.167 -175.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 112.06 -161.66 12.67 Favored Glycine 0 C--N 1.351 1.415 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.438 ' HA ' ' O ' ' A' ' 64' ' ' VAL . 17.5 m120 -73.69 138.14 44.52 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-N 117.16 0.48 . . . . 0.0 111.568 -178.212 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 92.8 t -130.45 146.62 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 124.748 1.219 . . . . 0.0 110.126 -176.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.686 ' HG2' HD13 ' A' ' 88' ' ' ILE . 34.6 mmt180 -85.23 126.68 33.87 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 167.497 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 43.0 t -73.54 111.7 8.89 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 172.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 77.6 p -95.36 -21.92 18.07 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-O 120.981 0.42 . . . . 0.0 109.907 -175.258 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 23.3 t -107.23 -171.29 1.85 Allowed 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.453 1.101 . . . . 0.0 110.578 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.28 136.68 20.91 Favored Pre-proline 0 CA--C 1.547 0.851 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 169.237 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -59.75 103.83 0.21 Allowed 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.502 2.135 . . . . 0.0 111.314 173.32 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 130.2 -6.08 6.01 Favored Glycine 0 C--N 1.342 0.904 0 CA-C-O 119.1 -0.833 . . . . 0.0 113.46 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 16.9 mm100 -67.31 -71.8 0.19 Allowed 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 117.876 0.838 . . . . 0.0 110.502 177.524 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -89.27 30.84 0.94 Allowed 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 172.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 64.63 -74.66 0.07 OUTLIER Glycine 0 C--N 1.355 1.618 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 -160.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.9 p -57.87 156.17 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.255 0 C-N-CA 125.387 1.475 . . . . 0.0 112.095 174.309 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 39.3 mt -84.04 151.51 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.526 1.13 . . . . 0.0 108.232 175.022 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -138.0 158.03 45.15 Favored 'General case' 0 N--CA 1.482 1.155 0 CA-C-N 118.298 0.499 . . . . 0.0 110.211 167.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.68 -171.71 34.77 Favored Glycine 0 C--N 1.344 0.994 0 CA-C-N 115.427 -0.806 . . . . 0.0 113.124 -174.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.2 m -122.91 135.23 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 123.441 0.696 . . . . 0.0 110.256 178.076 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 30.8 tp -68.37 134.12 49.76 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 122.969 0.508 . . . . 0.0 110.176 -177.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.686 HD13 ' HG2' ' A' ' 72' ' ' ARG . 16.7 pt -132.02 167.21 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 123.81 0.844 . . . . 0.0 111.062 -175.539 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 62.5 mtt-85 -117.66 49.42 1.23 Allowed 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 123.71 0.804 . . . . 0.0 110.166 -175.077 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -68.2 -58.74 3.96 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.072 0.463 . . . . 0.0 110.515 177.587 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.78 166.8 11.47 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.112 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.416 ' HB3' ' HA ' ' A' ' 96' ' ' HIS . 7.8 mm-40 56.94 73.0 0.47 Allowed 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 125.723 1.609 . . . . 0.0 113.057 174.708 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 22.7 m-70 -97.04 -69.97 0.74 Allowed 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 123.916 0.886 . . . . 0.0 109.249 174.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 9.3 t-80 -81.5 -64.17 1.24 Allowed 'General case' 0 C--N 1.351 0.666 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 178.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 33.6 p80 -79.36 140.06 37.59 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 172.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' HIS . . . . . 0.416 ' HA ' ' HB3' ' A' ' 92' ' ' GLU . 80.6 m-70 -119.45 35.32 4.88 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 174.145 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 40.4 t60 -139.14 140.28 37.86 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.525 1.13 . . . . 0.0 108.686 178.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 50.8 p-80 . . . . . 0 CA--C 1.551 1.014 0 C-N-CA 124.382 1.073 . . . . 0.0 109.376 178.433 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.296 0 CA-C-O 119.693 -0.504 . . . . 0.0 112.226 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -158.67 153.11 24.25 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 123.178 0.591 . . . . 0.0 109.938 -176.5 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.16 84.5 4.38 Favored 'General case' 0 C--O 1.239 0.535 0 C-N-CA 123.513 0.725 . . . . 0.0 109.835 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 34.2 ttp180 -85.57 122.01 29.08 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.071 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.4 m -75.48 136.14 25.61 Favored 'Isoleucine or valine' 0 C--O 1.246 0.912 0 C-N-CA 123.144 0.578 . . . . 0.0 110.856 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -81.4 84.06 6.77 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 174.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LEU . . . . . 0.414 HD12 ' HB2' ' A' ' 9' ' ' ARG . 0.3 OUTLIER -91.48 96.18 10.36 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 179.082 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 33.1 mm -74.17 80.86 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 175.557 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.414 ' HB2' HD12 ' A' ' 7' ' ' LEU . 20.0 tpt180 -88.69 97.2 10.99 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.32 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 58.8 p -86.08 107.26 17.74 Favored 'General case' 0 CA--C 1.539 0.549 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 175.436 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.53 ' HB2' ' HB3' ' A' ' 14' ' ' ASN . 1.9 ppt_? -68.78 -17.78 64.09 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -171.494 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.26 -128.08 45.11 Favored Glycine 0 C--N 1.346 1.094 0 O-C-N 123.456 0.472 . . . . 0.0 112.896 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -84.62 73.75 2.6 Favored Glycine 0 C--N 1.343 0.948 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 173.319 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ASN . . . . . 0.53 ' HB3' ' HB2' ' A' ' 11' ' ' ARG . 18.5 p-10 -70.31 89.13 0.66 Allowed 'General case' 0 CA--C 1.548 0.894 0 CA-C-O 121.841 0.829 . . . . 0.0 111.299 -176.165 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 31.5 m -73.09 93.62 1.82 Allowed 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.378 177.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.518 ' HD2' HD12 ' A' ' 37' ' ' ILE . 24.5 ttmm -155.84 137.26 14.01 Favored 'General case' 0 C--O 1.241 0.647 0 C-N-CA 123.991 0.916 . . . . 0.0 109.383 -175.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 10.4 p -69.29 129.86 33.92 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.892 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 170.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.732 ' HB3' HG21 ' A' ' 82' ' ' VAL . 0.2 OUTLIER -71.72 -25.31 62.01 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 123.155 0.582 . . . . 0.0 111.294 -170.445 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.627 ' HB3' ' HB3' ' A' ' 24' ' ' ARG . 2.6 pp -155.42 137.77 14.88 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 123.252 0.621 . . . . 0.0 111.328 164.197 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -123.28 -45.1 2.11 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 172.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 38.2 t -72.2 139.32 48.13 Favored 'General case' 0 C--N 1.35 0.613 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 163.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -15.51 -63.35 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.019 0 C-N-CA 127.412 2.285 . . . . 0.0 116.224 -170.366 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.532 HG22 HD12 ' A' ' 40' ' ' ILE . 29.9 m -143.73 113.83 7.31 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 121.416 0.627 . . . . 0.0 109.906 -176.065 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.627 ' HB3' ' HB3' ' A' ' 19' ' ' LEU . 39.4 ttp180 -123.47 163.33 21.1 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 124.377 1.071 . . . . 0.0 108.265 177.114 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.1 tt -135.77 142.85 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.201 0.601 . . . . 0.0 110.183 -171.385 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.0 m-80 -84.98 102.5 13.23 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.6 t -95.2 107.93 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -172.161 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 42.1 t -93.58 103.09 14.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -64.24 116.68 29.85 Favored Pre-proline 0 CA--C 1.546 0.797 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 174.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.5 ' HG2' ' HG3' ' A' ' 31' ' ' GLU . 82.3 Cg_endo -73.33 -18.08 23.55 Favored 'Trans proline' 0 C--N 1.365 1.426 0 C-N-CA 122.361 2.04 . . . . 0.0 113.455 -173.513 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.5 ' HG3' ' HG2' ' A' ' 30' ' ' PRO . 20.8 mt-10 -95.86 -51.78 4.34 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.937 0.895 . . . . 0.0 110.757 -169.556 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 61.1 p -96.02 -7.26 36.79 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 123.56 0.744 . . . . 0.0 111.648 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.48 -0.65 80.19 Favored Glycine 0 C--N 1.355 1.595 0 CA-C-O 119.556 -0.58 . . . . 0.0 114.208 173.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.3 mtmp? -67.17 106.89 2.14 Favored 'General case' 0 C--N 1.353 0.758 0 C-N-CA 123.267 0.627 . . . . 0.0 111.572 -174.461 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.4 t -82.71 99.78 5.86 Favored 'Isoleucine or valine' 0 C--N 1.346 0.446 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 169.387 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -130.02 114.28 15.6 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 -167.056 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.518 HD12 ' HD2' ' A' ' 16' ' ' LYS . 26.7 mt -79.04 100.01 3.55 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -171.371 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.43 ' O ' ' HG3' ' A' ' 24' ' ' ARG . . . -104.61 163.3 12.58 Favored 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 123.523 0.729 . . . . 0.0 110.755 -175.619 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.598 ' HG2' ' HD3' ' A' ' 24' ' ' ARG . 17.8 mt-10 -105.92 136.11 46.16 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 123.242 0.617 . . . . 0.0 109.932 -167.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.532 HD12 HG22 ' A' ' 23' ' ' THR . 68.1 mt -77.41 112.4 15.31 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.972 0 CA-C-O 121.417 0.627 . . . . 0.0 110.668 -174.391 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 9.2 mtp180 -74.93 -55.04 6.18 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 124.308 1.043 . . . . 0.0 110.152 174.352 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -140.51 168.46 19.75 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 124.249 1.02 . . . . 0.0 108.81 -176.573 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.1 t -120.07 97.5 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 167.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.1 p -140.62 129.44 25.38 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 CA-C-N 115.408 -0.815 . . . . 0.0 110.411 -166.52 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -132.82 -63.21 0.79 Allowed 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.925 0.89 . . . . 0.0 109.351 177.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 21.3 p-10 -121.66 88.54 2.95 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 121.927 0.87 . . . . 0.0 110.166 -178.046 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.5 p -128.68 107.07 9.38 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.733 0.813 . . . . 0.0 109.076 174.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -66.38 -60.77 2.45 Favored 'General case' 0 C--N 1.347 0.487 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 173.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -116.84 114.72 39.34 Favored Pre-proline 0 CA--C 1.544 0.717 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 175.259 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_exo -66.45 -6.84 16.04 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 123.363 2.709 . . . . 0.0 114.216 -177.11 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 79.4 t60 -56.93 119.3 6.02 Favored 'General case' 0 C--N 1.358 0.938 0 C-N-CA 123.414 0.685 . . . . 0.0 109.875 172.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 76.8 t80 59.51 87.44 0.08 Allowed 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.946 1.298 . . . . 0.0 110.546 -175.267 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.3 m -81.54 178.51 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.283 174.16 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -94.12 -175.2 3.61 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.296 0.638 . . . . 0.0 109.788 172.291 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 74.0 ttt180 -69.03 156.1 39.21 Favored 'General case' 0 CA--C 1.549 0.927 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 172.758 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -75.84 66.25 2.07 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 123.315 0.646 . . . . 0.0 110.597 178.434 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 40.5 mm -72.58 83.87 0.39 Allowed 'Isoleucine or valine' 0 C--O 1.244 0.773 0 C-N-CA 124.139 0.976 . . . . 0.0 109.749 176.611 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 37.8 mt -81.5 105.62 11.61 Favored 'Isoleucine or valine' 0 C--N 1.344 0.331 0 N-CA-C 107.699 -1.222 . . . . 0.0 107.699 174.58 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 5.7 p -139.62 168.24 20.27 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.414 1.086 . . . . 0.0 108.509 -177.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 52.5 mtm180 -61.03 125.24 23.01 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 122.754 0.422 . . . . 0.0 111.105 -178.424 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.82 -10.24 68.38 Favored Glycine 0 C--N 1.34 0.783 0 CA-C-N 115.196 -0.911 . . . . 0.0 114.154 -176.557 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.62 156.83 36.33 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-N 117.482 0.641 . . . . 0.0 110.847 177.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.464 HG21 ' HG3' ' A' ' 90' ' ' GLU . 99.2 t -109.08 124.39 65.71 Favored 'Isoleucine or valine' 0 C--O 1.242 0.699 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 175.042 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.1 m -105.58 146.19 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 172.527 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -94.73 139.24 31.52 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 124.206 1.003 . . . . 0.0 109.011 176.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 76.7 p -138.09 177.38 7.92 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 124.799 1.24 . . . . 0.0 107.816 177.512 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.7 m-80 -84.04 8.93 13.77 Favored 'General case' 0 N--CA 1.481 1.092 0 O-C-N 122.339 -0.226 . . . . 0.0 111.419 175.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 62.8 mt -104.8 -14.22 15.6 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 123.386 0.674 . . . . 0.0 110.498 171.388 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 134.7 -148.49 19.54 Favored Glycine 0 C--N 1.343 0.942 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 -176.023 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -101.9 145.9 28.58 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 176.133 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.1 t -129.82 141.28 46.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 C-N-CA 123.62 0.768 . . . . 0.0 109.706 -176.377 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.702 ' HG2' HD13 ' A' ' 88' ' ' ILE . 26.8 mmt180 -81.14 139.17 35.76 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 170.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 67.3 t -84.62 103.74 12.12 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.747 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 169.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 72.1 p -100.06 -17.29 17.55 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.176 0.59 . . . . 0.0 110.854 -171.138 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 60.2 p -118.67 179.63 4.08 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.966 0.906 . . . . 0.0 109.963 176.46 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 14.4 ptp180 -78.75 151.85 77.13 Favored Pre-proline 0 CA--C 1.552 1.032 0 C-N-CA 123.082 0.553 . . . . 0.0 110.645 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.656 ' HA ' HG13 ' A' ' 83' ' ' ILE . 85.1 Cg_endo -76.41 16.07 0.93 Allowed 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 122.879 2.386 . . . . 0.0 114.58 -178.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.81 58.88 0.42 Allowed Glycine 0 C--N 1.346 1.093 0 N-CA-C 112.216 -0.354 . . . . 0.0 112.216 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 -118.83 110.26 17.0 Favored 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 171.236 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.3 t70 67.62 -1.37 1.64 Allowed 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 124.433 1.093 . . . . 0.0 111.217 -169.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' GLY . . . . . 0.455 ' O ' HD21 ' A' ' 19' ' ' LEU . . . 95.47 5.83 60.1 Favored Glycine 0 C--N 1.349 1.3 0 CA-C-O 119.479 -0.623 . . . . 0.0 112.677 -174.355 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.732 HG21 ' HB3' ' A' ' 18' ' ' ARG . 11.4 p -126.26 164.29 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 123.435 0.694 . . . . 0.0 111.07 -175.444 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.656 HG13 ' HA ' ' A' ' 77' ' ' PRO . 3.4 mp -109.61 147.02 14.32 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 124.473 1.109 . . . . 0.0 108.664 178.263 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -119.69 155.82 31.68 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 123.596 0.759 . . . . 0.0 109.345 169.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.63 -175.12 36.57 Favored Glycine 0 C--N 1.345 1.065 0 N-CA-C 114.017 0.367 . . . . 0.0 114.017 -176.286 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.6 m -130.71 140.37 48.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 C-N-CA 123.469 0.707 . . . . 0.0 110.419 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 33.6 tp -75.47 112.85 12.22 Favored 'General case' 0 CA--C 1.549 0.937 0 CA-C-O 121.303 0.573 . . . . 0.0 111.624 -172.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.702 HD13 ' HG2' ' A' ' 72' ' ' ARG . 9.3 pt -110.02 179.01 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.19 0 C-N-CA 125.059 1.344 . . . . 0.0 110.488 178.062 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 47.5 mmt-85 -132.03 62.48 1.64 Allowed 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 123.438 0.695 . . . . 0.0 109.412 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.464 ' HG3' HG21 ' A' ' 63' ' ' VAL . 37.6 mm-40 -68.77 -63.06 1.13 Allowed 'General case' 0 N--CA 1.491 1.605 0 CA-C-O 121.464 0.65 . . . . 0.0 110.09 177.736 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 70.6 mt -105.57 127.77 53.22 Favored 'General case' 0 C--O 1.242 0.66 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 172.029 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -65.58 93.28 0.16 Allowed 'General case' 0 CA--C 1.548 0.88 0 O-C-N 123.78 0.675 . . . . 0.0 110.372 -178.444 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 37.5 m-70 -120.28 86.57 2.59 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 124.061 0.944 . . . . 0.0 109.051 177.03 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -159.56 164.05 34.6 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-N 115.306 -0.861 . . . . 0.0 108.783 173.457 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -110.72 168.67 9.29 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 122.817 0.447 . . . . 0.0 110.086 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 55.8 m80 -72.51 143.26 48.42 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 171.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 8.7 p80 -69.69 155.56 40.33 Favored 'General case' 0 CA--C 1.551 0.988 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.501 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 . . . . . 0 C--O 1.247 0.948 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 172.422 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.912 0 N-CA-C 112.005 -0.438 . . . . 0.0 112.005 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.439 ' HA ' HH11 ' A' ' 3' ' ' ARG . 2.9 p30 -140.63 173.92 11.02 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 124.019 0.928 . . . . 0.0 110.637 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.439 HH11 ' HA ' ' A' ' 2' ' ' ASP . 1.8 mpt_? -116.66 91.69 3.66 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.234 0.614 . . . . 0.0 109.697 -175.063 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 50.8 mtm180 -98.8 99.12 10.17 Favored 'General case' 0 C--O 1.242 0.685 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 174.22 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.3 p -119.25 109.62 27.12 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 168.682 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.6 tpt180 -91.05 95.84 10.31 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 123.227 0.611 . . . . 0.0 109.702 -172.281 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -88.25 89.73 8.11 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-O 121.263 0.554 . . . . 0.0 109.989 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 69.2 mt -92.42 130.18 41.92 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 175.41 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 6.0 ppt_? -147.79 155.18 41.4 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 123.568 0.747 . . . . 0.0 111.368 -177.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 29.0 p -127.99 106.15 8.89 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 124.023 0.929 . . . . 0.0 108.984 174.591 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 4.0 mmp_? -106.9 150.73 26.11 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 123.737 0.815 . . . . 0.0 110.665 -177.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -134.14 63.82 0.61 Allowed Glycine 0 C--N 1.338 0.639 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.19 87.89 0.12 Allowed Glycine 0 CA--C 1.53 0.995 0 O-C-N 123.974 0.455 . . . . 0.0 112.912 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 27.0 t-20 -73.07 116.89 14.14 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.658 0.783 . . . . 0.0 109.554 176.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 37.2 p -72.19 89.36 1.17 Allowed 'General case' 0 CA--C 1.549 0.915 0 CA-C-O 121.514 0.673 . . . . 0.0 110.092 178.294 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.73 152.97 19.2 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.271 -0.877 . . . . 0.0 112.009 -173.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.2 t -84.34 131.97 32.69 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 123.499 0.719 . . . . 0.0 109.741 -178.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 3.8 mpt_? -73.35 -35.08 65.93 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 124.058 0.943 . . . . 0.0 111.39 -170.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -151.2 152.32 33.12 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.297 0.639 . . . . 0.0 110.278 -176.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.94 -36.84 0.2 Allowed 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 123.43 0.692 . . . . 0.0 109.797 178.13 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 44.2 m -87.24 -158.28 0.43 Allowed 'General case' 0 CA--C 1.555 1.17 0 C-N-CA 124.104 0.962 . . . . 0.0 110.237 173.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -28.67 128.78 0.08 Allowed 'General case' 0 N--CA 1.501 2.123 0 C-N-CA 125.117 1.367 . . . . 0.0 112.931 169.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.498 ' HB ' ' HB ' ' A' ' 40' ' ' ILE . 6.4 m -64.49 131.52 47.33 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.772 0.829 . . . . 0.0 112.894 -164.363 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 22.9 mmt85 -104.95 134.31 48.28 Favored 'General case' 0 C--O 1.244 0.768 0 C-N-CA 124.275 1.03 . . . . 0.0 109.45 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.4 tt -140.29 135.91 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 123.995 0.918 . . . . 0.0 109.394 -178.734 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 20.7 m-80 -87.14 103.36 15.33 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.5 t -98.42 110.11 25.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 C-N-CA 123.884 0.874 . . . . 0.0 109.196 -172.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.456 HG22 HG22 ' A' ' 35' ' ' VAL . 38.2 t -92.66 103.54 14.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -60.51 116.82 19.72 Favored Pre-proline 0 CA--C 1.549 0.918 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -76.75 -11.17 18.43 Favored 'Trans proline' 0 C--N 1.363 1.326 0 C-N-CA 122.958 2.439 . . . . 0.0 113.379 -174.13 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -81.89 -52.47 7.06 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 123.087 0.555 . . . . 0.0 109.583 -176.38 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 65.4 p -96.37 -31.85 12.66 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 114.774 -1.103 . . . . 0.0 112.026 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 94.03 8.61 60.21 Favored Glycine 0 N--CA 1.475 1.247 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.494 -173.514 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.7 mmtp -72.66 108.92 5.93 Favored 'General case' 0 C--N 1.359 0.982 0 C-N-CA 123.18 0.592 . . . . 0.0 111.678 -177.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.456 HG22 HG22 ' A' ' 28' ' ' VAL . 24.8 t -82.91 120.17 33.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 172.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 13.1 tp10 -140.29 130.33 24.83 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.463 0.705 . . . . 0.0 109.479 -177.36 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 46.0 mt -78.0 103.79 5.37 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -179.025 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.439 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -89.83 166.12 13.72 Favored 'General case' 0 C--O 1.24 0.558 0 C-N-CA 123.694 0.798 . . . . 0.0 111.037 177.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 -114.39 124.94 53.2 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 115.314 -0.857 . . . . 0.0 108.925 176.577 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.498 ' HB ' ' HB ' ' A' ' 23' ' ' THR . 67.8 mt -79.79 111.37 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 C-N-CA 122.958 0.503 . . . . 0.0 109.775 -173.658 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 71.9 mtt180 -64.86 -46.83 80.19 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 123.798 0.839 . . . . 0.0 110.376 176.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 62.5 t30 -164.5 172.51 13.21 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.932 -170.134 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 25.2 m -98.33 133.26 41.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.929 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 170.644 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.7 p -163.0 94.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-O 122.355 1.074 . . . . 0.0 109.563 176.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.679 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -94.45 -32.75 13.39 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.069 179.51 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -167.03 -17.48 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.814 0.846 . . . . 0.0 110.296 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.5 t -57.95 111.69 1.25 Allowed 'General case' 0 CA--C 1.557 1.243 0 CA-C-O 121.921 0.867 . . . . 0.0 111.41 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.08 164.08 22.7 Favored 'General case' 0 C--O 1.243 0.719 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.409 -178.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.3 m120 56.31 68.35 2.3 Favored Pre-proline 0 CA--C 1.553 1.071 0 C-N-CA 124.062 0.945 . . . . 0.0 109.356 -172.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo -77.54 11.81 2.06 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 123.006 2.47 . . . . 0.0 114.28 -170.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 33.5 m80 -74.26 -47.41 35.22 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 123.169 0.588 . . . . 0.0 110.85 -177.155 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 85.5 t80 -76.22 -29.62 57.64 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.222 175.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 85.6 t -58.21 105.0 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-O 121.531 0.682 . . . . 0.0 110.093 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 47.3 ttt180 -83.31 153.96 24.36 Favored 'General case' 0 C--O 1.242 0.668 0 C-N-CA 125.14 1.376 . . . . 0.0 108.932 177.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 37.6 ttm180 -59.23 94.21 0.02 OUTLIER 'General case' 0 C--N 1.355 0.846 0 CA-C-O 121.187 0.518 . . . . 0.0 109.627 176.093 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -80.17 -159.38 0.22 Allowed 'General case' 0 CA--C 1.552 1.047 0 C-N-CA 124.164 0.985 . . . . 0.0 109.035 178.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 50.1 mt -90.38 100.37 10.94 Favored 'Isoleucine or valine' 0 C--O 1.241 0.635 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -167.046 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 71.3 mt -61.98 116.93 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 114.372 -1.285 . . . . 0.0 109.952 -178.174 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.438 ' HA ' ' HG2' ' A' ' 77' ' ' PRO . 40.6 p -126.8 167.2 16.11 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 124.073 0.949 . . . . 0.0 110.017 -177.854 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 32.5 ttp180 -64.03 138.5 58.49 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 123.127 0.571 . . . . 0.0 110.269 177.303 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.32 -39.17 3.04 Favored Glycine 0 C--N 1.335 0.521 0 CA-C-O 119.926 -0.374 . . . . 0.0 112.778 -176.364 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -61.63 135.87 57.79 Favored 'General case' 0 C--N 1.356 0.859 0 C-N-CA 123.665 0.786 . . . . 0.0 110.821 179.334 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.679 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 42.2 t -87.51 133.15 31.01 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 176.472 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 18.4 m -113.52 150.5 15.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 C-N-CA 124.171 0.989 . . . . 0.0 109.024 177.325 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -95.65 125.44 40.24 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 106.098 -1.815 . . . . 0.0 106.098 174.276 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.439 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 61.3 p -122.05 177.71 5.21 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 26.7 p-10 -69.54 -18.26 63.65 Favored 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.063 175.08 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.6 mt -85.12 -43.7 13.63 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 122.965 0.506 . . . . 0.0 110.582 174.596 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 155.93 -150.8 22.26 Favored Glycine 0 C--N 1.344 0.984 0 N-CA-C 111.925 -0.47 . . . . 0.0 111.925 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.408 ' N ' HD22 ' A' ' 70' ' ' ASN . 1.0 OUTLIER -79.94 126.02 30.48 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-N 117.488 0.644 . . . . 0.0 109.335 178.118 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 57.7 t -125.07 138.2 55.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 123.741 0.817 . . . . 0.0 110.638 -178.245 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.718 ' HG2' HD13 ' A' ' 88' ' ' ILE . 17.8 mmt180 -83.65 131.46 34.95 Favored 'General case' 0 N--CA 1.483 1.188 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 168.368 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.519 HG11 ' HG3' ' A' ' 77' ' ' PRO . 66.3 t -79.02 105.86 9.04 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 169.251 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 41.6 p -93.8 -30.94 14.58 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 123.392 0.677 . . . . 0.0 110.727 -171.38 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 49.0 m -96.88 178.05 5.42 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.248 177.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.774 ' HB2' ' HB2' ' A' ' 79' ' ' GLN . 80.2 mtp180 -74.36 124.52 89.94 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.109 170.288 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.519 ' HG3' HG11 ' A' ' 73' ' ' VAL . 32.0 Cg_exo -62.12 104.01 0.32 Allowed 'Trans proline' 0 C--N 1.373 1.841 0 C-N-CA 122.481 2.12 . . . . 0.0 111.293 173.562 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.34 24.82 17.86 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-N 116.06 -0.518 . . . . 0.0 113.347 -178.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLN . . . . . 0.774 ' HB2' ' HB2' ' A' ' 76' ' ' ARG . 24.7 tm0? -65.9 -58.65 5.09 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 176.329 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -84.12 -9.3 58.69 Favored 'General case' 0 N--CA 1.487 1.377 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.763 173.622 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 117.33 -53.14 0.65 Allowed Glycine 0 C--N 1.336 0.559 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -163.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 10.1 p -87.03 165.7 2.09 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.131 0 C-N-CA 123.886 0.874 . . . . 0.0 110.703 177.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 18.5 mt -96.38 148.49 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.888 0 C-N-CA 124.039 0.936 . . . . 0.0 108.605 173.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 17.4 m-80 -131.75 149.01 52.61 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 123.252 0.621 . . . . 0.0 109.699 177.356 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.45 -173.27 32.92 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 115.735 -0.666 . . . . 0.0 114.092 -174.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.6 m -129.79 141.72 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 C-N-CA 123.551 0.74 . . . . 0.0 110.107 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 20.1 tp -75.88 105.31 6.85 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 121.022 0.439 . . . . 0.0 109.924 -178.003 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.718 HD13 ' HG2' ' A' ' 72' ' ' ARG . 11.0 pt -107.21 -173.46 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 123.432 0.693 . . . . 0.0 110.222 -179.413 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 60.7 mtt85 -139.95 77.47 1.61 Allowed 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 123.146 0.578 . . . . 0.0 109.734 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.458 ' HG2' HD12 ' A' ' 88' ' ' ILE . 56.5 mm-40 -68.58 -65.51 0.69 Allowed 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 167.023 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 60.7 mt -80.82 -164.51 0.74 Allowed 'General case' 0 CA--C 1.549 0.927 0 CA-C-N 114.429 -1.26 . . . . 0.0 108.934 170.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 62.42 21.18 12.41 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 123.226 0.61 . . . . 0.0 111.513 172.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 6.3 p80 -117.14 170.83 8.36 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.67 0.788 . . . . 0.0 110.807 -171.141 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -136.57 -59.44 0.72 Allowed 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.127 0.971 . . . . 0.0 108.463 172.077 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -94.16 -53.16 4.07 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.023 -177.239 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 60.6 t-80 -108.49 117.11 33.31 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 122.982 0.513 . . . . 0.0 111.63 -173.722 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 42.4 t60 -95.73 148.26 22.75 Favored 'General case' 0 N--CA 1.483 1.209 0 C-N-CA 124.96 1.304 . . . . 0.0 108.665 169.586 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 81.1 t60 . . . . . 0 N--CA 1.487 1.386 0 C-N-CA 123.241 0.616 . . . . 0.0 110.67 178.667 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.376 0 N-CA-C 111.591 -0.604 . . . . 0.0 111.591 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 36.6 m-20 -70.25 105.17 2.87 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.761 0.824 . . . . 0.0 110.224 -179.018 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -72.31 92.88 1.44 Allowed 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 177.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 -56.66 112.64 1.35 Allowed 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 123.775 0.83 . . . . 0.0 111.026 -173.728 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 61.7 t -77.72 104.77 5.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 36.7 ptt180 -60.97 123.49 17.75 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 123.693 0.797 . . . . 0.0 111.645 -176.093 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LEU . . . . . 0.43 HD13 HH21 ' A' ' 9' ' ' ARG . 55.3 mt -81.55 83.22 7.07 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.545 0.738 . . . . 0.0 109.874 -177.147 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 41.4 mm -89.27 73.84 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 CA-C-O 121.703 0.763 . . . . 0.0 109.056 -175.44 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.43 HH21 HD13 ' A' ' 7' ' ' LEU . 5.6 ppt_? -157.74 -176.34 5.88 Favored 'General case' 0 CA--C 1.538 0.494 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.735 -174.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.429 HG23 ' HD3' ' A' ' 9' ' ' ARG . 40.2 p 50.76 76.65 0.15 Allowed 'General case' 0 N--CA 1.482 1.151 0 C-N-CA 125.37 1.468 . . . . 0.0 112.37 178.062 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 2.4 ppt_? -153.92 170.4 21.13 Favored 'General case' 0 C--O 1.243 0.762 0 CA-C-N 114.876 -1.057 . . . . 0.0 109.657 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 118.22 -168.03 13.05 Favored Glycine 0 C--N 1.343 0.938 0 CA-C-N 116.717 -0.219 . . . . 0.0 112.734 176.136 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -85.65 61.95 4.49 Favored Glycine 0 C--N 1.341 0.841 0 N-CA-C 112.295 -0.322 . . . . 0.0 112.295 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -74.48 172.7 11.5 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.971 0.909 . . . . 0.0 111.385 176.7 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 40.3 p -68.37 81.46 0.25 Allowed 'General case' 0 CA--C 1.546 0.826 0 CA-C-O 121.767 0.794 . . . . 0.0 110.338 174.737 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -95.36 154.99 16.92 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.924 -179.041 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 16.4 m -124.2 -149.15 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.813 0 C-N-CA 124.119 0.967 . . . . 0.0 108.897 -176.377 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.6 mmm-85 -75.12 -156.74 0.06 Allowed 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 123.314 0.645 . . . . 0.0 110.713 174.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.403 ' HB3' ' HB2' ' A' ' 24' ' ' ARG . 2.9 pp -77.06 40.36 0.26 Allowed 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -178.071 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -62.53 -24.2 67.38 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.969 0.908 . . . . 0.0 111.655 174.217 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 16.7 p -53.12 -58.03 8.41 Favored 'General case' 0 CA--C 1.549 0.942 0 O-C-N 124.245 0.966 . . . . 0.0 110.15 172.629 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ASP . . . . . 0.451 ' HB3' ' OE1' ' A' ' 39' ' ' GLU . 22.0 t70 -170.91 -76.06 0.02 OUTLIER 'General case' 0 N--CA 1.479 0.986 0 O-C-N 124.234 0.959 . . . . 0.0 108.513 167.497 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.459 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 6.9 m -145.4 116.02 7.67 Favored 'General case' 0 C--N 1.351 0.64 0 C-N-CA 123.185 0.594 . . . . 0.0 109.745 176.522 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.403 ' HB2' ' HB3' ' A' ' 19' ' ' LEU . 38.6 mmt180 -107.12 145.13 32.85 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.731 0.812 . . . . 0.0 110.362 -177.512 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.9 tt -147.41 144.34 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 C-N-CA 124.167 0.987 . . . . 0.0 109.441 175.513 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -91.59 100.85 13.52 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 173.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 62.0 t -89.56 111.03 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 123.808 0.843 . . . . 0.0 109.247 -175.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.502 HG22 HG22 ' A' ' 35' ' ' VAL . 41.4 t -101.45 108.72 24.12 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 C-N-CA 123.666 0.786 . . . . 0.0 109.333 -176.303 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -58.74 114.82 9.79 Favored Pre-proline 0 N--CA 1.473 0.715 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 171.67 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -78.1 -5.89 15.42 Favored 'Trans proline' 0 C--N 1.363 1.334 0 C-N-CA 122.374 2.049 . . . . 0.0 112.911 -175.571 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -95.86 -53.31 3.73 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 123.827 0.851 . . . . 0.0 111.203 -178.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 59.3 p -90.67 -30.85 16.88 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.485 0.714 . . . . 0.0 111.44 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.9 -11.54 57.52 Favored Glycine 0 C--N 1.343 0.952 0 CA-C-N 116.139 -0.482 . . . . 0.0 113.158 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -68.53 124.73 24.38 Favored 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 123.482 0.713 . . . . 0.0 111.426 -170.128 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.502 HG22 HG22 ' A' ' 28' ' ' VAL . 22.2 t -95.95 133.99 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 175.198 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -140.99 137.19 32.84 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 171.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 39.7 mt -79.82 129.5 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 178.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.29 167.71 18.05 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 123.88 0.872 . . . . 0.0 111.289 -171.678 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.459 ' HA ' ' O ' ' A' ' 23' ' ' THR . 56.0 mm-40 -104.32 118.77 37.43 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 124.441 1.096 . . . . 0.0 110.98 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.446 HG23 ' HB ' ' A' ' 64' ' ' VAL . 68.1 mt -78.85 111.4 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 122.704 0.402 . . . . 0.0 110.544 -175.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -82.81 -56.48 3.8 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.358 1.063 . . . . 0.0 111.623 178.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.587 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 33.9 t30 -106.25 133.95 50.15 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 175.709 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.432 ' HA ' HG12 ' A' ' 64' ' ' VAL . 33.6 m -102.99 -5.07 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -175.544 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.706 HG21 HG21 ' A' ' 53' ' ' VAL . 3.7 p -137.37 104.0 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 CA-C-O 121.297 0.57 . . . . 0.0 111.794 -170.791 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.597 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 33.5 mm-40 55.33 -164.36 0.13 Allowed 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 166.396 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 8.1 p30 -80.79 -3.98 52.96 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.1 0.96 . . . . 0.0 110.949 171.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.401 HG22 ' HB2' ' A' ' 45' ' ' GLU . 8.8 t -79.01 140.06 38.05 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-O 121.609 0.719 . . . . 0.0 110.951 -178.323 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -130.16 27.16 5.13 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 114.378 -1.283 . . . . 0.0 108.705 172.31 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 48.0 t-20 -105.68 93.19 6.95 Favored Pre-proline 0 N--CA 1.474 0.775 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 176.041 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -82.37 13.07 2.65 Favored 'Trans proline' 0 C--N 1.372 1.775 0 C-N-CA 122.422 2.081 . . . . 0.0 113.628 -175.007 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 55.2 t-80 -69.71 -48.61 58.95 Favored 'General case' 0 C--N 1.351 0.67 0 C-N-CA 122.445 0.298 . . . . 0.0 110.498 176.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -88.37 -28.01 21.25 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 123.397 0.435 . . . . 0.0 111.144 -178.34 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.706 HG21 HG21 ' A' ' 44' ' ' VAL . 5.7 p -116.59 104.78 17.14 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 CA-C-O 122.204 1.002 . . . . 0.0 111.387 -179.522 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 34.0 mmt180 -114.33 -0.73 13.75 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 124.163 0.985 . . . . 0.0 110.366 167.399 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 16.2 mtm180 -78.83 79.82 5.21 Favored 'General case' 0 C--O 1.244 0.793 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 170.316 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -86.06 65.21 8.99 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 121.944 0.878 . . . . 0.0 110.052 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 64.4 mt -108.83 119.56 58.62 Favored 'Isoleucine or valine' 0 C--O 1.242 0.696 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 176.07 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 57.7 mt -65.83 119.85 11.59 Favored 'Isoleucine or valine' 0 C--N 1.348 0.515 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 173.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 26.7 m -118.1 147.97 42.76 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -178.139 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 31.6 ttt-85 -60.69 134.09 56.74 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 172.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.57 -41.71 2.74 Favored Glycine 0 C--N 1.346 1.112 0 CA-C-O 119.892 -0.393 . . . . 0.0 112.43 -175.152 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -60.56 134.89 57.52 Favored 'General case' 0 C--N 1.357 0.896 0 C-N-CA 123.53 0.732 . . . . 0.0 110.708 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.597 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 98.2 t -73.55 120.48 22.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 O-C-N 123.722 0.639 . . . . 0.0 110.634 -178.592 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.446 ' HB ' HG23 ' A' ' 40' ' ' ILE . 26.3 m -105.41 126.89 60.54 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.294 171.167 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.587 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 33.8 tt0 -92.68 134.82 34.65 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 106.087 -1.82 . . . . 0.0 106.087 177.602 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 71.3 p -117.22 -178.59 3.48 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 -177.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -59.44 -23.15 62.44 Favored 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 123.057 0.543 . . . . 0.0 110.896 171.287 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 89.0 mt -88.79 -51.76 5.48 Favored 'General case' 0 C--N 1.353 0.733 0 C-N-CA 124.267 1.027 . . . . 0.0 110.018 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 164.53 -170.36 39.65 Favored Glycine 0 C--N 1.337 0.608 0 CA-C-N 115.549 -0.751 . . . . 0.0 112.155 -177.407 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.451 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 14.0 m120 -75.73 143.49 42.02 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.393 0.677 . . . . 0.0 110.772 -174.116 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.2 t -137.04 147.48 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 123.857 0.863 . . . . 0.0 110.079 -174.049 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.687 ' HG2' HD13 ' A' ' 88' ' ' ILE . 36.4 mmt180 -93.01 120.75 33.64 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 168.454 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 43.9 t -75.82 98.65 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.438 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 71.1 p -74.36 -34.52 63.4 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.715 0.806 . . . . 0.0 111.417 178.732 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' SER . . . . . 0.554 ' HB2' ' HB2' ' A' ' 84' ' ' ASN . 39.2 t -79.8 170.08 17.01 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.778 0.831 . . . . 0.0 111.581 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -82.73 106.43 6.82 Favored Pre-proline 0 CA--C 1.546 0.816 0 N-CA-C 107.246 -1.391 . . . . 0.0 107.246 166.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.404 ' HB3' HG23 ' A' ' 83' ' ' ILE . 65.9 Cg_endo -82.16 69.62 7.41 Favored 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 123.443 2.762 . . . . 0.0 112.44 -172.021 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.09 -32.15 0.1 Allowed Glycine 0 C--N 1.333 0.37 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.817 -178.129 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -64.58 111.37 2.68 Favored 'General case' 0 C--N 1.359 0.981 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 174.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.4 t70 76.71 -22.95 0.26 Allowed 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 125.338 1.455 . . . . 0.0 112.384 -177.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 102.55 -8.58 54.97 Favored Glycine 0 C--N 1.345 1.078 0 CA-C-O 119.932 -0.371 . . . . 0.0 112.487 -175.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -86.57 116.95 30.1 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 CA-C-O 121.641 0.734 . . . . 0.0 109.94 -179.186 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.404 HG23 ' HB3' ' A' ' 77' ' ' PRO . 38.6 mt -98.54 132.75 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 175.669 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.554 ' HB2' ' HB2' ' A' ' 75' ' ' SER . 66.3 m-20 -136.07 154.52 51.0 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 123.725 0.81 . . . . 0.0 109.03 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.438 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -168.93 -173.98 37.12 Favored Glycine 0 C--N 1.34 0.754 0 O-C-N 123.385 0.428 . . . . 0.0 113.992 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.7 m -123.47 134.24 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.075 0 C-N-CA 124.028 0.931 . . . . 0.0 110.364 177.536 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 46.7 tp -66.21 127.55 32.62 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 123.182 0.593 . . . . 0.0 111.447 -176.037 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.687 HD13 ' HG2' ' A' ' 72' ' ' ARG . 33.2 pt -126.21 -176.67 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 C-N-CA 125.189 1.396 . . . . 0.0 109.378 173.25 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 82.0 mtt85 -137.83 88.29 2.32 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 123.321 0.649 . . . . 0.0 109.923 -177.032 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -100.85 -48.22 4.54 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 123.4 0.68 . . . . 0.0 109.44 178.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 88.8 mt -119.37 -175.1 2.87 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 124.911 1.284 . . . . 0.0 109.793 -178.043 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -122.15 106.66 11.35 Favored 'General case' 0 C--O 1.239 0.515 0 C-N-CA 123.496 0.718 . . . . 0.0 109.675 177.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 20.2 t60 -115.16 -50.92 2.73 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 171.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 44.0 t-80 -144.15 60.57 1.36 Allowed 'General case' 0 C--O 1.241 0.615 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 167.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -74.3 148.24 41.58 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 114.11 -1.405 . . . . 0.0 108.523 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 47.7 t60 66.35 81.41 0.2 Allowed 'General case' 0 N--CA 1.48 1.05 0 O-C-N 124.112 0.883 . . . . 0.0 108.997 -171.077 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 9.3 t60 -80.86 -25.75 37.43 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 123.133 0.573 . . . . 0.0 110.559 -176.547 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 47.2 t-80 . . . . . 0 C--O 1.252 1.2 0 CA-C-O 118.532 -0.747 . . . . 0.0 109.118 178.448 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.628 0 N-CA-C 112.29 -0.324 . . . . 0.0 112.29 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -85.84 143.14 28.43 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.672 0.789 . . . . 0.0 109.985 -179.125 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 74.3 mmt-85 -86.81 68.99 10.27 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 174.023 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.461 ' H ' ' HD3' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -67.9 115.41 7.4 Favored 'General case' 0 CA--C 1.544 0.725 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.964 179.875 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 7.1 p -83.58 132.2 32.01 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 C-N-CA 123.123 0.569 . . . . 0.0 110.13 -178.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 28.0 ttm-85 -92.97 92.43 7.85 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 174.205 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 97.5 mt -73.65 96.18 2.44 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.716 0.806 . . . . 0.0 110.231 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 58.7 mt -104.72 109.43 27.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 174.129 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -77.98 177.13 8.51 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.539 1.136 . . . . 0.0 110.551 173.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.5 p -69.33 -74.78 0.12 Allowed 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 123.074 0.55 . . . . 0.0 110.141 176.046 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -174.46 -65.32 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.976 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 176.598 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -179.5 155.36 15.58 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.431 -178.667 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.54 85.39 0.35 Allowed Glycine 0 CA--C 1.533 1.212 0 CA-C-N 117.027 0.414 . . . . 0.0 113.732 -174.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -100.9 170.98 7.94 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 123.856 0.862 . . . . 0.0 110.17 175.559 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 49.0 m -85.15 114.55 22.36 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 123.241 0.616 . . . . 0.0 110.336 178.454 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -90.44 165.86 13.58 Favored 'General case' 0 C--O 1.243 0.739 0 C-N-CA 124.109 0.964 . . . . 0.0 108.65 172.546 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.6 p -80.51 158.87 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.815 175.557 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.407 ' HD2' ' O ' ' A' ' 81' ' ' GLY . 32.8 ptt180 -63.76 -170.03 0.03 OUTLIER 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 124.623 1.169 . . . . 0.0 111.822 174.812 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.537 ' HB3' ' H ' ' A' ' 24' ' ' ARG . 1.9 pt? -57.1 90.61 0.01 OUTLIER 'General case' 0 CA--C 1.555 1.17 0 CA-C-O 122.215 1.007 . . . . 0.0 110.738 172.171 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -142.26 8.9 1.84 Allowed 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 124.651 1.18 . . . . 0.0 110.284 -177.432 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 25.5 m -157.26 -42.21 0.07 Allowed 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.64 1.176 . . . . 0.0 108.798 -171.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -145.14 150.79 37.39 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-N 114.232 -1.349 . . . . 0.0 108.526 178.242 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.528 HG22 HD12 ' A' ' 40' ' ' ILE . 33.0 m -63.35 113.51 3.27 Favored 'General case' 0 C--N 1.353 0.754 0 C-N-CA 123.272 0.629 . . . . 0.0 109.876 -179.556 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.554 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 17.0 mtm180 -130.81 166.0 21.77 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.918 0.887 . . . . 0.0 111.497 -173.019 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 14.0 tt -150.88 150.28 13.54 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.447 -170.108 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.8 m-80 -94.08 100.39 12.51 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 175.008 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.7 t -88.7 112.39 23.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.022 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.434 HG13 HG22 ' A' ' 35' ' ' VAL . 17.3 t -101.41 100.6 10.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.437 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -178.206 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -58.38 120.39 43.93 Favored Pre-proline 0 CA--C 1.552 1.021 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 177.311 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -71.78 -15.75 29.88 Favored 'Trans proline' 0 C--N 1.366 1.469 0 C-N-CA 122.845 2.364 . . . . 0.0 113.555 -172.092 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -91.75 -52.12 4.9 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.919 0.487 . . . . 0.0 110.325 -175.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.3 p -88.66 -32.85 17.81 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.637 0.775 . . . . 0.0 112.375 -177.42 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.64 3.9 68.29 Favored Glycine 0 N--CA 1.479 1.559 0 CA-C-O 120.097 -0.28 . . . . 0.0 113.14 -174.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.0 mmtm -63.05 109.24 1.42 Allowed 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.753 0.821 . . . . 0.0 111.692 179.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.434 HG22 HG13 ' A' ' 28' ' ' VAL . 41.1 t -90.45 111.82 23.99 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 172.161 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -129.62 131.42 46.46 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.608 0.763 . . . . 0.0 110.233 -174.557 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 53.4 mt -76.26 115.23 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.426 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.75 153.81 40.38 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.946 0.898 . . . . 0.0 109.977 -174.492 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.554 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 2.7 mp0 -93.58 124.09 37.34 Favored 'General case' 0 C--O 1.244 0.79 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 -176.065 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.528 HD12 HG22 ' A' ' 23' ' ' THR . 56.0 mt -75.04 109.46 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -178.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 67.8 mtp180 -71.72 -42.62 67.12 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 124.59 1.156 . . . . 0.0 110.349 -178.173 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -159.64 170.13 22.25 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-N 114.822 -1.081 . . . . 0.0 108.646 -176.439 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.679 HG12 HG12 ' A' ' 64' ' ' VAL . 3.5 m -119.58 90.68 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 C-N-CA 124.712 1.205 . . . . 0.0 107.964 176.328 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.7 p -147.37 141.53 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 CA-C-O 121.256 0.55 . . . . 0.0 111.442 -166.491 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.443 ' HB3' ' HB ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -142.42 -83.46 0.18 Allowed 'General case' 0 CA--C 1.549 0.933 0 C-N-CA 125.405 1.482 . . . . 0.0 108.526 178.823 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -114.37 15.1 18.03 Favored 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 124.927 1.291 . . . . 0.0 109.409 171.429 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 64.8 p 55.6 78.85 0.18 Allowed 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 125.744 1.618 . . . . 0.0 111.709 -177.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -71.66 -37.41 70.8 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.309 179.48 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 15.5 m120 -114.95 91.92 28.53 Favored Pre-proline 0 N--CA 1.484 1.227 0 C-N-CA 123.872 0.869 . . . . 0.0 108.719 174.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -62.24 110.94 1.13 Allowed 'Trans proline' 0 C--N 1.38 2.203 0 C-N-CA 123.573 2.848 . . . . 0.0 113.017 -176.462 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.0 t60 77.52 -7.26 1.86 Allowed 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 125.55 1.54 . . . . 0.0 112.88 172.055 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -68.16 117.07 9.5 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 122.881 0.472 . . . . 0.0 110.893 -177.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 18.5 t -71.04 -20.54 21.72 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.146 0 C-N-CA 123.525 0.73 . . . . 0.0 109.888 177.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 59.5 mtp85 -73.11 6.49 2.7 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 123.888 0.875 . . . . 0.0 112.504 173.582 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.73 -9.29 58.51 Favored 'General case' 0 CA--C 1.558 1.286 0 C-N-CA 123.248 0.619 . . . . 0.0 110.306 169.843 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 31.2 p-10 -56.96 -20.15 22.12 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 123.797 0.839 . . . . 0.0 111.388 172.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.3 mt -67.31 90.97 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.09 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 166.254 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.9 mt -82.68 151.92 4.04 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.701 -179.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 75.8 p -128.69 170.53 13.17 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.852 0.861 . . . . 0.0 109.615 174.183 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.3 ttm180 -71.9 138.14 47.94 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 171.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.77 -14.62 51.43 Favored Glycine 0 C--N 1.343 0.97 0 C-N-CA 123.249 0.452 . . . . 0.0 113.028 -177.385 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -70.85 141.36 51.27 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 123.334 0.653 . . . . 0.0 109.486 177.194 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.443 ' HB ' ' HB3' ' A' ' 45' ' ' GLU . 77.1 t -91.16 118.42 36.39 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.81 -179.695 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.679 HG12 HG12 ' A' ' 43' ' ' VAL . 34.1 m -103.31 135.85 38.88 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.422 174.291 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -86.27 127.01 34.71 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 174.634 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 32.6 p -128.6 174.32 9.5 Favored 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.491 ' ND2' ' HB2' ' A' ' 39' ' ' GLU . 94.2 m-20 -65.03 -12.64 52.77 Favored 'General case' 0 N--CA 1.482 1.128 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 178.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.1 mt -95.6 -47.89 6.04 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 176.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 167.57 -161.96 35.76 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.828 178.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -75.12 142.69 43.58 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.189 0.596 . . . . 0.0 110.015 175.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.0 t -135.88 146.45 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.268 0 C-N-CA 123.155 0.582 . . . . 0.0 110.111 -174.801 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.65 ' HG2' HD13 ' A' ' 88' ' ' ILE . 33.7 mmt180 -91.65 119.7 31.77 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 171.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.2 t -73.36 122.62 26.64 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.2 p -108.56 -32.67 7.29 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.536 0.735 . . . . 0.0 110.26 -172.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.6 t -97.73 -178.77 4.22 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.62 0.768 . . . . 0.0 110.147 178.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.44 128.92 73.65 Favored Pre-proline 0 CA--C 1.552 1.033 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 174.462 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -68.66 103.66 1.02 Allowed 'Trans proline' 0 C--N 1.373 1.843 0 C-N-CA 123.024 2.483 . . . . 0.0 113.837 -173.092 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 73.37 -0.78 46.57 Favored Glycine 0 C--N 1.344 1.004 0 CA-C-N 115.217 -0.901 . . . . 0.0 114.961 171.128 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 31.8 mm-40 -67.81 -43.51 79.49 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 123.28 0.632 . . . . 0.0 111.689 -172.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.539 ' HB3' HG12 ' A' ' 82' ' ' VAL . 24.6 t70 -89.06 3.68 50.9 Favored 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 123.618 0.767 . . . . 0.0 110.75 175.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' GLY . . . . . 0.407 ' O ' ' HD2' ' A' ' 18' ' ' ARG . . . 81.42 37.16 18.37 Favored Glycine 0 C--N 1.343 0.933 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -171.375 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.539 HG12 ' HB3' ' A' ' 80' ' ' ASP . 13.3 p -162.28 140.54 2.26 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 CA-C-N 114.541 -0.83 . . . . 0.0 109.809 -174.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.4 mt -121.61 128.8 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 N-CA-C 104.904 -2.258 . . . . 0.0 104.904 165.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -120.81 153.35 37.21 Favored 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -172.7 179.66 44.06 Favored Glycine 0 N--CA 1.446 -0.643 0 O-C-N 123.99 0.806 . . . . 0.0 113.588 175.385 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.1 m -123.36 136.16 60.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 124.05 0.94 . . . . 0.0 110.007 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 27.0 tp -66.56 134.16 51.81 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 123.011 0.524 . . . . 0.0 111.133 -174.338 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.65 HD13 ' HG2' ' A' ' 72' ' ' ARG . 34.1 pt -135.06 175.1 11.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.785 1.234 . . . . 0.0 109.59 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 39.1 mtt180 -130.88 84.15 2.17 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.451 0.7 . . . . 0.0 109.284 -176.185 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.8 mm-40 -95.8 -77.05 0.48 Allowed 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.145 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 77.4 mt -85.04 94.62 8.87 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 169.096 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -60.72 128.63 37.49 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 123.083 0.553 . . . . 0.0 111.725 -176.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.1 t60 -77.09 -29.8 55.12 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 169.432 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -167.81 133.03 1.89 Allowed 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 125.051 1.34 . . . . 0.0 107.692 170.361 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 54.2 t-80 -170.8 -33.83 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 123.412 0.685 . . . . 0.0 109.777 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -71.04 88.91 0.79 Allowed 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 123.913 0.885 . . . . 0.0 109.06 175.644 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 22.1 p80 -74.32 -35.81 63.67 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.549 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 48.3 t60 . . . . . 0 C--O 1.243 0.737 0 C-N-CA 124.219 1.007 . . . . 0.0 108.342 177.113 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.731 0 N-CA-C 112.494 -0.242 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -75.04 104.06 5.47 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 123.717 0.807 . . . . 0.0 110.41 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 56.4 mtm180 -79.94 73.19 6.73 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.636 0.774 . . . . 0.0 110.192 175.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 60.7 ttt180 -78.9 83.81 4.99 Favored 'General case' 0 CA--C 1.539 0.521 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 174.461 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.6 t -87.23 93.5 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 115.424 -0.807 . . . . 0.0 108.889 -178.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? -73.24 92.61 1.78 Allowed 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 93.8 mt -75.53 103.46 5.66 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.504 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.0 tt -74.05 130.72 35.78 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 124.026 0.93 . . . . 0.0 110.937 -178.582 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 53.7 ttp180 -142.62 156.25 45.05 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.773 0.829 . . . . 0.0 109.344 175.382 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 88.4 m 66.16 101.49 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 125.212 1.405 . . . . 0.0 110.25 -171.292 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 31.3 mmt180 -77.42 -38.76 49.02 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.497 174.676 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.55 158.55 25.81 Favored Glycine 0 C--N 1.339 0.7 0 CA-C-N 114.814 -1.084 . . . . 0.0 111.1 -174.272 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 173.99 109.9 0.24 Allowed Glycine 0 C--N 1.333 0.416 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -178.039 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 41.3 t-20 -142.29 93.58 2.55 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 -177.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 64.8 p -98.69 112.29 24.4 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 124.021 0.928 . . . . 0.0 109.582 177.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.9 mmtp -120.11 -80.22 0.62 Allowed 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 123.253 0.621 . . . . 0.0 110.643 -178.401 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 13.4 p -153.17 146.63 14.67 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 C-N-CA 123.59 0.756 . . . . 0.0 109.32 -175.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 18.3 mmm180 -82.35 -156.19 0.16 Allowed 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 123.647 0.779 . . . . 0.0 109.842 176.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -79.9 42.57 0.55 Allowed 'General case' 0 CA--C 1.56 1.335 0 CA-C-O 121.94 0.876 . . . . 0.0 110.736 171.552 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -87.33 48.96 1.72 Allowed 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 124.88 1.272 . . . . 0.0 110.135 -174.225 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.9 m -151.3 -57.35 0.16 Allowed 'General case' 0 C--O 1.24 0.564 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -162.33 172.63 15.34 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 125.153 1.381 . . . . 0.0 107.819 176.004 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 26.3 m -62.87 116.38 5.21 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.311 0.644 . . . . 0.0 110.35 -176.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 17.3 tpp85 -110.22 141.48 43.1 Favored 'General case' 0 C--O 1.241 0.637 0 C-N-CA 123.561 0.745 . . . . 0.0 110.446 -171.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 16.2 tt -139.94 147.41 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.953 0.901 . . . . 0.0 109.506 178.109 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -97.59 102.38 14.13 Favored 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 170.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.537 HG22 HG21 ' A' ' 71' ' ' VAL . 96.5 t -82.91 106.14 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 C-N-CA 123.957 0.903 . . . . 0.0 109.698 -177.287 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 86' ' ' VAL . 40.0 t -97.21 102.86 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.24 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -56.1 116.59 12.86 Favored Pre-proline 0 CA--C 1.549 0.923 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 173.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -72.91 -19.48 23.39 Favored 'Trans proline' 0 C--N 1.368 1.556 0 C-N-CA 122.332 2.022 . . . . 0.0 113.378 -172.686 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -81.88 -51.21 8.32 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 123.264 0.626 . . . . 0.0 110.465 -175.181 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.7 p -92.31 -25.78 18.42 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.876 0.87 . . . . 0.0 111.446 -177.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.2 4.65 71.18 Favored Glycine 0 N--CA 1.473 1.113 0 CA-C-O 119.597 -0.557 . . . . 0.0 113.119 -178.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -72.08 112.68 8.37 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.157 0.583 . . . . 0.0 111.811 -173.216 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.451 HG22 HG22 ' A' ' 28' ' ' VAL . 39.1 t -82.6 115.18 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 171.503 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -130.79 130.0 43.13 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.96 0.904 . . . . 0.0 109.123 -179.817 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 59.4 mt -78.93 125.61 38.42 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 C-N-CA 122.91 0.484 . . . . 0.0 110.139 -177.319 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -134.17 170.99 14.86 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 124.575 1.15 . . . . 0.0 110.02 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -117.79 135.73 53.87 Favored 'General case' 0 C--O 1.243 0.748 0 C-N-CA 123.329 0.652 . . . . 0.0 109.547 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.1 mt -78.51 112.35 16.43 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.726 0 O-C-N 123.893 0.746 . . . . 0.0 110.311 -175.817 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 72.6 mtp180 -64.69 -53.93 39.6 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.842 1.257 . . . . 0.0 110.365 175.417 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 55.5 t30 -143.75 157.65 44.24 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.522 0.729 . . . . 0.0 109.535 -176.209 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 55.3 t -121.33 -39.09 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 122.925 0.49 . . . . 0.0 110.374 179.134 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.3 p -64.18 122.0 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-O 121.179 0.514 . . . . 0.0 110.37 -179.27 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -86.54 13.65 8.12 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 123.901 0.881 . . . . 0.0 113.175 -168.259 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -70.44 -29.51 66.11 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 123.224 0.609 . . . . 0.0 112.092 -176.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 32.6 p 52.79 28.91 6.87 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 125.464 1.505 . . . . 0.0 111.447 -171.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -115.51 35.96 4.17 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 124.1 0.96 . . . . 0.0 110.864 -170.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 36.8 t30 67.53 94.88 0.05 OUTLIER Pre-proline 0 N--CA 1.484 1.23 0 C-N-CA 124.782 1.233 . . . . 0.0 110.916 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -71.52 78.42 1.63 Allowed 'Trans proline' 0 C--N 1.375 1.935 0 C-N-CA 122.899 2.399 . . . . 0.0 111.818 175.487 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.4 t-80 -65.61 105.81 1.31 Allowed 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 123.388 0.675 . . . . 0.0 109.497 179.225 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 60.83 74.15 0.46 Allowed 'General case' 0 C--O 1.239 0.524 0 O-C-N 124.757 1.286 . . . . 0.0 109.332 -169.022 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.9 p -57.81 104.6 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 CA-C-N 114.889 -1.051 . . . . 0.0 110.976 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 32.4 ptt180 -144.7 176.88 9.1 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.323 -173.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 11.4 mmt180 58.61 30.83 20.39 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 124.191 0.996 . . . . 0.0 110.706 178.696 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -70.76 79.17 0.61 Allowed 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.246 1.018 . . . . 0.0 110.859 -174.509 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.4 HG22 HG23 ' A' ' 59' ' ' THR . 41.1 mm -79.32 83.77 1.13 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.63 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 178.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.4 mt -72.71 118.26 17.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 CA-C-N 114.726 -1.125 . . . . 0.0 108.222 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.4 HG23 HG22 ' A' ' 57' ' ' ILE . 7.5 p -131.61 170.46 14.73 Favored 'General case' 0 C--O 1.243 0.726 0 C-N-CA 124.872 1.269 . . . . 0.0 108.952 -175.366 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -69.52 130.79 43.43 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 177.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.95 -15.34 63.62 Favored Glycine 0 C--N 1.345 1.029 0 CA-C-O 119.48 -0.622 . . . . 0.0 113.531 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.62 134.3 49.74 Favored 'General case' 0 C--O 1.246 0.878 0 C-N-CA 122.957 0.503 . . . . 0.0 110.342 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 67.1 t -88.55 112.88 24.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 176.291 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.3 m -102.94 138.56 26.73 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -88.11 126.45 35.12 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 61.3 p -134.0 172.49 12.75 Favored 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 124.097 0.959 . . . . 0.0 109.091 -175.725 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -71.88 -13.12 61.57 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 112.331 0.493 . . . . 0.0 112.331 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 88.5 mt -97.12 -15.34 21.0 Favored 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 123.3 0.64 . . . . 0.0 111.336 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.09 -147.88 19.52 Favored Glycine 0 C--N 1.341 0.848 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 -173.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -109.75 143.0 40.17 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 117.486 0.643 . . . . 0.0 109.404 177.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.537 HG21 HG22 ' A' ' 27' ' ' VAL . 22.0 t -128.73 144.96 36.42 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 123.425 0.69 . . . . 0.0 109.862 -174.345 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.632 ' HG2' HD13 ' A' ' 88' ' ' ILE . 10.5 mmt180 -94.94 123.71 38.56 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 168.295 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 56.9 t -76.22 94.92 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.4 p -85.15 -39.84 17.42 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.307 0.643 . . . . 0.0 111.109 -178.237 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.4 m -77.65 164.55 25.22 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.911 173.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 24.3 mmt180 -65.88 130.23 94.41 Favored Pre-proline 0 CA--C 1.548 0.87 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 172.339 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -77.62 43.16 1.29 Allowed 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 123.502 2.801 . . . . 0.0 112.387 175.586 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -170.95 -137.3 2.27 Favored Glycine 0 C--N 1.334 0.461 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -172.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 21.2 tm0? 67.88 -72.33 0.1 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 124.608 1.163 . . . . 0.0 110.136 -177.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.425 ' HB3' HG12 ' A' ' 82' ' ' VAL . 33.3 t70 -91.45 -12.93 33.25 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 124.211 1.004 . . . . 0.0 110.31 171.106 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 94.56 -6.49 70.9 Favored Glycine 0 C--N 1.343 0.968 0 C-N-CA 123.386 0.517 . . . . 0.0 112.981 -174.06 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.425 HG12 ' HB3' ' A' ' 80' ' ' ASP . 14.5 p -92.83 141.42 14.68 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.512 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 31.5 mt -96.09 146.87 6.58 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -152.66 152.07 31.33 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -169.0 -167.34 29.48 Favored Glycine 0 C--N 1.343 0.972 0 CA-C-O 120.015 -0.325 . . . . 0.0 113.028 -178.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.509 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 35.9 m -116.46 132.68 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 123.776 0.83 . . . . 0.0 110.925 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 38.8 tp -71.63 106.07 3.91 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.463 0.705 . . . . 0.0 111.13 -176.457 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.632 HD13 ' HG2' ' A' ' 72' ' ' ARG . 41.4 pt -97.34 171.65 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.524 0.73 . . . . 0.0 110.262 175.252 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 16.7 mmt180 -115.22 21.15 14.4 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.671 0.788 . . . . 0.0 110.235 -173.108 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.449 ' HB2' HD12 ' A' ' 88' ' ' ILE . 33.9 tt0 -64.8 -75.9 0.08 Allowed 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.433 0.693 . . . . 0.0 112.657 -164.343 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 58.3 mt -81.33 69.08 7.88 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-O 121.834 0.826 . . . . 0.0 110.316 -173.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -77.77 121.27 23.83 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -62.52 -28.4 69.82 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 122.288 0.235 . . . . 0.0 111.497 -174.76 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 35.4 t60 -74.27 -36.59 63.82 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 122.966 0.506 . . . . 0.0 110.638 177.077 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -58.85 128.99 40.0 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 123.607 0.763 . . . . 0.0 109.949 -179.25 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 69.6 t60 -60.74 111.67 1.72 Allowed 'General case' 0 CA--C 1.544 0.741 0 O-C-N 124.26 0.975 . . . . 0.0 111.047 -175.501 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 74.5 t60 -63.88 137.15 57.9 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 115.256 -0.884 . . . . 0.0 109.217 172.579 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 38.9 p-80 . . . . . 0 C--O 1.25 1.124 0 C-N-CA 124.109 0.964 . . . . 0.0 109.312 -178.254 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.785 0 N-CA-C 112.651 -0.18 . . . . 0.0 112.651 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -84.01 117.02 23.13 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 123.537 0.735 . . . . 0.0 109.71 -179.28 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 22.6 mmm180 -110.3 123.84 50.56 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 123.049 0.54 . . . . 0.0 110.043 -179.582 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 15.7 ptt180 -145.16 97.41 3.0 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 124.23 1.012 . . . . 0.0 109.292 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 38.3 t -92.22 103.55 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 123.191 0.596 . . . . 0.0 109.515 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 55.3 ttt180 -110.03 138.74 45.98 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.598 0.759 . . . . 0.0 109.636 178.349 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -157.06 101.47 1.93 Allowed 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 177.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.2 tt -114.55 135.1 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 124.243 1.017 . . . . 0.0 109.244 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -125.64 117.68 24.03 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.704 0.802 . . . . 0.0 109.302 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 35.9 p -72.04 89.16 1.11 Allowed 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 123.79 0.836 . . . . 0.0 110.44 -178.381 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 25.1 mmt180 -105.42 117.24 33.5 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.011 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 177.7 50.99 0.07 OUTLIER Glycine 0 C--N 1.34 0.776 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 178.233 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.31 111.99 4.37 Favored Glycine 0 C--N 1.354 1.574 0 N-CA-C 112.259 -0.336 . . . . 0.0 112.259 -176.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 39.6 m-80 -76.19 107.43 8.42 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.108 0.563 . . . . 0.0 110.254 -178.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 15.4 p -72.46 96.93 1.99 Allowed 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.215 0.606 . . . . 0.0 110.076 174.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 13.2 ptmm? -76.45 99.22 4.82 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.107 173.414 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.9 p -163.53 162.34 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 123.74 0.816 . . . . 0.0 109.702 -169.434 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.1 mpt_? -74.05 171.4 13.58 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 123.975 0.91 . . . . 0.0 110.502 177.261 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.441 ' HB3' ' HB2' ' A' ' 24' ' ' ARG . 2.0 pp -62.04 143.08 57.09 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.078 0.551 . . . . 0.0 112.45 -178.548 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -159.7 116.02 2.52 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.798 0.839 . . . . 0.0 108.86 -179.308 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 45.4 m 68.55 -70.33 0.13 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 125.138 1.375 . . . . 0.0 111.174 -175.105 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ASP . . . . . 0.545 ' HB2' HH12 ' A' ' 24' ' ' ARG . 3.7 m-20 -77.24 109.68 11.32 Favored 'General case' 0 C--O 1.247 0.945 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 175.505 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 26.2 m -65.24 132.59 49.49 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 122.984 0.514 . . . . 0.0 110.694 -177.226 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.545 HH12 ' HB2' ' A' ' 22' ' ' ASP . 77.3 mmt-85 -102.21 134.8 44.89 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.42 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 14.2 tt -140.18 136.11 37.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 123.85 0.86 . . . . 0.0 109.745 -175.771 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.2 m-80 -85.55 100.59 12.02 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 177.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.2 t -87.4 108.23 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -176.313 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 40.9 t -95.54 101.67 12.7 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -63.83 116.43 26.69 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 175.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -71.47 -19.76 28.17 Favored 'Trans proline' 0 C--N 1.368 1.559 0 C-N-CA 123.232 2.621 . . . . 0.0 113.194 -171.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -92.67 -52.94 4.39 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 123.499 0.72 . . . . 0.0 110.822 -171.423 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 62.8 p -90.9 -27.83 18.5 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 123.424 0.69 . . . . 0.0 111.476 -177.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.62 4.73 69.87 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-N 116.416 -0.356 . . . . 0.0 113.369 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -71.45 118.74 14.65 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 123.293 0.637 . . . . 0.0 110.818 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.4 t -108.33 134.84 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 123.679 0.792 . . . . 0.0 108.908 177.255 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -152.22 148.81 28.02 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 122.87 0.468 . . . . 0.0 110.357 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.429 HG22 ' HD2' ' A' ' 24' ' ' ARG . 51.6 mt -87.12 98.31 7.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.89 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.21 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -95.87 172.21 8.16 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 124.282 1.033 . . . . 0.0 110.646 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -108.26 131.99 54.13 Favored 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 176.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.495 HG12 HG22 ' A' ' 66' ' ' THR . 57.1 mt -75.27 112.66 13.1 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 177.697 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 40.4 mtt-85 -73.11 -52.9 12.52 Favored 'General case' 0 N--CA 1.475 0.825 0 CA-C-O 122.253 1.025 . . . . 0.0 109.418 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.613 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 29.8 t30 -126.04 112.3 15.71 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 113.365 -1.743 . . . . 0.0 108.73 -169.663 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.8 m -81.08 -15.8 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 123.175 0.59 . . . . 0.0 111.282 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -78.8 143.9 11.92 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.917 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 174.76 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.38 -57.85 3.56 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 175.751 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 7.2 p30 171.98 123.33 0.02 OUTLIER 'General case' 0 C--O 1.245 0.819 0 C-N-CA 125.994 1.717 . . . . 0.0 107.376 -176.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 20.2 p -143.91 -74.18 0.26 Allowed 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.644 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -175.12 115.3 0.15 Allowed 'General case' 0 C--O 1.239 0.514 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -177.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 72.2 m-20 62.78 88.73 0.12 Allowed Pre-proline 0 CA--C 1.551 0.993 0 C-N-CA 123.968 0.907 . . . . 0.0 109.913 -173.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -76.03 17.47 0.72 Allowed 'Trans proline' 0 C--N 1.375 1.945 0 C-N-CA 122.944 2.429 . . . . 0.0 114.219 -174.028 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.6 t60 -83.4 62.23 6.63 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 123.637 0.775 . . . . 0.0 110.005 178.357 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 48.6 t80 53.03 67.03 1.06 Allowed 'General case' 0 CA--C 1.556 1.19 0 C-N-CA 125.364 1.466 . . . . 0.0 112.128 179.514 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.43 HG23 ' HG2' ' A' ' 54' ' ' ARG . 12.2 m -94.15 -21.41 5.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.671 171.319 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.43 ' HG2' HG23 ' A' ' 53' ' ' VAL . 9.3 mmm180 -108.38 158.89 17.1 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 124.058 0.943 . . . . 0.0 108.754 177.062 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 31.2 mmm180 -82.29 171.07 14.65 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.447 0.699 . . . . 0.0 111.494 -176.004 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 20.4 m-80 -78.5 21.05 0.39 Allowed 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.808 0.843 . . . . 0.0 111.83 177.087 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.1 mt -72.98 93.68 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 174.091 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.403 ' O ' ' HG3' ' A' ' 77' ' ' PRO . 82.9 mt -93.75 128.68 44.97 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.379 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 38.1 p -126.3 164.29 21.37 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.569 0.748 . . . . 0.0 109.657 -177.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 45.2 ttp180 -73.47 141.41 46.83 Favored 'General case' 0 N--CA 1.482 1.138 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 176.504 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.88 2.57 90.33 Favored Glycine 0 C--N 1.345 1.06 0 O-C-N 123.198 0.311 . . . . 0.0 112.971 -176.338 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.0 163.12 16.46 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 123.525 0.73 . . . . 0.0 110.774 179.285 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 38.8 t -110.01 124.85 67.09 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 173.319 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 20.9 m -112.88 168.45 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 168.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.613 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 28.0 tt0 -115.19 134.33 55.24 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 170.711 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.495 HG22 HG12 ' A' ' 40' ' ' ILE . 43.8 p -123.87 -177.77 3.85 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.843 0.857 . . . . 0.0 109.551 -173.611 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.8 m-20 -58.38 -28.72 65.42 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 122.933 0.493 . . . . 0.0 111.318 175.402 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 77.8 mt -90.07 -45.71 8.97 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.258 0.623 . . . . 0.0 110.748 -178.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 165.66 -166.04 38.29 Favored Glycine 0 N--CA 1.477 1.416 0 CA-C-O 119.715 -0.492 . . . . 0.0 112.093 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -73.26 132.98 43.78 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 117.653 0.727 . . . . 0.0 109.843 176.609 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 65.2 t -128.74 144.89 36.67 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.905 0 C-N-CA 124.402 1.081 . . . . 0.0 110.29 -174.006 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.553 ' HG2' HG21 ' A' ' 88' ' ' ILE . 33.2 mmt180 -84.98 121.25 27.51 Favored 'General case' 0 N--CA 1.479 1.017 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 168.309 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.5 t -73.21 122.88 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.063 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 70.9 p -107.72 -23.9 11.92 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 123.179 0.592 . . . . 0.0 110.999 -176.129 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 45.7 m -93.05 176.92 6.23 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-O 121.309 0.576 . . . . 0.0 111.751 176.645 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 30.8 mmt180 -106.65 127.09 28.8 Favored Pre-proline 0 C--O 1.241 0.635 0 CA-C-N 114.839 -1.073 . . . . 0.0 108.404 171.159 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.403 ' HG3' ' O ' ' A' ' 58' ' ' ILE . 37.1 Cg_endo -60.24 120.24 7.89 Favored 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 123.228 2.619 . . . . 0.0 112.474 -176.54 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 91.38 -36.68 3.56 Favored Glycine 0 C--N 1.341 0.824 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.994 176.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 14.3 mm100 -64.24 -31.81 73.15 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.691 0.796 . . . . 0.0 111.836 -174.316 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -106.24 6.23 30.55 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.718 0.807 . . . . 0.0 111.566 178.639 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 85.57 -61.32 4.59 Favored Glycine 0 C--N 1.349 1.276 0 C-N-CA 123.086 0.374 . . . . 0.0 112.273 -175.467 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -113.26 159.52 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 124.467 1.107 . . . . 0.0 108.793 175.757 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 25' ' ' ILE . 41.1 mt -92.52 147.68 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 174.443 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -125.37 162.98 23.58 Favored 'General case' 0 C--O 1.246 0.888 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 171.577 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.28 179.38 41.41 Favored Glycine 0 C--N 1.335 0.519 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.952 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.2 m -121.42 131.0 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 C-N-CA 123.433 0.693 . . . . 0.0 109.437 175.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 21.4 tp -67.26 131.27 45.42 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.132 0.573 . . . . 0.0 110.006 -177.028 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.553 HG21 ' HG2' ' A' ' 72' ' ' ARG . 33.4 pt -123.15 161.12 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 121.665 0.745 . . . . 0.0 111.276 -176.647 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 26.5 mmt180 -115.94 8.29 14.63 Favored 'General case' 0 CA--C 1.548 0.884 0 CA-C-N 114.195 -1.366 . . . . 0.0 109.636 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -60.28 -62.14 2.09 Favored 'General case' 0 C--N 1.358 0.951 0 C-N-CA 123.959 0.904 . . . . 0.0 112.237 -172.445 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 22.4 mt -66.64 152.73 44.79 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 123.364 0.415 . . . . 0.0 111.035 -179.031 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 15.1 tp10 -58.93 -43.4 91.14 Favored 'General case' 0 N--CA 1.472 0.673 0 O-C-N 124.352 1.032 . . . . 0.0 110.039 -176.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 9.2 t-80 58.22 31.84 21.29 Favored 'General case' 0 CA--C 1.552 1.048 0 C-N-CA 124.646 1.178 . . . . 0.0 111.664 172.422 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 16.3 m170 -80.33 71.22 7.11 Favored 'General case' 0 N--CA 1.478 0.939 0 CA-C-O 122.188 0.994 . . . . 0.0 109.39 174.524 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -121.17 9.53 10.49 Favored 'General case' 0 CA--C 1.555 1.138 0 CA-C-N 113.86 -1.518 . . . . 0.0 108.542 178.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 40.5 t60 -150.69 145.37 25.77 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 126.175 1.79 . . . . 0.0 107.563 -177.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -69.71 119.96 14.74 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 123.411 0.684 . . . . 0.0 110.909 -177.024 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 4.2 t60 . . . . . 0 CA--C 1.551 0.985 0 C-N-CA 123.601 0.76 . . . . 0.0 109.133 178.938 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.325 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -167.89 172.25 9.17 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.037 0.935 . . . . 0.0 109.009 -177.51 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -68.02 144.64 55.04 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 122.762 0.425 . . . . 0.0 111.253 177.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 5.5 mmp_? -79.35 169.95 17.33 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-N 115.395 -0.821 . . . . 0.0 109.699 175.172 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.7 t -60.42 93.15 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 C-N-CA 123.402 0.681 . . . . 0.0 109.257 179.177 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.7 ptt180 -80.53 154.19 27.66 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.293 -171.211 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -81.27 -6.75 59.22 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.997 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 60.4 mt -70.83 97.16 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.76 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 169.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 3.2 ppt_? -107.02 -6.25 17.59 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.127 0.971 . . . . 0.0 111.198 -177.286 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 25.5 m -66.64 89.75 0.16 Allowed 'General case' 0 CA--C 1.552 1.033 0 C-N-CA 123.69 0.796 . . . . 0.0 111.146 -174.154 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 25.6 tpt180 -170.42 105.13 0.28 Allowed 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.261 1.424 . . . . 0.0 107.449 179.273 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 127.87 179.89 16.11 Favored Glycine 0 N--CA 1.466 0.699 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -175.657 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 162.33 -133.09 2.99 Favored Glycine 0 C--N 1.339 0.733 0 N-CA-C 111.532 -0.627 . . . . 0.0 111.532 -179.143 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -83.54 73.76 10.18 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 176.554 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 86.8 m -137.19 111.0 8.15 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.16 -0.927 . . . . 0.0 108.781 177.002 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.584 ' HE3' HD11 ' A' ' 37' ' ' ILE . 0.0 OUTLIER -165.11 158.57 16.82 Favored 'General case' 0 C--O 1.24 0.585 0 C-N-CA 123.374 0.67 . . . . 0.0 109.669 177.799 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 7.9 p -70.7 146.07 12.3 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 165.373 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.72 175.75 2.81 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 122.65 0.38 . . . . 0.0 110.76 174.283 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.439 HD21 ' HA ' ' A' ' 82' ' ' VAL . 2.2 pt? -52.41 102.72 0.05 Allowed 'General case' 0 CA--C 1.559 1.323 0 CA-C-O 121.94 0.876 . . . . 0.0 110.939 174.614 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -135.32 -54.3 0.79 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.079 -175.392 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 38.0 p -63.04 -40.09 96.67 Favored 'General case' 0 CA--C 1.546 0.816 0 CA-C-N 114.706 -1.133 . . . . 0.0 110.724 175.043 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -158.96 153.44 24.22 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 124.205 1.002 . . . . 0.0 109.158 178.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.44 HG22 HD12 ' A' ' 40' ' ' ILE . 91.4 m -76.21 110.39 10.67 Favored 'General case' 0 CA--C 1.548 0.868 0 CA-C-O 121.624 0.726 . . . . 0.0 111.177 -176.284 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.518 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 36.8 mtm180 -127.23 170.1 12.79 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.835 1.254 . . . . 0.0 110.81 177.276 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.1 tt -135.7 136.21 50.51 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-N 114.566 -1.197 . . . . 0.0 108.95 -179.226 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ASN . . . . . 0.437 ' HB2' HD22 ' A' ' 84' ' ' ASN . 71.1 m-20 -89.78 102.1 14.8 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 177.825 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.44 HG22 HG11 ' A' ' 71' ' ' VAL . 58.5 t -98.78 136.38 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 123.873 0.869 . . . . 0.0 110.563 -170.006 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.58 HG22 HG22 ' A' ' 35' ' ' VAL . 30.1 t -122.0 122.29 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -63.98 124.43 85.15 Favored Pre-proline 0 N--CA 1.48 1.027 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 171.098 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -68.79 -20.0 40.31 Favored 'Trans proline' 0 CA--C 1.554 1.488 0 C-N-CA 122.145 1.897 . . . . 0.0 112.476 178.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.465 ' HG3' HG23 ' A' ' 32' ' ' THR . 12.8 pt-20 -88.2 -51.35 5.82 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.02 0.928 . . . . 0.0 112.115 -176.794 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.465 HG23 ' HG3' ' A' ' 31' ' ' GLU . 70.4 p -97.87 -21.49 16.87 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.125 0.57 . . . . 0.0 111.792 -173.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.8 5.28 89.54 Favored Glycine 0 C--N 1.349 1.269 0 CA-C-O 119.682 -0.51 . . . . 0.0 113.524 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -73.68 123.89 24.94 Favored 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 123.27 0.628 . . . . 0.0 111.352 -174.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.58 HG22 HG22 ' A' ' 28' ' ' VAL . 24.8 t -95.73 128.86 46.55 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.712 0 C-N-CA 123.872 0.869 . . . . 0.0 109.422 176.126 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -141.42 133.8 28.18 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 124.483 1.113 . . . . 0.0 108.574 175.656 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.584 HD11 ' HE3' ' A' ' 16' ' ' LYS . 46.6 mt -79.32 98.92 3.14 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.46 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -86.02 158.93 19.73 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.703 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.518 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 38.9 mt-10 -101.82 124.95 48.31 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.48 0.712 . . . . 0.0 109.433 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.44 HD12 HG22 ' A' ' 23' ' ' THR . 61.7 mt -76.44 108.69 9.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 47.8 mtt180 -82.87 -53.26 6.0 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.261 1.024 . . . . 0.0 110.672 -179.389 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -146.04 160.07 42.39 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -176.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.607 ' HB ' HH22 ' A' ' 54' ' ' ARG . 30.9 m -116.95 29.7 2.48 Favored 'Isoleucine or valine' 0 C--O 1.246 0.877 0 C-N-CA 123.523 0.729 . . . . 0.0 112.03 -174.313 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 m -68.05 90.67 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 CA-C-O 122.086 0.946 . . . . 0.0 110.59 173.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.541 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 37.9 mt-10 -67.47 -36.17 80.62 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 114.483 -1.235 . . . . 0.0 110.635 178.656 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -133.72 118.42 18.08 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-N 114.541 -1.209 . . . . 0.0 108.11 179.68 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.452 HG21 HD11 ' A' ' 91' ' ' LEU . 55.3 p -82.07 -15.96 51.7 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 122.516 0.327 . . . . 0.0 111.472 178.128 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -68.53 -43.35 76.91 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 123.462 0.705 . . . . 0.0 110.437 175.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -162.83 90.42 1.27 Allowed Pre-proline 0 CA--C 1.55 0.95 0 C-N-CA 123.882 0.873 . . . . 0.0 109.278 175.625 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.87 116.7 4.75 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.412 2.075 . . . . 0.0 110.823 174.114 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 46.8 m80 -73.44 92.91 1.91 Allowed 'General case' 0 C--O 1.243 0.711 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -80.36 74.86 7.2 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-O 121.86 0.838 . . . . 0.0 109.896 -176.116 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 11.5 t -111.59 -9.68 11.88 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.944 0 CA-C-N 114.576 -1.193 . . . . 0.0 108.075 169.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.607 HH22 ' HB ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -150.95 163.34 38.94 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.296 1.438 . . . . 0.0 109.554 -173.973 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 14.9 ptm180 -150.72 -49.24 0.12 Allowed 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 123.405 0.682 . . . . 0.0 110.594 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -96.19 -7.72 35.0 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 122.837 0.455 . . . . 0.0 110.291 177.344 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 72.9 mt -89.43 111.28 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 174.366 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.2 mt -115.29 140.45 36.64 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.558 0 C-N-CA 124.488 1.115 . . . . 0.0 108.434 179.6 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 33.9 p -126.15 174.4 8.52 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 124.134 0.974 . . . . 0.0 109.149 178.484 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 52.7 ttp180 -71.25 139.92 50.21 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 122.716 0.406 . . . . 0.0 110.154 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.76 -8.48 70.94 Favored Glycine 0 C--N 1.337 0.595 0 C-N-CA 123.644 0.64 . . . . 0.0 112.83 -177.16 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.94 134.54 52.21 Favored 'General case' 0 C--N 1.351 0.669 0 C-N-CA 123.611 0.765 . . . . 0.0 111.89 -177.008 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.541 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 44.1 t -90.76 112.87 25.69 Favored 'Isoleucine or valine' 0 C--N 1.344 0.341 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 169.624 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.6 m -106.26 147.13 12.07 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 123.482 0.713 . . . . 0.0 109.271 177.264 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -90.73 126.44 36.0 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 175.475 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.46 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 67.2 p -130.85 179.79 5.77 Favored 'General case' 0 C--O 1.239 0.552 0 C-N-CA 123.259 0.623 . . . . 0.0 109.774 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 19.2 p-10 -73.59 -14.69 61.23 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 123.341 0.656 . . . . 0.0 111.192 175.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.1 mt -91.16 -41.09 11.21 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 123.249 0.62 . . . . 0.0 110.325 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 155.79 -149.97 21.2 Favored Glycine 0 C--N 1.345 1.074 0 CA-C-N 116.239 -0.437 . . . . 0.0 112.056 175.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -78.91 128.49 33.38 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 173.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.44 HG11 HG22 ' A' ' 27' ' ' VAL . 48.7 t -126.85 140.33 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 122.792 0.437 . . . . 0.0 110.4 -178.42 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.743 ' HG2' HD13 ' A' ' 88' ' ' ILE . 29.2 mmt180 -88.89 131.5 35.09 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 169.461 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 82.2 t -76.87 106.72 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 171.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 40.5 p -96.38 -19.92 18.85 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.044 0.538 . . . . 0.0 110.92 -172.711 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' SER . . . . . 0.509 ' HB2' ' HB2' ' A' ' 84' ' ' ASN . 32.4 t -87.49 171.08 10.79 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.378 0.671 . . . . 0.0 110.391 175.32 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 -93.48 92.84 0.72 Allowed Pre-proline 0 CA--C 1.559 1.315 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 173.413 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -62.73 -46.36 11.41 Favored 'Trans proline' 0 C--N 1.384 2.422 0 C-N-CA 123.431 2.754 . . . . 0.0 113.958 -163.445 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -81.19 -13.5 80.71 Favored Glycine 0 C--N 1.345 1.039 0 CA-C-O 119.959 -0.356 . . . . 0.0 113.54 -177.201 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 18.5 mm-40 -90.14 -48.39 7.21 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 122.981 0.513 . . . . 0.0 111.352 -178.271 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -80.67 -14.05 58.48 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 122.82 0.448 . . . . 0.0 111.294 174.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 68.36 18.53 71.6 Favored Glycine 0 C--N 1.349 1.254 0 O-C-N 123.205 0.316 . . . . 0.0 112.785 -175.307 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.439 ' HA ' HD21 ' A' ' 19' ' ' LEU . 11.6 p -143.25 143.87 24.3 Favored 'Isoleucine or valine' 0 C--O 1.24 0.555 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 178.211 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 29.0 mt -106.37 117.63 52.5 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -176.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.509 ' HB2' ' HB2' ' A' ' 75' ' ' SER . 9.4 m120 -124.7 151.4 45.04 Favored 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.585 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.9 -178.26 34.72 Favored Glycine 0 C--N 1.339 0.733 0 N-CA-C 115.141 0.816 . . . . 0.0 115.141 -174.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.402 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 30.0 m -121.51 139.5 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.637 0.775 . . . . 0.0 110.147 175.699 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.3 tp -74.03 122.23 22.32 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.093 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.743 HD13 ' HG2' ' A' ' 72' ' ' ARG . 46.8 pt -124.06 -177.89 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 124.615 1.166 . . . . 0.0 109.198 175.208 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 29.5 mmm180 -139.45 90.67 2.43 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -176.623 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -88.95 -50.07 6.4 Favored 'General case' 0 N--CA 1.484 1.229 0 CA-C-O 121.496 0.665 . . . . 0.0 109.629 178.513 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.452 HD11 HG21 ' A' ' 47' ' ' THR . 69.1 mt -95.45 -179.2 4.68 Favored 'General case' 0 C--O 1.245 0.843 0 CA-C-N 114.508 -1.224 . . . . 0.0 109.735 176.402 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 64.91 70.9 0.47 Allowed 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.167 0.987 . . . . 0.0 111.457 175.404 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 8.5 p80 -161.19 161.53 30.96 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 115.036 -0.984 . . . . 0.0 110.025 -178.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 75.1 m-70 -70.84 102.74 2.43 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 175.288 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 -71.74 91.95 1.16 Allowed 'General case' 0 CA--C 1.554 1.101 0 C-N-CA 123.388 0.675 . . . . 0.0 111.974 -175.025 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 53.7 t-80 -76.1 -30.45 58.27 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.508 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -104.25 144.27 31.83 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 123.363 0.665 . . . . 0.0 109.537 176.207 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 49.8 t60 . . . . . 0 CA--C 1.548 0.904 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 176.347 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.965 0 CA-C-O 120.082 -0.288 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -70.48 98.78 1.5 Allowed 'General case' 0 C--N 1.354 0.763 0 C-N-CA 123.617 0.767 . . . . 0.0 109.178 175.021 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -89.13 120.56 30.63 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 122.888 0.475 . . . . 0.0 111.065 -176.424 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 24.1 ptt180 -157.14 141.09 16.15 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 123.723 0.809 . . . . 0.0 109.186 173.441 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 48.8 t -99.66 127.65 52.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 176.633 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 18.1 ttm180 -152.15 90.17 1.5 Allowed 'General case' 0 C--O 1.24 0.59 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 79.2 mt -81.75 91.32 6.45 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.551 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.6 tp -68.66 133.94 31.0 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.166 0 C-N-CA 123.387 0.675 . . . . 0.0 110.252 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -148.03 85.4 1.54 Allowed 'General case' 0 C--O 1.238 0.452 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 -176.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.1 m -95.77 90.28 5.6 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.486 -178.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -73.56 132.15 42.51 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 123.456 0.703 . . . . 0.0 110.394 176.772 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.2 64.27 0.07 OUTLIER Glycine 0 C--O 1.242 0.613 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.988 -175.525 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.39 75.65 0.66 Allowed Glycine 0 C--N 1.35 1.361 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 174.333 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -70.95 135.93 48.2 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 124.071 0.949 . . . . 0.0 110.878 -169.399 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 43.8 p -68.37 110.04 3.93 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 123.499 0.719 . . . . 0.0 109.597 176.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.464 ' HD2' ' H ' ' A' ' 16' ' ' LYS . 0.0 OUTLIER -109.68 -178.55 3.57 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 123.467 0.707 . . . . 0.0 111.514 -174.136 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.4 p -72.27 151.16 8.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.944 0 C-N-CA 124.396 1.078 . . . . 0.0 109.739 174.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 35.7 mmt180 -62.87 -68.69 0.32 Allowed 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -169.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.416 ' HA ' ' O ' ' A' ' 22' ' ' ASP . 2.6 pt? -140.52 26.13 2.16 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 -171.704 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.7 -21.69 59.25 Favored 'General case' 0 N--CA 1.484 1.227 0 N-CA-C 112.305 0.484 . . . . 0.0 112.305 178.047 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 70.7 m -132.81 -66.14 0.68 Allowed 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.69 0.796 . . . . 0.0 109.284 177.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ASP . . . . . 0.416 ' O ' ' HA ' ' A' ' 19' ' ' LEU . 1.7 m-20 -84.96 111.74 19.96 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.912 0.885 . . . . 0.0 108.662 174.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 52.8 m -65.43 111.36 3.04 Favored 'General case' 0 C--N 1.351 0.635 0 CA-C-N 118.28 0.491 . . . . 0.0 109.693 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.1 mmt180 -117.74 152.81 34.52 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-O 121.469 0.652 . . . . 0.0 111.599 -173.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.511 ' HB ' HD11 ' A' ' 40' ' ' ILE . 15.8 tt -141.96 142.18 28.3 Favored 'Isoleucine or valine' 0 C--O 1.241 0.643 0 CA-C-N 114.139 -1.391 . . . . 0.0 109.054 176.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -90.82 100.82 13.61 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 173.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.6 t -86.17 112.85 23.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.538 0 C-N-CA 124.623 1.169 . . . . 0.0 109.205 -175.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.405 HG22 HG22 ' A' ' 35' ' ' VAL . 41.5 t -94.81 100.33 10.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.549 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 176.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -64.16 113.65 11.07 Favored Pre-proline 0 CA--C 1.546 0.821 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 172.272 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.52 -1.18 11.38 Favored 'Trans proline' 0 C--N 1.364 1.378 0 C-N-CA 122.518 2.146 . . . . 0.0 113.591 -172.343 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -91.97 -52.68 4.6 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.337 0.655 . . . . 0.0 109.325 -177.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 66.7 p -93.29 -32.58 14.26 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 124.468 1.107 . . . . 0.0 111.909 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 93.51 6.98 62.17 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.986 -173.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -69.89 107.77 3.7 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 123.08 0.552 . . . . 0.0 110.994 -178.022 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.405 HG22 HG22 ' A' ' 28' ' ' VAL . 23.6 t -90.9 119.92 38.91 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 172.597 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -142.52 143.48 32.54 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 122.993 0.517 . . . . 0.0 110.466 -174.302 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 62.1 mt -77.45 123.85 34.82 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.86 0 C-N-CA 123.555 0.742 . . . . 0.0 109.661 179.068 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.41 158.12 36.8 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 123.89 0.876 . . . . 0.0 110.149 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -97.74 121.05 39.19 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.511 HD11 ' HB ' ' A' ' 25' ' ' ILE . 54.7 mt -77.74 112.55 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 72.3 mtm180 -80.71 -38.21 29.24 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 124.512 1.125 . . . . 0.0 111.113 -178.098 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 47.4 t-20 -140.76 138.95 34.51 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.7 m -93.96 -27.05 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 123.324 0.65 . . . . 0.0 112.425 -176.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.7 m -93.23 148.28 4.87 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-O 121.193 0.52 . . . . 0.0 110.711 179.271 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.426 ' HB3' ' HB ' ' A' ' 63' ' ' VAL . 8.4 pt-20 -94.35 93.19 7.56 Favored 'General case' 0 N--CA 1.479 0.975 0 C-N-CA 123.7 0.8 . . . . 0.0 111.517 -171.433 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 64.2 t30 71.77 -19.43 0.27 Allowed 'General case' 0 N--CA 1.502 2.142 0 C-N-CA 125.483 1.513 . . . . 0.0 113.224 173.09 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 37.8 p -67.16 98.07 0.57 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 124.356 1.063 . . . . 0.0 111.277 -169.508 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.21 -36.35 58.62 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 123.649 0.779 . . . . 0.0 110.96 -176.229 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -112.03 117.97 47.07 Favored Pre-proline 0 CA--C 1.554 1.13 0 C-N-CA 122.923 0.489 . . . . 0.0 110.001 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo -72.18 128.51 13.93 Favored 'Trans proline' 0 C--N 1.379 2.145 0 C-N-CA 123.09 2.526 . . . . 0.0 112.171 178.119 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 55.8 p-80 -161.27 -42.26 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 123.681 0.793 . . . . 0.0 110.219 175.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 20.7 m-85 -92.65 -47.93 6.85 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 169.272 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 16.7 m -92.85 163.93 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 168.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 2.4 tmm_? -171.24 -32.83 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -177.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 26.2 mtm180 -66.3 157.01 32.75 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 124.262 1.025 . . . . 0.0 111.643 -177.575 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -105.43 29.52 6.43 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.32 0.648 . . . . 0.0 109.86 178.039 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 15.8 tt -117.36 147.89 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 123.113 0.565 . . . . 0.0 109.703 -173.136 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 76.3 mt -91.58 143.56 11.02 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.698 0 C-N-CA 124.426 1.09 . . . . 0.0 109.723 175.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.46 HG23 ' HB2' ' A' ' 62' ' ' ALA . 3.3 t -131.32 172.16 12.49 Favored 'General case' 0 C--O 1.244 0.766 0 C-N-CA 123.915 0.886 . . . . 0.0 109.261 177.509 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 25.3 ttm180 -74.03 133.79 42.97 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -178.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.88 -2.83 82.36 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.956 -0.358 . . . . 0.0 112.924 -176.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.46 ' HB2' HG23 ' A' ' 59' ' ' THR . . . -77.6 132.06 38.1 Favored 'General case' 0 C--O 1.244 0.796 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 176.709 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.601 HG21 ' HG3' ' A' ' 90' ' ' GLU . 21.9 t -83.18 114.08 23.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 177.509 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 33.4 m -101.57 146.45 9.85 Favored 'Isoleucine or valine' 0 C--O 1.244 0.793 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 177.475 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.8 tp10 -95.83 128.24 42.54 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.354 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 63.2 p -124.86 177.86 5.8 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 24.0 p-10 -72.42 -12.26 61.03 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 122.794 0.438 . . . . 0.0 110.743 175.372 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.3 mt -93.41 -49.77 5.77 Favored 'General case' 0 C--N 1.357 0.918 0 C-N-CA 123.079 0.551 . . . . 0.0 110.425 175.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 168.73 -150.66 16.33 Favored Glycine 0 C--N 1.348 1.21 0 O-C-N 123.177 0.298 . . . . 0.0 113.253 178.585 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -88.23 118.09 27.59 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 123.836 0.854 . . . . 0.0 109.122 -178.688 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.2 t -121.27 144.86 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 C-N-CA 123.467 0.707 . . . . 0.0 109.4 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.497 ' HG3' HD13 ' A' ' 88' ' ' ILE . 24.4 mtt180 -109.66 131.91 54.63 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 171.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.1 t -80.36 98.99 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 O-C-N 124.172 0.92 . . . . 0.0 109.243 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 35.5 p -74.48 -28.59 61.08 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.792 0.837 . . . . 0.0 111.781 177.693 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.1 m -90.58 -170.78 2.83 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.921 177.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.412 ' HD2' ' N ' ' A' ' 76' ' ' ARG . 8.4 mpt_? -96.54 112.15 59.23 Favored Pre-proline 0 CA--C 1.545 0.784 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.301 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -62.37 96.02 0.15 Allowed 'Trans proline' 0 C--N 1.377 2.03 0 C-N-CA 123.148 2.565 . . . . 0.0 112.837 -172.11 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.77 -23.45 32.5 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.69 -0.686 . . . . 0.0 113.999 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -72.97 -30.43 63.83 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-N 117.956 0.878 . . . . 0.0 110.491 175.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -77.04 4.33 10.37 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 123.569 0.748 . . . . 0.0 111.287 171.038 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 90.62 -33.95 4.39 Favored Glycine 0 C--N 1.356 1.682 0 N-CA-C 111.596 -0.602 . . . . 0.0 111.596 -172.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.0 p -140.2 164.27 22.75 Favored 'Isoleucine or valine' 0 C--O 1.243 0.751 0 C-N-CA 124.729 1.212 . . . . 0.0 108.395 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 45.2 mt -84.5 132.88 30.53 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 173.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -133.66 144.66 49.34 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 -177.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -171.73 -172.74 38.02 Favored Glycine 0 C--N 1.342 0.901 0 N-CA-C 114.825 0.69 . . . . 0.0 114.825 -177.477 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 16.5 m -119.28 137.38 53.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 C-N-CA 123.943 0.897 . . . . 0.0 110.357 -176.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 41.8 tp -74.08 109.35 7.51 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 122.632 0.373 . . . . 0.0 110.438 -179.118 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.497 HD13 ' HG3' ' A' ' 72' ' ' ARG . 31.6 pt -102.52 179.6 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.83 0 C-N-CA 123.802 0.841 . . . . 0.0 109.865 174.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 5.0 mpt_? -125.76 55.96 1.42 Allowed 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.601 ' HG3' HG21 ' A' ' 63' ' ' VAL . 0.8 OUTLIER -60.47 -57.84 11.02 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 -179.967 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 74.9 mt -99.63 -151.86 0.4 Allowed 'General case' 0 CA--C 1.545 0.77 0 CA-C-N 114.7 -1.136 . . . . 0.0 107.946 169.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -122.02 148.83 44.33 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 165.563 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 51.4 t60 -92.53 30.68 1.47 Allowed 'General case' 0 CA--C 1.554 1.123 0 CA-C-O 122.284 1.04 . . . . 0.0 108.775 170.048 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -133.3 140.64 47.56 Favored 'General case' 0 C--O 1.24 0.596 0 C-N-CA 125.354 1.462 . . . . 0.0 107.446 -175.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 15.0 m-70 -60.53 132.0 52.5 Favored 'General case' 0 N--CA 1.476 0.859 0 O-C-N 123.931 0.769 . . . . 0.0 111.62 -177.567 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 11.5 m-70 -94.83 152.28 18.53 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.7 0.8 . . . . 0.0 109.47 170.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -74.73 94.91 2.78 Favored 'General case' 0 CA--C 1.54 0.56 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 174.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 10.4 m170 . . . . . 0 CA--C 1.548 0.871 0 C-N-CA 123.73 0.812 . . . . 0.0 109.959 177.134 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.706 0 N-CA-C 111.727 -0.549 . . . . 0.0 111.727 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -158.98 163.78 36.16 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.765 0.826 . . . . 0.0 110.255 -175.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 19.6 mmt180 -71.33 -2.55 16.71 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 123.762 0.825 . . . . 0.0 112.689 -177.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.8 ptm85 -59.93 131.37 50.65 Favored 'General case' 0 CA--C 1.552 1.052 0 C-N-CA 123.868 0.867 . . . . 0.0 110.986 176.014 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 85.9 t -111.63 99.45 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 174.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 11.4 ptm180 -83.77 86.73 7.1 Favored 'General case' 0 C--O 1.239 0.542 0 CA-C-O 122.005 0.907 . . . . 0.0 109.061 175.281 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 6.3 tt -65.87 128.11 34.71 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 114.365 -1.289 . . . . 0.0 109.839 -176.495 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -140.29 148.6 22.27 Favored 'Isoleucine or valine' 0 C--O 1.243 0.76 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -74.11 70.99 1.61 Allowed 'General case' 0 N--CA 1.485 1.318 0 CA-C-O 122.122 0.963 . . . . 0.0 110.313 174.766 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 10.2 t -77.2 137.87 39.11 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 114.808 -1.087 . . . . 0.0 110.087 -175.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -94.84 86.15 4.61 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.503 0.721 . . . . 0.0 110.291 -173.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -152.66 174.77 31.45 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 114.441 -1.254 . . . . 0.0 111.493 177.7 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.95 81.16 0.91 Allowed Glycine 0 C--N 1.342 0.901 0 C-N-CA 122.728 0.204 . . . . 0.0 112.935 -177.491 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 67.2 t30 -84.56 -14.45 48.84 Favored 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 123.505 0.722 . . . . 0.0 109.976 173.438 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.43 HG22 ' HD2' ' A' ' 16' ' ' LYS . 4.3 m -76.63 165.48 24.7 Favored 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 123.971 0.908 . . . . 0.0 110.178 177.761 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.43 ' HD2' HG22 ' A' ' 15' ' ' THR . 13.0 mptt 60.96 56.74 2.75 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 123.97 0.908 . . . . 0.0 109.729 -173.437 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.5 t -69.15 113.65 5.14 Favored 'Isoleucine or valine' 0 C--O 1.24 0.584 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.915 -178.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.445 ' HG2' ' H ' ' A' ' 20' ' ' ALA . 0.2 OUTLIER -63.33 -178.05 0.23 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 123.591 0.756 . . . . 0.0 110.769 171.591 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.484 HD22 ' HA ' ' A' ' 23' ' ' THR . 0.7 OUTLIER -54.81 -33.65 61.8 Favored 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -179.847 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.451 ' H ' HD12 ' A' ' 19' ' ' LEU . . . 52.41 74.91 0.25 Allowed 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 125.143 1.377 . . . . 0.0 112.615 171.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 12.9 t 74.52 -16.54 0.54 Allowed 'General case' 0 N--CA 1.496 1.837 0 C-N-CA 125.295 1.438 . . . . 0.0 112.855 -178.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -89.89 -176.19 4.85 Favored 'General case' 0 CA--C 1.548 0.878 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 173.325 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.539 HG22 HD12 ' A' ' 40' ' ' ILE . 52.4 m -141.32 115.21 9.14 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -177.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -127.18 158.82 36.08 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.543 0.737 . . . . 0.0 111.516 -175.465 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.479 ' HB ' HD11 ' A' ' 40' ' ' ILE . 16.1 tt -145.6 148.75 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.731 0.813 . . . . 0.0 110.395 -171.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 37.7 m-80 -89.32 103.6 16.22 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 172.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 75.8 t -89.39 109.82 20.84 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 C-N-CA 123.932 0.893 . . . . 0.0 109.053 -176.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 37.0 t -100.01 110.05 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 123.199 0.6 . . . . 0.0 109.654 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -59.2 112.68 5.48 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 170.338 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.2 -16.97 19.48 Favored 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 121.926 1.751 . . . . 0.0 111.747 179.104 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -94.37 -45.18 7.57 Favored 'General case' 0 CA--C 1.552 1.032 0 C-N-CA 124.344 1.058 . . . . 0.0 111.184 178.073 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.6 m -90.2 -20.01 23.54 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 123.362 0.665 . . . . 0.0 112.02 -175.14 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.17 -11.52 57.54 Favored Glycine 0 C--N 1.35 1.317 0 C-N-CA 123.422 0.534 . . . . 0.0 114.223 178.319 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -75.39 150.59 38.32 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.814 0.846 . . . . 0.0 112.132 -173.821 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 21.1 t -126.12 133.83 67.94 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.797 0.839 . . . . 0.0 108.774 174.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -147.61 141.3 25.61 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.611 0.764 . . . . 0.0 109.537 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 47.5 mt -81.92 122.87 37.43 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.8 0 N-CA-C 108.264 -1.014 . . . . 0.0 108.264 178.322 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.35 161.41 27.88 Favored 'General case' 0 C--O 1.236 0.382 0 C-N-CA 124.796 1.238 . . . . 0.0 109.517 -174.051 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -106.43 123.7 48.47 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -175.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.539 HD12 HG22 ' A' ' 23' ' ' THR . 59.5 mt -76.41 113.29 15.23 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 123.388 0.675 . . . . 0.0 109.955 -176.259 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -77.4 -53.29 7.83 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.634 1.174 . . . . 0.0 110.264 -178.183 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -140.23 166.61 24.22 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 124.158 0.983 . . . . 0.0 108.704 178.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 43.9 t -112.62 87.87 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 167.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.2 p -133.08 127.71 55.22 Favored 'Isoleucine or valine' 0 C--O 1.242 0.687 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.727 -177.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.565 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 13.6 pt-20 -88.72 -56.11 3.43 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.406 -175.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -148.12 159.34 44.03 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.422 1.089 . . . . 0.0 108.85 -176.238 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.461 HG23 HD22 ' A' ' 91' ' ' LEU . 59.7 p -78.88 -31.93 45.67 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 122.864 0.466 . . . . 0.0 110.778 176.337 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -71.45 84.2 0.82 Allowed 'General case' 0 CA--C 1.54 0.594 0 O-C-N 123.866 0.729 . . . . 0.0 109.605 178.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 59.36 84.09 0.2 Allowed Pre-proline 0 CA--C 1.548 0.887 0 C-N-CA 125.11 1.364 . . . . 0.0 111.406 -176.03 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -71.94 102.63 1.36 Allowed 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 122.174 1.916 . . . . 0.0 109.897 176.076 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 83.0 t60 -61.01 -26.85 67.89 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 122.636 0.374 . . . . 0.0 110.918 -177.445 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -73.45 87.65 1.58 Allowed 'General case' 0 CA--C 1.547 0.834 0 N-CA-C 108.126 -1.065 . . . . 0.0 108.126 164.552 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.7 t -64.8 -49.21 81.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 175.377 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 4.0 ppt_? -79.59 140.99 36.97 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-N 114.31 -1.314 . . . . 0.0 109.352 168.014 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 6.7 ppt_? -94.3 29.71 2.14 Favored 'General case' 0 N--CA 1.482 1.151 0 CA-C-O 121.229 0.538 . . . . 0.0 110.637 179.426 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 -131.11 -178.69 4.94 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 125.035 1.334 . . . . 0.0 109.536 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 49.4 mm 60.42 82.08 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.255 0 C-N-CA 125.05 1.34 . . . . 0.0 110.42 177.013 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 37.1 mt -83.23 144.4 10.14 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 113.962 -1.472 . . . . 0.0 109.595 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 17.5 p -122.82 167.94 12.89 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.051 0.941 . . . . 0.0 109.052 173.05 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 35.7 ttt180 -74.16 131.38 41.22 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 175.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.94 9.4 77.52 Favored Glycine 0 N--CA 1.465 0.613 0 O-C-N 124.076 0.86 . . . . 0.0 112.843 -175.386 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -83.16 160.95 21.73 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.145 0.578 . . . . 0.0 109.603 176.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.565 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 47.7 t -105.99 120.9 57.67 Favored 'Isoleucine or valine' 0 C--O 1.243 0.748 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 172.325 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.4 m -106.5 159.55 6.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.228 175.335 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -106.85 130.08 54.59 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 173.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.421 HG22 HG12 ' A' ' 40' ' ' ILE . 34.0 p -129.61 -175.18 3.51 Favored 'General case' 0 C--O 1.24 0.556 0 C-N-CA 123.241 0.616 . . . . 0.0 109.813 -176.06 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 73.3 m-20 -70.28 -19.26 63.11 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 123.134 0.574 . . . . 0.0 111.024 175.02 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 93.8 mt -99.45 -13.73 19.41 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.907 0.883 . . . . 0.0 111.755 -178.079 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.45 -164.16 22.42 Favored Glycine 0 C--N 1.35 1.32 0 O-C-N 123.349 0.406 . . . . 0.0 112.528 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -80.09 130.45 35.26 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.142 0.577 . . . . 0.0 110.394 177.76 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.6 t -125.5 138.9 52.93 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 C-N-CA 124.468 1.107 . . . . 0.0 110.663 -173.177 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.829 ' HG2' HD13 ' A' ' 88' ' ' ILE . 9.5 mmt180 -86.4 121.03 28.38 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 169.374 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 48.9 t -72.98 116.75 15.6 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.768 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.599 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 43.8 p -96.97 -24.58 15.75 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.456 0.702 . . . . 0.0 111.238 -172.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 23.3 t -108.55 178.5 4.47 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.533 0.733 . . . . 0.0 109.84 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 85.8 mtm180 -90.62 106.69 16.18 Favored Pre-proline 0 CA--C 1.552 1.049 0 C-N-CA 123.383 0.673 . . . . 0.0 109.976 -177.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -66.22 114.44 3.03 Favored 'Trans proline' 0 C--N 1.373 1.835 0 C-N-CA 123.101 2.534 . . . . 0.0 112.357 -175.356 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 141.94 -29.88 2.18 Favored Glycine 0 C--N 1.344 0.981 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.339 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -60.84 110.73 1.4 Allowed 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.342 0.657 . . . . 0.0 110.49 178.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.506 ' HB2' HG12 ' A' ' 82' ' ' VAL . 26.8 m-20 70.26 -15.79 0.33 Allowed 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 125.66 1.584 . . . . 0.0 114.04 178.565 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 98.05 12.52 45.84 Favored Glycine 0 C--N 1.342 0.907 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -169.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 80' ' ' ASP . 3.7 p -111.32 118.59 57.81 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 C-N-CA 123.603 0.761 . . . . 0.0 109.573 175.085 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.2 mt -98.24 148.03 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 170.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 -135.16 149.14 49.91 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 122.937 0.495 . . . . 0.0 109.819 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.25 -175.54 37.97 Favored Glycine 0 C--N 1.346 1.102 0 O-C-N 123.648 0.592 . . . . 0.0 113.482 -176.597 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.2 m -129.1 138.7 53.8 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 C-N-CA 124.248 1.019 . . . . 0.0 110.42 178.493 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.6 tp -73.86 122.73 22.96 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 121.094 0.473 . . . . 0.0 111.271 -175.333 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.829 HD13 ' HG2' ' A' ' 72' ' ' ARG . 40.1 pt -119.17 -179.65 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 123.884 0.874 . . . . 0.0 109.623 175.738 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 57.4 mtt180 -122.79 83.29 2.1 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 -176.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 36.2 mm-40 -93.2 -80.91 0.37 Allowed 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 175.087 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.461 HD22 HG23 ' A' ' 47' ' ' THR . 50.8 mt -83.12 96.88 8.53 Favored 'General case' 0 C--N 1.344 0.327 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -175.435 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -72.56 -9.44 58.58 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 123.304 0.642 . . . . 0.0 110.701 175.035 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 3.2 p80 -134.16 141.92 47.26 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.848 1.659 . . . . 0.0 107.964 173.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 6.0 t-160 -84.65 -46.21 11.73 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -177.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -89.91 123.65 34.03 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.279 0.632 . . . . 0.0 110.11 176.473 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 7.0 p80 -86.39 104.83 16.25 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.508 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 12.7 t60 -162.08 132.77 4.96 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 122.725 0.41 . . . . 0.0 110.39 -170.328 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 . . . . . 0 C--O 1.251 1.166 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 173.022 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.619 0 N-CA-C 111.667 -0.573 . . . . 0.0 111.667 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -73.08 96.13 2.14 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 122.917 0.487 . . . . 0.0 109.831 177.28 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 27.8 mmm180 -84.17 69.3 10.38 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.992 0.901 . . . . 0.0 109.828 -178.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 77.1 mtp180 -97.79 21.37 10.59 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.693 1.197 . . . . 0.0 110.923 -176.104 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 p -39.44 96.5 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.566 1.591 0 C-N-CA 125.552 1.541 . . . . 0.0 114.528 -170.168 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 45.81 66.31 0.96 Allowed 'General case' 0 C--N 1.358 0.973 0 C-N-CA 126.492 1.917 . . . . 0.0 112.038 176.773 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 51.6 tp -62.37 -38.33 89.13 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.646 -176.559 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 tt -61.6 148.7 9.49 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.486 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.103 178.56 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 24.6 tpt180 -55.1 -30.37 59.55 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 125.006 1.323 . . . . 0.0 112.66 -175.666 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 46.1 p -64.74 92.3 0.09 Allowed 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 123.443 0.697 . . . . 0.0 111.31 -178.024 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.9 mmt85 -108.0 143.74 36.28 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.385 1.074 . . . . 0.0 109.688 177.565 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -172.8 89.86 0.08 OUTLIER Glycine 0 C--N 1.338 0.639 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.844 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.5 20.19 8.38 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 111.546 -0.621 . . . . 0.0 111.546 170.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 17.5 m120 -133.07 88.34 2.49 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 123.974 0.91 . . . . 0.0 108.806 179.637 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 11.2 t -148.48 170.17 18.64 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.788 0.835 . . . . 0.0 109.446 178.452 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt 67.15 128.44 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.425 0 C-N-CA 125.05 1.34 . . . . 0.0 111.099 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 10.9 p -100.7 131.79 47.63 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 172.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.05 178.13 4.69 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 123.645 0.778 . . . . 0.0 109.944 176.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -55.26 122.32 10.83 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.4 0.68 . . . . 0.0 110.443 178.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -121.06 -85.54 0.66 Allowed 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -175.061 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 19.7 m -88.68 -26.75 21.67 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 172.58 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -80.77 162.13 24.22 Favored 'General case' 0 CA--C 1.548 0.866 0 CA-C-N 114.099 -1.41 . . . . 0.0 110.462 168.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.495 HG22 HD12 ' A' ' 40' ' ' ILE . 62.9 m -127.25 118.07 23.52 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.118 0.567 . . . . 0.0 109.973 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 41.8 mtt180 -115.01 163.6 15.36 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.732 0.813 . . . . 0.0 110.519 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.493 ' HB ' HD11 ' A' ' 40' ' ' ILE . 16.6 tt -141.75 135.49 30.03 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 124.025 0.93 . . . . 0.0 108.802 175.666 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -85.67 103.27 14.33 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 177.154 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -92.08 133.27 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 123.802 0.841 . . . . 0.0 109.886 -171.495 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 46.7 t -109.8 109.81 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 178.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -66.61 119.07 60.24 Favored Pre-proline 0 CA--C 1.545 0.78 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 176.184 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -66.11 -33.84 39.3 Favored 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 123.003 2.468 . . . . 0.0 113.667 -166.003 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -95.36 -40.4 9.54 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 112.85 0.685 . . . . 0.0 112.85 -171.61 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 71.3 p -89.51 -21.24 23.03 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 122.464 0.306 . . . . 0.0 111.533 179.673 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.49 2.76 90.63 Favored Glycine 0 C--N 1.347 1.192 0 CA-C-O 119.882 -0.399 . . . . 0.0 113.572 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.6 mmtp -68.25 107.26 2.73 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.504 0.722 . . . . 0.0 110.971 -177.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.2 t -92.59 126.11 45.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 174.664 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -154.21 146.79 24.12 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 123.831 0.853 . . . . 0.0 108.813 -176.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 45.2 mt -80.87 137.41 21.41 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -177.523 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.98 159.49 32.52 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.672 0.789 . . . . 0.0 109.713 -179.396 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 17.1 mm-40 -103.17 122.57 44.98 Favored 'General case' 0 C--O 1.241 0.651 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.495 HD12 HG22 ' A' ' 23' ' ' THR . 44.5 mt -76.95 110.11 12.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -176.612 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 62.3 mtt180 -73.85 -52.3 13.45 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.149 0.979 . . . . 0.0 110.91 178.722 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -140.75 164.11 31.09 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.817 0.847 . . . . 0.0 110.14 -176.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 70.8 t -132.14 103.25 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.168 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 176.691 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.2 p -162.33 96.81 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.562 1.431 0 CA-C-O 121.822 0.82 . . . . 0.0 109.603 -175.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.542 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 0.7 OUTLIER -72.83 -40.57 65.66 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.339 0.656 . . . . 0.0 112.769 -172.015 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -78.02 -21.15 51.19 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 122.812 0.445 . . . . 0.0 110.747 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 44.2 p 65.52 -58.45 0.3 Allowed 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 126.829 2.052 . . . . 0.0 111.733 -171.869 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -72.37 73.95 1.0 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 123.417 0.687 . . . . 0.0 110.978 173.703 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 50.4 t-20 -173.1 74.98 0.41 Allowed Pre-proline 0 CA--C 1.552 1.022 0 C-N-CA 125.213 1.405 . . . . 0.0 107.603 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -88.62 59.84 2.67 Favored 'Trans proline' 0 C--N 1.373 1.83 0 C-N-CA 123.314 2.676 . . . . 0.0 111.792 -177.22 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 8.1 t-160 -65.94 120.38 12.99 Favored 'General case' 0 CA--C 1.546 0.797 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.859 -175.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -52.81 -39.35 62.34 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 124.14 0.976 . . . . 0.0 113.241 -171.515 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 10.4 p -74.27 110.61 8.65 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.127 0 CA-C-O 121.525 0.679 . . . . 0.0 109.252 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 76.2 mtp180 -72.04 94.36 1.49 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.54 -178.322 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 28.8 mmm180 -122.48 103.93 9.04 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 175.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 25.3 p-10 -86.04 55.67 3.63 Favored 'General case' 0 CA--C 1.547 0.84 0 CA-C-O 122.119 0.962 . . . . 0.0 110.727 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.8 mm -77.55 93.02 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.539 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.1 mt -80.37 127.43 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 123.424 0.69 . . . . 0.0 109.764 -176.468 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 74.0 p -124.74 160.6 28.26 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 123.79 0.836 . . . . 0.0 109.427 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -75.68 128.23 34.77 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 122.964 0.506 . . . . 0.0 110.261 179.656 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.31 -1.24 58.82 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.441 -176.381 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.1 148.12 22.49 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.642 0.777 . . . . 0.0 111.479 -176.767 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.542 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 94.6 t -83.49 118.94 31.89 Favored 'Isoleucine or valine' 0 C--O 1.24 0.592 0 C-N-CA 123.406 0.682 . . . . 0.0 109.604 171.812 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.0 m -102.77 143.32 15.29 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 165.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -94.18 123.68 37.72 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.71 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 66.2 p -123.19 -173.08 2.64 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.141 0.577 . . . . 0.0 110.047 -175.05 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 58.2 m-20 -73.38 -26.99 61.23 Favored 'General case' 0 N--CA 1.478 0.932 0 CA-C-O 119.851 -0.118 . . . . 0.0 110.902 170.131 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.1 mt -84.13 -28.25 27.6 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 122.916 0.486 . . . . 0.0 111.843 -176.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 146.96 -149.55 21.71 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 178.579 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -85.55 128.11 34.65 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 175.522 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.7 t -121.72 128.6 75.78 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.526 0 C-N-CA 122.656 0.383 . . . . 0.0 110.862 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.546 ' HG2' HD13 ' A' ' 88' ' ' ILE . 22.6 mmt85 -85.58 123.29 30.83 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 171.845 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.6 t -72.32 100.13 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.555 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.515 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 47.5 p -95.4 -22.55 17.65 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 123.253 0.621 . . . . 0.0 110.803 -169.372 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 21.6 t -98.32 -177.81 3.83 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 169.498 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.663 ' HE ' ' HB3' ' A' ' 79' ' ' GLN . 39.6 ptt180 -75.26 144.0 77.71 Favored Pre-proline 0 CA--C 1.551 1.014 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 173.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -76.71 50.63 3.08 Favored 'Trans proline' 0 CA--C 1.559 1.762 0 C-N-CA 123.091 2.527 . . . . 0.0 113.273 174.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 172.8 67.08 0.05 OUTLIER Glycine 0 C--N 1.346 1.126 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.977 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLN . . . . . 0.663 ' HB3' ' HE ' ' A' ' 76' ' ' ARG . 1.7 pt20 -123.41 115.33 21.43 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.999 0.92 . . . . 0.0 108.604 172.562 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 62.39 19.3 11.01 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 124.339 1.055 . . . . 0.0 111.335 -176.013 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 92.86 -6.25 76.68 Favored Glycine 0 C--N 1.353 1.474 0 CA-C-N 116.033 -0.53 . . . . 0.0 112.496 178.547 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.8 p -120.3 163.71 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 123.004 0.522 . . . . 0.0 111.008 -175.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 42.3 mt -109.31 147.54 13.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 C-N-CA 124.696 1.198 . . . . 0.0 109.169 -178.753 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -130.03 155.5 46.03 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 118.414 0.552 . . . . 0.0 110.774 174.449 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.515 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -166.84 -169.38 30.37 Favored Glycine 0 C--N 1.348 1.199 0 CA-C-N 115.367 -0.833 . . . . 0.0 113.652 -177.611 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.1 m -125.61 146.8 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 CA-C-N 117.789 0.795 . . . . 0.0 111.045 178.144 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 17.5 tp -84.6 104.61 14.74 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 122.607 0.363 . . . . 0.0 111.224 -176.059 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.546 HD13 ' HG2' ' A' ' 72' ' ' ARG . 50.0 pt -93.71 174.95 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 123.08 0.552 . . . . 0.0 110.765 178.077 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -119.57 27.39 8.78 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 124.022 0.929 . . . . 0.0 110.298 -170.206 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.95 -61.41 2.4 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 124.378 1.071 . . . . 0.0 110.792 -170.361 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -127.26 109.46 11.84 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 165.732 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -63.05 132.29 51.46 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.233 0.613 . . . . 0.0 110.773 -179.135 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 26.5 p-80 -64.5 -31.23 72.35 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.898 0.479 . . . . 0.0 111.042 -177.173 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 32.1 t60 -80.21 79.48 6.77 Favored 'General case' 0 CA--C 1.541 0.63 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 170.039 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 53.3 t-80 -108.51 72.57 0.84 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 124.095 0.958 . . . . 0.0 109.742 -172.644 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 9.9 t60 -171.53 88.63 0.11 Allowed 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 175.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 10.3 t60 -76.2 93.36 3.36 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 176.544 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 14.7 p-80 . . . . . 0 CA--C 1.556 1.201 0 C-N-CA 122.891 0.476 . . . . 0.0 110.07 -179.671 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.366 0 N-CA-C 111.763 -0.535 . . . . 0.0 111.763 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -64.39 132.45 50.12 Favored 'General case' 0 C--N 1.352 0.7 0 C-N-CA 123.63 0.772 . . . . 0.0 110.081 177.231 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -131.2 147.04 52.55 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 174.409 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -72.64 80.68 1.1 Allowed 'General case' 0 CA--C 1.544 0.715 0 O-C-N 123.543 0.527 . . . . 0.0 109.819 177.665 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 61.0 t -72.71 120.06 20.62 Favored 'Isoleucine or valine' 0 C--N 1.345 0.387 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 174.426 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 15.4 tpp180 -59.15 116.79 4.09 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.966 0.906 . . . . 0.0 110.923 -169.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -74.53 81.44 1.97 Allowed 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 174.035 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 50.4 mt -79.42 78.84 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.462 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 176.364 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 35.6 ttm180 -73.3 115.15 12.31 Favored 'General case' 0 C--O 1.238 0.451 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.625 -178.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 32.1 p -83.36 62.91 6.99 Favored 'General case' 0 CA--C 1.547 0.831 0 CA-C-O 121.926 0.869 . . . . 0.0 110.945 -173.592 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 4.8 mmp_? -120.01 112.27 18.94 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.239 1.416 . . . . 0.0 107.888 175.031 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.77 77.37 1.9 Allowed Glycine 0 CA--C 1.529 0.944 0 O-C-N 123.773 0.671 . . . . 0.0 112.646 -175.748 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.69 19.43 4.47 Favored Glycine 0 N--CA 1.473 1.149 0 CA-C-O 119.941 -0.366 . . . . 0.0 113.101 -179.242 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -164.44 96.64 0.77 Allowed 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.803 0.841 . . . . 0.0 108.889 179.569 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 58.4 m -75.61 -37.98 59.35 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 123.426 0.69 . . . . 0.0 110.786 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -75.61 85.47 2.66 Favored 'General case' 0 CA--C 1.542 0.671 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.12 -178.199 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 23.7 t -119.22 139.85 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 123.866 0.866 . . . . 0.0 108.857 -179.573 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -65.25 148.75 51.13 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 171.14 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.578 HD22 ' HB2' ' A' ' 24' ' ' ARG . 0.9 OUTLIER -51.95 91.81 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 124.71 1.204 . . . . 0.0 112.745 -176.041 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -110.16 -14.08 14.25 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 114.449 -1.25 . . . . 0.0 111.424 -177.009 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 36.6 t -58.09 -46.21 85.9 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.846 0.858 . . . . 0.0 109.774 173.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -150.69 147.73 27.71 Favored 'General case' 0 C--O 1.244 0.782 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 168.074 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 63.7 m -68.98 111.84 5.25 Favored 'General case' 0 C--N 1.354 0.79 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 173.285 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.578 ' HB2' HD22 ' A' ' 19' ' ' LEU . 13.4 mmt85 -97.56 165.08 12.15 Favored 'General case' 0 C--O 1.244 0.771 0 CA-C-O 121.713 0.768 . . . . 0.0 110.441 -178.446 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.0 tt -136.54 134.18 49.2 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 CA-C-N 114.09 -1.413 . . . . 0.0 107.893 174.233 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 -88.68 100.53 13.19 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 179.177 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 91.7 t -87.32 116.04 28.96 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.169 -173.592 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.408 HG22 HG22 ' A' ' 35' ' ' VAL . 58.2 t -95.17 99.65 9.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -178.347 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.418 ' HB3' ' HB2' ' A' ' 34' ' ' LYS . 11.5 t70 -59.88 110.98 3.24 Favored Pre-proline 0 CA--C 1.545 0.774 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 170.277 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -82.73 -4.63 11.47 Favored 'Trans proline' 0 CA--C 1.547 1.131 0 C-N-CA 122.535 2.157 . . . . 0.0 113.043 -174.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -76.23 -58.58 3.2 Favored 'General case' 0 C--N 1.353 0.759 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -177.079 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.9 p -95.76 -32.73 12.58 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 114.578 -1.192 . . . . 0.0 112.127 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.01 14.39 19.05 Favored Glycine 0 N--CA 1.477 1.427 0 CA-C-O 119.793 -0.448 . . . . 0.0 113.224 -178.747 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.418 ' HB2' ' HB3' ' A' ' 29' ' ' ASP . 63.6 mttp -63.15 148.44 48.0 Favored 'General case' 0 N--CA 1.486 1.369 0 C-N-CA 122.757 0.423 . . . . 0.0 111.589 175.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.408 HG22 HG22 ' A' ' 28' ' ' VAL . 44.1 t -127.04 120.29 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 167.528 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -130.77 139.93 50.26 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.74 0.816 . . . . 0.0 110.062 -176.629 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 53.5 mt -79.15 120.46 30.39 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 177.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.24 155.5 33.08 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.964 0.905 . . . . 0.0 111.175 -173.367 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -99.19 127.32 45.15 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 174.638 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 61.6 mt -77.58 111.28 14.21 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 123.035 0.534 . . . . 0.0 110.612 -175.182 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.412 ' H ' ' HA ' ' A' ' 66' ' ' THR . 15.6 mmm180 -66.77 -44.34 81.63 Favored 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 123.718 0.807 . . . . 0.0 110.77 174.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.573 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 37.4 t30 -140.32 125.65 18.83 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.68 -169.583 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.436 HG12 HD11 ' A' ' 58' ' ' ILE . 17.9 m -87.86 -34.53 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 O-C-N 124.031 0.832 . . . . 0.0 111.686 -178.063 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.9 p -78.19 134.61 27.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 C-N-CA 122.784 0.434 . . . . 0.0 110.212 -177.01 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 14.5 pt-20 -59.35 111.97 1.57 Allowed 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 123.41 0.684 . . . . 0.0 111.8 -172.65 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 24.3 m-80 64.93 6.27 3.31 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 124.889 1.276 . . . . 0.0 113.358 172.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.444 HG23 ' ND2' ' A' ' 42' ' ' ASN . 44.2 p 52.29 28.39 5.64 Favored 'General case' 0 N--CA 1.5 2.038 0 C-N-CA 124.797 1.239 . . . . 0.0 111.431 -161.544 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.34 -47.77 39.73 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 124.244 1.018 . . . . 0.0 110.404 177.254 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 55.3 m-20 -75.95 114.77 40.33 Favored Pre-proline 0 CA--C 1.551 0.981 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.681 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -90.03 26.94 0.49 Allowed 'Trans proline' 0 C--N 1.372 1.79 0 C-N-CA 123.316 2.677 . . . . 0.0 113.168 -175.245 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 53.5 m-70 -86.42 146.08 26.58 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 123.274 0.63 . . . . 0.0 110.144 -179.553 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 26.4 p90 -80.48 -2.6 46.61 Favored 'General case' 0 N--CA 1.486 1.33 0 C-N-CA 123.549 0.74 . . . . 0.0 112.54 -176.037 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.9 m -79.37 49.49 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 C-N-CA 123.977 0.911 . . . . 0.0 111.788 179.053 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 45.9 mtt180 -91.76 51.28 1.82 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.992 0.917 . . . . 0.0 110.796 -174.303 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 6.2 mpt_? -78.1 178.4 7.58 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 168.645 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -82.03 58.31 3.88 Favored 'General case' 0 CA--C 1.556 1.183 0 CA-C-O 122.206 1.003 . . . . 0.0 109.207 175.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 49.9 mm -106.88 81.51 0.59 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.561 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 175.018 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.436 HD11 HG12 ' A' ' 43' ' ' VAL . 67.9 mt -101.67 144.23 13.45 Favored 'Isoleucine or valine' 0 C--O 1.24 0.58 0 CA-C-N 114.48 -1.236 . . . . 0.0 109.065 -176.302 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 11.2 p -136.08 165.3 26.03 Favored 'General case' 0 C--O 1.242 0.675 0 C-N-CA 123.934 0.893 . . . . 0.0 109.702 -178.643 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -63.77 140.82 58.91 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 123.934 0.893 . . . . 0.0 111.118 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.01 -25.34 25.86 Favored Glycine 0 C--N 1.341 0.845 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.938 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.87 139.51 56.51 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.314 0.646 . . . . 0.0 110.987 -178.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 45' ' ' GLU . 93.2 t -93.57 110.56 23.52 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 172.378 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.3 m -100.64 141.79 16.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 177.185 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.573 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 40.7 tt0 -94.01 136.99 33.72 Favored 'General case' 0 C--O 1.234 0.243 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.814 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.412 ' HA ' ' H ' ' A' ' 41' ' ' ARG . 81.5 p -130.03 176.52 8.0 Favored 'General case' 0 C--O 1.246 0.875 0 C-N-CA 123.972 0.909 . . . . 0.0 109.144 -179.184 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 18.6 p-10 -63.45 -24.44 67.83 Favored 'General case' 0 CA--C 1.542 0.661 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.986 173.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 86.5 mt -88.66 -34.01 17.39 Favored 'General case' 0 C--N 1.354 0.782 0 C-N-CA 123.143 0.577 . . . . 0.0 110.555 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 150.37 -150.09 22.06 Favored Glycine 0 C--N 1.343 0.923 0 CA-C-N 116.593 -0.276 . . . . 0.0 112.423 173.332 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -78.9 129.73 34.85 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.582 0.753 . . . . 0.0 109.038 -179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.8 t -127.85 137.5 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 123.063 0.545 . . . . 0.0 110.635 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.711 ' HG2' HD13 ' A' ' 88' ' ' ILE . 13.4 mmt180 -90.77 118.26 30.05 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 169.868 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.1 t -72.04 109.1 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 178.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.3 p -98.54 -50.97 4.09 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 -171.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' SER . . . . . 0.525 ' HB3' ' HB3' ' A' ' 84' ' ' ASN . 31.1 t -82.71 150.91 26.45 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.113 176.671 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.442 ' HD2' ' HD2' ' A' ' 77' ' ' PRO . 23.8 tpt180 -72.83 125.5 91.12 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 123.482 0.713 . . . . 0.0 109.611 175.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.442 ' HD2' ' HD2' ' A' ' 76' ' ' ARG . 85.2 Cg_exo -51.72 101.61 0.05 OUTLIER 'Trans proline' 0 C--N 1.378 2.084 0 C-N-CA 123.269 2.646 . . . . 0.0 111.509 163.713 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 140.4 -32.63 2.14 Favored Glycine 0 C--N 1.339 0.747 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 -176.009 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -65.94 113.34 4.34 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 171.343 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 30.5 t70 76.89 -19.12 0.44 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 125.523 1.529 . . . . 0.0 111.686 -170.667 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 109.4 -47.57 1.03 Allowed Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -171.556 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.3 p -75.11 165.77 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 C-N-CA 123.756 0.822 . . . . 0.0 111.074 178.754 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 30.2 mt -93.8 148.15 5.05 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 169.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.525 ' HB3' ' HB3' ' A' ' 75' ' ' SER . 3.4 t30 -136.56 147.35 46.97 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 174.603 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.53 -175.8 26.1 Favored Glycine 0 C--N 1.336 0.574 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.257 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.5 m -121.3 138.1 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 123.223 0.609 . . . . 0.0 109.9 174.776 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.4 ' HB3' ' HA ' ' A' ' 29' ' ' ASP . 41.9 tp -67.78 128.93 38.31 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 123.543 0.737 . . . . 0.0 110.128 178.32 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.711 HD13 ' HG2' ' A' ' 72' ' ' ARG . 44.5 pt -129.94 179.74 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 123.658 0.783 . . . . 0.0 110.702 -177.19 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 10.7 mmm180 -123.45 119.78 31.01 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 125.276 1.431 . . . . 0.0 107.247 171.59 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -149.83 -68.51 0.2 Allowed 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -177.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.408 ' H ' HD23 ' A' ' 91' ' ' LEU . 2.0 pt? -127.0 78.62 1.82 Allowed 'General case' 0 N--CA 1.477 0.893 0 CA-C-O 122.318 1.056 . . . . 0.0 110.917 -177.008 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -73.36 -10.31 59.61 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.247 174.284 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -63.87 95.35 0.11 Allowed 'General case' 0 C--O 1.241 0.617 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 169.811 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 85.8 m-70 -61.34 137.92 58.24 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.333 -0.849 . . . . 0.0 109.943 -178.365 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 52.6 m80 -72.17 86.86 1.07 Allowed 'General case' 0 CA--C 1.546 0.819 0 O-C-N 123.726 0.641 . . . . 0.0 111.188 -175.235 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 23.8 p-80 -97.6 90.36 4.99 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 124.644 1.178 . . . . 0.0 108.858 173.068 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 35.7 t-80 -87.72 118.79 27.46 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.759 0.824 . . . . 0.0 110.222 -176.498 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 19.6 p-80 . . . . . 0 CA--C 1.555 1.17 0 O-C-N 123.436 0.46 . . . . 0.0 109.912 173.984 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.582 0 N-CA-C 112.584 -0.206 . . . . 0.0 112.584 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 53.5 m-20 -103.44 125.19 49.89 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.433 0.693 . . . . 0.0 109.849 178.401 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -95.71 113.4 25.04 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 174.307 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 74.9 ttt180 -77.84 85.17 4.12 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 122.672 0.389 . . . . 0.0 110.377 -177.468 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 48.2 t -74.47 -25.4 19.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.77 174.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.2 tpp180 -70.68 85.77 0.65 Allowed 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 124.386 1.075 . . . . 0.0 110.166 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 1.6 tm? -116.26 89.7 3.17 Favored 'General case' 0 C--N 1.346 0.43 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.276 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 68.4 mt -91.01 134.74 28.72 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.841 173.398 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.75 138.83 39.68 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 123.809 0.843 . . . . 0.0 109.128 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 33.4 p -66.19 113.03 4.24 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 123.301 0.64 . . . . 0.0 110.883 -177.049 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -74.57 99.0 3.5 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 178.638 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -85.88 -172.79 49.07 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 116.374 -0.375 . . . . 0.0 112.522 176.402 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -169.42 -156.73 11.05 Favored Glycine 0 C--N 1.338 0.653 0 C-N-CA 121.933 -0.175 . . . . 0.0 112.775 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -88.9 10.09 22.53 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.637 0.775 . . . . 0.0 111.458 178.236 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 13.4 p -73.35 -174.89 1.75 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 123.886 0.874 . . . . 0.0 111.479 171.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.9 ttmp? 65.63 91.53 0.08 Allowed 'General case' 0 C--N 1.36 1.037 0 C-N-CA 124.696 1.199 . . . . 0.0 109.475 -175.376 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.4 p -64.95 162.14 2.57 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.165 0 C-N-CA 122.943 0.497 . . . . 0.0 110.663 -178.08 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.609 ' HD2' ' H ' ' A' ' 18' ' ' ARG . 0.2 OUTLIER -54.76 -46.38 74.34 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 124.941 1.296 . . . . 0.0 111.079 -175.652 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.511 ' HA ' HH21 ' A' ' 24' ' ' ARG . 2.0 pp -160.37 156.69 26.6 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 124.902 1.281 . . . . 0.0 109.417 172.583 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -142.01 -70.73 0.34 Allowed 'General case' 0 N--CA 1.483 1.214 0 CA-C-O 120.609 0.242 . . . . 0.0 111.113 -177.491 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 24.7 m -111.32 33.68 4.53 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -160.96 179.59 8.34 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 114.79 -1.095 . . . . 0.0 110.393 -168.676 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.418 HG22 HD12 ' A' ' 40' ' ' ILE . 5.2 m -127.49 114.58 17.65 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 176.352 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.511 HH21 ' HA ' ' A' ' 19' ' ' LEU . 57.4 mtm180 -123.34 161.15 25.25 Favored 'General case' 0 C--O 1.244 0.8 0 C-N-CA 123.296 0.638 . . . . 0.0 110.807 178.106 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.9 tt -145.65 141.24 22.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.745 -170.518 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -84.07 102.57 12.62 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 175.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.7 t -93.9 115.26 32.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 C-N-CA 124.18 0.992 . . . . 0.0 109.085 -171.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.5 t -104.65 106.97 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 124.327 1.051 . . . . 0.0 109.011 -177.543 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -69.16 111.48 8.69 Favored Pre-proline 0 CA--C 1.544 0.725 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 175.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -74.1 -7.43 19.84 Favored 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.712 2.274 . . . . 0.0 113.506 -170.101 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -96.02 -52.75 3.91 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 122.685 0.394 . . . . 0.0 111.221 -177.527 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 77.1 p -102.14 -29.86 11.48 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 123.367 0.667 . . . . 0.0 112.548 -175.82 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.39 20.91 14.0 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-O 119.734 -0.481 . . . . 0.0 113.766 177.583 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 60.8 mttp -67.43 105.66 1.87 Allowed 'General case' 0 N--CA 1.484 1.25 0 CA-C-N 117.308 0.554 . . . . 0.0 110.665 175.04 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 44.5 t -108.85 115.65 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.503 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.7 tp10 -153.72 147.55 25.38 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.111 0.564 . . . . 0.0 109.66 -174.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 44.7 mt -83.77 100.07 6.9 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -177.726 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -90.82 160.09 15.94 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.975 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.448 ' HB2' ' ND2' ' A' ' 67' ' ' ASN . 37.5 mt-10 -105.61 122.24 45.62 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -177.17 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.463 HG12 HG22 ' A' ' 66' ' ' THR . 50.9 mt -75.76 111.81 12.64 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -172.751 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -73.77 -40.16 63.67 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 123.807 0.843 . . . . 0.0 110.335 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -143.89 130.68 20.3 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.864 -173.231 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.405 HG12 HD11 ' A' ' 58' ' ' ILE . 29.4 m -83.25 -7.49 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 122.99 0.516 . . . . 0.0 111.754 -175.298 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 35.1 m -119.45 167.84 12.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 C-N-CA 123.492 0.717 . . . . 0.0 109.974 176.373 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.496 ' HB3' ' HB ' ' A' ' 63' ' ' VAL . 11.2 pt-20 -89.88 -39.24 13.17 Favored 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 170.707 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -151.06 145.7 25.68 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.913 0.885 . . . . 0.0 108.966 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.5 t -132.23 135.11 46.07 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.505 0.722 . . . . 0.0 109.066 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -107.3 -45.65 4.05 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 123.516 0.726 . . . . 0.0 111.169 -175.289 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -146.16 115.55 4.67 Favored Pre-proline 0 N--CA 1.478 0.949 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.09 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -79.04 27.52 0.52 Allowed 'Trans proline' 0 C--N 1.371 1.722 0 C-N-CA 123.116 2.544 . . . . 0.0 114.484 -171.747 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 7.4 p-80 -71.4 -29.0 64.42 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 122.646 0.378 . . . . 0.0 110.839 175.143 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -102.41 177.86 4.75 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.471 0.709 . . . . 0.0 109.342 168.098 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.9 t 55.97 43.71 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 C-N-CA 124.964 1.305 . . . . 0.0 110.194 -176.455 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 30.7 mmm180 -72.07 -50.24 29.89 Favored 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 174.522 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -71.25 123.44 22.24 Favored 'General case' 0 C--O 1.244 0.801 0 CA-C-N 114.843 -1.071 . . . . 0.0 108.168 165.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 35.3 m-80 -73.69 80.65 1.54 Allowed 'General case' 0 CA--C 1.544 0.712 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 174.657 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.7 tp -110.51 132.17 59.61 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.183 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.487 HD13 HG11 ' A' ' 64' ' ' VAL . 61.6 mt -114.42 144.37 22.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 124.171 0.988 . . . . 0.0 108.493 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 31.2 p -121.9 167.98 12.42 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.265 0.626 . . . . 0.0 110.55 179.416 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 39.5 ttp180 -71.72 131.09 42.64 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.005 178.108 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.2 -2.3 83.45 Favored Glycine 0 C--N 1.342 0.914 0 C-N-CA 123.607 0.622 . . . . 0.0 113.005 -177.698 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -85.18 132.55 34.27 Favored 'General case' 0 C--O 1.246 0.881 0 C-N-CA 123.408 0.683 . . . . 0.0 110.137 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.496 ' HB ' ' HB3' ' A' ' 45' ' ' GLU . 41.4 t -82.73 113.61 22.24 Favored 'Isoleucine or valine' 0 C--N 1.352 0.69 0 CA-C-O 121.01 0.433 . . . . 0.0 110.029 178.537 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.487 HG11 HD13 ' A' ' 58' ' ' ILE . 34.1 m -102.28 166.94 2.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 169.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -120.98 134.89 55.31 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 175.518 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.463 HG22 HG12 ' A' ' 40' ' ' ILE . 43.6 p -130.68 -176.23 3.91 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 124.263 1.025 . . . . 0.0 110.099 -171.347 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.448 ' ND2' ' HB2' ' A' ' 39' ' ' GLU . 97.3 m-20 -68.96 -23.59 64.15 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.06 175.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 73.8 mt -86.22 -41.34 14.72 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 123.183 0.302 . . . . 0.0 110.464 175.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 159.08 -159.29 30.25 Favored Glycine 0 C--N 1.345 1.045 0 O-C-N 123.443 0.464 . . . . 0.0 112.976 178.297 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 21.5 m120 -77.43 124.45 27.9 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 177.212 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 46.1 t -123.58 145.21 30.94 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.733 0 C-N-CA 124.438 1.095 . . . . 0.0 109.562 -175.704 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.443 ' HG3' HD13 ' A' ' 88' ' ' ILE . 30.1 mtt85 -107.7 137.04 46.44 Favored 'General case' 0 N--CA 1.483 1.18 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 168.337 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.476 HG11 ' HD3' ' A' ' 77' ' ' PRO . 58.1 t -75.09 120.26 24.32 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 O-C-N 124.273 0.983 . . . . 0.0 109.594 179.632 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.421 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 40.2 p -98.38 -20.95 16.86 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 123.447 0.699 . . . . 0.0 110.429 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' SER . . . . . 0.413 ' HB3' ' HB2' ' A' ' 84' ' ' ASN . 95.0 p -91.9 -173.16 3.41 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.379 0.672 . . . . 0.0 109.713 174.807 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 74.8 mtt180 -116.23 103.4 53.12 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 172.32 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.476 ' HD3' HG11 ' A' ' 73' ' ' VAL . 21.1 Cg_endo -57.71 151.54 54.86 Favored 'Trans proline' 0 C--N 1.382 2.297 0 C-N-CA 123.659 2.906 . . . . 0.0 113.632 -168.082 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.52 -35.01 4.2 Favored Glycine 0 C--N 1.349 1.292 0 CA-C-O 119.7 -0.5 . . . . 0.0 113.553 176.534 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 89.8 mt-30 -61.59 -57.77 10.75 Favored 'General case' 0 C--N 1.359 1.015 0 CA-C-O 121.351 0.596 . . . . 0.0 109.921 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -91.73 32.87 1.06 Allowed 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.376 177.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 65.07 -78.04 0.07 OUTLIER Glycine 0 C--N 1.361 1.949 0 C-N-CA 123.643 0.64 . . . . 0.0 112.831 -176.149 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.1 p -73.72 164.6 3.48 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.523 1.129 . . . . 0.0 110.441 178.476 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.448 HG12 ' HB3' ' A' ' 77' ' ' PRO . 15.9 mt -93.82 147.82 5.28 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 175.171 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.413 ' HB2' ' HB3' ' A' ' 75' ' ' SER . 3.0 m120 -123.79 147.73 47.3 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 171.11 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.421 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -165.3 -176.49 36.92 Favored Glycine 0 CA--C 1.526 0.755 0 O-C-N 123.383 0.427 . . . . 0.0 113.177 -177.172 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 16.0 m -122.62 139.11 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 C-N-CA 123.826 0.85 . . . . 0.0 110.871 178.576 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 19.4 tp -74.82 113.47 12.14 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 123.522 0.514 . . . . 0.0 109.968 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.443 HD13 ' HG3' ' A' ' 72' ' ' ARG . 34.5 pt -112.71 -177.17 0.82 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.733 0 C-N-CA 123.776 0.831 . . . . 0.0 109.883 178.019 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -133.04 100.77 4.98 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -178.377 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 70.2 mm-40 -119.26 -64.57 1.26 Allowed 'General case' 0 N--CA 1.477 0.897 0 CA-C-O 121.362 0.601 . . . . 0.0 109.491 177.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 70.8 mt -121.82 26.15 8.82 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.966 -173.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.96 -175.83 1.55 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 124.951 1.3 . . . . 0.0 112.19 -172.673 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 43.1 p-80 -57.66 109.86 0.78 Allowed 'General case' 0 CA--C 1.562 1.425 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 169.171 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -76.38 130.55 38.22 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.316 0.647 . . . . 0.0 111.373 -167.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 47.7 t-80 -83.94 74.29 10.24 Favored 'General case' 0 CA--C 1.551 0.996 0 C-N-CA 124.082 0.953 . . . . 0.0 111.109 -174.409 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 8.0 p80 -174.09 147.05 1.22 Allowed 'General case' 0 N--CA 1.484 1.244 0 C-N-CA 124.63 1.172 . . . . 0.0 109.826 175.321 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 64.0 t60 -66.23 -59.06 4.1 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 123.732 0.813 . . . . 0.0 110.907 177.259 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 62.9 t-80 . . . . . 0 CA--C 1.55 0.955 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.955 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.841 0 N-CA-C 112.704 -0.158 . . . . 0.0 112.704 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -123.98 128.29 49.17 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 123.963 0.905 . . . . 0.0 109.38 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 5.7 mmp_? -94.99 64.32 2.79 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 166.005 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 52.3 ttm-85 -70.16 112.96 6.89 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 113.763 -1.562 . . . . 0.0 110.661 -173.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.9 t -110.98 90.13 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 123.897 0.879 . . . . 0.0 109.016 177.535 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 74.8 mtp180 -79.43 110.52 14.8 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 177.788 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 87.5 mt -80.0 86.12 5.52 Favored 'General case' 0 CA--C 1.541 0.613 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 176.274 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 50.7 mm -91.3 111.3 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 N-CA-C 108.436 -0.949 . . . . 0.0 108.436 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.07 168.91 10.47 Favored 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 122.995 0.518 . . . . 0.0 111.845 -175.282 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 80.9 m -95.24 117.32 30.06 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 124.694 1.198 . . . . 0.0 110.146 -177.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.411 ' HD3' ' H ' ' A' ' 11' ' ' ARG . 0.0 OUTLIER -131.16 -33.99 1.47 Allowed 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 123.763 0.825 . . . . 0.0 110.973 -178.94 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 151.16 101.49 0.22 Allowed Glycine 0 C--N 1.341 0.814 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 -173.478 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -153.45 165.58 31.45 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 122.95 0.309 . . . . 0.0 112.549 -173.693 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 5.1 t30 -142.79 92.73 2.43 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 123.321 0.648 . . . . 0.0 109.802 -174.427 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 19.2 p -117.51 88.67 2.96 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 123.932 0.893 . . . . 0.0 109.088 174.264 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -118.83 153.44 34.49 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.738 0.815 . . . . 0.0 110.024 177.445 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 10.0 p -84.44 146.33 6.88 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 167.758 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 -81.54 -169.39 2.29 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 123.612 0.765 . . . . 0.0 110.42 177.158 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.579 HD22 ' HB2' ' A' ' 24' ' ' ARG . 1.1 pp -71.4 75.04 0.75 Allowed 'General case' 0 CA--C 1.558 1.279 0 CA-C-O 122.267 1.032 . . . . 0.0 111.663 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -89.41 -30.16 18.55 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.021 0.928 . . . . 0.0 111.565 -176.319 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.3 m -76.35 -44.64 35.64 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.402 0.681 . . . . 0.0 110.602 -177.406 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -147.77 131.21 16.67 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.697 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.526 ' HA ' HD13 ' A' ' 19' ' ' LEU . 29.8 m -68.27 119.18 12.4 Favored 'General case' 0 CA--C 1.54 0.579 0 O-C-N 123.993 0.808 . . . . 0.0 111.045 178.612 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.579 ' HB2' HD22 ' A' ' 19' ' ' LEU . 71.8 mtm180 -112.96 170.64 8.05 Favored 'General case' 0 C--O 1.243 0.727 0 C-N-CA 123.618 0.767 . . . . 0.0 110.119 177.71 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.9 tt -143.57 139.54 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.313 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 22.7 m-80 -88.2 100.16 12.76 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -84.0 109.89 17.99 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 C-N-CA 124.098 0.959 . . . . 0.0 109.187 -175.067 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 48.8 t -101.34 113.61 38.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.568 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -62.52 121.04 64.75 Favored Pre-proline 0 CA--C 1.547 0.835 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 177.87 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -71.91 -18.42 27.98 Favored 'Trans proline' 0 C--N 1.363 1.317 0 C-N-CA 122.344 2.029 . . . . 0.0 113.326 -172.474 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -92.94 -52.02 4.79 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.592 0.757 . . . . 0.0 110.881 -174.642 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 47.2 p -96.97 -29.08 13.88 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.638 0.775 . . . . 0.0 111.992 -176.175 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.34 4.41 55.07 Favored Glycine 0 N--CA 1.481 1.665 0 CA-C-O 119.272 -0.738 . . . . 0.0 114.388 176.743 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.9 mtmp? -63.19 108.0 1.17 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.528 0.731 . . . . 0.0 112.335 -173.669 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.2 t -90.62 116.47 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 C-N-CA 123.39 0.676 . . . . 0.0 109.378 176.742 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -144.59 139.4 28.09 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.329 0.652 . . . . 0.0 110.092 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 36.1 mt -79.76 133.84 28.87 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.885 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 -179.452 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.69 158.3 37.97 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 123.555 0.742 . . . . 0.0 111.441 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 32.6 mm-40 -92.15 121.43 33.69 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 177.664 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.0 mt -77.21 112.28 14.95 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 178.52 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -76.2 -51.98 11.01 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.086 0.954 . . . . 0.0 110.225 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -151.48 174.1 13.79 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.671 HG23 ' HE ' ' A' ' 54' ' ' ARG . 27.0 m -112.02 29.88 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.698 0 C-N-CA 123.208 0.603 . . . . 0.0 110.727 177.072 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.654 ' HA ' ' HG3' ' A' ' 54' ' ' ARG . 7.4 p -64.31 115.55 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 CA-C-O 121.781 0.8 . . . . 0.0 111.902 -176.237 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.74 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 36.1 tt0 -95.05 43.65 1.09 Allowed 'General case' 0 CA--C 1.552 1.026 0 C-N-CA 123.835 0.854 . . . . 0.0 110.169 -177.574 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 8.9 t30 55.24 83.9 0.08 Allowed 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 124.385 1.074 . . . . 0.0 110.745 -176.307 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 89.6 m -135.8 -72.18 0.46 Allowed 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.401 0.68 . . . . 0.0 109.504 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -175.81 -175.72 0.78 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 124.728 1.211 . . . . 0.0 108.811 -177.669 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 62.4 t30 -163.36 77.23 1.76 Allowed Pre-proline 0 CA--C 1.546 0.805 0 C-N-CA 123.615 0.766 . . . . 0.0 109.084 169.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.79 -45.41 0.24 Allowed 'Trans proline' 0 C--N 1.372 1.8 0 C-N-CA 122.64 2.227 . . . . 0.0 111.973 176.363 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.0 t-160 -164.92 -57.03 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -177.131 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -121.39 150.25 41.78 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 167.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 6.9 p -156.98 -40.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 123.106 0.562 . . . . 0.0 110.333 -178.111 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.671 ' HE ' HG23 ' A' ' 43' ' ' VAL . 22.6 mmm180 -134.26 153.31 51.94 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.524 0.73 . . . . 0.0 110.32 -174.235 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.651 ' HB2' HG12 ' A' ' 57' ' ' ILE . 29.1 mmt180 -96.54 -161.26 0.86 Allowed 'General case' 0 CA--C 1.55 0.942 0 C-N-CA 123.83 0.852 . . . . 0.0 109.791 177.296 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -88.34 -2.21 58.47 Favored 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.844 0.858 . . . . 0.0 110.046 170.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.651 HG12 ' HB2' ' A' ' 55' ' ' ARG . 43.0 pt -63.08 110.27 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.359 1.007 0 CA-C-O 122.083 0.944 . . . . 0.0 111.143 -177.445 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.444 ' O ' ' HG3' ' A' ' 77' ' ' PRO . 57.5 mt -102.47 108.72 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 107.721 -1.215 . . . . 0.0 107.721 173.036 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.9 p -99.53 151.93 20.59 Favored 'General case' 0 C--O 1.241 0.614 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 174.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 73.0 ttt180 -67.2 128.27 35.77 Favored 'General case' 0 CA--C 1.546 0.793 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 176.108 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.81 11.46 70.6 Favored Glycine 0 C--N 1.338 0.691 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.827 -176.841 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.94 148.21 23.92 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-N 117.353 0.577 . . . . 0.0 110.112 176.405 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.74 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 61.6 t -84.11 114.63 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 171.406 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 28.8 m -104.46 144.73 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 C-N-CA 123.025 0.53 . . . . 0.0 109.686 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -91.68 127.85 37.29 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 175.708 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 49.5 p -128.8 -179.97 5.38 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -68.29 -19.17 64.68 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 122.854 0.461 . . . . 0.0 111.585 176.149 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 96.4 mt -90.35 -46.72 8.2 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.242 0.617 . . . . 0.0 109.804 178.599 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 162.99 -153.46 24.02 Favored Glycine 0 C--N 1.339 0.74 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.749 177.078 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -76.78 137.36 39.22 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 122.864 0.465 . . . . 0.0 110.284 176.099 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.4 t -132.03 142.65 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 122.957 0.503 . . . . 0.0 109.861 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.572 ' HG2' HD13 ' A' ' 88' ' ' ILE . 33.4 mmt180 -89.75 123.02 33.38 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 170.311 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 66.2 t -75.78 95.79 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 -179.404 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 60.8 p -78.84 -41.72 29.37 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 122.925 0.49 . . . . 0.0 111.179 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' SER . . . . . 0.552 ' HB2' ' H ' ' A' ' 84' ' ' ASN . 50.3 m -91.42 115.1 27.76 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.0 176.254 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 7.3 tmm_? -55.75 135.22 72.2 Favored Pre-proline 0 CA--C 1.563 1.453 0 C-N-CA 125.099 1.359 . . . . 0.0 110.188 177.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.444 ' HG3' ' O ' ' A' ' 58' ' ' ILE . 36.9 Cg_endo -60.85 129.69 30.01 Favored 'Trans proline' 0 C--N 1.377 2.068 0 C-N-CA 123.026 2.484 . . . . 0.0 112.398 -177.343 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 115.23 -18.55 15.81 Favored Glycine 0 C--N 1.34 0.791 0 CA-C-O 119.678 -0.512 . . . . 0.0 112.688 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -67.74 98.3 0.7 Allowed 'General case' 0 C--N 1.355 0.842 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 177.662 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 74.33 -2.47 2.8 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 125.754 1.621 . . . . 0.0 112.083 -174.589 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.93 -0.42 82.19 Favored Glycine 0 C--N 1.348 1.233 0 C-N-CA 123.082 0.372 . . . . 0.0 112.469 -178.04 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -115.37 148.59 17.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 124.464 1.106 . . . . 0.0 109.671 175.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 35.6 mt -104.44 145.36 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 C-N-CA 123.081 0.553 . . . . 0.0 109.601 173.457 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.552 ' H ' ' HB2' ' A' ' 75' ' ' SER . 42.9 m-20 -130.19 154.86 47.11 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 174.345 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.87 -178.06 37.16 Favored Glycine 0 C--N 1.336 0.579 0 CA-C-O 119.825 -0.43 . . . . 0.0 112.837 -177.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.18 136.93 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 123.306 0.642 . . . . 0.0 110.739 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 45.7 tp -66.13 124.68 23.27 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 122.862 0.465 . . . . 0.0 111.753 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.572 HD13 ' HG2' ' A' ' 72' ' ' ARG . 45.4 pt -119.59 164.99 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 CA-C-O 121.586 0.708 . . . . 0.0 109.788 168.787 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ARG . . . . . 0.421 ' N ' HH11 ' A' ' 89' ' ' ARG . 0.0 OUTLIER -130.92 88.27 2.59 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -175.106 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -101.24 -64.63 1.03 Allowed 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 63.3 mt -70.9 142.87 51.12 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.371 174.68 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 71.93 -31.86 0.23 Allowed 'General case' 0 N--CA 1.496 1.853 0 C-N-CA 127.464 2.306 . . . . 0.0 113.479 -178.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' HIS . . . . . 0.408 ' HB2' ' HB3' ' A' ' 89' ' ' ARG . 13.3 t60 -71.42 -55.56 7.69 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 171.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 49.1 t-80 -82.62 74.93 9.55 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 165.757 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 16.2 p80 -82.8 176.13 9.56 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 114.521 -1.218 . . . . 0.0 111.221 -176.618 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 30.6 m170 -65.0 96.15 0.18 Allowed 'General case' 0 N--CA 1.474 0.752 0 O-C-N 123.951 0.782 . . . . 0.0 110.623 -177.028 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -144.74 92.78 2.32 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 178.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 36.9 m80 . . . . . 0 N--CA 1.477 0.882 0 C-N-CA 124.178 0.991 . . . . 0.0 108.886 -179.529 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.642 0 N-CA-C 112.09 -0.404 . . . . 0.0 112.09 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -69.0 83.09 0.32 Allowed 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.997 0.919 . . . . 0.0 111.214 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 25.7 mmt180 -132.6 43.53 2.98 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.652 1.181 . . . . 0.0 108.326 176.53 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -70.9 90.26 0.8 Allowed 'General case' 0 CA--C 1.551 1.008 0 CA-C-N 114.869 -1.059 . . . . 0.0 110.558 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 41.1 t -68.83 118.59 13.25 Favored 'Isoleucine or valine' 0 C--O 1.242 0.665 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.15 179.179 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 42.8 ttm180 -68.83 -28.22 66.54 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.854 0.862 . . . . 0.0 111.38 -177.38 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.8 tt 64.22 57.3 1.24 Allowed 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 -171.584 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 9.1 tt -85.19 129.63 37.49 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.76 0 CA-C-N 114.43 -1.259 . . . . 0.0 109.283 179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 63.4 mtm180 -135.31 94.67 3.15 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 177.269 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 20.6 p -97.17 139.89 32.48 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 123.486 0.715 . . . . 0.0 110.118 -179.192 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -136.84 110.55 8.09 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -123.21 164.45 16.22 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -93.7 -155.58 31.93 Favored Glycine 0 C--N 1.34 0.763 0 O-C-N 123.627 0.251 . . . . 0.0 113.168 -178.667 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.8 t-20 -129.09 102.06 6.31 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.781 0.832 . . . . 0.0 109.299 -176.509 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 34.2 m -94.65 112.35 24.1 Favored 'General case' 0 CA--C 1.541 0.605 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 176.732 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -71.79 149.97 44.81 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 123.538 0.735 . . . . 0.0 111.431 -174.453 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.1 p -119.55 151.26 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 C-N-CA 123.741 0.816 . . . . 0.0 110.959 -176.439 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.681 ' HA ' ' HE ' ' A' ' 18' ' ' ARG . 0.2 OUTLIER -105.01 126.63 52.27 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.074 0.95 . . . . 0.0 109.478 176.542 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.483 HD22 ' H ' ' A' ' 24' ' ' ARG . 86.0 mt 77.04 -41.98 0.4 Allowed 'General case' 0 N--CA 1.489 1.523 0 C-N-CA 125.859 1.664 . . . . 0.0 112.368 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 73.39 -76.92 0.06 Allowed 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 125.66 1.584 . . . . 0.0 111.94 172.304 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.532 ' HB2' ' NH2' ' A' ' 24' ' ' ARG . 16.8 m -102.5 -43.75 5.55 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 122.967 0.507 . . . . 0.0 110.847 -177.317 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ASP . . . . . 0.422 ' O ' ' HG2' ' A' ' 24' ' ' ARG . 21.4 t70 -153.2 177.01 11.3 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.098 0.559 . . . . 0.0 110.522 -172.612 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 28.0 m -67.19 120.94 14.6 Favored 'General case' 0 C--N 1.352 0.685 0 C-N-CA 123.491 0.716 . . . . 0.0 110.141 177.026 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.532 ' NH2' ' HB2' ' A' ' 21' ' ' SER . 24.6 mmt85 -116.72 147.78 41.69 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 123.994 0.917 . . . . 0.0 111.409 -170.093 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.6 tt -148.63 142.2 18.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-N 114.185 -1.37 . . . . 0.0 108.527 -178.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ASN . . . . . 0.408 ' OD1' HG23 ' A' ' 82' ' ' VAL . 14.5 m120 -93.89 100.65 12.78 Favored 'General case' 0 C--O 1.241 0.644 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 175.532 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 87.5 t -91.71 116.57 33.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.439 0 CA-C-N 114.353 -1.294 . . . . 0.0 108.461 -176.287 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.447 HG22 HG22 ' A' ' 35' ' ' VAL . 35.0 t -98.51 109.88 24.84 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.366 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -62.86 117.69 34.83 Favored Pre-proline 0 CA--C 1.548 0.891 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 172.472 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -66.1 -31.94 44.52 Favored 'Trans proline' 0 C--N 1.366 1.475 0 C-N-CA 122.698 2.265 . . . . 0.0 113.269 -170.079 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -94.33 -46.15 7.17 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 123.179 0.592 . . . . 0.0 110.857 -175.556 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.6 m -84.87 -29.34 25.34 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.125 0.57 . . . . 0.0 111.006 -173.624 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.66 5.96 73.86 Favored Glycine 0 C--N 1.345 1.038 0 CA-C-O 119.567 -0.574 . . . . 0.0 113.976 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 95.6 mttt -60.12 106.08 0.47 Allowed 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.052 0.541 . . . . 0.0 111.228 178.042 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.447 HG22 HG22 ' A' ' 28' ' ' VAL . 61.6 t -94.47 107.84 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 168.535 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -137.0 137.67 39.68 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 122.799 0.439 . . . . 0.0 109.944 -171.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 37.9 mt -75.74 99.14 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 177.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.458 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -89.45 157.4 18.14 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 123.737 0.815 . . . . 0.0 111.503 175.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -107.33 122.41 46.51 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.804 0.842 . . . . 0.0 109.179 178.466 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 64.7 mt -78.0 115.44 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 123.363 0.665 . . . . 0.0 110.845 -171.284 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 35.1 mmt180 -78.15 -53.78 6.98 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.417 1.087 . . . . 0.0 110.42 178.535 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.498 ' HB3' HG12 ' A' ' 44' ' ' VAL . 49.5 m-80 -131.54 153.88 49.39 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 123.666 0.786 . . . . 0.0 110.043 -175.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.459 ' HA ' HG12 ' A' ' 64' ' ' VAL . 33.7 m -118.42 6.76 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.117 0.967 . . . . 0.0 110.97 177.621 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.498 HG12 ' HB3' ' A' ' 42' ' ' ASN . 6.3 p -68.51 107.55 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.058 0 CA-C-O 121.614 0.721 . . . . 0.0 110.681 -177.302 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -59.38 143.12 50.55 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.247 174.042 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 7.0 m120 -75.74 82.44 2.71 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 176.443 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.3 m -117.15 149.77 39.82 Favored 'General case' 0 C--O 1.241 0.653 0 C-N-CA 124.92 1.288 . . . . 0.0 108.817 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -66.61 90.07 0.16 Allowed 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 171.021 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 60.84 90.81 0.09 OUTLIER Pre-proline 0 CA--C 1.552 1.042 0 C-N-CA 124.518 1.127 . . . . 0.0 110.752 -172.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_exo -70.89 81.14 1.13 Allowed 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.523 2.149 . . . . 0.0 111.553 175.681 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 28.3 p80 -98.91 84.35 3.07 Favored 'General case' 0 N--CA 1.481 1.101 0 CA-C-O 121.559 0.695 . . . . 0.0 110.323 -176.724 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 55.66 23.83 6.55 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 124.334 1.054 . . . . 0.0 112.454 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 18.0 m -71.02 -32.04 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 175.392 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -141.28 158.62 43.64 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 125.668 1.587 . . . . 0.0 107.766 167.029 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 89.7 mtm180 -84.17 -172.05 3.95 Favored 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 172.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 60.2 m-80 -81.26 64.13 5.87 Favored 'General case' 0 N--CA 1.483 1.209 0 CA-C-O 121.929 0.871 . . . . 0.0 109.971 176.277 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 2.0 pp -132.89 170.38 20.14 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 125.051 1.34 . . . . 0.0 110.116 177.698 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.7 mt -102.34 130.68 51.84 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 C-N-CA 124.495 1.118 . . . . 0.0 109.162 -179.308 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 35.2 p -123.73 156.1 36.63 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.499 0.719 . . . . 0.0 109.737 177.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 60.5 ttt180 -74.71 123.51 25.04 Favored 'General case' 0 CA--C 1.544 0.715 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -178.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.99 4.19 67.27 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.086 -173.137 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.62 158.69 22.93 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.146 0.473 . . . . 0.0 110.737 175.837 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 68.8 t -97.26 111.24 26.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 171.752 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.459 HG12 ' HA ' ' A' ' 43' ' ' VAL . 29.6 m -108.38 137.97 37.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 173.726 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -91.16 142.32 27.87 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.109 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.458 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 61.7 p -128.07 178.76 5.99 Favored 'General case' 0 C--O 1.246 0.898 0 C-N-CA 124.146 0.979 . . . . 0.0 109.144 179.481 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -57.92 -25.72 61.26 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 123.584 0.754 . . . . 0.0 111.571 173.12 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 75.0 mt -83.52 -49.48 9.21 Favored 'General case' 0 C--N 1.351 0.632 0 C-N-CA 123.526 0.73 . . . . 0.0 109.244 178.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 161.01 -163.89 34.51 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-N 115.27 -0.877 . . . . 0.0 111.394 -177.065 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 -75.46 139.08 42.04 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-O 121.084 0.469 . . . . 0.0 110.148 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 83.9 t -133.72 144.59 35.37 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 C-N-CA 125.096 1.358 . . . . 0.0 109.272 -171.18 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.747 ' HG2' HD13 ' A' ' 88' ' ' ILE . 7.0 mmt85 -96.33 122.43 39.21 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 171.603 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 47.2 t -70.57 109.09 2.76 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.438 HG21 HG13 ' A' ' 86' ' ' VAL . 44.6 p -90.48 -30.45 17.3 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.13 0.572 . . . . 0.0 110.986 -171.078 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 25.9 t -113.71 -169.9 1.6 Allowed 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.871 0.868 . . . . 0.0 109.416 -178.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 18.4 mtp180 -70.11 144.57 92.81 Favored Pre-proline 0 CA--C 1.554 1.104 0 C-N-CA 123.432 0.693 . . . . 0.0 110.711 174.724 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.407 ' HA ' HG12 ' A' ' 83' ' ' ILE . 88.3 Cg_endo -78.8 162.02 27.05 Favored 'Trans proline' 0 C--N 1.366 1.486 0 C-N-CA 122.307 2.004 . . . . 0.0 112.29 173.879 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.437 ' H ' HG12 ' A' ' 83' ' ' ILE . . . 57.4 -89.18 0.02 OUTLIER Glycine 0 C--N 1.346 1.089 0 CA-C-N 115.635 -0.712 . . . . 0.0 113.283 -175.561 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . 0.257 12.3 pt20 53.23 -66.41 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 C-N-CA 127.74 2.416 . . . . 0.0 114.328 -178.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -146.38 41.75 1.16 Allowed 'General case' 0 N--CA 1.476 0.854 0 CA-C-O 122.255 1.026 . . . . 0.0 108.518 178.284 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 64.47 16.99 61.51 Favored Glycine 0 C--N 1.351 1.377 0 CA-C-N 115.026 -0.988 . . . . 0.0 113.061 -173.293 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.408 HG23 ' OD1' ' A' ' 26' ' ' ASN . 3.8 p -132.69 88.92 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 CA-C-O 122.595 1.188 . . . . 0.0 110.074 -174.031 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.437 HG12 ' H ' ' A' ' 78' ' ' GLY . 34.2 mt -83.31 149.06 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 171.273 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -118.04 143.67 46.23 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 172.156 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.7 179.49 30.75 Favored Glycine 0 C--N 1.336 0.539 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.829 178.741 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.438 HG13 HG21 ' A' ' 74' ' ' THR . 15.7 m -129.36 137.34 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 C-N-CA 123.784 0.834 . . . . 0.0 110.235 174.536 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.16 105.71 3.5 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 122.655 0.382 . . . . 0.0 110.082 -178.197 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.747 HD13 ' HG2' ' A' ' 72' ' ' ARG . 39.1 pt -96.83 168.07 1.63 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.588 0 CA-C-O 121.583 0.706 . . . . 0.0 110.477 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 84.3 mtt180 -127.96 26.91 5.77 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.936 177.683 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -58.12 -62.91 1.48 Allowed 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 172.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.0 mt -104.04 116.16 31.74 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 158.031 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -74.67 150.55 39.51 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 171.148 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 40.5 t60 -63.52 94.5 0.09 Allowed 'General case' 0 N--CA 1.481 1.107 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -178.1 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -63.0 113.06 2.87 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 124.644 1.178 . . . . 0.0 112.807 -165.045 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -84.21 135.57 34.3 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 123.952 0.901 . . . . 0.0 109.577 179.587 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 57.55 55.2 5.81 Favored 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 123.57 0.748 . . . . 0.0 111.66 177.285 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 27.8 t-80 -156.34 122.54 5.01 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 123.914 0.885 . . . . 0.0 109.221 -178.818 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 54.6 t-80 . . . . . 0 CA--C 1.558 1.253 0 C-N-CA 124.494 1.118 . . . . 0.0 109.641 -176.166 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.594 0 N-CA-C 111.457 -0.657 . . . . 0.0 111.457 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -135.65 114.94 12.47 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.633 0.773 . . . . 0.0 109.324 -177.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 5.5 mpt_? -110.37 91.97 3.86 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 171.703 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -101.5 82.95 2.37 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.625 -174.671 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 95.8 t -128.07 138.14 55.53 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 123.797 0.839 . . . . 0.0 109.793 -176.291 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -103.73 131.91 50.47 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 123.958 0.903 . . . . 0.0 109.031 171.641 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 6.6 tt -75.17 107.73 7.45 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 -178.573 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 17.3 tt -104.16 119.04 52.34 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.806 0 CA-C-O 121.274 0.559 . . . . 0.0 109.615 179.358 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 3.4 tmt_? -72.96 133.11 44.19 Favored 'General case' 0 C--O 1.241 0.632 0 C-N-CA 123.565 0.746 . . . . 0.0 109.536 177.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 38.2 p -66.98 100.93 0.78 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 122.911 0.484 . . . . 0.0 110.621 179.081 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.0 mmm180 -68.79 91.25 0.44 Allowed 'General case' 0 C--N 1.347 0.497 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.883 176.82 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -153.8 148.84 20.0 Favored Glycine 0 C--O 1.239 0.468 0 CA-C-N 115.072 -0.967 . . . . 0.0 112.029 -176.606 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -135.83 -62.04 0.06 OUTLIER Glycine 0 C--N 1.339 0.734 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 176.799 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -80.43 89.75 5.61 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 175.522 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 74.4 p -115.06 101.87 9.41 Favored 'General case' 0 C--O 1.24 0.592 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 176.549 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp -72.2 82.86 1.01 Allowed 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 122.975 0.51 . . . . 0.0 110.525 -177.636 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 84.2 t -80.86 145.3 9.17 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 124.053 0.941 . . . . 0.0 108.793 174.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -64.86 -172.24 0.08 Allowed 'General case' 0 CA--C 1.556 1.21 0 C-N-CA 123.722 0.809 . . . . 0.0 111.696 177.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.703 HD22 ' HB2' ' A' ' 24' ' ' ARG . 1.8 pp -75.96 57.96 1.12 Allowed 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 122.281 1.038 . . . . 0.0 113.131 -174.298 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -96.65 -20.87 17.97 Favored 'General case' 0 N--CA 1.469 0.492 0 C-N-CA 124.554 1.142 . . . . 0.0 110.079 174.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.9 p -68.2 -34.73 76.8 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 124.003 0.921 . . . . 0.0 110.575 175.012 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -149.61 126.27 11.01 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 173.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.448 HG22 HD12 ' A' ' 40' ' ' ILE . 34.1 m -70.16 112.48 6.55 Favored 'General case' 0 C--O 1.243 0.723 0 CA-C-O 121.474 0.654 . . . . 0.0 110.903 -176.705 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.703 ' HB2' HD22 ' A' ' 19' ' ' LEU . 99.0 mtt180 -128.9 175.36 8.71 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-N 114.867 -1.06 . . . . 0.0 111.148 -176.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 14.3 tt -144.97 148.16 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.932 0.893 . . . . 0.0 109.347 -173.08 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -90.61 102.95 15.69 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 174.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 97.2 t -87.87 113.3 24.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 124.1 0.96 . . . . 0.0 108.904 -178.675 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.464 HG22 HG22 ' A' ' 35' ' ' VAL . 26.3 t -98.83 103.88 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.722 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -53.85 107.93 0.99 Allowed Pre-proline 0 CA--C 1.544 0.713 0 C-N-CA 123.677 0.791 . . . . 0.0 108.981 167.442 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -69.09 -24.21 33.0 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.273 1.982 . . . . 0.0 113.022 -174.275 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -80.41 -50.4 10.16 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 123.213 0.605 . . . . 0.0 111.13 -177.014 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 40.9 p -94.21 -9.69 35.42 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -178.627 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.03 -3.18 66.29 Favored Glycine 0 N--CA 1.478 1.476 0 N-CA-C 114.166 0.426 . . . . 0.0 114.166 178.854 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -75.1 125.34 28.73 Favored 'General case' 0 N--CA 1.479 1.013 0 C-N-CA 123.774 0.83 . . . . 0.0 112.932 -170.209 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.464 HG22 HG22 ' A' ' 28' ' ' VAL . 17.1 t -104.03 135.4 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 123.535 0.734 . . . . 0.0 109.549 177.685 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -146.77 146.53 30.31 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.503 0.721 . . . . 0.0 109.41 174.122 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 49.2 mt -78.15 100.71 3.39 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 174.344 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -92.72 153.82 18.69 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.294 0.638 . . . . 0.0 111.331 176.029 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.453 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 36.8 mt-10 -93.34 123.17 36.45 Favored 'General case' 0 C--O 1.244 0.804 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -178.29 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.448 HD12 HG22 ' A' ' 23' ' ' THR . 53.4 mt -74.93 112.26 12.13 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.85 0 O-C-N 123.43 0.456 . . . . 0.0 109.974 -175.602 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.6 mtp180 -77.24 -53.86 7.2 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 124.188 0.995 . . . . 0.0 111.036 178.486 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.532 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 53.8 t30 -134.81 146.58 49.44 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.032 -172.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.4 m -123.5 -21.52 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 123.625 0.77 . . . . 0.0 111.638 178.551 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.515 HG12 ' OD1' ' A' ' 42' ' ' ASN . 12.6 p -70.88 89.88 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.365 1.246 0 CA-C-O 122.998 1.38 . . . . 0.0 110.729 -172.504 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.54 ' HG3' ' H ' ' A' ' 63' ' ' VAL . 1.3 tm-20 -88.97 164.28 15.18 Favored 'General case' 0 C--O 1.242 0.71 0 CA-C-N 114.007 -1.452 . . . . 0.0 107.651 178.464 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 49.8 t-20 -69.26 85.59 0.39 Allowed 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 121.499 0.666 . . . . 0.0 109.322 175.148 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.3 t -120.8 114.07 21.08 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.298 1.039 . . . . 0.0 108.312 176.02 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . 60.82 21.11 11.25 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 124.509 1.124 . . . . 0.0 111.939 -174.48 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 20.3 m120 56.68 95.71 0.05 OUTLIER Pre-proline 0 CA--C 1.555 1.164 0 C-N-CA 124.784 1.234 . . . . 0.0 110.543 -170.085 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -59.4 119.92 7.45 Favored 'Trans proline' 0 C--N 1.374 1.883 0 C-N-CA 123.377 2.718 . . . . 0.0 112.848 -173.602 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 19.3 p80 -140.89 104.18 4.63 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.628 0.771 . . . . 0.0 109.675 -178.527 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 38.1 t80 56.69 30.17 17.06 Favored 'General case' 0 CA--C 1.559 1.317 0 C-N-CA 124.268 1.027 . . . . 0.0 110.628 -179.032 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 7.2 p -81.35 113.85 21.38 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.929 0 CA-C-O 121.37 0.605 . . . . 0.0 110.563 -175.249 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.406 ' NE ' ' HA ' ' A' ' 54' ' ' ARG . 1.0 OUTLIER -102.53 84.72 2.48 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 173.759 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 29.9 tpt180 -164.03 99.26 0.86 Allowed 'General case' 0 C--O 1.241 0.615 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 -174.138 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -87.43 54.56 3.18 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 123.762 0.825 . . . . 0.0 108.884 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 10.7 tp -95.15 121.64 45.9 Favored 'Isoleucine or valine' 0 C--O 1.243 0.749 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 -179.446 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 55.5 mt -93.83 130.06 43.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 173.225 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 76.2 p -117.15 159.26 22.89 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.222 0.609 . . . . 0.0 110.005 -176.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 77.7 ttt180 -74.4 115.43 13.91 Favored 'General case' 0 CA--C 1.546 0.813 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.047 -177.335 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.84 6.12 49.81 Favored Glycine 0 N--CA 1.47 0.959 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.78 -177.284 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.25 162.24 25.81 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.118 0.567 . . . . 0.0 111.014 -178.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.54 ' H ' ' HG3' ' A' ' 45' ' ' GLU . 59.0 t -103.3 110.61 30.31 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 174.743 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.6 m -105.82 142.52 18.67 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 176.049 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.532 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 34.8 tt0 -92.24 134.84 34.51 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 176.522 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 51.4 p -129.99 179.99 5.55 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 123.926 0.89 . . . . 0.0 108.87 178.216 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -76.1 -1.47 26.19 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 122.52 0.328 . . . . 0.0 111.336 175.066 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 82.8 mt -106.36 -9.07 16.91 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.704 0.802 . . . . 0.0 111.065 171.542 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 120.62 -166.04 13.85 Favored Glycine 0 C--N 1.351 1.393 0 C-N-CA 122.826 0.251 . . . . 0.0 113.018 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 20.2 m120 -77.64 137.87 38.78 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 123.01 0.524 . . . . 0.0 110.745 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.1 t -133.85 142.24 41.88 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.001 0 C-N-CA 124.727 1.211 . . . . 0.0 110.546 -171.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.669 ' HG2' HG21 ' A' ' 88' ' ' ILE . 30.0 mmt180 -85.15 132.34 34.31 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 170.646 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 45.6 t -76.94 106.52 6.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 172.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.463 HG21 HG13 ' A' ' 86' ' ' VAL . 74.1 p -95.93 -32.55 12.56 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 121.562 0.696 . . . . 0.0 110.629 -170.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.1 t -92.38 174.41 7.31 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.925 175.175 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 85.0 mtp180 -75.73 114.89 40.97 Favored Pre-proline 0 CA--C 1.546 0.802 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 171.185 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -62.46 112.93 1.73 Allowed 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 123.415 2.743 . . . . 0.0 113.084 -171.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.96 36.99 26.77 Favored Glycine 0 C--N 1.348 1.196 0 CA-C-N 115.388 -0.824 . . . . 0.0 112.245 -178.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 57.4 tp60 -70.7 -49.89 42.29 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.283 0.633 . . . . 0.0 109.946 179.259 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -121.39 56.15 1.05 Allowed 'General case' 0 N--CA 1.482 1.146 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 175.668 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 67.12 -16.98 0.3 Allowed Glycine 0 CA--C 1.538 1.52 0 N-CA-C 115.412 0.925 . . . . 0.0 115.412 -173.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.611 HG23 HD21 ' A' ' 19' ' ' LEU . 13.7 p -119.93 151.75 22.57 Favored 'Isoleucine or valine' 0 C--O 1.243 0.711 0 C-N-CA 124.229 1.012 . . . . 0.0 110.756 -171.829 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 28.3 mt -109.25 143.34 19.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 114.935 -1.03 . . . . 0.0 108.61 174.077 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -124.21 152.63 42.69 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 122.967 0.507 . . . . 0.0 109.647 172.662 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.5 -176.7 35.73 Favored Glycine 0 C--N 1.344 1.011 0 CA-C-N 115.323 -0.853 . . . . 0.0 112.956 -175.48 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.463 HG13 HG21 ' A' ' 74' ' ' THR . 27.7 m -130.33 144.24 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 123.317 0.647 . . . . 0.0 110.242 178.039 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.9 tp -72.14 126.86 30.84 Favored 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.585 -178.473 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.669 HG21 ' HG2' ' A' ' 72' ' ' ARG . 12.7 pt -125.21 171.31 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.189 0 C-N-CA 123.919 0.887 . . . . 0.0 110.319 -178.246 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 93.0 mtt180 -120.94 71.24 0.93 Allowed 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.424 0.69 . . . . 0.0 109.257 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 21.4 mm-40 -93.47 -78.74 0.42 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 122.86 0.464 . . . . 0.0 110.244 179.387 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 35.5 mt -104.64 140.24 38.32 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 123.868 0.867 . . . . 0.0 109.057 -170.261 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -90.61 120.53 31.76 Favored 'General case' 0 C--O 1.242 0.709 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 173.256 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 56.8 t-80 -70.61 83.16 0.61 Allowed 'General case' 0 CA--C 1.547 0.863 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 171.083 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 56.3 t60 -116.16 136.15 53.28 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 114.27 -1.332 . . . . 0.0 110.319 -168.24 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 1.5 p80 -64.63 105.58 1.0 Allowed 'General case' 0 CA--C 1.547 0.835 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 171.269 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -65.3 -22.8 66.88 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 123.25 0.62 . . . . 0.0 111.521 -172.429 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 35.4 m-70 -104.45 167.01 10.02 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.548 0.739 . . . . 0.0 109.616 175.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 49.8 t-80 . . . . . 0 CA--C 1.553 1.075 0 CA-C-O 118.809 -0.615 . . . . 0.0 109.763 -176.82 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.582 0 N-CA-C 112.033 -0.427 . . . . 0.0 112.033 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -150.65 134.71 16.85 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 123.32 0.648 . . . . 0.0 110.131 -178.612 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -90.3 86.21 6.43 Favored 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.42 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 23.9 ptt180 -77.35 79.88 3.86 Favored 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.896 0.855 . . . . 0.0 110.57 178.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 p -142.33 100.21 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.959 0 C-N-CA 123.937 0.895 . . . . 0.0 109.611 -179.204 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 43.3 ttm105 -78.7 -23.33 45.63 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.393 177.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.1 tm? 63.06 78.08 0.31 Allowed 'General case' 0 C--N 1.358 0.962 0 C-N-CA 125.082 1.353 . . . . 0.0 109.294 178.433 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.1 tt -98.89 105.64 17.66 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.373 -173.668 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -109.26 174.48 5.85 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 124.01 0.924 . . . . 0.0 110.177 177.22 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 44.3 p -52.02 118.17 3.28 Favored 'General case' 0 CA--C 1.556 1.178 0 C-N-CA 124.522 1.129 . . . . 0.0 112.584 -175.157 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.3 tpp180 -69.97 108.23 3.94 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 123.64 0.776 . . . . 0.0 109.98 177.58 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 166.87 -170.45 41.32 Favored Glycine 0 C--N 1.341 0.832 0 O-C-N 123.101 0.251 . . . . 0.0 112.799 177.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -85.12 62.5 4.51 Favored Glycine 0 C--N 1.348 1.227 0 N-CA-C 112.021 -0.432 . . . . 0.0 112.021 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 27.6 m-80 -86.24 60.54 6.29 Favored 'General case' 0 C--O 1.245 0.835 0 C-N-CA 124.105 0.962 . . . . 0.0 109.436 -178.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 41.8 p -78.27 78.52 4.74 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 122.002 0.906 . . . . 0.0 110.514 -174.637 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -114.35 -44.8 3.08 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 114.484 -1.234 . . . . 0.0 107.897 178.482 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 12.7 p -84.15 137.17 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.746 0 CA-C-N 115.259 -0.882 . . . . 0.0 108.626 168.27 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 7.0 mpt_? -78.53 -74.28 0.28 Allowed 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -179.41 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 8.7 mp -102.67 124.36 48.06 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.211 1.004 . . . . 0.0 108.497 175.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -98.9 65.16 1.48 Allowed 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.6 m 64.23 14.41 8.64 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 124.851 1.26 . . . . 0.0 112.226 -176.379 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -141.54 149.69 41.16 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 123.983 0.913 . . . . 0.0 109.272 -177.187 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.469 HG22 HD12 ' A' ' 40' ' ' ILE . 14.1 m -72.19 113.15 8.91 Favored 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 123.256 0.622 . . . . 0.0 110.763 -171.281 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 14.3 mmt180 -113.34 145.54 40.92 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.997 0.919 . . . . 0.0 110.929 -177.577 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 17.5 tt -140.26 145.73 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 123.48 0.712 . . . . 0.0 110.674 -177.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -93.08 102.86 15.19 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 171.576 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.6 t -88.79 106.95 17.27 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 C-N-CA 123.972 0.909 . . . . 0.0 109.185 -176.505 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.402 HG13 HG22 ' A' ' 35' ' ' VAL . 61.8 t -95.85 100.53 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -62.47 111.78 5.32 Favored Pre-proline 0 CA--C 1.547 0.834 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 172.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -71.84 -22.83 23.02 Favored 'Trans proline' 0 C--N 1.365 1.401 0 C-N-CA 122.295 1.997 . . . . 0.0 113.648 -165.533 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -95.66 -44.16 7.59 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 122.802 0.441 . . . . 0.0 112.166 -176.058 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 44.4 p -87.17 -25.34 24.11 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 122.465 0.306 . . . . 0.0 111.376 -178.748 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.12 6.57 74.91 Favored Glycine 0 C--N 1.348 1.213 0 CA-C-O 119.35 -0.694 . . . . 0.0 114.04 179.028 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -71.87 107.15 4.5 Favored 'General case' 0 CA--C 1.544 0.714 0 CA-C-N 117.406 0.603 . . . . 0.0 111.016 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.402 HG22 HG13 ' A' ' 28' ' ' VAL . 40.7 t -97.19 109.61 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 174.275 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -136.02 137.59 41.34 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.336 0.654 . . . . 0.0 109.723 -171.652 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 62.1 mt -77.14 131.46 34.74 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.568 0 C-N-CA 123.547 0.739 . . . . 0.0 109.113 179.204 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.471 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -131.04 165.02 24.13 Favored 'General case' 0 C--O 1.241 0.612 0 C-N-CA 123.544 0.738 . . . . 0.0 111.061 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -103.79 116.85 33.06 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 114.633 -1.167 . . . . 0.0 108.682 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.469 HD12 HG22 ' A' ' 23' ' ' THR . 62.9 mt -76.88 110.05 12.03 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.4 mtm180 -82.26 -39.58 22.81 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.822 178.728 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.501 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 93.7 m-20 -128.26 129.53 46.53 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.445 0.698 . . . . 0.0 109.949 -178.876 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.4 HG21 ' HA ' ' A' ' 56' ' ' ASN . 27.5 m -97.16 -11.82 8.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 123.92 0.888 . . . . 0.0 109.809 173.618 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.4 p -67.89 107.46 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.142 0 O-C-N 124.014 0.822 . . . . 0.0 110.078 175.014 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.525 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -67.58 -38.12 83.6 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.728 1.211 . . . . 0.0 111.792 -179.724 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -151.91 130.53 12.28 Favored 'General case' 0 C--O 1.241 0.64 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.81 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 45.6 p -64.97 92.34 0.1 Allowed 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 121.626 0.727 . . . . 0.0 110.39 -179.117 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -139.52 86.35 2.11 Favored 'General case' 0 C--O 1.241 0.652 0 C-N-CA 124.395 1.078 . . . . 0.0 109.425 -176.368 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 56.23 51.21 5.86 Favored Pre-proline 0 CA--C 1.568 1.64 0 C-N-CA 124.802 1.241 . . . . 0.0 111.013 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.8 -15.51 29.89 Favored 'Trans proline' 0 C--N 1.387 2.566 0 C-N-CA 123.041 2.494 . . . . 0.0 113.69 -166.733 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 25.8 t-80 -71.01 -45.56 63.76 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 122.578 0.351 . . . . 0.0 110.147 176.315 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 87.1 t80 -63.54 -37.27 86.67 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.317 175.529 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.568 HG12 ' H ' ' A' ' 55' ' ' ARG . 46.4 t -71.65 -80.49 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.204 178.738 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 71.2 ttt180 64.83 7.74 4.11 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 124.848 1.259 . . . . 0.0 111.868 178.473 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.568 ' H ' HG12 ' A' ' 53' ' ' VAL . 29.3 mmt85 -81.19 125.86 30.8 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 123.276 0.631 . . . . 0.0 111.342 -170.808 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.4 ' HA ' HG21 ' A' ' 43' ' ' VAL . 4.7 t30 -81.19 4.2 21.04 Favored 'General case' 0 CA--C 1.557 1.232 0 C-N-CA 123.71 0.804 . . . . 0.0 109.129 169.713 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.6 mt -60.59 87.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.364 1.216 0 C-N-CA 124.394 1.078 . . . . 0.0 109.517 171.315 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 79.9 mt -83.17 134.1 27.65 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.484 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 177.622 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 59.2 p -117.5 166.24 12.59 Favored 'General case' 0 C--O 1.242 0.679 0 C-N-CA 122.949 0.5 . . . . 0.0 110.873 -176.47 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.405 ' HA ' ' O ' ' A' ' 73' ' ' VAL . 57.3 mtt180 -70.89 127.13 31.56 Favored 'General case' 0 C--N 1.349 0.55 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 175.342 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.47 -6.13 77.69 Favored Glycine 0 C--N 1.341 0.812 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.823 -175.752 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.76 139.54 38.41 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 117.28 0.54 . . . . 0.0 110.519 177.265 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 45' ' ' GLU . 48.6 t -89.63 118.54 35.11 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 C-N-CA 123.43 0.692 . . . . 0.0 110.122 178.787 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.4 m -104.15 151.46 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 O-C-N 121.603 -0.685 . . . . 0.0 109.331 171.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.501 ' HB3' ' HB2' ' A' ' 42' ' ' ASN . 34.2 tt0 -102.84 134.09 46.83 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 176.834 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.471 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 60.0 p -132.28 -176.74 4.18 Favored 'General case' 0 C--O 1.243 0.762 0 C-N-CA 123.665 0.786 . . . . 0.0 109.379 -179.739 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -76.69 -8.26 56.92 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.846 175.078 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 58.4 mt -97.02 -14.96 21.29 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 123.58 0.752 . . . . 0.0 110.653 174.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 120.94 -156.97 16.04 Favored Glycine 0 C--N 1.347 1.141 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.742 -176.193 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.409 ' O ' HD12 ' A' ' 87' ' ' LEU . 18.9 m120 -80.4 138.87 36.7 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 122.993 0.517 . . . . 0.0 111.48 179.388 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.9 t -125.87 135.17 64.72 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 C-N-CA 123.83 0.852 . . . . 0.0 109.82 178.549 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.643 ' HG2' HD13 ' A' ' 88' ' ' ILE . 10.9 mmt-85 -83.19 114.77 21.58 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 167.629 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 60' ' ' ARG . 45.3 t -80.03 96.45 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.9 p -78.67 -22.1 47.28 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 123.951 0.9 . . . . 0.0 110.897 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 49.3 m -95.92 -169.08 1.87 Allowed 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.926 0.89 . . . . 0.0 110.886 176.289 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -108.05 156.43 38.31 Favored Pre-proline 0 CA--C 1.547 0.848 0 C-N-CA 123.288 0.635 . . . . 0.0 109.652 173.509 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.449 ' HA ' HG12 ' A' ' 83' ' ' ILE . 68.5 Cg_endo -71.41 132.02 19.98 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.085 1.857 . . . . 0.0 111.946 178.488 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.412 ' H ' HG12 ' A' ' 83' ' ' ILE . . . 72.84 12.52 78.64 Favored Glycine 0 C--N 1.35 1.315 0 CA-C-O 119.571 -0.572 . . . . 0.0 114.331 174.737 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -74.28 134.1 42.62 Favored 'General case' 0 C--N 1.351 0.666 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.2 t70 68.08 -3.65 1.2 Allowed 'General case' 0 CA--C 1.565 1.537 0 C-N-CA 123.642 0.777 . . . . 0.0 111.579 -179.157 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 122.18 -13.93 8.95 Favored Glycine 0 C--N 1.355 1.623 0 CA-C-O 119.23 -0.761 . . . . 0.0 113.735 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.4 p -148.77 163.91 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 CA-C-N 118.469 1.134 . . . . 0.0 111.377 -179.006 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.449 HG12 ' HA ' ' A' ' 77' ' ' PRO . 10.0 mt -83.8 149.37 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 175.281 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 27.5 m-80 -140.17 152.96 46.45 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 122.775 0.43 . . . . 0.0 110.173 -178.648 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -170.8 -170.33 34.89 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-O 119.98 -0.345 . . . . 0.0 113.061 179.483 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.7 m -126.07 136.81 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 124.096 0.958 . . . . 0.0 110.943 179.098 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.409 HD12 ' O ' ' A' ' 70' ' ' ASN . 18.9 tp -72.26 127.02 31.26 Favored 'General case' 0 N--CA 1.483 1.221 0 CA-C-O 120.852 0.358 . . . . 0.0 111.602 -174.327 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.643 HD13 ' HG2' ' A' ' 72' ' ' ARG . 7.8 pt -118.67 170.32 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 C-N-CA 124.79 1.236 . . . . 0.0 109.488 177.382 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 12.8 mmt180 -118.56 19.88 13.15 Favored 'General case' 0 N--CA 1.486 1.371 0 C-N-CA 122.738 0.415 . . . . 0.0 110.535 -169.723 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -50.43 -75.84 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.876 0 C-N-CA 124.422 1.089 . . . . 0.0 113.85 -164.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.6 mt -77.94 94.54 4.61 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -178.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -61.38 99.12 0.1 Allowed 'General case' 0 C--O 1.241 0.648 0 O-C-N 123.971 0.794 . . . . 0.0 109.478 176.038 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -75.38 80.77 2.45 Favored 'General case' 0 C--N 1.347 0.462 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 -178.561 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -76.45 99.11 4.79 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.422 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 75.2 t60 -95.0 68.25 3.16 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -176.466 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 34.4 m170 58.16 77.59 0.28 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 124.961 1.304 . . . . 0.0 111.959 -178.134 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -137.84 166.48 23.92 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 124.457 1.103 . . . . 0.0 109.336 177.04 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 67.8 m-70 . . . . . 0 N--CA 1.489 1.486 0 C-N-CA 124.137 0.975 . . . . 0.0 111.3 178.476 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.69 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -72.35 97.09 1.97 Allowed 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 123.582 0.753 . . . . 0.0 110.861 -175.09 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -90.16 95.77 10.36 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 176.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 42.1 ttm180 -150.41 93.91 2.04 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 123.77 0.828 . . . . 0.0 109.296 -177.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.9 p -84.95 85.37 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 CA-C-O 122.297 1.046 . . . . 0.0 109.067 173.835 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 28.7 tpt180 -76.3 105.74 7.52 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.331 -175.161 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 97.7 mt -128.02 118.58 23.76 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 124.124 0.97 . . . . 0.0 109.274 -179.324 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.1 tt -76.72 94.0 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.138 0 CA-C-O 121.631 0.729 . . . . 0.0 109.136 175.751 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 26.2 mmm180 -74.57 76.61 1.98 Allowed 'General case' 0 N--CA 1.48 1.059 0 CA-C-O 121.702 0.763 . . . . 0.0 111.001 -175.231 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 17.6 p -114.76 151.72 33.29 Favored 'General case' 0 C--O 1.242 0.702 0 C-N-CA 124.343 1.057 . . . . 0.0 108.839 177.605 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 22.8 tpp180 -62.08 97.39 0.08 Allowed 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.868 0.867 . . . . 0.0 111.083 -174.214 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -135.42 29.3 2.92 Favored Glycine 0 N--CA 1.472 1.078 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.546 179.411 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -174.27 171.02 44.21 Favored Glycine 0 C--N 1.338 0.685 0 N-CA-C 111.403 -0.679 . . . . 0.0 111.403 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -94.56 134.74 36.79 Favored 'General case' 0 C--O 1.244 0.807 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 176.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.0 m -69.84 93.79 0.78 Allowed 'General case' 0 C--O 1.24 0.581 0 O-C-N 123.72 0.637 . . . . 0.0 109.91 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 22.6 pttm -81.34 71.38 8.33 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-O 122.877 1.323 . . . . 0.0 109.454 176.408 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.6 p -93.09 142.41 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 CA-C-N 114.077 -1.419 . . . . 0.0 109.952 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.523 ' HB2' ' O ' ' A' ' 81' ' ' GLY . 0.0 OUTLIER -93.28 -160.98 0.8 Allowed 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 123.354 0.662 . . . . 0.0 109.547 174.06 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.79 64.78 1.83 Allowed 'General case' 0 N--CA 1.49 1.548 0 CA-C-O 121.857 0.837 . . . . 0.0 112.145 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -82.09 -31.71 30.61 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.727 0.811 . . . . 0.0 111.27 -176.524 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 32.4 t -125.11 -21.89 4.54 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 123.88 0.872 . . . . 0.0 110.631 -179.162 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -109.15 172.83 6.62 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 123.643 0.777 . . . . 0.0 109.572 -177.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.1 m -115.24 108.71 16.95 Favored 'General case' 0 C--O 1.243 0.737 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 167.24 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 12.9 tpp85 -113.28 136.16 53.05 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 123.477 0.711 . . . . 0.0 110.64 -175.113 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.8 tt -133.89 144.11 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 123.398 0.679 . . . . 0.0 110.451 177.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -93.98 107.85 19.72 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 171.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.407 HG22 HG21 ' A' ' 71' ' ' VAL . 86.6 t -91.63 108.37 19.91 Favored 'Isoleucine or valine' 0 C--O 1.241 0.654 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 -177.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 35' ' ' VAL . 51.6 t -107.32 99.27 8.24 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.128 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -59.02 116.55 16.14 Favored Pre-proline 0 CA--C 1.55 0.964 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 174.134 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_endo -73.79 -23.62 16.41 Favored 'Trans proline' 0 C--N 1.366 1.495 0 C-N-CA 122.279 1.986 . . . . 0.0 114.007 -171.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.47 ' HG3' HG23 ' A' ' 32' ' ' THR . 12.9 pt-20 -91.57 -50.33 5.83 Favored 'General case' 0 N--CA 1.479 0.975 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -176.059 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.47 HG23 ' HG3' ' A' ' 31' ' ' GLU . 75.3 p -91.38 -33.02 15.44 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 122.7 0.4 . . . . 0.0 111.452 -176.616 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.11 21.35 23.14 Favored Glycine 0 C--N 1.344 1.017 0 CA-C-O 119.292 -0.727 . . . . 0.0 114.106 177.23 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.0 mttp -56.92 106.48 0.31 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 117.364 0.582 . . . . 0.0 109.711 168.374 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.515 HG22 HG13 ' A' ' 28' ' ' VAL . 54.9 t -108.46 97.71 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 172.797 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -143.51 144.6 32.04 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 123.558 0.743 . . . . 0.0 109.295 -176.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 23.0 mt -85.43 133.21 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.43 173.43 10.85 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.283 1.433 . . . . 0.0 109.61 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -122.84 141.19 52.13 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 174.667 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 75.7 mt -83.03 114.16 23.4 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 C-N-CA 123.02 0.528 . . . . 0.0 110.041 -176.652 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 47.1 mtp180 -76.62 -49.6 15.85 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.13 0.972 . . . . 0.0 110.114 179.536 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -143.65 166.9 23.55 Favored 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.802 0.841 . . . . 0.0 108.951 -179.476 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.9 p -132.92 116.79 27.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.821 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 170.325 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -137.22 82.37 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 CA-C-O 122.222 1.011 . . . . 0.0 109.845 -177.036 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.749 ' HB3' ' H ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -105.69 -10.29 16.85 Favored 'General case' 0 N--CA 1.477 0.912 0 CA-C-N 114.186 -1.37 . . . . 0.0 110.306 171.886 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 67.4 m-20 63.52 61.16 1.04 Allowed 'General case' 0 C--O 1.243 0.73 0 C-N-CA 125.345 1.458 . . . . 0.0 112.171 173.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.4 t -69.77 -37.76 76.51 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 163.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -179.26 -177.1 0.44 Allowed 'General case' 0 C--O 1.241 0.609 0 C-N-CA 125.75 1.62 . . . . 0.0 108.64 -178.311 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 -63.77 114.66 14.21 Favored Pre-proline 0 N--CA 1.479 0.978 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 170.054 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -67.32 80.93 0.4 Allowed 'Trans proline' 0 C--N 1.382 2.316 0 C-N-CA 122.99 2.46 . . . . 0.0 113.065 -174.476 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 43.4 t-80 -94.22 80.52 4.01 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 175.263 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 43.6 m-85 -127.26 12.28 7.05 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.22 -177.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 47.5 t 59.98 67.61 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.91 0 C-N-CA 124.176 0.99 . . . . 0.0 109.4 -173.564 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 2.6 ptm180 56.31 9.19 0.49 Allowed 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 127.657 2.383 . . . . 0.0 114.673 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.3 mtm180 -86.9 141.82 28.47 Favored 'General case' 0 N--CA 1.48 1.064 0 CA-C-O 121.281 0.563 . . . . 0.0 111.114 -178.751 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.7 p-10 -95.53 94.04 7.53 Favored 'General case' 0 CA--C 1.547 0.83 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.045 179.281 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.1 mm -77.49 101.38 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.679 0.752 . . . . 0.0 109.193 175.7 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 75.6 mt -100.11 122.8 52.44 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 114.359 -1.291 . . . . 0.0 109.276 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 41.5 p -121.52 168.19 12.0 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 124.366 1.066 . . . . 0.0 109.284 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 59.0 ttp180 -74.59 130.26 39.24 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 176.137 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.36 -0.16 68.14 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 115.752 -0.658 . . . . 0.0 113.251 -172.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.3 149.94 35.29 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 122.812 0.445 . . . . 0.0 110.964 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.749 ' H ' ' HB3' ' A' ' 45' ' ' GLU . 50.0 t -99.41 110.4 26.55 Favored 'Isoleucine or valine' 0 C--O 1.244 0.765 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 173.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.1 m -104.83 142.25 18.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.228 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -101.79 120.32 40.18 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -178.411 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 38.5 p -125.14 179.13 5.19 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.313 0.645 . . . . 0.0 109.466 -173.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 23.2 p-10 -68.79 -14.92 63.33 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 123.008 0.523 . . . . 0.0 111.038 178.151 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.9 mt -93.51 -46.76 7.16 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.309 0.644 . . . . 0.0 109.501 175.546 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 159.18 -154.95 26.03 Favored Glycine 0 C--N 1.344 0.977 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.891 175.502 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -77.04 130.17 37.06 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.902 0.481 . . . . 0.0 110.615 178.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.407 HG21 HG22 ' A' ' 27' ' ' VAL . 36.9 t -128.18 140.47 49.1 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.871 0 C-N-CA 124.463 1.105 . . . . 0.0 109.355 -178.321 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.587 ' HG2' HD13 ' A' ' 88' ' ' ILE . 7.3 mmt-85 -85.57 131.59 34.33 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 170.076 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 59.0 t -76.16 110.13 10.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 173.239 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 68.9 p -101.54 -42.75 6.12 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 121.207 0.527 . . . . 0.0 109.737 -173.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 20.3 m -94.33 136.97 34.03 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.622 172.644 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 17.4 mtp180 -60.25 132.39 90.28 Favored Pre-proline 0 CA--C 1.553 1.067 0 O-C-N 124.047 0.842 . . . . 0.0 110.743 -178.626 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.411 ' HA ' HG12 ' A' ' 83' ' ' ILE . 76.2 Cg_exo -52.73 116.9 3.19 Favored 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 123.807 3.005 . . . . 0.0 114.847 -176.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.46 20.59 71.49 Favored Glycine 0 C--N 1.348 1.206 0 N-CA-C 115.491 0.956 . . . . 0.0 115.491 166.639 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -73.44 -48.16 35.87 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-N 118.111 0.955 . . . . 0.0 110.521 177.419 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -85.87 -3.44 58.92 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 123.401 0.68 . . . . 0.0 110.888 170.708 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' GLY . . . . . 0.523 ' O ' ' HB2' ' A' ' 18' ' ' ARG . . . 111.85 -9.12 27.65 Favored Glycine 0 C--O 1.219 -0.782 0 N-CA-C 111.97 -0.452 . . . . 0.0 111.97 -178.594 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.6 p -140.63 163.81 22.19 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.895 0 C-N-CA 123.34 0.656 . . . . 0.0 109.931 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.411 HG12 ' HA ' ' A' ' 77' ' ' PRO . 23.3 mt -91.99 147.39 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 172.273 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -130.92 156.69 44.64 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 171.763 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -169.74 -172.86 36.73 Favored Glycine 0 C--N 1.344 1.027 0 N-CA-C 114.172 0.429 . . . . 0.0 114.172 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 31.2 m -123.92 135.95 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 C-N-CA 123.694 0.798 . . . . 0.0 111.119 -179.472 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.0 tp -74.04 117.17 15.52 Favored 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.459 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.587 HD13 ' HG2' ' A' ' 72' ' ' ARG . 12.4 pt -116.22 168.75 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 124.191 0.997 . . . . 0.0 111.394 -169.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 17.1 mmt180 -112.55 92.09 3.89 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.418 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -121.42 -75.62 0.59 Allowed 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 123.278 0.631 . . . . 0.0 111.417 -173.492 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 39.5 mt -109.31 144.64 37.21 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.331 0.652 . . . . 0.0 110.261 -168.767 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -84.78 170.1 13.54 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 170.633 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 50.4 t-80 -63.03 96.48 0.09 Allowed 'General case' 0 C--O 1.246 0.909 0 CA-C-O 121.18 0.514 . . . . 0.0 110.078 174.785 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 8.2 m-70 -78.12 151.49 33.31 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.806 -178.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 25.9 m170 -83.03 -29.22 29.05 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.246 0.618 . . . . 0.0 109.521 172.593 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 29.4 t-80 51.87 85.35 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 125.846 1.658 . . . . 0.0 112.855 172.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -129.4 60.06 1.58 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 176.637 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 27.3 p80 . . . . . 0 N--CA 1.497 1.883 0 C-N-CA 125.819 1.648 . . . . 0.0 113.161 -178.86 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.069 0 CA-C-O 120.243 -0.199 . . . . 0.0 113.495 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 35.7 m-20 -104.28 110.36 22.55 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 123.124 0.57 . . . . 0.0 109.672 177.304 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 83.4 mtt180 -80.23 91.59 5.61 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 173.843 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 24.1 mtp180 -65.04 91.86 0.1 Allowed 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.902 0.881 . . . . 0.0 109.744 -178.79 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.8 p -80.16 133.6 29.25 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 115.252 -0.885 . . . . 0.0 111.2 -175.353 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 9.9 ptp180 -110.19 90.96 3.47 Favored 'General case' 0 CA--C 1.546 0.815 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 169.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 36.2 tp -84.78 86.16 7.37 Favored 'General case' 0 C--O 1.243 0.756 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -178.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.0 tt -149.62 128.55 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.908 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 26.9 ttm180 -147.74 90.62 1.86 Allowed 'General case' 0 C--O 1.241 0.625 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.56 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 37.2 p -80.38 84.76 5.96 Favored 'General case' 0 CA--C 1.544 0.745 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.364 -178.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 3.4 tmt_? -82.97 -59.79 2.37 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 177.866 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 66.44 -111.81 4.43 Favored Glycine 0 C--N 1.351 1.362 0 CA-C-N 115.67 -0.695 . . . . 0.0 113.742 177.696 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 153.13 156.38 7.56 Favored Glycine 0 C--N 1.343 0.968 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -176.66 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.5 t30 -143.88 128.16 17.77 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.515 0.726 . . . . 0.0 109.814 -176.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.9 p -136.87 140.08 42.11 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.413 1.085 . . . . 0.0 109.633 178.084 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -97.38 -179.48 4.51 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 121.383 0.611 . . . . 0.0 110.714 174.816 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.5 p -148.42 156.21 8.76 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.82 0 CA-C-N 114.643 -1.162 . . . . 0.0 108.486 177.049 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.31 179.6 1.94 Allowed 'General case' 0 N--CA 1.487 1.4 0 C-N-CA 122.491 0.316 . . . . 0.0 110.974 177.665 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.757 HD22 ' HB ' ' A' ' 82' ' ' VAL . 1.5 pt? -58.53 133.37 55.77 Favored 'General case' 0 CA--C 1.554 1.119 0 C-N-CA 123.236 0.614 . . . . 0.0 111.581 -179.085 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.25 -8.57 12.92 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.699 0.8 . . . . 0.0 110.035 172.39 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.516 ' HB2' HH21 ' A' ' 24' ' ' ARG . 33.4 m -104.18 -137.92 0.35 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 124.574 1.15 . . . . 0.0 109.378 179.195 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -82.28 -179.26 7.35 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.877 0.871 . . . . 0.0 110.941 -177.538 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.8 m -64.1 114.4 4.15 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 123.43 0.692 . . . . 0.0 110.889 -176.377 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.579 HH11 ' HG3' ' A' ' 24' ' ' ARG . 4.1 ttm-85 -119.65 170.17 9.43 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.049 -178.163 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.3 tt -136.69 140.68 42.7 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 CA-C-O 121.251 0.548 . . . . 0.0 111.194 -175.134 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.5 m-80 -92.05 100.71 13.3 Favored 'General case' 0 C--O 1.242 0.664 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 175.332 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 99.5 t -92.78 114.27 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 C-N-CA 123.734 0.813 . . . . 0.0 109.91 -173.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 35' ' ' VAL . 38.8 t -103.89 120.74 54.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 123.627 0.771 . . . . 0.0 109.103 -178.188 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -58.68 117.25 19.31 Favored Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 167.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.8 -17.66 28.98 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 121.867 1.711 . . . . 0.0 111.348 170.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -78.5 -53.96 6.66 Favored 'General case' 0 CA--C 1.555 1.137 0 C-N-CA 123.489 0.715 . . . . 0.0 112.107 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 47.0 p -100.9 -26.66 13.67 Favored 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -176.704 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.37 7.23 65.5 Favored Glycine 0 N--CA 1.476 1.348 0 CA-C-O 119.964 -0.353 . . . . 0.0 112.927 -178.032 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.2 mmtt -73.57 142.68 46.62 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 123.39 0.676 . . . . 0.0 110.846 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 28' ' ' VAL . 25.1 t -118.55 122.12 68.72 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 123.417 0.687 . . . . 0.0 109.463 179.122 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -135.37 136.46 41.49 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 123.738 0.815 . . . . 0.0 109.015 178.038 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 56.8 mt -79.19 100.19 3.75 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.092 0 C-N-CA 123.258 0.623 . . . . 0.0 109.383 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -95.67 163.23 13.28 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 172.57 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.457 ' HA ' ' HG3' ' A' ' 24' ' ' ARG . 34.0 mt-10 -102.65 137.13 41.27 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -175.672 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 57.5 mt -80.36 110.29 15.76 Favored 'Isoleucine or valine' 0 C--N 1.355 0.806 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 177.323 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 14.1 mtp180 -79.15 -53.82 6.61 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 124.58 1.152 . . . . 0.0 109.535 179.199 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -148.84 165.75 30.57 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.911 -175.711 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.531 HG11 ' HB3' ' A' ' 56' ' ' ASN . 30.3 m -103.33 13.02 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 123.593 0.757 . . . . 0.0 111.694 -179.39 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 p -67.34 92.47 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.06 0 CA-C-O 122.615 1.198 . . . . 0.0 109.966 177.794 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -61.43 -43.26 99.17 Favored 'General case' 0 N--CA 1.476 0.851 0 CA-C-N 114.029 -1.441 . . . . 0.0 109.862 173.495 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -177.12 -160.91 0.06 Allowed 'General case' 0 C--O 1.244 0.792 0 C-N-CA 125.999 1.719 . . . . 0.0 107.161 -179.572 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 19.0 m -63.42 -17.33 62.55 Favored 'General case' 0 CA--C 1.56 1.341 0 C-N-CA 122.829 0.452 . . . . 0.0 112.055 178.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.5 -37.05 72.33 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 124.474 1.11 . . . . 0.0 112.747 178.497 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -135.54 92.81 16.87 Favored Pre-proline 0 N--CA 1.48 1.033 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 173.58 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -96.34 7.51 1.66 Allowed 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 123.189 2.593 . . . . 0.0 112.587 169.805 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 61.6 m170 -84.67 106.23 16.07 Favored 'General case' 0 C--N 1.353 0.731 0 C-N-CA 123.544 0.738 . . . . 0.0 111.057 -172.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -116.62 75.22 0.95 Allowed 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 172.817 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 9.2 p -160.19 19.58 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.194 0 CA-C-O 122.442 1.115 . . . . 0.0 108.413 177.219 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 13.2 ptm180 -132.09 177.36 7.62 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 124.79 1.236 . . . . 0.0 110.604 -168.387 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.3 tpt180 -65.93 111.75 3.46 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 165.226 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.531 ' HB3' HG11 ' A' ' 43' ' ' VAL . 51.1 m-80 -66.14 89.2 0.12 Allowed 'General case' 0 CA--C 1.546 0.792 0 O-C-N 123.691 0.619 . . . . 0.0 110.238 179.327 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 69.6 mt -91.96 96.2 6.08 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.3 mt -82.13 142.68 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 171.341 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 67.5 p -119.19 166.48 12.91 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 123.536 0.734 . . . . 0.0 110.19 177.095 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 36.4 ttm105 -71.74 115.55 11.07 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 171.655 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.97 2.41 55.0 Favored Glycine 0 C--N 1.341 0.841 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.599 -174.677 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.81 132.71 34.38 Favored 'General case' 0 C--O 1.244 0.795 0 C-N-CA 122.875 0.47 . . . . 0.0 110.107 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.455 HG21 ' HG3' ' A' ' 90' ' ' GLU . 54.1 t -79.59 125.58 38.77 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.726 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 174.855 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 19.6 m -116.14 147.89 19.23 Favored 'Isoleucine or valine' 0 C--O 1.245 0.853 0 C-N-CA 123.885 0.874 . . . . 0.0 109.052 176.286 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -84.69 122.78 29.57 Favored 'General case' 0 N--CA 1.462 0.147 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -179.516 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 47.4 p -129.03 176.99 7.45 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -178.107 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 -65.82 -23.24 66.65 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 123.86 0.864 . . . . 0.0 111.362 177.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 85.1 mt -93.62 -38.61 11.26 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.122 0.569 . . . . 0.0 110.849 -179.148 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 152.22 -146.97 16.16 Favored Glycine 0 C--N 1.347 1.148 0 C-N-CA 121.573 -0.346 . . . . 0.0 113.175 174.126 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -68.38 109.18 3.53 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.008 0.923 . . . . 0.0 109.453 176.727 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 85.6 t -120.03 137.68 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 O-C-N 121.886 -0.509 . . . . 0.0 110.379 -179.218 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.487 ' HG3' HD11 ' A' ' 88' ' ' ILE . 31.1 mtt85 -105.08 129.77 53.43 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.669 0.387 . . . . 0.0 110.335 174.601 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.478 HG11 ' HG3' ' A' ' 77' ' ' PRO . 85.1 t -71.68 123.18 25.47 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 O-C-N 124.455 1.097 . . . . 0.0 110.259 -178.603 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.418 HG21 HG13 ' A' ' 86' ' ' VAL . 45.7 p -101.04 -22.28 14.78 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.971 0.908 . . . . 0.0 111.06 -174.89 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 20.7 t -105.11 -173.65 2.35 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 123.738 0.815 . . . . 0.0 110.268 -178.84 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 86.7 mtt180 -74.36 120.88 83.61 Favored Pre-proline 0 CA--C 1.544 0.717 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 168.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' PRO . . . . . 0.478 ' HG3' HG11 ' A' ' 73' ' ' VAL . 73.0 Cg_exo -54.32 102.17 0.08 OUTLIER 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 123.252 2.635 . . . . 0.0 112.98 178.36 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.497 ' N ' HG12 ' A' ' 83' ' ' ILE . . . 82.91 47.81 5.71 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.336 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 54.7 tp60 -64.93 -58.11 7.01 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 123.463 0.705 . . . . 0.0 110.405 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -98.31 16.49 21.35 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 123.616 0.766 . . . . 0.0 110.015 175.16 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 100.08 -20.99 46.62 Favored Glycine 0 C--N 1.35 1.31 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -173.08 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.757 ' HB ' HD22 ' A' ' 19' ' ' LEU . 14.1 p -110.92 158.31 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.542 1.137 . . . . 0.0 108.57 -178.855 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.497 HG12 ' N ' ' A' ' 78' ' ' GLY . 8.7 mt -110.78 151.3 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 123.624 0.769 . . . . 0.0 109.828 -177.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 79.9 m-20 -118.31 148.13 42.77 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 172.172 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.7 -179.97 36.71 Favored Glycine 0 C--N 1.348 1.207 0 O-C-N 123.452 0.47 . . . . 0.0 113.136 -179.348 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.418 HG13 HG21 ' A' ' 74' ' ' THR . 11.9 m -124.48 136.81 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 123.642 0.777 . . . . 0.0 111.423 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 50.8 tp -78.82 105.96 10.5 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.403 0.681 . . . . 0.0 110.982 -177.446 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.487 HD11 ' HG3' ' A' ' 72' ' ' ARG . 30.4 pt -123.41 -172.92 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 123.889 0.875 . . . . 0.0 109.507 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -132.68 110.91 10.74 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.159 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.455 ' HG3' HG21 ' A' ' 63' ' ' VAL . 41.3 mm-40 -115.94 -60.8 1.82 Allowed 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.027 0.531 . . . . 0.0 110.135 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.2 mt -72.51 -27.99 62.6 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 122.888 0.475 . . . . 0.0 110.256 179.008 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -118.17 44.47 2.21 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 124.151 0.98 . . . . 0.0 109.962 173.008 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -76.07 -17.22 59.73 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 124.254 1.022 . . . . 0.0 111.924 177.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 17.1 m170 73.59 127.96 0.04 OUTLIER 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 125.507 1.523 . . . . 0.0 108.782 -162.214 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -64.32 167.14 7.14 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.404 0.682 . . . . 0.0 111.301 -178.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 32.0 m170 -83.99 16.59 2.79 Favored 'General case' 0 N--CA 1.484 1.238 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -170.814 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 25.9 t-80 75.19 -52.48 0.66 Allowed 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 125.88 1.672 . . . . 0.0 110.591 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 72.4 m-70 . . . . . 0 C--O 1.248 0.992 0 C-N-CA 123.754 0.822 . . . . 0.0 108.803 166.735 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.611 0 N-CA-C 111.715 -0.554 . . . . 0.0 111.715 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -75.65 108.31 8.4 Favored 'General case' 0 C--N 1.352 0.704 0 C-N-CA 123.371 0.668 . . . . 0.0 110.593 179.403 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 4.8 ppt_? -137.29 141.65 41.93 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.509 0.723 . . . . 0.0 109.885 174.005 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 6.2 mpt_? -101.23 77.71 1.83 Allowed 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.013 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.7 p -73.12 -42.39 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.95 -177.445 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.5 ttt85 -98.43 147.2 24.96 Favored 'General case' 0 C--O 1.243 0.747 0 C-N-CA 124.069 0.947 . . . . 0.0 109.712 -178.587 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 6.4 tt -75.48 90.79 2.74 Favored 'General case' 0 CA--C 1.541 0.631 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 175.708 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 68.1 mt -100.1 122.83 52.47 Favored 'Isoleucine or valine' 0 C--O 1.241 0.614 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 166.609 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 47.0 mtm180 -59.09 149.94 26.44 Favored 'General case' 0 N--CA 1.483 1.199 0 O-C-N 123.377 0.423 . . . . 0.0 111.256 -173.469 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 32.3 p -50.56 92.72 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 125.025 1.33 . . . . 0.0 113.307 -168.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 31.7 tpt180 -144.03 146.18 32.69 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 124.403 1.081 . . . . 0.0 108.443 178.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.32 -7.54 78.17 Favored Glycine 0 C--N 1.344 1.023 0 CA-C-O 120.02 -0.322 . . . . 0.0 112.819 -175.326 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.69 85.14 1.18 Allowed Glycine 0 C--N 1.35 1.348 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 177.146 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -67.26 95.26 0.41 Allowed 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 177.335 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 34.6 p -86.37 174.28 9.13 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.906 0.882 . . . . 0.0 110.772 -179.26 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.86 40.43 1.99 Allowed 'General case' 0 N--CA 1.481 1.083 0 CA-C-O 121.976 0.893 . . . . 0.0 109.527 177.576 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.7 t -77.79 115.58 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.672 -179.735 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.3 mpt_? -84.93 -70.37 0.59 Allowed 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 169.835 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.454 HD22 ' HA ' ' A' ' 23' ' ' THR . 97.6 mt -104.51 -81.13 0.53 Allowed 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.487 0.715 . . . . 0.0 110.402 178.689 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 47.36 78.05 0.08 Allowed 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 125.286 1.434 . . . . 0.0 111.558 -174.13 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 19.5 t 76.18 -52.75 0.61 Allowed 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 125.399 1.48 . . . . 0.0 111.482 -176.688 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -69.91 177.04 3.31 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 124.08 0.952 . . . . 0.0 111.722 176.553 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.454 ' HA ' HD22 ' A' ' 19' ' ' LEU . 7.5 m -144.02 119.2 10.12 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.206 -172.784 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -101.14 147.81 25.81 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.445 0.698 . . . . 0.0 109.392 -177.751 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 17.4 tt -146.61 151.17 14.38 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 122.972 0.509 . . . . 0.0 110.324 177.683 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -100.03 102.45 13.81 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 168.755 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.33 110.9 21.12 Favored 'Isoleucine or valine' 0 C--O 1.243 0.724 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 178.449 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 53.5 t -100.51 99.51 8.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -60.14 114.09 9.01 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 172.855 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -76.25 -8.21 18.48 Favored 'Trans proline' 0 C--N 1.369 1.647 0 C-N-CA 122.795 2.33 . . . . 0.0 113.136 -173.317 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -84.17 -53.97 5.14 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.251 0.621 . . . . 0.0 109.867 -172.175 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 58.6 p -99.57 -33.21 10.73 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 124.032 0.933 . . . . 0.0 111.449 177.719 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.4 10.33 36.32 Favored Glycine 0 N--CA 1.476 1.359 0 CA-C-O 119.828 -0.429 . . . . 0.0 113.272 -176.374 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.2 mmmt -66.12 113.67 4.68 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.654 0.782 . . . . 0.0 111.484 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 38.1 t -104.26 125.44 59.04 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 C-N-CA 123.731 0.813 . . . . 0.0 109.268 176.278 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.433 ' HB3' HD11 ' A' ' 68' ' ' LEU . 8.9 tp10 -135.26 140.33 45.12 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.605 0.762 . . . . 0.0 109.612 178.191 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 65.5 mt -79.78 118.37 27.21 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 169.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.07 169.59 11.04 Favored 'General case' 0 C--O 1.242 0.706 0 C-N-CA 124.129 0.972 . . . . 0.0 109.083 -175.049 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -102.89 128.88 49.49 Favored 'General case' 0 C--O 1.244 0.771 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.5 mt -74.39 110.37 8.51 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 175.769 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 42.8 ttt180 -72.43 -37.74 68.52 Favored 'General case' 0 C--O 1.237 0.425 0 C-N-CA 124.28 1.032 . . . . 0.0 110.492 -175.037 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -160.67 148.8 16.21 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.036 -0.984 . . . . 0.0 108.624 -173.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 64' ' ' VAL . 40.5 t -109.98 88.24 1.09 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.753 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 178.635 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.9 p -140.51 135.96 35.7 Favored 'Isoleucine or valine' 0 C--O 1.244 0.79 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -178.668 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.736 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 36.4 mt-10 -99.08 -54.44 2.98 Favored 'General case' 0 C--O 1.241 0.61 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.534 -176.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.778 ' H ' ' HG3' ' A' ' 50' ' ' PRO . 18.5 m120 59.0 32.06 21.93 Favored 'General case' 0 N--CA 1.479 0.984 0 O-C-N 125.156 1.535 . . . . 0.0 110.236 -171.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 43.4 p -92.19 -59.4 2.1 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.389 175.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -156.33 75.87 0.88 Allowed 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 123.496 0.719 . . . . 0.0 109.465 176.472 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 64.27 95.25 0.05 OUTLIER Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 124.767 1.227 . . . . 0.0 111.257 178.072 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.778 ' HG3' ' H ' ' A' ' 46' ' ' ASN . 5.5 Cg_exo -73.87 -25.59 14.18 Favored 'Trans proline' 0 C--N 1.376 2.013 0 C-N-CA 123.267 2.645 . . . . 0.0 112.893 -178.558 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 33.9 m-70 -93.15 81.88 4.53 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.454 0.702 . . . . 0.0 109.498 -175.359 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 37.1 p90 -115.56 5.06 14.31 Favored 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 124.111 0.964 . . . . 0.0 110.26 173.513 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 7.1 p -155.29 148.96 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.73 0 C-N-CA 124.506 1.122 . . . . 0.0 108.919 -178.128 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.0 ttt180 -63.21 -64.64 0.85 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.153 0.581 . . . . 0.0 110.752 178.843 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 45.7 ttt180 -82.41 129.77 34.96 Favored 'General case' 0 C--N 1.348 0.507 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 176.067 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.1 m120 -79.6 70.49 6.09 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.397 0.679 . . . . 0.0 110.626 -176.595 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 50.8 mm -55.09 106.92 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.74 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.047 170.772 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 57.5 mt -66.93 123.37 19.84 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.257 -0.883 . . . . 0.0 108.791 177.255 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 28.5 p -125.21 161.07 27.69 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 124.374 1.07 . . . . 0.0 109.648 -176.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 58.1 ttp180 -69.71 127.2 32.11 Favored 'General case' 0 CA--C 1.547 0.864 0 C-N-CA 123.26 0.624 . . . . 0.0 109.451 175.51 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.98 -16.33 58.49 Favored Glycine 0 C--N 1.346 1.113 0 CA-C-O 119.739 -0.478 . . . . 0.0 112.994 -173.277 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.36 153.05 30.06 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 122.732 0.413 . . . . 0.0 110.742 179.289 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.736 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 78.0 t -98.19 124.26 51.16 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 CA-C-N 115.888 -0.597 . . . . 0.0 109.762 175.673 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.559 HG12 HG13 ' A' ' 43' ' ' VAL . 21.8 m -118.97 138.46 49.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 123.853 0.861 . . . . 0.0 109.068 174.548 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -101.07 137.43 39.44 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.436 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.437 HG21 HG21 ' A' ' 25' ' ' ILE . 71.2 p -129.17 -173.09 2.89 Favored 'General case' 0 C--O 1.242 0.681 0 C-N-CA 123.671 0.788 . . . . 0.0 110.113 -169.592 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -68.36 -9.98 51.83 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 123.381 0.673 . . . . 0.0 111.768 173.281 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.433 HD11 ' HB3' ' A' ' 36' ' ' GLU . 85.1 mt -106.65 -46.24 4.03 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.775 0.83 . . . . 0.0 110.459 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 167.37 -164.51 37.96 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 116.546 -0.297 . . . . 0.0 112.359 175.171 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -73.1 139.46 46.48 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.178 0.591 . . . . 0.0 109.507 175.236 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 61.5 t -134.81 142.14 41.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.754 0.822 . . . . 0.0 110.331 -170.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.599 ' HG2' HD13 ' A' ' 88' ' ' ILE . 8.3 mmt-85 -93.38 124.9 37.69 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 171.032 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 51.7 t -76.35 97.49 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.213 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 p -79.7 -38.62 33.09 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.659 0.784 . . . . 0.0 112.121 -177.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' SER . . . . . 0.487 ' HB3' ' HB2' ' A' ' 84' ' ' ASN . 23.2 t -90.55 -176.46 4.76 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.436 0.694 . . . . 0.0 110.457 179.804 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 59.6 mtt180 -83.59 113.6 48.08 Favored Pre-proline 0 CA--C 1.549 0.922 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.24 141.25 51.4 Favored 'Trans proline' 0 C--N 1.376 1.98 0 C-N-CA 123.254 2.636 . . . . 0.0 113.236 -171.062 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 83.13 18.91 63.81 Favored Glycine 0 C--N 1.347 1.142 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.112 177.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 12.8 pt20 -70.68 103.21 2.48 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.365 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 63.53 41.49 7.32 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 124.168 0.987 . . . . 0.0 110.905 -174.585 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 61.05 33.61 84.73 Favored Glycine 0 C--N 1.339 0.737 0 CA-C-N 114.864 -1.062 . . . . 0.0 115.293 -175.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -143.31 141.47 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.591 0.71 . . . . 0.0 110.922 168.676 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.444 ' O ' ' HA ' ' A' ' 25' ' ' ILE . 2.0 mp -93.7 146.98 5.86 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 174.259 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.487 ' HB2' ' HB3' ' A' ' 75' ' ' SER . 2.6 m-20 -126.31 137.99 53.54 Favored 'General case' 0 N--CA 1.484 1.225 0 CA-C-N 118.971 0.805 . . . . 0.0 109.508 174.026 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.44 -175.06 34.03 Favored Glycine 0 C--N 1.345 1.073 0 CA-C-N 115.994 -0.548 . . . . 0.0 113.075 -175.259 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 34.5 m -127.47 142.89 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 C-N-CA 123.441 0.696 . . . . 0.0 110.78 -177.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.3 tp -68.28 130.99 44.54 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 123.159 0.583 . . . . 0.0 110.673 -178.461 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.599 HD13 ' HG2' ' A' ' 72' ' ' ARG . 19.5 pt -133.42 170.21 20.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 124.157 0.983 . . . . 0.0 110.04 -175.417 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 13.2 mmt-85 -111.4 95.09 5.31 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 176.267 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' GLU . . . . . 0.453 ' HG3' HG11 ' A' ' 63' ' ' VAL . 47.7 mm-40 -105.93 -62.1 1.42 Allowed 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 171.338 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 74.6 mt -99.65 126.54 45.67 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.155 174.731 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -74.02 101.06 3.75 Favored 'General case' 0 CA--C 1.545 0.771 0 CA-C-O 121.667 0.746 . . . . 0.0 109.592 176.083 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 14.8 m-70 -65.65 141.88 58.24 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.056 178.397 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -115.74 97.45 6.13 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 123.119 0.568 . . . . 0.0 110.429 -174.388 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 13.5 p80 -128.61 -7.94 5.12 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.347 0.659 . . . . 0.0 109.885 169.274 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.7 m170 -68.46 -26.07 65.31 Favored 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 123.24 0.616 . . . . 0.0 109.83 173.752 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 31.8 t60 -62.7 -47.22 84.57 Favored 'General case' 0 C--N 1.349 0.551 0 C-N-CA 124.889 1.275 . . . . 0.0 110.657 179.462 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 21.1 t-80 . . . . . 0 C--O 1.25 1.131 0 C-N-CA 123.497 0.719 . . . . 0.0 109.838 -177.128 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.0 m . . . . . 0 CA--C 1.54 0.572 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -106.95 144.97 32.81 Favored 'General case' 0 C--O 1.243 0.752 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -177.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.9 tt -146.17 139.36 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.772 0 C-N-CA 123.589 0.756 . . . . 0.0 110.061 -178.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 -89.39 101.58 14.26 Favored 'General case' 0 C--O 1.239 0.543 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 175.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.2 t -87.29 110.17 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.8 t -98.22 100.24 10.2 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -61.2 112.29 5.61 Favored Pre-proline 0 CA--C 1.549 0.929 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 175.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -77.18 -17.78 14.77 Favored 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 122.268 1.979 . . . . 0.0 113.209 -168.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -96.87 -48.89 5.27 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 122.714 0.406 . . . . 0.0 110.996 178.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.534 HG21 ' HE3' ' A' ' 34' ' ' LYS . 2.8 m -90.93 -31.26 16.45 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.215 0.606 . . . . 0.0 111.581 -172.498 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 95.14 6.27 60.26 Favored Glycine 0 N--CA 1.476 1.316 0 CA-C-O 119.479 -0.623 . . . . 0.0 114.003 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.534 ' HE3' HG21 ' A' ' 32' ' ' THR . 92.1 mttt -63.78 106.72 1.04 Allowed 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 123.089 0.556 . . . . 0.0 110.839 177.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.6 t -103.93 106.86 21.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 175.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.503 ' HB3' HD11 ' A' ' 68' ' ' LEU . 10.3 tp10 -138.43 139.44 38.88 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 123.763 0.825 . . . . 0.0 109.812 -173.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 50.0 mt -83.15 100.85 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 176.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.8 173.24 7.41 Favored 'General case' 0 C--O 1.239 0.509 0 C-N-CA 123.962 0.905 . . . . 0.0 110.079 176.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -107.56 134.59 50.35 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 175.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 59.3 mt -75.57 110.26 10.23 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 173.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -82.01 -48.07 11.87 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.645 1.178 . . . . 0.0 110.236 -173.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -135.97 153.82 51.28 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 175.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.508 HG13 HG12 ' A' ' 64' ' ' VAL . 16.8 t . . . . . 0 N--CA 1.479 1.023 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 173.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 67.9 mt . . . . . 0 CA--C 1.542 0.658 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.4 mt -102.98 116.0 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 114.041 -1.436 . . . . 0.0 108.944 -174.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 39.4 p -117.54 162.89 17.26 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.631 0.772 . . . . 0.0 110.765 -176.358 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -67.02 135.66 54.07 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 123.006 0.522 . . . . 0.0 110.127 176.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.07 -2.94 85.77 Favored Glycine 0 C--N 1.344 0.991 0 O-C-N 123.595 0.56 . . . . 0.0 113.571 -175.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.02 145.79 30.04 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 117.283 0.541 . . . . 0.0 110.749 179.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.8 t -90.1 112.17 24.33 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 172.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.508 HG12 HG13 ' A' ' 43' ' ' VAL . 26.5 m -107.42 159.6 6.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 174.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -102.6 137.46 40.8 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 172.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 30.6 p -133.46 -175.46 3.82 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.418 0.687 . . . . 0.0 109.797 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -60.59 -27.0 67.38 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 123.692 0.797 . . . . 0.0 111.889 175.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.503 HD11 ' HB3' ' A' ' 36' ' ' GLU . 74.1 mt -100.24 -0.67 38.15 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.269 0.628 . . . . 0.0 111.167 -175.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 112.06 -161.66 12.67 Favored Glycine 0 C--N 1.351 1.415 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.438 ' HA ' ' O ' ' A' ' 64' ' ' VAL . 17.5 m120 -73.69 138.14 44.52 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-N 117.16 0.48 . . . . 0.0 111.568 -178.212 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 92.8 t -130.45 146.62 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 124.748 1.219 . . . . 0.0 110.126 -176.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.686 ' HG2' HD13 ' A' ' 88' ' ' ILE . 34.6 mmt180 -85.23 126.68 33.87 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 167.497 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 43.0 t -73.54 111.7 8.89 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 172.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 77.6 p -95.36 -21.92 18.07 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-O 120.981 0.42 . . . . 0.0 109.907 -175.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 23.3 t -107.23 -171.29 1.85 Allowed 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.453 1.101 . . . . 0.0 110.578 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.28 136.68 20.91 Favored Pre-proline 0 CA--C 1.547 0.851 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 169.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -59.75 103.83 0.21 Allowed 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.502 2.135 . . . . 0.0 111.314 173.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 130.2 -6.08 6.01 Favored Glycine 0 C--N 1.342 0.904 0 CA-C-O 119.1 -0.833 . . . . 0.0 113.46 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 16.9 mm100 -67.31 -71.8 0.19 Allowed 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 117.876 0.838 . . . . 0.0 110.502 177.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -89.27 30.84 0.94 Allowed 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 172.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 64.63 -74.66 0.07 OUTLIER Glycine 0 C--N 1.355 1.618 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 -160.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.9 p -57.87 156.17 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.255 0 C-N-CA 125.387 1.475 . . . . 0.0 112.095 174.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 39.3 mt -84.04 151.51 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.526 1.13 . . . . 0.0 108.232 175.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -138.0 158.03 45.15 Favored 'General case' 0 N--CA 1.482 1.155 0 CA-C-N 118.298 0.499 . . . . 0.0 110.211 167.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.68 -171.71 34.77 Favored Glycine 0 C--N 1.344 0.994 0 CA-C-N 115.427 -0.806 . . . . 0.0 113.124 -174.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.2 m -122.91 135.23 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 123.441 0.696 . . . . 0.0 110.256 178.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 30.8 tp -68.37 134.12 49.76 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 122.969 0.508 . . . . 0.0 110.176 -177.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.686 HD13 ' HG2' ' A' ' 72' ' ' ARG . 16.7 pt -132.02 167.21 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 123.81 0.844 . . . . 0.0 111.062 -175.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 62.5 mtt-85 -117.66 49.42 1.23 Allowed 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 123.71 0.804 . . . . 0.0 110.166 -175.077 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -68.2 -58.74 3.96 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.072 0.463 . . . . 0.0 110.515 177.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 95.5 mt . . . . . 0 C--O 1.241 0.639 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.112 179.523 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.532 HG22 HD12 ' A' ' 40' ' ' ILE . 29.9 m . . . . . 0 C--O 1.239 0.526 0 CA-C-O 121.416 0.627 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.598 ' HD3' ' HG2' ' A' ' 39' ' ' GLU . 39.4 ttp180 -123.47 163.33 21.1 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 124.377 1.071 . . . . 0.0 108.265 177.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.1 tt -135.77 142.85 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.201 0.601 . . . . 0.0 110.183 -171.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.0 m-80 -84.98 102.5 13.23 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.6 t -95.2 107.93 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -172.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 42.1 t -93.58 103.09 14.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -64.24 116.68 29.85 Favored Pre-proline 0 CA--C 1.546 0.797 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 174.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.5 ' HG2' ' HG3' ' A' ' 31' ' ' GLU . 82.3 Cg_endo -73.33 -18.08 23.55 Favored 'Trans proline' 0 C--N 1.365 1.426 0 C-N-CA 122.361 2.04 . . . . 0.0 113.455 -173.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.5 ' HG3' ' HG2' ' A' ' 30' ' ' PRO . 20.8 mt-10 -95.86 -51.78 4.34 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.937 0.895 . . . . 0.0 110.757 -169.556 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 61.1 p -96.02 -7.26 36.79 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 123.56 0.744 . . . . 0.0 111.648 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.48 -0.65 80.19 Favored Glycine 0 C--N 1.355 1.595 0 CA-C-O 119.556 -0.58 . . . . 0.0 114.208 173.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.3 mtmp? -67.17 106.89 2.14 Favored 'General case' 0 C--N 1.353 0.758 0 C-N-CA 123.267 0.627 . . . . 0.0 111.572 -174.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.4 t -82.71 99.78 5.86 Favored 'Isoleucine or valine' 0 C--N 1.346 0.446 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 169.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -130.02 114.28 15.6 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 -167.056 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.48 HG22 ' HG2' ' A' ' 24' ' ' ARG . 26.7 mt -79.04 100.01 3.55 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -171.371 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.43 ' O ' ' HG3' ' A' ' 24' ' ' ARG . . . -104.61 163.3 12.58 Favored 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 123.523 0.729 . . . . 0.0 110.755 -175.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.598 ' HG2' ' HD3' ' A' ' 24' ' ' ARG . 17.8 mt-10 -105.92 136.11 46.16 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 123.242 0.617 . . . . 0.0 109.932 -167.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.532 HD12 HG22 ' A' ' 23' ' ' THR . 68.1 mt -77.41 112.4 15.31 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.972 0 CA-C-O 121.417 0.627 . . . . 0.0 110.668 -174.391 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 9.2 mtp180 -74.93 -55.04 6.18 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 124.308 1.043 . . . . 0.0 110.152 174.352 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -140.51 168.46 19.75 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 124.249 1.02 . . . . 0.0 108.81 -176.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.1 t . . . . . 0 N--CA 1.478 0.93 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 167.757 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 40.5 mm . . . . . 0 C--O 1.244 0.773 0 CA-C-O 121.658 0.742 . . . . 0.0 109.749 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 37.8 mt -81.5 105.62 11.61 Favored 'Isoleucine or valine' 0 C--N 1.344 0.331 0 N-CA-C 107.699 -1.222 . . . . 0.0 107.699 174.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 5.7 p -139.62 168.24 20.27 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.414 1.086 . . . . 0.0 108.509 -177.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 52.5 mtm180 -61.03 125.24 23.01 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 122.754 0.422 . . . . 0.0 111.105 -178.424 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.82 -10.24 68.38 Favored Glycine 0 C--N 1.34 0.783 0 CA-C-N 115.196 -0.911 . . . . 0.0 114.154 -176.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.62 156.83 36.33 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-N 117.482 0.641 . . . . 0.0 110.847 177.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.464 HG21 ' HG3' ' A' ' 90' ' ' GLU . 99.2 t -109.08 124.39 65.71 Favored 'Isoleucine or valine' 0 C--O 1.242 0.699 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 175.042 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.1 m -105.58 146.19 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 172.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -94.73 139.24 31.52 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 124.206 1.003 . . . . 0.0 109.011 176.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 76.7 p -138.09 177.38 7.92 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 124.799 1.24 . . . . 0.0 107.816 177.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.7 m-80 -84.04 8.93 13.77 Favored 'General case' 0 N--CA 1.481 1.092 0 O-C-N 122.339 -0.226 . . . . 0.0 111.419 175.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 62.8 mt -104.8 -14.22 15.6 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 123.386 0.674 . . . . 0.0 110.498 171.388 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 134.7 -148.49 19.54 Favored Glycine 0 C--N 1.343 0.942 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 -176.023 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -101.9 145.9 28.58 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 176.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.1 t -129.82 141.28 46.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 C-N-CA 123.62 0.768 . . . . 0.0 109.706 -176.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.702 ' HG2' HD13 ' A' ' 88' ' ' ILE . 26.8 mmt180 -81.14 139.17 35.76 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 170.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 67.3 t -84.62 103.74 12.12 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.747 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 169.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 72.1 p -100.06 -17.29 17.55 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.176 0.59 . . . . 0.0 110.854 -171.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 60.2 p -118.67 179.63 4.08 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.966 0.906 . . . . 0.0 109.963 176.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 14.4 ptp180 -78.75 151.85 77.13 Favored Pre-proline 0 CA--C 1.552 1.032 0 C-N-CA 123.082 0.553 . . . . 0.0 110.645 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.656 ' HA ' HG13 ' A' ' 83' ' ' ILE . 85.1 Cg_endo -76.41 16.07 0.93 Allowed 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 122.879 2.386 . . . . 0.0 114.58 -178.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.81 58.88 0.42 Allowed Glycine 0 C--N 1.346 1.093 0 N-CA-C 112.216 -0.354 . . . . 0.0 112.216 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 -118.83 110.26 17.0 Favored 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 171.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.3 t70 67.62 -1.37 1.64 Allowed 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 124.433 1.093 . . . . 0.0 111.217 -169.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.47 5.83 60.1 Favored Glycine 0 C--N 1.349 1.3 0 CA-C-O 119.479 -0.623 . . . . 0.0 112.677 -174.355 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 11.4 p -126.26 164.29 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 123.435 0.694 . . . . 0.0 111.07 -175.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.656 HG13 ' HA ' ' A' ' 77' ' ' PRO . 3.4 mp -109.61 147.02 14.32 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 124.473 1.109 . . . . 0.0 108.664 178.263 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -119.69 155.82 31.68 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 123.596 0.759 . . . . 0.0 109.345 169.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.63 -175.12 36.57 Favored Glycine 0 C--N 1.345 1.065 0 N-CA-C 114.017 0.367 . . . . 0.0 114.017 -176.286 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.6 m -130.71 140.37 48.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 C-N-CA 123.469 0.707 . . . . 0.0 110.419 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 33.6 tp -75.47 112.85 12.22 Favored 'General case' 0 CA--C 1.549 0.937 0 CA-C-O 121.303 0.573 . . . . 0.0 111.624 -172.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.702 HD13 ' HG2' ' A' ' 72' ' ' ARG . 9.3 pt -110.02 179.01 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.19 0 C-N-CA 125.059 1.344 . . . . 0.0 110.488 178.062 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 47.5 mmt-85 -132.03 62.48 1.64 Allowed 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 123.438 0.695 . . . . 0.0 109.412 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.464 ' HG3' HG21 ' A' ' 63' ' ' VAL . 37.6 mm-40 -68.77 -63.06 1.13 Allowed 'General case' 0 N--CA 1.491 1.605 0 CA-C-O 121.464 0.65 . . . . 0.0 110.09 177.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 70.6 mt . . . . . 0 C--O 1.242 0.66 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 172.029 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.498 ' HB ' ' HB ' ' A' ' 40' ' ' ILE . 6.4 m . . . . . 0 CA--C 1.547 0.843 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 22.9 mmt85 -104.95 134.31 48.28 Favored 'General case' 0 C--O 1.244 0.768 0 C-N-CA 124.275 1.03 . . . . 0.0 109.45 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.4 tt -140.29 135.91 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 123.995 0.918 . . . . 0.0 109.394 -178.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 20.7 m-80 -87.14 103.36 15.33 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.5 t -98.42 110.11 25.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 C-N-CA 123.884 0.874 . . . . 0.0 109.196 -172.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.456 HG22 HG22 ' A' ' 35' ' ' VAL . 38.2 t -92.66 103.54 14.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -60.51 116.82 19.72 Favored Pre-proline 0 CA--C 1.549 0.918 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -76.75 -11.17 18.43 Favored 'Trans proline' 0 C--N 1.363 1.326 0 C-N-CA 122.958 2.439 . . . . 0.0 113.379 -174.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -81.89 -52.47 7.06 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 123.087 0.555 . . . . 0.0 109.583 -176.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 65.4 p -96.37 -31.85 12.66 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 114.774 -1.103 . . . . 0.0 112.026 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 94.03 8.61 60.21 Favored Glycine 0 N--CA 1.475 1.247 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.494 -173.514 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.7 mmtp -72.66 108.92 5.93 Favored 'General case' 0 C--N 1.359 0.982 0 C-N-CA 123.18 0.592 . . . . 0.0 111.678 -177.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.456 HG22 HG22 ' A' ' 28' ' ' VAL . 24.8 t -82.91 120.17 33.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 172.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 13.1 tp10 -140.29 130.33 24.83 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.463 0.705 . . . . 0.0 109.479 -177.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 46.0 mt -78.0 103.79 5.37 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -179.025 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.439 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -89.83 166.12 13.72 Favored 'General case' 0 C--O 1.24 0.558 0 C-N-CA 123.694 0.798 . . . . 0.0 111.037 177.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 -114.39 124.94 53.2 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 115.314 -0.857 . . . . 0.0 108.925 176.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.498 ' HB ' ' HB ' ' A' ' 23' ' ' THR . 67.8 mt -79.79 111.37 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 C-N-CA 122.958 0.503 . . . . 0.0 109.775 -173.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 71.9 mtt180 -64.86 -46.83 80.19 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 123.798 0.839 . . . . 0.0 110.376 176.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 62.5 t30 -164.5 172.51 13.21 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.932 -170.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 25.2 m . . . . . 0 CA--C 1.549 0.929 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 170.644 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 50.1 mt . . . . . 0 C--O 1.241 0.635 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 71.3 mt -61.98 116.93 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 114.372 -1.285 . . . . 0.0 109.952 -178.174 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.438 ' HA ' ' HG2' ' A' ' 77' ' ' PRO . 40.6 p -126.8 167.2 16.11 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 124.073 0.949 . . . . 0.0 110.017 -177.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 32.5 ttp180 -64.03 138.5 58.49 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 123.127 0.571 . . . . 0.0 110.269 177.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.32 -39.17 3.04 Favored Glycine 0 C--N 1.335 0.521 0 CA-C-O 119.926 -0.374 . . . . 0.0 112.778 -176.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -61.63 135.87 57.79 Favored 'General case' 0 C--N 1.356 0.859 0 C-N-CA 123.665 0.786 . . . . 0.0 110.821 179.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 42.2 t -87.51 133.15 31.01 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 176.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 18.4 m -113.52 150.5 15.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 C-N-CA 124.171 0.989 . . . . 0.0 109.024 177.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -95.65 125.44 40.24 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 106.098 -1.815 . . . . 0.0 106.098 174.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.439 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 61.3 p -122.05 177.71 5.21 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 26.7 p-10 -69.54 -18.26 63.65 Favored 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.063 175.08 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.6 mt -85.12 -43.7 13.63 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 122.965 0.506 . . . . 0.0 110.582 174.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 155.93 -150.8 22.26 Favored Glycine 0 C--N 1.344 0.984 0 N-CA-C 111.925 -0.47 . . . . 0.0 111.925 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.408 ' N ' HD22 ' A' ' 70' ' ' ASN . 1.0 OUTLIER -79.94 126.02 30.48 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-N 117.488 0.644 . . . . 0.0 109.335 178.118 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 57.7 t -125.07 138.2 55.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 123.741 0.817 . . . . 0.0 110.638 -178.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.718 ' HG2' HD13 ' A' ' 88' ' ' ILE . 17.8 mmt180 -83.65 131.46 34.95 Favored 'General case' 0 N--CA 1.483 1.188 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 168.368 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.519 HG11 ' HG3' ' A' ' 77' ' ' PRO . 66.3 t -79.02 105.86 9.04 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 169.251 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 41.6 p -93.8 -30.94 14.58 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 123.392 0.677 . . . . 0.0 110.727 -171.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 49.0 m -96.88 178.05 5.42 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.248 177.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.774 ' HB2' ' HB2' ' A' ' 79' ' ' GLN . 80.2 mtp180 -74.36 124.52 89.94 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.109 170.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.519 ' HG3' HG11 ' A' ' 73' ' ' VAL . 32.0 Cg_exo -62.12 104.01 0.32 Allowed 'Trans proline' 0 C--N 1.373 1.841 0 C-N-CA 122.481 2.12 . . . . 0.0 111.293 173.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.34 24.82 17.86 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-N 116.06 -0.518 . . . . 0.0 113.347 -178.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . 0.774 ' HB2' ' HB2' ' A' ' 76' ' ' ARG . 24.7 tm0? -65.9 -58.65 5.09 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 176.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -84.12 -9.3 58.69 Favored 'General case' 0 N--CA 1.487 1.377 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.763 173.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 117.33 -53.14 0.65 Allowed Glycine 0 C--N 1.336 0.559 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -163.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 10.1 p -87.03 165.7 2.09 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.131 0 C-N-CA 123.886 0.874 . . . . 0.0 110.703 177.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 18.5 mt -96.38 148.49 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.888 0 C-N-CA 124.039 0.936 . . . . 0.0 108.605 173.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 17.4 m-80 -131.75 149.01 52.61 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 123.252 0.621 . . . . 0.0 109.699 177.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.45 -173.27 32.92 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 115.735 -0.666 . . . . 0.0 114.092 -174.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.6 m -129.79 141.72 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 C-N-CA 123.551 0.74 . . . . 0.0 110.107 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 20.1 tp -75.88 105.31 6.85 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 121.022 0.439 . . . . 0.0 109.924 -178.003 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.718 HD13 ' HG2' ' A' ' 72' ' ' ARG . 11.0 pt -107.21 -173.46 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 123.432 0.693 . . . . 0.0 110.222 -179.413 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 60.7 mtt85 -139.95 77.47 1.61 Allowed 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 123.146 0.578 . . . . 0.0 109.734 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.458 ' HG2' HD12 ' A' ' 88' ' ' ILE . 56.5 mm-40 -68.58 -65.51 0.69 Allowed 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 167.023 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 60.7 mt . . . . . 0 CA--C 1.549 0.927 0 CA-C-N 114.429 -1.26 . . . . 0.0 108.934 170.881 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.459 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 6.9 m . . . . . 0 N--CA 1.471 0.61 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 38.6 mmt180 -107.12 145.13 32.85 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.731 0.812 . . . . 0.0 110.362 -177.512 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.9 tt -147.41 144.34 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 C-N-CA 124.167 0.987 . . . . 0.0 109.441 175.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -91.59 100.85 13.52 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 173.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 62.0 t -89.56 111.03 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 123.808 0.843 . . . . 0.0 109.247 -175.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.502 HG22 HG22 ' A' ' 35' ' ' VAL . 41.4 t -101.45 108.72 24.12 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 C-N-CA 123.666 0.786 . . . . 0.0 109.333 -176.303 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -58.74 114.82 9.79 Favored Pre-proline 0 N--CA 1.473 0.715 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 171.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -78.1 -5.89 15.42 Favored 'Trans proline' 0 C--N 1.363 1.334 0 C-N-CA 122.374 2.049 . . . . 0.0 112.911 -175.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -95.86 -53.31 3.73 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 123.827 0.851 . . . . 0.0 111.203 -178.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 59.3 p -90.67 -30.85 16.88 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.485 0.714 . . . . 0.0 111.44 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.9 -11.54 57.52 Favored Glycine 0 C--N 1.343 0.952 0 CA-C-N 116.139 -0.482 . . . . 0.0 113.158 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -68.53 124.73 24.38 Favored 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 123.482 0.713 . . . . 0.0 111.426 -170.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.502 HG22 HG22 ' A' ' 28' ' ' VAL . 22.2 t -95.95 133.99 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 175.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -140.99 137.19 32.84 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 171.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 39.7 mt -79.82 129.5 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 178.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.29 167.71 18.05 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 123.88 0.872 . . . . 0.0 111.289 -171.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.459 ' HA ' ' O ' ' A' ' 23' ' ' THR . 56.0 mm-40 -104.32 118.77 37.43 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 124.441 1.096 . . . . 0.0 110.98 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.446 HG23 ' HB ' ' A' ' 64' ' ' VAL . 68.1 mt -78.85 111.4 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 122.704 0.402 . . . . 0.0 110.544 -175.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -82.81 -56.48 3.8 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.358 1.063 . . . . 0.0 111.623 178.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.587 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 33.9 t30 -106.25 133.95 50.15 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 175.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.432 ' HA ' HG12 ' A' ' 64' ' ' VAL . 33.6 m . . . . . 0 N--CA 1.477 0.922 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -175.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 64.4 mt . . . . . 0 C--O 1.242 0.696 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 57.7 mt -65.83 119.85 11.59 Favored 'Isoleucine or valine' 0 C--N 1.348 0.515 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 173.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 26.7 m -118.1 147.97 42.76 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -178.139 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 31.6 ttt-85 -60.69 134.09 56.74 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 172.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.57 -41.71 2.74 Favored Glycine 0 C--N 1.346 1.112 0 CA-C-O 119.892 -0.393 . . . . 0.0 112.43 -175.152 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -60.56 134.89 57.52 Favored 'General case' 0 C--N 1.357 0.896 0 C-N-CA 123.53 0.732 . . . . 0.0 110.708 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 98.2 t -73.55 120.48 22.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 O-C-N 123.722 0.639 . . . . 0.0 110.634 -178.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.446 ' HB ' HG23 ' A' ' 40' ' ' ILE . 26.3 m -105.41 126.89 60.54 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.294 171.167 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.587 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 33.8 tt0 -92.68 134.82 34.65 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 106.087 -1.82 . . . . 0.0 106.087 177.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 71.3 p -117.22 -178.59 3.48 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 -177.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -59.44 -23.15 62.44 Favored 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 123.057 0.543 . . . . 0.0 110.896 171.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 89.0 mt -88.79 -51.76 5.48 Favored 'General case' 0 C--N 1.353 0.733 0 C-N-CA 124.267 1.027 . . . . 0.0 110.018 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 164.53 -170.36 39.65 Favored Glycine 0 C--N 1.337 0.608 0 CA-C-N 115.549 -0.751 . . . . 0.0 112.155 -177.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.451 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 14.0 m120 -75.73 143.49 42.02 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.393 0.677 . . . . 0.0 110.772 -174.116 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.2 t -137.04 147.48 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 123.857 0.863 . . . . 0.0 110.079 -174.049 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.687 ' HG2' HD13 ' A' ' 88' ' ' ILE . 36.4 mmt180 -93.01 120.75 33.64 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 168.454 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 43.9 t -75.82 98.65 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.438 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 71.1 p -74.36 -34.52 63.4 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.715 0.806 . . . . 0.0 111.417 178.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . 0.554 ' HB2' ' HB2' ' A' ' 84' ' ' ASN . 39.2 t -79.8 170.08 17.01 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.778 0.831 . . . . 0.0 111.581 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -82.73 106.43 6.82 Favored Pre-proline 0 CA--C 1.546 0.816 0 N-CA-C 107.246 -1.391 . . . . 0.0 107.246 166.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.404 ' HB3' HG23 ' A' ' 83' ' ' ILE . 65.9 Cg_endo -82.16 69.62 7.41 Favored 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 123.443 2.762 . . . . 0.0 112.44 -172.021 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.09 -32.15 0.1 Allowed Glycine 0 C--N 1.333 0.37 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.817 -178.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -64.58 111.37 2.68 Favored 'General case' 0 C--N 1.359 0.981 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 174.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.4 t70 76.71 -22.95 0.26 Allowed 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 125.338 1.455 . . . . 0.0 112.384 -177.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 102.55 -8.58 54.97 Favored Glycine 0 C--N 1.345 1.078 0 CA-C-O 119.932 -0.371 . . . . 0.0 112.487 -175.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -86.57 116.95 30.1 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 CA-C-O 121.641 0.734 . . . . 0.0 109.94 -179.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.404 HG23 ' HB3' ' A' ' 77' ' ' PRO . 38.6 mt -98.54 132.75 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 175.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.554 ' HB2' ' HB2' ' A' ' 75' ' ' SER . 66.3 m-20 -136.07 154.52 51.0 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 123.725 0.81 . . . . 0.0 109.03 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.438 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -168.93 -173.98 37.12 Favored Glycine 0 C--N 1.34 0.754 0 O-C-N 123.385 0.428 . . . . 0.0 113.992 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.7 m -123.47 134.24 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.075 0 C-N-CA 124.028 0.931 . . . . 0.0 110.364 177.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 46.7 tp -66.21 127.55 32.62 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 123.182 0.593 . . . . 0.0 111.447 -176.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.687 HD13 ' HG2' ' A' ' 72' ' ' ARG . 33.2 pt -126.21 -176.67 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 C-N-CA 125.189 1.396 . . . . 0.0 109.378 173.25 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 82.0 mtt85 -137.83 88.29 2.32 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 123.321 0.649 . . . . 0.0 109.923 -177.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -100.85 -48.22 4.54 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 123.4 0.68 . . . . 0.0 109.44 178.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 88.8 mt . . . . . 0 N--CA 1.476 0.855 0 C-N-CA 124.911 1.284 . . . . 0.0 109.793 -178.043 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.528 HG22 HD12 ' A' ' 40' ' ' ILE . 33.0 m . . . . . 0 N--CA 1.473 0.715 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.554 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 17.0 mtm180 -130.81 166.0 21.77 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.918 0.887 . . . . 0.0 111.497 -173.019 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 14.0 tt -150.88 150.28 13.54 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.447 -170.108 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.8 m-80 -94.08 100.39 12.51 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 175.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.7 t -88.7 112.39 23.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.022 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.434 HG13 HG22 ' A' ' 35' ' ' VAL . 17.3 t -101.41 100.6 10.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.437 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -178.206 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -58.38 120.39 43.93 Favored Pre-proline 0 CA--C 1.552 1.021 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 177.311 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -71.78 -15.75 29.88 Favored 'Trans proline' 0 C--N 1.366 1.469 0 C-N-CA 122.845 2.364 . . . . 0.0 113.555 -172.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -91.75 -52.12 4.9 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.919 0.487 . . . . 0.0 110.325 -175.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.3 p -88.66 -32.85 17.81 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.637 0.775 . . . . 0.0 112.375 -177.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.64 3.9 68.29 Favored Glycine 0 N--CA 1.479 1.559 0 CA-C-O 120.097 -0.28 . . . . 0.0 113.14 -174.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.0 mmtm -63.05 109.24 1.42 Allowed 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.753 0.821 . . . . 0.0 111.692 179.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.434 HG22 HG13 ' A' ' 28' ' ' VAL . 41.1 t -90.45 111.82 23.99 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 172.161 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -129.62 131.42 46.46 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.608 0.763 . . . . 0.0 110.233 -174.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 53.4 mt -76.26 115.23 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.75 153.81 40.38 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.946 0.898 . . . . 0.0 109.977 -174.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.554 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 2.7 mp0 -93.58 124.09 37.34 Favored 'General case' 0 C--O 1.244 0.79 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 -176.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.528 HD12 HG22 ' A' ' 23' ' ' THR . 56.0 mt -75.04 109.46 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -178.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 67.8 mtp180 -71.72 -42.62 67.12 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 124.59 1.156 . . . . 0.0 110.349 -178.173 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -159.64 170.13 22.25 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-N 114.822 -1.081 . . . . 0.0 108.646 -176.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.679 HG12 HG12 ' A' ' 64' ' ' VAL . 3.5 m . . . . . 0 CA--C 1.545 0.77 0 C-N-CA 124.712 1.205 . . . . 0.0 107.964 176.328 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.3 mt . . . . . 0 CA--C 1.553 1.09 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.9 mt -82.68 151.92 4.04 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.701 -179.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 75.8 p -128.69 170.53 13.17 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.852 0.861 . . . . 0.0 109.615 174.183 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.3 ttm180 -71.9 138.14 47.94 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 171.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.77 -14.62 51.43 Favored Glycine 0 C--N 1.343 0.97 0 C-N-CA 123.249 0.452 . . . . 0.0 113.028 -177.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -70.85 141.36 51.27 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 123.334 0.653 . . . . 0.0 109.486 177.194 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 77.1 t -91.16 118.42 36.39 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.81 -179.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.679 HG12 HG12 ' A' ' 43' ' ' VAL . 34.1 m -103.31 135.85 38.88 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.422 174.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -86.27 127.01 34.71 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 174.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 32.6 p -128.6 174.32 9.5 Favored 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.491 ' ND2' ' HB2' ' A' ' 39' ' ' GLU . 94.2 m-20 -65.03 -12.64 52.77 Favored 'General case' 0 N--CA 1.482 1.128 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 178.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.1 mt -95.6 -47.89 6.04 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 176.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 167.57 -161.96 35.76 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.828 178.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -75.12 142.69 43.58 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.189 0.596 . . . . 0.0 110.015 175.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.0 t -135.88 146.45 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.268 0 C-N-CA 123.155 0.582 . . . . 0.0 110.111 -174.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.65 ' HG2' HD13 ' A' ' 88' ' ' ILE . 33.7 mmt180 -91.65 119.7 31.77 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 171.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.2 t -73.36 122.62 26.64 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.2 p -108.56 -32.67 7.29 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.536 0.735 . . . . 0.0 110.26 -172.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.6 t -97.73 -178.77 4.22 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.62 0.768 . . . . 0.0 110.147 178.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.44 128.92 73.65 Favored Pre-proline 0 CA--C 1.552 1.033 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 174.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -68.66 103.66 1.02 Allowed 'Trans proline' 0 C--N 1.373 1.843 0 C-N-CA 123.024 2.483 . . . . 0.0 113.837 -173.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 73.37 -0.78 46.57 Favored Glycine 0 C--N 1.344 1.004 0 CA-C-N 115.217 -0.901 . . . . 0.0 114.961 171.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 31.8 mm-40 -67.81 -43.51 79.49 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 123.28 0.632 . . . . 0.0 111.689 -172.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.539 ' HB3' HG12 ' A' ' 82' ' ' VAL . 24.6 t70 -89.06 3.68 50.9 Favored 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 123.618 0.767 . . . . 0.0 110.75 175.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 81.42 37.16 18.37 Favored Glycine 0 C--N 1.343 0.933 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -171.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.539 HG12 ' HB3' ' A' ' 80' ' ' ASP . 13.3 p -162.28 140.54 2.26 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 CA-C-N 114.541 -0.83 . . . . 0.0 109.809 -174.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.4 mt -121.61 128.8 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 N-CA-C 104.904 -2.258 . . . . 0.0 104.904 165.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -120.81 153.35 37.21 Favored 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -172.7 179.66 44.06 Favored Glycine 0 N--CA 1.446 -0.643 0 O-C-N 123.99 0.806 . . . . 0.0 113.588 175.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.1 m -123.36 136.16 60.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 124.05 0.94 . . . . 0.0 110.007 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 27.0 tp -66.56 134.16 51.81 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 123.011 0.524 . . . . 0.0 111.133 -174.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.65 HD13 ' HG2' ' A' ' 72' ' ' ARG . 34.1 pt -135.06 175.1 11.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.785 1.234 . . . . 0.0 109.59 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 39.1 mtt180 -130.88 84.15 2.17 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.451 0.7 . . . . 0.0 109.284 -176.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.8 mm-40 -95.8 -77.05 0.48 Allowed 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 77.4 mt . . . . . 0 C--O 1.238 0.486 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 169.096 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 26.3 m . . . . . 0 CA--C 1.543 0.706 0 CA-C-O 120.807 0.337 . . . . 0.0 110.35 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 17.3 tpp85 -110.22 141.48 43.1 Favored 'General case' 0 C--O 1.241 0.637 0 C-N-CA 123.561 0.745 . . . . 0.0 110.446 -171.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 16.2 tt -139.94 147.41 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.953 0.901 . . . . 0.0 109.506 178.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -97.59 102.38 14.13 Favored 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 170.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.537 HG22 HG21 ' A' ' 71' ' ' VAL . 96.5 t -82.91 106.14 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 C-N-CA 123.957 0.903 . . . . 0.0 109.698 -177.287 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 86' ' ' VAL . 40.0 t -97.21 102.86 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -56.1 116.59 12.86 Favored Pre-proline 0 CA--C 1.549 0.923 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 173.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -72.91 -19.48 23.39 Favored 'Trans proline' 0 C--N 1.368 1.556 0 C-N-CA 122.332 2.022 . . . . 0.0 113.378 -172.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -81.88 -51.21 8.32 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 123.264 0.626 . . . . 0.0 110.465 -175.181 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.7 p -92.31 -25.78 18.42 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.876 0.87 . . . . 0.0 111.446 -177.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.2 4.65 71.18 Favored Glycine 0 N--CA 1.473 1.113 0 CA-C-O 119.597 -0.557 . . . . 0.0 113.119 -178.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -72.08 112.68 8.37 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.157 0.583 . . . . 0.0 111.811 -173.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.451 HG22 HG22 ' A' ' 28' ' ' VAL . 39.1 t -82.6 115.18 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 171.503 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -130.79 130.0 43.13 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.96 0.904 . . . . 0.0 109.123 -179.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 59.4 mt -78.93 125.61 38.42 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 C-N-CA 122.91 0.484 . . . . 0.0 110.139 -177.319 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -134.17 170.99 14.86 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 124.575 1.15 . . . . 0.0 110.02 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -117.79 135.73 53.87 Favored 'General case' 0 C--O 1.243 0.748 0 C-N-CA 123.329 0.652 . . . . 0.0 109.547 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.1 mt -78.51 112.35 16.43 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.726 0 O-C-N 123.893 0.746 . . . . 0.0 110.311 -175.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 72.6 mtp180 -64.69 -53.93 39.6 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.842 1.257 . . . . 0.0 110.365 175.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 55.5 t30 -143.75 157.65 44.24 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.522 0.729 . . . . 0.0 109.535 -176.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 55.3 t . . . . . 0 N--CA 1.485 1.311 0 C-N-CA 122.925 0.49 . . . . 0.0 110.374 179.134 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.4 HG22 HG23 ' A' ' 59' ' ' THR . 41.1 mm . . . . . 0 C--O 1.241 0.63 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.4 mt -72.71 118.26 17.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 CA-C-N 114.726 -1.125 . . . . 0.0 108.222 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.4 HG23 HG22 ' A' ' 57' ' ' ILE . 7.5 p -131.61 170.46 14.73 Favored 'General case' 0 C--O 1.243 0.726 0 C-N-CA 124.872 1.269 . . . . 0.0 108.952 -175.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -69.52 130.79 43.43 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 177.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.95 -15.34 63.62 Favored Glycine 0 C--N 1.345 1.029 0 CA-C-O 119.48 -0.622 . . . . 0.0 113.531 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.62 134.3 49.74 Favored 'General case' 0 C--O 1.246 0.878 0 C-N-CA 122.957 0.503 . . . . 0.0 110.342 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 67.1 t -88.55 112.88 24.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 176.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.3 m -102.94 138.56 26.73 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -88.11 126.45 35.12 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 61.3 p -134.0 172.49 12.75 Favored 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 124.097 0.959 . . . . 0.0 109.091 -175.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -71.88 -13.12 61.57 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 112.331 0.493 . . . . 0.0 112.331 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 88.5 mt -97.12 -15.34 21.0 Favored 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 123.3 0.64 . . . . 0.0 111.336 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.09 -147.88 19.52 Favored Glycine 0 C--N 1.341 0.848 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 -173.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -109.75 143.0 40.17 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 117.486 0.643 . . . . 0.0 109.404 177.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.537 HG21 HG22 ' A' ' 27' ' ' VAL . 22.0 t -128.73 144.96 36.42 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 123.425 0.69 . . . . 0.0 109.862 -174.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.632 ' HG2' HD13 ' A' ' 88' ' ' ILE . 10.5 mmt180 -94.94 123.71 38.56 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 168.295 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 56.9 t -76.22 94.92 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.4 p -85.15 -39.84 17.42 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.307 0.643 . . . . 0.0 111.109 -178.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.4 m -77.65 164.55 25.22 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.911 173.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 24.3 mmt180 -65.88 130.23 94.41 Favored Pre-proline 0 CA--C 1.548 0.87 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 172.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -77.62 43.16 1.29 Allowed 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 123.502 2.801 . . . . 0.0 112.387 175.586 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -170.95 -137.3 2.27 Favored Glycine 0 C--N 1.334 0.461 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -172.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 21.2 tm0? 67.88 -72.33 0.1 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 124.608 1.163 . . . . 0.0 110.136 -177.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.425 ' HB3' HG12 ' A' ' 82' ' ' VAL . 33.3 t70 -91.45 -12.93 33.25 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 124.211 1.004 . . . . 0.0 110.31 171.106 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 94.56 -6.49 70.9 Favored Glycine 0 C--N 1.343 0.968 0 C-N-CA 123.386 0.517 . . . . 0.0 112.981 -174.06 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.425 HG12 ' HB3' ' A' ' 80' ' ' ASP . 14.5 p -92.83 141.42 14.68 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.512 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 31.5 mt -96.09 146.87 6.58 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -152.66 152.07 31.33 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -169.0 -167.34 29.48 Favored Glycine 0 C--N 1.343 0.972 0 CA-C-O 120.015 -0.325 . . . . 0.0 113.028 -178.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.509 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 35.9 m -116.46 132.68 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 123.776 0.83 . . . . 0.0 110.925 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 38.8 tp -71.63 106.07 3.91 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.463 0.705 . . . . 0.0 111.13 -176.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.632 HD13 ' HG2' ' A' ' 72' ' ' ARG . 41.4 pt -97.34 171.65 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.524 0.73 . . . . 0.0 110.262 175.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 16.7 mmt180 -115.22 21.15 14.4 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.671 0.788 . . . . 0.0 110.235 -173.108 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.449 ' HB2' HD12 ' A' ' 88' ' ' ILE . 33.9 tt0 -64.8 -75.9 0.08 Allowed 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.433 0.693 . . . . 0.0 112.657 -164.343 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 58.3 mt . . . . . 0 N--CA 1.482 1.16 0 CA-C-O 121.834 0.826 . . . . 0.0 110.316 -173.446 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 26.2 m . . . . . 0 CA--C 1.537 0.455 0 CA-C-O 120.547 0.213 . . . . 0.0 110.694 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.429 ' HD2' HG22 ' A' ' 37' ' ' ILE . 77.3 mmt-85 -102.21 134.8 44.89 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.42 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 14.2 tt -140.18 136.11 37.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 123.85 0.86 . . . . 0.0 109.745 -175.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.2 m-80 -85.55 100.59 12.02 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 177.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.2 t -87.4 108.23 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -176.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 40.9 t -95.54 101.67 12.7 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -63.83 116.43 26.69 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 175.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -71.47 -19.76 28.17 Favored 'Trans proline' 0 C--N 1.368 1.559 0 C-N-CA 123.232 2.621 . . . . 0.0 113.194 -171.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -92.67 -52.94 4.39 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 123.499 0.72 . . . . 0.0 110.822 -171.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 62.8 p -90.9 -27.83 18.5 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 123.424 0.69 . . . . 0.0 111.476 -177.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.62 4.73 69.87 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-N 116.416 -0.356 . . . . 0.0 113.369 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -71.45 118.74 14.65 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 123.293 0.637 . . . . 0.0 110.818 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.4 t -108.33 134.84 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 123.679 0.792 . . . . 0.0 108.908 177.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -152.22 148.81 28.02 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 122.87 0.468 . . . . 0.0 110.357 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.429 HG22 ' HD2' ' A' ' 24' ' ' ARG . 51.6 mt -87.12 98.31 7.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.89 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.21 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -95.87 172.21 8.16 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 124.282 1.033 . . . . 0.0 110.646 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -108.26 131.99 54.13 Favored 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 176.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.495 HG12 HG22 ' A' ' 66' ' ' THR . 57.1 mt -75.27 112.66 13.1 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 177.697 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 40.4 mtt-85 -73.11 -52.9 12.52 Favored 'General case' 0 N--CA 1.475 0.825 0 CA-C-O 122.253 1.025 . . . . 0.0 109.418 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.613 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 29.8 t30 -126.04 112.3 15.71 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 113.365 -1.743 . . . . 0.0 108.73 -169.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.8 m . . . . . 0 N--CA 1.478 0.933 0 C-N-CA 123.175 0.59 . . . . 0.0 111.282 -179.013 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.1 mt . . . . . 0 CA--C 1.535 0.366 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.403 ' O ' ' HG3' ' A' ' 77' ' ' PRO . 82.9 mt -93.75 128.68 44.97 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.379 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 38.1 p -126.3 164.29 21.37 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.569 0.748 . . . . 0.0 109.657 -177.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 45.2 ttp180 -73.47 141.41 46.83 Favored 'General case' 0 N--CA 1.482 1.138 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 176.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.88 2.57 90.33 Favored Glycine 0 C--N 1.345 1.06 0 O-C-N 123.198 0.311 . . . . 0.0 112.971 -176.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.0 163.12 16.46 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 123.525 0.73 . . . . 0.0 110.774 179.285 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 38.8 t -110.01 124.85 67.09 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 173.319 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 20.9 m -112.88 168.45 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 168.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.613 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 28.0 tt0 -115.19 134.33 55.24 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 170.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.495 HG22 HG12 ' A' ' 40' ' ' ILE . 43.8 p -123.87 -177.77 3.85 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.843 0.857 . . . . 0.0 109.551 -173.611 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.8 m-20 -58.38 -28.72 65.42 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 122.933 0.493 . . . . 0.0 111.318 175.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 77.8 mt -90.07 -45.71 8.97 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.258 0.623 . . . . 0.0 110.748 -178.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 165.66 -166.04 38.29 Favored Glycine 0 N--CA 1.477 1.416 0 CA-C-O 119.715 -0.492 . . . . 0.0 112.093 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -73.26 132.98 43.78 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 117.653 0.727 . . . . 0.0 109.843 176.609 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 65.2 t -128.74 144.89 36.67 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.905 0 C-N-CA 124.402 1.081 . . . . 0.0 110.29 -174.006 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.553 ' HG2' HG21 ' A' ' 88' ' ' ILE . 33.2 mmt180 -84.98 121.25 27.51 Favored 'General case' 0 N--CA 1.479 1.017 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 168.309 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.5 t -73.21 122.88 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 70.9 p -107.72 -23.9 11.92 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 123.179 0.592 . . . . 0.0 110.999 -176.129 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 45.7 m -93.05 176.92 6.23 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-O 121.309 0.576 . . . . 0.0 111.751 176.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 30.8 mmt180 -106.65 127.09 28.8 Favored Pre-proline 0 C--O 1.241 0.635 0 CA-C-N 114.839 -1.073 . . . . 0.0 108.404 171.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.403 ' HG3' ' O ' ' A' ' 58' ' ' ILE . 37.1 Cg_endo -60.24 120.24 7.89 Favored 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 123.228 2.619 . . . . 0.0 112.474 -176.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 91.38 -36.68 3.56 Favored Glycine 0 C--N 1.341 0.824 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.994 176.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 14.3 mm100 -64.24 -31.81 73.15 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.691 0.796 . . . . 0.0 111.836 -174.316 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -106.24 6.23 30.55 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.718 0.807 . . . . 0.0 111.566 178.639 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 85.57 -61.32 4.59 Favored Glycine 0 C--N 1.349 1.276 0 C-N-CA 123.086 0.374 . . . . 0.0 112.273 -175.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -113.26 159.52 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 124.467 1.107 . . . . 0.0 108.793 175.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 25' ' ' ILE . 41.1 mt -92.52 147.68 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 174.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -125.37 162.98 23.58 Favored 'General case' 0 C--O 1.246 0.888 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 171.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.28 179.38 41.41 Favored Glycine 0 C--N 1.335 0.519 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.952 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.2 m -121.42 131.0 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 C-N-CA 123.433 0.693 . . . . 0.0 109.437 175.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 21.4 tp -67.26 131.27 45.42 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.132 0.573 . . . . 0.0 110.006 -177.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.553 HG21 ' HG2' ' A' ' 72' ' ' ARG . 33.4 pt -123.15 161.12 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 121.665 0.745 . . . . 0.0 111.276 -176.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 26.5 mmt180 -115.94 8.29 14.63 Favored 'General case' 0 CA--C 1.548 0.884 0 CA-C-N 114.195 -1.366 . . . . 0.0 109.636 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -60.28 -62.14 2.09 Favored 'General case' 0 C--N 1.358 0.951 0 C-N-CA 123.959 0.904 . . . . 0.0 112.237 -172.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 22.4 mt . . . . . 0 N--CA 1.473 0.721 0 O-C-N 123.364 0.415 . . . . 0.0 111.035 -179.031 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.44 HG22 HD12 ' A' ' 40' ' ' ILE . 91.4 m . . . . . 0 CA--C 1.548 0.868 0 CA-C-O 121.624 0.726 . . . . 0.0 111.177 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.518 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 36.8 mtm180 -127.23 170.1 12.79 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.835 1.254 . . . . 0.0 110.81 177.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.1 tt -135.7 136.21 50.51 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-N 114.566 -1.197 . . . . 0.0 108.95 -179.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . 0.437 ' HB2' HD22 ' A' ' 84' ' ' ASN . 71.1 m-20 -89.78 102.1 14.8 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 177.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.44 HG22 HG11 ' A' ' 71' ' ' VAL . 58.5 t -98.78 136.38 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 123.873 0.869 . . . . 0.0 110.563 -170.006 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.58 HG22 HG22 ' A' ' 35' ' ' VAL . 30.1 t -122.0 122.29 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -63.98 124.43 85.15 Favored Pre-proline 0 N--CA 1.48 1.027 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 171.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -68.79 -20.0 40.31 Favored 'Trans proline' 0 CA--C 1.554 1.488 0 C-N-CA 122.145 1.897 . . . . 0.0 112.476 178.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.465 ' HG3' HG23 ' A' ' 32' ' ' THR . 12.8 pt-20 -88.2 -51.35 5.82 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.02 0.928 . . . . 0.0 112.115 -176.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.465 HG23 ' HG3' ' A' ' 31' ' ' GLU . 70.4 p -97.87 -21.49 16.87 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.125 0.57 . . . . 0.0 111.792 -173.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.8 5.28 89.54 Favored Glycine 0 C--N 1.349 1.269 0 CA-C-O 119.682 -0.51 . . . . 0.0 113.524 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -73.68 123.89 24.94 Favored 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 123.27 0.628 . . . . 0.0 111.352 -174.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.58 HG22 HG22 ' A' ' 28' ' ' VAL . 24.8 t -95.73 128.86 46.55 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.712 0 C-N-CA 123.872 0.869 . . . . 0.0 109.422 176.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -141.42 133.8 28.18 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 124.483 1.113 . . . . 0.0 108.574 175.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 46.6 mt -79.32 98.92 3.14 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.46 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -86.02 158.93 19.73 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.703 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.518 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 38.9 mt-10 -101.82 124.95 48.31 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.48 0.712 . . . . 0.0 109.433 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.44 HD12 HG22 ' A' ' 23' ' ' THR . 61.7 mt -76.44 108.69 9.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 47.8 mtt180 -82.87 -53.26 6.0 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.261 1.024 . . . . 0.0 110.672 -179.389 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -146.04 160.07 42.39 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -176.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.9 m . . . . . 0 C--O 1.246 0.877 0 C-N-CA 123.523 0.729 . . . . 0.0 112.03 -174.313 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 72.9 mt . . . . . 0 N--CA 1.472 0.646 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.2 mt -115.29 140.45 36.64 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.558 0 C-N-CA 124.488 1.115 . . . . 0.0 108.434 179.6 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 33.9 p -126.15 174.4 8.52 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 124.134 0.974 . . . . 0.0 109.149 178.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 52.7 ttp180 -71.25 139.92 50.21 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 122.716 0.406 . . . . 0.0 110.154 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.76 -8.48 70.94 Favored Glycine 0 C--N 1.337 0.595 0 C-N-CA 123.644 0.64 . . . . 0.0 112.83 -177.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.94 134.54 52.21 Favored 'General case' 0 C--N 1.351 0.669 0 C-N-CA 123.611 0.765 . . . . 0.0 111.89 -177.008 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 44.1 t -90.76 112.87 25.69 Favored 'Isoleucine or valine' 0 C--N 1.344 0.341 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 169.624 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.6 m -106.26 147.13 12.07 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 123.482 0.713 . . . . 0.0 109.271 177.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -90.73 126.44 36.0 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 175.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.46 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 67.2 p -130.85 179.79 5.77 Favored 'General case' 0 C--O 1.239 0.552 0 C-N-CA 123.259 0.623 . . . . 0.0 109.774 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 19.2 p-10 -73.59 -14.69 61.23 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 123.341 0.656 . . . . 0.0 111.192 175.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.1 mt -91.16 -41.09 11.21 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 123.249 0.62 . . . . 0.0 110.325 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 155.79 -149.97 21.2 Favored Glycine 0 C--N 1.345 1.074 0 CA-C-N 116.239 -0.437 . . . . 0.0 112.056 175.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -78.91 128.49 33.38 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 173.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.44 HG11 HG22 ' A' ' 27' ' ' VAL . 48.7 t -126.85 140.33 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 122.792 0.437 . . . . 0.0 110.4 -178.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.743 ' HG2' HD13 ' A' ' 88' ' ' ILE . 29.2 mmt180 -88.89 131.5 35.09 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 169.461 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 82.2 t -76.87 106.72 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 171.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 40.5 p -96.38 -19.92 18.85 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.044 0.538 . . . . 0.0 110.92 -172.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . 0.509 ' HB2' ' HB2' ' A' ' 84' ' ' ASN . 32.4 t -87.49 171.08 10.79 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.378 0.671 . . . . 0.0 110.391 175.32 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 -93.48 92.84 0.72 Allowed Pre-proline 0 CA--C 1.559 1.315 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 173.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -62.73 -46.36 11.41 Favored 'Trans proline' 0 C--N 1.384 2.422 0 C-N-CA 123.431 2.754 . . . . 0.0 113.958 -163.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -81.19 -13.5 80.71 Favored Glycine 0 C--N 1.345 1.039 0 CA-C-O 119.959 -0.356 . . . . 0.0 113.54 -177.201 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 18.5 mm-40 -90.14 -48.39 7.21 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 122.981 0.513 . . . . 0.0 111.352 -178.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -80.67 -14.05 58.48 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 122.82 0.448 . . . . 0.0 111.294 174.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 68.36 18.53 71.6 Favored Glycine 0 C--N 1.349 1.254 0 O-C-N 123.205 0.316 . . . . 0.0 112.785 -175.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 11.6 p -143.25 143.87 24.3 Favored 'Isoleucine or valine' 0 C--O 1.24 0.555 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 178.211 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 29.0 mt -106.37 117.63 52.5 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -176.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.509 ' HB2' ' HB2' ' A' ' 75' ' ' SER . 9.4 m120 -124.7 151.4 45.04 Favored 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.9 -178.26 34.72 Favored Glycine 0 C--N 1.339 0.733 0 N-CA-C 115.141 0.816 . . . . 0.0 115.141 -174.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.402 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 30.0 m -121.51 139.5 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.637 0.775 . . . . 0.0 110.147 175.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.3 tp -74.03 122.23 22.32 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.093 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.743 HD13 ' HG2' ' A' ' 72' ' ' ARG . 46.8 pt -124.06 -177.89 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 124.615 1.166 . . . . 0.0 109.198 175.208 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 29.5 mmm180 -139.45 90.67 2.43 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -176.623 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -88.95 -50.07 6.4 Favored 'General case' 0 N--CA 1.484 1.229 0 CA-C-O 121.496 0.665 . . . . 0.0 109.629 178.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 69.1 mt . . . . . 0 C--O 1.245 0.843 0 CA-C-N 114.508 -1.224 . . . . 0.0 109.735 176.402 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 52.8 m . . . . . 0 N--CA 1.47 0.557 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.1 mmt180 -117.74 152.81 34.52 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-O 121.469 0.652 . . . . 0.0 111.599 -173.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.511 ' HB ' HD11 ' A' ' 40' ' ' ILE . 15.8 tt -141.96 142.18 28.3 Favored 'Isoleucine or valine' 0 C--O 1.241 0.643 0 CA-C-N 114.139 -1.391 . . . . 0.0 109.054 176.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -90.82 100.82 13.61 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 173.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.6 t -86.17 112.85 23.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.538 0 C-N-CA 124.623 1.169 . . . . 0.0 109.205 -175.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.405 HG22 HG22 ' A' ' 35' ' ' VAL . 41.5 t -94.81 100.33 10.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.549 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 176.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -64.16 113.65 11.07 Favored Pre-proline 0 CA--C 1.546 0.821 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 172.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.52 -1.18 11.38 Favored 'Trans proline' 0 C--N 1.364 1.378 0 C-N-CA 122.518 2.146 . . . . 0.0 113.591 -172.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -91.97 -52.68 4.6 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.337 0.655 . . . . 0.0 109.325 -177.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 66.7 p -93.29 -32.58 14.26 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 124.468 1.107 . . . . 0.0 111.909 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 93.51 6.98 62.17 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.986 -173.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -69.89 107.77 3.7 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 123.08 0.552 . . . . 0.0 110.994 -178.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.405 HG22 HG22 ' A' ' 28' ' ' VAL . 23.6 t -90.9 119.92 38.91 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 172.597 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -142.52 143.48 32.54 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 122.993 0.517 . . . . 0.0 110.466 -174.302 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 62.1 mt -77.45 123.85 34.82 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.86 0 C-N-CA 123.555 0.742 . . . . 0.0 109.661 179.068 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.41 158.12 36.8 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 123.89 0.876 . . . . 0.0 110.149 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -97.74 121.05 39.19 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.511 HD11 ' HB ' ' A' ' 25' ' ' ILE . 54.7 mt -77.74 112.55 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 72.3 mtm180 -80.71 -38.21 29.24 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 124.512 1.125 . . . . 0.0 111.113 -178.098 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 47.4 t-20 -140.76 138.95 34.51 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.7 m . . . . . 0 N--CA 1.478 0.969 0 C-N-CA 123.324 0.65 . . . . 0.0 112.425 -176.584 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 15.8 tt . . . . . 0 N--CA 1.476 0.864 0 CA-C-O 121.268 0.556 . . . . 0.0 109.703 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 76.3 mt -91.58 143.56 11.02 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.698 0 C-N-CA 124.426 1.09 . . . . 0.0 109.723 175.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.46 HG23 ' HB2' ' A' ' 62' ' ' ALA . 3.3 t -131.32 172.16 12.49 Favored 'General case' 0 C--O 1.244 0.766 0 C-N-CA 123.915 0.886 . . . . 0.0 109.261 177.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 25.3 ttm180 -74.03 133.79 42.97 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -178.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.88 -2.83 82.36 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.956 -0.358 . . . . 0.0 112.924 -176.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.46 ' HB2' HG23 ' A' ' 59' ' ' THR . . . -77.6 132.06 38.1 Favored 'General case' 0 C--O 1.244 0.796 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 176.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.601 HG21 ' HG3' ' A' ' 90' ' ' GLU . 21.9 t -83.18 114.08 23.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 177.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 33.4 m -101.57 146.45 9.85 Favored 'Isoleucine or valine' 0 C--O 1.244 0.793 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 177.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.8 tp10 -95.83 128.24 42.54 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 63.2 p -124.86 177.86 5.8 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 24.0 p-10 -72.42 -12.26 61.03 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 122.794 0.438 . . . . 0.0 110.743 175.372 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.3 mt -93.41 -49.77 5.77 Favored 'General case' 0 C--N 1.357 0.918 0 C-N-CA 123.079 0.551 . . . . 0.0 110.425 175.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 168.73 -150.66 16.33 Favored Glycine 0 C--N 1.348 1.21 0 O-C-N 123.177 0.298 . . . . 0.0 113.253 178.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -88.23 118.09 27.59 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 123.836 0.854 . . . . 0.0 109.122 -178.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.2 t -121.27 144.86 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 C-N-CA 123.467 0.707 . . . . 0.0 109.4 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.497 ' HG3' HD13 ' A' ' 88' ' ' ILE . 24.4 mtt180 -109.66 131.91 54.63 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 171.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.1 t -80.36 98.99 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 O-C-N 124.172 0.92 . . . . 0.0 109.243 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 35.5 p -74.48 -28.59 61.08 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.792 0.837 . . . . 0.0 111.781 177.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.1 m -90.58 -170.78 2.83 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.921 177.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.412 ' HD2' ' N ' ' A' ' 76' ' ' ARG . 8.4 mpt_? -96.54 112.15 59.23 Favored Pre-proline 0 CA--C 1.545 0.784 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -62.37 96.02 0.15 Allowed 'Trans proline' 0 C--N 1.377 2.03 0 C-N-CA 123.148 2.565 . . . . 0.0 112.837 -172.11 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.77 -23.45 32.5 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.69 -0.686 . . . . 0.0 113.999 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -72.97 -30.43 63.83 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-N 117.956 0.878 . . . . 0.0 110.491 175.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -77.04 4.33 10.37 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 123.569 0.748 . . . . 0.0 111.287 171.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 90.62 -33.95 4.39 Favored Glycine 0 C--N 1.356 1.682 0 N-CA-C 111.596 -0.602 . . . . 0.0 111.596 -172.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.0 p -140.2 164.27 22.75 Favored 'Isoleucine or valine' 0 C--O 1.243 0.751 0 C-N-CA 124.729 1.212 . . . . 0.0 108.395 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 45.2 mt -84.5 132.88 30.53 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 173.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -133.66 144.66 49.34 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 -177.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -171.73 -172.74 38.02 Favored Glycine 0 C--N 1.342 0.901 0 N-CA-C 114.825 0.69 . . . . 0.0 114.825 -177.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 16.5 m -119.28 137.38 53.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 C-N-CA 123.943 0.897 . . . . 0.0 110.357 -176.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 41.8 tp -74.08 109.35 7.51 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 122.632 0.373 . . . . 0.0 110.438 -179.118 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.497 HD13 ' HG3' ' A' ' 72' ' ' ARG . 31.6 pt -102.52 179.6 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.83 0 C-N-CA 123.802 0.841 . . . . 0.0 109.865 174.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 5.0 mpt_? -125.76 55.96 1.42 Allowed 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.601 ' HG3' HG21 ' A' ' 63' ' ' VAL . 0.8 OUTLIER -60.47 -57.84 11.02 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 -179.967 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 74.9 mt . . . . . 0 CA--C 1.545 0.77 0 CA-C-N 114.7 -1.136 . . . . 0.0 107.946 169.974 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.539 HG22 HD12 ' A' ' 40' ' ' ILE . 52.4 m . . . . . 0 CA--C 1.537 0.448 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -127.18 158.82 36.08 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.543 0.737 . . . . 0.0 111.516 -175.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.479 ' HB ' HD11 ' A' ' 40' ' ' ILE . 16.1 tt -145.6 148.75 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.731 0.813 . . . . 0.0 110.395 -171.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 37.7 m-80 -89.32 103.6 16.22 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 172.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 75.8 t -89.39 109.82 20.84 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 C-N-CA 123.932 0.893 . . . . 0.0 109.053 -176.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 37.0 t -100.01 110.05 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 123.199 0.6 . . . . 0.0 109.654 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -59.2 112.68 5.48 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 170.338 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.2 -16.97 19.48 Favored 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 121.926 1.751 . . . . 0.0 111.747 179.104 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -94.37 -45.18 7.57 Favored 'General case' 0 CA--C 1.552 1.032 0 C-N-CA 124.344 1.058 . . . . 0.0 111.184 178.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.6 m -90.2 -20.01 23.54 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 123.362 0.665 . . . . 0.0 112.02 -175.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.17 -11.52 57.54 Favored Glycine 0 C--N 1.35 1.317 0 C-N-CA 123.422 0.534 . . . . 0.0 114.223 178.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -75.39 150.59 38.32 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.814 0.846 . . . . 0.0 112.132 -173.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 21.1 t -126.12 133.83 67.94 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.797 0.839 . . . . 0.0 108.774 174.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -147.61 141.3 25.61 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.611 0.764 . . . . 0.0 109.537 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 47.5 mt -81.92 122.87 37.43 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.8 0 N-CA-C 108.264 -1.014 . . . . 0.0 108.264 178.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.35 161.41 27.88 Favored 'General case' 0 C--O 1.236 0.382 0 C-N-CA 124.796 1.238 . . . . 0.0 109.517 -174.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -106.43 123.7 48.47 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -175.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.539 HD12 HG22 ' A' ' 23' ' ' THR . 59.5 mt -76.41 113.29 15.23 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 123.388 0.675 . . . . 0.0 109.955 -176.259 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -77.4 -53.29 7.83 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.634 1.174 . . . . 0.0 110.264 -178.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -140.23 166.61 24.22 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 124.158 0.983 . . . . 0.0 108.704 178.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 43.9 t . . . . . 0 N--CA 1.475 0.787 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 167.997 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 49.4 mm . . . . . 0 N--CA 1.484 1.255 0 CA-C-O 122.566 1.174 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 37.1 mt -83.23 144.4 10.14 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 113.962 -1.472 . . . . 0.0 109.595 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 17.5 p -122.82 167.94 12.89 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.051 0.941 . . . . 0.0 109.052 173.05 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 35.7 ttt180 -74.16 131.38 41.22 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 175.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.94 9.4 77.52 Favored Glycine 0 N--CA 1.465 0.613 0 O-C-N 124.076 0.86 . . . . 0.0 112.843 -175.386 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -83.16 160.95 21.73 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.145 0.578 . . . . 0.0 109.603 176.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.7 t -105.99 120.9 57.67 Favored 'Isoleucine or valine' 0 C--O 1.243 0.748 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 172.325 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.4 m -106.5 159.55 6.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.228 175.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -106.85 130.08 54.59 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 173.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.421 HG22 HG12 ' A' ' 40' ' ' ILE . 34.0 p -129.61 -175.18 3.51 Favored 'General case' 0 C--O 1.24 0.556 0 C-N-CA 123.241 0.616 . . . . 0.0 109.813 -176.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 73.3 m-20 -70.28 -19.26 63.11 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 123.134 0.574 . . . . 0.0 111.024 175.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 93.8 mt -99.45 -13.73 19.41 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.907 0.883 . . . . 0.0 111.755 -178.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.45 -164.16 22.42 Favored Glycine 0 C--N 1.35 1.32 0 O-C-N 123.349 0.406 . . . . 0.0 112.528 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -80.09 130.45 35.26 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.142 0.577 . . . . 0.0 110.394 177.76 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.6 t -125.5 138.9 52.93 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 C-N-CA 124.468 1.107 . . . . 0.0 110.663 -173.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.829 ' HG2' HD13 ' A' ' 88' ' ' ILE . 9.5 mmt180 -86.4 121.03 28.38 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 169.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 48.9 t -72.98 116.75 15.6 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.768 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 43.8 p -96.97 -24.58 15.75 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.456 0.702 . . . . 0.0 111.238 -172.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 23.3 t -108.55 178.5 4.47 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.533 0.733 . . . . 0.0 109.84 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 85.8 mtm180 -90.62 106.69 16.18 Favored Pre-proline 0 CA--C 1.552 1.049 0 C-N-CA 123.383 0.673 . . . . 0.0 109.976 -177.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -66.22 114.44 3.03 Favored 'Trans proline' 0 C--N 1.373 1.835 0 C-N-CA 123.101 2.534 . . . . 0.0 112.357 -175.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 141.94 -29.88 2.18 Favored Glycine 0 C--N 1.344 0.981 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.339 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -60.84 110.73 1.4 Allowed 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.342 0.657 . . . . 0.0 110.49 178.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.506 ' HB2' HG12 ' A' ' 82' ' ' VAL . 26.8 m-20 70.26 -15.79 0.33 Allowed 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 125.66 1.584 . . . . 0.0 114.04 178.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 98.05 12.52 45.84 Favored Glycine 0 C--N 1.342 0.907 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -169.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 80' ' ' ASP . 3.7 p -111.32 118.59 57.81 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 C-N-CA 123.603 0.761 . . . . 0.0 109.573 175.085 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.2 mt -98.24 148.03 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 170.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -135.16 149.14 49.91 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 122.937 0.495 . . . . 0.0 109.819 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.25 -175.54 37.97 Favored Glycine 0 C--N 1.346 1.102 0 O-C-N 123.648 0.592 . . . . 0.0 113.482 -176.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.2 m -129.1 138.7 53.8 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 C-N-CA 124.248 1.019 . . . . 0.0 110.42 178.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.6 tp -73.86 122.73 22.96 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 121.094 0.473 . . . . 0.0 111.271 -175.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.829 HD13 ' HG2' ' A' ' 72' ' ' ARG . 40.1 pt -119.17 -179.65 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 123.884 0.874 . . . . 0.0 109.623 175.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 57.4 mtt180 -122.79 83.29 2.1 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 -176.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 36.2 mm-40 -93.2 -80.91 0.37 Allowed 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 175.087 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 50.8 mt . . . . . 0 C--N 1.344 0.327 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -175.435 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.495 HG22 HD12 ' A' ' 40' ' ' ILE . 62.9 m . . . . . 0 N--CA 1.473 0.723 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 41.8 mtt180 -115.01 163.6 15.36 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.732 0.813 . . . . 0.0 110.519 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.493 ' HB ' HD11 ' A' ' 40' ' ' ILE . 16.6 tt -141.75 135.49 30.03 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 124.025 0.93 . . . . 0.0 108.802 175.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -85.67 103.27 14.33 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 177.154 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -92.08 133.27 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 123.802 0.841 . . . . 0.0 109.886 -171.495 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 46.7 t -109.8 109.81 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 178.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -66.61 119.07 60.24 Favored Pre-proline 0 CA--C 1.545 0.78 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 176.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -66.11 -33.84 39.3 Favored 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 123.003 2.468 . . . . 0.0 113.667 -166.003 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -95.36 -40.4 9.54 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 112.85 0.685 . . . . 0.0 112.85 -171.61 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 71.3 p -89.51 -21.24 23.03 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 122.464 0.306 . . . . 0.0 111.533 179.673 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.49 2.76 90.63 Favored Glycine 0 C--N 1.347 1.192 0 CA-C-O 119.882 -0.399 . . . . 0.0 113.572 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.6 mmtp -68.25 107.26 2.73 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.504 0.722 . . . . 0.0 110.971 -177.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.2 t -92.59 126.11 45.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 174.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -154.21 146.79 24.12 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 123.831 0.853 . . . . 0.0 108.813 -176.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 45.2 mt -80.87 137.41 21.41 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -177.523 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.98 159.49 32.52 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.672 0.789 . . . . 0.0 109.713 -179.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 17.1 mm-40 -103.17 122.57 44.98 Favored 'General case' 0 C--O 1.241 0.651 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.495 HD12 HG22 ' A' ' 23' ' ' THR . 44.5 mt -76.95 110.11 12.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -176.612 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 62.3 mtt180 -73.85 -52.3 13.45 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.149 0.979 . . . . 0.0 110.91 178.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -140.75 164.11 31.09 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.817 0.847 . . . . 0.0 110.14 -176.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 70.8 t . . . . . 0 N--CA 1.482 1.168 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 176.691 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.8 mm . . . . . 0 CA--C 1.538 0.513 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.1 mt -80.37 127.43 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 123.424 0.69 . . . . 0.0 109.764 -176.468 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 74.0 p -124.74 160.6 28.26 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 123.79 0.836 . . . . 0.0 109.427 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -75.68 128.23 34.77 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 122.964 0.506 . . . . 0.0 110.261 179.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.31 -1.24 58.82 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.441 -176.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.1 148.12 22.49 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.642 0.777 . . . . 0.0 111.479 -176.767 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 94.6 t -83.49 118.94 31.89 Favored 'Isoleucine or valine' 0 C--O 1.24 0.592 0 C-N-CA 123.406 0.682 . . . . 0.0 109.604 171.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.0 m -102.77 143.32 15.29 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 165.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -94.18 123.68 37.72 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 66.2 p -123.19 -173.08 2.64 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.141 0.577 . . . . 0.0 110.047 -175.05 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 58.2 m-20 -73.38 -26.99 61.23 Favored 'General case' 0 N--CA 1.478 0.932 0 CA-C-O 119.851 -0.118 . . . . 0.0 110.902 170.131 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.1 mt -84.13 -28.25 27.6 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 122.916 0.486 . . . . 0.0 111.843 -176.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 146.96 -149.55 21.71 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 178.579 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -85.55 128.11 34.65 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 175.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.7 t -121.72 128.6 75.78 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.526 0 C-N-CA 122.656 0.383 . . . . 0.0 110.862 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.546 ' HG2' HD13 ' A' ' 88' ' ' ILE . 22.6 mmt85 -85.58 123.29 30.83 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 171.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.6 t -72.32 100.13 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.515 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 47.5 p -95.4 -22.55 17.65 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 123.253 0.621 . . . . 0.0 110.803 -169.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 21.6 t -98.32 -177.81 3.83 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 169.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.663 ' HE ' ' HB3' ' A' ' 79' ' ' GLN . 39.6 ptt180 -75.26 144.0 77.71 Favored Pre-proline 0 CA--C 1.551 1.014 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 173.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -76.71 50.63 3.08 Favored 'Trans proline' 0 CA--C 1.559 1.762 0 C-N-CA 123.091 2.527 . . . . 0.0 113.273 174.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 172.8 67.08 0.05 OUTLIER Glycine 0 C--N 1.346 1.126 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.977 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . 0.663 ' HB3' ' HE ' ' A' ' 76' ' ' ARG . 1.7 pt20 -123.41 115.33 21.43 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.999 0.92 . . . . 0.0 108.604 172.562 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 62.39 19.3 11.01 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 124.339 1.055 . . . . 0.0 111.335 -176.013 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 92.86 -6.25 76.68 Favored Glycine 0 C--N 1.353 1.474 0 CA-C-N 116.033 -0.53 . . . . 0.0 112.496 178.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.8 p -120.3 163.71 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 123.004 0.522 . . . . 0.0 111.008 -175.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 42.3 mt -109.31 147.54 13.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 C-N-CA 124.696 1.198 . . . . 0.0 109.169 -178.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -130.03 155.5 46.03 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 118.414 0.552 . . . . 0.0 110.774 174.449 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.515 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -166.84 -169.38 30.37 Favored Glycine 0 C--N 1.348 1.199 0 CA-C-N 115.367 -0.833 . . . . 0.0 113.652 -177.611 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.1 m -125.61 146.8 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 CA-C-N 117.789 0.795 . . . . 0.0 111.045 178.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 17.5 tp -84.6 104.61 14.74 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 122.607 0.363 . . . . 0.0 111.224 -176.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.546 HD13 ' HG2' ' A' ' 72' ' ' ARG . 50.0 pt -93.71 174.95 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 123.08 0.552 . . . . 0.0 110.765 178.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -119.57 27.39 8.78 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 124.022 0.929 . . . . 0.0 110.298 -170.206 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.95 -61.41 2.4 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 124.378 1.071 . . . . 0.0 110.792 -170.361 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.541 0.606 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 165.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 63.7 m . . . . . 0 C--O 1.242 0.672 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 13.4 mmt85 -97.56 165.08 12.15 Favored 'General case' 0 C--O 1.244 0.771 0 CA-C-O 121.713 0.768 . . . . 0.0 110.441 -178.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.0 tt -136.54 134.18 49.2 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 CA-C-N 114.09 -1.413 . . . . 0.0 107.893 174.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . 0.427 ' HB2' HD22 ' A' ' 84' ' ' ASN . 82.8 m-20 -88.68 100.53 13.19 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 91.7 t -87.32 116.04 28.96 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.169 -173.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.408 HG22 HG22 ' A' ' 35' ' ' VAL . 58.2 t -95.17 99.65 9.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -178.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.418 ' HB3' ' HB2' ' A' ' 34' ' ' LYS . 11.5 t70 -59.88 110.98 3.24 Favored Pre-proline 0 CA--C 1.545 0.774 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 170.277 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -82.73 -4.63 11.47 Favored 'Trans proline' 0 CA--C 1.547 1.131 0 C-N-CA 122.535 2.157 . . . . 0.0 113.043 -174.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -76.23 -58.58 3.2 Favored 'General case' 0 C--N 1.353 0.759 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -177.079 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.9 p -95.76 -32.73 12.58 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 114.578 -1.192 . . . . 0.0 112.127 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.01 14.39 19.05 Favored Glycine 0 N--CA 1.477 1.427 0 CA-C-O 119.793 -0.448 . . . . 0.0 113.224 -178.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.418 ' HB2' ' HB3' ' A' ' 29' ' ' ASP . 63.6 mttp -63.15 148.44 48.0 Favored 'General case' 0 N--CA 1.486 1.369 0 C-N-CA 122.757 0.423 . . . . 0.0 111.589 175.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.408 HG22 HG22 ' A' ' 28' ' ' VAL . 44.1 t -127.04 120.29 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 167.528 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -130.77 139.93 50.26 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.74 0.816 . . . . 0.0 110.062 -176.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 53.5 mt -79.15 120.46 30.39 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 177.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.24 155.5 33.08 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.964 0.905 . . . . 0.0 111.175 -173.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -99.19 127.32 45.15 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 174.638 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 61.6 mt -77.58 111.28 14.21 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 123.035 0.534 . . . . 0.0 110.612 -175.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.412 ' H ' ' HA ' ' A' ' 66' ' ' THR . 15.6 mmm180 -66.77 -44.34 81.63 Favored 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 123.718 0.807 . . . . 0.0 110.77 174.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.573 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 37.4 t30 -140.32 125.65 18.83 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.68 -169.583 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.436 HG12 HD11 ' A' ' 58' ' ' ILE . 17.9 m . . . . . 0 N--CA 1.478 0.932 0 O-C-N 124.031 0.832 . . . . 0.0 111.686 -178.063 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 49.9 mm . . . . . 0 C--O 1.24 0.561 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.436 HD11 HG12 ' A' ' 43' ' ' VAL . 67.9 mt -101.67 144.23 13.45 Favored 'Isoleucine or valine' 0 C--O 1.24 0.58 0 CA-C-N 114.48 -1.236 . . . . 0.0 109.065 -176.302 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 11.2 p -136.08 165.3 26.03 Favored 'General case' 0 C--O 1.242 0.675 0 C-N-CA 123.934 0.893 . . . . 0.0 109.702 -178.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -63.77 140.82 58.91 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 123.934 0.893 . . . . 0.0 111.118 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.01 -25.34 25.86 Favored Glycine 0 C--N 1.341 0.845 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.938 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.87 139.51 56.51 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.314 0.646 . . . . 0.0 110.987 -178.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 93.2 t -93.57 110.56 23.52 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 172.378 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.3 m -100.64 141.79 16.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 177.185 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.573 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 40.7 tt0 -94.01 136.99 33.72 Favored 'General case' 0 C--O 1.234 0.243 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.412 ' HA ' ' H ' ' A' ' 41' ' ' ARG . 81.5 p -130.03 176.52 8.0 Favored 'General case' 0 C--O 1.246 0.875 0 C-N-CA 123.972 0.909 . . . . 0.0 109.144 -179.184 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 18.6 p-10 -63.45 -24.44 67.83 Favored 'General case' 0 CA--C 1.542 0.661 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.986 173.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 86.5 mt -88.66 -34.01 17.39 Favored 'General case' 0 C--N 1.354 0.782 0 C-N-CA 123.143 0.577 . . . . 0.0 110.555 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 150.37 -150.09 22.06 Favored Glycine 0 C--N 1.343 0.923 0 CA-C-N 116.593 -0.276 . . . . 0.0 112.423 173.332 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -78.9 129.73 34.85 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.582 0.753 . . . . 0.0 109.038 -179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.8 t -127.85 137.5 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 123.063 0.545 . . . . 0.0 110.635 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.711 ' HG2' HD13 ' A' ' 88' ' ' ILE . 13.4 mmt180 -90.77 118.26 30.05 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 169.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.1 t -72.04 109.1 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 178.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.3 p -98.54 -50.97 4.09 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 -171.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . 0.525 ' HB3' ' HB3' ' A' ' 84' ' ' ASN . 31.1 t -82.71 150.91 26.45 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.113 176.671 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.442 ' HD2' ' HD2' ' A' ' 77' ' ' PRO . 23.8 tpt180 -72.83 125.5 91.12 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 123.482 0.713 . . . . 0.0 109.611 175.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.442 ' HD2' ' HD2' ' A' ' 76' ' ' ARG . 85.2 Cg_exo -51.72 101.61 0.05 OUTLIER 'Trans proline' 0 C--N 1.378 2.084 0 C-N-CA 123.269 2.646 . . . . 0.0 111.509 163.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 140.4 -32.63 2.14 Favored Glycine 0 C--N 1.339 0.747 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 -176.009 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -65.94 113.34 4.34 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 171.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 30.5 t70 76.89 -19.12 0.44 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 125.523 1.529 . . . . 0.0 111.686 -170.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 109.4 -47.57 1.03 Allowed Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -171.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.3 p -75.11 165.77 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 C-N-CA 123.756 0.822 . . . . 0.0 111.074 178.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 30.2 mt -93.8 148.15 5.05 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 169.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.525 ' HB3' ' HB3' ' A' ' 75' ' ' SER . 25.6 t-20 -136.56 147.35 46.97 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 174.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.53 -175.8 26.1 Favored Glycine 0 C--N 1.336 0.574 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.257 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.5 m -121.3 138.1 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 123.223 0.609 . . . . 0.0 109.9 174.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.4 ' HB3' ' HA ' ' A' ' 29' ' ' ASP . 41.9 tp -67.78 128.93 38.31 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 123.543 0.737 . . . . 0.0 110.128 178.32 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.711 HD13 ' HG2' ' A' ' 72' ' ' ARG . 44.5 pt -129.94 179.74 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 123.658 0.783 . . . . 0.0 110.702 -177.19 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 10.7 mmm180 -123.45 119.78 31.01 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 125.276 1.431 . . . . 0.0 107.247 171.59 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -149.83 -68.51 0.2 Allowed 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -177.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.408 HD23 ' H ' ' A' ' 91' ' ' LEU . 2.0 pt? . . . . . 0 N--CA 1.477 0.893 0 CA-C-O 122.318 1.056 . . . . 0.0 110.917 -177.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.418 HG22 HD12 ' A' ' 40' ' ' ILE . 5.2 m . . . . . 0 N--CA 1.471 0.594 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.429 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 57.4 mtm180 -123.34 161.15 25.25 Favored 'General case' 0 C--O 1.244 0.8 0 C-N-CA 123.296 0.638 . . . . 0.0 110.807 178.106 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.9 tt -145.65 141.24 22.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.745 -170.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -84.07 102.57 12.62 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 175.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.7 t -93.9 115.26 32.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 C-N-CA 124.18 0.992 . . . . 0.0 109.085 -171.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.5 t -104.65 106.97 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 124.327 1.051 . . . . 0.0 109.011 -177.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -69.16 111.48 8.69 Favored Pre-proline 0 CA--C 1.544 0.725 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 175.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -74.1 -7.43 19.84 Favored 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.712 2.274 . . . . 0.0 113.506 -170.101 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -96.02 -52.75 3.91 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 122.685 0.394 . . . . 0.0 111.221 -177.527 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 77.1 p -102.14 -29.86 11.48 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 123.367 0.667 . . . . 0.0 112.548 -175.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.39 20.91 14.0 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-O 119.734 -0.481 . . . . 0.0 113.766 177.583 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 60.8 mttp -67.43 105.66 1.87 Allowed 'General case' 0 N--CA 1.484 1.25 0 CA-C-N 117.308 0.554 . . . . 0.0 110.665 175.04 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 44.5 t -108.85 115.65 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.7 tp10 -153.72 147.55 25.38 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.111 0.564 . . . . 0.0 109.66 -174.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 44.7 mt -83.77 100.07 6.9 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -177.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -90.82 160.09 15.94 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.975 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.448 ' HB2' ' ND2' ' A' ' 67' ' ' ASN . 37.5 mt-10 -105.61 122.24 45.62 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -177.17 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.463 HG12 HG22 ' A' ' 66' ' ' THR . 50.9 mt -75.76 111.81 12.64 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -172.751 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -73.77 -40.16 63.67 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 123.807 0.843 . . . . 0.0 110.335 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -143.89 130.68 20.3 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.864 -173.231 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.405 HG12 HD11 ' A' ' 58' ' ' ILE . 29.4 m . . . . . 0 N--CA 1.483 1.184 0 C-N-CA 122.99 0.516 . . . . 0.0 111.754 -175.298 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.7 tp . . . . . 0 C--O 1.24 0.587 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.487 HD13 HG11 ' A' ' 64' ' ' VAL . 61.6 mt -114.42 144.37 22.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 124.171 0.988 . . . . 0.0 108.493 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 31.2 p -121.9 167.98 12.42 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.265 0.626 . . . . 0.0 110.55 179.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 39.5 ttp180 -71.72 131.09 42.64 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.005 178.108 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.2 -2.3 83.45 Favored Glycine 0 C--N 1.342 0.914 0 C-N-CA 123.607 0.622 . . . . 0.0 113.005 -177.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -85.18 132.55 34.27 Favored 'General case' 0 C--O 1.246 0.881 0 C-N-CA 123.408 0.683 . . . . 0.0 110.137 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 41.4 t -82.73 113.61 22.24 Favored 'Isoleucine or valine' 0 C--N 1.352 0.69 0 CA-C-O 121.01 0.433 . . . . 0.0 110.029 178.537 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.487 HG11 HD13 ' A' ' 58' ' ' ILE . 34.1 m -102.28 166.94 2.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 169.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -120.98 134.89 55.31 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 175.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.463 HG22 HG12 ' A' ' 40' ' ' ILE . 43.6 p -130.68 -176.23 3.91 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 124.263 1.025 . . . . 0.0 110.099 -171.347 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.448 ' ND2' ' HB2' ' A' ' 39' ' ' GLU . 97.3 m-20 -68.96 -23.59 64.15 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.06 175.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 73.8 mt -86.22 -41.34 14.72 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 123.183 0.302 . . . . 0.0 110.464 175.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 159.08 -159.29 30.25 Favored Glycine 0 C--N 1.345 1.045 0 O-C-N 123.443 0.464 . . . . 0.0 112.976 178.297 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 21.5 m120 -77.43 124.45 27.9 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 177.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 46.1 t -123.58 145.21 30.94 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.733 0 C-N-CA 124.438 1.095 . . . . 0.0 109.562 -175.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.443 ' HG3' HD13 ' A' ' 88' ' ' ILE . 30.1 mtt85 -107.7 137.04 46.44 Favored 'General case' 0 N--CA 1.483 1.18 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 168.337 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.476 HG11 ' HD3' ' A' ' 77' ' ' PRO . 58.1 t -75.09 120.26 24.32 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 O-C-N 124.273 0.983 . . . . 0.0 109.594 179.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.421 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 40.2 p -98.38 -20.95 16.86 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 123.447 0.699 . . . . 0.0 110.429 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . 0.413 ' HB3' ' HB2' ' A' ' 84' ' ' ASN . 95.0 p -91.9 -173.16 3.41 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.379 0.672 . . . . 0.0 109.713 174.807 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 74.8 mtt180 -116.23 103.4 53.12 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 172.32 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.476 ' HD3' HG11 ' A' ' 73' ' ' VAL . 21.1 Cg_endo -57.71 151.54 54.86 Favored 'Trans proline' 0 C--N 1.382 2.297 0 C-N-CA 123.659 2.906 . . . . 0.0 113.632 -168.082 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.52 -35.01 4.2 Favored Glycine 0 C--N 1.349 1.292 0 CA-C-O 119.7 -0.5 . . . . 0.0 113.553 176.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 89.8 mt-30 -61.59 -57.77 10.75 Favored 'General case' 0 C--N 1.359 1.015 0 CA-C-O 121.351 0.596 . . . . 0.0 109.921 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -91.73 32.87 1.06 Allowed 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.376 177.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 65.07 -78.04 0.07 OUTLIER Glycine 0 C--N 1.361 1.949 0 C-N-CA 123.643 0.64 . . . . 0.0 112.831 -176.149 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.1 p -73.72 164.6 3.48 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.523 1.129 . . . . 0.0 110.441 178.476 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.448 HG12 ' HB3' ' A' ' 77' ' ' PRO . 15.9 mt -93.82 147.82 5.28 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 175.171 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.413 ' HB2' ' HB3' ' A' ' 75' ' ' SER . 1.0 OUTLIER -123.79 147.73 47.3 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 171.11 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.421 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -165.3 -176.49 36.92 Favored Glycine 0 CA--C 1.526 0.755 0 O-C-N 123.383 0.427 . . . . 0.0 113.177 -177.172 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 16.0 m -122.62 139.11 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 C-N-CA 123.826 0.85 . . . . 0.0 110.871 178.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 19.4 tp -74.82 113.47 12.14 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 123.522 0.514 . . . . 0.0 109.968 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.443 HD13 ' HG3' ' A' ' 72' ' ' ARG . 34.5 pt -112.71 -177.17 0.82 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.733 0 C-N-CA 123.776 0.831 . . . . 0.0 109.883 178.019 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -133.04 100.77 4.98 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -178.377 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 70.2 mm-40 -119.26 -64.57 1.26 Allowed 'General case' 0 N--CA 1.477 0.897 0 CA-C-O 121.362 0.601 . . . . 0.0 109.491 177.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 70.8 mt . . . . . 0 N--CA 1.479 0.999 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.966 -173.853 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 29.8 m . . . . . 0 CA--C 1.54 0.579 0 CA-C-O 120.933 0.397 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 71.8 mtm180 -112.96 170.64 8.05 Favored 'General case' 0 C--O 1.243 0.727 0 C-N-CA 123.618 0.767 . . . . 0.0 110.119 177.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.9 tt -143.57 139.54 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.313 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 22.7 m-80 -88.2 100.16 12.76 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -84.0 109.89 17.99 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 C-N-CA 124.098 0.959 . . . . 0.0 109.187 -175.067 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 48.8 t -101.34 113.61 38.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.568 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -62.52 121.04 64.75 Favored Pre-proline 0 CA--C 1.547 0.835 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 177.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -71.91 -18.42 27.98 Favored 'Trans proline' 0 C--N 1.363 1.317 0 C-N-CA 122.344 2.029 . . . . 0.0 113.326 -172.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -92.94 -52.02 4.79 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.592 0.757 . . . . 0.0 110.881 -174.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 47.2 p -96.97 -29.08 13.88 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.638 0.775 . . . . 0.0 111.992 -176.175 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.34 4.41 55.07 Favored Glycine 0 N--CA 1.481 1.665 0 CA-C-O 119.272 -0.738 . . . . 0.0 114.388 176.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.9 mtmp? -63.19 108.0 1.17 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.528 0.731 . . . . 0.0 112.335 -173.669 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.2 t -90.62 116.47 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 C-N-CA 123.39 0.676 . . . . 0.0 109.378 176.742 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -144.59 139.4 28.09 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.329 0.652 . . . . 0.0 110.092 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 36.1 mt -79.76 133.84 28.87 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.885 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 -179.452 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.69 158.3 37.97 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 123.555 0.742 . . . . 0.0 111.441 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 32.6 mm-40 -92.15 121.43 33.69 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 177.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.0 mt -77.21 112.28 14.95 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 178.52 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -76.2 -51.98 11.01 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.086 0.954 . . . . 0.0 110.225 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -151.48 174.1 13.79 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 CA--C 1.543 0.698 0 C-N-CA 123.208 0.603 . . . . 0.0 110.727 177.072 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 43.0 pt . . . . . 0 N--CA 1.475 0.81 0 CA-C-O 122.083 0.944 . . . . 0.0 111.143 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.444 ' O ' ' HG3' ' A' ' 77' ' ' PRO . 57.5 mt -102.47 108.72 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 107.721 -1.215 . . . . 0.0 107.721 173.036 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.9 p -99.53 151.93 20.59 Favored 'General case' 0 C--O 1.241 0.614 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 174.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 73.0 ttt180 -67.2 128.27 35.77 Favored 'General case' 0 CA--C 1.546 0.793 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 176.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.81 11.46 70.6 Favored Glycine 0 C--N 1.338 0.691 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.827 -176.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.94 148.21 23.92 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-N 117.353 0.577 . . . . 0.0 110.112 176.405 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 61.6 t -84.11 114.63 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 171.406 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 28.8 m -104.46 144.73 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 C-N-CA 123.025 0.53 . . . . 0.0 109.686 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -91.68 127.85 37.29 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 175.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 49.5 p -128.8 -179.97 5.38 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -68.29 -19.17 64.68 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 122.854 0.461 . . . . 0.0 111.585 176.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 96.4 mt -90.35 -46.72 8.2 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.242 0.617 . . . . 0.0 109.804 178.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 162.99 -153.46 24.02 Favored Glycine 0 C--N 1.339 0.74 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.749 177.078 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -76.78 137.36 39.22 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 122.864 0.465 . . . . 0.0 110.284 176.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.4 t -132.03 142.65 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 122.957 0.503 . . . . 0.0 109.861 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.572 ' HG2' HD13 ' A' ' 88' ' ' ILE . 33.4 mmt180 -89.75 123.02 33.38 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 170.311 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 66.2 t -75.78 95.79 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 -179.404 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 60.8 p -78.84 -41.72 29.37 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 122.925 0.49 . . . . 0.0 111.179 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . 0.552 ' HB2' ' H ' ' A' ' 84' ' ' ASN . 50.3 m -91.42 115.1 27.76 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.0 176.254 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 7.3 tmm_? -55.75 135.22 72.2 Favored Pre-proline 0 CA--C 1.563 1.453 0 C-N-CA 125.099 1.359 . . . . 0.0 110.188 177.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.444 ' HG3' ' O ' ' A' ' 58' ' ' ILE . 36.9 Cg_endo -60.85 129.69 30.01 Favored 'Trans proline' 0 C--N 1.377 2.068 0 C-N-CA 123.026 2.484 . . . . 0.0 112.398 -177.343 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 115.23 -18.55 15.81 Favored Glycine 0 C--N 1.34 0.791 0 CA-C-O 119.678 -0.512 . . . . 0.0 112.688 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -67.74 98.3 0.7 Allowed 'General case' 0 C--N 1.355 0.842 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 177.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 74.33 -2.47 2.8 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 125.754 1.621 . . . . 0.0 112.083 -174.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.93 -0.42 82.19 Favored Glycine 0 C--N 1.348 1.233 0 C-N-CA 123.082 0.372 . . . . 0.0 112.469 -178.04 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -115.37 148.59 17.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 124.464 1.106 . . . . 0.0 109.671 175.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 35.6 mt -104.44 145.36 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 C-N-CA 123.081 0.553 . . . . 0.0 109.601 173.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.552 ' H ' ' HB2' ' A' ' 75' ' ' SER . 42.9 m-20 -130.19 154.86 47.11 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 174.345 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.87 -178.06 37.16 Favored Glycine 0 C--N 1.336 0.579 0 CA-C-O 119.825 -0.43 . . . . 0.0 112.837 -177.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.18 136.93 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 123.306 0.642 . . . . 0.0 110.739 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 45.7 tp -66.13 124.68 23.27 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 122.862 0.465 . . . . 0.0 111.753 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.572 HD13 ' HG2' ' A' ' 72' ' ' ARG . 45.4 pt -119.59 164.99 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 CA-C-O 121.586 0.708 . . . . 0.0 109.788 168.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . 0.421 HH11 ' N ' ' A' ' 89' ' ' ARG . 0.0 OUTLIER -130.92 88.27 2.59 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -175.106 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -101.24 -64.63 1.03 Allowed 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 63.3 mt . . . . . 0 CA--C 1.54 0.581 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.371 174.68 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 28.0 m . . . . . 0 CA--C 1.541 0.607 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 24.6 mmt85 -116.72 147.78 41.69 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 123.994 0.917 . . . . 0.0 111.409 -170.093 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.6 tt -148.63 142.2 18.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-N 114.185 -1.37 . . . . 0.0 108.527 -178.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . 0.558 ' ND2' HG23 ' A' ' 82' ' ' VAL . 29.4 m-80 -93.89 100.65 12.78 Favored 'General case' 0 C--O 1.241 0.644 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 175.532 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 87.5 t -91.71 116.57 33.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.439 0 CA-C-N 114.353 -1.294 . . . . 0.0 108.461 -176.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.447 HG22 HG22 ' A' ' 35' ' ' VAL . 35.0 t -98.51 109.88 24.84 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.366 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -62.86 117.69 34.83 Favored Pre-proline 0 CA--C 1.548 0.891 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 172.472 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -66.1 -31.94 44.52 Favored 'Trans proline' 0 C--N 1.366 1.475 0 C-N-CA 122.698 2.265 . . . . 0.0 113.269 -170.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -94.33 -46.15 7.17 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 123.179 0.592 . . . . 0.0 110.857 -175.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.6 m -84.87 -29.34 25.34 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.125 0.57 . . . . 0.0 111.006 -173.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.66 5.96 73.86 Favored Glycine 0 C--N 1.345 1.038 0 CA-C-O 119.567 -0.574 . . . . 0.0 113.976 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 95.6 mttt -60.12 106.08 0.47 Allowed 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.052 0.541 . . . . 0.0 111.228 178.042 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.447 HG22 HG22 ' A' ' 28' ' ' VAL . 61.6 t -94.47 107.84 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 168.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -137.0 137.67 39.68 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 122.799 0.439 . . . . 0.0 109.944 -171.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 37.9 mt -75.74 99.14 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 177.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.458 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -89.45 157.4 18.14 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 123.737 0.815 . . . . 0.0 111.503 175.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -107.33 122.41 46.51 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.804 0.842 . . . . 0.0 109.179 178.466 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 64.7 mt -78.0 115.44 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 123.363 0.665 . . . . 0.0 110.845 -171.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 35.1 mmt180 -78.15 -53.78 6.98 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.417 1.087 . . . . 0.0 110.42 178.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 49.5 m-80 -131.54 153.88 49.39 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 123.666 0.786 . . . . 0.0 110.043 -175.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.459 ' HA ' HG12 ' A' ' 64' ' ' VAL . 33.7 m . . . . . 0 N--CA 1.475 0.808 0 C-N-CA 124.117 0.967 . . . . 0.0 110.97 177.621 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 2.0 pp . . . . . 0 CA--C 1.54 0.589 0 CA-C-O 120.943 0.402 . . . . 0.0 110.116 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.7 mt -102.34 130.68 51.84 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 C-N-CA 124.495 1.118 . . . . 0.0 109.162 -179.308 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 35.2 p -123.73 156.1 36.63 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.499 0.719 . . . . 0.0 109.737 177.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 60.5 ttt180 -74.71 123.51 25.04 Favored 'General case' 0 CA--C 1.544 0.715 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -178.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.99 4.19 67.27 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.086 -173.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.62 158.69 22.93 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.146 0.473 . . . . 0.0 110.737 175.837 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 68.8 t -97.26 111.24 26.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 171.752 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.459 HG12 ' HA ' ' A' ' 43' ' ' VAL . 29.6 m -108.38 137.97 37.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 173.726 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -91.16 142.32 27.87 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.109 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.458 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 61.7 p -128.07 178.76 5.99 Favored 'General case' 0 C--O 1.246 0.898 0 C-N-CA 124.146 0.979 . . . . 0.0 109.144 179.481 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -57.92 -25.72 61.26 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 123.584 0.754 . . . . 0.0 111.571 173.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 75.0 mt -83.52 -49.48 9.21 Favored 'General case' 0 C--N 1.351 0.632 0 C-N-CA 123.526 0.73 . . . . 0.0 109.244 178.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 161.01 -163.89 34.51 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-N 115.27 -0.877 . . . . 0.0 111.394 -177.065 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 -75.46 139.08 42.04 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-O 121.084 0.469 . . . . 0.0 110.148 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 83.9 t -133.72 144.59 35.37 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 C-N-CA 125.096 1.358 . . . . 0.0 109.272 -171.18 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.747 ' HG2' HD13 ' A' ' 88' ' ' ILE . 7.0 mmt85 -96.33 122.43 39.21 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 171.603 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 47.2 t -70.57 109.09 2.76 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.438 HG21 HG13 ' A' ' 86' ' ' VAL . 44.6 p -90.48 -30.45 17.3 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.13 0.572 . . . . 0.0 110.986 -171.078 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 25.9 t -113.71 -169.9 1.6 Allowed 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.871 0.868 . . . . 0.0 109.416 -178.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 18.4 mtp180 -70.11 144.57 92.81 Favored Pre-proline 0 CA--C 1.554 1.104 0 C-N-CA 123.432 0.693 . . . . 0.0 110.711 174.724 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.407 ' HA ' HG12 ' A' ' 83' ' ' ILE . 88.3 Cg_endo -78.8 162.02 27.05 Favored 'Trans proline' 0 C--N 1.366 1.486 0 C-N-CA 122.307 2.004 . . . . 0.0 112.29 173.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.437 ' H ' HG12 ' A' ' 83' ' ' ILE . . . 57.4 -89.18 0.02 OUTLIER Glycine 0 C--N 1.346 1.089 0 CA-C-N 115.635 -0.712 . . . . 0.0 113.283 -175.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . 0.257 12.3 pt20 53.23 -66.41 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 C-N-CA 127.74 2.416 . . . . 0.0 114.328 -178.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -146.38 41.75 1.16 Allowed 'General case' 0 N--CA 1.476 0.854 0 CA-C-O 122.255 1.026 . . . . 0.0 108.518 178.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 64.47 16.99 61.51 Favored Glycine 0 C--N 1.351 1.377 0 CA-C-N 115.026 -0.988 . . . . 0.0 113.061 -173.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.558 HG23 ' ND2' ' A' ' 26' ' ' ASN . 3.8 p -132.69 88.92 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 CA-C-O 122.595 1.188 . . . . 0.0 110.074 -174.031 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.437 HG12 ' H ' ' A' ' 78' ' ' GLY . 34.2 mt -83.31 149.06 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 171.273 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -118.04 143.67 46.23 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 172.156 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.7 179.49 30.75 Favored Glycine 0 C--N 1.336 0.539 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.829 178.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.438 HG13 HG21 ' A' ' 74' ' ' THR . 15.7 m -129.36 137.34 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 C-N-CA 123.784 0.834 . . . . 0.0 110.235 174.536 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.16 105.71 3.5 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 122.655 0.382 . . . . 0.0 110.082 -178.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.747 HD13 ' HG2' ' A' ' 72' ' ' ARG . 39.1 pt -96.83 168.07 1.63 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.588 0 CA-C-O 121.583 0.706 . . . . 0.0 110.477 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 84.3 mtt180 -127.96 26.91 5.77 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.936 177.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -58.12 -62.91 1.48 Allowed 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 172.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.0 mt . . . . . 0 C--N 1.333 -0.129 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 158.031 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.448 HG22 HD12 ' A' ' 40' ' ' ILE . 34.1 m . . . . . 0 C--O 1.243 0.723 0 CA-C-O 121.474 0.654 . . . . 0.0 110.903 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.453 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 99.0 mtt180 -128.9 175.36 8.71 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-N 114.867 -1.06 . . . . 0.0 111.148 -176.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 14.3 tt -144.97 148.16 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.932 0.893 . . . . 0.0 109.347 -173.08 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -90.61 102.95 15.69 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 174.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 97.2 t -87.87 113.3 24.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 124.1 0.96 . . . . 0.0 108.904 -178.675 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.464 HG22 HG22 ' A' ' 35' ' ' VAL . 26.3 t -98.83 103.88 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.722 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -53.85 107.93 0.99 Allowed Pre-proline 0 CA--C 1.544 0.713 0 C-N-CA 123.677 0.791 . . . . 0.0 108.981 167.442 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -69.09 -24.21 33.0 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.273 1.982 . . . . 0.0 113.022 -174.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -80.41 -50.4 10.16 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 123.213 0.605 . . . . 0.0 111.13 -177.014 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 40.9 p -94.21 -9.69 35.42 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -178.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.03 -3.18 66.29 Favored Glycine 0 N--CA 1.478 1.476 0 N-CA-C 114.166 0.426 . . . . 0.0 114.166 178.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -75.1 125.34 28.73 Favored 'General case' 0 N--CA 1.479 1.013 0 C-N-CA 123.774 0.83 . . . . 0.0 112.932 -170.209 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.464 HG22 HG22 ' A' ' 28' ' ' VAL . 17.1 t -104.03 135.4 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 123.535 0.734 . . . . 0.0 109.549 177.685 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -146.77 146.53 30.31 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.503 0.721 . . . . 0.0 109.41 174.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 49.2 mt -78.15 100.71 3.39 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 174.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -92.72 153.82 18.69 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.294 0.638 . . . . 0.0 111.331 176.029 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.453 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 36.8 mt-10 -93.34 123.17 36.45 Favored 'General case' 0 C--O 1.244 0.804 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -178.29 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.448 HD12 HG22 ' A' ' 23' ' ' THR . 53.4 mt -74.93 112.26 12.13 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.85 0 O-C-N 123.43 0.456 . . . . 0.0 109.974 -175.602 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.6 mtp180 -77.24 -53.86 7.2 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 124.188 0.995 . . . . 0.0 111.036 178.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.532 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 53.8 t30 -134.81 146.58 49.44 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.032 -172.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.4 m . . . . . 0 N--CA 1.481 1.096 0 C-N-CA 123.625 0.77 . . . . 0.0 111.638 178.551 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 10.7 tp . . . . . 0 C--O 1.243 0.749 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 55.5 mt -93.83 130.06 43.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 173.225 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 76.2 p -117.15 159.26 22.89 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.222 0.609 . . . . 0.0 110.005 -176.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 77.7 ttt180 -74.4 115.43 13.91 Favored 'General case' 0 CA--C 1.546 0.813 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.047 -177.335 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.84 6.12 49.81 Favored Glycine 0 N--CA 1.47 0.959 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.78 -177.284 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.25 162.24 25.81 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.118 0.567 . . . . 0.0 111.014 -178.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.0 t -103.3 110.61 30.31 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 174.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.6 m -105.82 142.52 18.67 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 176.049 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.532 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 34.8 tt0 -92.24 134.84 34.51 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 176.522 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 51.4 p -129.99 179.99 5.55 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 123.926 0.89 . . . . 0.0 108.87 178.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -76.1 -1.47 26.19 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 122.52 0.328 . . . . 0.0 111.336 175.066 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 82.8 mt -106.36 -9.07 16.91 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.704 0.802 . . . . 0.0 111.065 171.542 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 120.62 -166.04 13.85 Favored Glycine 0 C--N 1.351 1.393 0 C-N-CA 122.826 0.251 . . . . 0.0 113.018 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 20.2 m120 -77.64 137.87 38.78 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 123.01 0.524 . . . . 0.0 110.745 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.1 t -133.85 142.24 41.88 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.001 0 C-N-CA 124.727 1.211 . . . . 0.0 110.546 -171.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.669 ' HG2' HG21 ' A' ' 88' ' ' ILE . 30.0 mmt180 -85.15 132.34 34.31 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 170.646 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 45.6 t -76.94 106.52 6.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 172.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.463 HG21 HG13 ' A' ' 86' ' ' VAL . 74.1 p -95.93 -32.55 12.56 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 121.562 0.696 . . . . 0.0 110.629 -170.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.1 t -92.38 174.41 7.31 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.925 175.175 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 85.0 mtp180 -75.73 114.89 40.97 Favored Pre-proline 0 CA--C 1.546 0.802 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 171.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -62.46 112.93 1.73 Allowed 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 123.415 2.743 . . . . 0.0 113.084 -171.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.96 36.99 26.77 Favored Glycine 0 C--N 1.348 1.196 0 CA-C-N 115.388 -0.824 . . . . 0.0 112.245 -178.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 57.4 tp60 -70.7 -49.89 42.29 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.283 0.633 . . . . 0.0 109.946 179.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -121.39 56.15 1.05 Allowed 'General case' 0 N--CA 1.482 1.146 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 175.668 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 67.12 -16.98 0.3 Allowed Glycine 0 CA--C 1.538 1.52 0 N-CA-C 115.412 0.925 . . . . 0.0 115.412 -173.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 13.7 p -119.93 151.75 22.57 Favored 'Isoleucine or valine' 0 C--O 1.243 0.711 0 C-N-CA 124.229 1.012 . . . . 0.0 110.756 -171.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 28.3 mt -109.25 143.34 19.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 114.935 -1.03 . . . . 0.0 108.61 174.077 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -124.21 152.63 42.69 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 122.967 0.507 . . . . 0.0 109.647 172.662 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.5 -176.7 35.73 Favored Glycine 0 C--N 1.344 1.011 0 CA-C-N 115.323 -0.853 . . . . 0.0 112.956 -175.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.463 HG13 HG21 ' A' ' 74' ' ' THR . 27.7 m -130.33 144.24 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 123.317 0.647 . . . . 0.0 110.242 178.039 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.9 tp -72.14 126.86 30.84 Favored 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.585 -178.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.669 HG21 ' HG2' ' A' ' 72' ' ' ARG . 12.7 pt -125.21 171.31 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.189 0 C-N-CA 123.919 0.887 . . . . 0.0 110.319 -178.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 93.0 mtt180 -120.94 71.24 0.93 Allowed 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.424 0.69 . . . . 0.0 109.257 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 21.4 mm-40 -93.47 -78.74 0.42 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 122.86 0.464 . . . . 0.0 110.244 179.387 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 35.5 mt . . . . . 0 N--CA 1.468 0.429 0 C-N-CA 123.868 0.867 . . . . 0.0 109.057 -170.261 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.469 HG22 HD12 ' A' ' 40' ' ' ILE . 14.1 m . . . . . 0 CA--C 1.555 1.143 0 CA-C-O 120.509 0.195 . . . . 0.0 110.763 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 14.3 mmt180 -113.34 145.54 40.92 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.997 0.919 . . . . 0.0 110.929 -177.577 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 17.5 tt -140.26 145.73 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 123.48 0.712 . . . . 0.0 110.674 -177.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -93.08 102.86 15.19 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 171.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.6 t -88.79 106.95 17.27 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 C-N-CA 123.972 0.909 . . . . 0.0 109.185 -176.505 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.402 HG13 HG22 ' A' ' 35' ' ' VAL . 61.8 t -95.85 100.53 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -62.47 111.78 5.32 Favored Pre-proline 0 CA--C 1.547 0.834 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 172.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -71.84 -22.83 23.02 Favored 'Trans proline' 0 C--N 1.365 1.401 0 C-N-CA 122.295 1.997 . . . . 0.0 113.648 -165.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -95.66 -44.16 7.59 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 122.802 0.441 . . . . 0.0 112.166 -176.058 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 44.4 p -87.17 -25.34 24.11 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 122.465 0.306 . . . . 0.0 111.376 -178.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.12 6.57 74.91 Favored Glycine 0 C--N 1.348 1.213 0 CA-C-O 119.35 -0.694 . . . . 0.0 114.04 179.028 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -71.87 107.15 4.5 Favored 'General case' 0 CA--C 1.544 0.714 0 CA-C-N 117.406 0.603 . . . . 0.0 111.016 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.402 HG22 HG13 ' A' ' 28' ' ' VAL . 40.7 t -97.19 109.61 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 174.275 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -136.02 137.59 41.34 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.336 0.654 . . . . 0.0 109.723 -171.652 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 62.1 mt -77.14 131.46 34.74 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.568 0 C-N-CA 123.547 0.739 . . . . 0.0 109.113 179.204 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.471 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -131.04 165.02 24.13 Favored 'General case' 0 C--O 1.241 0.612 0 C-N-CA 123.544 0.738 . . . . 0.0 111.061 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -103.79 116.85 33.06 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 114.633 -1.167 . . . . 0.0 108.682 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.469 HD12 HG22 ' A' ' 23' ' ' THR . 62.9 mt -76.88 110.05 12.03 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.4 mtm180 -82.26 -39.58 22.81 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.822 178.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.501 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 93.7 m-20 -128.26 129.53 46.53 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.445 0.698 . . . . 0.0 109.949 -178.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.479 1.006 0 C-N-CA 123.92 0.888 . . . . 0.0 109.809 173.618 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.6 mt . . . . . 0 CA--C 1.546 0.805 0 CA-C-O 121.306 0.574 . . . . 0.0 109.517 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 79.9 mt -83.17 134.1 27.65 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.484 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 177.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 59.2 p -117.5 166.24 12.59 Favored 'General case' 0 C--O 1.242 0.679 0 C-N-CA 122.949 0.5 . . . . 0.0 110.873 -176.47 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.405 ' HA ' ' O ' ' A' ' 73' ' ' VAL . 57.3 mtt180 -70.89 127.13 31.56 Favored 'General case' 0 C--N 1.349 0.55 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 175.342 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.47 -6.13 77.69 Favored Glycine 0 C--N 1.341 0.812 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.823 -175.752 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.76 139.54 38.41 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 117.28 0.54 . . . . 0.0 110.519 177.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.465 HG13 HD11 ' A' ' 88' ' ' ILE . 48.6 t -89.63 118.54 35.11 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 C-N-CA 123.43 0.692 . . . . 0.0 110.122 178.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.4 m -104.15 151.46 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 O-C-N 121.603 -0.685 . . . . 0.0 109.331 171.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.501 ' HB3' ' HB2' ' A' ' 42' ' ' ASN . 34.2 tt0 -102.84 134.09 46.83 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 176.834 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.471 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 60.0 p -132.28 -176.74 4.18 Favored 'General case' 0 C--O 1.243 0.762 0 C-N-CA 123.665 0.786 . . . . 0.0 109.379 -179.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -76.69 -8.26 56.92 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.846 175.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 58.4 mt -97.02 -14.96 21.29 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 123.58 0.752 . . . . 0.0 110.653 174.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 120.94 -156.97 16.04 Favored Glycine 0 C--N 1.347 1.141 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.742 -176.193 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.409 ' O ' HD12 ' A' ' 87' ' ' LEU . 18.9 m120 -80.4 138.87 36.7 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 122.993 0.517 . . . . 0.0 111.48 179.388 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.9 t -125.87 135.17 64.72 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 C-N-CA 123.83 0.852 . . . . 0.0 109.82 178.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.643 ' HG2' HD13 ' A' ' 88' ' ' ILE . 10.9 mmt-85 -83.19 114.77 21.58 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 167.629 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 60' ' ' ARG . 45.3 t -80.03 96.45 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.9 p -78.67 -22.1 47.28 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 123.951 0.9 . . . . 0.0 110.897 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 49.3 m -95.92 -169.08 1.87 Allowed 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.926 0.89 . . . . 0.0 110.886 176.289 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -108.05 156.43 38.31 Favored Pre-proline 0 CA--C 1.547 0.848 0 C-N-CA 123.288 0.635 . . . . 0.0 109.652 173.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.449 ' HA ' HG12 ' A' ' 83' ' ' ILE . 68.5 Cg_endo -71.41 132.02 19.98 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.085 1.857 . . . . 0.0 111.946 178.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.412 ' H ' HG12 ' A' ' 83' ' ' ILE . . . 72.84 12.52 78.64 Favored Glycine 0 C--N 1.35 1.315 0 CA-C-O 119.571 -0.572 . . . . 0.0 114.331 174.737 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -74.28 134.1 42.62 Favored 'General case' 0 C--N 1.351 0.666 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.2 t70 68.08 -3.65 1.2 Allowed 'General case' 0 CA--C 1.565 1.537 0 C-N-CA 123.642 0.777 . . . . 0.0 111.579 -179.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 122.18 -13.93 8.95 Favored Glycine 0 C--N 1.355 1.623 0 CA-C-O 119.23 -0.761 . . . . 0.0 113.735 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.4 p -148.77 163.91 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 CA-C-N 118.469 1.134 . . . . 0.0 111.377 -179.006 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.449 HG12 ' HA ' ' A' ' 77' ' ' PRO . 10.0 mt -83.8 149.37 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 175.281 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 27.5 m-80 -140.17 152.96 46.45 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 122.775 0.43 . . . . 0.0 110.173 -178.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -170.8 -170.33 34.89 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-O 119.98 -0.345 . . . . 0.0 113.061 179.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.7 m -126.07 136.81 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 124.096 0.958 . . . . 0.0 110.943 179.098 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.409 HD12 ' O ' ' A' ' 70' ' ' ASN . 18.9 tp -72.26 127.02 31.26 Favored 'General case' 0 N--CA 1.483 1.221 0 CA-C-O 120.852 0.358 . . . . 0.0 111.602 -174.327 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.643 HD13 ' HG2' ' A' ' 72' ' ' ARG . 7.8 pt -118.67 170.32 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 C-N-CA 124.79 1.236 . . . . 0.0 109.488 177.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 12.8 mmt180 -118.56 19.88 13.15 Favored 'General case' 0 N--CA 1.486 1.371 0 C-N-CA 122.738 0.415 . . . . 0.0 110.535 -169.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -50.43 -75.84 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.876 0 C-N-CA 124.422 1.089 . . . . 0.0 113.85 -164.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.6 mt . . . . . 0 C--O 1.24 0.576 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -178.915 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.1 m . . . . . 0 C--O 1.243 0.737 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 12.9 tpp85 -113.28 136.16 53.05 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 123.477 0.711 . . . . 0.0 110.64 -175.113 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.8 tt -133.89 144.11 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 123.398 0.679 . . . . 0.0 110.451 177.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -93.98 107.85 19.72 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 171.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.407 HG22 HG21 ' A' ' 71' ' ' VAL . 86.6 t -91.63 108.37 19.91 Favored 'Isoleucine or valine' 0 C--O 1.241 0.654 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 -177.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 35' ' ' VAL . 51.6 t -107.32 99.27 8.24 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.128 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -59.02 116.55 16.14 Favored Pre-proline 0 CA--C 1.55 0.964 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 174.134 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_endo -73.79 -23.62 16.41 Favored 'Trans proline' 0 C--N 1.366 1.495 0 C-N-CA 122.279 1.986 . . . . 0.0 114.007 -171.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.47 ' HG3' HG23 ' A' ' 32' ' ' THR . 12.9 pt-20 -91.57 -50.33 5.83 Favored 'General case' 0 N--CA 1.479 0.975 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -176.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.47 HG23 ' HG3' ' A' ' 31' ' ' GLU . 75.3 p -91.38 -33.02 15.44 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 122.7 0.4 . . . . 0.0 111.452 -176.616 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.11 21.35 23.14 Favored Glycine 0 C--N 1.344 1.017 0 CA-C-O 119.292 -0.727 . . . . 0.0 114.106 177.23 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.0 mttp -56.92 106.48 0.31 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 117.364 0.582 . . . . 0.0 109.711 168.374 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.515 HG22 HG13 ' A' ' 28' ' ' VAL . 54.9 t -108.46 97.71 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 172.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -143.51 144.6 32.04 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 123.558 0.743 . . . . 0.0 109.295 -176.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 23.0 mt -85.43 133.21 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.43 173.43 10.85 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.283 1.433 . . . . 0.0 109.61 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -122.84 141.19 52.13 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 174.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 75.7 mt -83.03 114.16 23.4 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 C-N-CA 123.02 0.528 . . . . 0.0 110.041 -176.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 47.1 mtp180 -76.62 -49.6 15.85 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.13 0.972 . . . . 0.0 110.114 179.536 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -143.65 166.9 23.55 Favored 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.802 0.841 . . . . 0.0 108.951 -179.476 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.9 p . . . . . 0 N--CA 1.475 0.821 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 170.325 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.1 mm . . . . . 0 N--CA 1.474 0.734 0 CA-C-O 121.679 0.752 . . . . 0.0 109.193 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 75.6 mt -100.11 122.8 52.44 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 114.359 -1.291 . . . . 0.0 109.276 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 41.5 p -121.52 168.19 12.0 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 124.366 1.066 . . . . 0.0 109.284 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 59.0 ttp180 -74.59 130.26 39.24 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 176.137 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.36 -0.16 68.14 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 115.752 -0.658 . . . . 0.0 113.251 -172.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.3 149.94 35.29 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 122.812 0.445 . . . . 0.0 110.964 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.0 t -99.41 110.4 26.55 Favored 'Isoleucine or valine' 0 C--O 1.244 0.765 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 173.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.1 m -104.83 142.25 18.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.228 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -101.79 120.32 40.18 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -178.411 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 38.5 p -125.14 179.13 5.19 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.313 0.645 . . . . 0.0 109.466 -173.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 23.2 p-10 -68.79 -14.92 63.33 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 123.008 0.523 . . . . 0.0 111.038 178.151 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.9 mt -93.51 -46.76 7.16 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.309 0.644 . . . . 0.0 109.501 175.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 159.18 -154.95 26.03 Favored Glycine 0 C--N 1.344 0.977 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.891 175.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -77.04 130.17 37.06 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.902 0.481 . . . . 0.0 110.615 178.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.407 HG21 HG22 ' A' ' 27' ' ' VAL . 36.9 t -128.18 140.47 49.1 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.871 0 C-N-CA 124.463 1.105 . . . . 0.0 109.355 -178.321 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.587 ' HG2' HD13 ' A' ' 88' ' ' ILE . 7.3 mmt-85 -85.57 131.59 34.33 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 170.076 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 59.0 t -76.16 110.13 10.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 173.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 68.9 p -101.54 -42.75 6.12 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 121.207 0.527 . . . . 0.0 109.737 -173.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 20.3 m -94.33 136.97 34.03 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.622 172.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 17.4 mtp180 -60.25 132.39 90.28 Favored Pre-proline 0 CA--C 1.553 1.067 0 O-C-N 124.047 0.842 . . . . 0.0 110.743 -178.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.411 ' HA ' HG12 ' A' ' 83' ' ' ILE . 76.2 Cg_exo -52.73 116.9 3.19 Favored 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 123.807 3.005 . . . . 0.0 114.847 -176.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.46 20.59 71.49 Favored Glycine 0 C--N 1.348 1.206 0 N-CA-C 115.491 0.956 . . . . 0.0 115.491 166.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -73.44 -48.16 35.87 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-N 118.111 0.955 . . . . 0.0 110.521 177.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -85.87 -3.44 58.92 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 123.401 0.68 . . . . 0.0 110.888 170.708 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 111.85 -9.12 27.65 Favored Glycine 0 C--O 1.219 -0.782 0 N-CA-C 111.97 -0.452 . . . . 0.0 111.97 -178.594 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.6 p -140.63 163.81 22.19 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.895 0 C-N-CA 123.34 0.656 . . . . 0.0 109.931 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.411 HG12 ' HA ' ' A' ' 77' ' ' PRO . 23.3 mt -91.99 147.39 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 172.273 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -130.92 156.69 44.64 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 171.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -169.74 -172.86 36.73 Favored Glycine 0 C--N 1.344 1.027 0 N-CA-C 114.172 0.429 . . . . 0.0 114.172 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 31.2 m -123.92 135.95 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 C-N-CA 123.694 0.798 . . . . 0.0 111.119 -179.472 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.0 tp -74.04 117.17 15.52 Favored 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.459 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.587 HD13 ' HG2' ' A' ' 72' ' ' ARG . 12.4 pt -116.22 168.75 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 124.191 0.997 . . . . 0.0 111.394 -169.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 17.1 mmt180 -112.55 92.09 3.89 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -121.42 -75.62 0.59 Allowed 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 123.278 0.631 . . . . 0.0 111.417 -173.492 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 39.5 mt . . . . . 0 N--CA 1.473 0.676 0 C-N-CA 123.331 0.652 . . . . 0.0 110.261 -168.767 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.8 m . . . . . 0 N--CA 1.477 0.909 0 CA-C-O 121.227 0.536 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.579 HH11 ' HG3' ' A' ' 24' ' ' ARG . 4.1 ttm-85 -119.65 170.17 9.43 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.049 -178.163 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.3 tt -136.69 140.68 42.7 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 CA-C-O 121.251 0.548 . . . . 0.0 111.194 -175.134 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.5 m-80 -92.05 100.71 13.3 Favored 'General case' 0 C--O 1.242 0.664 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 175.332 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 99.5 t -92.78 114.27 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 C-N-CA 123.734 0.813 . . . . 0.0 109.91 -173.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 35' ' ' VAL . 38.8 t -103.89 120.74 54.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 123.627 0.771 . . . . 0.0 109.103 -178.188 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -58.68 117.25 19.31 Favored Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 167.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.8 -17.66 28.98 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 121.867 1.711 . . . . 0.0 111.348 170.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -78.5 -53.96 6.66 Favored 'General case' 0 CA--C 1.555 1.137 0 C-N-CA 123.489 0.715 . . . . 0.0 112.107 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 47.0 p -100.9 -26.66 13.67 Favored 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -176.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.37 7.23 65.5 Favored Glycine 0 N--CA 1.476 1.348 0 CA-C-O 119.964 -0.353 . . . . 0.0 112.927 -178.032 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.2 mmtt -73.57 142.68 46.62 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 123.39 0.676 . . . . 0.0 110.846 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 28' ' ' VAL . 25.1 t -118.55 122.12 68.72 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 123.417 0.687 . . . . 0.0 109.463 179.122 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -135.37 136.46 41.49 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 123.738 0.815 . . . . 0.0 109.015 178.038 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 56.8 mt -79.19 100.19 3.75 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.092 0 C-N-CA 123.258 0.623 . . . . 0.0 109.383 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -95.67 163.23 13.28 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 172.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.457 ' HA ' ' HG3' ' A' ' 24' ' ' ARG . 34.0 mt-10 -102.65 137.13 41.27 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -175.672 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 57.5 mt -80.36 110.29 15.76 Favored 'Isoleucine or valine' 0 C--N 1.355 0.806 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 177.323 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 14.1 mtp180 -79.15 -53.82 6.61 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 124.58 1.152 . . . . 0.0 109.535 179.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -148.84 165.75 30.57 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.911 -175.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 N--CA 1.48 1.068 0 C-N-CA 123.593 0.757 . . . . 0.0 111.694 -179.39 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 69.6 mt . . . . . 0 C--O 1.24 0.56 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.3 mt -82.13 142.68 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 171.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 67.5 p -119.19 166.48 12.91 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 123.536 0.734 . . . . 0.0 110.19 177.095 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 36.4 ttm105 -71.74 115.55 11.07 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 171.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.97 2.41 55.0 Favored Glycine 0 C--N 1.341 0.841 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.599 -174.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.81 132.71 34.38 Favored 'General case' 0 C--O 1.244 0.795 0 C-N-CA 122.875 0.47 . . . . 0.0 110.107 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.455 HG21 ' HG3' ' A' ' 90' ' ' GLU . 54.1 t -79.59 125.58 38.77 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.726 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 174.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 19.6 m -116.14 147.89 19.23 Favored 'Isoleucine or valine' 0 C--O 1.245 0.853 0 C-N-CA 123.885 0.874 . . . . 0.0 109.052 176.286 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -84.69 122.78 29.57 Favored 'General case' 0 N--CA 1.462 0.147 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -179.516 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 47.4 p -129.03 176.99 7.45 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -178.107 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 -65.82 -23.24 66.65 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 123.86 0.864 . . . . 0.0 111.362 177.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 85.1 mt -93.62 -38.61 11.26 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.122 0.569 . . . . 0.0 110.849 -179.148 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 152.22 -146.97 16.16 Favored Glycine 0 C--N 1.347 1.148 0 C-N-CA 121.573 -0.346 . . . . 0.0 113.175 174.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -68.38 109.18 3.53 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.008 0.923 . . . . 0.0 109.453 176.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 85.6 t -120.03 137.68 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 O-C-N 121.886 -0.509 . . . . 0.0 110.379 -179.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.487 ' HG3' HD11 ' A' ' 88' ' ' ILE . 31.1 mtt85 -105.08 129.77 53.43 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.669 0.387 . . . . 0.0 110.335 174.601 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.478 HG11 ' HG3' ' A' ' 77' ' ' PRO . 85.1 t -71.68 123.18 25.47 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 O-C-N 124.455 1.097 . . . . 0.0 110.259 -178.603 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.418 HG21 HG13 ' A' ' 86' ' ' VAL . 45.7 p -101.04 -22.28 14.78 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.971 0.908 . . . . 0.0 111.06 -174.89 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 20.7 t -105.11 -173.65 2.35 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 123.738 0.815 . . . . 0.0 110.268 -178.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 86.7 mtt180 -74.36 120.88 83.61 Favored Pre-proline 0 CA--C 1.544 0.717 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 168.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . 0.478 ' HG3' HG11 ' A' ' 73' ' ' VAL . 73.0 Cg_exo -54.32 102.17 0.08 OUTLIER 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 123.252 2.635 . . . . 0.0 112.98 178.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.497 ' N ' HG12 ' A' ' 83' ' ' ILE . . . 82.91 47.81 5.71 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.336 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 54.7 tp60 -64.93 -58.11 7.01 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 123.463 0.705 . . . . 0.0 110.405 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -98.31 16.49 21.35 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 123.616 0.766 . . . . 0.0 110.015 175.16 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 100.08 -20.99 46.62 Favored Glycine 0 C--N 1.35 1.31 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -173.08 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 14.1 p -110.92 158.31 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.542 1.137 . . . . 0.0 108.57 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.497 HG12 ' N ' ' A' ' 78' ' ' GLY . 8.7 mt -110.78 151.3 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 123.624 0.769 . . . . 0.0 109.828 -177.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 79.9 m-20 -118.31 148.13 42.77 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 172.172 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.7 -179.97 36.71 Favored Glycine 0 C--N 1.348 1.207 0 O-C-N 123.452 0.47 . . . . 0.0 113.136 -179.348 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.418 HG13 HG21 ' A' ' 74' ' ' THR . 11.9 m -124.48 136.81 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 123.642 0.777 . . . . 0.0 111.423 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 50.8 tp -78.82 105.96 10.5 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.403 0.681 . . . . 0.0 110.982 -177.446 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.487 HD11 ' HG3' ' A' ' 72' ' ' ARG . 30.4 pt -123.41 -172.92 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 123.889 0.875 . . . . 0.0 109.507 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -132.68 110.91 10.74 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.159 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.455 ' HG3' HG21 ' A' ' 63' ' ' VAL . 41.3 mm-40 -115.94 -60.8 1.82 Allowed 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.027 0.531 . . . . 0.0 110.135 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.2 mt . . . . . 0 N--CA 1.474 0.744 0 C-N-CA 122.888 0.475 . . . . 0.0 110.256 179.008 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.5 m . . . . . 0 CA--C 1.535 0.376 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -101.14 147.81 25.81 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.445 0.698 . . . . 0.0 109.392 -177.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 17.4 tt -146.61 151.17 14.38 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 122.972 0.509 . . . . 0.0 110.324 177.683 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -100.03 102.45 13.81 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 168.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.33 110.9 21.12 Favored 'Isoleucine or valine' 0 C--O 1.243 0.724 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 178.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 53.5 t -100.51 99.51 8.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -60.14 114.09 9.01 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 172.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -76.25 -8.21 18.48 Favored 'Trans proline' 0 C--N 1.369 1.647 0 C-N-CA 122.795 2.33 . . . . 0.0 113.136 -173.317 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -84.17 -53.97 5.14 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.251 0.621 . . . . 0.0 109.867 -172.175 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 58.6 p -99.57 -33.21 10.73 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 124.032 0.933 . . . . 0.0 111.449 177.719 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.4 10.33 36.32 Favored Glycine 0 N--CA 1.476 1.359 0 CA-C-O 119.828 -0.429 . . . . 0.0 113.272 -176.374 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.2 mmmt -66.12 113.67 4.68 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.654 0.782 . . . . 0.0 111.484 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 38.1 t -104.26 125.44 59.04 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 C-N-CA 123.731 0.813 . . . . 0.0 109.268 176.278 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.433 ' HB3' HD11 ' A' ' 68' ' ' LEU . 8.9 tp10 -135.26 140.33 45.12 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.605 0.762 . . . . 0.0 109.612 178.191 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 65.5 mt -79.78 118.37 27.21 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 169.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.07 169.59 11.04 Favored 'General case' 0 C--O 1.242 0.706 0 C-N-CA 124.129 0.972 . . . . 0.0 109.083 -175.049 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -102.89 128.88 49.49 Favored 'General case' 0 C--O 1.244 0.771 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.5 mt -74.39 110.37 8.51 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 175.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 42.8 ttt180 -72.43 -37.74 68.52 Favored 'General case' 0 C--O 1.237 0.425 0 C-N-CA 124.28 1.032 . . . . 0.0 110.492 -175.037 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -160.67 148.8 16.21 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.036 -0.984 . . . . 0.0 108.624 -173.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 64' ' ' VAL . 40.5 t . . . . . 0 C--O 1.243 0.753 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 178.635 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 50.8 mm . . . . . 0 C--O 1.243 0.74 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 57.5 mt -66.93 123.37 19.84 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.257 -0.883 . . . . 0.0 108.791 177.255 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 28.5 p -125.21 161.07 27.69 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 124.374 1.07 . . . . 0.0 109.648 -176.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 58.1 ttp180 -69.71 127.2 32.11 Favored 'General case' 0 CA--C 1.547 0.864 0 C-N-CA 123.26 0.624 . . . . 0.0 109.451 175.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.98 -16.33 58.49 Favored Glycine 0 C--N 1.346 1.113 0 CA-C-O 119.739 -0.478 . . . . 0.0 112.994 -173.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.36 153.05 30.06 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 122.732 0.413 . . . . 0.0 110.742 179.289 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.453 HG11 ' HG3' ' A' ' 90' ' ' GLU . 78.0 t -98.19 124.26 51.16 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 CA-C-N 115.888 -0.597 . . . . 0.0 109.762 175.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.559 HG12 HG13 ' A' ' 43' ' ' VAL . 21.8 m -118.97 138.46 49.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 123.853 0.861 . . . . 0.0 109.068 174.548 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -101.07 137.43 39.44 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.436 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.437 HG21 HG21 ' A' ' 25' ' ' ILE . 71.2 p -129.17 -173.09 2.89 Favored 'General case' 0 C--O 1.242 0.681 0 C-N-CA 123.671 0.788 . . . . 0.0 110.113 -169.592 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -68.36 -9.98 51.83 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 123.381 0.673 . . . . 0.0 111.768 173.281 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.433 HD11 ' HB3' ' A' ' 36' ' ' GLU . 85.1 mt -106.65 -46.24 4.03 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.775 0.83 . . . . 0.0 110.459 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 167.37 -164.51 37.96 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 116.546 -0.297 . . . . 0.0 112.359 175.171 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -73.1 139.46 46.48 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.178 0.591 . . . . 0.0 109.507 175.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 61.5 t -134.81 142.14 41.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.754 0.822 . . . . 0.0 110.331 -170.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.599 ' HG2' HD13 ' A' ' 88' ' ' ILE . 8.3 mmt-85 -93.38 124.9 37.69 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 171.032 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 51.7 t -76.35 97.49 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.213 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 p -79.7 -38.62 33.09 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.659 0.784 . . . . 0.0 112.121 -177.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . 0.487 ' HB3' ' HB2' ' A' ' 84' ' ' ASN . 23.2 t -90.55 -176.46 4.76 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.436 0.694 . . . . 0.0 110.457 179.804 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 59.6 mtt180 -83.59 113.6 48.08 Favored Pre-proline 0 CA--C 1.549 0.922 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.24 141.25 51.4 Favored 'Trans proline' 0 C--N 1.376 1.98 0 C-N-CA 123.254 2.636 . . . . 0.0 113.236 -171.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 83.13 18.91 63.81 Favored Glycine 0 C--N 1.347 1.142 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.112 177.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -70.68 103.21 2.48 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 63.53 41.49 7.32 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 124.168 0.987 . . . . 0.0 110.905 -174.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 61.05 33.61 84.73 Favored Glycine 0 C--N 1.339 0.737 0 CA-C-N 114.864 -1.062 . . . . 0.0 115.293 -175.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -143.31 141.47 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.591 0.71 . . . . 0.0 110.922 168.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.444 ' O ' ' HA ' ' A' ' 25' ' ' ILE . 2.0 mp -93.7 146.98 5.86 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 174.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.487 ' HB2' ' HB3' ' A' ' 75' ' ' SER . 2.6 m-20 -126.31 137.99 53.54 Favored 'General case' 0 N--CA 1.484 1.225 0 CA-C-N 118.971 0.805 . . . . 0.0 109.508 174.026 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.44 -175.06 34.03 Favored Glycine 0 C--N 1.345 1.073 0 CA-C-N 115.994 -0.548 . . . . 0.0 113.075 -175.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 34.5 m -127.47 142.89 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 C-N-CA 123.441 0.696 . . . . 0.0 110.78 -177.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.3 tp -68.28 130.99 44.54 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 123.159 0.583 . . . . 0.0 110.673 -178.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.599 HD13 ' HG2' ' A' ' 72' ' ' ARG . 19.5 pt -133.42 170.21 20.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 124.157 0.983 . . . . 0.0 110.04 -175.417 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 13.2 mmt-85 -111.4 95.09 5.31 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 176.267 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' GLU . . . . . 0.453 ' HG3' HG11 ' A' ' 63' ' ' VAL . 47.7 mm-40 -105.93 -62.1 1.42 Allowed 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 171.338 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 74.6 mt . . . . . 0 C--O 1.239 0.532 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.155 174.731 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.575 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -67.62 116.82 8.77 Favored 'General case' 0 C--O 1.243 0.76 0 C-N-CA 123.503 0.721 . . . . 0.0 109.867 177.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 30.2 mmm180 -85.58 75.81 10.09 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.83 0.824 . . . . 0.0 109.668 -179.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.6 ptp180 -75.88 102.06 5.39 Favored 'General case' 0 CA--C 1.548 0.889 0 CA-C-N 114.405 -1.27 . . . . 0.0 110.657 -176.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 58.9 t -87.75 118.63 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 CA-C-N 115.657 -0.702 . . . . 0.0 109.67 178.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 53.3 ttp180 -116.3 77.83 1.14 Allowed 'General case' 0 C--O 1.24 0.59 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 173.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 58.1 tp -76.56 97.43 4.37 Favored 'General case' 0 CA--C 1.541 0.626 0 CA-C-N 116.253 -0.43 . . . . 0.0 109.914 -177.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 37.0 mt -98.95 87.59 1.51 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.698 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 173.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 71.8 ttt180 -61.53 130.09 44.29 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.71 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 10.1 m -77.43 77.11 3.96 Favored 'General case' 0 CA--C 1.545 0.758 0 CA-C-O 121.744 0.783 . . . . 0.0 109.591 -177.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -87.47 112.28 22.03 Favored 'General case' 0 CA--C 1.544 0.747 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 -179.233 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 175.71 92.97 0.09 OUTLIER Glycine 0 C--N 1.345 1.076 0 O-C-N 123.619 0.574 . . . . 0.0 112.497 -177.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -112.93 -138.62 7.22 Favored Glycine 0 C--N 1.341 0.86 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 173.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.5 m120 -121.39 28.15 7.92 Favored 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 124.049 0.94 . . . . 0.0 109.763 177.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.1 p -65.36 108.53 1.98 Allowed 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 123.915 0.886 . . . . 0.0 111.27 -178.199 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 55.1 tttp -82.18 118.28 22.96 Favored 'General case' 0 C--O 1.238 0.487 0 C-N-CA 123.828 0.851 . . . . 0.0 109.644 177.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.6 p -166.4 155.13 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.908 0 C-N-CA 124.077 0.951 . . . . 0.0 109.203 -177.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 58.3 mtt180 -74.23 149.01 41.03 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 173.291 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.46 ' H ' HD23 ' A' ' 19' ' ' LEU . 1.8 pt? -48.43 100.09 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.135 0 C-N-CA 124.655 1.182 . . . . 0.0 113.404 -175.297 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -164.82 -55.97 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 124.86 1.264 . . . . 0.0 108.103 177.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 11.5 p -97.05 -10.85 25.3 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.723 0.809 . . . . 0.0 110.995 173.006 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . 0.4 ' O ' ' HA ' ' A' ' 19' ' ' LEU . 3.8 m-20 -148.27 94.44 2.31 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 124.643 1.177 . . . . 0.0 107.919 176.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.0 m -67.72 114.1 6.05 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 123.06 0.544 . . . . 0.0 109.709 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -106.95 144.97 32.81 Favored 'General case' 0 C--O 1.243 0.752 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 -177.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.9 tt -146.17 139.36 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.772 0 C-N-CA 123.589 0.756 . . . . 0.0 110.061 -178.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 -89.39 101.58 14.26 Favored 'General case' 0 C--O 1.239 0.543 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 175.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.2 t -87.29 110.17 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.8 t -98.22 100.24 10.2 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -61.2 112.29 5.61 Favored Pre-proline 0 CA--C 1.549 0.929 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 175.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -77.18 -17.78 14.77 Favored 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 122.268 1.979 . . . . 0.0 113.209 -168.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -96.87 -48.89 5.27 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 122.714 0.406 . . . . 0.0 110.996 178.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.534 HG21 ' HE3' ' A' ' 34' ' ' LYS . 2.8 m -90.93 -31.26 16.45 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.215 0.606 . . . . 0.0 111.581 -172.498 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 95.14 6.27 60.26 Favored Glycine 0 N--CA 1.476 1.316 0 CA-C-O 119.479 -0.623 . . . . 0.0 114.003 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.534 ' HE3' HG21 ' A' ' 32' ' ' THR . 92.1 mttt -63.78 106.72 1.04 Allowed 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 123.089 0.556 . . . . 0.0 110.839 177.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.6 t -103.93 106.86 21.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 175.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.503 ' HB3' HD11 ' A' ' 68' ' ' LEU . 10.3 tp10 -138.43 139.44 38.88 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 123.763 0.825 . . . . 0.0 109.812 -173.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 50.0 mt -83.15 100.85 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 176.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.8 173.24 7.41 Favored 'General case' 0 C--O 1.239 0.509 0 C-N-CA 123.962 0.905 . . . . 0.0 110.079 176.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -107.56 134.59 50.35 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 175.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 59.3 mt -75.57 110.26 10.23 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 173.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -82.01 -48.07 11.87 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.645 1.178 . . . . 0.0 110.236 -173.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -135.97 153.82 51.28 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 175.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.508 HG13 HG12 ' A' ' 64' ' ' VAL . 16.8 t -110.16 42.31 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.023 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 173.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.2 p -70.8 87.68 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.942 0 CA-C-N 114.129 -1.396 . . . . 0.0 110.02 177.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.401 ' HG2' ' H ' ' A' ' 63' ' ' VAL . 3.1 tm-20 -106.39 -50.35 3.16 Favored 'General case' 0 CA--C 1.536 0.427 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 171.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -129.21 -30.02 2.21 Favored 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.323 179.015 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.4 t -75.31 80.7 2.4 Favored 'General case' 0 CA--C 1.554 1.125 0 CA-C-O 122.386 1.089 . . . . 0.0 110.717 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.01 137.78 32.46 Favored 'General case' 0 C--O 1.24 0.557 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.589 -178.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 44.4 m-80 66.48 119.83 0.02 OUTLIER Pre-proline 0 N--CA 1.481 1.107 0 C-N-CA 125.507 1.523 . . . . 0.0 111.249 -176.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_exo -50.34 99.98 0.04 OUTLIER 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 123.34 2.694 . . . . 0.0 113.641 172.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 30.2 p-80 -121.05 73.12 1.01 Allowed 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 123.434 0.693 . . . . 0.0 109.692 175.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 61.6 t80 61.46 23.87 14.07 Favored 'General case' 0 N--CA 1.492 1.666 0 C-N-CA 124.3 1.04 . . . . 0.0 110.341 -178.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 16.3 m -100.12 137.14 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 O-C-N 121.333 -0.854 . . . . 0.0 111.418 -176.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 13.5 ptm180 -143.2 28.27 1.53 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 124.746 1.218 . . . . 0.0 108.44 174.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.409 ' HG2' ' H ' ' A' ' 57' ' ' ILE . 26.3 ttm180 -59.06 112.02 1.53 Allowed 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.353 1.061 . . . . 0.0 111.696 -174.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.3 t30 -107.51 31.27 5.55 Favored 'General case' 0 CA--C 1.556 1.182 0 CA-C-O 122.057 0.932 . . . . 0.0 109.157 175.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.409 ' H ' ' HG2' ' A' ' 55' ' ' ARG . 67.9 mt -81.96 84.79 1.64 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 169.333 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.4 mt -102.98 116.0 45.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 114.041 -1.436 . . . . 0.0 108.944 -174.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 39.4 p -117.54 162.89 17.26 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 123.631 0.772 . . . . 0.0 110.765 -176.358 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -67.02 135.66 54.07 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 123.006 0.522 . . . . 0.0 110.127 176.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.07 -2.94 85.77 Favored Glycine 0 C--N 1.344 0.991 0 O-C-N 123.595 0.56 . . . . 0.0 113.571 -175.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.02 145.79 30.04 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 117.283 0.541 . . . . 0.0 110.749 179.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.401 ' H ' ' HG2' ' A' ' 45' ' ' GLU . 50.8 t -90.1 112.17 24.33 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 172.067 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.508 HG12 HG13 ' A' ' 43' ' ' VAL . 26.5 m -107.42 159.6 6.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 174.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -102.6 137.46 40.8 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 172.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 30.6 p -133.46 -175.46 3.82 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.418 0.687 . . . . 0.0 109.797 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -60.59 -27.0 67.38 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 123.692 0.797 . . . . 0.0 111.889 175.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.503 HD11 ' HB3' ' A' ' 36' ' ' GLU . 74.1 mt -100.24 -0.67 38.15 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.269 0.628 . . . . 0.0 111.167 -175.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 112.06 -161.66 12.67 Favored Glycine 0 C--N 1.351 1.415 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.438 ' HA ' ' O ' ' A' ' 64' ' ' VAL . 17.5 m120 -73.69 138.14 44.52 Favored 'General case' 0 N--CA 1.477 0.889 0 CA-C-N 117.16 0.48 . . . . 0.0 111.568 -178.212 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 92.8 t -130.45 146.62 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 124.748 1.219 . . . . 0.0 110.126 -176.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.686 ' HG2' HD13 ' A' ' 88' ' ' ILE . 34.6 mmt180 -85.23 126.68 33.87 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 167.497 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 43.0 t -73.54 111.7 8.89 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 172.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 77.6 p -95.36 -21.92 18.07 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-O 120.981 0.42 . . . . 0.0 109.907 -175.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 23.3 t -107.23 -171.29 1.85 Allowed 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.453 1.101 . . . . 0.0 110.578 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.28 136.68 20.91 Favored Pre-proline 0 CA--C 1.547 0.851 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 169.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -59.75 103.83 0.21 Allowed 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.502 2.135 . . . . 0.0 111.314 173.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 130.2 -6.08 6.01 Favored Glycine 0 C--N 1.342 0.904 0 CA-C-O 119.1 -0.833 . . . . 0.0 113.46 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 16.9 mm100 -67.31 -71.8 0.19 Allowed 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 117.876 0.838 . . . . 0.0 110.502 177.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -89.27 30.84 0.94 Allowed 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 172.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 64.63 -74.66 0.07 OUTLIER Glycine 0 C--N 1.355 1.618 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 -160.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.9 p -57.87 156.17 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.255 0 C-N-CA 125.387 1.475 . . . . 0.0 112.095 174.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 39.3 mt -84.04 151.51 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 124.526 1.13 . . . . 0.0 108.232 175.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -138.0 158.03 45.15 Favored 'General case' 0 N--CA 1.482 1.155 0 CA-C-N 118.298 0.499 . . . . 0.0 110.211 167.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.68 -171.71 34.77 Favored Glycine 0 C--N 1.344 0.994 0 CA-C-N 115.427 -0.806 . . . . 0.0 113.124 -174.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.2 m -122.91 135.23 63.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 123.441 0.696 . . . . 0.0 110.256 178.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 30.8 tp -68.37 134.12 49.76 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 122.969 0.508 . . . . 0.0 110.176 -177.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.686 HD13 ' HG2' ' A' ' 72' ' ' ARG . 16.7 pt -132.02 167.21 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 123.81 0.844 . . . . 0.0 111.062 -175.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 62.5 mtt-85 -117.66 49.42 1.23 Allowed 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 123.71 0.804 . . . . 0.0 110.166 -175.077 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -68.2 -58.74 3.96 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.072 0.463 . . . . 0.0 110.515 177.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.78 166.8 11.47 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.112 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.416 ' HB3' ' HA ' ' A' ' 96' ' ' HIS . 7.8 mm-40 56.94 73.0 0.47 Allowed 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 125.723 1.609 . . . . 0.0 113.057 174.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 22.7 m-70 -97.04 -69.97 0.74 Allowed 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 123.916 0.886 . . . . 0.0 109.249 174.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 9.3 t-80 -81.5 -64.17 1.24 Allowed 'General case' 0 C--N 1.351 0.666 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 178.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 33.6 p80 -79.36 140.06 37.59 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 172.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . 0.416 ' HA ' ' HB3' ' A' ' 92' ' ' GLU . 80.6 m-70 -119.45 35.32 4.88 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 174.145 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 40.4 t60 -139.14 140.28 37.86 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.525 1.13 . . . . 0.0 108.686 178.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 50.8 p-80 . . . . . 0 CA--C 1.551 1.014 0 C-N-CA 124.382 1.073 . . . . 0.0 109.376 178.433 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.296 0 CA-C-O 119.693 -0.504 . . . . 0.0 112.226 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -158.67 153.11 24.25 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 123.178 0.591 . . . . 0.0 109.938 -176.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.16 84.5 4.38 Favored 'General case' 0 C--O 1.239 0.535 0 C-N-CA 123.513 0.725 . . . . 0.0 109.835 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 34.2 ttp180 -85.57 122.01 29.08 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.4 m -75.48 136.14 25.61 Favored 'Isoleucine or valine' 0 C--O 1.246 0.912 0 C-N-CA 123.144 0.578 . . . . 0.0 110.856 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -81.4 84.06 6.77 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 174.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . 0.414 HD12 ' HB2' ' A' ' 9' ' ' ARG . 0.3 OUTLIER -91.48 96.18 10.36 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 179.082 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 33.1 mm -74.17 80.86 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 175.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.414 ' HB2' HD12 ' A' ' 7' ' ' LEU . 20.0 tpt180 -88.69 97.2 10.99 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.32 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 58.8 p -86.08 107.26 17.74 Favored 'General case' 0 CA--C 1.539 0.549 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 175.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.53 ' HB2' ' HB3' ' A' ' 14' ' ' ASN . 1.9 ppt_? -68.78 -17.78 64.09 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -171.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 60.26 -128.08 45.11 Favored Glycine 0 C--N 1.346 1.094 0 O-C-N 123.456 0.472 . . . . 0.0 112.896 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -84.62 73.75 2.6 Favored Glycine 0 C--N 1.343 0.948 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 173.319 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . 0.53 ' HB3' ' HB2' ' A' ' 11' ' ' ARG . 18.5 p-10 -70.31 89.13 0.66 Allowed 'General case' 0 CA--C 1.548 0.894 0 CA-C-O 121.841 0.829 . . . . 0.0 111.299 -176.165 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 31.5 m -73.09 93.62 1.82 Allowed 'General case' 0 CA--C 1.543 0.701 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.378 177.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.518 ' HD2' HD12 ' A' ' 37' ' ' ILE . 24.5 ttmm -155.84 137.26 14.01 Favored 'General case' 0 C--O 1.241 0.647 0 C-N-CA 123.991 0.916 . . . . 0.0 109.383 -175.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 10.4 p -69.29 129.86 33.92 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.892 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 170.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.732 ' HB3' HG21 ' A' ' 82' ' ' VAL . 0.2 OUTLIER -71.72 -25.31 62.01 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 123.155 0.582 . . . . 0.0 111.294 -170.445 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.627 ' HB3' ' HB3' ' A' ' 24' ' ' ARG . 2.6 pp -155.42 137.77 14.88 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 123.252 0.621 . . . . 0.0 111.328 164.197 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -123.28 -45.1 2.11 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 172.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 38.2 t -72.2 139.32 48.13 Favored 'General case' 0 C--N 1.35 0.613 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 163.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -15.51 -63.35 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.019 0 C-N-CA 127.412 2.285 . . . . 0.0 116.224 -170.366 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.532 HG22 HD12 ' A' ' 40' ' ' ILE . 29.9 m -143.73 113.83 7.31 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 121.416 0.627 . . . . 0.0 109.906 -176.065 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.627 ' HB3' ' HB3' ' A' ' 19' ' ' LEU . 39.4 ttp180 -123.47 163.33 21.1 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 124.377 1.071 . . . . 0.0 108.265 177.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.1 tt -135.77 142.85 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.201 0.601 . . . . 0.0 110.183 -171.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.0 m-80 -84.98 102.5 13.23 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.6 t -95.2 107.93 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -172.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 42.1 t -93.58 103.09 14.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.428 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -64.24 116.68 29.85 Favored Pre-proline 0 CA--C 1.546 0.797 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 174.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.5 ' HG2' ' HG3' ' A' ' 31' ' ' GLU . 82.3 Cg_endo -73.33 -18.08 23.55 Favored 'Trans proline' 0 C--N 1.365 1.426 0 C-N-CA 122.361 2.04 . . . . 0.0 113.455 -173.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.5 ' HG3' ' HG2' ' A' ' 30' ' ' PRO . 20.8 mt-10 -95.86 -51.78 4.34 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 123.937 0.895 . . . . 0.0 110.757 -169.556 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 61.1 p -96.02 -7.26 36.79 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 123.56 0.744 . . . . 0.0 111.648 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.48 -0.65 80.19 Favored Glycine 0 C--N 1.355 1.595 0 CA-C-O 119.556 -0.58 . . . . 0.0 114.208 173.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.3 mtmp? -67.17 106.89 2.14 Favored 'General case' 0 C--N 1.353 0.758 0 C-N-CA 123.267 0.627 . . . . 0.0 111.572 -174.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.4 t -82.71 99.78 5.86 Favored 'Isoleucine or valine' 0 C--N 1.346 0.446 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 169.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -130.02 114.28 15.6 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 -167.056 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.518 HD12 ' HD2' ' A' ' 16' ' ' LYS . 26.7 mt -79.04 100.01 3.55 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -171.371 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.43 ' O ' ' HG3' ' A' ' 24' ' ' ARG . . . -104.61 163.3 12.58 Favored 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 123.523 0.729 . . . . 0.0 110.755 -175.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.598 ' HG2' ' HD3' ' A' ' 24' ' ' ARG . 17.8 mt-10 -105.92 136.11 46.16 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 123.242 0.617 . . . . 0.0 109.932 -167.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.532 HD12 HG22 ' A' ' 23' ' ' THR . 68.1 mt -77.41 112.4 15.31 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.972 0 CA-C-O 121.417 0.627 . . . . 0.0 110.668 -174.391 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 9.2 mtp180 -74.93 -55.04 6.18 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 124.308 1.043 . . . . 0.0 110.152 174.352 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -140.51 168.46 19.75 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 124.249 1.02 . . . . 0.0 108.81 -176.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.1 t -120.07 97.5 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 167.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.1 p -140.62 129.44 25.38 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 CA-C-N 115.408 -0.815 . . . . 0.0 110.411 -166.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -132.82 -63.21 0.79 Allowed 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.925 0.89 . . . . 0.0 109.351 177.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 21.3 p-10 -121.66 88.54 2.95 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 121.927 0.87 . . . . 0.0 110.166 -178.046 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.5 p -128.68 107.07 9.38 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.733 0.813 . . . . 0.0 109.076 174.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -66.38 -60.77 2.45 Favored 'General case' 0 C--N 1.347 0.487 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 173.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -116.84 114.72 39.34 Favored Pre-proline 0 CA--C 1.544 0.717 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 175.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_exo -66.45 -6.84 16.04 Favored 'Trans proline' 0 C--N 1.379 2.171 0 C-N-CA 123.363 2.709 . . . . 0.0 114.216 -177.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 79.4 t60 -56.93 119.3 6.02 Favored 'General case' 0 C--N 1.358 0.938 0 C-N-CA 123.414 0.685 . . . . 0.0 109.875 172.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 76.8 t80 59.51 87.44 0.08 Allowed 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 124.946 1.298 . . . . 0.0 110.546 -175.267 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.3 m -81.54 178.51 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.283 174.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 15.4 ptp180 -94.12 -175.2 3.61 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.296 0.638 . . . . 0.0 109.788 172.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 74.0 ttt180 -69.03 156.1 39.21 Favored 'General case' 0 CA--C 1.549 0.927 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 172.758 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -75.84 66.25 2.07 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 123.315 0.646 . . . . 0.0 110.597 178.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 40.5 mm -72.58 83.87 0.39 Allowed 'Isoleucine or valine' 0 C--O 1.244 0.773 0 C-N-CA 124.139 0.976 . . . . 0.0 109.749 176.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 37.8 mt -81.5 105.62 11.61 Favored 'Isoleucine or valine' 0 C--N 1.344 0.331 0 N-CA-C 107.699 -1.222 . . . . 0.0 107.699 174.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 5.7 p -139.62 168.24 20.27 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 124.414 1.086 . . . . 0.0 108.509 -177.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 52.5 mtm180 -61.03 125.24 23.01 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 122.754 0.422 . . . . 0.0 111.105 -178.424 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.82 -10.24 68.38 Favored Glycine 0 C--N 1.34 0.783 0 CA-C-N 115.196 -0.911 . . . . 0.0 114.154 -176.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.62 156.83 36.33 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-N 117.482 0.641 . . . . 0.0 110.847 177.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.464 HG21 ' HG3' ' A' ' 90' ' ' GLU . 99.2 t -109.08 124.39 65.71 Favored 'Isoleucine or valine' 0 C--O 1.242 0.699 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 175.042 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.1 m -105.58 146.19 12.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 172.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -94.73 139.24 31.52 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 124.206 1.003 . . . . 0.0 109.011 176.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 76.7 p -138.09 177.38 7.92 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 124.799 1.24 . . . . 0.0 107.816 177.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.7 m-80 -84.04 8.93 13.77 Favored 'General case' 0 N--CA 1.481 1.092 0 O-C-N 122.339 -0.226 . . . . 0.0 111.419 175.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 62.8 mt -104.8 -14.22 15.6 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 123.386 0.674 . . . . 0.0 110.498 171.388 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 134.7 -148.49 19.54 Favored Glycine 0 C--N 1.343 0.942 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 -176.023 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -101.9 145.9 28.58 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 176.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 19.1 t -129.82 141.28 46.83 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 C-N-CA 123.62 0.768 . . . . 0.0 109.706 -176.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.702 ' HG2' HD13 ' A' ' 88' ' ' ILE . 26.8 mmt180 -81.14 139.17 35.76 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 170.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 67.3 t -84.62 103.74 12.12 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.747 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 169.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 72.1 p -100.06 -17.29 17.55 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.176 0.59 . . . . 0.0 110.854 -171.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 60.2 p -118.67 179.63 4.08 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.966 0.906 . . . . 0.0 109.963 176.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 14.4 ptp180 -78.75 151.85 77.13 Favored Pre-proline 0 CA--C 1.552 1.032 0 C-N-CA 123.082 0.553 . . . . 0.0 110.645 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.656 ' HA ' HG13 ' A' ' 83' ' ' ILE . 85.1 Cg_endo -76.41 16.07 0.93 Allowed 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 122.879 2.386 . . . . 0.0 114.58 -178.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.81 58.88 0.42 Allowed Glycine 0 C--N 1.346 1.093 0 N-CA-C 112.216 -0.354 . . . . 0.0 112.216 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 -118.83 110.26 17.0 Favored 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 171.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.3 t70 67.62 -1.37 1.64 Allowed 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 124.433 1.093 . . . . 0.0 111.217 -169.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . 0.455 ' O ' HD21 ' A' ' 19' ' ' LEU . . . 95.47 5.83 60.1 Favored Glycine 0 C--N 1.349 1.3 0 CA-C-O 119.479 -0.623 . . . . 0.0 112.677 -174.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.732 HG21 ' HB3' ' A' ' 18' ' ' ARG . 11.4 p -126.26 164.29 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 123.435 0.694 . . . . 0.0 111.07 -175.444 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.656 HG13 ' HA ' ' A' ' 77' ' ' PRO . 3.4 mp -109.61 147.02 14.32 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 124.473 1.109 . . . . 0.0 108.664 178.263 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -119.69 155.82 31.68 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 123.596 0.759 . . . . 0.0 109.345 169.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -166.63 -175.12 36.57 Favored Glycine 0 C--N 1.345 1.065 0 N-CA-C 114.017 0.367 . . . . 0.0 114.017 -176.286 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.6 m -130.71 140.37 48.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 C-N-CA 123.469 0.707 . . . . 0.0 110.419 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 33.6 tp -75.47 112.85 12.22 Favored 'General case' 0 CA--C 1.549 0.937 0 CA-C-O 121.303 0.573 . . . . 0.0 111.624 -172.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.702 HD13 ' HG2' ' A' ' 72' ' ' ARG . 9.3 pt -110.02 179.01 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.19 0 C-N-CA 125.059 1.344 . . . . 0.0 110.488 178.062 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 47.5 mmt-85 -132.03 62.48 1.64 Allowed 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 123.438 0.695 . . . . 0.0 109.412 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.464 ' HG3' HG21 ' A' ' 63' ' ' VAL . 37.6 mm-40 -68.77 -63.06 1.13 Allowed 'General case' 0 N--CA 1.491 1.605 0 CA-C-O 121.464 0.65 . . . . 0.0 110.09 177.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 70.6 mt -105.57 127.77 53.22 Favored 'General case' 0 C--O 1.242 0.66 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 172.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -65.58 93.28 0.16 Allowed 'General case' 0 CA--C 1.548 0.88 0 O-C-N 123.78 0.675 . . . . 0.0 110.372 -178.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 37.5 m-70 -120.28 86.57 2.59 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 124.061 0.944 . . . . 0.0 109.051 177.03 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -159.56 164.05 34.6 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-N 115.306 -0.861 . . . . 0.0 108.783 173.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -110.72 168.67 9.29 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 122.817 0.447 . . . . 0.0 110.086 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 55.8 m80 -72.51 143.26 48.42 Favored 'General case' 0 C--O 1.242 0.7 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 171.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 8.7 p80 -69.69 155.56 40.33 Favored 'General case' 0 CA--C 1.551 0.988 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.501 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 . . . . . 0 C--O 1.247 0.948 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 172.422 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.912 0 N-CA-C 112.005 -0.438 . . . . 0.0 112.005 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.439 ' HA ' HH11 ' A' ' 3' ' ' ARG . 2.9 p30 -140.63 173.92 11.02 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 124.019 0.928 . . . . 0.0 110.637 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.439 HH11 ' HA ' ' A' ' 2' ' ' ASP . 1.8 mpt_? -116.66 91.69 3.66 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.234 0.614 . . . . 0.0 109.697 -175.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 50.8 mtm180 -98.8 99.12 10.17 Favored 'General case' 0 C--O 1.242 0.685 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 174.22 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.3 p -119.25 109.62 27.12 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.766 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 168.682 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.6 tpt180 -91.05 95.84 10.31 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 123.227 0.611 . . . . 0.0 109.702 -172.281 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -88.25 89.73 8.11 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-O 121.263 0.554 . . . . 0.0 109.989 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 69.2 mt -92.42 130.18 41.92 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 175.41 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 6.0 ppt_? -147.79 155.18 41.4 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 123.568 0.747 . . . . 0.0 111.368 -177.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 29.0 p -127.99 106.15 8.89 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 124.023 0.929 . . . . 0.0 108.984 174.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 4.0 mmp_? -106.9 150.73 26.11 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 123.737 0.815 . . . . 0.0 110.665 -177.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -134.14 63.82 0.61 Allowed Glycine 0 C--N 1.338 0.639 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.19 87.89 0.12 Allowed Glycine 0 CA--C 1.53 0.995 0 O-C-N 123.974 0.455 . . . . 0.0 112.912 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 27.0 t-20 -73.07 116.89 14.14 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.658 0.783 . . . . 0.0 109.554 176.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 37.2 p -72.19 89.36 1.17 Allowed 'General case' 0 CA--C 1.549 0.915 0 CA-C-O 121.514 0.673 . . . . 0.0 110.092 178.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.73 152.97 19.2 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.271 -0.877 . . . . 0.0 112.009 -173.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 57.2 t -84.34 131.97 32.69 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 123.499 0.719 . . . . 0.0 109.741 -178.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 3.8 mpt_? -73.35 -35.08 65.93 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 124.058 0.943 . . . . 0.0 111.39 -170.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -151.2 152.32 33.12 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.297 0.639 . . . . 0.0 110.278 -176.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.94 -36.84 0.2 Allowed 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 123.43 0.692 . . . . 0.0 109.797 178.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 44.2 m -87.24 -158.28 0.43 Allowed 'General case' 0 CA--C 1.555 1.17 0 C-N-CA 124.104 0.962 . . . . 0.0 110.237 173.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -28.67 128.78 0.08 Allowed 'General case' 0 N--CA 1.501 2.123 0 C-N-CA 125.117 1.367 . . . . 0.0 112.931 169.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.498 ' HB ' ' HB ' ' A' ' 40' ' ' ILE . 6.4 m -64.49 131.52 47.33 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.772 0.829 . . . . 0.0 112.894 -164.363 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 22.9 mmt85 -104.95 134.31 48.28 Favored 'General case' 0 C--O 1.244 0.768 0 C-N-CA 124.275 1.03 . . . . 0.0 109.45 179.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.4 tt -140.29 135.91 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 123.995 0.918 . . . . 0.0 109.394 -178.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 20.7 m-80 -87.14 103.36 15.33 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.5 t -98.42 110.11 25.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 C-N-CA 123.884 0.874 . . . . 0.0 109.196 -172.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.456 HG22 HG22 ' A' ' 35' ' ' VAL . 38.2 t -92.66 103.54 14.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -60.51 116.82 19.72 Favored Pre-proline 0 CA--C 1.549 0.918 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 173.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -76.75 -11.17 18.43 Favored 'Trans proline' 0 C--N 1.363 1.326 0 C-N-CA 122.958 2.439 . . . . 0.0 113.379 -174.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -81.89 -52.47 7.06 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 123.087 0.555 . . . . 0.0 109.583 -176.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 65.4 p -96.37 -31.85 12.66 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 114.774 -1.103 . . . . 0.0 112.026 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 94.03 8.61 60.21 Favored Glycine 0 N--CA 1.475 1.247 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.494 -173.514 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.7 mmtp -72.66 108.92 5.93 Favored 'General case' 0 C--N 1.359 0.982 0 C-N-CA 123.18 0.592 . . . . 0.0 111.678 -177.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.456 HG22 HG22 ' A' ' 28' ' ' VAL . 24.8 t -82.91 120.17 33.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 172.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 13.1 tp10 -140.29 130.33 24.83 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.463 0.705 . . . . 0.0 109.479 -177.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 46.0 mt -78.0 103.79 5.37 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 -179.025 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.439 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -89.83 166.12 13.72 Favored 'General case' 0 C--O 1.24 0.558 0 C-N-CA 123.694 0.798 . . . . 0.0 111.037 177.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 -114.39 124.94 53.2 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 115.314 -0.857 . . . . 0.0 108.925 176.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.498 ' HB ' ' HB ' ' A' ' 23' ' ' THR . 67.8 mt -79.79 111.37 16.49 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 C-N-CA 122.958 0.503 . . . . 0.0 109.775 -173.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 71.9 mtt180 -64.86 -46.83 80.19 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 123.798 0.839 . . . . 0.0 110.376 176.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 62.5 t30 -164.5 172.51 13.21 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.932 -170.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 25.2 m -98.33 133.26 41.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.929 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 170.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.7 p -163.0 94.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-O 122.355 1.074 . . . . 0.0 109.563 176.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.679 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -94.45 -32.75 13.39 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.069 179.51 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -167.03 -17.48 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.814 0.846 . . . . 0.0 110.296 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.5 t -57.95 111.69 1.25 Allowed 'General case' 0 CA--C 1.557 1.243 0 CA-C-O 121.921 0.867 . . . . 0.0 111.41 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.08 164.08 22.7 Favored 'General case' 0 C--O 1.243 0.719 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.409 -178.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.3 m120 56.31 68.35 2.3 Favored Pre-proline 0 CA--C 1.553 1.071 0 C-N-CA 124.062 0.945 . . . . 0.0 109.356 -172.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_endo -77.54 11.81 2.06 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 123.006 2.47 . . . . 0.0 114.28 -170.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 33.5 m80 -74.26 -47.41 35.22 Favored 'General case' 0 N--CA 1.476 0.856 0 C-N-CA 123.169 0.588 . . . . 0.0 110.85 -177.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 85.5 t80 -76.22 -29.62 57.64 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.222 175.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 85.6 t -58.21 105.0 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-O 121.531 0.682 . . . . 0.0 110.093 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 47.3 ttt180 -83.31 153.96 24.36 Favored 'General case' 0 C--O 1.242 0.668 0 C-N-CA 125.14 1.376 . . . . 0.0 108.932 177.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 37.6 ttm180 -59.23 94.21 0.02 OUTLIER 'General case' 0 C--N 1.355 0.846 0 CA-C-O 121.187 0.518 . . . . 0.0 109.627 176.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -80.17 -159.38 0.22 Allowed 'General case' 0 CA--C 1.552 1.047 0 C-N-CA 124.164 0.985 . . . . 0.0 109.035 178.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 50.1 mt -90.38 100.37 10.94 Favored 'Isoleucine or valine' 0 C--O 1.241 0.635 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -167.046 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 71.3 mt -61.98 116.93 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 114.372 -1.285 . . . . 0.0 109.952 -178.174 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.438 ' HA ' ' HG2' ' A' ' 77' ' ' PRO . 40.6 p -126.8 167.2 16.11 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 124.073 0.949 . . . . 0.0 110.017 -177.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 32.5 ttp180 -64.03 138.5 58.49 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 123.127 0.571 . . . . 0.0 110.269 177.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.32 -39.17 3.04 Favored Glycine 0 C--N 1.335 0.521 0 CA-C-O 119.926 -0.374 . . . . 0.0 112.778 -176.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -61.63 135.87 57.79 Favored 'General case' 0 C--N 1.356 0.859 0 C-N-CA 123.665 0.786 . . . . 0.0 110.821 179.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.679 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 42.2 t -87.51 133.15 31.01 Favored 'Isoleucine or valine' 0 C--O 1.242 0.675 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 176.472 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 18.4 m -113.52 150.5 15.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 C-N-CA 124.171 0.989 . . . . 0.0 109.024 177.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -95.65 125.44 40.24 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 106.098 -1.815 . . . . 0.0 106.098 174.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.439 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 61.3 p -122.05 177.71 5.21 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 26.7 p-10 -69.54 -18.26 63.65 Favored 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.063 175.08 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.6 mt -85.12 -43.7 13.63 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 122.965 0.506 . . . . 0.0 110.582 174.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 155.93 -150.8 22.26 Favored Glycine 0 C--N 1.344 0.984 0 N-CA-C 111.925 -0.47 . . . . 0.0 111.925 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.408 ' N ' HD22 ' A' ' 70' ' ' ASN . 1.0 OUTLIER -79.94 126.02 30.48 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-N 117.488 0.644 . . . . 0.0 109.335 178.118 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 57.7 t -125.07 138.2 55.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 123.741 0.817 . . . . 0.0 110.638 -178.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.718 ' HG2' HD13 ' A' ' 88' ' ' ILE . 17.8 mmt180 -83.65 131.46 34.95 Favored 'General case' 0 N--CA 1.483 1.188 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 168.368 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.519 HG11 ' HG3' ' A' ' 77' ' ' PRO . 66.3 t -79.02 105.86 9.04 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 169.251 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 41.6 p -93.8 -30.94 14.58 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 123.392 0.677 . . . . 0.0 110.727 -171.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 49.0 m -96.88 178.05 5.42 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.248 177.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.774 ' HB2' ' HB2' ' A' ' 79' ' ' GLN . 80.2 mtp180 -74.36 124.52 89.94 Favored Pre-proline 0 CA--C 1.545 0.775 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.109 170.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.519 ' HG3' HG11 ' A' ' 73' ' ' VAL . 32.0 Cg_exo -62.12 104.01 0.32 Allowed 'Trans proline' 0 C--N 1.373 1.841 0 C-N-CA 122.481 2.12 . . . . 0.0 111.293 173.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.34 24.82 17.86 Favored Glycine 0 C--N 1.344 0.991 0 CA-C-N 116.06 -0.518 . . . . 0.0 113.347 -178.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . 0.774 ' HB2' ' HB2' ' A' ' 76' ' ' ARG . 24.7 tm0? -65.9 -58.65 5.09 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 176.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -84.12 -9.3 58.69 Favored 'General case' 0 N--CA 1.487 1.377 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.763 173.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 117.33 -53.14 0.65 Allowed Glycine 0 C--N 1.336 0.559 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -163.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 10.1 p -87.03 165.7 2.09 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.131 0 C-N-CA 123.886 0.874 . . . . 0.0 110.703 177.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 18.5 mt -96.38 148.49 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.888 0 C-N-CA 124.039 0.936 . . . . 0.0 108.605 173.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 17.4 m-80 -131.75 149.01 52.61 Favored 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 123.252 0.621 . . . . 0.0 109.699 177.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -164.45 -173.27 32.92 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 115.735 -0.666 . . . . 0.0 114.092 -174.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.6 m -129.79 141.72 45.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 C-N-CA 123.551 0.74 . . . . 0.0 110.107 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 20.1 tp -75.88 105.31 6.85 Favored 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 121.022 0.439 . . . . 0.0 109.924 -178.003 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.718 HD13 ' HG2' ' A' ' 72' ' ' ARG . 11.0 pt -107.21 -173.46 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 C-N-CA 123.432 0.693 . . . . 0.0 110.222 -179.413 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 60.7 mtt85 -139.95 77.47 1.61 Allowed 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 123.146 0.578 . . . . 0.0 109.734 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.458 ' HG2' HD12 ' A' ' 88' ' ' ILE . 56.5 mm-40 -68.58 -65.51 0.69 Allowed 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 167.023 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 60.7 mt -80.82 -164.51 0.74 Allowed 'General case' 0 CA--C 1.549 0.927 0 CA-C-N 114.429 -1.26 . . . . 0.0 108.934 170.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 62.42 21.18 12.41 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 123.226 0.61 . . . . 0.0 111.513 172.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 6.3 p80 -117.14 170.83 8.36 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.67 0.788 . . . . 0.0 110.807 -171.141 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -136.57 -59.44 0.72 Allowed 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.127 0.971 . . . . 0.0 108.463 172.077 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -94.16 -53.16 4.07 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.023 -177.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 60.6 t-80 -108.49 117.11 33.31 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 122.982 0.513 . . . . 0.0 111.63 -173.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 42.4 t60 -95.73 148.26 22.75 Favored 'General case' 0 N--CA 1.483 1.209 0 C-N-CA 124.96 1.304 . . . . 0.0 108.665 169.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 81.1 t60 . . . . . 0 N--CA 1.487 1.386 0 C-N-CA 123.241 0.616 . . . . 0.0 110.67 178.667 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.376 0 N-CA-C 111.591 -0.604 . . . . 0.0 111.591 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 36.6 m-20 -70.25 105.17 2.87 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.761 0.824 . . . . 0.0 110.224 -179.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -72.31 92.88 1.44 Allowed 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 177.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 -56.66 112.64 1.35 Allowed 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 123.775 0.83 . . . . 0.0 111.026 -173.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 61.7 t -77.72 104.77 5.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 36.7 ptt180 -60.97 123.49 17.75 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 123.693 0.797 . . . . 0.0 111.645 -176.093 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . 0.43 HD13 HH21 ' A' ' 9' ' ' ARG . 55.3 mt -81.55 83.22 7.07 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.545 0.738 . . . . 0.0 109.874 -177.147 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 41.4 mm -89.27 73.84 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 CA-C-O 121.703 0.763 . . . . 0.0 109.056 -175.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.43 HH21 HD13 ' A' ' 7' ' ' LEU . 5.6 ppt_? -157.74 -176.34 5.88 Favored 'General case' 0 CA--C 1.538 0.494 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.735 -174.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.429 HG23 ' HD3' ' A' ' 9' ' ' ARG . 40.2 p 50.76 76.65 0.15 Allowed 'General case' 0 N--CA 1.482 1.151 0 C-N-CA 125.37 1.468 . . . . 0.0 112.37 178.062 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 2.4 ppt_? -153.92 170.4 21.13 Favored 'General case' 0 C--O 1.243 0.762 0 CA-C-N 114.876 -1.057 . . . . 0.0 109.657 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 118.22 -168.03 13.05 Favored Glycine 0 C--N 1.343 0.938 0 CA-C-N 116.717 -0.219 . . . . 0.0 112.734 176.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -85.65 61.95 4.49 Favored Glycine 0 C--N 1.341 0.841 0 N-CA-C 112.295 -0.322 . . . . 0.0 112.295 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -74.48 172.7 11.5 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.971 0.909 . . . . 0.0 111.385 176.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 40.3 p -68.37 81.46 0.25 Allowed 'General case' 0 CA--C 1.546 0.826 0 CA-C-O 121.767 0.794 . . . . 0.0 110.338 174.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -95.36 154.99 16.92 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.924 -179.041 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 16.4 m -124.2 -149.15 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.813 0 C-N-CA 124.119 0.967 . . . . 0.0 108.897 -176.377 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.6 mmm-85 -75.12 -156.74 0.06 Allowed 'General case' 0 CA--C 1.556 1.186 0 C-N-CA 123.314 0.645 . . . . 0.0 110.713 174.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.403 ' HB3' ' HB2' ' A' ' 24' ' ' ARG . 2.9 pp -77.06 40.36 0.26 Allowed 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -178.071 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -62.53 -24.2 67.38 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.969 0.908 . . . . 0.0 111.655 174.217 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 16.7 p -53.12 -58.03 8.41 Favored 'General case' 0 CA--C 1.549 0.942 0 O-C-N 124.245 0.966 . . . . 0.0 110.15 172.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . 0.451 ' HB3' ' OE1' ' A' ' 39' ' ' GLU . 22.0 t70 -170.91 -76.06 0.02 OUTLIER 'General case' 0 N--CA 1.479 0.986 0 O-C-N 124.234 0.959 . . . . 0.0 108.513 167.497 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.459 ' O ' ' HA ' ' A' ' 39' ' ' GLU . 6.9 m -145.4 116.02 7.67 Favored 'General case' 0 C--N 1.351 0.64 0 C-N-CA 123.185 0.594 . . . . 0.0 109.745 176.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.403 ' HB2' ' HB3' ' A' ' 19' ' ' LEU . 38.6 mmt180 -107.12 145.13 32.85 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.731 0.812 . . . . 0.0 110.362 -177.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.9 tt -147.41 144.34 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 C-N-CA 124.167 0.987 . . . . 0.0 109.441 175.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -91.59 100.85 13.52 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 173.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 62.0 t -89.56 111.03 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 123.808 0.843 . . . . 0.0 109.247 -175.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.502 HG22 HG22 ' A' ' 35' ' ' VAL . 41.4 t -101.45 108.72 24.12 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 C-N-CA 123.666 0.786 . . . . 0.0 109.333 -176.303 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -58.74 114.82 9.79 Favored Pre-proline 0 N--CA 1.473 0.715 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 171.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -78.1 -5.89 15.42 Favored 'Trans proline' 0 C--N 1.363 1.334 0 C-N-CA 122.374 2.049 . . . . 0.0 112.911 -175.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -95.86 -53.31 3.73 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 123.827 0.851 . . . . 0.0 111.203 -178.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 59.3 p -90.67 -30.85 16.88 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.485 0.714 . . . . 0.0 111.44 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 101.9 -11.54 57.52 Favored Glycine 0 C--N 1.343 0.952 0 CA-C-N 116.139 -0.482 . . . . 0.0 113.158 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 71.3 mmtt -68.53 124.73 24.38 Favored 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 123.482 0.713 . . . . 0.0 111.426 -170.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.502 HG22 HG22 ' A' ' 28' ' ' VAL . 22.2 t -95.95 133.99 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 175.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -140.99 137.19 32.84 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 171.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 39.7 mt -79.82 129.5 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 178.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.29 167.71 18.05 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 123.88 0.872 . . . . 0.0 111.289 -171.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.459 ' HA ' ' O ' ' A' ' 23' ' ' THR . 56.0 mm-40 -104.32 118.77 37.43 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 124.441 1.096 . . . . 0.0 110.98 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.446 HG23 ' HB ' ' A' ' 64' ' ' VAL . 68.1 mt -78.85 111.4 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 122.704 0.402 . . . . 0.0 110.544 -175.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.3 mmm180 -82.81 -56.48 3.8 Favored 'General case' 0 CA--C 1.546 0.823 0 C-N-CA 124.358 1.063 . . . . 0.0 111.623 178.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.587 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 33.9 t30 -106.25 133.95 50.15 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 175.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.432 ' HA ' HG12 ' A' ' 64' ' ' VAL . 33.6 m -102.99 -5.07 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -175.544 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.706 HG21 HG21 ' A' ' 53' ' ' VAL . 3.7 p -137.37 104.0 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 CA-C-O 121.297 0.57 . . . . 0.0 111.794 -170.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.597 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 33.5 mm-40 55.33 -164.36 0.13 Allowed 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 166.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 8.1 p30 -80.79 -3.98 52.96 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.1 0.96 . . . . 0.0 110.949 171.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.401 HG22 ' HB2' ' A' ' 45' ' ' GLU . 8.8 t -79.01 140.06 38.05 Favored 'General case' 0 CA--C 1.544 0.722 0 CA-C-O 121.609 0.719 . . . . 0.0 110.951 -178.323 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -130.16 27.16 5.13 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 114.378 -1.283 . . . . 0.0 108.705 172.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 48.0 t-20 -105.68 93.19 6.95 Favored Pre-proline 0 N--CA 1.474 0.775 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 176.041 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -82.37 13.07 2.65 Favored 'Trans proline' 0 C--N 1.372 1.775 0 C-N-CA 122.422 2.081 . . . . 0.0 113.628 -175.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 55.2 t-80 -69.71 -48.61 58.95 Favored 'General case' 0 C--N 1.351 0.67 0 C-N-CA 122.445 0.298 . . . . 0.0 110.498 176.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -88.37 -28.01 21.25 Favored 'General case' 0 N--CA 1.475 0.809 0 O-C-N 123.397 0.435 . . . . 0.0 111.144 -178.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.706 HG21 HG21 ' A' ' 44' ' ' VAL . 5.7 p -116.59 104.78 17.14 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 CA-C-O 122.204 1.002 . . . . 0.0 111.387 -179.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 34.0 mmt180 -114.33 -0.73 13.75 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 124.163 0.985 . . . . 0.0 110.366 167.399 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 16.2 mtm180 -78.83 79.82 5.21 Favored 'General case' 0 C--O 1.244 0.793 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 170.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -86.06 65.21 8.99 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 121.944 0.878 . . . . 0.0 110.052 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 64.4 mt -108.83 119.56 58.62 Favored 'Isoleucine or valine' 0 C--O 1.242 0.696 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 176.07 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 57.7 mt -65.83 119.85 11.59 Favored 'Isoleucine or valine' 0 C--N 1.348 0.515 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 173.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 26.7 m -118.1 147.97 42.76 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -178.139 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 31.6 ttt-85 -60.69 134.09 56.74 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 172.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.57 -41.71 2.74 Favored Glycine 0 C--N 1.346 1.112 0 CA-C-O 119.892 -0.393 . . . . 0.0 112.43 -175.152 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -60.56 134.89 57.52 Favored 'General case' 0 C--N 1.357 0.896 0 C-N-CA 123.53 0.732 . . . . 0.0 110.708 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.597 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 98.2 t -73.55 120.48 22.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 O-C-N 123.722 0.639 . . . . 0.0 110.634 -178.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.446 ' HB ' HG23 ' A' ' 40' ' ' ILE . 26.3 m -105.41 126.89 60.54 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.294 171.167 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.587 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 33.8 tt0 -92.68 134.82 34.65 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 106.087 -1.82 . . . . 0.0 106.087 177.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 71.3 p -117.22 -178.59 3.48 Favored 'General case' 0 C--O 1.241 0.631 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 -177.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -59.44 -23.15 62.44 Favored 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 123.057 0.543 . . . . 0.0 110.896 171.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 89.0 mt -88.79 -51.76 5.48 Favored 'General case' 0 C--N 1.353 0.733 0 C-N-CA 124.267 1.027 . . . . 0.0 110.018 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 164.53 -170.36 39.65 Favored Glycine 0 C--N 1.337 0.608 0 CA-C-N 115.549 -0.751 . . . . 0.0 112.155 -177.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.451 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 14.0 m120 -75.73 143.49 42.02 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.393 0.677 . . . . 0.0 110.772 -174.116 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.2 t -137.04 147.48 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 C-N-CA 123.857 0.863 . . . . 0.0 110.079 -174.049 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.687 ' HG2' HD13 ' A' ' 88' ' ' ILE . 36.4 mmt180 -93.01 120.75 33.64 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 168.454 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 43.9 t -75.82 98.65 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.438 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 71.1 p -74.36 -34.52 63.4 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.715 0.806 . . . . 0.0 111.417 178.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . 0.554 ' HB2' ' HB2' ' A' ' 84' ' ' ASN . 39.2 t -79.8 170.08 17.01 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.778 0.831 . . . . 0.0 111.581 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -82.73 106.43 6.82 Favored Pre-proline 0 CA--C 1.546 0.816 0 N-CA-C 107.246 -1.391 . . . . 0.0 107.246 166.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.404 ' HB3' HG23 ' A' ' 83' ' ' ILE . 65.9 Cg_endo -82.16 69.62 7.41 Favored 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 123.443 2.762 . . . . 0.0 112.44 -172.021 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.09 -32.15 0.1 Allowed Glycine 0 C--N 1.333 0.37 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.817 -178.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -64.58 111.37 2.68 Favored 'General case' 0 C--N 1.359 0.981 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 174.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.4 t70 76.71 -22.95 0.26 Allowed 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 125.338 1.455 . . . . 0.0 112.384 -177.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 102.55 -8.58 54.97 Favored Glycine 0 C--N 1.345 1.078 0 CA-C-O 119.932 -0.371 . . . . 0.0 112.487 -175.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -86.57 116.95 30.1 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 CA-C-O 121.641 0.734 . . . . 0.0 109.94 -179.186 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.404 HG23 ' HB3' ' A' ' 77' ' ' PRO . 38.6 mt -98.54 132.75 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 175.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.554 ' HB2' ' HB2' ' A' ' 75' ' ' SER . 66.3 m-20 -136.07 154.52 51.0 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 123.725 0.81 . . . . 0.0 109.03 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.438 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -168.93 -173.98 37.12 Favored Glycine 0 C--N 1.34 0.754 0 O-C-N 123.385 0.428 . . . . 0.0 113.992 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.7 m -123.47 134.24 66.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.075 0 C-N-CA 124.028 0.931 . . . . 0.0 110.364 177.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 46.7 tp -66.21 127.55 32.62 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 123.182 0.593 . . . . 0.0 111.447 -176.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.687 HD13 ' HG2' ' A' ' 72' ' ' ARG . 33.2 pt -126.21 -176.67 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 C-N-CA 125.189 1.396 . . . . 0.0 109.378 173.25 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 82.0 mtt85 -137.83 88.29 2.32 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 123.321 0.649 . . . . 0.0 109.923 -177.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -100.85 -48.22 4.54 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 123.4 0.68 . . . . 0.0 109.44 178.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 88.8 mt -119.37 -175.1 2.87 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 124.911 1.284 . . . . 0.0 109.793 -178.043 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -122.15 106.66 11.35 Favored 'General case' 0 C--O 1.239 0.515 0 C-N-CA 123.496 0.718 . . . . 0.0 109.675 177.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 20.2 t60 -115.16 -50.92 2.73 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 171.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 44.0 t-80 -144.15 60.57 1.36 Allowed 'General case' 0 C--O 1.241 0.615 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 167.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -74.3 148.24 41.58 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 114.11 -1.405 . . . . 0.0 108.523 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 47.7 t60 66.35 81.41 0.2 Allowed 'General case' 0 N--CA 1.48 1.05 0 O-C-N 124.112 0.883 . . . . 0.0 108.997 -171.077 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 10.6 t-160 -80.86 -25.75 37.43 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 123.133 0.573 . . . . 0.0 110.559 -176.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 47.2 t-80 . . . . . 0 C--O 1.252 1.2 0 CA-C-O 118.532 -0.747 . . . . 0.0 109.118 178.448 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.628 0 N-CA-C 112.29 -0.324 . . . . 0.0 112.29 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -85.84 143.14 28.43 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.672 0.789 . . . . 0.0 109.985 -179.125 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 74.3 mmt-85 -86.81 68.99 10.27 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 174.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.461 ' H ' ' HD3' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -67.9 115.41 7.4 Favored 'General case' 0 CA--C 1.544 0.725 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.964 179.875 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 7.1 p -83.58 132.2 32.01 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 C-N-CA 123.123 0.569 . . . . 0.0 110.13 -178.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 28.0 ttm-85 -92.97 92.43 7.85 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 174.205 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 97.5 mt -73.65 96.18 2.44 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 123.716 0.806 . . . . 0.0 110.231 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 58.7 mt -104.72 109.43 27.53 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 174.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -77.98 177.13 8.51 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.539 1.136 . . . . 0.0 110.551 173.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.5 p -69.33 -74.78 0.12 Allowed 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 123.074 0.55 . . . . 0.0 110.141 176.046 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -174.46 -65.32 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.976 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 176.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -179.5 155.36 15.58 Favored Glycine 0 C--N 1.34 0.785 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.431 -178.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.54 85.39 0.35 Allowed Glycine 0 CA--C 1.533 1.212 0 CA-C-N 117.027 0.414 . . . . 0.0 113.732 -174.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -100.9 170.98 7.94 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 123.856 0.862 . . . . 0.0 110.17 175.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 49.0 m -85.15 114.55 22.36 Favored 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 123.241 0.616 . . . . 0.0 110.336 178.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -90.44 165.86 13.58 Favored 'General case' 0 C--O 1.243 0.739 0 C-N-CA 124.109 0.964 . . . . 0.0 108.65 172.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.6 p -80.51 158.87 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.815 175.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.407 ' HD2' ' O ' ' A' ' 81' ' ' GLY . 32.8 ptt180 -63.76 -170.03 0.03 OUTLIER 'General case' 0 CA--C 1.552 1.035 0 C-N-CA 124.623 1.169 . . . . 0.0 111.822 174.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.537 ' HB3' ' H ' ' A' ' 24' ' ' ARG . 1.9 pt? -57.1 90.61 0.01 OUTLIER 'General case' 0 CA--C 1.555 1.17 0 CA-C-O 122.215 1.007 . . . . 0.0 110.738 172.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -142.26 8.9 1.84 Allowed 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 124.651 1.18 . . . . 0.0 110.284 -177.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 25.5 m -157.26 -42.21 0.07 Allowed 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.64 1.176 . . . . 0.0 108.798 -171.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -145.14 150.79 37.39 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-N 114.232 -1.349 . . . . 0.0 108.526 178.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.528 HG22 HD12 ' A' ' 40' ' ' ILE . 33.0 m -63.35 113.51 3.27 Favored 'General case' 0 C--N 1.353 0.754 0 C-N-CA 123.272 0.629 . . . . 0.0 109.876 -179.556 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.554 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 17.0 mtm180 -130.81 166.0 21.77 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.918 0.887 . . . . 0.0 111.497 -173.019 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 14.0 tt -150.88 150.28 13.54 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.447 -170.108 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 19.8 m-80 -94.08 100.39 12.51 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 175.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.7 t -88.7 112.39 23.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.022 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.434 HG13 HG22 ' A' ' 35' ' ' VAL . 17.3 t -101.41 100.6 10.71 Favored 'Isoleucine or valine' 0 C--O 1.237 0.437 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -178.206 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -58.38 120.39 43.93 Favored Pre-proline 0 CA--C 1.552 1.021 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 177.311 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -71.78 -15.75 29.88 Favored 'Trans proline' 0 C--N 1.366 1.469 0 C-N-CA 122.845 2.364 . . . . 0.0 113.555 -172.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -91.75 -52.12 4.9 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.919 0.487 . . . . 0.0 110.325 -175.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.3 p -88.66 -32.85 17.81 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.637 0.775 . . . . 0.0 112.375 -177.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.64 3.9 68.29 Favored Glycine 0 N--CA 1.479 1.559 0 CA-C-O 120.097 -0.28 . . . . 0.0 113.14 -174.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.0 mmtm -63.05 109.24 1.42 Allowed 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.753 0.821 . . . . 0.0 111.692 179.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.434 HG22 HG13 ' A' ' 28' ' ' VAL . 41.1 t -90.45 111.82 23.99 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 172.161 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -129.62 131.42 46.46 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.608 0.763 . . . . 0.0 110.233 -174.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 53.4 mt -76.26 115.23 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.75 153.81 40.38 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.946 0.898 . . . . 0.0 109.977 -174.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.554 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 2.7 mp0 -93.58 124.09 37.34 Favored 'General case' 0 C--O 1.244 0.79 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 -176.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.528 HD12 HG22 ' A' ' 23' ' ' THR . 56.0 mt -75.04 109.46 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -178.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 67.8 mtp180 -71.72 -42.62 67.12 Favored 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 124.59 1.156 . . . . 0.0 110.349 -178.173 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -159.64 170.13 22.25 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-N 114.822 -1.081 . . . . 0.0 108.646 -176.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.679 HG12 HG12 ' A' ' 64' ' ' VAL . 3.5 m -119.58 90.68 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 C-N-CA 124.712 1.205 . . . . 0.0 107.964 176.328 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.7 p -147.37 141.53 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 CA-C-O 121.256 0.55 . . . . 0.0 111.442 -166.491 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.443 ' HB3' ' HB ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -142.42 -83.46 0.18 Allowed 'General case' 0 CA--C 1.549 0.933 0 C-N-CA 125.405 1.482 . . . . 0.0 108.526 178.823 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -114.37 15.1 18.03 Favored 'General case' 0 CA--C 1.553 1.076 0 C-N-CA 124.927 1.291 . . . . 0.0 109.409 171.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 64.8 p 55.6 78.85 0.18 Allowed 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 125.744 1.618 . . . . 0.0 111.709 -177.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -71.66 -37.41 70.8 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.309 179.48 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 15.5 m120 -114.95 91.92 28.53 Favored Pre-proline 0 N--CA 1.484 1.227 0 C-N-CA 123.872 0.869 . . . . 0.0 108.719 174.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -62.24 110.94 1.13 Allowed 'Trans proline' 0 C--N 1.38 2.203 0 C-N-CA 123.573 2.848 . . . . 0.0 113.017 -176.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.0 t60 77.52 -7.26 1.86 Allowed 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 125.55 1.54 . . . . 0.0 112.88 172.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -68.16 117.07 9.5 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 122.881 0.472 . . . . 0.0 110.893 -177.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 18.5 t -71.04 -20.54 21.72 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.146 0 C-N-CA 123.525 0.73 . . . . 0.0 109.888 177.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 59.5 mtp85 -73.11 6.49 2.7 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 123.888 0.875 . . . . 0.0 112.504 173.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.73 -9.29 58.51 Favored 'General case' 0 CA--C 1.558 1.286 0 C-N-CA 123.248 0.619 . . . . 0.0 110.306 169.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 31.2 p-10 -56.96 -20.15 22.12 Favored 'General case' 0 N--CA 1.49 1.535 0 C-N-CA 123.797 0.839 . . . . 0.0 111.388 172.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.3 mt -67.31 90.97 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.09 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 166.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.9 mt -82.68 151.92 4.04 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.701 -179.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 75.8 p -128.69 170.53 13.17 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.852 0.861 . . . . 0.0 109.615 174.183 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.3 ttm180 -71.9 138.14 47.94 Favored 'General case' 0 CA--C 1.541 0.62 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 171.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.77 -14.62 51.43 Favored Glycine 0 C--N 1.343 0.97 0 C-N-CA 123.249 0.452 . . . . 0.0 113.028 -177.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -70.85 141.36 51.27 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 123.334 0.653 . . . . 0.0 109.486 177.194 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.443 ' HB ' ' HB3' ' A' ' 45' ' ' GLU . 77.1 t -91.16 118.42 36.39 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.81 -179.695 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.679 HG12 HG12 ' A' ' 43' ' ' VAL . 34.1 m -103.31 135.85 38.88 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.422 174.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -86.27 127.01 34.71 Favored 'General case' 0 CA--C 1.534 0.356 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 174.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 32.6 p -128.6 174.32 9.5 Favored 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.491 ' ND2' ' HB2' ' A' ' 39' ' ' GLU . 94.2 m-20 -65.03 -12.64 52.77 Favored 'General case' 0 N--CA 1.482 1.128 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 178.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.1 mt -95.6 -47.89 6.04 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 176.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 167.57 -161.96 35.76 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.828 178.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -75.12 142.69 43.58 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.189 0.596 . . . . 0.0 110.015 175.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.0 t -135.88 146.45 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.268 0 C-N-CA 123.155 0.582 . . . . 0.0 110.111 -174.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.65 ' HG2' HD13 ' A' ' 88' ' ' ILE . 33.7 mmt180 -91.65 119.7 31.77 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 171.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.2 t -73.36 122.62 26.64 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.2 p -108.56 -32.67 7.29 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.536 0.735 . . . . 0.0 110.26 -172.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.6 t -97.73 -178.77 4.22 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.62 0.768 . . . . 0.0 110.147 178.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.44 128.92 73.65 Favored Pre-proline 0 CA--C 1.552 1.033 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 174.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -68.66 103.66 1.02 Allowed 'Trans proline' 0 C--N 1.373 1.843 0 C-N-CA 123.024 2.483 . . . . 0.0 113.837 -173.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 73.37 -0.78 46.57 Favored Glycine 0 C--N 1.344 1.004 0 CA-C-N 115.217 -0.901 . . . . 0.0 114.961 171.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 31.8 mm-40 -67.81 -43.51 79.49 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 123.28 0.632 . . . . 0.0 111.689 -172.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.539 ' HB3' HG12 ' A' ' 82' ' ' VAL . 24.6 t70 -89.06 3.68 50.9 Favored 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 123.618 0.767 . . . . 0.0 110.75 175.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . 0.407 ' O ' ' HD2' ' A' ' 18' ' ' ARG . . . 81.42 37.16 18.37 Favored Glycine 0 C--N 1.343 0.933 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -171.375 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.539 HG12 ' HB3' ' A' ' 80' ' ' ASP . 13.3 p -162.28 140.54 2.26 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 CA-C-N 114.541 -0.83 . . . . 0.0 109.809 -174.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.4 mt -121.61 128.8 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 N-CA-C 104.904 -2.258 . . . . 0.0 104.904 165.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -120.81 153.35 37.21 Favored 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -172.7 179.66 44.06 Favored Glycine 0 N--CA 1.446 -0.643 0 O-C-N 123.99 0.806 . . . . 0.0 113.588 175.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.1 m -123.36 136.16 60.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 124.05 0.94 . . . . 0.0 110.007 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 27.0 tp -66.56 134.16 51.81 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 123.011 0.524 . . . . 0.0 111.133 -174.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.65 HD13 ' HG2' ' A' ' 72' ' ' ARG . 34.1 pt -135.06 175.1 11.78 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.785 1.234 . . . . 0.0 109.59 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 39.1 mtt180 -130.88 84.15 2.17 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.451 0.7 . . . . 0.0 109.284 -176.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 28.8 mm-40 -95.8 -77.05 0.48 Allowed 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 77.4 mt -85.04 94.62 8.87 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 169.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -60.72 128.63 37.49 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 123.083 0.553 . . . . 0.0 111.725 -176.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.1 t60 -77.09 -29.8 55.12 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 169.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -167.81 133.03 1.89 Allowed 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 125.051 1.34 . . . . 0.0 107.692 170.361 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 54.2 t-80 -170.8 -33.83 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 123.412 0.685 . . . . 0.0 109.777 -179.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -71.04 88.91 0.79 Allowed 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 123.913 0.885 . . . . 0.0 109.06 175.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 22.1 p80 -74.32 -35.81 63.67 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.549 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 48.3 t60 . . . . . 0 C--O 1.243 0.737 0 C-N-CA 124.219 1.007 . . . . 0.0 108.342 177.113 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.731 0 N-CA-C 112.494 -0.242 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -75.04 104.06 5.47 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 123.717 0.807 . . . . 0.0 110.41 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 56.4 mtm180 -79.94 73.19 6.73 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 123.636 0.774 . . . . 0.0 110.192 175.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 60.7 ttt180 -78.9 83.81 4.99 Favored 'General case' 0 CA--C 1.539 0.521 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 174.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.6 t -87.23 93.5 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 115.424 -0.807 . . . . 0.0 108.889 -178.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? -73.24 92.61 1.78 Allowed 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 93.8 mt -75.53 103.46 5.66 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.504 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.0 tt -74.05 130.72 35.78 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 124.026 0.93 . . . . 0.0 110.937 -178.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 53.7 ttp180 -142.62 156.25 45.05 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.773 0.829 . . . . 0.0 109.344 175.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 88.4 m 66.16 101.49 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 125.212 1.405 . . . . 0.0 110.25 -171.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 31.3 mmt180 -77.42 -38.76 49.02 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.497 174.676 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 102.55 158.55 25.81 Favored Glycine 0 C--N 1.339 0.7 0 CA-C-N 114.814 -1.084 . . . . 0.0 111.1 -174.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 173.99 109.9 0.24 Allowed Glycine 0 C--N 1.333 0.416 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -178.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 41.3 t-20 -142.29 93.58 2.55 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 -177.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 64.8 p -98.69 112.29 24.4 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 124.021 0.928 . . . . 0.0 109.582 177.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.9 mmtp -120.11 -80.22 0.62 Allowed 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 123.253 0.621 . . . . 0.0 110.643 -178.401 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 13.4 p -153.17 146.63 14.67 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 C-N-CA 123.59 0.756 . . . . 0.0 109.32 -175.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 18.3 mmm180 -82.35 -156.19 0.16 Allowed 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 123.647 0.779 . . . . 0.0 109.842 176.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -79.9 42.57 0.55 Allowed 'General case' 0 CA--C 1.56 1.335 0 CA-C-O 121.94 0.876 . . . . 0.0 110.736 171.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -87.33 48.96 1.72 Allowed 'General case' 0 CA--C 1.546 0.799 0 C-N-CA 124.88 1.272 . . . . 0.0 110.135 -174.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.9 m -151.3 -57.35 0.16 Allowed 'General case' 0 C--O 1.24 0.564 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -162.33 172.63 15.34 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 125.153 1.381 . . . . 0.0 107.819 176.004 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 26.3 m -62.87 116.38 5.21 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.311 0.644 . . . . 0.0 110.35 -176.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 17.3 tpp85 -110.22 141.48 43.1 Favored 'General case' 0 C--O 1.241 0.637 0 C-N-CA 123.561 0.745 . . . . 0.0 110.446 -171.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 16.2 tt -139.94 147.41 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.953 0.901 . . . . 0.0 109.506 178.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -97.59 102.38 14.13 Favored 'General case' 0 CA--C 1.538 0.491 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 170.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.537 HG22 HG21 ' A' ' 71' ' ' VAL . 96.5 t -82.91 106.14 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 C-N-CA 123.957 0.903 . . . . 0.0 109.698 -177.287 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 86' ' ' VAL . 40.0 t -97.21 102.86 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -56.1 116.59 12.86 Favored Pre-proline 0 CA--C 1.549 0.923 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 173.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -72.91 -19.48 23.39 Favored 'Trans proline' 0 C--N 1.368 1.556 0 C-N-CA 122.332 2.022 . . . . 0.0 113.378 -172.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -81.88 -51.21 8.32 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 123.264 0.626 . . . . 0.0 110.465 -175.181 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.7 p -92.31 -25.78 18.42 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.876 0.87 . . . . 0.0 111.446 -177.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.2 4.65 71.18 Favored Glycine 0 N--CA 1.473 1.113 0 CA-C-O 119.597 -0.557 . . . . 0.0 113.119 -178.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -72.08 112.68 8.37 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.157 0.583 . . . . 0.0 111.811 -173.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.451 HG22 HG22 ' A' ' 28' ' ' VAL . 39.1 t -82.6 115.18 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 171.503 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -130.79 130.0 43.13 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.96 0.904 . . . . 0.0 109.123 -179.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 59.4 mt -78.93 125.61 38.42 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 C-N-CA 122.91 0.484 . . . . 0.0 110.139 -177.319 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -134.17 170.99 14.86 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 124.575 1.15 . . . . 0.0 110.02 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 25.6 mt-10 -117.79 135.73 53.87 Favored 'General case' 0 C--O 1.243 0.748 0 C-N-CA 123.329 0.652 . . . . 0.0 109.547 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.1 mt -78.51 112.35 16.43 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.726 0 O-C-N 123.893 0.746 . . . . 0.0 110.311 -175.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 72.6 mtp180 -64.69 -53.93 39.6 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.842 1.257 . . . . 0.0 110.365 175.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 55.5 t30 -143.75 157.65 44.24 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 123.522 0.729 . . . . 0.0 109.535 -176.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 55.3 t -121.33 -39.09 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 C-N-CA 122.925 0.49 . . . . 0.0 110.374 179.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.3 p -64.18 122.0 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-O 121.179 0.514 . . . . 0.0 110.37 -179.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -86.54 13.65 8.12 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 123.901 0.881 . . . . 0.0 113.175 -168.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -70.44 -29.51 66.11 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 123.224 0.609 . . . . 0.0 112.092 -176.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 32.6 p 52.79 28.91 6.87 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 125.464 1.505 . . . . 0.0 111.447 -171.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -115.51 35.96 4.17 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 124.1 0.96 . . . . 0.0 110.864 -170.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 36.8 t30 67.53 94.88 0.05 OUTLIER Pre-proline 0 N--CA 1.484 1.23 0 C-N-CA 124.782 1.233 . . . . 0.0 110.916 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -71.52 78.42 1.63 Allowed 'Trans proline' 0 C--N 1.375 1.935 0 C-N-CA 122.899 2.399 . . . . 0.0 111.818 175.487 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.4 t-80 -65.61 105.81 1.31 Allowed 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 123.388 0.675 . . . . 0.0 109.497 179.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 60.83 74.15 0.46 Allowed 'General case' 0 C--O 1.239 0.524 0 O-C-N 124.757 1.286 . . . . 0.0 109.332 -169.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.9 p -57.81 104.6 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 CA-C-N 114.889 -1.051 . . . . 0.0 110.976 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 32.4 ptt180 -144.7 176.88 9.1 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.323 -173.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 11.4 mmt180 58.61 30.83 20.39 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 124.191 0.996 . . . . 0.0 110.706 178.696 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -70.76 79.17 0.61 Allowed 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.246 1.018 . . . . 0.0 110.859 -174.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.4 HG22 HG23 ' A' ' 59' ' ' THR . 41.1 mm -79.32 83.77 1.13 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.63 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 178.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.4 mt -72.71 118.26 17.55 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.267 0 CA-C-N 114.726 -1.125 . . . . 0.0 108.222 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.4 HG23 HG22 ' A' ' 57' ' ' ILE . 7.5 p -131.61 170.46 14.73 Favored 'General case' 0 C--O 1.243 0.726 0 C-N-CA 124.872 1.269 . . . . 0.0 108.952 -175.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -69.52 130.79 43.43 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 177.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.95 -15.34 63.62 Favored Glycine 0 C--N 1.345 1.029 0 CA-C-O 119.48 -0.622 . . . . 0.0 113.531 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.62 134.3 49.74 Favored 'General case' 0 C--O 1.246 0.878 0 C-N-CA 122.957 0.503 . . . . 0.0 110.342 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 67.1 t -88.55 112.88 24.52 Favored 'Isoleucine or valine' 0 C--O 1.239 0.54 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 176.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.3 m -102.94 138.56 26.73 Favored 'Isoleucine or valine' 0 C--O 1.238 0.487 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -88.11 126.45 35.12 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 176.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 61.3 p -134.0 172.49 12.75 Favored 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 124.097 0.959 . . . . 0.0 109.091 -175.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -71.88 -13.12 61.57 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 112.331 0.493 . . . . 0.0 112.331 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 88.5 mt -97.12 -15.34 21.0 Favored 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 123.3 0.64 . . . . 0.0 111.336 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.09 -147.88 19.52 Favored Glycine 0 C--N 1.341 0.848 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 -173.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -109.75 143.0 40.17 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 117.486 0.643 . . . . 0.0 109.404 177.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.537 HG21 HG22 ' A' ' 27' ' ' VAL . 22.0 t -128.73 144.96 36.42 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 123.425 0.69 . . . . 0.0 109.862 -174.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.632 ' HG2' HD13 ' A' ' 88' ' ' ILE . 10.5 mmt180 -94.94 123.71 38.56 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 168.295 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 56.9 t -76.22 94.92 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.716 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.4 p -85.15 -39.84 17.42 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.307 0.643 . . . . 0.0 111.109 -178.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.4 m -77.65 164.55 25.22 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.911 173.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 24.3 mmt180 -65.88 130.23 94.41 Favored Pre-proline 0 CA--C 1.548 0.87 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 172.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -77.62 43.16 1.29 Allowed 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 123.502 2.801 . . . . 0.0 112.387 175.586 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -170.95 -137.3 2.27 Favored Glycine 0 C--N 1.334 0.461 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -172.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 21.2 tm0? 67.88 -72.33 0.1 Allowed 'General case' 0 N--CA 1.486 1.325 0 C-N-CA 124.608 1.163 . . . . 0.0 110.136 -177.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.425 ' HB3' HG12 ' A' ' 82' ' ' VAL . 33.3 t70 -91.45 -12.93 33.25 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 124.211 1.004 . . . . 0.0 110.31 171.106 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 94.56 -6.49 70.9 Favored Glycine 0 C--N 1.343 0.968 0 C-N-CA 123.386 0.517 . . . . 0.0 112.981 -174.06 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.425 HG12 ' HB3' ' A' ' 80' ' ' ASP . 14.5 p -92.83 141.42 14.68 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.512 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 31.5 mt -96.09 146.87 6.58 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -152.66 152.07 31.33 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -169.0 -167.34 29.48 Favored Glycine 0 C--N 1.343 0.972 0 CA-C-O 120.015 -0.325 . . . . 0.0 113.028 -178.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.509 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 35.9 m -116.46 132.68 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 123.776 0.83 . . . . 0.0 110.925 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 38.8 tp -71.63 106.07 3.91 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 123.463 0.705 . . . . 0.0 111.13 -176.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.632 HD13 ' HG2' ' A' ' 72' ' ' ARG . 41.4 pt -97.34 171.65 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.524 0.73 . . . . 0.0 110.262 175.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 16.7 mmt180 -115.22 21.15 14.4 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.671 0.788 . . . . 0.0 110.235 -173.108 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.449 ' HB2' HD12 ' A' ' 88' ' ' ILE . 33.9 tt0 -64.8 -75.9 0.08 Allowed 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.433 0.693 . . . . 0.0 112.657 -164.343 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 58.3 mt -81.33 69.08 7.88 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-O 121.834 0.826 . . . . 0.0 110.316 -173.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -77.77 121.27 23.83 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -62.52 -28.4 69.82 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 122.288 0.235 . . . . 0.0 111.497 -174.76 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 35.4 t60 -74.27 -36.59 63.82 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 122.966 0.506 . . . . 0.0 110.638 177.077 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.1 t60 -58.85 128.99 40.0 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 123.607 0.763 . . . . 0.0 109.949 -179.25 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 69.6 t60 -60.74 111.67 1.72 Allowed 'General case' 0 CA--C 1.544 0.741 0 O-C-N 124.26 0.975 . . . . 0.0 111.047 -175.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 74.5 t60 -63.88 137.15 57.9 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 115.256 -0.884 . . . . 0.0 109.217 172.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 38.9 p-80 . . . . . 0 C--O 1.25 1.124 0 C-N-CA 124.109 0.964 . . . . 0.0 109.312 -178.254 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.785 0 N-CA-C 112.651 -0.18 . . . . 0.0 112.651 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -84.01 117.02 23.13 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 123.537 0.735 . . . . 0.0 109.71 -179.28 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 22.6 mmm180 -110.3 123.84 50.56 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 123.049 0.54 . . . . 0.0 110.043 -179.582 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 15.7 ptt180 -145.16 97.41 3.0 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 124.23 1.012 . . . . 0.0 109.292 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 38.3 t -92.22 103.55 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 123.191 0.596 . . . . 0.0 109.515 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 55.3 ttt180 -110.03 138.74 45.98 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.598 0.759 . . . . 0.0 109.636 178.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -157.06 101.47 1.93 Allowed 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 177.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.2 tt -114.55 135.1 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 124.243 1.017 . . . . 0.0 109.244 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -125.64 117.68 24.03 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.704 0.802 . . . . 0.0 109.302 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 35.9 p -72.04 89.16 1.11 Allowed 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 123.79 0.836 . . . . 0.0 110.44 -178.381 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 25.1 mmt180 -105.42 117.24 33.5 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.011 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 177.7 50.99 0.07 OUTLIER Glycine 0 C--N 1.34 0.776 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 178.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.31 111.99 4.37 Favored Glycine 0 C--N 1.354 1.574 0 N-CA-C 112.259 -0.336 . . . . 0.0 112.259 -176.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 39.6 m-80 -76.19 107.43 8.42 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.108 0.563 . . . . 0.0 110.254 -178.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 15.4 p -72.46 96.93 1.99 Allowed 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 123.215 0.606 . . . . 0.0 110.076 174.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 13.2 ptmm? -76.45 99.22 4.82 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.107 173.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 14.9 p -163.53 162.34 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 123.74 0.816 . . . . 0.0 109.702 -169.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.1 mpt_? -74.05 171.4 13.58 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 123.975 0.91 . . . . 0.0 110.502 177.261 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.441 ' HB3' ' HB2' ' A' ' 24' ' ' ARG . 2.0 pp -62.04 143.08 57.09 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.078 0.551 . . . . 0.0 112.45 -178.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -159.7 116.02 2.52 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.798 0.839 . . . . 0.0 108.86 -179.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 45.4 m 68.55 -70.33 0.13 Allowed 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 125.138 1.375 . . . . 0.0 111.174 -175.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . 0.545 ' HB2' HH12 ' A' ' 24' ' ' ARG . 3.7 m-20 -77.24 109.68 11.32 Favored 'General case' 0 C--O 1.247 0.945 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 175.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 26.2 m -65.24 132.59 49.49 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 122.984 0.514 . . . . 0.0 110.694 -177.226 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.545 HH12 ' HB2' ' A' ' 22' ' ' ASP . 77.3 mmt-85 -102.21 134.8 44.89 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.42 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 14.2 tt -140.18 136.11 37.27 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 123.85 0.86 . . . . 0.0 109.745 -175.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 25.2 m-80 -85.55 100.59 12.02 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 177.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.2 t -87.4 108.23 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -176.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 40.9 t -95.54 101.67 12.7 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.412 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -63.83 116.43 26.69 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 175.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -71.47 -19.76 28.17 Favored 'Trans proline' 0 C--N 1.368 1.559 0 C-N-CA 123.232 2.621 . . . . 0.0 113.194 -171.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -92.67 -52.94 4.39 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 123.499 0.72 . . . . 0.0 110.822 -171.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 62.8 p -90.9 -27.83 18.5 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 123.424 0.69 . . . . 0.0 111.476 -177.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.62 4.73 69.87 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-N 116.416 -0.356 . . . . 0.0 113.369 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -71.45 118.74 14.65 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 123.293 0.637 . . . . 0.0 110.818 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.4 t -108.33 134.84 48.97 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 123.679 0.792 . . . . 0.0 108.908 177.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -152.22 148.81 28.02 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 122.87 0.468 . . . . 0.0 110.357 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.429 HG22 ' HD2' ' A' ' 24' ' ' ARG . 51.6 mt -87.12 98.31 7.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.89 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.21 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -95.87 172.21 8.16 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 124.282 1.033 . . . . 0.0 110.646 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -108.26 131.99 54.13 Favored 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 176.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.495 HG12 HG22 ' A' ' 66' ' ' THR . 57.1 mt -75.27 112.66 13.1 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.602 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 177.697 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 40.4 mtt-85 -73.11 -52.9 12.52 Favored 'General case' 0 N--CA 1.475 0.825 0 CA-C-O 122.253 1.025 . . . . 0.0 109.418 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.613 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 29.8 t30 -126.04 112.3 15.71 Favored 'General case' 0 CA--C 1.538 0.512 0 CA-C-N 113.365 -1.743 . . . . 0.0 108.73 -169.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.422 HG11 HD22 ' A' ' 56' ' ' ASN . 28.8 m -81.08 -15.8 12.48 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 123.175 0.59 . . . . 0.0 111.282 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -78.8 143.9 11.92 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.917 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 174.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.38 -57.85 3.56 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 175.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 7.2 p30 171.98 123.33 0.02 OUTLIER 'General case' 0 C--O 1.245 0.819 0 C-N-CA 125.994 1.717 . . . . 0.0 107.376 -176.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 20.2 p -143.91 -74.18 0.26 Allowed 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -175.12 115.3 0.15 Allowed 'General case' 0 C--O 1.239 0.514 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -177.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 72.2 m-20 62.78 88.73 0.12 Allowed Pre-proline 0 CA--C 1.551 0.993 0 C-N-CA 123.968 0.907 . . . . 0.0 109.913 -173.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -76.03 17.47 0.72 Allowed 'Trans proline' 0 C--N 1.375 1.945 0 C-N-CA 122.944 2.429 . . . . 0.0 114.219 -174.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.6 t60 -83.4 62.23 6.63 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 123.637 0.775 . . . . 0.0 110.005 178.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 48.6 t80 53.03 67.03 1.06 Allowed 'General case' 0 CA--C 1.556 1.19 0 C-N-CA 125.364 1.466 . . . . 0.0 112.128 179.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.43 HG23 ' HG2' ' A' ' 54' ' ' ARG . 12.2 m -94.15 -21.41 5.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.671 171.319 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.43 ' HG2' HG23 ' A' ' 53' ' ' VAL . 9.3 mmm180 -108.38 158.89 17.1 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 124.058 0.943 . . . . 0.0 108.754 177.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 31.2 mmm180 -82.29 171.07 14.65 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.447 0.699 . . . . 0.0 111.494 -176.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.422 HD22 HG11 ' A' ' 43' ' ' VAL . 13.9 m120 -78.5 21.05 0.39 Allowed 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.808 0.843 . . . . 0.0 111.83 177.087 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.1 mt -72.98 93.68 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 174.091 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.403 ' O ' ' HG3' ' A' ' 77' ' ' PRO . 82.9 mt -93.75 128.68 44.97 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.379 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 38.1 p -126.3 164.29 21.37 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.569 0.748 . . . . 0.0 109.657 -177.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 45.2 ttp180 -73.47 141.41 46.83 Favored 'General case' 0 N--CA 1.482 1.138 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 176.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.88 2.57 90.33 Favored Glycine 0 C--N 1.345 1.06 0 O-C-N 123.198 0.311 . . . . 0.0 112.971 -176.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.0 163.12 16.46 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 123.525 0.73 . . . . 0.0 110.774 179.285 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 38.8 t -110.01 124.85 67.09 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 173.319 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 20.9 m -112.88 168.45 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 168.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.613 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 28.0 tt0 -115.19 134.33 55.24 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 170.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.495 HG22 HG12 ' A' ' 40' ' ' ILE . 43.8 p -123.87 -177.77 3.85 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.843 0.857 . . . . 0.0 109.551 -173.611 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.8 m-20 -58.38 -28.72 65.42 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 122.933 0.493 . . . . 0.0 111.318 175.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 77.8 mt -90.07 -45.71 8.97 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.258 0.623 . . . . 0.0 110.748 -178.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 165.66 -166.04 38.29 Favored Glycine 0 N--CA 1.477 1.416 0 CA-C-O 119.715 -0.492 . . . . 0.0 112.093 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -73.26 132.98 43.78 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 117.653 0.727 . . . . 0.0 109.843 176.609 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 65.2 t -128.74 144.89 36.67 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.905 0 C-N-CA 124.402 1.081 . . . . 0.0 110.29 -174.006 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.553 ' HG2' HG21 ' A' ' 88' ' ' ILE . 33.2 mmt180 -84.98 121.25 27.51 Favored 'General case' 0 N--CA 1.479 1.017 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 168.309 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.5 t -73.21 122.88 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 70.9 p -107.72 -23.9 11.92 Favored 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 123.179 0.592 . . . . 0.0 110.999 -176.129 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 45.7 m -93.05 176.92 6.23 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-O 121.309 0.576 . . . . 0.0 111.751 176.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 30.8 mmt180 -106.65 127.09 28.8 Favored Pre-proline 0 C--O 1.241 0.635 0 CA-C-N 114.839 -1.073 . . . . 0.0 108.404 171.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.403 ' HG3' ' O ' ' A' ' 58' ' ' ILE . 37.1 Cg_endo -60.24 120.24 7.89 Favored 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 123.228 2.619 . . . . 0.0 112.474 -176.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 91.38 -36.68 3.56 Favored Glycine 0 C--N 1.341 0.824 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.994 176.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 14.3 mm100 -64.24 -31.81 73.15 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.691 0.796 . . . . 0.0 111.836 -174.316 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -106.24 6.23 30.55 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.718 0.807 . . . . 0.0 111.566 178.639 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 85.57 -61.32 4.59 Favored Glycine 0 C--N 1.349 1.276 0 C-N-CA 123.086 0.374 . . . . 0.0 112.273 -175.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -113.26 159.52 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 124.467 1.107 . . . . 0.0 108.793 175.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 25' ' ' ILE . 41.1 mt -92.52 147.68 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 174.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -125.37 162.98 23.58 Favored 'General case' 0 C--O 1.246 0.888 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 171.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.28 179.38 41.41 Favored Glycine 0 C--N 1.335 0.519 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.952 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.2 m -121.42 131.0 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 C-N-CA 123.433 0.693 . . . . 0.0 109.437 175.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 21.4 tp -67.26 131.27 45.42 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.132 0.573 . . . . 0.0 110.006 -177.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.553 HG21 ' HG2' ' A' ' 72' ' ' ARG . 33.4 pt -123.15 161.12 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 121.665 0.745 . . . . 0.0 111.276 -176.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 26.5 mmt180 -115.94 8.29 14.63 Favored 'General case' 0 CA--C 1.548 0.884 0 CA-C-N 114.195 -1.366 . . . . 0.0 109.636 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -60.28 -62.14 2.09 Favored 'General case' 0 C--N 1.358 0.951 0 C-N-CA 123.959 0.904 . . . . 0.0 112.237 -172.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 22.4 mt -66.64 152.73 44.79 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 123.364 0.415 . . . . 0.0 111.035 -179.031 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 15.1 tp10 -58.93 -43.4 91.14 Favored 'General case' 0 N--CA 1.472 0.673 0 O-C-N 124.352 1.032 . . . . 0.0 110.039 -176.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 9.2 t-80 58.22 31.84 21.29 Favored 'General case' 0 CA--C 1.552 1.048 0 C-N-CA 124.646 1.178 . . . . 0.0 111.664 172.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 16.3 m170 -80.33 71.22 7.11 Favored 'General case' 0 N--CA 1.478 0.939 0 CA-C-O 122.188 0.994 . . . . 0.0 109.39 174.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -121.17 9.53 10.49 Favored 'General case' 0 CA--C 1.555 1.138 0 CA-C-N 113.86 -1.518 . . . . 0.0 108.542 178.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 40.5 t60 -150.69 145.37 25.77 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 126.175 1.79 . . . . 0.0 107.563 -177.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -69.71 119.96 14.74 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 123.411 0.684 . . . . 0.0 110.909 -177.024 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 4.2 t60 . . . . . 0 CA--C 1.551 0.985 0 C-N-CA 123.601 0.76 . . . . 0.0 109.133 178.938 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.325 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -167.89 172.25 9.17 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 124.037 0.935 . . . . 0.0 109.009 -177.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -68.02 144.64 55.04 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 122.762 0.425 . . . . 0.0 111.253 177.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 5.5 mmp_? -79.35 169.95 17.33 Favored 'General case' 0 N--CA 1.481 1.079 0 CA-C-N 115.395 -0.821 . . . . 0.0 109.699 175.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.7 t -60.42 93.15 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 C-N-CA 123.402 0.681 . . . . 0.0 109.257 179.177 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.7 ptt180 -80.53 154.19 27.66 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.293 -171.211 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -81.27 -6.75 59.22 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.997 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 60.4 mt -70.83 97.16 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.76 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 169.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 3.2 ppt_? -107.02 -6.25 17.59 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.127 0.971 . . . . 0.0 111.198 -177.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 25.5 m -66.64 89.75 0.16 Allowed 'General case' 0 CA--C 1.552 1.033 0 C-N-CA 123.69 0.796 . . . . 0.0 111.146 -174.154 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 25.6 tpt180 -170.42 105.13 0.28 Allowed 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.261 1.424 . . . . 0.0 107.449 179.273 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 127.87 179.89 16.11 Favored Glycine 0 N--CA 1.466 0.699 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -175.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 162.33 -133.09 2.99 Favored Glycine 0 C--N 1.339 0.733 0 N-CA-C 111.532 -0.627 . . . . 0.0 111.532 -179.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -83.54 73.76 10.18 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 176.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 86.8 m -137.19 111.0 8.15 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.16 -0.927 . . . . 0.0 108.781 177.002 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.584 ' HE3' HD11 ' A' ' 37' ' ' ILE . 0.0 OUTLIER -165.11 158.57 16.82 Favored 'General case' 0 C--O 1.24 0.585 0 C-N-CA 123.374 0.67 . . . . 0.0 109.669 177.799 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 7.9 p -70.7 146.07 12.3 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 165.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.72 175.75 2.81 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 122.65 0.38 . . . . 0.0 110.76 174.283 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.439 HD21 ' HA ' ' A' ' 82' ' ' VAL . 2.2 pt? -52.41 102.72 0.05 Allowed 'General case' 0 CA--C 1.559 1.323 0 CA-C-O 121.94 0.876 . . . . 0.0 110.939 174.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -135.32 -54.3 0.79 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.079 -175.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 38.0 p -63.04 -40.09 96.67 Favored 'General case' 0 CA--C 1.546 0.816 0 CA-C-N 114.706 -1.133 . . . . 0.0 110.724 175.043 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -158.96 153.44 24.22 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 124.205 1.002 . . . . 0.0 109.158 178.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.44 HG22 HD12 ' A' ' 40' ' ' ILE . 91.4 m -76.21 110.39 10.67 Favored 'General case' 0 CA--C 1.548 0.868 0 CA-C-O 121.624 0.726 . . . . 0.0 111.177 -176.284 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.518 ' HG2' ' HA ' ' A' ' 39' ' ' GLU . 36.8 mtm180 -127.23 170.1 12.79 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 124.835 1.254 . . . . 0.0 110.81 177.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.1 tt -135.7 136.21 50.51 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-N 114.566 -1.197 . . . . 0.0 108.95 -179.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . 0.437 ' HB2' HD22 ' A' ' 84' ' ' ASN . 71.1 m-20 -89.78 102.1 14.8 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 177.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.44 HG22 HG11 ' A' ' 71' ' ' VAL . 58.5 t -98.78 136.38 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 123.873 0.869 . . . . 0.0 110.563 -170.006 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.58 HG22 HG22 ' A' ' 35' ' ' VAL . 30.1 t -122.0 122.29 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -63.98 124.43 85.15 Favored Pre-proline 0 N--CA 1.48 1.027 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 171.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -68.79 -20.0 40.31 Favored 'Trans proline' 0 CA--C 1.554 1.488 0 C-N-CA 122.145 1.897 . . . . 0.0 112.476 178.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.465 ' HG3' HG23 ' A' ' 32' ' ' THR . 12.8 pt-20 -88.2 -51.35 5.82 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.02 0.928 . . . . 0.0 112.115 -176.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.465 HG23 ' HG3' ' A' ' 31' ' ' GLU . 70.4 p -97.87 -21.49 16.87 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.125 0.57 . . . . 0.0 111.792 -173.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.8 5.28 89.54 Favored Glycine 0 C--N 1.349 1.269 0 CA-C-O 119.682 -0.51 . . . . 0.0 113.524 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -73.68 123.89 24.94 Favored 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 123.27 0.628 . . . . 0.0 111.352 -174.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.58 HG22 HG22 ' A' ' 28' ' ' VAL . 24.8 t -95.73 128.86 46.55 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.712 0 C-N-CA 123.872 0.869 . . . . 0.0 109.422 176.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 14.1 tp10 -141.42 133.8 28.18 Favored 'General case' 0 C--O 1.239 0.53 0 C-N-CA 124.483 1.113 . . . . 0.0 108.574 175.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.584 HD11 ' HE3' ' A' ' 16' ' ' LYS . 46.6 mt -79.32 98.92 3.14 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.46 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -86.02 158.93 19.73 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.703 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.518 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 38.9 mt-10 -101.82 124.95 48.31 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 123.48 0.712 . . . . 0.0 109.433 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.44 HD12 HG22 ' A' ' 23' ' ' THR . 61.7 mt -76.44 108.69 9.5 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 47.8 mtt180 -82.87 -53.26 6.0 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.261 1.024 . . . . 0.0 110.672 -179.389 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 59.8 t30 -146.04 160.07 42.39 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 -176.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.607 ' HB ' HH22 ' A' ' 54' ' ' ARG . 30.9 m -116.95 29.7 2.48 Favored 'Isoleucine or valine' 0 C--O 1.246 0.877 0 C-N-CA 123.523 0.729 . . . . 0.0 112.03 -174.313 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 m -68.05 90.67 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 CA-C-O 122.086 0.946 . . . . 0.0 110.59 173.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.541 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 37.9 mt-10 -67.47 -36.17 80.62 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 114.483 -1.235 . . . . 0.0 110.635 178.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -133.72 118.42 18.08 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-N 114.541 -1.209 . . . . 0.0 108.11 179.68 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.452 HG21 HD11 ' A' ' 91' ' ' LEU . 55.3 p -82.07 -15.96 51.7 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 122.516 0.327 . . . . 0.0 111.472 178.128 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -68.53 -43.35 76.91 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 123.462 0.705 . . . . 0.0 110.437 175.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -162.83 90.42 1.27 Allowed Pre-proline 0 CA--C 1.55 0.95 0 C-N-CA 123.882 0.873 . . . . 0.0 109.278 175.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.87 116.7 4.75 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.412 2.075 . . . . 0.0 110.823 174.114 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 46.8 m80 -73.44 92.91 1.91 Allowed 'General case' 0 C--O 1.243 0.711 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -80.36 74.86 7.2 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-O 121.86 0.838 . . . . 0.0 109.896 -176.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 11.5 t -111.59 -9.68 11.88 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.944 0 CA-C-N 114.576 -1.193 . . . . 0.0 108.075 169.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.607 HH22 ' HB ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -150.95 163.34 38.94 Favored 'General case' 0 CA--C 1.546 0.806 0 C-N-CA 125.296 1.438 . . . . 0.0 109.554 -173.973 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 14.9 ptm180 -150.72 -49.24 0.12 Allowed 'General case' 0 N--CA 1.482 1.147 0 C-N-CA 123.405 0.682 . . . . 0.0 110.594 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -96.19 -7.72 35.0 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 122.837 0.455 . . . . 0.0 110.291 177.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 72.9 mt -89.43 111.28 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 174.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.2 mt -115.29 140.45 36.64 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.558 0 C-N-CA 124.488 1.115 . . . . 0.0 108.434 179.6 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 33.9 p -126.15 174.4 8.52 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 124.134 0.974 . . . . 0.0 109.149 178.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 52.7 ttp180 -71.25 139.92 50.21 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 122.716 0.406 . . . . 0.0 110.154 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.76 -8.48 70.94 Favored Glycine 0 C--N 1.337 0.595 0 C-N-CA 123.644 0.64 . . . . 0.0 112.83 -177.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.94 134.54 52.21 Favored 'General case' 0 C--N 1.351 0.669 0 C-N-CA 123.611 0.765 . . . . 0.0 111.89 -177.008 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.541 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 44.1 t -90.76 112.87 25.69 Favored 'Isoleucine or valine' 0 C--N 1.344 0.341 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 169.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.6 m -106.26 147.13 12.07 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 123.482 0.713 . . . . 0.0 109.271 177.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -90.73 126.44 36.0 Favored 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 175.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.46 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 67.2 p -130.85 179.79 5.77 Favored 'General case' 0 C--O 1.239 0.552 0 C-N-CA 123.259 0.623 . . . . 0.0 109.774 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 19.2 p-10 -73.59 -14.69 61.23 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 123.341 0.656 . . . . 0.0 111.192 175.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.1 mt -91.16 -41.09 11.21 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 123.249 0.62 . . . . 0.0 110.325 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 155.79 -149.97 21.2 Favored Glycine 0 C--N 1.345 1.074 0 CA-C-N 116.239 -0.437 . . . . 0.0 112.056 175.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 22.1 m120 -78.91 128.49 33.38 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 173.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.44 HG11 HG22 ' A' ' 27' ' ' VAL . 48.7 t -126.85 140.33 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 122.792 0.437 . . . . 0.0 110.4 -178.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.743 ' HG2' HD13 ' A' ' 88' ' ' ILE . 29.2 mmt180 -88.89 131.5 35.09 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 169.461 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 82.2 t -76.87 106.72 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 171.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 40.5 p -96.38 -19.92 18.85 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.044 0.538 . . . . 0.0 110.92 -172.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . 0.509 ' HB2' ' HB2' ' A' ' 84' ' ' ASN . 32.4 t -87.49 171.08 10.79 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.378 0.671 . . . . 0.0 110.391 175.32 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 -93.48 92.84 0.72 Allowed Pre-proline 0 CA--C 1.559 1.315 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 173.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -62.73 -46.36 11.41 Favored 'Trans proline' 0 C--N 1.384 2.422 0 C-N-CA 123.431 2.754 . . . . 0.0 113.958 -163.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -81.19 -13.5 80.71 Favored Glycine 0 C--N 1.345 1.039 0 CA-C-O 119.959 -0.356 . . . . 0.0 113.54 -177.201 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 18.5 mm-40 -90.14 -48.39 7.21 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 122.981 0.513 . . . . 0.0 111.352 -178.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -80.67 -14.05 58.48 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 122.82 0.448 . . . . 0.0 111.294 174.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 68.36 18.53 71.6 Favored Glycine 0 C--N 1.349 1.254 0 O-C-N 123.205 0.316 . . . . 0.0 112.785 -175.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.439 ' HA ' HD21 ' A' ' 19' ' ' LEU . 11.6 p -143.25 143.87 24.3 Favored 'Isoleucine or valine' 0 C--O 1.24 0.555 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 178.211 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 29.0 mt -106.37 117.63 52.5 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -176.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.509 ' HB2' ' HB2' ' A' ' 75' ' ' SER . 9.4 m120 -124.7 151.4 45.04 Favored 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 178.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -160.9 -178.26 34.72 Favored Glycine 0 C--N 1.339 0.733 0 N-CA-C 115.141 0.816 . . . . 0.0 115.141 -174.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.402 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 30.0 m -121.51 139.5 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.637 0.775 . . . . 0.0 110.147 175.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.3 tp -74.03 122.23 22.32 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.093 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.743 HD13 ' HG2' ' A' ' 72' ' ' ARG . 46.8 pt -124.06 -177.89 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 C-N-CA 124.615 1.166 . . . . 0.0 109.198 175.208 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 29.5 mmm180 -139.45 90.67 2.43 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -176.623 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -88.95 -50.07 6.4 Favored 'General case' 0 N--CA 1.484 1.229 0 CA-C-O 121.496 0.665 . . . . 0.0 109.629 178.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.452 HD11 HG21 ' A' ' 47' ' ' THR . 69.1 mt -95.45 -179.2 4.68 Favored 'General case' 0 C--O 1.245 0.843 0 CA-C-N 114.508 -1.224 . . . . 0.0 109.735 176.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 64.91 70.9 0.47 Allowed 'General case' 0 N--CA 1.477 0.919 0 C-N-CA 124.167 0.987 . . . . 0.0 111.457 175.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 8.5 p80 -161.19 161.53 30.96 Favored 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 115.036 -0.984 . . . . 0.0 110.025 -178.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 75.1 m-70 -70.84 102.74 2.43 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 175.288 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 -71.74 91.95 1.16 Allowed 'General case' 0 CA--C 1.554 1.101 0 C-N-CA 123.388 0.675 . . . . 0.0 111.974 -175.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 53.7 t-80 -76.1 -30.45 58.27 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.508 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -104.25 144.27 31.83 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 123.363 0.665 . . . . 0.0 109.537 176.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 49.8 t60 . . . . . 0 CA--C 1.548 0.904 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 176.347 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.965 0 CA-C-O 120.082 -0.288 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -70.48 98.78 1.5 Allowed 'General case' 0 C--N 1.354 0.763 0 C-N-CA 123.617 0.767 . . . . 0.0 109.178 175.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -89.13 120.56 30.63 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 122.888 0.475 . . . . 0.0 111.065 -176.424 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 24.1 ptt180 -157.14 141.09 16.15 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 123.723 0.809 . . . . 0.0 109.186 173.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 48.8 t -99.66 127.65 52.27 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 176.633 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 18.1 ttm180 -152.15 90.17 1.5 Allowed 'General case' 0 C--O 1.24 0.59 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 79.2 mt -81.75 91.32 6.45 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.551 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.6 tp -68.66 133.94 31.0 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.166 0 C-N-CA 123.387 0.675 . . . . 0.0 110.252 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 31.9 tpt180 -148.03 85.4 1.54 Allowed 'General case' 0 C--O 1.238 0.452 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 -176.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.1 m -95.77 90.28 5.6 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.486 -178.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -73.56 132.15 42.51 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 123.456 0.703 . . . . 0.0 110.394 176.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 179.2 64.27 0.07 OUTLIER Glycine 0 C--O 1.242 0.613 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.988 -175.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.39 75.65 0.66 Allowed Glycine 0 C--N 1.35 1.361 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 174.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -70.95 135.93 48.2 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 124.071 0.949 . . . . 0.0 110.878 -169.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 43.8 p -68.37 110.04 3.93 Favored 'General case' 0 CA--C 1.55 0.964 0 C-N-CA 123.499 0.719 . . . . 0.0 109.597 176.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.464 ' H ' ' HD2' ' A' ' 16' ' ' LYS . 0.0 OUTLIER -109.68 -178.55 3.57 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 123.467 0.707 . . . . 0.0 111.514 -174.136 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.4 p -72.27 151.16 8.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.944 0 C-N-CA 124.396 1.078 . . . . 0.0 109.739 174.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 35.7 mmt180 -62.87 -68.69 0.32 Allowed 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -169.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.416 ' HA ' ' O ' ' A' ' 22' ' ' ASP . 2.6 pt? -140.52 26.13 2.16 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 -171.704 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.7 -21.69 59.25 Favored 'General case' 0 N--CA 1.484 1.227 0 N-CA-C 112.305 0.484 . . . . 0.0 112.305 178.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 70.7 m -132.81 -66.14 0.68 Allowed 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.69 0.796 . . . . 0.0 109.284 177.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . 0.416 ' O ' ' HA ' ' A' ' 19' ' ' LEU . 1.7 m-20 -84.96 111.74 19.96 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.912 0.885 . . . . 0.0 108.662 174.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 52.8 m -65.43 111.36 3.04 Favored 'General case' 0 C--N 1.351 0.635 0 CA-C-N 118.28 0.491 . . . . 0.0 109.693 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 16.1 mmt180 -117.74 152.81 34.52 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-O 121.469 0.652 . . . . 0.0 111.599 -173.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.511 ' HB ' HD11 ' A' ' 40' ' ' ILE . 15.8 tt -141.96 142.18 28.3 Favored 'Isoleucine or valine' 0 C--O 1.241 0.643 0 CA-C-N 114.139 -1.391 . . . . 0.0 109.054 176.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 88.5 m-20 -90.82 100.82 13.61 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 173.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.6 t -86.17 112.85 23.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.538 0 C-N-CA 124.623 1.169 . . . . 0.0 109.205 -175.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.405 HG22 HG22 ' A' ' 35' ' ' VAL . 41.5 t -94.81 100.33 10.91 Favored 'Isoleucine or valine' 0 C--O 1.239 0.549 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 176.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -64.16 113.65 11.07 Favored Pre-proline 0 CA--C 1.546 0.821 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 172.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.52 -1.18 11.38 Favored 'Trans proline' 0 C--N 1.364 1.378 0 C-N-CA 122.518 2.146 . . . . 0.0 113.591 -172.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -91.97 -52.68 4.6 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.337 0.655 . . . . 0.0 109.325 -177.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 66.7 p -93.29 -32.58 14.26 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 124.468 1.107 . . . . 0.0 111.909 -179.198 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 93.51 6.98 62.17 Favored Glycine 0 CA--C 1.53 1.01 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.986 -173.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -69.89 107.77 3.7 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 123.08 0.552 . . . . 0.0 110.994 -178.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.405 HG22 HG22 ' A' ' 28' ' ' VAL . 23.6 t -90.9 119.92 38.91 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 172.597 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -142.52 143.48 32.54 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 122.993 0.517 . . . . 0.0 110.466 -174.302 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 62.1 mt -77.45 123.85 34.82 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.86 0 C-N-CA 123.555 0.742 . . . . 0.0 109.661 179.068 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.41 158.12 36.8 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 123.89 0.876 . . . . 0.0 110.149 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -97.74 121.05 39.19 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.511 HD11 ' HB ' ' A' ' 25' ' ' ILE . 54.7 mt -77.74 112.55 15.84 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 72.3 mtm180 -80.71 -38.21 29.24 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 124.512 1.125 . . . . 0.0 111.113 -178.098 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 47.4 t-20 -140.76 138.95 34.51 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -179.107 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.7 m -93.96 -27.05 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 123.324 0.65 . . . . 0.0 112.425 -176.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.7 m -93.23 148.28 4.87 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.762 0 CA-C-O 121.193 0.52 . . . . 0.0 110.711 179.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.426 ' HB3' ' HB ' ' A' ' 63' ' ' VAL . 8.4 pt-20 -94.35 93.19 7.56 Favored 'General case' 0 N--CA 1.479 0.975 0 C-N-CA 123.7 0.8 . . . . 0.0 111.517 -171.433 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 64.2 t30 71.77 -19.43 0.27 Allowed 'General case' 0 N--CA 1.502 2.142 0 C-N-CA 125.483 1.513 . . . . 0.0 113.224 173.09 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 37.8 p -67.16 98.07 0.57 Allowed 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 124.356 1.063 . . . . 0.0 111.277 -169.508 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.21 -36.35 58.62 Favored 'General case' 0 N--CA 1.47 0.533 0 C-N-CA 123.649 0.779 . . . . 0.0 110.96 -176.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -112.03 117.97 47.07 Favored Pre-proline 0 CA--C 1.554 1.13 0 C-N-CA 122.923 0.489 . . . . 0.0 110.001 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_exo -72.18 128.51 13.93 Favored 'Trans proline' 0 C--N 1.379 2.145 0 C-N-CA 123.09 2.526 . . . . 0.0 112.171 178.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 55.8 p-80 -161.27 -42.26 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 123.681 0.793 . . . . 0.0 110.219 175.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 20.7 m-85 -92.65 -47.93 6.85 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 169.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 16.7 m -92.85 163.93 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 168.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 2.4 tmm_? -171.24 -32.83 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -177.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 26.2 mtm180 -66.3 157.01 32.75 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 124.262 1.025 . . . . 0.0 111.643 -177.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -105.43 29.52 6.43 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.32 0.648 . . . . 0.0 109.86 178.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 15.8 tt -117.36 147.89 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 123.113 0.565 . . . . 0.0 109.703 -173.136 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 76.3 mt -91.58 143.56 11.02 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.698 0 C-N-CA 124.426 1.09 . . . . 0.0 109.723 175.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.46 HG23 ' HB2' ' A' ' 62' ' ' ALA . 3.3 t -131.32 172.16 12.49 Favored 'General case' 0 C--O 1.244 0.766 0 C-N-CA 123.915 0.886 . . . . 0.0 109.261 177.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 25.3 ttm180 -74.03 133.79 42.97 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 -178.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 81.88 -2.83 82.36 Favored Glycine 0 C--N 1.35 1.352 0 CA-C-O 119.956 -0.358 . . . . 0.0 112.924 -176.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.46 ' HB2' HG23 ' A' ' 59' ' ' THR . . . -77.6 132.06 38.1 Favored 'General case' 0 C--O 1.244 0.796 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 176.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.601 HG21 ' HG3' ' A' ' 90' ' ' GLU . 21.9 t -83.18 114.08 23.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 177.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 33.4 m -101.57 146.45 9.85 Favored 'Isoleucine or valine' 0 C--O 1.244 0.793 0 N-CA-C 108.717 -0.846 . . . . 0.0 108.717 177.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 12.8 tp10 -95.83 128.24 42.54 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 63.2 p -124.86 177.86 5.8 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 24.0 p-10 -72.42 -12.26 61.03 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 122.794 0.438 . . . . 0.0 110.743 175.372 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.3 mt -93.41 -49.77 5.77 Favored 'General case' 0 C--N 1.357 0.918 0 C-N-CA 123.079 0.551 . . . . 0.0 110.425 175.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 168.73 -150.66 16.33 Favored Glycine 0 C--N 1.348 1.21 0 O-C-N 123.177 0.298 . . . . 0.0 113.253 178.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -88.23 118.09 27.59 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 123.836 0.854 . . . . 0.0 109.122 -178.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.2 t -121.27 144.86 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 C-N-CA 123.467 0.707 . . . . 0.0 109.4 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.497 ' HG3' HD13 ' A' ' 88' ' ' ILE . 24.4 mtt180 -109.66 131.91 54.63 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 171.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.1 t -80.36 98.99 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 O-C-N 124.172 0.92 . . . . 0.0 109.243 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 35.5 p -74.48 -28.59 61.08 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 123.792 0.837 . . . . 0.0 111.781 177.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.1 m -90.58 -170.78 2.83 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.921 177.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.412 ' HD2' ' N ' ' A' ' 76' ' ' ARG . 8.4 mpt_? -96.54 112.15 59.23 Favored Pre-proline 0 CA--C 1.545 0.784 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -62.37 96.02 0.15 Allowed 'Trans proline' 0 C--N 1.377 2.03 0 C-N-CA 123.148 2.565 . . . . 0.0 112.837 -172.11 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.77 -23.45 32.5 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.69 -0.686 . . . . 0.0 113.999 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -72.97 -30.43 63.83 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-N 117.956 0.878 . . . . 0.0 110.491 175.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -77.04 4.33 10.37 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 123.569 0.748 . . . . 0.0 111.287 171.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 90.62 -33.95 4.39 Favored Glycine 0 C--N 1.356 1.682 0 N-CA-C 111.596 -0.602 . . . . 0.0 111.596 -172.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.0 p -140.2 164.27 22.75 Favored 'Isoleucine or valine' 0 C--O 1.243 0.751 0 C-N-CA 124.729 1.212 . . . . 0.0 108.395 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 45.2 mt -84.5 132.88 30.53 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 173.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -133.66 144.66 49.34 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 -177.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -171.73 -172.74 38.02 Favored Glycine 0 C--N 1.342 0.901 0 N-CA-C 114.825 0.69 . . . . 0.0 114.825 -177.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 16.5 m -119.28 137.38 53.39 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 C-N-CA 123.943 0.897 . . . . 0.0 110.357 -176.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 41.8 tp -74.08 109.35 7.51 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 122.632 0.373 . . . . 0.0 110.438 -179.118 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.497 HD13 ' HG3' ' A' ' 72' ' ' ARG . 31.6 pt -102.52 179.6 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.83 0 C-N-CA 123.802 0.841 . . . . 0.0 109.865 174.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 5.0 mpt_? -125.76 55.96 1.42 Allowed 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.601 ' HG3' HG21 ' A' ' 63' ' ' VAL . 0.8 OUTLIER -60.47 -57.84 11.02 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 -179.967 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 74.9 mt -99.63 -151.86 0.4 Allowed 'General case' 0 CA--C 1.545 0.77 0 CA-C-N 114.7 -1.136 . . . . 0.0 107.946 169.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -122.02 148.83 44.33 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 165.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 51.4 t60 -92.53 30.68 1.47 Allowed 'General case' 0 CA--C 1.554 1.123 0 CA-C-O 122.284 1.04 . . . . 0.0 108.775 170.048 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -133.3 140.64 47.56 Favored 'General case' 0 C--O 1.24 0.596 0 C-N-CA 125.354 1.462 . . . . 0.0 107.446 -175.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 15.0 m-70 -60.53 132.0 52.5 Favored 'General case' 0 N--CA 1.476 0.859 0 O-C-N 123.931 0.769 . . . . 0.0 111.62 -177.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 11.5 m-70 -94.83 152.28 18.53 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.7 0.8 . . . . 0.0 109.47 170.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -74.73 94.91 2.78 Favored 'General case' 0 CA--C 1.54 0.56 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 174.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 10.4 m170 . . . . . 0 CA--C 1.548 0.871 0 C-N-CA 123.73 0.812 . . . . 0.0 109.959 177.134 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.706 0 N-CA-C 111.727 -0.549 . . . . 0.0 111.727 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -158.98 163.78 36.16 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.765 0.826 . . . . 0.0 110.255 -175.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 19.6 mmt180 -71.33 -2.55 16.71 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 123.762 0.825 . . . . 0.0 112.689 -177.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 7.8 ptm85 -59.93 131.37 50.65 Favored 'General case' 0 CA--C 1.552 1.052 0 C-N-CA 123.868 0.867 . . . . 0.0 110.986 176.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 85.9 t -111.63 99.45 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 174.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 11.4 ptm180 -83.77 86.73 7.1 Favored 'General case' 0 C--O 1.239 0.542 0 CA-C-O 122.005 0.907 . . . . 0.0 109.061 175.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 6.3 tt -65.87 128.11 34.71 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-N 114.365 -1.289 . . . . 0.0 109.839 -176.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -140.29 148.6 22.27 Favored 'Isoleucine or valine' 0 C--O 1.243 0.76 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -74.11 70.99 1.61 Allowed 'General case' 0 N--CA 1.485 1.318 0 CA-C-O 122.122 0.963 . . . . 0.0 110.313 174.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 10.2 t -77.2 137.87 39.11 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 114.808 -1.087 . . . . 0.0 110.087 -175.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -94.84 86.15 4.61 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 123.503 0.721 . . . . 0.0 110.291 -173.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -152.66 174.77 31.45 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 114.441 -1.254 . . . . 0.0 111.493 177.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.95 81.16 0.91 Allowed Glycine 0 C--N 1.342 0.901 0 C-N-CA 122.728 0.204 . . . . 0.0 112.935 -177.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 67.2 t30 -84.56 -14.45 48.84 Favored 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 123.505 0.722 . . . . 0.0 109.976 173.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.43 HG22 ' HD2' ' A' ' 16' ' ' LYS . 4.3 m -76.63 165.48 24.7 Favored 'General case' 0 CA--C 1.552 1.04 0 C-N-CA 123.971 0.908 . . . . 0.0 110.178 177.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.43 ' HD2' HG22 ' A' ' 15' ' ' THR . 13.0 mptt 60.96 56.74 2.75 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 123.97 0.908 . . . . 0.0 109.729 -173.437 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.5 t -69.15 113.65 5.14 Favored 'Isoleucine or valine' 0 C--O 1.24 0.584 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.915 -178.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.445 ' HG2' ' H ' ' A' ' 20' ' ' ALA . 0.2 OUTLIER -63.33 -178.05 0.23 Allowed 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 123.591 0.756 . . . . 0.0 110.769 171.591 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.484 HD22 ' HA ' ' A' ' 23' ' ' THR . 0.7 OUTLIER -54.81 -33.65 61.8 Favored 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -179.847 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.451 ' H ' HD12 ' A' ' 19' ' ' LEU . . . 52.41 74.91 0.25 Allowed 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 125.143 1.377 . . . . 0.0 112.615 171.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 12.9 t 74.52 -16.54 0.54 Allowed 'General case' 0 N--CA 1.496 1.837 0 C-N-CA 125.295 1.438 . . . . 0.0 112.855 -178.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -89.89 -176.19 4.85 Favored 'General case' 0 CA--C 1.548 0.878 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 173.325 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.539 HG22 HD12 ' A' ' 40' ' ' ILE . 52.4 m -141.32 115.21 9.14 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -177.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -127.18 158.82 36.08 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.543 0.737 . . . . 0.0 111.516 -175.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.479 ' HB ' HD11 ' A' ' 40' ' ' ILE . 16.1 tt -145.6 148.75 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.731 0.813 . . . . 0.0 110.395 -171.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 37.7 m-80 -89.32 103.6 16.22 Favored 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 172.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 75.8 t -89.39 109.82 20.84 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 C-N-CA 123.932 0.893 . . . . 0.0 109.053 -176.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 37.0 t -100.01 110.05 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 123.199 0.6 . . . . 0.0 109.654 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -59.2 112.68 5.48 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 170.338 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.2 -16.97 19.48 Favored 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 121.926 1.751 . . . . 0.0 111.747 179.104 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -94.37 -45.18 7.57 Favored 'General case' 0 CA--C 1.552 1.032 0 C-N-CA 124.344 1.058 . . . . 0.0 111.184 178.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.6 m -90.2 -20.01 23.54 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 123.362 0.665 . . . . 0.0 112.02 -175.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.17 -11.52 57.54 Favored Glycine 0 C--N 1.35 1.317 0 C-N-CA 123.422 0.534 . . . . 0.0 114.223 178.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 46.5 mmtm -75.39 150.59 38.32 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.814 0.846 . . . . 0.0 112.132 -173.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 21.1 t -126.12 133.83 67.94 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.797 0.839 . . . . 0.0 108.774 174.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 14.3 tp10 -147.61 141.3 25.61 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.611 0.764 . . . . 0.0 109.537 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 47.5 mt -81.92 122.87 37.43 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.8 0 N-CA-C 108.264 -1.014 . . . . 0.0 108.264 178.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.35 161.41 27.88 Favored 'General case' 0 C--O 1.236 0.382 0 C-N-CA 124.796 1.238 . . . . 0.0 109.517 -174.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -106.43 123.7 48.47 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -175.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.539 HD12 HG22 ' A' ' 23' ' ' THR . 59.5 mt -76.41 113.29 15.23 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 C-N-CA 123.388 0.675 . . . . 0.0 109.955 -176.259 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -77.4 -53.29 7.83 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.634 1.174 . . . . 0.0 110.264 -178.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -140.23 166.61 24.22 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 124.158 0.983 . . . . 0.0 108.704 178.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 43.9 t -112.62 87.87 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 167.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.2 p -133.08 127.71 55.22 Favored 'Isoleucine or valine' 0 C--O 1.242 0.687 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.727 -177.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.565 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 13.6 pt-20 -88.72 -56.11 3.43 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.406 -175.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 9.6 m120 -148.12 159.34 44.03 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.422 1.089 . . . . 0.0 108.85 -176.238 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.461 HG23 HD22 ' A' ' 91' ' ' LEU . 59.7 p -78.88 -31.93 45.67 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 122.864 0.466 . . . . 0.0 110.778 176.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -71.45 84.2 0.82 Allowed 'General case' 0 CA--C 1.54 0.594 0 O-C-N 123.866 0.729 . . . . 0.0 109.605 178.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 59.36 84.09 0.2 Allowed Pre-proline 0 CA--C 1.548 0.887 0 C-N-CA 125.11 1.364 . . . . 0.0 111.406 -176.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -71.94 102.63 1.36 Allowed 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 122.174 1.916 . . . . 0.0 109.897 176.076 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 83.0 t60 -61.01 -26.85 67.89 Favored 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 122.636 0.374 . . . . 0.0 110.918 -177.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -73.45 87.65 1.58 Allowed 'General case' 0 CA--C 1.547 0.834 0 N-CA-C 108.126 -1.065 . . . . 0.0 108.126 164.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 48.7 t -64.8 -49.21 81.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 175.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 4.0 ppt_? -79.59 140.99 36.97 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-N 114.31 -1.314 . . . . 0.0 109.352 168.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 6.7 ppt_? -94.3 29.71 2.14 Favored 'General case' 0 N--CA 1.482 1.151 0 CA-C-O 121.229 0.538 . . . . 0.0 110.637 179.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 -131.11 -178.69 4.94 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 125.035 1.334 . . . . 0.0 109.536 178.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 49.4 mm 60.42 82.08 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.255 0 C-N-CA 125.05 1.34 . . . . 0.0 110.42 177.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 37.1 mt -83.23 144.4 10.14 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 113.962 -1.472 . . . . 0.0 109.595 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 17.5 p -122.82 167.94 12.89 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.051 0.941 . . . . 0.0 109.052 173.05 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 35.7 ttt180 -74.16 131.38 41.22 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 175.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.94 9.4 77.52 Favored Glycine 0 N--CA 1.465 0.613 0 O-C-N 124.076 0.86 . . . . 0.0 112.843 -175.386 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -83.16 160.95 21.73 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.145 0.578 . . . . 0.0 109.603 176.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.565 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 47.7 t -105.99 120.9 57.67 Favored 'Isoleucine or valine' 0 C--O 1.243 0.748 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 172.325 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.4 m -106.5 159.55 6.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.228 175.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -106.85 130.08 54.59 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 173.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.421 HG22 HG12 ' A' ' 40' ' ' ILE . 34.0 p -129.61 -175.18 3.51 Favored 'General case' 0 C--O 1.24 0.556 0 C-N-CA 123.241 0.616 . . . . 0.0 109.813 -176.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 73.3 m-20 -70.28 -19.26 63.11 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 123.134 0.574 . . . . 0.0 111.024 175.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 93.8 mt -99.45 -13.73 19.41 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 123.907 0.883 . . . . 0.0 111.755 -178.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.45 -164.16 22.42 Favored Glycine 0 C--N 1.35 1.32 0 O-C-N 123.349 0.406 . . . . 0.0 112.528 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -80.09 130.45 35.26 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.142 0.577 . . . . 0.0 110.394 177.76 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.6 t -125.5 138.9 52.93 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 C-N-CA 124.468 1.107 . . . . 0.0 110.663 -173.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.829 ' HG2' HD13 ' A' ' 88' ' ' ILE . 9.5 mmt180 -86.4 121.03 28.38 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 169.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 48.9 t -72.98 116.75 15.6 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.768 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 43.8 p -96.97 -24.58 15.75 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.456 0.702 . . . . 0.0 111.238 -172.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 23.3 t -108.55 178.5 4.47 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.533 0.733 . . . . 0.0 109.84 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 85.8 mtm180 -90.62 106.69 16.18 Favored Pre-proline 0 CA--C 1.552 1.049 0 C-N-CA 123.383 0.673 . . . . 0.0 109.976 -177.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -66.22 114.44 3.03 Favored 'Trans proline' 0 C--N 1.373 1.835 0 C-N-CA 123.101 2.534 . . . . 0.0 112.357 -175.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 141.94 -29.88 2.18 Favored Glycine 0 C--N 1.344 0.981 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.339 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -60.84 110.73 1.4 Allowed 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.342 0.657 . . . . 0.0 110.49 178.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.506 ' HB2' HG12 ' A' ' 82' ' ' VAL . 26.8 m-20 70.26 -15.79 0.33 Allowed 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 125.66 1.584 . . . . 0.0 114.04 178.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 98.05 12.52 45.84 Favored Glycine 0 C--N 1.342 0.907 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -169.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 80' ' ' ASP . 3.7 p -111.32 118.59 57.81 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 C-N-CA 123.603 0.761 . . . . 0.0 109.573 175.085 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.2 mt -98.24 148.03 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 170.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -135.16 149.14 49.91 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 122.937 0.495 . . . . 0.0 109.819 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -168.25 -175.54 37.97 Favored Glycine 0 C--N 1.346 1.102 0 O-C-N 123.648 0.592 . . . . 0.0 113.482 -176.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.2 m -129.1 138.7 53.8 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 C-N-CA 124.248 1.019 . . . . 0.0 110.42 178.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.6 tp -73.86 122.73 22.96 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 121.094 0.473 . . . . 0.0 111.271 -175.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.829 HD13 ' HG2' ' A' ' 72' ' ' ARG . 40.1 pt -119.17 -179.65 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 123.884 0.874 . . . . 0.0 109.623 175.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 57.4 mtt180 -122.79 83.29 2.1 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 -176.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 36.2 mm-40 -93.2 -80.91 0.37 Allowed 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 175.087 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.461 HD22 HG23 ' A' ' 47' ' ' THR . 50.8 mt -83.12 96.88 8.53 Favored 'General case' 0 C--N 1.344 0.327 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -175.435 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -72.56 -9.44 58.58 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 123.304 0.642 . . . . 0.0 110.701 175.035 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 3.2 p80 -134.16 141.92 47.26 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.848 1.659 . . . . 0.0 107.964 173.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 6.0 t-160 -84.65 -46.21 11.73 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -177.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -89.91 123.65 34.03 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.279 0.632 . . . . 0.0 110.11 176.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 7.0 p80 -86.39 104.83 16.25 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 12.7 t60 -162.08 132.77 4.96 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 122.725 0.41 . . . . 0.0 110.39 -170.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 . . . . . 0 C--O 1.251 1.166 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 173.022 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.619 0 N-CA-C 111.667 -0.573 . . . . 0.0 111.667 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -73.08 96.13 2.14 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 122.917 0.487 . . . . 0.0 109.831 177.28 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 27.8 mmm180 -84.17 69.3 10.38 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.992 0.901 . . . . 0.0 109.828 -178.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 77.1 mtp180 -97.79 21.37 10.59 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.693 1.197 . . . . 0.0 110.923 -176.104 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.4 p -39.44 96.5 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.566 1.591 0 C-N-CA 125.552 1.541 . . . . 0.0 114.528 -170.168 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 45.81 66.31 0.96 Allowed 'General case' 0 C--N 1.358 0.973 0 C-N-CA 126.492 1.917 . . . . 0.0 112.038 176.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 51.6 tp -62.37 -38.33 89.13 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.646 -176.559 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 tt -61.6 148.7 9.49 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.486 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.103 178.56 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 24.6 tpt180 -55.1 -30.37 59.55 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 125.006 1.323 . . . . 0.0 112.66 -175.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 46.1 p -64.74 92.3 0.09 Allowed 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 123.443 0.697 . . . . 0.0 111.31 -178.024 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.9 mmt85 -108.0 143.74 36.28 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 124.385 1.074 . . . . 0.0 109.688 177.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -172.8 89.86 0.08 OUTLIER Glycine 0 C--N 1.338 0.639 0 CA-C-N 115.679 -0.691 . . . . 0.0 111.844 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -121.5 20.19 8.38 Favored Glycine 0 C--N 1.336 0.568 0 N-CA-C 111.546 -0.621 . . . . 0.0 111.546 170.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 17.5 m120 -133.07 88.34 2.49 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 123.974 0.91 . . . . 0.0 108.806 179.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 11.2 t -148.48 170.17 18.64 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.788 0.835 . . . . 0.0 109.446 178.452 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt 67.15 128.44 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.425 0 C-N-CA 125.05 1.34 . . . . 0.0 111.099 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 10.9 p -100.7 131.79 47.63 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 172.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.05 178.13 4.69 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 123.645 0.778 . . . . 0.0 109.944 176.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -55.26 122.32 10.83 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.4 0.68 . . . . 0.0 110.443 178.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -121.06 -85.54 0.66 Allowed 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -175.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 19.7 m -88.68 -26.75 21.67 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 172.58 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -80.77 162.13 24.22 Favored 'General case' 0 CA--C 1.548 0.866 0 CA-C-N 114.099 -1.41 . . . . 0.0 110.462 168.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.495 HG22 HD12 ' A' ' 40' ' ' ILE . 62.9 m -127.25 118.07 23.52 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.118 0.567 . . . . 0.0 109.973 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 41.8 mtt180 -115.01 163.6 15.36 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.732 0.813 . . . . 0.0 110.519 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.493 ' HB ' HD11 ' A' ' 40' ' ' ILE . 16.6 tt -141.75 135.49 30.03 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 124.025 0.93 . . . . 0.0 108.802 175.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -85.67 103.27 14.33 Favored 'General case' 0 C--O 1.24 0.589 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 177.154 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -92.08 133.27 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 123.802 0.841 . . . . 0.0 109.886 -171.495 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 46.7 t -109.8 109.81 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 178.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -66.61 119.07 60.24 Favored Pre-proline 0 CA--C 1.545 0.78 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 176.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -66.11 -33.84 39.3 Favored 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 123.003 2.468 . . . . 0.0 113.667 -166.003 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -95.36 -40.4 9.54 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 112.85 0.685 . . . . 0.0 112.85 -171.61 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 71.3 p -89.51 -21.24 23.03 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 122.464 0.306 . . . . 0.0 111.533 179.673 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.49 2.76 90.63 Favored Glycine 0 C--N 1.347 1.192 0 CA-C-O 119.882 -0.399 . . . . 0.0 113.572 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 33.6 mmtp -68.25 107.26 2.73 Favored 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.504 0.722 . . . . 0.0 110.971 -177.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.2 t -92.59 126.11 45.12 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 174.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -154.21 146.79 24.12 Favored 'General case' 0 C--O 1.239 0.503 0 C-N-CA 123.831 0.853 . . . . 0.0 108.813 -176.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 45.2 mt -80.87 137.41 21.41 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -177.523 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.98 159.49 32.52 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.672 0.789 . . . . 0.0 109.713 -179.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 17.1 mm-40 -103.17 122.57 44.98 Favored 'General case' 0 C--O 1.241 0.651 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.495 HD12 HG22 ' A' ' 23' ' ' THR . 44.5 mt -76.95 110.11 12.21 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -176.612 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 62.3 mtt180 -73.85 -52.3 13.45 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.149 0.979 . . . . 0.0 110.91 178.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -140.75 164.11 31.09 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.817 0.847 . . . . 0.0 110.14 -176.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 70.8 t -132.14 103.25 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.168 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 176.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.2 p -162.33 96.81 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.562 1.431 0 CA-C-O 121.822 0.82 . . . . 0.0 109.603 -175.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.542 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 0.7 OUTLIER -72.83 -40.57 65.66 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.339 0.656 . . . . 0.0 112.769 -172.015 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -78.02 -21.15 51.19 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 122.812 0.445 . . . . 0.0 110.747 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 44.2 p 65.52 -58.45 0.3 Allowed 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 126.829 2.052 . . . . 0.0 111.733 -171.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -72.37 73.95 1.0 Allowed 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 123.417 0.687 . . . . 0.0 110.978 173.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 50.4 t-20 -173.1 74.98 0.41 Allowed Pre-proline 0 CA--C 1.552 1.022 0 C-N-CA 125.213 1.405 . . . . 0.0 107.603 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -88.62 59.84 2.67 Favored 'Trans proline' 0 C--N 1.373 1.83 0 C-N-CA 123.314 2.676 . . . . 0.0 111.792 -177.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 8.1 t-160 -65.94 120.38 12.99 Favored 'General case' 0 CA--C 1.546 0.797 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.859 -175.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -52.81 -39.35 62.34 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 124.14 0.976 . . . . 0.0 113.241 -171.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 10.4 p -74.27 110.61 8.65 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.127 0 CA-C-O 121.525 0.679 . . . . 0.0 109.252 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 76.2 mtp180 -72.04 94.36 1.49 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.54 -178.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 28.8 mmm180 -122.48 103.93 9.04 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 175.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 25.3 p-10 -86.04 55.67 3.63 Favored 'General case' 0 CA--C 1.547 0.84 0 CA-C-O 122.119 0.962 . . . . 0.0 110.727 179.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.8 mm -77.55 93.02 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.539 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 72.1 mt -80.37 127.43 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 123.424 0.69 . . . . 0.0 109.764 -176.468 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 74.0 p -124.74 160.6 28.26 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 123.79 0.836 . . . . 0.0 109.427 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -75.68 128.23 34.77 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 122.964 0.506 . . . . 0.0 110.261 179.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 98.31 -1.24 58.82 Favored Glycine 0 C--N 1.34 0.754 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.441 -176.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -94.1 148.12 22.49 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.642 0.777 . . . . 0.0 111.479 -176.767 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.542 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 94.6 t -83.49 118.94 31.89 Favored 'Isoleucine or valine' 0 C--O 1.24 0.592 0 C-N-CA 123.406 0.682 . . . . 0.0 109.604 171.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.0 m -102.77 143.32 15.29 Favored 'Isoleucine or valine' 0 C--O 1.24 0.574 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 165.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -94.18 123.68 37.72 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 66.2 p -123.19 -173.08 2.64 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.141 0.577 . . . . 0.0 110.047 -175.05 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 58.2 m-20 -73.38 -26.99 61.23 Favored 'General case' 0 N--CA 1.478 0.932 0 CA-C-O 119.851 -0.118 . . . . 0.0 110.902 170.131 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 70.1 mt -84.13 -28.25 27.6 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 122.916 0.486 . . . . 0.0 111.843 -176.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 146.96 -149.55 21.71 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 178.579 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -85.55 128.11 34.65 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 175.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.7 t -121.72 128.6 75.78 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.526 0 C-N-CA 122.656 0.383 . . . . 0.0 110.862 -179.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.546 ' HG2' HD13 ' A' ' 88' ' ' ILE . 22.6 mmt85 -85.58 123.29 30.83 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 171.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.6 t -72.32 100.13 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.515 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 47.5 p -95.4 -22.55 17.65 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 123.253 0.621 . . . . 0.0 110.803 -169.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 21.6 t -98.32 -177.81 3.83 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 169.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.663 ' HE ' ' HB3' ' A' ' 79' ' ' GLN . 39.6 ptt180 -75.26 144.0 77.71 Favored Pre-proline 0 CA--C 1.551 1.014 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 173.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -76.71 50.63 3.08 Favored 'Trans proline' 0 CA--C 1.559 1.762 0 C-N-CA 123.091 2.527 . . . . 0.0 113.273 174.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 172.8 67.08 0.05 OUTLIER Glycine 0 C--N 1.346 1.126 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.977 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . 0.663 ' HB3' ' HE ' ' A' ' 76' ' ' ARG . 1.7 pt20 -123.41 115.33 21.43 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.999 0.92 . . . . 0.0 108.604 172.562 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 62.39 19.3 11.01 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 124.339 1.055 . . . . 0.0 111.335 -176.013 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 92.86 -6.25 76.68 Favored Glycine 0 C--N 1.353 1.474 0 CA-C-N 116.033 -0.53 . . . . 0.0 112.496 178.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.8 p -120.3 163.71 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 C-N-CA 123.004 0.522 . . . . 0.0 111.008 -175.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 42.3 mt -109.31 147.54 13.73 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 C-N-CA 124.696 1.198 . . . . 0.0 109.169 -178.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -130.03 155.5 46.03 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 118.414 0.552 . . . . 0.0 110.774 174.449 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.515 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -166.84 -169.38 30.37 Favored Glycine 0 C--N 1.348 1.199 0 CA-C-N 115.367 -0.833 . . . . 0.0 113.652 -177.611 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.1 m -125.61 146.8 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 CA-C-N 117.789 0.795 . . . . 0.0 111.045 178.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 17.5 tp -84.6 104.61 14.74 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 122.607 0.363 . . . . 0.0 111.224 -176.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.546 HD13 ' HG2' ' A' ' 72' ' ' ARG . 50.0 pt -93.71 174.95 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 123.08 0.552 . . . . 0.0 110.765 178.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -119.57 27.39 8.78 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 124.022 0.929 . . . . 0.0 110.298 -170.206 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.95 -61.41 2.4 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 124.378 1.071 . . . . 0.0 110.792 -170.361 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -127.26 109.46 11.84 Favored 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 165.732 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 12.0 tp10 -63.05 132.29 51.46 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 123.233 0.613 . . . . 0.0 110.773 -179.135 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 26.5 p-80 -64.5 -31.23 72.35 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.898 0.479 . . . . 0.0 111.042 -177.173 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 32.1 t60 -80.21 79.48 6.77 Favored 'General case' 0 CA--C 1.541 0.63 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 170.039 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 53.3 t-80 -108.51 72.57 0.84 Allowed 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 124.095 0.958 . . . . 0.0 109.742 -172.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 9.9 t60 -171.53 88.63 0.11 Allowed 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 175.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 10.3 t60 -76.2 93.36 3.36 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 176.544 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 14.7 p-80 . . . . . 0 CA--C 1.556 1.201 0 C-N-CA 122.891 0.476 . . . . 0.0 110.07 -179.671 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.366 0 N-CA-C 111.763 -0.535 . . . . 0.0 111.763 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -64.39 132.45 50.12 Favored 'General case' 0 C--N 1.352 0.7 0 C-N-CA 123.63 0.772 . . . . 0.0 110.081 177.231 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -131.2 147.04 52.55 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 174.409 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -72.64 80.68 1.1 Allowed 'General case' 0 CA--C 1.544 0.715 0 O-C-N 123.543 0.527 . . . . 0.0 109.819 177.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 61.0 t -72.71 120.06 20.62 Favored 'Isoleucine or valine' 0 C--N 1.345 0.387 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 174.426 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 15.4 tpp180 -59.15 116.79 4.09 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 123.966 0.906 . . . . 0.0 110.923 -169.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -74.53 81.44 1.97 Allowed 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 174.035 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 50.4 mt -79.42 78.84 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.462 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 176.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 35.6 ttm180 -73.3 115.15 12.31 Favored 'General case' 0 C--O 1.238 0.451 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.625 -178.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 32.1 p -83.36 62.91 6.99 Favored 'General case' 0 CA--C 1.547 0.831 0 CA-C-O 121.926 0.869 . . . . 0.0 110.945 -173.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 4.8 mmp_? -120.01 112.27 18.94 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 125.239 1.416 . . . . 0.0 107.888 175.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.77 77.37 1.9 Allowed Glycine 0 CA--C 1.529 0.944 0 O-C-N 123.773 0.671 . . . . 0.0 112.646 -175.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -132.69 19.43 4.47 Favored Glycine 0 N--CA 1.473 1.149 0 CA-C-O 119.941 -0.366 . . . . 0.0 113.101 -179.242 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . 0.496 HD22 HG22 ' A' ' 17' ' ' VAL . 9.4 t30 -164.44 96.64 0.77 Allowed 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.803 0.841 . . . . 0.0 108.889 179.569 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 58.4 m -75.61 -37.98 59.35 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 123.426 0.69 . . . . 0.0 110.786 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -75.61 85.47 2.66 Favored 'General case' 0 CA--C 1.542 0.671 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.12 -178.199 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.496 HG22 HD22 ' A' ' 14' ' ' ASN . 23.7 t -119.22 139.85 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 123.866 0.866 . . . . 0.0 108.857 -179.573 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -65.25 148.75 51.13 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 171.14 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.578 HD22 ' HB2' ' A' ' 24' ' ' ARG . 0.9 OUTLIER -51.95 91.81 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 124.71 1.204 . . . . 0.0 112.745 -176.041 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -110.16 -14.08 14.25 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 114.449 -1.25 . . . . 0.0 111.424 -177.009 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 36.6 t -58.09 -46.21 85.9 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.846 0.858 . . . . 0.0 109.774 173.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -150.69 147.73 27.71 Favored 'General case' 0 C--O 1.244 0.782 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 168.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 63.7 m -68.98 111.84 5.25 Favored 'General case' 0 C--N 1.354 0.79 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 173.285 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.578 ' HB2' HD22 ' A' ' 19' ' ' LEU . 13.4 mmt85 -97.56 165.08 12.15 Favored 'General case' 0 C--O 1.244 0.771 0 CA-C-O 121.713 0.768 . . . . 0.0 110.441 -178.446 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 13.0 tt -136.54 134.18 49.2 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 CA-C-N 114.09 -1.413 . . . . 0.0 107.893 174.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . 0.427 ' HB2' HD22 ' A' ' 84' ' ' ASN . 82.8 m-20 -88.68 100.53 13.19 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 91.7 t -87.32 116.04 28.96 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.169 -173.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.408 HG22 HG22 ' A' ' 35' ' ' VAL . 58.2 t -95.17 99.65 9.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -178.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.418 ' HB3' ' HB2' ' A' ' 34' ' ' LYS . 11.5 t70 -59.88 110.98 3.24 Favored Pre-proline 0 CA--C 1.545 0.774 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 170.277 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -82.73 -4.63 11.47 Favored 'Trans proline' 0 CA--C 1.547 1.131 0 C-N-CA 122.535 2.157 . . . . 0.0 113.043 -174.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.5 mm-40 -76.23 -58.58 3.2 Favored 'General case' 0 C--N 1.353 0.759 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -177.079 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.9 p -95.76 -32.73 12.58 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 114.578 -1.192 . . . . 0.0 112.127 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 107.01 14.39 19.05 Favored Glycine 0 N--CA 1.477 1.427 0 CA-C-O 119.793 -0.448 . . . . 0.0 113.224 -178.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.418 ' HB2' ' HB3' ' A' ' 29' ' ' ASP . 63.6 mttp -63.15 148.44 48.0 Favored 'General case' 0 N--CA 1.486 1.369 0 C-N-CA 122.757 0.423 . . . . 0.0 111.589 175.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.408 HG22 HG22 ' A' ' 28' ' ' VAL . 44.1 t -127.04 120.29 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 167.528 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 16.7 mm-40 -130.77 139.93 50.26 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 123.74 0.816 . . . . 0.0 110.062 -176.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 53.5 mt -79.15 120.46 30.39 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 177.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.24 155.5 33.08 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 123.964 0.905 . . . . 0.0 111.175 -173.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -99.19 127.32 45.15 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 174.638 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 61.6 mt -77.58 111.28 14.21 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 C-N-CA 123.035 0.534 . . . . 0.0 110.612 -175.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.412 ' H ' ' HA ' ' A' ' 66' ' ' THR . 15.6 mmm180 -66.77 -44.34 81.63 Favored 'General case' 0 N--CA 1.483 1.225 0 C-N-CA 123.718 0.807 . . . . 0.0 110.77 174.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.573 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 37.4 t30 -140.32 125.65 18.83 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.68 -169.583 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.436 HG12 HD11 ' A' ' 58' ' ' ILE . 17.9 m -87.86 -34.53 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 O-C-N 124.031 0.832 . . . . 0.0 111.686 -178.063 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.9 p -78.19 134.61 27.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 C-N-CA 122.784 0.434 . . . . 0.0 110.212 -177.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 14.5 pt-20 -59.35 111.97 1.57 Allowed 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 123.41 0.684 . . . . 0.0 111.8 -172.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.501 HD22 HD22 ' A' ' 91' ' ' LEU . 14.7 m120 64.93 6.27 3.31 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 124.889 1.276 . . . . 0.0 113.358 172.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.444 HG23 ' ND2' ' A' ' 42' ' ' ASN . 44.2 p 52.29 28.39 5.64 Favored 'General case' 0 N--CA 1.5 2.038 0 C-N-CA 124.797 1.239 . . . . 0.0 111.431 -161.544 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.34 -47.77 39.73 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 124.244 1.018 . . . . 0.0 110.404 177.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 55.3 m-20 -75.95 114.77 40.33 Favored Pre-proline 0 CA--C 1.551 0.981 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.681 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -90.03 26.94 0.49 Allowed 'Trans proline' 0 C--N 1.372 1.79 0 C-N-CA 123.316 2.677 . . . . 0.0 113.168 -175.245 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 53.5 m-70 -86.42 146.08 26.58 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 123.274 0.63 . . . . 0.0 110.144 -179.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 26.4 p90 -80.48 -2.6 46.61 Favored 'General case' 0 N--CA 1.486 1.33 0 C-N-CA 123.549 0.74 . . . . 0.0 112.54 -176.037 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.9 m -79.37 49.49 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 C-N-CA 123.977 0.911 . . . . 0.0 111.788 179.053 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 45.9 mtt180 -91.76 51.28 1.82 Allowed 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.992 0.917 . . . . 0.0 110.796 -174.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 6.2 mpt_? -78.1 178.4 7.58 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 168.645 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -82.03 58.31 3.88 Favored 'General case' 0 CA--C 1.556 1.183 0 CA-C-O 122.206 1.003 . . . . 0.0 109.207 175.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 49.9 mm -106.88 81.51 0.59 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.561 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 175.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.436 HD11 HG12 ' A' ' 43' ' ' VAL . 67.9 mt -101.67 144.23 13.45 Favored 'Isoleucine or valine' 0 C--O 1.24 0.58 0 CA-C-N 114.48 -1.236 . . . . 0.0 109.065 -176.302 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 11.2 p -136.08 165.3 26.03 Favored 'General case' 0 C--O 1.242 0.675 0 C-N-CA 123.934 0.893 . . . . 0.0 109.702 -178.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -63.77 140.82 58.91 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 123.934 0.893 . . . . 0.0 111.118 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.01 -25.34 25.86 Favored Glycine 0 C--N 1.341 0.845 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.938 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.87 139.51 56.51 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.314 0.646 . . . . 0.0 110.987 -178.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 45' ' ' GLU . 93.2 t -93.57 110.56 23.52 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 172.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.3 m -100.64 141.79 16.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 177.185 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.573 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 40.7 tt0 -94.01 136.99 33.72 Favored 'General case' 0 C--O 1.234 0.243 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.412 ' HA ' ' H ' ' A' ' 41' ' ' ARG . 81.5 p -130.03 176.52 8.0 Favored 'General case' 0 C--O 1.246 0.875 0 C-N-CA 123.972 0.909 . . . . 0.0 109.144 -179.184 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 18.6 p-10 -63.45 -24.44 67.83 Favored 'General case' 0 CA--C 1.542 0.661 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.986 173.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 86.5 mt -88.66 -34.01 17.39 Favored 'General case' 0 C--N 1.354 0.782 0 C-N-CA 123.143 0.577 . . . . 0.0 110.555 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 150.37 -150.09 22.06 Favored Glycine 0 C--N 1.343 0.923 0 CA-C-N 116.593 -0.276 . . . . 0.0 112.423 173.332 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -78.9 129.73 34.85 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.582 0.753 . . . . 0.0 109.038 -179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.8 t -127.85 137.5 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 123.063 0.545 . . . . 0.0 110.635 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.711 ' HG2' HD13 ' A' ' 88' ' ' ILE . 13.4 mmt180 -90.77 118.26 30.05 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 169.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 58.1 t -72.04 109.1 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 178.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 29.3 p -98.54 -50.97 4.09 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 -171.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . 0.525 ' HB3' ' HB3' ' A' ' 84' ' ' ASN . 31.1 t -82.71 150.91 26.45 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.113 176.671 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.442 ' HD2' ' HD2' ' A' ' 77' ' ' PRO . 23.8 tpt180 -72.83 125.5 91.12 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 123.482 0.713 . . . . 0.0 109.611 175.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.442 ' HD2' ' HD2' ' A' ' 76' ' ' ARG . 85.2 Cg_exo -51.72 101.61 0.05 OUTLIER 'Trans proline' 0 C--N 1.378 2.084 0 C-N-CA 123.269 2.646 . . . . 0.0 111.509 163.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 140.4 -32.63 2.14 Favored Glycine 0 C--N 1.339 0.747 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 -176.009 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -65.94 113.34 4.34 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 171.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 30.5 t70 76.89 -19.12 0.44 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 125.523 1.529 . . . . 0.0 111.686 -170.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 109.4 -47.57 1.03 Allowed Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 -171.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.3 p -75.11 165.77 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 C-N-CA 123.756 0.822 . . . . 0.0 111.074 178.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 30.2 mt -93.8 148.15 5.05 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 169.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.525 ' HB3' ' HB3' ' A' ' 75' ' ' SER . 25.6 t-20 -136.56 147.35 46.97 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 174.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.53 -175.8 26.1 Favored Glycine 0 C--N 1.336 0.574 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.257 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.5 m -121.3 138.1 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 123.223 0.609 . . . . 0.0 109.9 174.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.4 ' HB3' ' HA ' ' A' ' 29' ' ' ASP . 41.9 tp -67.78 128.93 38.31 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 123.543 0.737 . . . . 0.0 110.128 178.32 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.711 HD13 ' HG2' ' A' ' 72' ' ' ARG . 44.5 pt -129.94 179.74 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 123.658 0.783 . . . . 0.0 110.702 -177.19 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 10.7 mmm180 -123.45 119.78 31.01 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 125.276 1.431 . . . . 0.0 107.247 171.59 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -149.83 -68.51 0.2 Allowed 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -177.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.501 HD22 HD22 ' A' ' 46' ' ' ASN . 2.0 pt? -127.0 78.62 1.82 Allowed 'General case' 0 N--CA 1.477 0.893 0 CA-C-O 122.318 1.056 . . . . 0.0 110.917 -177.008 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -73.36 -10.31 59.61 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.247 174.284 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -63.87 95.35 0.11 Allowed 'General case' 0 C--O 1.241 0.617 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 169.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 85.8 m-70 -61.34 137.92 58.24 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.333 -0.849 . . . . 0.0 109.943 -178.365 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 52.6 m80 -72.17 86.86 1.07 Allowed 'General case' 0 CA--C 1.546 0.819 0 O-C-N 123.726 0.641 . . . . 0.0 111.188 -175.235 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 23.8 p-80 -97.6 90.36 4.99 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 124.644 1.178 . . . . 0.0 108.858 173.068 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 35.7 t-80 -87.72 118.79 27.46 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.759 0.824 . . . . 0.0 110.222 -176.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 19.6 p-80 . . . . . 0 CA--C 1.555 1.17 0 O-C-N 123.436 0.46 . . . . 0.0 109.912 173.984 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.582 0 N-CA-C 112.584 -0.206 . . . . 0.0 112.584 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 53.5 m-20 -103.44 125.19 49.89 Favored 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.433 0.693 . . . . 0.0 109.849 178.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -95.71 113.4 25.04 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 174.307 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 74.9 ttt180 -77.84 85.17 4.12 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 122.672 0.389 . . . . 0.0 110.377 -177.468 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 48.2 t -74.47 -25.4 19.33 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.77 174.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.2 tpp180 -70.68 85.77 0.65 Allowed 'General case' 0 CA--C 1.548 0.88 0 C-N-CA 124.386 1.075 . . . . 0.0 110.166 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 1.6 tm? -116.26 89.7 3.17 Favored 'General case' 0 C--N 1.346 0.43 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 179.276 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 68.4 mt -91.01 134.74 28.72 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.841 173.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.75 138.83 39.68 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 123.809 0.843 . . . . 0.0 109.128 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 33.4 p -66.19 113.03 4.24 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 123.301 0.64 . . . . 0.0 110.883 -177.049 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 4.6 tmm_? -74.57 99.0 3.5 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 178.638 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -85.88 -172.79 49.07 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 116.374 -0.375 . . . . 0.0 112.522 176.402 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -169.42 -156.73 11.05 Favored Glycine 0 C--N 1.338 0.653 0 C-N-CA 121.933 -0.175 . . . . 0.0 112.775 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -88.9 10.09 22.53 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.637 0.775 . . . . 0.0 111.458 178.236 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 13.4 p -73.35 -174.89 1.75 Allowed 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 123.886 0.874 . . . . 0.0 111.479 171.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.9 ttmp? 65.63 91.53 0.08 Allowed 'General case' 0 C--N 1.36 1.037 0 C-N-CA 124.696 1.199 . . . . 0.0 109.475 -175.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.4 p -64.95 162.14 2.57 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.165 0 C-N-CA 122.943 0.497 . . . . 0.0 110.663 -178.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.609 ' H ' ' HD2' ' A' ' 18' ' ' ARG . 0.2 OUTLIER -54.76 -46.38 74.34 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 124.941 1.296 . . . . 0.0 111.079 -175.652 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.511 ' HA ' HH21 ' A' ' 24' ' ' ARG . 2.0 pp -160.37 156.69 26.6 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 124.902 1.281 . . . . 0.0 109.417 172.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -142.01 -70.73 0.34 Allowed 'General case' 0 N--CA 1.483 1.214 0 CA-C-O 120.609 0.242 . . . . 0.0 111.113 -177.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 24.7 m -111.32 33.68 4.53 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.403 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -160.96 179.59 8.34 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 114.79 -1.095 . . . . 0.0 110.393 -168.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.418 HG22 HD12 ' A' ' 40' ' ' ILE . 5.2 m -127.49 114.58 17.65 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 176.352 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.511 HH21 ' HA ' ' A' ' 19' ' ' LEU . 57.4 mtm180 -123.34 161.15 25.25 Favored 'General case' 0 C--O 1.244 0.8 0 C-N-CA 123.296 0.638 . . . . 0.0 110.807 178.106 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.9 tt -145.65 141.24 22.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.745 -170.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -84.07 102.57 12.62 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 175.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.7 t -93.9 115.26 32.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 C-N-CA 124.18 0.992 . . . . 0.0 109.085 -171.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.5 t -104.65 106.97 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 124.327 1.051 . . . . 0.0 109.011 -177.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -69.16 111.48 8.69 Favored Pre-proline 0 CA--C 1.544 0.725 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 175.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -74.1 -7.43 19.84 Favored 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.712 2.274 . . . . 0.0 113.506 -170.101 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -96.02 -52.75 3.91 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 122.685 0.394 . . . . 0.0 111.221 -177.527 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 77.1 p -102.14 -29.86 11.48 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 123.367 0.667 . . . . 0.0 112.548 -175.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.39 20.91 14.0 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-O 119.734 -0.481 . . . . 0.0 113.766 177.583 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 60.8 mttp -67.43 105.66 1.87 Allowed 'General case' 0 N--CA 1.484 1.25 0 CA-C-N 117.308 0.554 . . . . 0.0 110.665 175.04 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 44.5 t -108.85 115.65 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.7 tp10 -153.72 147.55 25.38 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.111 0.564 . . . . 0.0 109.66 -174.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 44.7 mt -83.77 100.07 6.9 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -177.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -90.82 160.09 15.94 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.975 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.448 ' HB2' ' ND2' ' A' ' 67' ' ' ASN . 37.5 mt-10 -105.61 122.24 45.62 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -177.17 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.463 HG12 HG22 ' A' ' 66' ' ' THR . 50.9 mt -75.76 111.81 12.64 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -172.751 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -73.77 -40.16 63.67 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 123.807 0.843 . . . . 0.0 110.335 178.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -143.89 130.68 20.3 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.864 -173.231 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.405 HG12 HD11 ' A' ' 58' ' ' ILE . 29.4 m -83.25 -7.49 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 122.99 0.516 . . . . 0.0 111.754 -175.298 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 35.1 m -119.45 167.84 12.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 C-N-CA 123.492 0.717 . . . . 0.0 109.974 176.373 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.496 ' HB3' ' HB ' ' A' ' 63' ' ' VAL . 11.2 pt-20 -89.88 -39.24 13.17 Favored 'General case' 0 N--CA 1.477 0.899 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 170.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -151.06 145.7 25.68 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.913 0.885 . . . . 0.0 108.966 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.5 t -132.23 135.11 46.07 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.505 0.722 . . . . 0.0 109.066 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -107.3 -45.65 4.05 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 123.516 0.726 . . . . 0.0 111.169 -175.289 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -146.16 115.55 4.67 Favored Pre-proline 0 N--CA 1.478 0.949 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.09 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -79.04 27.52 0.52 Allowed 'Trans proline' 0 C--N 1.371 1.722 0 C-N-CA 123.116 2.544 . . . . 0.0 114.484 -171.747 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.2 p80 -71.4 -29.0 64.42 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 122.646 0.378 . . . . 0.0 110.839 175.143 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 18.5 m-85 -102.41 177.86 4.75 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.471 0.709 . . . . 0.0 109.342 168.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.9 t 55.97 43.71 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 C-N-CA 124.964 1.305 . . . . 0.0 110.194 -176.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 30.7 mmm180 -72.07 -50.24 29.89 Favored 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 174.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -71.25 123.44 22.24 Favored 'General case' 0 C--O 1.244 0.801 0 CA-C-N 114.843 -1.071 . . . . 0.0 108.168 165.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 35.3 m-80 -73.69 80.65 1.54 Allowed 'General case' 0 CA--C 1.544 0.712 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 174.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.7 tp -110.51 132.17 59.61 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 179.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.487 HD13 HG11 ' A' ' 64' ' ' VAL . 61.6 mt -114.42 144.37 22.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 124.171 0.988 . . . . 0.0 108.493 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 31.2 p -121.9 167.98 12.42 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.265 0.626 . . . . 0.0 110.55 179.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 39.5 ttp180 -71.72 131.09 42.64 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.005 178.108 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.2 -2.3 83.45 Favored Glycine 0 C--N 1.342 0.914 0 C-N-CA 123.607 0.622 . . . . 0.0 113.005 -177.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -85.18 132.55 34.27 Favored 'General case' 0 C--O 1.246 0.881 0 C-N-CA 123.408 0.683 . . . . 0.0 110.137 179.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.496 ' HB ' ' HB3' ' A' ' 45' ' ' GLU . 41.4 t -82.73 113.61 22.24 Favored 'Isoleucine or valine' 0 C--N 1.352 0.69 0 CA-C-O 121.01 0.433 . . . . 0.0 110.029 178.537 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.487 HG11 HD13 ' A' ' 58' ' ' ILE . 34.1 m -102.28 166.94 2.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 169.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 26.4 tt0 -120.98 134.89 55.31 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 175.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.463 HG22 HG12 ' A' ' 40' ' ' ILE . 43.6 p -130.68 -176.23 3.91 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 124.263 1.025 . . . . 0.0 110.099 -171.347 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.448 ' ND2' ' HB2' ' A' ' 39' ' ' GLU . 97.3 m-20 -68.96 -23.59 64.15 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.06 175.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 73.8 mt -86.22 -41.34 14.72 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 123.183 0.302 . . . . 0.0 110.464 175.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 159.08 -159.29 30.25 Favored Glycine 0 C--N 1.345 1.045 0 O-C-N 123.443 0.464 . . . . 0.0 112.976 178.297 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 21.5 m120 -77.43 124.45 27.9 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 177.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 46.1 t -123.58 145.21 30.94 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.733 0 C-N-CA 124.438 1.095 . . . . 0.0 109.562 -175.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.443 ' HG3' HD13 ' A' ' 88' ' ' ILE . 30.1 mtt85 -107.7 137.04 46.44 Favored 'General case' 0 N--CA 1.483 1.18 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 168.337 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.476 HG11 ' HD3' ' A' ' 77' ' ' PRO . 58.1 t -75.09 120.26 24.32 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 O-C-N 124.273 0.983 . . . . 0.0 109.594 179.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.421 ' H ' ' HA2' ' A' ' 85' ' ' GLY . 40.2 p -98.38 -20.95 16.86 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 123.447 0.699 . . . . 0.0 110.429 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . 0.413 ' HB3' ' HB2' ' A' ' 84' ' ' ASN . 95.0 p -91.9 -173.16 3.41 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.379 0.672 . . . . 0.0 109.713 174.807 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 74.8 mtt180 -116.23 103.4 53.12 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 172.32 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.476 ' HD3' HG11 ' A' ' 73' ' ' VAL . 21.1 Cg_endo -57.71 151.54 54.86 Favored 'Trans proline' 0 C--N 1.382 2.297 0 C-N-CA 123.659 2.906 . . . . 0.0 113.632 -168.082 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.52 -35.01 4.2 Favored Glycine 0 C--N 1.349 1.292 0 CA-C-O 119.7 -0.5 . . . . 0.0 113.553 176.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 89.8 mt-30 -61.59 -57.77 10.75 Favored 'General case' 0 C--N 1.359 1.015 0 CA-C-O 121.351 0.596 . . . . 0.0 109.921 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -91.73 32.87 1.06 Allowed 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.376 177.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 65.07 -78.04 0.07 OUTLIER Glycine 0 C--N 1.361 1.949 0 C-N-CA 123.643 0.64 . . . . 0.0 112.831 -176.149 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 9.1 p -73.72 164.6 3.48 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.523 1.129 . . . . 0.0 110.441 178.476 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.448 HG12 ' HB3' ' A' ' 77' ' ' PRO . 15.9 mt -93.82 147.82 5.28 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 175.171 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.413 ' HB2' ' HB3' ' A' ' 75' ' ' SER . 1.0 OUTLIER -123.79 147.73 47.3 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 171.11 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.421 ' HA2' ' H ' ' A' ' 74' ' ' THR . . . -165.3 -176.49 36.92 Favored Glycine 0 CA--C 1.526 0.755 0 O-C-N 123.383 0.427 . . . . 0.0 113.177 -177.172 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 16.0 m -122.62 139.11 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 C-N-CA 123.826 0.85 . . . . 0.0 110.871 178.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 19.4 tp -74.82 113.47 12.14 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 123.522 0.514 . . . . 0.0 109.968 179.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.443 HD13 ' HG3' ' A' ' 72' ' ' ARG . 34.5 pt -112.71 -177.17 0.82 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.733 0 C-N-CA 123.776 0.831 . . . . 0.0 109.883 178.019 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -133.04 100.77 4.98 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -178.377 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 70.2 mm-40 -119.26 -64.57 1.26 Allowed 'General case' 0 N--CA 1.477 0.897 0 CA-C-O 121.362 0.601 . . . . 0.0 109.491 177.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 70.8 mt -121.82 26.15 8.82 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.966 -173.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.96 -175.83 1.55 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 124.951 1.3 . . . . 0.0 112.19 -172.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 43.1 p-80 -57.66 109.86 0.78 Allowed 'General case' 0 CA--C 1.562 1.425 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 169.171 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -76.38 130.55 38.22 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.316 0.647 . . . . 0.0 111.373 -167.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 47.7 t-80 -83.94 74.29 10.24 Favored 'General case' 0 CA--C 1.551 0.996 0 C-N-CA 124.082 0.953 . . . . 0.0 111.109 -174.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 8.0 p80 -174.09 147.05 1.22 Allowed 'General case' 0 N--CA 1.484 1.244 0 C-N-CA 124.63 1.172 . . . . 0.0 109.826 175.321 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 64.0 t60 -66.23 -59.06 4.1 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 123.732 0.813 . . . . 0.0 110.907 177.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 62.9 t-80 . . . . . 0 CA--C 1.55 0.955 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.955 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.841 0 N-CA-C 112.704 -0.158 . . . . 0.0 112.704 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -123.98 128.29 49.17 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 123.963 0.905 . . . . 0.0 109.38 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 5.7 mmp_? -94.99 64.32 2.79 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 166.005 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 52.3 ttm-85 -70.16 112.96 6.89 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 113.763 -1.562 . . . . 0.0 110.661 -173.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.9 t -110.98 90.13 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 123.897 0.879 . . . . 0.0 109.016 177.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 74.8 mtp180 -79.43 110.52 14.8 Favored 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 177.788 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 87.5 mt -80.0 86.12 5.52 Favored 'General case' 0 CA--C 1.541 0.613 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 176.274 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 50.7 mm -91.3 111.3 23.63 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 N-CA-C 108.436 -0.949 . . . . 0.0 108.436 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.07 168.91 10.47 Favored 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 122.995 0.518 . . . . 0.0 111.845 -175.282 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 80.9 m -95.24 117.32 30.06 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 124.694 1.198 . . . . 0.0 110.146 -177.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.411 ' HD3' ' H ' ' A' ' 11' ' ' ARG . 0.0 OUTLIER -131.16 -33.99 1.47 Allowed 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 123.763 0.825 . . . . 0.0 110.973 -178.94 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 151.16 101.49 0.22 Allowed Glycine 0 C--N 1.341 0.814 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 -173.478 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -153.45 165.58 31.45 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 122.95 0.309 . . . . 0.0 112.549 -173.693 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 5.1 t30 -142.79 92.73 2.43 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 123.321 0.648 . . . . 0.0 109.802 -174.427 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 19.2 p -117.51 88.67 2.96 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 123.932 0.893 . . . . 0.0 109.088 174.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -118.83 153.44 34.49 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.738 0.815 . . . . 0.0 110.024 177.445 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 10.0 p -84.44 146.33 6.88 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 167.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 -81.54 -169.39 2.29 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 123.612 0.765 . . . . 0.0 110.42 177.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.579 HD22 ' HB2' ' A' ' 24' ' ' ARG . 1.1 pp -71.4 75.04 0.75 Allowed 'General case' 0 CA--C 1.558 1.279 0 CA-C-O 122.267 1.032 . . . . 0.0 111.663 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -89.41 -30.16 18.55 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.021 0.928 . . . . 0.0 111.565 -176.319 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 20.3 m -76.35 -44.64 35.64 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.402 0.681 . . . . 0.0 110.602 -177.406 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -147.77 131.21 16.67 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.526 ' HA ' HD13 ' A' ' 19' ' ' LEU . 29.8 m -68.27 119.18 12.4 Favored 'General case' 0 CA--C 1.54 0.579 0 O-C-N 123.993 0.808 . . . . 0.0 111.045 178.612 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.579 ' HB2' HD22 ' A' ' 19' ' ' LEU . 71.8 mtm180 -112.96 170.64 8.05 Favored 'General case' 0 C--O 1.243 0.727 0 C-N-CA 123.618 0.767 . . . . 0.0 110.119 177.71 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.9 tt -143.57 139.54 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.313 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 22.7 m-80 -88.2 100.16 12.76 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 177.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -84.0 109.89 17.99 Favored 'Isoleucine or valine' 0 C--O 1.239 0.526 0 C-N-CA 124.098 0.959 . . . . 0.0 109.187 -175.067 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 48.8 t -101.34 113.61 38.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 179.568 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -62.52 121.04 64.75 Favored Pre-proline 0 CA--C 1.547 0.835 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 177.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -71.91 -18.42 27.98 Favored 'Trans proline' 0 C--N 1.363 1.317 0 C-N-CA 122.344 2.029 . . . . 0.0 113.326 -172.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -92.94 -52.02 4.79 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.592 0.757 . . . . 0.0 110.881 -174.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 47.2 p -96.97 -29.08 13.88 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.638 0.775 . . . . 0.0 111.992 -176.175 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 100.34 4.41 55.07 Favored Glycine 0 N--CA 1.481 1.665 0 CA-C-O 119.272 -0.738 . . . . 0.0 114.388 176.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.9 mtmp? -63.19 108.0 1.17 Allowed 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.528 0.731 . . . . 0.0 112.335 -173.669 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.2 t -90.62 116.47 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 C-N-CA 123.39 0.676 . . . . 0.0 109.378 176.742 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -144.59 139.4 28.09 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.329 0.652 . . . . 0.0 110.092 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 36.1 mt -79.76 133.84 28.87 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.885 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 -179.452 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.69 158.3 37.97 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 123.555 0.742 . . . . 0.0 111.441 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 32.6 mm-40 -92.15 121.43 33.69 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 177.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.0 mt -77.21 112.28 14.95 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 178.52 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -76.2 -51.98 11.01 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.086 0.954 . . . . 0.0 110.225 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -151.48 174.1 13.79 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.671 HG23 ' HE ' ' A' ' 54' ' ' ARG . 27.0 m -112.02 29.88 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.698 0 C-N-CA 123.208 0.603 . . . . 0.0 110.727 177.072 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.654 ' HA ' ' HG3' ' A' ' 54' ' ' ARG . 7.4 p -64.31 115.55 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 CA-C-O 121.781 0.8 . . . . 0.0 111.902 -176.237 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.74 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 36.1 tt0 -95.05 43.65 1.09 Allowed 'General case' 0 CA--C 1.552 1.026 0 C-N-CA 123.835 0.854 . . . . 0.0 110.169 -177.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 8.9 t30 55.24 83.9 0.08 Allowed 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 124.385 1.074 . . . . 0.0 110.745 -176.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 89.6 m -135.8 -72.18 0.46 Allowed 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.401 0.68 . . . . 0.0 109.504 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -175.81 -175.72 0.78 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 124.728 1.211 . . . . 0.0 108.811 -177.669 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 62.4 t30 -163.36 77.23 1.76 Allowed Pre-proline 0 CA--C 1.546 0.805 0 C-N-CA 123.615 0.766 . . . . 0.0 109.084 169.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.79 -45.41 0.24 Allowed 'Trans proline' 0 C--N 1.372 1.8 0 C-N-CA 122.64 2.227 . . . . 0.0 111.973 176.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.0 t-160 -164.92 -57.03 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -177.131 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -121.39 150.25 41.78 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 167.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 6.9 p -156.98 -40.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 C-N-CA 123.106 0.562 . . . . 0.0 110.333 -178.111 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.671 ' HE ' HG23 ' A' ' 43' ' ' VAL . 22.6 mmm180 -134.26 153.31 51.94 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.524 0.73 . . . . 0.0 110.32 -174.235 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.651 ' HB2' HG12 ' A' ' 57' ' ' ILE . 29.1 mmt180 -96.54 -161.26 0.86 Allowed 'General case' 0 CA--C 1.55 0.942 0 C-N-CA 123.83 0.852 . . . . 0.0 109.791 177.296 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -88.34 -2.21 58.47 Favored 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.844 0.858 . . . . 0.0 110.046 170.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.651 HG12 ' HB2' ' A' ' 55' ' ' ARG . 43.0 pt -63.08 110.27 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.359 1.007 0 CA-C-O 122.083 0.944 . . . . 0.0 111.143 -177.445 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.444 ' O ' ' HG3' ' A' ' 77' ' ' PRO . 57.5 mt -102.47 108.72 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 107.721 -1.215 . . . . 0.0 107.721 173.036 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 19.9 p -99.53 151.93 20.59 Favored 'General case' 0 C--O 1.241 0.614 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 174.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 73.0 ttt180 -67.2 128.27 35.77 Favored 'General case' 0 CA--C 1.546 0.793 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 176.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.81 11.46 70.6 Favored Glycine 0 C--N 1.338 0.691 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.827 -176.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.94 148.21 23.92 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-N 117.353 0.577 . . . . 0.0 110.112 176.405 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.74 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 61.6 t -84.11 114.63 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 171.406 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 28.8 m -104.46 144.73 14.07 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 C-N-CA 123.025 0.53 . . . . 0.0 109.686 174.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -91.68 127.85 37.29 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 175.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 49.5 p -128.8 -179.97 5.38 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 179.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -68.29 -19.17 64.68 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 122.854 0.461 . . . . 0.0 111.585 176.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 96.4 mt -90.35 -46.72 8.2 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 123.242 0.617 . . . . 0.0 109.804 178.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 162.99 -153.46 24.02 Favored Glycine 0 C--N 1.339 0.74 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.749 177.078 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -76.78 137.36 39.22 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 122.864 0.465 . . . . 0.0 110.284 176.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.4 t -132.03 142.65 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 122.957 0.503 . . . . 0.0 109.861 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.572 ' HG2' HD13 ' A' ' 88' ' ' ILE . 33.4 mmt180 -89.75 123.02 33.38 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 170.311 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 66.2 t -75.78 95.79 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 -179.404 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 60.8 p -78.84 -41.72 29.37 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 122.925 0.49 . . . . 0.0 111.179 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . 0.552 ' HB2' ' H ' ' A' ' 84' ' ' ASN . 50.3 m -91.42 115.1 27.76 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.0 176.254 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 7.3 tmm_? -55.75 135.22 72.2 Favored Pre-proline 0 CA--C 1.563 1.453 0 C-N-CA 125.099 1.359 . . . . 0.0 110.188 177.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.444 ' HG3' ' O ' ' A' ' 58' ' ' ILE . 36.9 Cg_endo -60.85 129.69 30.01 Favored 'Trans proline' 0 C--N 1.377 2.068 0 C-N-CA 123.026 2.484 . . . . 0.0 112.398 -177.343 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 115.23 -18.55 15.81 Favored Glycine 0 C--N 1.34 0.791 0 CA-C-O 119.678 -0.512 . . . . 0.0 112.688 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -67.74 98.3 0.7 Allowed 'General case' 0 C--N 1.355 0.842 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 177.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 74.33 -2.47 2.8 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 125.754 1.621 . . . . 0.0 112.083 -174.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.93 -0.42 82.19 Favored Glycine 0 C--N 1.348 1.233 0 C-N-CA 123.082 0.372 . . . . 0.0 112.469 -178.04 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.3 p -115.37 148.59 17.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 124.464 1.106 . . . . 0.0 109.671 175.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 35.6 mt -104.44 145.36 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 C-N-CA 123.081 0.553 . . . . 0.0 109.601 173.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.552 ' H ' ' HB2' ' A' ' 75' ' ' SER . 42.9 m-20 -130.19 154.86 47.11 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 174.345 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.87 -178.06 37.16 Favored Glycine 0 C--N 1.336 0.579 0 CA-C-O 119.825 -0.43 . . . . 0.0 112.837 -177.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.18 136.93 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 123.306 0.642 . . . . 0.0 110.739 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 45.7 tp -66.13 124.68 23.27 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 122.862 0.465 . . . . 0.0 111.753 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.572 HD13 ' HG2' ' A' ' 72' ' ' ARG . 45.4 pt -119.59 164.99 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 CA-C-O 121.586 0.708 . . . . 0.0 109.788 168.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . 0.421 HH11 ' N ' ' A' ' 89' ' ' ARG . 0.0 OUTLIER -130.92 88.27 2.59 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -175.106 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -101.24 -64.63 1.03 Allowed 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 63.3 mt -70.9 142.87 51.12 Favored 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 114.935 -1.03 . . . . 0.0 109.371 174.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 71.93 -31.86 0.23 Allowed 'General case' 0 N--CA 1.496 1.853 0 C-N-CA 127.464 2.306 . . . . 0.0 113.479 -178.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . 0.408 ' HB2' ' HB3' ' A' ' 89' ' ' ARG . 13.3 t60 -71.42 -55.56 7.69 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 171.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 49.1 t-80 -82.62 74.93 9.55 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 165.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 16.2 p80 -82.8 176.13 9.56 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 114.521 -1.218 . . . . 0.0 111.221 -176.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 30.6 m170 -65.0 96.15 0.18 Allowed 'General case' 0 N--CA 1.474 0.752 0 O-C-N 123.951 0.782 . . . . 0.0 110.623 -177.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -144.74 92.78 2.32 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 178.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 36.9 m80 . . . . . 0 N--CA 1.477 0.882 0 C-N-CA 124.178 0.991 . . . . 0.0 108.886 -179.529 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.642 0 N-CA-C 112.09 -0.404 . . . . 0.0 112.09 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -69.0 83.09 0.32 Allowed 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.997 0.919 . . . . 0.0 111.214 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 25.7 mmt180 -132.6 43.53 2.98 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.652 1.181 . . . . 0.0 108.326 176.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -70.9 90.26 0.8 Allowed 'General case' 0 CA--C 1.551 1.008 0 CA-C-N 114.869 -1.059 . . . . 0.0 110.558 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 41.1 t -68.83 118.59 13.25 Favored 'Isoleucine or valine' 0 C--O 1.242 0.665 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.15 179.179 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 42.8 ttm180 -68.83 -28.22 66.54 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 123.854 0.862 . . . . 0.0 111.38 -177.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.8 tt 64.22 57.3 1.24 Allowed 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 -171.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 9.1 tt -85.19 129.63 37.49 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.76 0 CA-C-N 114.43 -1.259 . . . . 0.0 109.283 179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 63.4 mtm180 -135.31 94.67 3.15 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 177.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 20.6 p -97.17 139.89 32.48 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 123.486 0.715 . . . . 0.0 110.118 -179.192 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -136.84 110.55 8.09 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -123.21 164.45 16.22 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -93.7 -155.58 31.93 Favored Glycine 0 C--N 1.34 0.763 0 O-C-N 123.627 0.251 . . . . 0.0 113.168 -178.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.8 t-20 -129.09 102.06 6.31 Favored 'General case' 0 CA--C 1.544 0.742 0 C-N-CA 123.781 0.832 . . . . 0.0 109.299 -176.509 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 34.2 m -94.65 112.35 24.1 Favored 'General case' 0 CA--C 1.541 0.605 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 176.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -71.79 149.97 44.81 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 123.538 0.735 . . . . 0.0 111.431 -174.453 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.1 p -119.55 151.26 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 C-N-CA 123.741 0.816 . . . . 0.0 110.959 -176.439 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.681 ' HE ' ' HA ' ' A' ' 18' ' ' ARG . 0.2 OUTLIER -105.01 126.63 52.27 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 124.074 0.95 . . . . 0.0 109.478 176.542 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.483 HD22 ' H ' ' A' ' 24' ' ' ARG . 86.0 mt 77.04 -41.98 0.4 Allowed 'General case' 0 N--CA 1.489 1.523 0 C-N-CA 125.859 1.664 . . . . 0.0 112.368 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 73.39 -76.92 0.06 Allowed 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 125.66 1.584 . . . . 0.0 111.94 172.304 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.532 ' HB2' ' NH2' ' A' ' 24' ' ' ARG . 16.8 m -102.5 -43.75 5.55 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 122.967 0.507 . . . . 0.0 110.847 -177.317 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . 0.422 ' O ' ' HG2' ' A' ' 24' ' ' ARG . 21.4 t70 -153.2 177.01 11.3 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.098 0.559 . . . . 0.0 110.522 -172.612 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 28.0 m -67.19 120.94 14.6 Favored 'General case' 0 C--N 1.352 0.685 0 C-N-CA 123.491 0.716 . . . . 0.0 110.141 177.026 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.532 ' NH2' ' HB2' ' A' ' 21' ' ' SER . 24.6 mmt85 -116.72 147.78 41.69 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 123.994 0.917 . . . . 0.0 111.409 -170.093 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 12.6 tt -148.63 142.2 18.63 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 CA-C-N 114.185 -1.37 . . . . 0.0 108.527 -178.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . 0.558 ' ND2' HG23 ' A' ' 82' ' ' VAL . 29.4 m-80 -93.89 100.65 12.78 Favored 'General case' 0 C--O 1.241 0.644 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 175.532 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 87.5 t -91.71 116.57 33.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.439 0 CA-C-N 114.353 -1.294 . . . . 0.0 108.461 -176.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.447 HG22 HG22 ' A' ' 35' ' ' VAL . 35.0 t -98.51 109.88 24.84 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.366 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -62.86 117.69 34.83 Favored Pre-proline 0 CA--C 1.548 0.891 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 172.472 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -66.1 -31.94 44.52 Favored 'Trans proline' 0 C--N 1.366 1.475 0 C-N-CA 122.698 2.265 . . . . 0.0 113.269 -170.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -94.33 -46.15 7.17 Favored 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 123.179 0.592 . . . . 0.0 110.857 -175.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.6 m -84.87 -29.34 25.34 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.125 0.57 . . . . 0.0 111.006 -173.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.66 5.96 73.86 Favored Glycine 0 C--N 1.345 1.038 0 CA-C-O 119.567 -0.574 . . . . 0.0 113.976 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 95.6 mttt -60.12 106.08 0.47 Allowed 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.052 0.541 . . . . 0.0 111.228 178.042 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.447 HG22 HG22 ' A' ' 28' ' ' VAL . 61.6 t -94.47 107.84 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 168.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -137.0 137.67 39.68 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 122.799 0.439 . . . . 0.0 109.944 -171.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 37.9 mt -75.74 99.14 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 177.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.458 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -89.45 157.4 18.14 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 123.737 0.815 . . . . 0.0 111.503 175.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -107.33 122.41 46.51 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.804 0.842 . . . . 0.0 109.179 178.466 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 64.7 mt -78.0 115.44 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 123.363 0.665 . . . . 0.0 110.845 -171.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 35.1 mmt180 -78.15 -53.78 6.98 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.417 1.087 . . . . 0.0 110.42 178.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.498 ' HB3' HG12 ' A' ' 44' ' ' VAL . 49.5 m-80 -131.54 153.88 49.39 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 123.666 0.786 . . . . 0.0 110.043 -175.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.459 ' HA ' HG12 ' A' ' 64' ' ' VAL . 33.7 m -118.42 6.76 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.117 0.967 . . . . 0.0 110.97 177.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.498 HG12 ' HB3' ' A' ' 42' ' ' ASN . 6.3 p -68.51 107.55 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.058 0 CA-C-O 121.614 0.721 . . . . 0.0 110.681 -177.302 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -59.38 143.12 50.55 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.247 174.042 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.47 HD21 HG11 ' A' ' 63' ' ' VAL . 39.6 m-20 -75.74 82.44 2.71 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 176.443 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.3 m -117.15 149.77 39.82 Favored 'General case' 0 C--O 1.241 0.653 0 C-N-CA 124.92 1.288 . . . . 0.0 108.817 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -66.61 90.07 0.16 Allowed 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 171.021 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 60.84 90.81 0.09 OUTLIER Pre-proline 0 CA--C 1.552 1.042 0 C-N-CA 124.518 1.127 . . . . 0.0 110.752 -172.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_exo -70.89 81.14 1.13 Allowed 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.523 2.149 . . . . 0.0 111.553 175.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 28.3 p80 -98.91 84.35 3.07 Favored 'General case' 0 N--CA 1.481 1.101 0 CA-C-O 121.559 0.695 . . . . 0.0 110.323 -176.724 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 55.66 23.83 6.55 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 124.334 1.054 . . . . 0.0 112.454 179.207 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 18.0 m -71.02 -32.04 47.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 175.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -141.28 158.62 43.64 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 125.668 1.587 . . . . 0.0 107.766 167.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 89.7 mtm180 -84.17 -172.05 3.95 Favored 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 172.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 60.2 m-80 -81.26 64.13 5.87 Favored 'General case' 0 N--CA 1.483 1.209 0 CA-C-O 121.929 0.871 . . . . 0.0 109.971 176.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 2.0 pp -132.89 170.38 20.14 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 125.051 1.34 . . . . 0.0 110.116 177.698 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.7 mt -102.34 130.68 51.84 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 C-N-CA 124.495 1.118 . . . . 0.0 109.162 -179.308 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 35.2 p -123.73 156.1 36.63 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.499 0.719 . . . . 0.0 109.737 177.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 60.5 ttt180 -74.71 123.51 25.04 Favored 'General case' 0 CA--C 1.544 0.715 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -178.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.99 4.19 67.27 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.086 -173.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.62 158.69 22.93 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.146 0.473 . . . . 0.0 110.737 175.837 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.47 HG11 HD21 ' A' ' 46' ' ' ASN . 68.8 t -97.26 111.24 26.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 171.752 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.459 HG12 ' HA ' ' A' ' 43' ' ' VAL . 29.6 m -108.38 137.97 37.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 173.726 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -91.16 142.32 27.87 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.109 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.458 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 61.7 p -128.07 178.76 5.99 Favored 'General case' 0 C--O 1.246 0.898 0 C-N-CA 124.146 0.979 . . . . 0.0 109.144 179.481 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -57.92 -25.72 61.26 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 123.584 0.754 . . . . 0.0 111.571 173.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 75.0 mt -83.52 -49.48 9.21 Favored 'General case' 0 C--N 1.351 0.632 0 C-N-CA 123.526 0.73 . . . . 0.0 109.244 178.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 161.01 -163.89 34.51 Favored Glycine 0 C--N 1.338 0.677 0 CA-C-N 115.27 -0.877 . . . . 0.0 111.394 -177.065 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 -75.46 139.08 42.04 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-O 121.084 0.469 . . . . 0.0 110.148 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 83.9 t -133.72 144.59 35.37 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 C-N-CA 125.096 1.358 . . . . 0.0 109.272 -171.18 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.747 ' HG2' HD13 ' A' ' 88' ' ' ILE . 7.0 mmt85 -96.33 122.43 39.21 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 171.603 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 47.2 t -70.57 109.09 2.76 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.438 HG21 HG13 ' A' ' 86' ' ' VAL . 44.6 p -90.48 -30.45 17.3 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.13 0.572 . . . . 0.0 110.986 -171.078 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 25.9 t -113.71 -169.9 1.6 Allowed 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.871 0.868 . . . . 0.0 109.416 -178.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 18.4 mtp180 -70.11 144.57 92.81 Favored Pre-proline 0 CA--C 1.554 1.104 0 C-N-CA 123.432 0.693 . . . . 0.0 110.711 174.724 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.407 ' HA ' HG12 ' A' ' 83' ' ' ILE . 88.3 Cg_endo -78.8 162.02 27.05 Favored 'Trans proline' 0 C--N 1.366 1.486 0 C-N-CA 122.307 2.004 . . . . 0.0 112.29 173.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.437 ' H ' HG12 ' A' ' 83' ' ' ILE . . . 57.4 -89.18 0.02 OUTLIER Glycine 0 C--N 1.346 1.089 0 CA-C-N 115.635 -0.712 . . . . 0.0 113.283 -175.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . 0.257 12.3 pt20 53.23 -66.41 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.679 0 C-N-CA 127.74 2.416 . . . . 0.0 114.328 -178.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -146.38 41.75 1.16 Allowed 'General case' 0 N--CA 1.476 0.854 0 CA-C-O 122.255 1.026 . . . . 0.0 108.518 178.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 64.47 16.99 61.51 Favored Glycine 0 C--N 1.351 1.377 0 CA-C-N 115.026 -0.988 . . . . 0.0 113.061 -173.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.558 HG23 ' ND2' ' A' ' 26' ' ' ASN . 3.8 p -132.69 88.92 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 CA-C-O 122.595 1.188 . . . . 0.0 110.074 -174.031 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.437 HG12 ' H ' ' A' ' 78' ' ' GLY . 34.2 mt -83.31 149.06 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 171.273 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -118.04 143.67 46.23 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 172.156 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.7 179.49 30.75 Favored Glycine 0 C--N 1.336 0.539 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.829 178.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.438 HG13 HG21 ' A' ' 74' ' ' THR . 15.7 m -129.36 137.34 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 C-N-CA 123.784 0.834 . . . . 0.0 110.235 174.536 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.16 105.71 3.5 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 122.655 0.382 . . . . 0.0 110.082 -178.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.747 HD13 ' HG2' ' A' ' 72' ' ' ARG . 39.1 pt -96.83 168.07 1.63 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.588 0 CA-C-O 121.583 0.706 . . . . 0.0 110.477 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 84.3 mtt180 -127.96 26.91 5.77 Favored 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.936 177.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -58.12 -62.91 1.48 Allowed 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 172.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.0 mt -104.04 116.16 31.74 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 158.031 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -74.67 150.55 39.51 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 171.148 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 40.5 t60 -63.52 94.5 0.09 Allowed 'General case' 0 N--CA 1.481 1.107 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -178.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 39.8 m80 -63.0 113.06 2.87 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 124.644 1.178 . . . . 0.0 112.807 -165.045 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -84.21 135.57 34.3 Favored 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 123.952 0.901 . . . . 0.0 109.577 179.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 57.55 55.2 5.81 Favored 'General case' 0 N--CA 1.481 1.117 0 C-N-CA 123.57 0.748 . . . . 0.0 111.66 177.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 27.8 t-80 -156.34 122.54 5.01 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 123.914 0.885 . . . . 0.0 109.221 -178.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 54.6 t-80 . . . . . 0 CA--C 1.558 1.253 0 C-N-CA 124.494 1.118 . . . . 0.0 109.641 -176.166 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.594 0 N-CA-C 111.457 -0.657 . . . . 0.0 111.457 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -135.65 114.94 12.47 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.633 0.773 . . . . 0.0 109.324 -177.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 5.5 mpt_? -110.37 91.97 3.86 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 171.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -101.5 82.95 2.37 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.625 -174.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 95.8 t -128.07 138.14 55.53 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 123.797 0.839 . . . . 0.0 109.793 -176.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -103.73 131.91 50.47 Favored 'General case' 0 N--CA 1.472 0.672 0 C-N-CA 123.958 0.903 . . . . 0.0 109.031 171.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 6.6 tt -75.17 107.73 7.45 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 -178.573 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 17.3 tt -104.16 119.04 52.34 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.806 0 CA-C-O 121.274 0.559 . . . . 0.0 109.615 179.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 3.4 tmt_? -72.96 133.11 44.19 Favored 'General case' 0 C--O 1.241 0.632 0 C-N-CA 123.565 0.746 . . . . 0.0 109.536 177.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 38.2 p -66.98 100.93 0.78 Allowed 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 122.911 0.484 . . . . 0.0 110.621 179.081 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.0 mmm180 -68.79 91.25 0.44 Allowed 'General case' 0 C--N 1.347 0.497 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.883 176.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -153.8 148.84 20.0 Favored Glycine 0 C--O 1.239 0.468 0 CA-C-N 115.072 -0.967 . . . . 0.0 112.029 -176.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -135.83 -62.04 0.06 OUTLIER Glycine 0 C--N 1.339 0.734 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 176.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -80.43 89.75 5.61 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 175.522 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 74.4 p -115.06 101.87 9.41 Favored 'General case' 0 C--O 1.24 0.592 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 176.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp -72.2 82.86 1.01 Allowed 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 122.975 0.51 . . . . 0.0 110.525 -177.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 84.2 t -80.86 145.3 9.17 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 124.053 0.941 . . . . 0.0 108.793 174.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -64.86 -172.24 0.08 Allowed 'General case' 0 CA--C 1.556 1.21 0 C-N-CA 123.722 0.809 . . . . 0.0 111.696 177.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.703 HD22 ' HB2' ' A' ' 24' ' ' ARG . 1.8 pp -75.96 57.96 1.12 Allowed 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 122.281 1.038 . . . . 0.0 113.131 -174.298 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -96.65 -20.87 17.97 Favored 'General case' 0 N--CA 1.469 0.492 0 C-N-CA 124.554 1.142 . . . . 0.0 110.079 174.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.9 p -68.2 -34.73 76.8 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 124.003 0.921 . . . . 0.0 110.575 175.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -149.61 126.27 11.01 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 173.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.448 HG22 HD12 ' A' ' 40' ' ' ILE . 34.1 m -70.16 112.48 6.55 Favored 'General case' 0 C--O 1.243 0.723 0 CA-C-O 121.474 0.654 . . . . 0.0 110.903 -176.705 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.703 ' HB2' HD22 ' A' ' 19' ' ' LEU . 99.0 mtt180 -128.9 175.36 8.71 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-N 114.867 -1.06 . . . . 0.0 111.148 -176.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 14.3 tt -144.97 148.16 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.932 0.893 . . . . 0.0 109.347 -173.08 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -90.61 102.95 15.69 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 174.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 97.2 t -87.87 113.3 24.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 C-N-CA 124.1 0.96 . . . . 0.0 108.904 -178.675 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.464 HG22 HG22 ' A' ' 35' ' ' VAL . 26.3 t -98.83 103.88 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.722 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -53.85 107.93 0.99 Allowed Pre-proline 0 CA--C 1.544 0.713 0 C-N-CA 123.677 0.791 . . . . 0.0 108.981 167.442 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -69.09 -24.21 33.0 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.273 1.982 . . . . 0.0 113.022 -174.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -80.41 -50.4 10.16 Favored 'General case' 0 CA--C 1.548 0.881 0 C-N-CA 123.213 0.605 . . . . 0.0 111.13 -177.014 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 40.9 p -94.21 -9.69 35.42 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -178.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.03 -3.18 66.29 Favored Glycine 0 N--CA 1.478 1.476 0 N-CA-C 114.166 0.426 . . . . 0.0 114.166 178.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -75.1 125.34 28.73 Favored 'General case' 0 N--CA 1.479 1.013 0 C-N-CA 123.774 0.83 . . . . 0.0 112.932 -170.209 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.464 HG22 HG22 ' A' ' 28' ' ' VAL . 17.1 t -104.03 135.4 41.94 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 C-N-CA 123.535 0.734 . . . . 0.0 109.549 177.685 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -146.77 146.53 30.31 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.503 0.721 . . . . 0.0 109.41 174.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 49.2 mt -78.15 100.71 3.39 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.752 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 174.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -92.72 153.82 18.69 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.294 0.638 . . . . 0.0 111.331 176.029 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.453 ' HA ' ' HG2' ' A' ' 24' ' ' ARG . 36.8 mt-10 -93.34 123.17 36.45 Favored 'General case' 0 C--O 1.244 0.804 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -178.29 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.448 HD12 HG22 ' A' ' 23' ' ' THR . 53.4 mt -74.93 112.26 12.13 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.85 0 O-C-N 123.43 0.456 . . . . 0.0 109.974 -175.602 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.6 mtp180 -77.24 -53.86 7.2 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 124.188 0.995 . . . . 0.0 111.036 178.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.532 ' HB3' ' HB3' ' A' ' 65' ' ' GLU . 53.8 t30 -134.81 146.58 49.44 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.032 -172.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.4 m -123.5 -21.52 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 123.625 0.77 . . . . 0.0 111.638 178.551 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.515 HG12 ' OD1' ' A' ' 42' ' ' ASN . 12.6 p -70.88 89.88 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.365 1.246 0 CA-C-O 122.998 1.38 . . . . 0.0 110.729 -172.504 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.54 ' HG3' ' H ' ' A' ' 63' ' ' VAL . 1.3 tm-20 -88.97 164.28 15.18 Favored 'General case' 0 C--O 1.242 0.71 0 CA-C-N 114.007 -1.452 . . . . 0.0 107.651 178.464 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 49.8 t-20 -69.26 85.59 0.39 Allowed 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 121.499 0.666 . . . . 0.0 109.322 175.148 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.3 t -120.8 114.07 21.08 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.298 1.039 . . . . 0.0 108.312 176.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . 60.82 21.11 11.25 Favored 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 124.509 1.124 . . . . 0.0 111.939 -174.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 20.3 m120 56.68 95.71 0.05 OUTLIER Pre-proline 0 CA--C 1.555 1.164 0 C-N-CA 124.784 1.234 . . . . 0.0 110.543 -170.085 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -59.4 119.92 7.45 Favored 'Trans proline' 0 C--N 1.374 1.883 0 C-N-CA 123.377 2.718 . . . . 0.0 112.848 -173.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 19.3 p80 -140.89 104.18 4.63 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.628 0.771 . . . . 0.0 109.675 -178.527 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 38.1 t80 56.69 30.17 17.06 Favored 'General case' 0 CA--C 1.559 1.317 0 C-N-CA 124.268 1.027 . . . . 0.0 110.628 -179.032 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 7.2 p -81.35 113.85 21.38 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.929 0 CA-C-O 121.37 0.605 . . . . 0.0 110.563 -175.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.406 ' HA ' ' NE ' ' A' ' 54' ' ' ARG . 1.0 OUTLIER -102.53 84.72 2.48 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 173.759 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 29.9 tpt180 -164.03 99.26 0.86 Allowed 'General case' 0 C--O 1.241 0.615 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 -174.138 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -87.43 54.56 3.18 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 123.762 0.825 . . . . 0.0 108.884 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 10.7 tp -95.15 121.64 45.9 Favored 'Isoleucine or valine' 0 C--O 1.243 0.749 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 -179.446 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 55.5 mt -93.83 130.06 43.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 173.225 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 76.2 p -117.15 159.26 22.89 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.222 0.609 . . . . 0.0 110.005 -176.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 77.7 ttt180 -74.4 115.43 13.91 Favored 'General case' 0 CA--C 1.546 0.813 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.047 -177.335 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.84 6.12 49.81 Favored Glycine 0 N--CA 1.47 0.959 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.78 -177.284 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.25 162.24 25.81 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.118 0.567 . . . . 0.0 111.014 -178.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.54 ' H ' ' HG3' ' A' ' 45' ' ' GLU . 59.0 t -103.3 110.61 30.31 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 174.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.6 m -105.82 142.52 18.67 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 176.049 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.532 ' HB3' ' HB3' ' A' ' 42' ' ' ASN . 34.8 tt0 -92.24 134.84 34.51 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 176.522 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 51.4 p -129.99 179.99 5.55 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 123.926 0.89 . . . . 0.0 108.87 178.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -76.1 -1.47 26.19 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 122.52 0.328 . . . . 0.0 111.336 175.066 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 82.8 mt -106.36 -9.07 16.91 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 123.704 0.802 . . . . 0.0 111.065 171.542 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 120.62 -166.04 13.85 Favored Glycine 0 C--N 1.351 1.393 0 C-N-CA 122.826 0.251 . . . . 0.0 113.018 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 20.2 m120 -77.64 137.87 38.78 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 123.01 0.524 . . . . 0.0 110.745 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.1 t -133.85 142.24 41.88 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.001 0 C-N-CA 124.727 1.211 . . . . 0.0 110.546 -171.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.669 ' HG2' HG21 ' A' ' 88' ' ' ILE . 30.0 mmt180 -85.15 132.34 34.31 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 170.646 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 45.6 t -76.94 106.52 6.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 172.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.463 HG21 HG13 ' A' ' 86' ' ' VAL . 74.1 p -95.93 -32.55 12.56 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 121.562 0.696 . . . . 0.0 110.629 -170.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.1 t -92.38 174.41 7.31 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.925 175.175 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 85.0 mtp180 -75.73 114.89 40.97 Favored Pre-proline 0 CA--C 1.546 0.802 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 171.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -62.46 112.93 1.73 Allowed 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 123.415 2.743 . . . . 0.0 113.084 -171.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.96 36.99 26.77 Favored Glycine 0 C--N 1.348 1.196 0 CA-C-N 115.388 -0.824 . . . . 0.0 112.245 -178.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 57.4 tp60 -70.7 -49.89 42.29 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.283 0.633 . . . . 0.0 109.946 179.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -121.39 56.15 1.05 Allowed 'General case' 0 N--CA 1.482 1.146 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 175.668 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 67.12 -16.98 0.3 Allowed Glycine 0 CA--C 1.538 1.52 0 N-CA-C 115.412 0.925 . . . . 0.0 115.412 -173.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.611 HG23 HD21 ' A' ' 19' ' ' LEU . 13.7 p -119.93 151.75 22.57 Favored 'Isoleucine or valine' 0 C--O 1.243 0.711 0 C-N-CA 124.229 1.012 . . . . 0.0 110.756 -171.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 28.3 mt -109.25 143.34 19.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 114.935 -1.03 . . . . 0.0 108.61 174.077 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -124.21 152.63 42.69 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 122.967 0.507 . . . . 0.0 109.647 172.662 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.5 -176.7 35.73 Favored Glycine 0 C--N 1.344 1.011 0 CA-C-N 115.323 -0.853 . . . . 0.0 112.956 -175.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.463 HG13 HG21 ' A' ' 74' ' ' THR . 27.7 m -130.33 144.24 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 123.317 0.647 . . . . 0.0 110.242 178.039 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.9 tp -72.14 126.86 30.84 Favored 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.585 -178.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.669 HG21 ' HG2' ' A' ' 72' ' ' ARG . 12.7 pt -125.21 171.31 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.189 0 C-N-CA 123.919 0.887 . . . . 0.0 110.319 -178.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 93.0 mtt180 -120.94 71.24 0.93 Allowed 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 123.424 0.69 . . . . 0.0 109.257 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 21.4 mm-40 -93.47 -78.74 0.42 Allowed 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 122.86 0.464 . . . . 0.0 110.244 179.387 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 35.5 mt -104.64 140.24 38.32 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 123.868 0.867 . . . . 0.0 109.057 -170.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -90.61 120.53 31.76 Favored 'General case' 0 C--O 1.242 0.709 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 173.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 56.8 t-80 -70.61 83.16 0.61 Allowed 'General case' 0 CA--C 1.547 0.863 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 171.083 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 56.3 t60 -116.16 136.15 53.28 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 114.27 -1.332 . . . . 0.0 110.319 -168.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 1.5 p80 -64.63 105.58 1.0 Allowed 'General case' 0 CA--C 1.547 0.835 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 171.269 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -65.3 -22.8 66.88 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 123.25 0.62 . . . . 0.0 111.521 -172.429 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 35.4 m-70 -104.45 167.01 10.02 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 123.548 0.739 . . . . 0.0 109.616 175.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 49.8 t-80 . . . . . 0 CA--C 1.553 1.075 0 CA-C-O 118.809 -0.615 . . . . 0.0 109.763 -176.82 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.582 0 N-CA-C 112.033 -0.427 . . . . 0.0 112.033 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -150.65 134.71 16.85 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 123.32 0.648 . . . . 0.0 110.131 -178.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -90.3 86.21 6.43 Favored 'General case' 0 CA--C 1.541 0.619 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.42 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 23.9 ptt180 -77.35 79.88 3.86 Favored 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.896 0.855 . . . . 0.0 110.57 178.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 2.9 p -142.33 100.21 0.82 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.959 0 C-N-CA 123.937 0.895 . . . . 0.0 109.611 -179.204 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 43.3 ttm105 -78.7 -23.33 45.63 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.393 177.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.1 tm? 63.06 78.08 0.31 Allowed 'General case' 0 C--N 1.358 0.962 0 C-N-CA 125.082 1.353 . . . . 0.0 109.294 178.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.1 tt -98.89 105.64 17.66 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.373 -173.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -109.26 174.48 5.85 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 124.01 0.924 . . . . 0.0 110.177 177.22 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 44.3 p -52.02 118.17 3.28 Favored 'General case' 0 CA--C 1.556 1.178 0 C-N-CA 124.522 1.129 . . . . 0.0 112.584 -175.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.3 tpp180 -69.97 108.23 3.94 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 123.64 0.776 . . . . 0.0 109.98 177.58 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 166.87 -170.45 41.32 Favored Glycine 0 C--N 1.341 0.832 0 O-C-N 123.101 0.251 . . . . 0.0 112.799 177.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -85.12 62.5 4.51 Favored Glycine 0 C--N 1.348 1.227 0 N-CA-C 112.021 -0.432 . . . . 0.0 112.021 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 27.6 m-80 -86.24 60.54 6.29 Favored 'General case' 0 C--O 1.245 0.835 0 C-N-CA 124.105 0.962 . . . . 0.0 109.436 -178.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 41.8 p -78.27 78.52 4.74 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 122.002 0.906 . . . . 0.0 110.514 -174.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -114.35 -44.8 3.08 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 114.484 -1.234 . . . . 0.0 107.897 178.482 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 12.7 p -84.15 137.17 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.746 0 CA-C-N 115.259 -0.882 . . . . 0.0 108.626 168.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 7.0 mpt_? -78.53 -74.28 0.28 Allowed 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -179.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 8.7 mp -102.67 124.36 48.06 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 124.211 1.004 . . . . 0.0 108.497 175.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -98.9 65.16 1.48 Allowed 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 31.6 m 64.23 14.41 8.64 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 124.851 1.26 . . . . 0.0 112.226 -176.379 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -141.54 149.69 41.16 Favored 'General case' 0 N--CA 1.471 0.615 0 C-N-CA 123.983 0.913 . . . . 0.0 109.272 -177.187 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.469 HG22 HD12 ' A' ' 40' ' ' ILE . 14.1 m -72.19 113.15 8.91 Favored 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 123.256 0.622 . . . . 0.0 110.763 -171.281 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 14.3 mmt180 -113.34 145.54 40.92 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.997 0.919 . . . . 0.0 110.929 -177.577 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 17.5 tt -140.26 145.73 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 123.48 0.712 . . . . 0.0 110.674 -177.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -93.08 102.86 15.19 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 171.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.6 t -88.79 106.95 17.27 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 C-N-CA 123.972 0.909 . . . . 0.0 109.185 -176.505 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.402 HG13 HG22 ' A' ' 35' ' ' VAL . 61.8 t -95.85 100.53 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -62.47 111.78 5.32 Favored Pre-proline 0 CA--C 1.547 0.834 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 172.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -71.84 -22.83 23.02 Favored 'Trans proline' 0 C--N 1.365 1.401 0 C-N-CA 122.295 1.997 . . . . 0.0 113.648 -165.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -95.66 -44.16 7.59 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 122.802 0.441 . . . . 0.0 112.166 -176.058 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 44.4 p -87.17 -25.34 24.11 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 122.465 0.306 . . . . 0.0 111.376 -178.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.12 6.57 74.91 Favored Glycine 0 C--N 1.348 1.213 0 CA-C-O 119.35 -0.694 . . . . 0.0 114.04 179.028 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -71.87 107.15 4.5 Favored 'General case' 0 CA--C 1.544 0.714 0 CA-C-N 117.406 0.603 . . . . 0.0 111.016 -179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.402 HG22 HG13 ' A' ' 28' ' ' VAL . 40.7 t -97.19 109.61 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 174.275 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -136.02 137.59 41.34 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.336 0.654 . . . . 0.0 109.723 -171.652 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 62.1 mt -77.14 131.46 34.74 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.568 0 C-N-CA 123.547 0.739 . . . . 0.0 109.113 179.204 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.471 ' HB1' ' HB ' ' A' ' 66' ' ' THR . . . -131.04 165.02 24.13 Favored 'General case' 0 C--O 1.241 0.612 0 C-N-CA 123.544 0.738 . . . . 0.0 111.061 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -103.79 116.85 33.06 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-N 114.633 -1.167 . . . . 0.0 108.682 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.469 HD12 HG22 ' A' ' 23' ' ' THR . 62.9 mt -76.88 110.05 12.03 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 20.4 mtm180 -82.26 -39.58 22.81 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.822 178.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.501 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 93.7 m-20 -128.26 129.53 46.53 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.445 0.698 . . . . 0.0 109.949 -178.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.4 HG21 ' HA ' ' A' ' 56' ' ' ASN . 27.5 m -97.16 -11.82 8.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 123.92 0.888 . . . . 0.0 109.809 173.618 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.4 p -67.89 107.46 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.142 0 O-C-N 124.014 0.822 . . . . 0.0 110.078 175.014 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.525 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -67.58 -38.12 83.6 Favored 'General case' 0 N--CA 1.482 1.149 0 C-N-CA 124.728 1.211 . . . . 0.0 111.792 -179.724 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -151.91 130.53 12.28 Favored 'General case' 0 C--O 1.241 0.64 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 178.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 45.6 p -64.97 92.34 0.1 Allowed 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 121.626 0.727 . . . . 0.0 110.39 -179.117 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -139.52 86.35 2.11 Favored 'General case' 0 C--O 1.241 0.652 0 C-N-CA 124.395 1.078 . . . . 0.0 109.425 -176.368 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 56.23 51.21 5.86 Favored Pre-proline 0 CA--C 1.568 1.64 0 C-N-CA 124.802 1.241 . . . . 0.0 111.013 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.8 -15.51 29.89 Favored 'Trans proline' 0 C--N 1.387 2.566 0 C-N-CA 123.041 2.494 . . . . 0.0 113.69 -166.733 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 25.8 t-80 -71.01 -45.56 63.76 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 122.578 0.351 . . . . 0.0 110.147 176.315 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 87.1 t80 -63.54 -37.27 86.67 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.317 175.529 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.568 HG12 ' H ' ' A' ' 55' ' ' ARG . 46.4 t -71.65 -80.49 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.204 178.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 71.2 ttt180 64.83 7.74 4.11 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 124.848 1.259 . . . . 0.0 111.868 178.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.568 ' H ' HG12 ' A' ' 53' ' ' VAL . 29.3 mmt85 -81.19 125.86 30.8 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 123.276 0.631 . . . . 0.0 111.342 -170.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.4 ' HA ' HG21 ' A' ' 43' ' ' VAL . 20.2 t-20 -81.19 4.2 21.04 Favored 'General case' 0 CA--C 1.557 1.232 0 C-N-CA 123.71 0.804 . . . . 0.0 109.129 169.713 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.6 mt -60.59 87.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.364 1.216 0 C-N-CA 124.394 1.078 . . . . 0.0 109.517 171.315 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 79.9 mt -83.17 134.1 27.65 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.484 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 177.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 59.2 p -117.5 166.24 12.59 Favored 'General case' 0 C--O 1.242 0.679 0 C-N-CA 122.949 0.5 . . . . 0.0 110.873 -176.47 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.405 ' HA ' ' O ' ' A' ' 73' ' ' VAL . 57.3 mtt180 -70.89 127.13 31.56 Favored 'General case' 0 C--N 1.349 0.55 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 175.342 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.47 -6.13 77.69 Favored Glycine 0 C--N 1.341 0.812 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.823 -175.752 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.76 139.54 38.41 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 117.28 0.54 . . . . 0.0 110.519 177.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 45' ' ' GLU . 48.6 t -89.63 118.54 35.11 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 C-N-CA 123.43 0.692 . . . . 0.0 110.122 178.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 29.4 m -104.15 151.46 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 O-C-N 121.603 -0.685 . . . . 0.0 109.331 171.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.501 ' HB3' ' HB2' ' A' ' 42' ' ' ASN . 34.2 tt0 -102.84 134.09 46.83 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 176.834 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.471 ' HB ' ' HB1' ' A' ' 38' ' ' ALA . 60.0 p -132.28 -176.74 4.18 Favored 'General case' 0 C--O 1.243 0.762 0 C-N-CA 123.665 0.786 . . . . 0.0 109.379 -179.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -76.69 -8.26 56.92 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.846 175.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 58.4 mt -97.02 -14.96 21.29 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 123.58 0.752 . . . . 0.0 110.653 174.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 120.94 -156.97 16.04 Favored Glycine 0 C--N 1.347 1.141 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.742 -176.193 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.409 ' O ' HD12 ' A' ' 87' ' ' LEU . 18.9 m120 -80.4 138.87 36.7 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 122.993 0.517 . . . . 0.0 111.48 179.388 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.9 t -125.87 135.17 64.72 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 C-N-CA 123.83 0.852 . . . . 0.0 109.82 178.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.643 ' HG2' HD13 ' A' ' 88' ' ' ILE . 10.9 mmt-85 -83.19 114.77 21.58 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 167.629 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 60' ' ' ARG . 45.3 t -80.03 96.45 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.9 p -78.67 -22.1 47.28 Favored 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 123.951 0.9 . . . . 0.0 110.897 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 49.3 m -95.92 -169.08 1.87 Allowed 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.926 0.89 . . . . 0.0 110.886 176.289 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -108.05 156.43 38.31 Favored Pre-proline 0 CA--C 1.547 0.848 0 C-N-CA 123.288 0.635 . . . . 0.0 109.652 173.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.449 ' HA ' HG12 ' A' ' 83' ' ' ILE . 68.5 Cg_endo -71.41 132.02 19.98 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.085 1.857 . . . . 0.0 111.946 178.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.412 ' H ' HG12 ' A' ' 83' ' ' ILE . . . 72.84 12.52 78.64 Favored Glycine 0 C--N 1.35 1.315 0 CA-C-O 119.571 -0.572 . . . . 0.0 114.331 174.737 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -74.28 134.1 42.62 Favored 'General case' 0 C--N 1.351 0.666 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.2 t70 68.08 -3.65 1.2 Allowed 'General case' 0 CA--C 1.565 1.537 0 C-N-CA 123.642 0.777 . . . . 0.0 111.579 -179.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 122.18 -13.93 8.95 Favored Glycine 0 C--N 1.355 1.623 0 CA-C-O 119.23 -0.761 . . . . 0.0 113.735 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.4 p -148.77 163.91 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 CA-C-N 118.469 1.134 . . . . 0.0 111.377 -179.006 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.449 HG12 ' HA ' ' A' ' 77' ' ' PRO . 10.0 mt -83.8 149.37 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 175.281 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 27.5 m-80 -140.17 152.96 46.45 Favored 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 122.775 0.43 . . . . 0.0 110.173 -178.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -170.8 -170.33 34.89 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-O 119.98 -0.345 . . . . 0.0 113.061 179.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 18.7 m -126.07 136.81 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 C-N-CA 124.096 0.958 . . . . 0.0 110.943 179.098 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.409 HD12 ' O ' ' A' ' 70' ' ' ASN . 18.9 tp -72.26 127.02 31.26 Favored 'General case' 0 N--CA 1.483 1.221 0 CA-C-O 120.852 0.358 . . . . 0.0 111.602 -174.327 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.643 HD13 ' HG2' ' A' ' 72' ' ' ARG . 7.8 pt -118.67 170.32 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 C-N-CA 124.79 1.236 . . . . 0.0 109.488 177.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 12.8 mmt180 -118.56 19.88 13.15 Favored 'General case' 0 N--CA 1.486 1.371 0 C-N-CA 122.738 0.415 . . . . 0.0 110.535 -169.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -50.43 -75.84 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.876 0 C-N-CA 124.422 1.089 . . . . 0.0 113.85 -164.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.6 mt -77.94 94.54 4.61 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -178.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -61.38 99.12 0.1 Allowed 'General case' 0 C--O 1.241 0.648 0 O-C-N 123.971 0.794 . . . . 0.0 109.478 176.038 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -75.38 80.77 2.45 Favored 'General case' 0 C--N 1.347 0.462 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 -178.561 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -76.45 99.11 4.79 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.422 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 75.2 t60 -95.0 68.25 3.16 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -176.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 34.4 m170 58.16 77.59 0.28 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 124.961 1.304 . . . . 0.0 111.959 -178.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -137.84 166.48 23.92 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 124.457 1.103 . . . . 0.0 109.336 177.04 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 67.8 m-70 . . . . . 0 N--CA 1.489 1.486 0 C-N-CA 124.137 0.975 . . . . 0.0 111.3 178.476 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.69 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -72.35 97.09 1.97 Allowed 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 123.582 0.753 . . . . 0.0 110.861 -175.09 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -90.16 95.77 10.36 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 176.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 42.1 ttm180 -150.41 93.91 2.04 Favored 'General case' 0 C--O 1.241 0.615 0 C-N-CA 123.77 0.828 . . . . 0.0 109.296 -177.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.9 p -84.95 85.37 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 CA-C-O 122.297 1.046 . . . . 0.0 109.067 173.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 28.7 tpt180 -76.3 105.74 7.52 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.331 -175.161 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 97.7 mt -128.02 118.58 23.76 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 124.124 0.97 . . . . 0.0 109.274 -179.324 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.1 tt -76.72 94.0 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.138 0 CA-C-O 121.631 0.729 . . . . 0.0 109.136 175.751 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 26.2 mmm180 -74.57 76.61 1.98 Allowed 'General case' 0 N--CA 1.48 1.059 0 CA-C-O 121.702 0.763 . . . . 0.0 111.001 -175.231 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 17.6 p -114.76 151.72 33.29 Favored 'General case' 0 C--O 1.242 0.702 0 C-N-CA 124.343 1.057 . . . . 0.0 108.839 177.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 22.8 tpp180 -62.08 97.39 0.08 Allowed 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 123.868 0.867 . . . . 0.0 111.083 -174.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -135.42 29.3 2.92 Favored Glycine 0 N--CA 1.472 1.078 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.546 179.411 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -174.27 171.02 44.21 Favored Glycine 0 C--N 1.338 0.685 0 N-CA-C 111.403 -0.679 . . . . 0.0 111.403 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -94.56 134.74 36.79 Favored 'General case' 0 C--O 1.244 0.807 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 176.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.0 m -69.84 93.79 0.78 Allowed 'General case' 0 C--O 1.24 0.581 0 O-C-N 123.72 0.637 . . . . 0.0 109.91 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 22.6 pttm -81.34 71.38 8.33 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-O 122.877 1.323 . . . . 0.0 109.454 176.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 8.6 p -93.09 142.41 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 CA-C-N 114.077 -1.419 . . . . 0.0 109.952 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.523 ' HB2' ' O ' ' A' ' 81' ' ' GLY . 0.0 OUTLIER -93.28 -160.98 0.8 Allowed 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 123.354 0.662 . . . . 0.0 109.547 174.06 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.79 64.78 1.83 Allowed 'General case' 0 N--CA 1.49 1.548 0 CA-C-O 121.857 0.837 . . . . 0.0 112.145 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -82.09 -31.71 30.61 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.727 0.811 . . . . 0.0 111.27 -176.524 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 32.4 t -125.11 -21.89 4.54 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 123.88 0.872 . . . . 0.0 110.631 -179.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -109.15 172.83 6.62 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 123.643 0.777 . . . . 0.0 109.572 -177.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.1 m -115.24 108.71 16.95 Favored 'General case' 0 C--O 1.243 0.737 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 167.24 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 12.9 tpp85 -113.28 136.16 53.05 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 123.477 0.711 . . . . 0.0 110.64 -175.113 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.8 tt -133.89 144.11 36.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 123.398 0.679 . . . . 0.0 110.451 177.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -93.98 107.85 19.72 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 171.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.407 HG22 HG21 ' A' ' 71' ' ' VAL . 86.6 t -91.63 108.37 19.91 Favored 'Isoleucine or valine' 0 C--O 1.241 0.654 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 -177.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.515 HG13 HG22 ' A' ' 35' ' ' VAL . 51.6 t -107.32 99.27 8.24 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.128 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -59.02 116.55 16.14 Favored Pre-proline 0 CA--C 1.55 0.964 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 174.134 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_endo -73.79 -23.62 16.41 Favored 'Trans proline' 0 C--N 1.366 1.495 0 C-N-CA 122.279 1.986 . . . . 0.0 114.007 -171.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.47 ' HG3' HG23 ' A' ' 32' ' ' THR . 12.9 pt-20 -91.57 -50.33 5.83 Favored 'General case' 0 N--CA 1.479 0.975 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -176.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.47 HG23 ' HG3' ' A' ' 31' ' ' GLU . 75.3 p -91.38 -33.02 15.44 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 122.7 0.4 . . . . 0.0 111.452 -176.616 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 96.11 21.35 23.14 Favored Glycine 0 C--N 1.344 1.017 0 CA-C-O 119.292 -0.727 . . . . 0.0 114.106 177.23 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.0 mttp -56.92 106.48 0.31 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 117.364 0.582 . . . . 0.0 109.711 168.374 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.515 HG22 HG13 ' A' ' 28' ' ' VAL . 54.9 t -108.46 97.71 6.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 172.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -143.51 144.6 32.04 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 123.558 0.743 . . . . 0.0 109.295 -176.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 23.0 mt -85.43 133.21 29.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.43 173.43 10.85 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.283 1.433 . . . . 0.0 109.61 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -122.84 141.19 52.13 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 174.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 75.7 mt -83.03 114.16 23.4 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 C-N-CA 123.02 0.528 . . . . 0.0 110.041 -176.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 47.1 mtp180 -76.62 -49.6 15.85 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 124.13 0.972 . . . . 0.0 110.114 179.536 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -143.65 166.9 23.55 Favored 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.802 0.841 . . . . 0.0 108.951 -179.476 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.9 p -132.92 116.79 27.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.821 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 170.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -137.22 82.37 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 CA-C-O 122.222 1.011 . . . . 0.0 109.845 -177.036 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.749 ' HB3' ' H ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -105.69 -10.29 16.85 Favored 'General case' 0 N--CA 1.477 0.912 0 CA-C-N 114.186 -1.37 . . . . 0.0 110.306 171.886 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 67.4 m-20 63.52 61.16 1.04 Allowed 'General case' 0 C--O 1.243 0.73 0 C-N-CA 125.345 1.458 . . . . 0.0 112.171 173.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.4 t -69.77 -37.76 76.51 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 163.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -179.26 -177.1 0.44 Allowed 'General case' 0 C--O 1.241 0.609 0 C-N-CA 125.75 1.62 . . . . 0.0 108.64 -178.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 -63.77 114.66 14.21 Favored Pre-proline 0 N--CA 1.479 0.978 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 170.054 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -67.32 80.93 0.4 Allowed 'Trans proline' 0 C--N 1.382 2.316 0 C-N-CA 122.99 2.46 . . . . 0.0 113.065 -174.476 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 43.4 t-80 -94.22 80.52 4.01 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 175.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 43.6 m-85 -127.26 12.28 7.05 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.22 -177.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 47.5 t 59.98 67.61 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.91 0 C-N-CA 124.176 0.99 . . . . 0.0 109.4 -173.564 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 2.6 ptm180 56.31 9.19 0.49 Allowed 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 127.657 2.383 . . . . 0.0 114.673 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 54.3 mtm180 -86.9 141.82 28.47 Favored 'General case' 0 N--CA 1.48 1.064 0 CA-C-O 121.281 0.563 . . . . 0.0 111.114 -178.751 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.7 p-10 -95.53 94.04 7.53 Favored 'General case' 0 CA--C 1.547 0.83 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.045 179.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.1 mm -77.49 101.38 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.679 0.752 . . . . 0.0 109.193 175.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 75.6 mt -100.11 122.8 52.44 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 114.359 -1.291 . . . . 0.0 109.276 -176.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 41.5 p -121.52 168.19 12.0 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 124.366 1.066 . . . . 0.0 109.284 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 59.0 ttp180 -74.59 130.26 39.24 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 176.137 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 93.36 -0.16 68.14 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 115.752 -0.658 . . . . 0.0 113.251 -172.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.3 149.94 35.29 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 122.812 0.445 . . . . 0.0 110.964 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.749 ' H ' ' HB3' ' A' ' 45' ' ' GLU . 50.0 t -99.41 110.4 26.55 Favored 'Isoleucine or valine' 0 C--O 1.244 0.765 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 173.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 27.1 m -104.83 142.25 18.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.228 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -101.79 120.32 40.18 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -178.411 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 38.5 p -125.14 179.13 5.19 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.313 0.645 . . . . 0.0 109.466 -173.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 23.2 p-10 -68.79 -14.92 63.33 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 123.008 0.523 . . . . 0.0 111.038 178.151 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.9 mt -93.51 -46.76 7.16 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 123.309 0.644 . . . . 0.0 109.501 175.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 159.18 -154.95 26.03 Favored Glycine 0 C--N 1.344 0.977 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.891 175.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -77.04 130.17 37.06 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.902 0.481 . . . . 0.0 110.615 178.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.407 HG21 HG22 ' A' ' 27' ' ' VAL . 36.9 t -128.18 140.47 49.1 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.871 0 C-N-CA 124.463 1.105 . . . . 0.0 109.355 -178.321 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.587 ' HG2' HD13 ' A' ' 88' ' ' ILE . 7.3 mmt-85 -85.57 131.59 34.33 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 170.076 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 59.0 t -76.16 110.13 10.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 173.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 68.9 p -101.54 -42.75 6.12 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 121.207 0.527 . . . . 0.0 109.737 -173.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 20.3 m -94.33 136.97 34.03 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.622 172.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 17.4 mtp180 -60.25 132.39 90.28 Favored Pre-proline 0 CA--C 1.553 1.067 0 O-C-N 124.047 0.842 . . . . 0.0 110.743 -178.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.411 ' HA ' HG12 ' A' ' 83' ' ' ILE . 76.2 Cg_exo -52.73 116.9 3.19 Favored 'Trans proline' 0 C--N 1.375 1.923 0 C-N-CA 123.807 3.005 . . . . 0.0 114.847 -176.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 78.46 20.59 71.49 Favored Glycine 0 C--N 1.348 1.206 0 N-CA-C 115.491 0.956 . . . . 0.0 115.491 166.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -73.44 -48.16 35.87 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-N 118.111 0.955 . . . . 0.0 110.521 177.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -85.87 -3.44 58.92 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 123.401 0.68 . . . . 0.0 110.888 170.708 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . 0.523 ' O ' ' HB2' ' A' ' 18' ' ' ARG . . . 111.85 -9.12 27.65 Favored Glycine 0 C--O 1.219 -0.782 0 N-CA-C 111.97 -0.452 . . . . 0.0 111.97 -178.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 12.6 p -140.63 163.81 22.19 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.895 0 C-N-CA 123.34 0.656 . . . . 0.0 109.931 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.411 HG12 ' HA ' ' A' ' 77' ' ' PRO . 23.3 mt -91.99 147.39 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 172.273 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -130.92 156.69 44.64 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 171.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -169.74 -172.86 36.73 Favored Glycine 0 C--N 1.344 1.027 0 N-CA-C 114.172 0.429 . . . . 0.0 114.172 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 31.2 m -123.92 135.95 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 C-N-CA 123.694 0.798 . . . . 0.0 111.119 -179.472 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 34.0 tp -74.04 117.17 15.52 Favored 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.459 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.587 HD13 ' HG2' ' A' ' 72' ' ' ARG . 12.4 pt -116.22 168.75 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 124.191 0.997 . . . . 0.0 111.394 -169.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 17.1 mmt180 -112.55 92.09 3.89 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . . . . . . . . . 18.3 mm-40 -121.42 -75.62 0.59 Allowed 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 123.278 0.631 . . . . 0.0 111.417 -173.492 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 39.5 mt -109.31 144.64 37.21 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.331 0.652 . . . . 0.0 110.261 -168.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -84.78 170.1 13.54 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 170.633 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 50.4 t-80 -63.03 96.48 0.09 Allowed 'General case' 0 C--O 1.246 0.909 0 CA-C-O 121.18 0.514 . . . . 0.0 110.078 174.785 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 51.8 m170 -78.12 151.49 33.31 Favored 'General case' 0 C--O 1.238 0.455 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.806 -178.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 25.9 m170 -83.03 -29.22 29.05 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.246 0.618 . . . . 0.0 109.521 172.593 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 29.4 t-80 51.87 85.35 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 125.846 1.658 . . . . 0.0 112.855 172.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -129.4 60.06 1.58 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 176.637 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 27.3 p80 . . . . . 0 N--CA 1.497 1.883 0 C-N-CA 125.819 1.648 . . . . 0.0 113.161 -178.86 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.069 0 CA-C-O 120.243 -0.199 . . . . 0.0 113.495 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 35.7 m-20 -104.28 110.36 22.55 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 123.124 0.57 . . . . 0.0 109.672 177.304 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 83.4 mtt180 -80.23 91.59 5.61 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 173.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 24.1 mtp180 -65.04 91.86 0.1 Allowed 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.902 0.881 . . . . 0.0 109.744 -178.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.8 p -80.16 133.6 29.25 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 115.252 -0.885 . . . . 0.0 111.2 -175.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 9.9 ptp180 -110.19 90.96 3.47 Favored 'General case' 0 CA--C 1.546 0.815 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 169.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 36.2 tp -84.78 86.16 7.37 Favored 'General case' 0 C--O 1.243 0.756 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -178.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.0 tt -149.62 128.55 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.908 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 26.9 ttm180 -147.74 90.62 1.86 Allowed 'General case' 0 C--O 1.241 0.625 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 176.56 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 37.2 p -80.38 84.76 5.96 Favored 'General case' 0 CA--C 1.544 0.745 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.364 -178.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 3.4 tmt_? -82.97 -59.79 2.37 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 177.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 66.44 -111.81 4.43 Favored Glycine 0 C--N 1.351 1.362 0 CA-C-N 115.67 -0.695 . . . . 0.0 113.742 177.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 153.13 156.38 7.56 Favored Glycine 0 C--N 1.343 0.968 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -176.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 28.5 t30 -143.88 128.16 17.77 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.515 0.726 . . . . 0.0 109.814 -176.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.9 p -136.87 140.08 42.11 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.413 1.085 . . . . 0.0 109.633 178.084 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -97.38 -179.48 4.51 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 121.383 0.611 . . . . 0.0 110.714 174.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 11.5 p -148.42 156.21 8.76 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.82 0 CA-C-N 114.643 -1.162 . . . . 0.0 108.486 177.049 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.31 179.6 1.94 Allowed 'General case' 0 N--CA 1.487 1.4 0 C-N-CA 122.491 0.316 . . . . 0.0 110.974 177.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.757 HD22 ' HB ' ' A' ' 82' ' ' VAL . 1.5 pt? -58.53 133.37 55.77 Favored 'General case' 0 CA--C 1.554 1.119 0 C-N-CA 123.236 0.614 . . . . 0.0 111.581 -179.085 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.25 -8.57 12.92 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.699 0.8 . . . . 0.0 110.035 172.39 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.516 ' HB2' HH21 ' A' ' 24' ' ' ARG . 33.4 m -104.18 -137.92 0.35 Allowed 'General case' 0 CA--C 1.553 1.091 0 C-N-CA 124.574 1.15 . . . . 0.0 109.378 179.195 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -82.28 -179.26 7.35 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 123.877 0.871 . . . . 0.0 110.941 -177.538 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.8 m -64.1 114.4 4.15 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 123.43 0.692 . . . . 0.0 110.889 -176.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.579 HH11 ' HG3' ' A' ' 24' ' ' ARG . 4.1 ttm-85 -119.65 170.17 9.43 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.049 -178.163 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 18.3 tt -136.69 140.68 42.7 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 CA-C-O 121.251 0.548 . . . . 0.0 111.194 -175.134 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 31.5 m-80 -92.05 100.71 13.3 Favored 'General case' 0 C--O 1.242 0.664 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 175.332 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 99.5 t -92.78 114.27 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 C-N-CA 123.734 0.813 . . . . 0.0 109.91 -173.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 35' ' ' VAL . 38.8 t -103.89 120.74 54.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 123.627 0.771 . . . . 0.0 109.103 -178.188 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -58.68 117.25 19.31 Favored Pre-proline 0 CA--C 1.541 0.6 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 167.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.8 -17.66 28.98 Favored 'Trans proline' 0 C--N 1.367 1.504 0 C-N-CA 121.867 1.711 . . . . 0.0 111.348 170.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -78.5 -53.96 6.66 Favored 'General case' 0 CA--C 1.555 1.137 0 C-N-CA 123.489 0.715 . . . . 0.0 112.107 -179.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 47.0 p -100.9 -26.66 13.67 Favored 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -176.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.37 7.23 65.5 Favored Glycine 0 N--CA 1.476 1.348 0 CA-C-O 119.964 -0.353 . . . . 0.0 112.927 -178.032 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.2 mmtt -73.57 142.68 46.62 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 123.39 0.676 . . . . 0.0 110.846 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.434 HG22 HG22 ' A' ' 28' ' ' VAL . 25.1 t -118.55 122.12 68.72 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.053 0 C-N-CA 123.417 0.687 . . . . 0.0 109.463 179.122 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -135.37 136.46 41.49 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 123.738 0.815 . . . . 0.0 109.015 178.038 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 56.8 mt -79.19 100.19 3.75 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.092 0 C-N-CA 123.258 0.623 . . . . 0.0 109.383 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -95.67 163.23 13.28 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 172.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.457 ' HA ' ' HG3' ' A' ' 24' ' ' ARG . 34.0 mt-10 -102.65 137.13 41.27 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -175.672 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 57.5 mt -80.36 110.29 15.76 Favored 'Isoleucine or valine' 0 C--N 1.355 0.806 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 177.323 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 14.1 mtp180 -79.15 -53.82 6.61 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 124.58 1.152 . . . . 0.0 109.535 179.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -148.84 165.75 30.57 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.911 -175.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.531 HG11 ' HB3' ' A' ' 56' ' ' ASN . 30.3 m -103.33 13.02 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 123.593 0.757 . . . . 0.0 111.694 -179.39 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 p -67.34 92.47 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.06 0 CA-C-O 122.615 1.198 . . . . 0.0 109.966 177.794 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -61.43 -43.26 99.17 Favored 'General case' 0 N--CA 1.476 0.851 0 CA-C-N 114.029 -1.441 . . . . 0.0 109.862 173.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -177.12 -160.91 0.06 Allowed 'General case' 0 C--O 1.244 0.792 0 C-N-CA 125.999 1.719 . . . . 0.0 107.161 -179.572 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 19.0 m -63.42 -17.33 62.55 Favored 'General case' 0 CA--C 1.56 1.341 0 C-N-CA 122.829 0.452 . . . . 0.0 112.055 178.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -57.5 -37.05 72.33 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 124.474 1.11 . . . . 0.0 112.747 178.497 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -135.54 92.81 16.87 Favored Pre-proline 0 N--CA 1.48 1.033 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 173.58 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -96.34 7.51 1.66 Allowed 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 123.189 2.593 . . . . 0.0 112.587 169.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 61.6 m170 -84.67 106.23 16.07 Favored 'General case' 0 C--N 1.353 0.731 0 C-N-CA 123.544 0.738 . . . . 0.0 111.057 -172.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -116.62 75.22 0.95 Allowed 'General case' 0 CA--C 1.542 0.664 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 172.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 9.2 p -160.19 19.58 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.194 0 CA-C-O 122.442 1.115 . . . . 0.0 108.413 177.219 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 13.2 ptm180 -132.09 177.36 7.62 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 124.79 1.236 . . . . 0.0 110.604 -168.387 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.3 tpt180 -65.93 111.75 3.46 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 165.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.531 ' HB3' HG11 ' A' ' 43' ' ' VAL . 51.1 m-80 -66.14 89.2 0.12 Allowed 'General case' 0 CA--C 1.546 0.792 0 O-C-N 123.691 0.619 . . . . 0.0 110.238 179.327 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 69.6 mt -91.96 96.2 6.08 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 56.3 mt -82.13 142.68 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 171.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 67.5 p -119.19 166.48 12.91 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 123.536 0.734 . . . . 0.0 110.19 177.095 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 36.4 ttm105 -71.74 115.55 11.07 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 171.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 100.97 2.41 55.0 Favored Glycine 0 C--N 1.341 0.841 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.599 -174.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.81 132.71 34.38 Favored 'General case' 0 C--O 1.244 0.795 0 C-N-CA 122.875 0.47 . . . . 0.0 110.107 176.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.455 HG21 ' HG3' ' A' ' 90' ' ' GLU . 54.1 t -79.59 125.58 38.77 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.726 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 174.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 19.6 m -116.14 147.89 19.23 Favored 'Isoleucine or valine' 0 C--O 1.245 0.853 0 C-N-CA 123.885 0.874 . . . . 0.0 109.052 176.286 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -84.69 122.78 29.57 Favored 'General case' 0 N--CA 1.462 0.147 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -179.516 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 47.4 p -129.03 176.99 7.45 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -178.107 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 -65.82 -23.24 66.65 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 123.86 0.864 . . . . 0.0 111.362 177.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 85.1 mt -93.62 -38.61 11.26 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.122 0.569 . . . . 0.0 110.849 -179.148 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 152.22 -146.97 16.16 Favored Glycine 0 C--N 1.347 1.148 0 C-N-CA 121.573 -0.346 . . . . 0.0 113.175 174.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -68.38 109.18 3.53 Favored 'General case' 0 N--CA 1.477 0.895 0 C-N-CA 124.008 0.923 . . . . 0.0 109.453 176.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 85.6 t -120.03 137.68 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 O-C-N 121.886 -0.509 . . . . 0.0 110.379 -179.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.487 ' HG3' HD11 ' A' ' 88' ' ' ILE . 31.1 mtt85 -105.08 129.77 53.43 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.669 0.387 . . . . 0.0 110.335 174.601 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.478 HG11 ' HG3' ' A' ' 77' ' ' PRO . 85.1 t -71.68 123.18 25.47 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 O-C-N 124.455 1.097 . . . . 0.0 110.259 -178.603 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.418 HG21 HG13 ' A' ' 86' ' ' VAL . 45.7 p -101.04 -22.28 14.78 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.971 0.908 . . . . 0.0 111.06 -174.89 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 20.7 t -105.11 -173.65 2.35 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 123.738 0.815 . . . . 0.0 110.268 -178.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 86.7 mtt180 -74.36 120.88 83.61 Favored Pre-proline 0 CA--C 1.544 0.717 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 168.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . 0.478 ' HG3' HG11 ' A' ' 73' ' ' VAL . 73.0 Cg_exo -54.32 102.17 0.08 OUTLIER 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 123.252 2.635 . . . . 0.0 112.98 178.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.497 ' N ' HG12 ' A' ' 83' ' ' ILE . . . 82.91 47.81 5.71 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.228 -0.896 . . . . 0.0 112.336 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 54.7 tp60 -64.93 -58.11 7.01 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 123.463 0.705 . . . . 0.0 110.405 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -98.31 16.49 21.35 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 123.616 0.766 . . . . 0.0 110.015 175.16 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 100.08 -20.99 46.62 Favored Glycine 0 C--N 1.35 1.31 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -173.08 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.757 ' HB ' HD22 ' A' ' 19' ' ' LEU . 14.1 p -110.92 158.31 11.45 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.542 1.137 . . . . 0.0 108.57 -178.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.497 HG12 ' N ' ' A' ' 78' ' ' GLY . 8.7 mt -110.78 151.3 12.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 123.624 0.769 . . . . 0.0 109.828 -177.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 79.9 m-20 -118.31 148.13 42.77 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 172.172 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -161.7 -179.97 36.71 Favored Glycine 0 C--N 1.348 1.207 0 O-C-N 123.452 0.47 . . . . 0.0 113.136 -179.348 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.418 HG13 HG21 ' A' ' 74' ' ' THR . 11.9 m -124.48 136.81 59.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 C-N-CA 123.642 0.777 . . . . 0.0 111.423 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 50.8 tp -78.82 105.96 10.5 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 123.403 0.681 . . . . 0.0 110.982 -177.446 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.487 HD11 ' HG3' ' A' ' 72' ' ' ARG . 30.4 pt -123.41 -172.92 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 123.889 0.875 . . . . 0.0 109.507 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -132.68 110.91 10.74 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 -179.159 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.455 ' HG3' HG21 ' A' ' 63' ' ' VAL . 41.3 mm-40 -115.94 -60.8 1.82 Allowed 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.027 0.531 . . . . 0.0 110.135 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 52.2 mt -72.51 -27.99 62.6 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 122.888 0.475 . . . . 0.0 110.256 179.008 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -118.17 44.47 2.21 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 124.151 0.98 . . . . 0.0 109.962 173.008 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -76.07 -17.22 59.73 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 124.254 1.022 . . . . 0.0 111.924 177.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 17.1 m170 73.59 127.96 0.04 OUTLIER 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 125.507 1.523 . . . . 0.0 108.782 -162.214 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -64.32 167.14 7.14 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 123.404 0.682 . . . . 0.0 111.301 -178.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 32.0 m170 -83.99 16.59 2.79 Favored 'General case' 0 N--CA 1.484 1.238 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -170.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 25.9 t-80 75.19 -52.48 0.66 Allowed 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 125.88 1.672 . . . . 0.0 110.591 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 72.4 m-70 . . . . . 0 C--O 1.248 0.992 0 C-N-CA 123.754 0.822 . . . . 0.0 108.803 166.735 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.611 0 N-CA-C 111.715 -0.554 . . . . 0.0 111.715 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 25.8 m-20 -75.65 108.31 8.4 Favored 'General case' 0 C--N 1.352 0.704 0 C-N-CA 123.371 0.668 . . . . 0.0 110.593 179.403 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 4.8 ppt_? -137.29 141.65 41.93 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.509 0.723 . . . . 0.0 109.885 174.005 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 6.2 mpt_? -101.23 77.71 1.83 Allowed 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.013 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 6.7 p -73.12 -42.39 58.8 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.95 -177.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.5 ttt85 -98.43 147.2 24.96 Favored 'General case' 0 C--O 1.243 0.747 0 C-N-CA 124.069 0.947 . . . . 0.0 109.712 -178.587 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 6.4 tt -75.48 90.79 2.74 Favored 'General case' 0 CA--C 1.541 0.631 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 175.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 68.1 mt -100.1 122.83 52.47 Favored 'Isoleucine or valine' 0 C--O 1.241 0.614 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 166.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 47.0 mtm180 -59.09 149.94 26.44 Favored 'General case' 0 N--CA 1.483 1.199 0 O-C-N 123.377 0.423 . . . . 0.0 111.256 -173.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 32.3 p -50.56 92.72 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 125.025 1.33 . . . . 0.0 113.307 -168.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 31.7 tpt180 -144.03 146.18 32.69 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 124.403 1.081 . . . . 0.0 108.443 178.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.32 -7.54 78.17 Favored Glycine 0 C--N 1.344 1.023 0 CA-C-O 120.02 -0.322 . . . . 0.0 112.819 -175.326 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.69 85.14 1.18 Allowed Glycine 0 C--N 1.35 1.348 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 177.146 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -67.26 95.26 0.41 Allowed 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 177.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 34.6 p -86.37 174.28 9.13 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.906 0.882 . . . . 0.0 110.772 -179.26 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.86 40.43 1.99 Allowed 'General case' 0 N--CA 1.481 1.083 0 CA-C-O 121.976 0.893 . . . . 0.0 109.527 177.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 58.7 t -77.79 115.58 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.672 -179.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.3 mpt_? -84.93 -70.37 0.59 Allowed 'General case' 0 CA--C 1.539 0.528 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 169.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.454 HD22 ' HA ' ' A' ' 23' ' ' THR . 97.6 mt -104.51 -81.13 0.53 Allowed 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.487 0.715 . . . . 0.0 110.402 178.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 47.36 78.05 0.08 Allowed 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 125.286 1.434 . . . . 0.0 111.558 -174.13 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 19.5 t 76.18 -52.75 0.61 Allowed 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 125.399 1.48 . . . . 0.0 111.482 -176.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -69.91 177.04 3.31 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 124.08 0.952 . . . . 0.0 111.722 176.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.454 ' HA ' HD22 ' A' ' 19' ' ' LEU . 7.5 m -144.02 119.2 10.12 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.206 -172.784 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -101.14 147.81 25.81 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.445 0.698 . . . . 0.0 109.392 -177.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.444 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 17.4 tt -146.61 151.17 14.38 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 122.972 0.509 . . . . 0.0 110.324 177.683 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -100.03 102.45 13.81 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 168.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.33 110.9 21.12 Favored 'Isoleucine or valine' 0 C--O 1.243 0.724 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 178.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 53.5 t -100.51 99.51 8.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -60.14 114.09 9.01 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 172.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -76.25 -8.21 18.48 Favored 'Trans proline' 0 C--N 1.369 1.647 0 C-N-CA 122.795 2.33 . . . . 0.0 113.136 -173.317 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -84.17 -53.97 5.14 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.251 0.621 . . . . 0.0 109.867 -172.175 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 58.6 p -99.57 -33.21 10.73 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 124.032 0.933 . . . . 0.0 111.449 177.719 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 103.4 10.33 36.32 Favored Glycine 0 N--CA 1.476 1.359 0 CA-C-O 119.828 -0.429 . . . . 0.0 113.272 -176.374 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.2 mmmt -66.12 113.67 4.68 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 123.654 0.782 . . . . 0.0 111.484 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 38.1 t -104.26 125.44 59.04 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 C-N-CA 123.731 0.813 . . . . 0.0 109.268 176.278 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.433 ' HB3' HD11 ' A' ' 68' ' ' LEU . 8.9 tp10 -135.26 140.33 45.12 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 123.605 0.762 . . . . 0.0 109.612 178.191 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 65.5 mt -79.78 118.37 27.21 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 169.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.07 169.59 11.04 Favored 'General case' 0 C--O 1.242 0.706 0 C-N-CA 124.129 0.972 . . . . 0.0 109.083 -175.049 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.1 mm-40 -102.89 128.88 49.49 Favored 'General case' 0 C--O 1.244 0.771 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.5 mt -74.39 110.37 8.51 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 175.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 42.8 ttt180 -72.43 -37.74 68.52 Favored 'General case' 0 C--O 1.237 0.425 0 C-N-CA 124.28 1.032 . . . . 0.0 110.492 -175.037 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -160.67 148.8 16.21 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.036 -0.984 . . . . 0.0 108.624 -173.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 64' ' ' VAL . 40.5 t -109.98 88.24 1.09 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.753 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 178.635 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.9 p -140.51 135.96 35.7 Favored 'Isoleucine or valine' 0 C--O 1.244 0.79 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -178.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.736 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 36.4 mt-10 -99.08 -54.44 2.98 Favored 'General case' 0 C--O 1.241 0.61 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.534 -176.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.778 ' H ' ' HG3' ' A' ' 50' ' ' PRO . 90.5 m-20 59.0 32.06 21.93 Favored 'General case' 0 N--CA 1.479 0.984 0 O-C-N 125.156 1.535 . . . . 0.0 110.236 -171.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 43.4 p -92.19 -59.4 2.1 Favored 'General case' 0 CA--C 1.544 0.75 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.389 175.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -156.33 75.87 0.88 Allowed 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 123.496 0.719 . . . . 0.0 109.465 176.472 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 64.27 95.25 0.05 OUTLIER Pre-proline 0 CA--C 1.558 1.261 0 C-N-CA 124.767 1.227 . . . . 0.0 111.257 178.072 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.778 ' HG3' ' H ' ' A' ' 46' ' ' ASN . 5.5 Cg_exo -73.87 -25.59 14.18 Favored 'Trans proline' 0 C--N 1.376 2.013 0 C-N-CA 123.267 2.645 . . . . 0.0 112.893 -178.558 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 33.9 m-70 -93.15 81.88 4.53 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 123.454 0.702 . . . . 0.0 109.498 -175.359 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 37.1 p90 -115.56 5.06 14.31 Favored 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 124.111 0.964 . . . . 0.0 110.26 173.513 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 7.1 p -155.29 148.96 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.73 0 C-N-CA 124.506 1.122 . . . . 0.0 108.919 -178.128 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.0 ttt180 -63.21 -64.64 0.85 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.153 0.581 . . . . 0.0 110.752 178.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 45.7 ttt180 -82.41 129.77 34.96 Favored 'General case' 0 C--N 1.348 0.507 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 176.067 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.1 m120 -79.6 70.49 6.09 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.397 0.679 . . . . 0.0 110.626 -176.595 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 50.8 mm -55.09 106.92 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.74 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.047 170.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 57.5 mt -66.93 123.37 19.84 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.257 -0.883 . . . . 0.0 108.791 177.255 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 28.5 p -125.21 161.07 27.69 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 124.374 1.07 . . . . 0.0 109.648 -176.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 58.1 ttp180 -69.71 127.2 32.11 Favored 'General case' 0 CA--C 1.547 0.864 0 C-N-CA 123.26 0.624 . . . . 0.0 109.451 175.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.98 -16.33 58.49 Favored Glycine 0 C--N 1.346 1.113 0 CA-C-O 119.739 -0.478 . . . . 0.0 112.994 -173.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.36 153.05 30.06 Favored 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 122.732 0.413 . . . . 0.0 110.742 179.289 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.736 ' HB ' ' HA ' ' A' ' 45' ' ' GLU . 78.0 t -98.19 124.26 51.16 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 CA-C-N 115.888 -0.597 . . . . 0.0 109.762 175.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.559 HG12 HG13 ' A' ' 43' ' ' VAL . 21.8 m -118.97 138.46 49.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 123.853 0.861 . . . . 0.0 109.068 174.548 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -101.07 137.43 39.44 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -179.436 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.437 HG21 HG21 ' A' ' 25' ' ' ILE . 71.2 p -129.17 -173.09 2.89 Favored 'General case' 0 C--O 1.242 0.681 0 C-N-CA 123.671 0.788 . . . . 0.0 110.113 -169.592 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -68.36 -9.98 51.83 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 123.381 0.673 . . . . 0.0 111.768 173.281 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.433 HD11 ' HB3' ' A' ' 36' ' ' GLU . 85.1 mt -106.65 -46.24 4.03 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.775 0.83 . . . . 0.0 110.459 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 167.37 -164.51 37.96 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 116.546 -0.297 . . . . 0.0 112.359 175.171 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -73.1 139.46 46.48 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.178 0.591 . . . . 0.0 109.507 175.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 61.5 t -134.81 142.14 41.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.754 0.822 . . . . 0.0 110.331 -170.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.599 ' HG2' HD13 ' A' ' 88' ' ' ILE . 8.3 mmt-85 -93.38 124.9 37.69 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 171.032 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 51.7 t -76.35 97.49 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.213 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 p -79.7 -38.62 33.09 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.659 0.784 . . . . 0.0 112.121 -177.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . 0.487 ' HB3' ' HB2' ' A' ' 84' ' ' ASN . 23.2 t -90.55 -176.46 4.76 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.436 0.694 . . . . 0.0 110.457 179.804 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 59.6 mtt180 -83.59 113.6 48.08 Favored Pre-proline 0 CA--C 1.549 0.922 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -68.24 141.25 51.4 Favored 'Trans proline' 0 C--N 1.376 1.98 0 C-N-CA 123.254 2.636 . . . . 0.0 113.236 -171.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 83.13 18.91 63.81 Favored Glycine 0 C--N 1.347 1.142 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.112 177.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -70.68 103.21 2.48 Favored 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 63.53 41.49 7.32 Favored 'General case' 0 N--CA 1.484 1.271 0 C-N-CA 124.168 0.987 . . . . 0.0 110.905 -174.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 61.05 33.61 84.73 Favored Glycine 0 C--N 1.339 0.737 0 CA-C-N 114.864 -1.062 . . . . 0.0 115.293 -175.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 8.3 p -143.31 141.47 26.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.591 0.71 . . . . 0.0 110.922 168.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.444 ' O ' ' HA ' ' A' ' 25' ' ' ILE . 2.0 mp -93.7 146.98 5.86 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 174.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.487 ' HB2' ' HB3' ' A' ' 75' ' ' SER . 2.6 m-20 -126.31 137.99 53.54 Favored 'General case' 0 N--CA 1.484 1.225 0 CA-C-N 118.971 0.805 . . . . 0.0 109.508 174.026 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -163.44 -175.06 34.03 Favored Glycine 0 C--N 1.345 1.073 0 CA-C-N 115.994 -0.548 . . . . 0.0 113.075 -175.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 34.5 m -127.47 142.89 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 C-N-CA 123.441 0.696 . . . . 0.0 110.78 -177.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 31.3 tp -68.28 130.99 44.54 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 123.159 0.583 . . . . 0.0 110.673 -178.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.599 HD13 ' HG2' ' A' ' 72' ' ' ARG . 19.5 pt -133.42 170.21 20.38 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 C-N-CA 124.157 0.983 . . . . 0.0 110.04 -175.417 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 13.2 mmt-85 -111.4 95.09 5.31 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 176.267 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' GLU . . . . . 0.453 ' HG3' HG11 ' A' ' 63' ' ' VAL . 47.7 mm-40 -105.93 -62.1 1.42 Allowed 'General case' 0 N--CA 1.487 1.424 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 171.338 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.557 HD21 HD22 ' A' ' 46' ' ' ASN . 74.6 mt -99.65 126.54 45.67 Favored 'General case' 0 C--O 1.239 0.532 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.155 174.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -74.02 101.06 3.75 Favored 'General case' 0 CA--C 1.545 0.771 0 CA-C-O 121.667 0.746 . . . . 0.0 109.592 176.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 14.8 m-70 -65.65 141.88 58.24 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.056 178.397 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -115.74 97.45 6.13 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 123.119 0.568 . . . . 0.0 110.429 -174.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 13.5 p80 -128.61 -7.94 5.12 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.347 0.659 . . . . 0.0 109.885 169.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' HIS . . . . . . . . . . . . . 22.7 m170 -68.46 -26.07 65.31 Favored 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 123.24 0.616 . . . . 0.0 109.83 173.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 31.8 t60 -62.7 -47.22 84.57 Favored 'General case' 0 C--N 1.349 0.551 0 C-N-CA 124.889 1.275 . . . . 0.0 110.657 179.462 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' HIS . . . . . . . . . . . . . 21.1 t-80 . . . . . 0 C--O 1.25 1.131 0 C-N-CA 123.497 0.719 . . . . 0.0 109.838 -177.128 . . . . . . . . 0 0 . 1 stop_ save_